### (19) World Intellectual Property Organization

International Bureau



### 

(43) International Publication Date 15 September 2005 (15.09.2005)

### (10) International Publication Number WO 2005/085861 A2

(51) International Patent Classification7: 33/50

G01N 33/574,

(21) International Application Number:

PCT/EP2005/050897

(22) International Filing Date: 1 March 2005 (01.03.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

04100858.2

3 March 2004 (03.03.2004) EP

04100857.4

3 March 2004 (03.03.2004) EP

(71) Applicant (for all designated States except US): ORIDIS BIOMED FORSCHUNGS- UND ENTWICKLUNGS GMBH [AT/AT]; Stiftingtalstrasse 3-5, A-8010 Graz

(72) Inventors; and

(75) Inventors/Applicants (for US only): GUELLY, Christian [AT/AT]; Purgstall 281, A-8063 Eggesdorf b. Graz (AT). STROHMAIER, Heimo [AT/AT]; Plüddemanngasse 75d, A-8010 Graz (AT). BUCK, Charles [US/US]; 2512 Nottingham Place, West Lafayette, IN 47906 (US). ZAT-LOUKAL, Kurt [AT/AT]; Oridis Biomed Forschungsund Entwicklungs GmbH, Sternwirtweg 22c, A-8047 Graz (AT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NUCLEIC ACIDS AND ENCODED POLYPEPTIDES FOR USE IN LIVER DISORDERS AND EPITHELIAL CAN-

(57) Abstract: The invention relates to nucleic acids and to corresponding encoded polypeptides and to their use for the diagnosis, prevention and/or treatment of liver disorders and neoplastic disorders, especially cancer of the liver and other epithelial tissues, benign liver neoplasms such as adenoma and other proliferative liver disorders such as focal nodular hyperplasia (FNH) and cirrhosis. The invention further relates to methods of diagnosing and treating these disorders.

WO 2005/085861 PCT/EP2005/050897

## Description

1

# NUCLEIC ACIDS AND ENCODED POLYPEPTIDES FOR USE IN LIVER DISORDERS AND EPITHELIAL CANCER.

### **Technical Field**

:-

[003]

[001] The invention relates to nucleotides and to corresponding encoded proteins and to their use for the diagnosis, prevention and/or treatment of liver disorders and neoplastic disorders, especially cancer of the liver and other epithelial tissues, benign liver neoplasms such as adenoma and other proliferative liver disorders such as focal nodular hyperplasia (FNH) and cirrhosis. The invention further relates to methods of diagnosing and treating these disorders.

[002] The development of cancer in general is characterized by genetic mutations that alter activity of important cellular pathways including, for example, proliferation, apoptosis (cell death), response to stress and epithelial/stroma interactions. It is increasingly recognized that identification of nucleic acids that are deregulated in cancer can provide important new insight into the mechanisms of neoplastic transformation. Identification of deregulated nucleic acid expression in precancerous stages, such as macro regenerative nodules and the "large" and "small" cell change in liver cancer, provide understanding of early events in malignant transformation. Similarly, identification of deregulated gene expression in disorders characterized by tissue proliferation and remodeling, such as FNH and cirrhosis in the liver may distinguish nucleic acids involved in proliferation and malignant transformation. Together such deregulated nucleic acids and the encoded gene products have potential as new diagnostic markers for cancer. Moreover, the products of these deregulated nucleic acids per se are targets for therapeutic intervention in the prevention and/or treatment of these disorders in human patients.

The liver plays a vital role in the metabolism of proteins, lipids, carbohydrates, nucleic acids and vitamins. There are numerous disorders effecting the liver that cannot be diagnosed, prevented or treated effectively, such as hepatocellular carcinoma (HCC). Examination of HCC is particularly well suited for the identification of deregulated gene expression in cancer. This is because tissue samples of HCC can be obtained from surgically resected tumors and the tumors are well circumscribed solid structures with little stromal tissue. Furthermore, as indicated above, there is the possibility for comparative analyses of benign and malignant tumors as well as cirrhosis, a non-neoplastic condition. If the limitations in the art of identifying differentially expressed genes associated with liver disorders could be overcome, this comparative approach may enable identification of deregulated nucleic acids

specifically involved in the processes of cellular proliferation and tissue remodeling in a mature organ (e.g., in cirrhosis) as well as the identification and discrimination of gene expression alterations associated with hyperplasia (such as FNH) and with benign and malignant neoplasms (e.g., adenoma and HCC). In HCC there is an urgent need for new and better diagnostic and therapeutic capabilities. Deregulated genes in liver cancer may also be highly relevant to other cancers of the gastrointestinal tract and indeed with other carcinomas (epithelial derived cancers) as these tissues share a common embryological origin.

[004]

On a global basis, hepatocellular carcinoma (HCC) belongs to the most common malignant tumors accounting for about 1 million deaths/year (Ishak et al., 1999, Atlas of Tumor Pathology. Fascicle 31. Armed Forces Institute of Pathology, Washington, DC).

[005]

Definitive diagnosis of neoplastic liver disorders such as HCC and many other tumors relies upon histopathological evaluation of biopsy specimens. This invasive surgical procedure is generally not undertaken until symptoms appear and the disease is then most often in advanced stages, thereby limiting therapeutic intervention options. Thus there is a need to improve diagnostics and methods of diagnosis. In addition, early diagnosis is crucial but hampered by late onset or even a lack of specific clinical symptoms. At diagnosis most HCC tumors are no longer amenable to surgical resection (except encapsulated tumors or the fibrolamellar variants) (Chen and Jeng, 1997, J. Gastroențerol. Hepatol.,, 12:329-34); moreover, they are highly resistant to cytostatic therapy (Kawata et al., 2001, Br. J. Cancer, 84:886-91). Overall, death usually occurs within 1 year after diagnosis. Thus, markers for early detection, prognostic indicators, and effective prevention and/or treatment regimens for HCC are highly desirable in this field.

[006]

In contrast, unlike the well-studied situation in colorectal cancer, liver adenoma may not represent a precursor lesion of HCC. Similarly, although cirrhosis and hepatitis viral infections are clearly risk factors for HCC, these conditions are not prerequisite for the development of HCC. Certain liver lesions may represent HCC prestages such as macro regenerative nodular hyperplasia, but this is not yet confirmed (Shortell and Schwartz, 1991, Surg Gynecol Obstet., 173:426-31; Anthony, P. in MacSween et al, eds. Pathology of the Liver. 2001, Churchill Livingstone, Edinburgh). Although these disorders are diagnosed by histopathological investigation of liver resections and liver biopsies, no efficient method exists for earlier or non-invasive detection of these conditions. Again, there is immediate need for diagnostic and prognostic markers for these neoplasms and for non-invasive detection of these disorders.

[007]

Within the past decade, several technologies have made it possible to monitor the

expression level of a large number of transcripts within a cell at any one time (see, e.g., Schena et al., 1995, Science, 270:467-470; Blanchard et al., 1996, Nature Biotechnology, 1996, 14:1649). Transcript array technology has been utilized for the identification of genes that are up regulated or down regulated in various disordered states. Several recent studies have utilized this technology to examine changes in gene expression in HCC. These studies have variously revealed deregulation (i.e., over- and underexpression) of genes encoding liver specific proteins in HCC cell lines and HCC tissues relative to controls. Moreover the studies revealed genes essential for cell cycle control, stress response, apoptosis, lipid metabolism, cell-cell-interaction, DNA repair and cytokine and growth factor production (e.g., Graveel et al, 2001, Oncogene, 20:2704-12; Tackels-Horne et al, 2001, Cancer, 92: 395-405; Xu et al, 2001, Cancer Res., 61:3176-81). However, there is little concordance in the gene expression patterns reported in these studies that may be due to differences in experimental design and/or to the heterogeneity of HCC tissue per se. Moreover, the etiologies of these HCCs are an important factor. Chronic hepatitis B and C virus infections are the major causes of HCC but damage from alcohol and chronic liver metabolic disorders are also recognized to result in HCC and the mechanisms responsible for development of a tumor from these different etiologies are likely to differ. Taken together, until now no satisfactory diagnostics and methods of diagnosing have been developed in order to be able to intervene in liver disorders.

[800]

The same applies to the therapy of liver disorders, and epithelial cancers. For HCC for instance, there is no effective therapeutic option except resection and transplantation but these approaches are only applicable in early stages of HCC, limited by the access to donor livers, and associated with severe risks for the patient. In addition, these approaches are extremely expensive. These cancers respond very poorly to chemotherapeutics, most likely due the normal liver function in detoxification and export of harmful compounds. Several other therapeutic options, such as chemoembolization, cryotherapy and ethanol injection are still in an experimental phase and the efficacy of these is not established. Surgical intervention remains the best treatment option but it is not possible to define with precision the extent of the tumor. This invasive procedure therefore, is suboptimal from the perspective of treatment. Furthermore, the lack of early diagnostics for specific liver dysfunctions leads most often to advanced progression of the disease that further confounds therapeutic options and dramatically increases patient mortality from these diseases (Jansen P.L., 1999, Neth. J. Med., 55:287-292). Thus until now no satisfactory therapies have been developed in order to be able to intervene in liver disorders, and other epithelial cancers. Furthermore, in the state of the art, recognition of the different subtypes of liver disorders such as HCC precursor lesions, benign liver neoplasms, and metabolic

liver diseases such as alcoholic liver disease and cirrhosis, as revealed by differential gene expression, have not been disclosed. A summary of the key disease features of some of the disorders evaluated in the invention is provided in Table 1.

### [009] Table 1: Diseases features

Table 1

DISORDER	Cellular proliferati on	Tissue remodeli ng	Clonal cell expansio n	Neoplasi a	Transformatio n/ Malignant potential
Cirrhosis	+	+			
FNH	+	+	+/-		
Adenoma	+	+	+	+	
нсс	+	+	+	+	+

### **Summary of the Invention**

[010] The invention relates to nucleotides and to corresponding encoded proteins and their use for the diagnosis, prevention and/or treatment of liver disorders, especially of hepatocellular carcinoma (HCC), and epithelial cancers, pre-cancerous liver lesions, benign neoplasms such as adenoma, and other proliferative liver disorders such as focal nodular hyperplasia (FNH) and cirrhosis. The invention also relates to vectors and cells comprising such nucleic acids, and to antibodies or antibody fragments directed against said polypeptides and nucleic acids.

[011] The invention further relates to methods of diagnosing and treating these disorders.

The evaluation of multiple disorders with overlapping but distinct morphological and clinical features provides new information for identification and discrimination and ultimately new therapeutic strategies for these disorders according to invention.

### **Disclosure of Invention**

[012] A unique approach employed in this invention utilizes discrete, pathologist-confirmed liver cancer pathologies for production of disease specific cDNA libraries enriched in genes specifically up- and down-regulated in HCC compared with a pool of non-neoplastic human livers. The library is a genome-wide representation of deregulated gene expression in HCC and therefore includes all potential HCC deregulated genes. Repetitive hybridization to these library clones with labeled expressed nucleic acids from many additional discrete, pathologist-confirmed liver cancer samples (HCCs) and non-malignant liver lesions indicated nucleic acids highly deregulated in HCC. The surprising finding is that this approach provides deregulated

nucleic acids that had not previously been identified as well as many deregulated nucleic acids that were not before associated with HCC, the elevated expression of which can also be associated with other neoplasms. These HCC deregulated genes and proteins are the subject of this invention.

[013] The screening and verification strategy is already inventive *per se* owing to the elaborate and defined choice of parameters. Identification of differentially expressed genes according to the invention relies upon histopathologically distinguished liver disease tissue for comparison of gene expression changes in disorders of the human liver. Non-diseased reference liver samples for the experiments are also diagnostically confirmed.

[014] The object of the invention is a method of diagnosis of a liver disorder, liver cancer and/or epithelial cancer, wherein at least one compound selected from the group consisting of a polypeptide according to the sequence SEQ ID 1 to SEQ ID 93 (Table 2A to 2D), a functional variant thereof, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, an antibody or a fragment of the antibody directed against one of the aforementioned polypeptides, or variants thereof, is identified in the sample of a patient and compared with at least one compound of a reference library or of a reference sample.

[015] Another object of the invention is a method of treating a patient suffering from a liver disorder or an epithelial cancer, wherein at least one compound selected from the group consisting of a polypeptide according to the SEQ ID 1 to SEQ ID 93, a functional variant of one of the aforementioned polypeptides, a nucleic acid encoding one of the aforementioned polypeptides or a functional variant thereof, a variant of one of the aforementioned nucleic acids, a nucleic acid which is a non-functional mutant variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, a cell comprising one of the aforementioned nucleic acids, a cell comprising the aforementioned vector, an antibody or a fragment of one of the aforementioned antibodies directed against one of the aforementioned polypeptides or against a functional variant thereof, a vector comprising a nucleic acid coding for one of the aforementioned antibodies, a vector comprising a nucleic acid coding for one of the aforementioned antibody fragments, a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibodies, and a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibody fragments, is administered to the patient in need of a the treatment in a therapeutically effective amount.

[016] Another aspect of the invention is a pharmaceutical composition comprising at least one compound selected from the group consisting of a polypeptide according to the

invention, a functional variant thereof, a nucleic acid encoding one of the aforementioned polypeptides or a functional variant thereof, a variant of one of the aforementioned nucleic acids, a nucleic acid which is a non-functional mutant variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, a cell comprising one of the aforementioned nucleic acids, a cell comprising the aforementioned vector, an antibody directed against one of the aforementioned polypeptides, an antibody directed against a functional variant of one of the aforementioned polypeptides, a fragment of one of the aforementioned antibodies, a vector comprising a nucleic acid coding for one of the aforementioned antibody fragments, a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibody fragments, a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibodies, and a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibodies, and a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibody fragments and, optionally, suitable additives or auxiliaries.

The accession numbers of the polypeptides according to the invention and their cDNAs are shown in Table 2A to 2D.

[018]

[017]

[019]

[020]

[021]

[022]

[023]

[024]

[025]

[026]

[027]

[028]

[029]

[030]

[031]

[032]

[033]

[034]

[035]

[036]

[037]

[038]

[039] [040] [041] [042] [043] [044]

[045] [046]

Table 2A to 2D: Polypeptides and cDNAs with their respective SEQ ID numbers and accession numbers from the GenBank database.

[048]

[047]

Table 2A

Gene	Polypeptide	Accession	DNA	Accession number
	(SEQ ID)	number	(SEQ ID)	
PI4K2	1	NP-060895	94	NM_018425
ZNF216	2	NP_005998	95	NM_006007
AKR1C1	3	NP_001344	96	NM_001353
dUT	4	NP_001939	97	NM_001948
PACE4	5	NP_002561	98	NM_002570
BIGH3	6	NP_000349	99	NM_000358
PRKAR1A	7	NP_002725	100	NM_002734
s.t. Ocia	8	NP_060300	101	NM_017830
SDCCAG28	9	NP_006636	102	NM_006645
PRDX1	10	NP_002565	103	NM_002574
TMP21	11	NP_006818	104	NM_006827
IQGAP2	12	NP_006624	105	NM_006633
Rab2	13	NP_002856	106	NM_002865
ARFI	14	NP_001649	107	NM_001658
HSPC1	15	NP_005339	108	NM_005348
TLR5	16	NP_003259	109	NM_003268
GAP-SH3	17	NP_005745	110	NM_005754
Crisp-3	18	NP_006052	111	NM_006061
TM4SF4	19	NP_004608	112	NM_004617

AQP9	20	NP_066190	113	NM_020980
LOC51716	21	NP_057364	114	NM_016280
Cystatin	22	NP_000091	115	NM_000100
Ki	23	NP_005780	116	NM_005789

[049] [050]

[051]

Table 2B

Table 2B				
Gene	Polypeptide (SEQ ID)	Accession number	DNA (SEQ ID)	Accession number
Porimin	24	NP_443164	117	NM_052932
PTPRZ1	25	NP_002842	118	NM_002851
Rab9 effector p40	26	NP_005824	119	NM_005833
RBap48	27	NP_005601	120	NM_005610
PABPC1	28	NP_002559	121	NM_002568
NF1/B2	29	NP_005587	122	NM_005596
··· RPL7	30	NP_000962	123	· NM_000971
HNRPDL	31	NP_005454	124	NM_005463
OBCL6	32	novel	125	novel
SNRPG	33	NP_003087	126	NM_003096
KREV-1	34	NP_002875	127	NM_002884
DRB5	35	NP_003833	128	NM_003842
PKCI-1	36	NP_005331	129	NM_005340
IMPACT	37	NP_060909	130	NM_018439
BMI	38	NP_005171	131	NM_005180
G3BP	39	NP_005745	132	NM_005754
RHEB2	40	NP_005605	133	NM_005614
MARCKS	41	NP_002347	134	NM_002356
ALURBP	42	NP_003124	135	NM_003133
PPGB	43	NP_000299	136	NM_000308
GRB2	44	NP_002077	137	NM_002086

TRAPI	45	NP_057376	138	NM_016292
PDHB	46	NP_000916	139	NM_000925
DAD-1	47	NP_001335	140	NM_001344
PSME2	48	NP_002809	141	NM_002818
QP-C	49	NP_006285	142	NM_006294
MTRPS33	50	NP_444263	143	NM_053035

[052]

Table 2C

Gene	Polypeptide	Accession	DNA	
Gene	(SEQ ID)	number	(SEQ ID)	Accession number
ARF4	51	NP_001651	144	NM_001660
DDB1	52	NP_001914	145	NM_001923
GNG10	53	NP_004116	146	NM_004125
DP1	54	NP_002810	147	NM_002819
ATP1B1	55	NP_001668	148	NM_001677
SLC25A3	56	NP_002626	149	NM_002635
SNC6	57	NP_003923	150	NM_003932
OMG	58	NP_002535	151	NM_002544
PB1S	59	NP_002784	152	NM_002793
RPS21	60	NP_001015	153	NM_001024
MMP-2	61	NP_004521	154	NM_004530
YWHAZ	62	NP_663723	155	NM_145690
PPP3R1	63	NP_671709	156	NM_147180
CTNNA1	64	NP_001894	157	NM_001903
ADCYAP1	65	NP_001108	158	NM_001117
syntenin	66	NP_005616	159	NM_005625
topoisomerase IIb	67	NP_001059	160	NM_001068
<b>UMP-CMPK</b>	68	NP_057392	161	NM_016308
PSMD4	69	NP_722544	162	NM_153822
hu_BTF3	70	NP_001198	163	NM_001207
rhoA	71	NP_001655	164	NM_001664

LDH-B	72	NP_002291	165	NM_002300
TBXA2-R	73	NP_001051	166	NM_001060
hu_CAP	74	NP_006357	167	NM_006366
hu_PP2a-cat	75	NP_002706	168	NM_002715
SDHC	76	NP_002992	169	NM_003001

[053]

Table 2D

Gene	Polypeptide (SEQ ID)	Accession number	DNA (SEQ ID)	Accession number
hu_GDP-di2	77	NP_001166	170	NM_001175
CCNI	78	NP_006826	171	NM_006835
Mac25	79	NP_001544	172	NM_001553
ТВР	80	NP_003185	173	NM_003194
FDX1	81	NP_004100	174	NM_004109
NLVCF	82	NP_003767	175	NM_003776
GNG3	83	NP_036334	176	NM_012202
RCN2	84	NP_002893	177	NM_002902
hu_adk2	85	NP_001616	178	NM_001625
hu_Dcsa19	86	NP_009035	179	NM_007104
c/EBP	87	NP_001797	180	NM_001806
Rab GG	88	NP_004573	181	NM_004582
**c-syn-1	89	NP_002028	182	NM_002037
**c-syn-2	90	NP_694592	183	NM_153047
**c-syn-3	91	NP_694593	184	NM_153048
PPP1R15A	92	NP_055145	185	NM_01433
SCL5A6	93	NP_066918	186	NM_021095

[054]

[(\*\*)c-syn represents three alternative nucleotide transcripts with corresponding three protein products]

[055]

[056] A subset of these nucleic acids according to the invention have been shown by RT-PCR analysis to be specifically expressed or deregulated in other cancers of epithelial origin and preferably not in corresponding normal human tissue(s). These nucleic acids

include SEQ ID Nos. 94 to 186 (provided in Table 2A to 2D). Deregulated nucleic acids in liver cancer may preferably be highly relevant to other cancers of the gastrointestinal tract as these tissues share a common embryological origin. Consequently, these nucleic acids and the encoded polypeptides may preferably be similarly utilized for diagnostics methods, pharmaceutical compositions and methods of prevention and/or treatment of these epithelial cancers.

[057]

The polypeptides and nucleic acids according to the invention have in common that they are differentially expressed in a sample isolated from a patient suffering from a disorder according to the invention compared to a reference sample. The regulation of the polypeptides and nucleic acids according to the invention is essential for the pathologic process and which are thus in a direct or indirect relationship with diagnosis, prevention and/or treatment of disorders according to the invention. The polypeptides and the nucleic acids according to the invention do not belong to the targets known until now such that surprising and completely novel approaches for diagnosis and therapy result from this invention.

[058]

Generally, the analysis of differentially expressed genes in tissues is less likely to result in errors in the form of artifactual false-positive clones than the analysis of cell culture systems. In addition to the fact that existing cell culture systems cannot adequately simulate the complexity of pathological processes in the tissue, the variations in cell behavior in the culture environment lead to nucleic acid and polypeptide expression patterns with questionable relation to the actual pathologic state. These problems may be less pronounced by an approach that utilizes gene expression in normal and diseased human tissue but again multiple variables confound clear identification of differential gene expression that is directly relevant to disease. For example, differentially expressed nucleic acids may result from inter-individual differences, metabolic state and/or clinical treatment paradigm. Further, large scale gene expression studies using cDNA microarrays do not indicate the cellular source of variation in gene expression. In addition, a differential gene expression study including all or most genes produces a very large volume of data that confounds identification of key disease-associated gene expression changes. Consequently, an approach that includes large scale profiling of gene expression from tissue from liver disorders that are defined only generally (as for example, "liver tumors") is unlikely to illuminate key genes involved in the disease process and it is these key genes that represent best targets for diagnostics and therapeutic intervention.

[059]

On account of these difficulties, the success of the screening is significantly dependent on the choice of the experimental parameters. While the methods used are based on established procedures, the screening and verification strategy is already inventive *per se* owing to the elaborate and defined choice of parameters. A unique

approach employed in this invention utilizes discrete, pathologist-confirmed liver cancer pathologies for production of disease specific cDNA libraries enriched in nucleic acids specifically up- and down-regulated in HCC compared with a pool of non-neoplastic human livers. Non-diseased reference liver samples for the experiments are also diagnostically confirmed and pooled from 3 independent samples to reduce detection of false positives resulting from inter-individual variations. Nucleic acids commonly expressed at similar levels in the reference liver pool and in diseased liver (i.e., HCC) are removed by the generation of subtractive suppressive hybridization (SSH) cDNA libraries (Diatchenko et al., 1996, Proc. Natl. Acad. Sci. USA, 93:6025-6030). These cDNAs are highly enriched for nucleic acids both up- and down-regulated in HCC but do not represent those that are not differentially expressed. Each of several thousand SSH clones were amplified by the polymerase chain reaction (PCR) and affixed to glass slides in custom cDNA microarrays. RNA from additional pathologist-confirmed liver disorders is converted to fluorescently-labeled cDNA for competitive hybridization with the pooled non-diseased liver RNA on the microarrays. The resulting ratio of hybridization intensity reveals nucleic acids specifically deregulated in liver disorders. In addition to providing a pool of candidate cDNAs highly enriched for differentially expressed genes, the SSH library represents on a genome-wide scale most if not all differentially expressed genes with far fewer clones than in standard cDNA libraries. This feature thereby focuses on nucleic acids specifically deregulated in disease. The SSH libraries generated in this invention include cDNA clones from nucleic acids that are essentially not expressed in normal liver and thereby not represented in conventional cDNA libraries or on genome-scale cDNA microarrays.

[060]

Overexpression of the sequences according to the invention in liver disorder tissue compared to normal liver is confirmed by independent analysis of RNA levels with sequence-specific quantitative RT-PCR (Q-PCR). In these verification experiments, PCR product corresponding to the cellular RNA levels of the sequences according to the invention are monitored by fluorescent detection of the specific PCR product. The fluorescent signal is provided either by a sequence specific hydrolysis probe oligonucleotide (primer) in the TaqMan/Assay-on-Demand procedure (Figure 100 to 103) or by a fluorescent double stranded DNA binding dye such as SYBR green (Figure 104). Levels of PCR products corresponding to the sequences according to the invention are normalized for experimental variability by comparison with the levels of 'housekeeping' genes including \( \mathbb{B} \)-actin, which are considered relatively invariant in disease or following experimental manipulations. The reference gene primers used for TaqMan Q-PCR analyses are GAPDH-p1, (SEQ ID 187); GAPDH-p2, (SEQ ID 188); GAPDH-p3, (SEQ ID 189); \( \mathbb{B} \) Actin-p1, (SEQ ID 190); \( \mathbb{B} \) Actin-p2, (SEQ ID 191); and

ßActin-p3, (SEQ ID 192). The reference gene primers used for SYBR Green analyses are ßActin-p4, (SEQ ID 193); and ßActin-p5, (SEQ ID 194). The determination of RNA levels relative to these housekeeping genes in Q-PCR experiments is performed according to the method of Pffafl (Nucleic Acids Research, 2001, 29(9):e45). These techniques are well known to a person skilled in the art.

- [061] Furthermore, expression of HCC deregulated genes according to this invention correlates with proliferation of hepatoma cells (Hep3B, HepG2) following for example 8 hours and 12 hours serum stimulation of quiescent cells. This finding supports the suggestion that overexpression of the sequences according to the invention is functionally significant for proliferative liver disorders such as liver cancer.
- [062] Compared to the state of the art, these polypeptides and nucleic acids surprisingly allow improved, more sensitive, earlier, faster, and/or non-invasive diagnosis of the liver disorders and/or epithelial cancers. The nucleic acids and polypeptides according to the invention can be utilized for the diagnosis, prevention and treatment of liver disorders, and epithelial cancers.
- [063] The present invention relates to at least one polypeptide comprising a sequence according to one of the SEQ ID 1 to SEQ ID 93, or a functional variant thereof. The invention also relates to a nucleic acid coding for the polypeptide or a functional variant thereof.
- In preferred embodiment the polypeptide consists of the sequence according to the SEQ ID 1. In another preferred embodiment the nucleic acid consists of the sequence according to the SEQ ID 94.
- [065] Compared to the state of the art, these polypeptides and nucleic acids surprisingly allow improved, more sensitive, earlier, faster, and/or non-invasive diagnosis of the liver disorders and/or epithelial cancers.
- In another aspect of the invention the invention relates to the use of at least one polypeptide according to the SEQ ID 1 to SEQ ID 93, a functional variant of the polypeptide, a nucleic acid encoding one of the aforementioned polypeptides, a nucleic acid encoding the functional variant, a variant of one of the aforementioned nucleic acids, a nucleic acid which is a non-functional mutant variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, a cell comprising the aforementioned vector, an antibody directed against one of the aforementioned polypeptides, an antibody directed against a functional variant of one of the aforementioned polypeptides, a fragment of one of the aforementioned antibodies, a vector comprising a nucleic acid coding for one of the aforementioned antibody fragments, a

cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibodies, and/or at least one cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibody fragments, for the diagnosis, prevention and/or treatment of disorders according to the invention. Further embodiments of the invention are described in detail below.

[067] When compared to the state of the art of therapy of liver disorders, and/or epithelial cancers the use of these components surprisingly provide an improved, sustained and/or more effective diagnosis, prevention and/or treatment of disorders according to the invention.

The term "polypeptide" refers to the full length of the polypeptide according to the invention. In a preferred embodiment the term "polypeptide" also includes isolated polypeptides and polypeptides that are prepared by recombinant methods, e.g. by isolation and purification from a sample, by screening a library and by protein synthesis by conventional methods, all of these methods being generally known to the person skilled in the art. Preferably, the entire polypeptide or parts thereof can be synthesized, for example, with the aid of the conventional synthesis such as the Merrifield technique. In another preferred embodiment, parts of the polypeptides according to the invention can be utilized to obtain antisera or specific monoclonal antibodies, which may be used to screen suitable gene libraries prepared to express the encoded protein sequences in order to identify further functional variants of the polypeptides according to the invention.

[069] The term "polypeptide according to the invention" refers to the polypeptides according to the SEQ ID 1 to SEQ ID 93 (Table 2A to 2D).

[070] The term "functional variants" of a polypeptide within the meaning of the present invention refers to polypeptides which have a sequence homology, in particular a sequence identity, of about 70%, preferably about 80%, in particular about 90%, especially about 95%, most preferred of 98 % with the polypeptide having the amino acid sequence according to one of the SEQ ID 1 to SEQ ID 93. Such functional variants are, for example, the polypeptides homologous to a polypeptide according to the invention, which originate from organisms other than human, preferably from non-human mammals such as, for example mouse, rats, monkeys and pigs. Other examples of functional variants are polypeptides that are encoded by different alleles of the gene, in different individuals, in different organs of an organism or in different developmental phases.

[071] Functional variants, for example, also include polypeptides that are encoded by a nucleic acid which is isolated from non-liver-tissue, e.g. embryonic tissue, but after expression in a cell involved in liver disorders have the designated functions.

Functional variants preferably also include naturally occurring or synthetic mutations,

[074]

particularly mutations that quantitatively alter the activity of the peptides encoded by these sequences. Further, such variants may preferably arise from differential splicing of the encoding gene.

[072] "Functional variants" refer to polypeptides that have essentially the same biological funtion(s) as the corresponding polypeptide according to the invention. Such biological function can be assayed in a functional assay.

In order to test whether a candidate polypeptide is a functional variant of a polypeptide according the invention, the candidate polypeptide can be analyzed in a functional assay generally known to the person skilled in the art, which assay is suitable to assay the biological function of the corresponding polypeptide according to the invention. Such functional assay comprise for example cell culture systems; enzymatic assays, the generation of mice in which the genes are deleted ("knocked out") or mice that are transgenic for gene encoding the candidate polypeptide, etc. If the candidate polypeptide demonstrates or directly interferes with essentially the same biological function as the corresponding polypeptide according to the invention, the candidate polypeptide is a functional variant of the corresponding polypeptide, provided that the candidate polypeptide fulfills the requirements on the level of % sequence identity mentioned above.

Furthermore, the term "functional variant" encompasses polypeptides that are preferably differentially expressed in patients suffering from liver disorders, or other epithelial cancers relative to a reference sample or a reference library, including polypeptides expressed from mutated genes or from genes differentially spliced, provided that the candidate functional variant polypeptide fulfills the criteria of a functional variant on the level of % sequence identity. Such expression analysis can be carried out by methods generally known to the person skilled in the art.

[075] "Functional variants" of the polypeptide can also be parts of the polypeptide according to the invention with a length of at least from about 7 to about 1000 amino acids, preferably of at least 10 amino acids, more preferably at least 20, most preferred at least 50, for example at least 100, for example at least 200, for example at least 300, for example at least 400, for example at least 500 amino acids provided that they have essentially the same biological function(s) as the corresponding polypeptide according to the invention. Functional variants, such as in fusion proteins, may contain either on one or both ends additional aminoacid stretch(es), preferably 1 to 50 amino acids, more preferably 20 amino acids. Also included are deletions of the polypeptides according to the invention, in the range from about 1-30, preferably from about 1-15, in particular from about 1-5 amino acids provided that they have essentially the same biological function(s) as the corresponding polypeptide according to the invention. For example, the first amino acid

methionine can be absent without the function of the polypeptide being significantly altered. Also, post-translational modifications, for example lipid anchors or phosphoryl groups may be present or absent in variants.

"Sequence identity" refers to the degree of identity (% identity) of two sequences, that in the case of polypeptides can be determined by means of for example BLASTP 2.0.1 and in the case of nucleic acids by means of for example BLASTN 2.014, wherein the Filter is set off and BLOSUM is 62 (Altschul et al., 1997, Nucleic Acids Res., 25:3389-3402).

"Sequence homology" refers to the similarity (% positives) of two polypeptide sequences determined by means of for example BLASTP 2.0.1 wherein the Filter is set off and BLOSUM is 62 (Altschul et al., 1997, Nucleic Acids Res., 25:3389-3402).

[078] The term "liver disorder" refers to and comprises all kinds of disorders that preferably affect the anatomy, physiology, metabolic, and/or genetic activities of the liver, that preferably affect the generation of new liver cells, and/or the regeneration of the liver, as a whole or parts thereof preferably transiently, temporarily, chronically or permanently in a pathological way. Preferably also included are inherited liver disorders and neoplastic liver disorders. Liver disorder is further understood to preferably comprise liver disorders caused by trauma, intoxication, in particular by alcohol, drugs or food intoxication, radiation, infection, cholestasis, immune reactions. and by inherited metabolic liver diseases. Preferred examples of liver disorders include cirrhosis, alcoholic liver disease, chronic hepatitis, Wilson's Disease, and haemochromatosis. Preferably further included are autoimmune-disorders wherein the autoimmune response is directed against at least one polypeptide according to the invention. Within the meaning of the present invention the term "liver disorder" preferably also encompasses liver cancer, for example hepatocellular carcinoma (HCC), benign liver neoplasms such as adenoma and/or FNH. Preferably HCC further comprises subtypes of the mentioned disorders, preferably including liver cancers characterized by intracellular proteinaceous inclusion bodies, HCCs characterized by hepatocyte steatosis, and fibrolamellar HCC. For example, precancerous lesions are preferably also included such as those characterized by increased hepatocyte cell size (the "large cell" change), and those characterized by decreased hepatocyte cell size (the "small cell" change) as well as macro regenerative (hyperplastic) nodules (Anthony, P. in MacSween et al, eds. Pathology of the Liver, 2001, Churchill Livingstone. Edinburgh).

[079] The term "epithelial cancer" within the meaning of the invention includes adenocarcinomas of any organ other than the liver, preferably of the lung, stomach, kidney, colon, prostate, skin and breast, and refers to disorders of these organs in which epithelial cell components of the tissue are transformed resulting in a malignant tumor identified according to the standard diagnostic procedures as generally known to a person skilled in the art.

[080] Within the meaning of the invention the term "disorder according to the invention" encompasses epithelial cancer and liver disorders as defined above.

In the case of polypeptides, the term "differential expression of a polypeptide" refers to the relative level of expression of the polypeptide in an isolated sample from a patient compared to the expression of the polypeptide in a reference sample or a reference library. The expression can be determined by methods generally known to the person skilled in the art. Examples of such methods include immunohistochemical or immunoblot or ELISA detection of the polypeptide with antibodies specific for the polypeptide. Detection of the polypeptide through genetic manipulation to label the polypeptide and detection in a model system is preferably also included such as by tagging the polypeptide in a transgene for expression in a model system.

[082] The term "sample" refers to a biomaterial comprising liver tissue or liver cells, also tissue from another organ subject to malignant transformation or a cell from this organ, blood, serum, plasma, ascitic fluid, pleural effusions, cerebral spinal fluid, saliva, urine, semen or feces.

The sample can be isolated from a patient or another subject by means of methods including invasive or non-invasive methods. Invasive methods are generally known to the skilled artisan and comprise for example isolation of the sample by means of puncturing, surgical removal of the sample from the opened body or by means of endoscopic instruments. Minimally invasive and non-invasive methods are also known to the person skilled in the art and include for example, collecting body fluids such as blood, serum, plasma, ascitic, pleural and cerebral spinal fluid, saliva, urine, semen, and feces. Preferably the non-invasive methods do not require penetrating or opening the body of a patient or subject through openings other than the body openings naturally present such as the mouth, ear, nose, rectum, urethra, and open wounds.

[084] The term "minimally invasive" procedure refers to methods generally known, especially by persons skilled in the art, for obtaining patient sample material that do preferably not require anesthesia, can be routinely accomplished in a physician office or clinic and are either not painful or only nominally painful. The most common example of a minimally invasive procedure is venupuncture.

[085] The term "reference sample" refers to a sample that serves as an appropriate control to evaluate the differential expression of a nucleic acid and/or a polypeptide according to the invention in a given sample isolated from a patient; the choice of such appropriate reference sample is generally known to the person skilled in the art.

Examples of reference samples include samples isolated from a non-diseased organ or tissue or cell(s) of the same patient or from another subject, wherein the non-diseased

organ or tissue or cell(s) is selected from the group consisting of liver tissue or liver cells, blood, or the samples described above. For comparison to expression in the sample isolated from a patient with the liver disorder, the reference sample may also include a sample isolated from a non-diseased organ or tissue or cell(s) of a different patient, wherein the liver disordered-tissue or cell(s) is selected from the sample group listed above. Moreover the reference may include samples from healthy donors, preferably matched to the age and sex of the patient.

[086]

The term "reference library" refers to a library of clones representing expressed genes, which library is preferably prepared from non-diseased liver tissue or cells. The reference library may also derive from mRNA from non-diseased liver tissue or cells and may also comprise a data base comprising data on non-diseased tissue expression of nucleic acids. For comparison of the expression of the nucleic acids or polypeptides according to the invention in a sample isolated from a patient with the disordered liver, the reference library may comprise an expression library prepared from liver disorder-diseased liver tissue or cells and a data base comprising data on liver disorder-specific expression of nucleic acids.

[087]

The term "patient" within the meaning of the invention includes animals, preferably mammals, and humans, dead or alive. The patient is either suffering from a liver disorder, and/or other epithelial cancer, subject to analysis, preventive measures, therapy and/or diagnosis in the context of liver disorder and/or other epithelial cancer.

~. [088]

The term "subject" within the meaning of the invention includes animals, preferably mammals, and humans, dead or alive that is not suffering from a liver disorders and/or other epithelial cancer and thus represent a preferred appropriate control for the determination of differential expression of nucleic acids and/or polypeptides according to the invention in a patient.

[089]

The term "effective treatment" within the meaning of the invention refers to a treatment that preferably cures the patient from at least one disorder according to the invention and/or that improves the pathological condition of the patient with respect to at least one symptom associated with the disorder, preferably 3 symptoms, more preferably 5 symptoms, most preferably 10 symptoms associated with the disorder; preferably on a transient, short-term (in the order of hours to days), long-term (in the order of weeks, months or years) or permanent basis, wherein the improvement of the pathological condition may be preferably constant, increasing, decreasing, continuously changing or oscillatory in magnitude as long as the overall effect is a significant improvement of the symptoms compared with a control patient. Therapeutic efficacy and toxicity, e.g. ED<sub>50</sub> and LD<sub>50</sub> may be determined by standard pharmacological procedures in cell cultures or experimental animals. The dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio

LD<sub>50</sub>/ED<sub>50</sub>. Pharmaceutical compositions that exhibit large therapeutic indexes are preferred. The dose must be adjusted to the age, weight and condition of the individual patient to be treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.

- [090] The actual dosage depends on the nature and severity of the disorder being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated, that pharmaceutical compositions comprising of from about 0.1 to 500 mg of the active ingredient per individual dose, preferably of from about 1 to 100 mg, most preferred from about 1 to 10 mg, are suitable for therapeutic treatments.
- [091] The active ingredient may be administered in one or several dosages per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 mg/kg intravenously (i.v.) and 1 mg perorally (p.o.). Preferred ranges are from 0.1 mg/kg/day to about 10 mg/kg/day i.v. and from 1 mg/kg/day to about 100 mg/kg/day p.o.
- [092] In another aspect the invention relates to a fusion protein comprising a polypeptide according to the SEQ ID 1 to 93, or a functional variant thereof.
- A "fusion protein" refers to a polypeptide comprising at least one polypeptide according to the SEQ ID 1 to SEQ ID 93, a functional variant or part thereof and at least one component A selected from polypeptide, peptide and/or peptide analogue that is linked to the polypeptide according to the invention by means of covalent or non-covalent binding such as e.g. hydrogen bonds, generally known to the person skilled in the art. Preferred examples of component A for fusion proteins are polypeptide, peptide and/or peptide analogues that facilitate easier detection of the fusion proteins; these are, for example, "green-fluorescent-protein", or variants thereof. Also included are fusion proteins that facilitate purification of the recombinant protein such as "Histags", or fusions that increase the immunogenicity of the protein.
- [094] Fusion proteins according to the invention can be produced by methods generally known to the person skilled in the art. The fusion proteins according to the invention can be used for the diagnosis, prevention and or treatment of liver disorders and/or epithelial cancer.
- [095] Compared to the state of the art, these fusion proteins surprisingly allow improved, more sensitive, earlier, faster, and/or non-invasive diagnosis and/or improved, sustained and/or more effective treatment of the liver disorders and/or epithelial cancers.
- [096] Preferred nucleic acids according to the invention comprise a sequence according to one of SEQ ID 94 to SEQ ID 186, or a variant thereof. In particular the invention

relates to nucleic acids according to the invention that have been isolated.

- [097] Compared to the state of the art, these nucleic acids and polypeptides surprisingly allow improved, more sensitive, earlier, faster, and/or non-invasive diagnosis and/or improved, sustained and/or more effective treatment of the liver disorders and/or epithelial cancers.
- [098] The term "nucleic acid according to the invention" refers to the nucleic acids corresponding to the SEQ ID 94 to SEQ ID 186 and/or variants thereof.
- [099] The term "encoding nucleic acid" relates to a DNA sequence that codes for an isolatable bioactive polypeptide according to the invention or a precursor thereof. The polypeptide can be encoded by a sequence of full length or any part of the coding sequence as long as the biological function, such as for example receptor-activity, is essentially retained (cf. definition of functional variant).
- It is known that small alterations in the sequence of the nucleic acids described above can be present, for example, due to the degeneration of the genetic code, or that untranslated sequences can be attached to the 5' and/or 3' end of the nucleic acid without significantly affecting the activity of the encoded polypeptide. This invention, therefore, also comprises so-called naturally occurring and artificially generated "variants" of the nucleic acids described above.
- [101] Preferably, the nucleic acids used according to the invention are DNA or RNA, preferably a DNA, in particular a double-stranded DNA. In particular the nucleic acid according to the invention may be an RNA molecule, preferably single-stranded or a double-stranded RNA molecule. The sequence of the nucleic acids may further comprise at least one intron and/or one polyA sequence.
- [102] Nucleic acids according to the invention can be produced by methods generally known to the skilled artisan and have also been described in detail below.
- "Variant" within the meaning of the invention refers to all DNA sequences that are complementary to a DNA sequence, which hybridize with the reference sequence under stringent conditions and have a similar activity to the corresponding nucleic acid according to the invention. The nucleic acids according to the invention can also be used in the form of their antisense sequence.
- "Variant" of the nucleic acids can also be homologues from other species with sequence identity preferably 80%, in particular 90%, most preferred 95%.
- [105] "Variant" of the nucleic acids can also be parts of the nucleic acid according to the present invention with at least about 8 nucleotides length, preferably with at least about 16 nucleotides length, in particular with at least about 21 nucleotides length, more preferably with at least about 30 nucleotides length, even more preferably with at least about 40 nucleotides length, most preferably with at least about 50 nucleotides length as long as the parts have a similar activity to the corresponding polypeptide according

[107]

to the invention. Such a functional activity of an expressed polypeptide encoded by such a nucleic acid can be assayed using the functional assays described further above.

[106] In a preferred embodiment of the invention the nucleic acid comprises a nucleic acid having a sequence complementary to a nucleic acid according to the invention, or a variant thereof. Preferably the nucleic acid comprises a non-functional mutant variant of the nucleic acid according to the invention, or a variant thereof.

In particular the invention relates to a nucleic acid having a complementary sequence wherein the nucleic acid is an antisense molecule or an RNA interference molecule.

The term "non-functional mutant variant of a nucleic acid" refers to a nucleic acid derived from a nucleic acid according to the invention, or a variant thereof having been mutated such that the polypeptide encoded by the non-functional mutant variant of the nucleic acid exhibits a biological activity which in comparison the non-mutated polypeptide is significantly decreased or abolished. Such activity of the polypeptide encoded by the non-functional mutant variant nucleic acid can be determined by means of a functional assay as described above for the evaluation of functional variants. The construction and screening of such non-functional mutant variant derived from a nucleic acid according to the invention are generally known to the person skilled in the art. Such "non-functional mutant variant of a nucleic acid" according to the invention can be expressed in a patient and will preferably abolish or diminish the level of expression of the targeted nucleic acid by competing with the native mRNA molecules for translation into polypeptides by the ribosomes.

[109] "Stringent hybridization conditions" refer to those conditions in which hybridization takes place at 60°C in 2.5 xSSC buffer and remains stable following a number of washing steps at 37°C in a buffer of lower salt concentration.

The term "differential expression of a nucleic acid" refers to the relative level of expression of the nucleic acid in an isolated sample from a patient compared to the expression of the nucleic acid in a reference sample or a reference library. Definitions of reference samples and reference libraries have been described in detail above. The expression can be determined by methods generally known to the person skilled in the art. Examples of such methods include RNA blot (northern) analysis, nuclease protection, in situ hybridization, reverse transcriptase PCR (RT-PCR; including quantitative kinetic RT-PCR). cDNA and oligonucleotide microarrays are also included as such methods.

[111]

Preferred embodiment of the invention relates to the HCC up-regulated phosphatidylinositol 4-kinase type II (PI4K2) polypeptide (Accession. No. NP\_060895, SEQ ID 1) and to the nucleic acid PI4K2 (Accession. No. NM\_018425, SEQ ID 94)

coding for the polypeptide. The prevalent phosphatidylinositol (PtdIns) phosphate kinase activity in many mammalian cell types is conferred by the widespread type 2 kinase (PI4K2). The human type 2 isoform has been partially purified from plasma membrane rafts of human A431 epidermoid carcinoma cells. (Minogue S. et al., 2001. J Biol Chem., 18; 276(20):16635-40. Epub 2001 Feb 13). The predicted amino acid sequence revealed two isoforms: 2alpha and 2beta. The type 2alpha mRNA appears to be expressed ubiquitously in human tissues, and homologues appear to be expressed in all eukaryotes, but the gene encoding this PtdIns family member, however, has not previously been reported to be expressed at elevated levels in disorders according to the invention, in particular in HCC.

- [113] Expression of this mRNA is elevated on average almost 2-fold relative to non-diseased liver in 46% of the HCC cases profiled (see Figure 1, Table 3A). Elevated expression of the encoding mRNA is also evident in FNH (to even a higher extent than in HCC; Figure 9/Table 4A), but not in cirrhotic livers subjected to this cDNA microarray expression profiling procedure (Figure 9 and Table 3A). For this and the other nucleic acids according to the invention, this value for expression includes the expression value ratio data from all of the (28) HCC samples subjected to the cDNA microarray expression profiling experiments, including the values from samples that are not elevated by 2-fold or greater.
- These results should confirm that the differential upregulated expression of the PI4K2 cDNA sequence is highly specific for disorders according to the invention.

  Therefore the PI4K2 polypeptide and/or the encoding nucleic acid can be utilized for the diagnosis, prevention and treatment of disorders according to the invention
- [115] In another preferred embodiment the nucleic according to the invention is the Zinc finger protein 216, ZNF216 cDNA (SEQ ID 95) which includes the open reading frame encoding ZNF216 polypeptide (SEQ ID 2). The ZNF216 polypeptide (GenBank sequence NP\_005998) is another embodiment of the invention. The ZNF216 gene is identical to the already reported cochlear-expressed gene (Scott DA. et al., 1998, Gene, 215(2): 461-469) that maps to the DFNB7/11 interval for autosomal recessive nonsyndromic hearing loss (ARNSHL) located on human chromosome 9q13-q21. Although ZNF216 gene is highly conserved between human and mouse, containing two regions that show homology to the putative zinc finger domains of other proteins, the polypeptide sequence has unknown function. Based on homology to bovine cDNA tag A2, ZNF216 may play a role in development of vessel endothelium from precursor cells suggesting a potential regulatory role in neovascularization. In this line it was recently suggested that ZNF216 and its A20-like zinc finger domain (ZnF-A20) have redundant and distinct role in regulating NF-kappaB activation and apoptosis (Huang J. published online ahead of print January 30, 2004, J. Biol. Chem,

10.1074/jbc.M309491200). The gene encoding this zinc finger family member, however, has not previously been reported to be expressed at elevated levels in disorders according to the invention, in particular in HCC.

- The expression in HCC of RNA corresponding to assembled sequence SEQ ID 95 is confirmed experimentally. The initial sequence upregulated in HCC relative to non-diseased liver identified as an SSH cDNA clone corresponds to GenBank sequence NM\_006007. The expression of sequences of this clone has not previously been reported in liver or in HCC.
- In a preferred embodiment the polypeptide according to the invention is the ZNF216 polypeptide (SEQ ID 2) which is surprisingly identified from an mRNA identified to be upregulated in HCC by an average of 16-fold relative to non-diseased liver (Figure 1) in 54% of the profiled cases (Table 3A). Similarly, elevated expression of the encoding mRNA relative to non-diseased liver is also evident in FNH but not in cirrhotic livers (see Figure 10, Tables 4A/5A).
- cDNA sequences encoding this polypeptide and overlapping with this mRNA might be identified with reverse transcriptase PCR analysis and these nucleic acids can be similarly elevated in HCC. Furthermore, high expression specificity of the ZNF216 cDNA can be confirmed by quantitative assessment (Q-PCR) in HCC, FNH and Cirrhosis in comparison to expression pattern in normal tissue(s). The TaqMan procedure utilizing the parallel examination of both GAPDH and \$\mathbb{B}\$-actin as reference genes should verify a large over expression of ZNF216 cDNA (SEQ ID 95) in HCC when compared to FNH and Cirrhosis. For TaqMan analyses ZNF 216 expression might be determined with gene specific oligonucleotide primers including ZNF216-p1, 5'-gagaggacaaaataactaccc-3', SEQ ID 195 (from nucleotide 611- 631 of SEQ ID 95 forward strand), ZNF216-p2, 5'-caattcaggagctttttcttca-3', SEQ ID 196 (from nucleotide 726-705 of SEQ ID 95 reverse strand) and the "hydrolysis" probe ZNF216-pr, 5'-tactgggctgagaaactgatggactgggctga-3' SEQ ID 198 (from nucleotide 694-663 of SEQ ID 95 reverse strand).
- [119] Furthermore, the expression of this HCC-deregulated gene correlates with proliferation of hepatoma cells, showing 2-fold and 3-fold increase of ZNF216 mRNA in Hep3B cell line upon 8 hours and 12 hours serum stimulation of quiescent cells, respectively (see Figure 106).
- [120] These results demonstrate that ZNF216 polypeptide (SEQ ID 2) and the nucleic acid encoding the polypeptide (SEQ ID 95) can be employed in the prevention and therapy of disorders according to the invention, in particular for the treatment of hyperplastic (including neoplastic) liver diseases. With regard to the treatment it is preferred to carry out the treatment such that the expression of the ZNF216 polypeptide or of the nucleic acid encoding the polypeptide is reduced and/or inhibited,

for example by administering antisense oligonucleotides or RNA interference molecules that specifically interact with the nucleic acid encoding the ZNF216 polypeptide. Alternatively the treatment may be carried out such that the activity of the ZNF216 polypeptide is reduced and/or inhibited, for example by administering an antibody directed against the ZNF216 polypeptide or an antibody fragment thereof which block the activity of the ZNF216 polypeptide to a patient in need of such treatment. Compared to the state of the art, this ZNF216 polypeptide and/or ZNF216 nucleic acid surprisingly allow improved, more sensitive, earlier, faster, and/or non-invasive diagnosis and/or improved, sustained and/or more effective.

- [121] In another preferred embodiment the nucleic acid according to the invention is the AKR1C1 nucleic acid (SEQ ID 96) that represents the sequence of an HCC deregulated cDNA clone. This gene encodes the Aldo-keto reductase family 1 member C1 sharing high sequence identity with three other gene members and is localized at chromosome 10p15-p14 (Stolz, A. et al, 1993, J. Biol. Chem., 268: 10448-10457). These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity and may assist in the rapid intracellular transport of bile acids from the sinusoidal to the canalicular pole of the cell, and thereby having a role in monitoring the intrahepatic bile acid concentration. The AKR1C1 regulates progesterone action by converting the hormone into its inactive metabolite 20 alpha-hydroxyprogesterone, and toxicologically this enzyme activates polycyclic aromatic hydrocarbon trans-dihydrodiols to redox-cycling o-quinones. However, the significance of its potent induction by Michael acceptors and oxidative stress is unknown (Burczynski ME. et al., J Biol Chem., 2001, 276(4): 2890-2897). Expression of sequences corresponding to this clone has been already reported in several tissues (including liver) and some tumors (including prostate, breast; e.g., Wiebe JP and Lewis MJ., 2003, BMC Cancer, 3(1): 9) but the sequence has not previously been described to be upregulated in HCC.
- In liver samples from HCC patients expression of the mRNA encoding this polypeptide is surprisingly elevated relative to non-diseased liver by an average value of 7-fold in 79% cases profiled (Figure 1, Table 3A). Elevated expression of the encoding mRNA relative to non-diseased liver is also evident in FNH but not in cirrhotic livers (Figure 11, Table 4A/5A).
- Independent RT-PCR analysis of expression levels of AKR1C1 mRNA in HCC relative to normal liver are determined with gene specific oligonucleotide primers including: AKR1C1-p1, 5'- ttggaaaggtcactgaaaaatct-3' (SEQ ID 199) and AKR1C1-p2, 5'-gctggctgcggttgaagttgg-3' (SEQ ID 200) verifying the specific expression of this gene (SEQ ID 96) in HCCs when compared to normal liver samples (Figure 104).

- Furthermore, the expression of this HCC-deregulated mRNA is showing 2-fold and 5-fold increase by serum stimulation of quiescent hepatoma cells (HepG2) upon 8 hours and 12 hours, respectively (Figure 107).
- [125] The target gene encoded polypeptide enzymatic activity clearly shows the correlation between the upregulation of AKR1C1 gene transcript in HCC with the approximately 2-fold induction of the AKR1C1 enzymatic activity suggesting that elevated expression of this sequence is correlated with human liver tumor cell proliferation (Table 9).
- [126] In yet another preferred embodiment the nucleic acid according to the invention is the dUTP pyrophosphatase, dUT nucleic acid (SEO ID 97) which has been disclosed before (Accession. No NM\_001948) encoding the dUT polypeptide (Accession. No NP\_001939, SEQ ID 4). dUTP pyrophosphatase involved in nucleotide metabolism produces dUMP (through hydrolysis of dUTP), the immediate precursor of thymidine nucleotides and decreases the intracellular concentration of dUTP so that uracil cannot be incorporated into DNA (McIntosh E.M.et al., 1992; PNAS, 89: 8020-8024). Nuclear DUT-DUT-N (18 kDa) and mitochondrial DUT-M (23 kDa) isoforms of the protein have been identified in humans and arise from the same gene by the alternative use of 5' exons. DUT-N protein and mRNA levels are tightly regulated to coincide with DNA replication. DUT-N is phosphorylated by cyclin-dependent kinases (Ladner R.D., 1996, J. Biol. Chem., 271: 7745-7751). Recently, it has been shown that these isoforms are aberrantly expressed in some cancers (Pugacheva E.N. et al., 2002, Oncogene, 21(30): 4595-4600) but the geneencoding these isoforms has not previously been reported to be expressed at elevated levels in HCC.
- [127] Expression of the mRNA encoding the dUT polypeptide is induced by an average of 7-fold relative to non-diseased liver in 47% of the HCC cases profiled (Figure 1, Table 3A). Similarly, elevated expression of the encoding mRNA is also evident in FNH by an average 10.6-fold induction relative to non-diseased liver in 40% of the FNH cases profiled but not in the cirrhotic livers (Figure 12, Tables 4A/5A).
- Independent RT-PCR analyses of expression levels of dUT mRNA might be determined with gene specific oligonucleotide primers including primers for TaqMan analysis, for example: dUT-p1: 5'-ccgcgggctacgacctg-3', SEQ ID 201 (from nucleotide 153-169 of the SEQ ID 97 forward strand), dUT-p2, 5'-agccactcttccataacacc-3', SEQ ID 202 (from nucleotide 268-249 of the SEQ ID 97 reverse strand) and fluorescently-labeled probe dUT-pr, 5'-tgtccgttttcacaacagctttctccataggt-3', SEQ ID 203 (spanning bases from 227-197 of the SEQ ID 97 reverse strand).
- [129] Furthermore, a specific high-affinity inhibitor blocks proliferation of hepatoma cells (Hep3B/HepG2); the specific small molecule inhibitor (DMT-dU (5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyuridine; Sigma; No. D7279) (Persson, T. et al.,

1996, Bioorg. Med. Chem., 4: 553-556) stimulates a cytostatic and anti-proliferative response (Figures 108 to 109) in these cells.

- [130] These results should confirm that the differential upregulated expression of the dUT cDNA sequence is highly specific for disorders according to the invention. Therefore the dUT polypeptide and/or the encoding nucleic acid can be utilized for the diagnosis, prevention and treatment of disorders according to the invention.
- Another preferred embodiment of the invention relates to the HCC up-regulated Paired basic amino acid cleaving enzyme 4, PACE4 polypeptide (Accession. No. NP\_002561, SEQ ID 5) and to the nucleic acid PACE4 (Accession. No. NM\_002570, SEQ ID 98) coding for the polypeptide. The protein encoded by this gene belongs to the subtilisin/kexin-like proprotein convertase family while representing a calcium-dependent serine endoprotease that can efficiently cleave precursor proteins at their paired basic amino acid processing sites [consensus site: RX(K/R)R]. Expression of this gene has been already reported in several tissues (including liver) and suggested to play a role in tumor progression (in colon cancer, e.g. Khatib AM. et al., J Biol Chem., 2001, 276(33):30686-30693), but the sequence has not previously been described to be upregulated in HCC.
- [132] Expression of this mRNA is elevated on average by 24-fold relative to non-diseased liver in 57% of the HCC cases profiled (see Figure 1, Table 3A). Elevated expression of the encoding mRNA is also evident in FNH (to a lesser extent than in HCC; Figure 13/Table 4A), but not in cirrhotic livers subjected to this cDNA microarray expression profiling procedure (Figure 13 and Table 5A).
- [133] Taqman RT-PCR analyses of expression levels of PACE4 mRNA (Assay ID Catalogue Number: Hs00159844\_m1, Applied Biosystems, USA, see Table 6) verify and confirm the specific elevation of the PACE4 cDNA (Figure 3A) showing upregulation in 7/17 HCCs, 3/3 FNHs, in 3/3 Cirrhosis and in 0/3 non-neoplastic livers (NNL).
- Furthermore, the expression of this HCC-deregulated mRNA is showing 2.4-fold and 6.7-fold increase by serum stimulation of quiescent hepatoma cells (HepG2) upon 8 hours and 12 hours, respectively (Figure 107).
- [135] These findings suggest a functionally significant role for PACE4 in disorders according to the invention, especially in HCC. Therefore the PACE4 polypeptide and/ or the encoding nucleic acid can be utilized for the diagnosis, prevention and treatment of disorders according to the invention.
- In another preferred embodiment invention relates to the HCC up-regulated
  Transforming growth factor Beta-induced I, BIGH3 polypeptide (Accession number
  NP\_000349; SEQ ID 6) and to the nucleic acid BIGH3 (Accession number
  NM\_000358; SEQ ID 99) coding for the polypeptide. cDNA corresponding to this

mRNA has been identified in cDNA libraries expressed in many tissues but at low levels; and highly expressed in the corneal epithelium. This gene known to be induced by TGF-beta binds specifically to collagens and may regulate cell adhesion (Skonier J. et al., 1994, DNA Cell Biol., 6: 571-584). BIGH3 gene has been shown to be up-regulated in oesophageal adenocarcinoma tissue (Hourihan RN. et al., 2003, Anticancer Res., 23(1A):161-5), but the sequence has not previously been reported to be up-regulated in disorders according to the invention, in particular in HCC.

- [137] Expression of this mRNA is elevated on average by 5-fold relative to non-diseased liver in 79% of the HCC cases profiled (see Figure 1 and Table 3A). Similar analysis reveals elevated expression of this mRNA in 80% of the FNH cases profiled (Figure 14/Table 4A).
- [138] The HCC induction of the BIGH3 gene is then verified by amplification of the sequence from the cDNA with primer pairs specific to BIGH3 nucleic acid (Assay ID Catalogue Number: Hs00154671\_m1) in the Assay-On-Demand (Applied Biosystems, USA) quantitative PCR method and also confirming that the BIGH3 mRNA is not deregulated in cirrhosis (Figure 100).
- [139] These findings suggest that the BIGH3 polypeptide and/or a functional variant thereof and/or the encoding nucleic acid and/or a variant thereof can be utilized for the diagnosis, prevention and treatment of disorders according to the invention (in particular for the diagnosis of in HCC and FNH).
- In another preferred embodiment the polypeptide according to the invention is the PRKAR1A polypeptide (Accession number NP\_002725; SEQ ID 7) which is surprisingly identified from an mRNA identified to be upregulated in HCC (Accession number NM\_002734; SEQ ID 100). PRKAR1A, a critical component of the cAMP signaling pathway represents a type I regulatory alpha subunit of cAMP-dependent protein kinase, suggested as a dominant negative regulator of transcription in somatic cell hybrids (Sandberg, M. et al., 1987, Biochem. Biophys. Res. Commun., 149:939-945). The inactive form of the enzyme is composed of two regulatory chains and two catalytic chains. Activation by cAMP produces two active catalytic monomers and a regulatory dimer that binds four cAMP molecules (Jones, K.W. et al., 1991, Cell, 66:861-872). Structural information of the protein is not yet obtained. PRKAR1A is likely to be expressed in many tissues. However, the sequence has not previously been reported to be up-regulated in disorders according to the invention, in particular in HCC.
- The mRNA encoding this polypeptide is elevated an average of 3-fold relative to non-diseased liver in 39% HCCs profiled (see Figure 1 and Table 3A) and similarly in FNH, but not in cirrhotic livers (Figure 15 and Tables 4A/5A).
- [142] Independent verification analyses of expression levels of PRKAR1A mRNA might

be determined with gene specific oligonucleotide primers including, for example primer pairs specific to PRKAR1A nucleic acid (Assay ID Catalogue Number: Hs0000267597\_m1) in the Assay-On-Demand (Applied Biosystems, USA) quantitative PCR method.

- [143] These results suggest that the strongly upregulated expression of the PRKAR1A cDNA sequence is highly specific for disorders according to the invention, especially in HCC and FNH. Therefore the PRKAR1A polypeptide and/or the encoding nucleic acid can be utilized for the diagnosis, prevention and treatment of disorders according to the invention.
- In a further preferred embodiment the invention relates to the s.t. Ocia nucleic acid (Accession number NM\_017830; SEQ ID 101) coding for the Ovarian carcinoma immunoreactive antigen, s.t. Ocia polypeptide (Accession number NP\_060300; SEQ ID 8) which may be expressed at low levels in many tissues and known to be elevated in ovarian cancer (Luo LY. et al., 2001, Biochem Biophys Res Commun., 12; 280(1): 401-406). The gene encoding this putative tumor antigen, however, has not previously been described in liver cancer and not being reported to be expressed at elevated levels in disorders according to the invention, in particular in HCC.
- The mRNA encoding this polypeptide is elevated an average of 2.4-fold relative to non-diseased liver (NL) in 32% HCCs profiled (Figure 1 and Table 3A).mRNA levels are marginally elevated in FNH relative to non-diseased liver(Figure 16 and Table 4A). This mRNA is otherwise detected only infrequently in normal and cirrhotic livers subjected here to expression profiling.
- Independent RT-PCR analyses of expression levels of s.t.Ocia mRNA are determined with gene specific oligonucleotide primers (Assay ID Catalogue Number: Hs00215197\_m1, Applied Biosystems, USA) in the Assay-On-Demand quantitative PCR method confirming that the s.t.Ocia mRNA is not deregulated in cirrhosis (Figure 101/ Table 6).
- These results suggest that the upregulated expression of the s.t.Ocia cDNA sequence is highly specific for disorders according to the invention, especially HCC. Therefore the s.t.Ocia polypeptide and/or the encoding nucleic acid can be utilized for the diagnosis, prevention and treatment of disorders according to the invention, in particular for the diagnosis of HCC and FNH.
- In yet another preferred embodiment the invention relates to the serologically defined colon cancer antigen 28, SDCCAG28 nucleic acid (Accession number NM\_006645; SEQ ID 102). The cDNA clones corresponding to the SDCCAG28 mRNA have been identified in many tissues including colon and other cancers (Scanlan, M.J. et al., 1998, Int. J. Cancer, 76:652-658), but neither this mRNA nor the encoded polypeptide have been previously implicated in disorders according to the

invention, in particular in liver disorders or in HCC. The invention further relates to the polypeptide encoding for the SDCCAG28, a predicted polypeptide of 40.5 kDa (SDCCAG28, SEQ ID 9; NP\_006636 in the GenBank database). The presence of this polypeptide has not been described in any cell or tissue and its function has not been reported, primary sequence suggests similarity to phosphatidylcholine transfer protein 2 (Lai, C.-H., 2000, Genome Res., 10: 703-713).

- [149] mRNA encoding this polypeptide is elevated an average 3-fold in 71% of the HCCs examined and similarly by nearly 7-fold in FNH (40% cases), all relative to non-diseased liver (Figures 1 and 17, Tables 3A/4A).
- [150] Independent RT-PCR analyses of expression levels of SDCCAG28 mRNA are determined with gene specific oligonucleotide primers (Assay ID Catalogue Number: Hs00246405\_m1) as described for the BIGH3 gene, confirming that the SDCCAG28 mRNA is not deregulated in cirrhosis (Figure 3B). The Assay-on-Demand Q-PCR shows upregulation in 8/17 HCCs, 2/3 FNHs, 1/3 Cirrhosis and 0/3 NNL of profiled cases.
- [151] Additionally, expression of this HCC-deregulated gene correlates with proliferation of hepatomacells, showing almost 2-fold and 4- fold increase of SDCCAG28 mRNA in hepatoma cell line (Hep3B) upon 8 hours and 12 hours serum stimulation of quiescent cells, respectively (see Figure 106).
- [152] Furthermore, the protein expression analyses show increase of SDCCAG28 protein signal in HCCs when compared to normal liver (Figure 105). The results support the functional significance of SDCCAG28 for disorders according to the invention, in particular for HCC.
- [153] These data suggest that SDCCAG28 polypeptide and/or the encoding nucleic acid can be utilized for the diagnosis, prevention and treatment of disorders according to the invention.
- In yet another preferred embodiment the nucleic acid according to the invention is the Peroxiredoxin 1 transcript variant 1, PRDX1 nucleic acid (SEQ ID 103) which has been disclosed before (Accession. No. NM\_002574) encoding the PRDX1 polypeptide (Accession. No. NP\_002565; SEQ ID 10), a member of the peroxiredoxin family of antioxidant enzymes (Prxs) that also control cytokine-induced peroxide levels which mediate signal transduction in mammalian cells. Prxs can be regulated by changes to phosphorylation, redox and possibly oligomerization states (Wood, Z.A., et al., 2003, Trends Biochem. Sci., 28 (1): 32-40). Three transcript variants encoding the same protein have been identified for this gene. The PRDX1 has been shown to be upregulated in human breast cancer (Noh DY et al., 2001, Anticancer Res., 21 (3B): 2085- 2090). However, neither PRDX1 nucleic acid nor the PRDX1 polypeptide had been recognized with respect to elevated levels in HCC.

- [155] Expression of the mRNA encoding this polypeptide is elevated an average of 3.6-fold relative to non-diseased liver in 71% HCC cases profiled (Figure 1, Table 3A). Elevated expression of the encoding mRNA is also evident in other liver disorders (FNH, Cirrhosis) (Figure 18 and Tables 4A/5A).
- [156] Independent verification analyses of expression levels of PRDX1 mRNA might be determined with gene specific oligonucleotide primers including, for example primer pairs specific to PRDX1 nucleic acid (Assay ID Catalogue Number: Hs00602020\_m1) in the Assay-On-Demand (Applied Biosystems, USA) quantitative PCR method.
- [157] These findings suggest that the PRDX1 polypeptide and/or a functional variant thereof and/or the encoding nucleic acid and/or a variant thereof can be utilized for the diagnosis, prevention and treatment of disorders according to the invention.
- [158] In yet another preferred embodiment the nucleic acid according to the invention is the Transmembrane trafficking protein, TMP21 nucleic acid (SEO ID 104) which has been disclosed before (Accession. No NM\_006827) encoding the TMP21 polypeptide (Accession No. NP\_006818, SEQ ID 11). Tmp21 is involved in biosynthetic transport from the endoplasmic reticulum to the Golgi complex (Blum, R., et al., 1996, J. Biol. Chem. 271, 17183-17189). There are two known Tmp21 isoforms -I and -II, wherein hum-Tmp21-II is transcribed, but not translated (Horer J et al., 1999, DNA Seq., 10(2): 121-6). Recent data report that phorbol esters translocate beta2-chimaerin (member of "non-protein kinase C" (PKC) phorbol ester/diacylglycerol receptors family) to the perinuclear region and promote its association with Tmp21-I in a PKC-independent manner (Wang H and Kazanietz MG, J Biol Chem, 2002; 277(6): 4541-4550). Thus, Tmp21-I might be serving as an anchoring protein that determines the intracellular localization of these novel phorbol ester receptors. The gene encoding both isoforms has not previously been reported to be expressed at elevated levels in disorders according to the invention, in particular in HCC.
- [159] Expression of the mRNA encoding the TMP21 polypeptide is induced by an average of 8.5-fold relative to non-diseased liver in 26% of the HCC cases profiled (Figure 1, Table 3A). Similarly, elevated expression of the encoding mRNA is also evident in FNH but not in the cirrhotic livers (see Figure 19 and Tables 4A/5A).
- [160] Furthermore, the expression of this HCC-deregulated mRNA is showing 2.6-fold and 3.5-fold increase by serum stimulation of quiescent hepatoma cells (HepG2) upon 8 hours and 12 hours, respectively (Figure 107).
- These results show that the differential upregulated expression of the TMP21 cDNA sequence is highly specific for disorders according to the invention. Therefore the TMP21 polypeptide and/or the encoding nucleic acid can be utilized for the diagnosis, prevention and treatment of disorders according to the invention
- [162] In yet another preferred embodiment the nucleic acid according to the invention is

the IQ motif containing GTPase-activating protein 2, IQGAP2 nucleic acid (SEQ ID 105) which has been disclosed before (Accession No. NM\_006633) encoding the IQGAP2 polypeptide (Accession No. NP\_006624, SEQ ID 12). This liver specific protein has been reported to harbor a potential actin binding domain and to interact with calmodulin and Rho family GTPases (Brill S et al., 1996, Mol Cell Biol.; 16(9): 4869-4878). The recent observations identify a physiologic scaffolding function for IQGAP2 representing a functional genomic unit in humans uniquely evolved to regulate thrombin-induced plateletcytoskeletal actin reorganization (Schmidt VA., 2003, Blood, 101(8): 3021-3028), but the gene encoding these isoforms has not previously been reported to be expressed at elevated levels in HCC.

[163] Expression of the mRNA encoding the IQGAP2 polypeptide is induced by an average of 4-fold relative to non-diseased liver in 71% of the HCC cases profiled (Figure 1, Table 3A). Similarly, elevated expression of the encoding mRNA is also evident in FNH but not in the cirrhotic livers (Figure 20 and Tables 4A/5A).

The HCC induction of the IQGAP2 gene can then be verified by amplification of the sequence from the cDNA with primer pairs specific to IQGAP2 nucleic acid (Assay ID Catalogue Number: Hs00183606\_m1) in the Assay-On-Demand (Applied Biosystems, USA) quantitative PCR method. These data suggest that the IQGAP2 polypeptide and/or the encoding nucleic acid can be utilized for the diagnosis, prevention and treatment of disorders according to the invention.

[165] In yet another preferred embodiment the nucleic acid according to the invention is the member of RAS oncogene family, Rab2 nucleic acid (SEQ ID 106) which has been disclosed before (Accession No. NM\_002865) encoding the Rab2 polypeptide (Accession No. NP\_002865, SEQ ID 13). The small GTPase Rab2 is a resident of pre-Golgi intermediates and required for protein transport from the endoplasmic reticulum (ER) to the Golgi complex (Tisdale, E. J. et al., 1992, J. Cell Biol., 119: 749-761). The Rab2 protein, like all small GTPases, contains conserved GTP-binding domains as well as hypervariable carboxyl-terminal and amino-terminal domains. It is suggested that the NH2 terminus of Rab2 is required for its function and for direct interaction with components of the transport machinery involved in the maturation of pre-Golgi intermediates. Rab2 interacts directly with atypical protein kinase C (aPKC) iota/ lambda and inhibits aPKC iota/lambda-dependent glyceraldehyde-3-phosphate dehydrogenase phosphorylation (Tisdale, E.J.2003, J Biol Chem.; 278(52):52524-30). Though overexpression in lymphoid and myeloid malignancies has been reported. neither Rab2 nucleic acid nor the Rab2 polypeptide has been recognized with respect to elevated levels in disorders according to the invention, preferably in HCC.

[166] Expression of the mRNA encoding this polypeptide is elevated an average of 5-fold relative to non-diseased liver in 71% of the HCC cases profiled (Figure 2, Table 3A).

- Elevated expression of the encoding mRNA is also evident in FNH but not in cirrhosis (Figure 21 and Tables 4A/5A).
- [167] Furthermore, the expression of this HCC-deregulated mRNA is 5.5-fold and almost 8-fold increased by serum stimulation of quiescent hepatoma cells (Hep3B) upon 8 hours and 12 hours, respectively (Figure 106).
- [168] These findings suggest that the Rab2 polypeptide and/or the encoding nucleic acid can be utilized for the diagnosis, prevention and treatment of disorders according to the invention.
- In another preferred embodiment the nucleic according to the invention is the Clone

  6 cDNA (OBCL6, SEQ ID 125), which is assembled by identification of overlapping sequences from the non-redundant GenBank sequence databases. The initial EST sequence upregulated in HCC relative to non-diseased liver identified with cDNA microarray analysis shows the highest similarity (almost 100% identical) to human genomic clone AL035420 (human DNA sequence from clone RP4-550H1 on chromosome 20q11.1-11.22 containing a high mobility group protein pseudogene). It may be that extending the length of this HCC-deregulated cDNA sequence will reveal that the corresponding RNA encodes a not yet described human protein. Another alternative is that the encoded polypeptide may result from one of the small open reading frames in this sequence. Even further, this RNA may be not translated into polypeptide but may have functional (e.g., regulatory) properties itself.
- Surprisingly the sequence from this mRNA is represented at much higher levels in HCC than in normal human liver. This mRNA is elevated an average of 6-fold or more relative to non-diseased liver in 68% of HCC samples profiled (Table 3B, Figure 3). Clone 6 is also elevated 8-fold or more relative to non-diseased liver in FNHs examined, but not in cirrhosis (Figure 40, Tables 4b/5B). Independent RT-PCR analyses of expression levels of might be determined with gene specific oligonucleotide primers. These results show that the strongly upregulated expression of the Clone 6 cDNA sequence is highly specific for disorders according to the invention, especially in HCC and FNH.
- Overexpression of the polypeptide and/or the encoding RNA therefore, may be useful for diagnosis of liver disorders. These results clearly demonstrate that the Clone 6 polypeptide and the nucleic acid (SEQ ID 125) encoding the polypeptide (SEQ ID 32) and a functional variant thereof can be utilized for diagnosis, prevention and treatment of disorders according to the invention, in particular for HCC and FNH.
- With regard to the treatment it is preferred to carry out the treatment such that the expression of the OBCL6 polypeptide and/or a functional variant thereof; or of the nucleic acid encoding the polypeptide and/or a functional variant thereof is reduced and/or inhibited, for example by administering antisense oligonucleotides or small in-

terfering RNA molecules that specifically interact with the nucleic acid defined in SEQ ID 125 potentially encoding the OBCL6 polypeptide and/or a functional variant thereof.

- [173] The treatment may be carried out, for example, such that the activity of the Clone 6 polypeptide and/or a functional variant thereof are reduced and/or inhibited, for instance by administering an antibody directed against the OBCL6 polypeptide and/or a functional variant thereof, or an antibody fragment thereof which block the activity of the Clone 6 polypeptide and/or a functional variant thereof to a patient in need of such treatment. Compared to the state of the art, the OBCL6 polypeptide and/or a functional variant thereof; and/or OBCL6 nucleic acid surprisingly allow improved, more sensitive, earlier, faster, and/or non-invasive diagnosis and/or improved, sustained and/or more effective treatment of the liver disorders and/or other epithelial cancer.
- Alternatively, the OBCL6 RNA may be not translated into a polypeptide but may have functional (e.g., regulatory) properties itself. The disease relevance of non-coding regulatory RNAs is now becoming apparent as evidenced, for example, by the role of the non-coding RNA "bantam" involved in cellular proliferation in the eukaryote Drosophila (Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Cell (2003) Apr4; 113(1):25-36), and by microRNA-23 that interacts with the transcription factor HES-1 to hinder neuronal differentiation (Kawasaki, H. and Tiara, K. Nature, 2003, 423:838-842).
- [175] For example, reduction of the level of Clone 6 RNA (knock-down) in proliferating human hepatoma cells with small interfering RNA (siRNA) oligonucleotides can support a functionally significant role for elevated expression of Clone 6 RNA in liver disorders, especially liver cancer.
- [176] Further aspect of the invention represents an isolated polypeptide comprising a sequence according to the SEQ ID 32 or a functional variant thereof. Another preferred embodiment is a fusion protein, wherein the fusion protein contains the polypeptide according to the SEQ ID 32 or a functional variant thereof.
- Yet another preferred feature of the invention is an isolated nucleic acid according to the SEQ ID 125 or a variant thereof. Further preferred embodiment represents the nucleic acid according to the SEQ ID 125 or a variant thereof, wherein the nucleic acid is a single-stranded or double-stranded RNA.
- [178] Still another aspect of the invention represents a nucleic acid according to the SEQ ID 125 or a variant thereof encoding the polypeptide according to the SEQ ID 32 or a functional variant thereof.
- Yet another feature of the invention is a vector, wherein the vector contains a nucleic acid selected from the group consisting of a nucleic acid according to the SEQ

ID 125 or a variant thereof encoding the polypeptide according to the SEQ ID 32 or a functional variant thereof. The vector is preferably selected from the group consisting of a knock-out gene construct, a plasmid, a shuttle vector, a phagemid, a cosmid, a viral vector, and an expression vector.

[180] Another aspect of the invention represents a cell, wherein the cell contains the nucleic acid according to the SEQ ID 125 or a variant thereof encoding the polypeptide according to the SEQ ID 32 or a functional variant thereof. In another preferred embodiment the cell is transformed with a vector containing a nucleic acid selected from the group consisting of a nucleic acid according to the SEO ID 125 or a variant thereof encoding the polypeptide according to the SEQ ID 32 or a functional variant thereof. In still further embodiment of the invention the cell is a transgenic embryonic non-human stem cell.

[181] Yet another feature of the invention represents a transgenic non-human mammal, wherein the transgenic non-human mammal contains the nucleic acid according to the SEQ ID 125 or a variant thereof encoding the polypeptide according to the SEQ ID 32 or a functional variant thereof.

[182] Further aspect is an antibody or an antibody fragment thereof, wherein the antibody is directed against the polypeptide according to the SEQ ID 32 or a functional variant thereof, or against a nucleic acid coding for the polypeptide.

[183] The cDNA expression levels relative to a non-diseased liver (NL) reference sample of sequences according to the invention assessed in tissues from human liver disorders, including Hepatocellular Carcinoma (HCC), Focal Nodular Hyperplasia (FNH) and Cirrhosis (Cirrh.) samples are shown in Tables 3A to 3D, 4A to 4D and 5A to 5D, respectively (median of log values data between diseased and non-diseased samples obtained from competitive hybridisation to custom-made cDNA microarrays). Median represents 50th percentile of values for each sequence (SEQ ID 94 to 186) per group (HCC, FNH and Cirrh). Number of the samples profiled and the calculated percentage of valid/detectable signals (% detected) are provided. (\*) annotates duplicates of the HCCs, FNHs, and Cirrh. profiled.

[184]

[185]

[186]

[187]

[188]

[189]

[190]

[191]

[192]

[193] [194]

[195]

[196]

Tables 3A to 3D: Summary of c DNA microarray expression level ratios (HCC vs NL).

Table 3A

Gene	Median log 2	Median-fol d induction	HCC microarray hybridizatio ns (No)	Detected (%)
PI4K2	0.75	1.68	28	54
ZNF216	4.01	16.07	28	54
AKR1C1	2.78	6.86	56	79
dUT	2.80	6.96	28	46
PACE4	4.60	24.23	28	57
BIGH3	2.31	4.95	28	79
PRKAR1A	1.73	3.32	56	39
s.t. Ocia	1.29	2.45	56	32
SDCCAG28	1.64	3.12	28	71
PRDX1	1.86	3.63	56	71
TMP21	3.08	8.46	56	27
IQGAP2	2.00	3.99	28	71
Rab2	2.38	5.21	28	71
ARFI	3.12	8.71	28	54
HSPC1	2.19	4.55	56	23
TLR5	1.55	2.93	28	64
GAP-SH3	1.72	3.29	28	71
Crisp-3	1.92	3.77	28	57
TM4SF4	1.70	3.24	56	32
AQP9	1.17	2.25	84	36
LOC51716	0.85	1.80	112	72
Cystatin	3.28	9.70	28	46

47

36

			 	_		1
Ki	2.55	5.85	28		68	
			 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \			1

[197] [198]

Table 3B

Gene	Median log 2	Median-fol d induction	HCC microarray hybridizati ons (No)	Detected (%)
Porimin	3.00	7.97	56	9
PTPRZ1	1.94	3.84	84	13
Rab9 effector p40	3.49	11.26	28	39
RBap48	3.10	8.58	28	50
PABPC1	3.69	12.89	28	61
NF1/B2	0.72	1.65	56	57
RPL7	3.08	8.46	140	19
HNRPDL	1.78	3.44	140	26
OBCL6	2.59	6.02,,,	28	32
SNRPG	2.39	5.26	56	23
KREV-1	1.51	2.85	28	61
DRB5	1.62	3.08	28	79
PKCI-1	0.62	1.54	. 28	82
IMPACT	4.03	16.37	28	36
ВМІ	3.52	11.48	56	16
G3BP	3.40	10.56	28	46
RHEB2	3.31	9.92	28	57
MARCKS	2.68	6.43	56	43
ALURBP	3.01	8.04	28	36
PPGB	2.70	6.49	28	79
GRB2	2.75	6.71	28	43
TRAPI	3.24	9.44	56	20
PDHB	3.05	8.25	28	46

[199]

Table 3C

Table 3C					
Gene	Median log <sub>2</sub>	Median-fol d induction	HCC microarray hybridizati ons (No)	D	etected (%)
DAD-1	2.02	4.06	56		63
PSME2	2.61	6.11	28		32
QP-C	2.27	4.83	28		79
MTRPS33	2.63	6.20	56		25
ARF4	3.02	8.12	28		36
DDB1	2.23	4.70	28		32
GNG10	1.80	3.49	56		66
DP1	2.68	6.40	56		27
ATPIBI	2.35	5.11	56		39
SLC25A3	2.25	4.75	56		39
SNC6	1.86	3.63	28		61
OMG	2.17	4.51	28		36
PB1S	2.17	4.51	28		36
RPS21	1.75	3.35	112		62
MMP-2	1.80	3.48	28		39
YWHAZ	1.87	3.66	28		89
PPP3R1	1.83	3.56	56		46
CTNNA1	1.11	2.15	112		29
ADCYAP1	0.74	1.67	28		4
syntenin	1.93	3.82	28		79
topoisomeras e IIb	2.25	4.76	28		18
UMP-CMPK	1.63	3.09	84		18
PSMD4	2.48	5.59	56		29
hu_BTF3	1.83	3.57	28		86
rhoA	1.68	3.21	28		68

[200]

Table 3D

			нсс	
Gene	Median log <sub>2</sub>	Median-fol d induction	microarra y hy- bridization s (No)	Detected (%)
LDH-B	1.58	2.99	56	63
TBXA2-R	1.64	3.12	56	38
hu_CAP	1.58	2.98	28	54
hu_PP2a-cat	1.49	2.82	196	6
SDHC	1.55	2.94	56	36
hu_GDP-di2	1.54	2.90	28	32
CCNI	1.70	3.26	28	64
Mac25	1.58	2.98	28	14
TBP	1.10	2.14	84	39
FDX1	1.79	3.46	28	36
NLVCF	1.34	2.53	56	32
GNG3	1.32	2.49	28	32
RCN2	1.88	3.67	56	25
hu_adk2	1.00	2.00	28	46
hu_Dcsa19	1.54	2.91	28	93
c/EBP	1.64	3.11	84	24
Rab GG	1.29	2.44	28	54
**c-syn	2.24	4.74	56	18
PPP1R15A	1.34	2.54	28	36
SCL5A6	3.70	13.00	28	36

[201]

[202] [(\*\*) c-syn represents three alternative nucleotide transcripts with corresponding three protein products

[203]

[204] Tables 4A to 4D: Summary of c DNA microarray expression level ratios (FNH

vs NL). Table 4A

Gene	Median log 2	Median-fol d induction	FNH microarray hybridizati ons (No)	Detected (%)
PI4K2	1.97	3.91	5	80
ZNF216	2.86	7.25	5	40
AKR1C1	1.18	2.27	10	70
dUT	3.41	10.60	5	40
PACE4	3.65	12.57	5	60
BIGH3	2.02	4.06	5	80
PRKARIA	1.71	3.28	10	40
s.t. Ocia	0.48	1.40	10	40
SDCCAG28	2.73	6.61	5	40
PRDX1	0.65	1.57	10	70
TMP21	3.68	12.81	10	20
IQGAP2	2.33	5.01	.5	80
Rab2	2.57	5.95	5	60
ARF1	2.07	4.18	5	40
HSPC1	2.19	4.57	10	30
TLR5	1.95	3.86	5	60
GAP-SH3	2.86	7.24	5	60
Crisp-3	1.45	2.73	5	60
TM4SF4	2.07	4.19	10	50
AQP9	0.60	1.51	15	33
LOC51716	0.67	1.59	20	75
Cystatin	2.10	4.28	5	20
Ki	2.14	4.41	5	60

[205]

. . .

Table 4B

····-				·
Gene	Median log 2	Median-fol	FNH	Detected (%)

		d induction	microarray hybridizati ons (No)	
Porimin	NA	NA	10	0
PTPRZ1	2.89	7.43	15	20
Rab9 effector p40	NA	NA	5	0
RBap48	3.54	11.67	5	40
PABPC1	1.81	3.50	5	40
NF1/B2	0.64	1.56	10	70
RPL7	3.67	12.69	25	12
HNRPDL	2.25	4.75	25	16
OBCL6	3.07	8.42	5	40
SNRPG	1.38	2.60	10	20
KREV-1	3.73	13.29	5	80
DRB5	0.82	1.77	5	80
PKCI-1	-0.03	0.98	5	80
IMPACT	¹:NA	NA	5	0
ВМІ	2.97	7.82	10	10
G3BP	3.60	12.13	5	20
RHEB2	3.28	9.68	5	20
MARCKS	1.75	3.35	10	40
ALURBP	1.15	2.22	5	20
PPGB	2.35	5.10	5	80
GRB2	2.89	7.41	5	20
TRAP1	NA	NA	10	0
PDHB	3.79	13.79	5	60

[206]

Table 4C

Gene	Median log 2	ledian-fol d nduction	FNH microarray hybridizati ons (No)	Detected (%)
DAD-1	2.01	4.02	10	60
PSME2	NA	NA	5	0
QP-C	1.15	2.21	5	80
MTRPS33	2.88	7.34	10	10
ARF4	3.78	13.76	5	80
DDB1	2.97	7.86	5	40
GNG10	2.87	7.32	10	70
DP1	2.58	5.97	10	20
ATP1B1	1.70	3.26	10	10
SLC25A3	2.95	7.74	10	30
SNC6	0.76	1.69	5	40
OMG	3.31	9.94	5	60
PB1S	1.39	2.62	5	20
RPS21	1.41	2.65	20	50 **
MMP-2	4.28	19.41	5	20
YWHAZ	1.00	2.00	5	80
PPP3R1	1.54	2.90	10	30
CTNNA1	2.08	4.24	. 20	40
ADCYAP1	, NA	NA	5	0
syntenin	1.83	3.55	5	80
topoisomeras e IIb	2.96	7.75	5	40
UMP-CMPK	3.02	8.11	15	27
PSMD4	1.34	2.53	10	10
hu_BTF3	1.01	2.01	5	80
rhoA	1.16	2.23	5	60

[207]

Table 4D

Gene	Median log <sub>2</sub>		Median-fol d induction		FNH microarra y hy- bridization s (No)	Detected (%)
LDH-B	1.58		2.99		10	80
TBXA2-R	1.64		3.12		10	40
hu_CAP	1.58		2.98		5	60
hu_PP2a-cat	1.49		2.82		35	11
SDHC	1.55		2.94		10	0
hu_GDP-di2	1.54		2.90		5	40
CCNI	1.70		3.26		5	80
Mac25	1.58		2.98		5	20
TBP	1.10		2.14		15	27
FDX1	1.79		3.46		5	40
NLVCF	1.34		2.53		10	10
GNG3	1.32		2.49	ì	5	80
RCN2	1.88		3.67		10	10
hu_adk2	1.00		2.00		5	80
hu_Dcsa19	1.54		2.91		5	100
c/EBP	1.64		3.11		15	20
Rab GG	1.29		2.44		5	60
**c-syn	2.24		4.74	1	10	10
PPP1R15A	1.34		2.54		5	20
SCL5A6	3.70	-	13.00		5	20

[208]

[209] [(\*\*) c-syn represents three alternative nucleotide transcripts with corresponding three protein products

[210]

[211] Tables 5A to 5D: Summary of c DNA microarray expression level ratios (Cirrh. vs NL).

Table 5A

<del></del>				
Gene	Median log	Median-fol d induction	Cirrh. microarray hybridizati ons (No)	Detected (%)
PI4K2	-0.23	0.85	8	88
ZNF216	NA	NA	8	0
AKR1C1	-0.72	0.61	16	50
dUT	0.40	1.32	8	13
PACE4	0.68	1.60	8	13
BIGH3	1.04	2.05	8	38
PRKAR1A	0.80	1.74	16	13
s.t. Ocia	0.12	1.09	16	6
SDCCAG28	0.35	1.28	8	25
PRDX1	1.38	2.60	16	44
TMP21	NA	NA	16	0
IQGAP2	0.51	1.42	8	50
Rab2	0.88	1.84	8	25 ⁺₁
ARFI	1.24	2.36	8	25
HSPC1	-2.55	0.17	16	19
TLR5	1.08	2.12	8	38
GAP-SH3	1.60	3.04	8	25
Crisp-3	1.06	2.09	8	25
TM4SF4	1.23	2.35	16	25
AQP9	0.80	1.74	24	33
LOC51716	-0.56	0.68	32	66
Cystatin	3.15	8.88	8	25
Ki	1.01	2.01	8	25

[212]

Table 5B

Gene	Median log	Median-fol	Cirrh.	Detected (%)
Gene	Median log 2	d	microarray	Detected (%)

		induction	hybridizati ons (No)	
Porimin	1.13	2.19	16	6
PTPRZI	1.21	2.32	24	8
Rab9 effector p40	NA	NA	8	o
RBap48	2.46	5.50	8	13
PABPC1	3.47	11.06	8	13
NF1/B2	1.33	2.51	16	44
RPL7	0.98	1.97	40	5
HNRPDL	-0.33	0.80	40	8
OBCL6	NA	NA	8	0
SNRPG	0.17	1.12	16	13
KREV-1	1.64	3.12	8	38
DRB5	0.32	1.25	8	63
PKCI-1	0.71	1.64	8	75
IMPACT	1.68	3.21	8	25
BMI	2.68	6.41	16	19
G3BP	1.60	3.03	8	13
RHEB2	1.04	2.06	8	13
MARCKS	1.77	3.40	16	25
ALURBP	-1.13	0.46	8	13
PPGB	1.66	3.16	8	50
GRB2	2.62	6.14	8	25
TRAP1	3.06	8.33	16	13
PDHB	1.43	2.69	8	38

[213]

[214]

Table 5C

Gene	Median log 2	Median-fol d induction	Cirrh. microarray hybridizati ons (No)	Detected (%)
DAD-1	1.61	3.05	16	31
PSME2	0.98	1.97	8	38
QP-C	2.87	7.31	8	63
MTRPS33	NA	NA	16	0
ARF4	3.98	15.74	8	13
DDB1	4.11	17.30	8	13
GNG10	1.81	3.51	16	50
DP1	1.33	2.51	16	13
ATP1B1	2.33	5.02	16	19
SLC25A3	0.99	1.99	16	25
SNC6	1.11	2.16	8	50
OMG	1.95	3.87	8	25
PB1S	0.98	1.98	8	38
RPS21	1.16	2.24	· 32	47
MMP-2	1.00	2.00	8	38
YWHAZ	1.48	2.79	8	75
PPP3R1	1.40	2.64	16	31 .
CTNNAI	-0.46	0.73	32	22
ADCYAP1	NA	NA	8	0
syntenin	1.26	2.40	8	75
topoisomeras e IIb	-0.10	0.93	8	13
UMP-CMPK	1.51	2.85	24	8
PSMD4	-1.63	0.32	16	13
hu_BTF3	1.73	3.33	8	63
rhoA	1.49	2.81	8	50

Table 5D

Gene	Median log 2	Median-fol d induction	 Cirrh.micr oarray hy- bridization s (No)		Detected (%)
LDH-B	0.91	1.89	16	1	75
TBXA2-R	1.05	2.07	16		31
hu_CAP	1.63	3.10	8		25 ·
hu_PP2a-cat	2.13	4.38	56		7
SDHC	NA	NA	16		0
hu_GDP-di2	1.44	2.71	8		50
CCNI	1.12	2.18	8		50
Mac25	1.09	2.13	8		25
TBP	0.76	1.69	24		4
FDX1	1.33	2.52	8		25
NLVCF	1.30	2.47	16		13
GNG3	-0.38	0.77	8		25
RCN2	1.35	2.56	16		6 4
hu_adk2	1.59	3.00	8		13
hu_Dcsa19	1.29	2.45	8		88
c/EBP	0.25	1.19	24		13
Rab GG	0.56	1.48	8		38
**c-syn	1.62	3.08	16		13
PPP1R15A	0.86	1.81	8		38
SCL5A6	3.95	15.45	8		25

[216]

[217] [(\*\*) c-syn represents three alternative nucleotide transcripts with corresponding three protein products]

[218]

[219] The quantitative assessment of gene expression (SEQ IDs: 102; 99; 101; 106; 98; 96) by RT-PCR (Q-PCR) in Hepatocellular Carcinoma (HCC), Focal Nodular Hyperplasia (FNH) and Cirrhosis (Cirrh) samples is compared to expression pattern in

normal liver (NL), shown inTable 6 (median of log 2 values). Median represents 50<sup>th</sup> percentile of values for each sequence per group (HCC, FNH and Cirrh). Number of the samples profiled (SDCCAG28, BIGH3, s.t.OCIA, Rab2 and PACE4) represent 18 HCC, 3 FNH/Cirrh./NL; and for AKR1C1 7 HCC and 4 NL. Percentage of valid/ detectable signals for SEQ IDs 102; 99; 101; 106; 98; 96 (% detected) is equal to 100%, with exception of PACE4 (\*) for which 94.45% HCC cases are detected.

[220]

WO 2005/085861

Table 6: Summary of differential gene expression levels (SEQ IDs: 102; 99; 101; 106; 98; 96) verified by RT-PCR

Table 6	Ta	bl	e	6
---------	----	----	---	---

Tissue	SDCCAG 28	BIGH3	s.t.OCIA	R	ab2	PACE4	AKR1C 1
HCC	0.75	1.54	1.6	2	2.25	0.5*	3.20
FNH	1.29	2.4	2.23		2.63	1.51	NA
Cirrh.	-0.28	0.51	0.83	1	.27	1.89	NA
NL	-1.34	0	0.53	(	).22	0	0.93

[222]

The quantitative assessment of gene expression of TMF4SF4 and DAD-1 in Hepatocellular Carcinoma (HCC), Focal Nodular Hyperplasia (FNH) and Cirrhosis (Cirrh) samples is compared to expression pattern in normal liver (NL), shown in Tables 7A/7B respectively (median of log<sub>2</sub> values). Median represents 50<sup>th</sup> percentile of values for each sequence (SEQ ID 112 and SEQ ID 140) per group (HCC, FNH and Cirrh). Median- fold induction is calculated according to following formula: "2<sup>x</sup>" ("x" represents median of log<sub>2</sub> values). Number of the samples profiled (TM4SF4 and DAD-1 genes) represent 18 HCC, 3 FNH/Cirrh/NL.

[224]

[225] Table 7A/7B: Summary of differential gene expression levels (SEQ ID 112 and SEQ ID 140) verified by RT-PCR.

[226]

6 **Table 7A** 

TM4SF4	Median log 2	Median-fold induction	Number of cases profiled
нсс	2.83	7.11	18
FNH	3.81	14.07	3
Ci <del>m</del> h.	2.66	6.30	3

WO 2005/085861

NL		0	1	3
	L.,			

[227]

Table 7B

DAD-1	Median log	Median-fold induction	Number of cases profiled
HCC	0.62	1.54	18
FNH	1.21	2.31	3
Cirrh.	0.14	1.10	3
NL	0.20	1.15	3

[228]

[229]

In another preferred embodiment of the invention the nucleic acid according to the invention can be used for the construction of antisense oligonucleotides (Zheng and Kemeny, 1995, Clin. Exp. Immunol., 100: 380-382) and/or ribozymes (Vaish et al., 1998, Nucleic Acids Res., 26: 5237-5242; Persidis, 1997, Nat. Biotechnol., 15: 921-922) and/or small interfering double stranded RNAs (Elbashir et al., 2001, Nature, 411: 494-498; Brummelkamp et al., 2002, Science, 296:550-553). In further preferred embodiments of the invention, the stability of the nucleic acid according to the invention can be decreased and/or the translation of the nucleic acid according to the invention inhibited by using RNA interference molecules (oligonucleotides). Thus, for example, the expression of the corresponding genes in cells can be decreased both in vivo and in vitro. Oligonucleotides can therefore be suitable as therapeutics. This strategy is also suitable, for example, for liver cells, in particular if the antisense oligonucleotides are complexed with liposomes. For use as a probe or as an "antisense" oligonucleotide, a single-stranded DNA or RNA is preferred. Small interfering RNA (siRNA) double stranded oligonucleotides can also be suitable as therapeutics. With this approach a short sequence or sequences of 15 to 22 nucleotides including sequence complementary to the sequence to be therapeutically targeted are exposed to the diseased tissue and serve to dramatically reduce or "knock down" the level of expression of the therapeutic target RNA sequence. siRNA therapeutic approaches in other diseases have been recently reported and are also applicable to liver disorders, liver cancers and other epithelial cancers (Filleur S. et al., Cancer Res., 2003; 63(14): 39-22).

[230] In a preferred embodiment a nucleic acid according to the invention has been prepared by recombinant methods, by screening a library or isolation from a sample obtained from a patient or a subject. In another preferred embodiment of the invention

the nucleic acid according to the invention has been prepared synthetically. Thus, the nucleic acid according to the invention can be synthesized, for example, chemically with the aid of the DNA sequences described in SEQ ID 94 to SEQ ID 186 and/or with the aid of the protein sequences described in SEQ ID 1 to SEQ ID 93 with reference to the genetic code, e.g. according to the phosphotriester method (see, for example, Uhlmann and Peyman, 1990, Chemical Reviews, 90:543-584).

- In another preferred embodiment, the invention relates to a nucleic acid according to the invention or a nucleic acid which is a non-functional mutant variant the nucleic acid or a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, which has been modified by attachment of chemical moieties to the nucleic acid to stabilize it against degradation, so that a high concentration of the nucleic acid is maintained in the cell over a long period (Beigelman et al., 1995, Nucleic Acids Res., 23: 3989-94; Dudycz, 1995, WO 95/11910; Macadam et al., 1998, WO 98/37240; Reese et al., 1997, WO 97/29116). Typically, such stabilization can be obtained by the introduction of one or more internucleotide phosphorus groups or by the introduction of one or more non-phosphorus internucleotides.
- [232] Preferred suitable modified internucleotides are summarized in Uhlmann and Peymann (1990 Chem. Rev. 90, 544; see also Beigelman et al., 1995 Nucleic Acids Res., 23: 3989-94; Dudycz, 1995, WO 95/11910; Macadam et al., 1998, WO 98/37240; Reese et al., 1997, WO 97/29116).
- In a further embodiment the invention relates to a vector comprising a nucleic acid according to the invention and/or a variant thereof, or a nucleic acid which is a non-functional mutant variant of the nucleic acid, or a nucleic acid having a sequence complementary to one the aforementioned nucleic acids. Preferably the vector is a knock-out gene construct, a plasmid, a shuttle vector, a phagemid, a cosmid, a viral vector, an expression vector and/or a vector applicable in gene therapy. The preparation of such constructs is generally known to the person skilled in the art.
- [234] An "expression vector" within the meaning of the present invention preferably comprises at least one promoter or enhancer, i.e. at least one regulatory element comprising at least one translation initiation signal, at least one of the nucleic acids according to the invention or a nucleic acid which is a non-functional mutant variant the nucleic acid or a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, one translation termination signal, a transcription termination signal, and a polyadenylation signal for the expression in eukaryotes.
- [235] For the expression of the gene concerned, in general a double-stranded DNA is preferred, the DNA region coding for the polypeptide being particularly preferred. In the case of eukaryotes this region begins with the first start codon (ATG) lying in a Kozak sequence (Kozak, 1987, Nucleic. Acids Res., 15: 8125-48) up to the next stop

codon (TAG, TGA or TAA), which lies in the same reading frame to the ATG. In the case of prokaryotes this region begins with the first AUG (or GUG) after a Shine-Dalgarno sequence and ends with the next stop codon (TAA, TAG or TGA), which lies in the same reading frame to the ATG.

Differentially expressed genes in HCC can contain liver or liver cancer genespecific regulatory sequences. These non-transcribed sequences, found in the tissue- or
disease-specific gene may be used to drive tissue- or disease-specific expression of
included therapeutic and/or tumor cell-cytotoxic genes. These regulatory sequences
may be used for liver cancer specific expression of a nucleic acid according to the
invention or a nucleic acid which is a non-functional mutant variant the nucleic acid or
a nucleic acid having a sequence complementary to one of the aforementioned nucleic
acids. The screening and construction of such regulatory sequences is generally known
to the person skilled in the art.

Suitable expression vectors can be prokaryotic or eukaryotic expression vectors. Examples of prokaryotic expression vectors are, for expression in *E. coli*, e.g. the vectors pGEM or pUC derivatives, examples of eukaryotic expression vectors are for expression in *Saccharomyces cerevisiae*, e.g. the vectors p426Met25 or p426GAL1 (Mumberg et al., 1994, Nucl. Acids Res., 22, 5767-5768), for expression in insect cells, e.g. *Baculovirus* vectors such as disclosed in EP-B1-0 127 839, and for expression in mammalian cells, e.g. the vectors Rc/CMV and Rc/RSV or SV40 vectors, which are all generally obtainable. Specific vectors for production of RNA interference following transfection, such as the pSUPER vector (Brummelkamp et al., 2002, Science, 296:550-553) are also included.

In general, the expression vectors also contain promoters suitable for the respective cell, such as, for example, the trp promoter for expression in *E. coli* (see, for example, EP-B1-0 154 133), the MET 25, GAL 1 or ADH2 promoter for expression in yeast (Russel et al., 1983, J. Biol. Chem., 258, 2674-2682; Mumberg, supra), the Baculovirus polyhedrin promoter, for expression in insect cells (see, for example, EP-B1-0 127 839). For expression in mammalian cells, for example, suitable promoters are those which allow a constitutive, regulatable, tissue-specific, cell-cycle-specific or metabolically specific expression in eukaryotic cells. Regulatory elements according to the present invention preferably are promoters, activator sequences, enhancers, silencers and/or repressor sequences.

[239] Examples of suitable regulatory elements which make possible constitutive expression in eukaryotes preferably are promoters which are recognized by the RNA polymerase III or viral promoters, CMV enhancer, CMV promoter, SV40 promoter or LTR promoters, e.g. from MMTV (mouse mammary tumor virus; Lee et al., 1981, Nature, 214, 228-232) and further viral promoter and activator sequences, derived

from, for example, adeno- and adeno-like viruses, HBV, HCV, HSV, HPV, EBV, HTLV or HIV.

- [240] Examples of regulatory elements which make possible regulated expression in eukaryotes are the tetracycline operator in combination with a corresponding repressor (Gossen et al., 1994, Curr. Opin. Biotechnol., 5:516-20).
- [241] Translation initiation signals, translation termination signals, transcription termination signals, and polyadenylation signals are generally known to the person skilled in the art and can be readily obtained from commercial laboratory suppliers.
- Preferably, the expression of the genes relevant for liver disorders and/or epithelial cancer takes place under the control of tissue-specific promoters, for example, under the control of liver-specific promoters such as albumin, alpha fetoprotein, apolipoprotein AI, alpha-1 antitrypsin, and the complement C5 and C8A genes (Schrem et al., 2002, Pharmacol. Rev., 54 129-58; Pontoglio et al., 2001, J. Expt. Med., 194:1683-1689). The regulatory sequences associated with genes highly deregulated in HCC as described herein also provide a preferable method for specific gene expression in these disorders.
- [243] Further examples of regulatory elements which make tissue-specific expression in eukaryotes possible are promoters or activator sequences from promoters or enhancers of those genes which code for proteins which are only expressed in certain cell types.
- [244] Examples of regulatory elements which make possible metabolically specific expression in eukaryotes are promoters which are regulated by hypoxia, by oxidative stress, by glucose deficiency, by phosphate concentration or by heat shock.
- [245] Examples of regulatory elements which make cell cycle-specific expression in eukaryotes possible are promoters of the following genes: cdc25A, cdc25B, cdc25C, cyclin A, cyclin E, cdc2, E2F-1 to E2F-5, B-myb or DHFR (Zwicker J. and Müller R., 1997, Trends Genet., 13:3-6). The use of cell cycle regulated promoters is particularly preferred in cases, in which expression of the polypeptides or nucleic acids according to the invention is to be restricted to proliferating cells.
- In order to make possible the introduction of nucleic acids as described above, or a nucleic acid which is a non-functional mutant variant of the nucleic acid and thus the expression of the polypeptide in a eukaryotic or prokaryotic cell by transfection, transformation or infection, the nucleic acid can be present as a plasmid, as part of a viral or non-viral vector. Suitable viral vectors here are particularly: baculoviruses, vaccinia viruses, adenoviruses, adeno-associated viruses, retroviruses and herpesviruses. Suitable non-viral vectors here are particularly: virosomes, liposomes, cationic lipids, or polylysine-conjugated DNA or naked DNA.
- [247] Plasmids, shuttle vectors, phagemids, and cosmids suitable for use according to the invention are also known to the person skilled in the art and are generally obtainable

from commercial laboratory suppliers.

- [248] Examples of vectors applicable in gene therapy are virus vectors, for example adenovirus vectors, retroviral vectors or vectors based on replicons of RNA viruses (Lindemann et al., 1997, Mol. Med. 3: 466-476; Springer et al., 1998, Mol. Cell. 2:549-558). Eukaryotic expression vectors are suitable in isolated form for gene therapy use, as naked DNA can penetrate, for example, into liver cells upon local application or via the blood supply.
- [249] Compared to the state of the art, this fusion construct surprisingly allows improved, more sensitive, earlier, faster, and/or non-invasive diagnosis and/or improved, sustained and/or more effective treatment of the liver disorders, and/or other epithelial cancers.
- [250] In another aspect the invention furthermore relates to a cell comprising a nucleic acid according to the invention and/or a variant thereof. Preferably the cell is transformed with a vector according to the invention. The cell preferably contains a nucleic acid wherein the nucleic acid is either a non-functional mutant variant of a nucleic acid according to the invention. In particular the cell contains a vector comprising a nucleic acid wherein the nucleic acid is a non-functional mutant variant of a nucleic acid according to the invention. Preferably the cell contains a nucleic acid having a sequence complementary to a nucleic acid according to the invention, or a variant thereof. Moreover the cell preferably contains a vector comprising a nucleic acid coding for an antibody according to the invention or a fragment of the antibody. The cell according to the invention may for example be a liver cell, comprising at least one of the aforementioned nucleic acids or a cell which is transformed using one of the above described vectors. Cells can be either prokaryotic or eukaryotic cells, heterologous or autologous cells. Examples of prokaryotic cells are E. coli and examples of eukaryotic cells include primary hepatocytes cells, hepatocytes cell lines such as HepG2 and Hep3B cells, yeast cells, for example Saccharomyces cerevisiae or insect cells.
- [251] Compared to the state of the art, the cell according to the invention surprisingly allows improved, more sensitive, earlier, faster, and/or non-invasive diagnosis and/or improved, sustained and/or more effective treatment of the liver disorders and/or other epithelial cancers.
- [252] In a preferred embodiment of the invention the cell is a transgenic embryonic non-human stem cell which comprises at least one nucleic acid according to the invention, at least one vector, at least one knock-out gene construct and/or at least one expression vector as described above.
- [253] Processes for the transformation of cells and/or stem cells are well known to a person skilled in the art and include, for example, electroporation or microinjection.

- In another aspect the invention relates to the provision of a transgenic non-human mammal comprising a compound selected from the group consisting of a nucleic acid according to the invention and/or a variant thereof, a nucleic acid which is a non-functional mutant variant the nucleic acid, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, one of the aforementioned nucleic acids in the form of a vector, of a knock-down or knock-out gene construct, and of an expression vector.
- Transgenic animals in general show a tissue-specifically increased expression of the nucleic acids and/or polypeptides and can be used for the analysis of liver disorders and/or epithelial cancers, such as for example HCC, and for development and evaluation of therapeutic strategies for such disorders. Transgenic animals may further be employed in the production of polypeptides according to the invention. The polypeptide produced by the animal may for example be enriched in a body fluid of the animal. The polypeptides according to the invention may for example be isolatable from a body fluid such as the milk.
- [256] Compared to the state of the art, this transgenic non-human mammal surprisingly allows improved, more sensitive, earlier, faster, and/or non-invasive analysis and/or diagnosis of liver disorders and/or other epithelial cancers.
- [257] Processes for the preparation of transgenic animals, in particular of transgenic mice. are likewise known to the person skilled in the art from e.g., US 5,625,122; US 5,698,765; US 5,583,278 and US 5,750,825 and include transgenic animals which can be produced, for example, by means of direct injection of expression vectors according to the invention into embryos or spermatocytes or by injection of the expression vectors into the pronucleus of the fertilized ovum or by means of the transfection of expression vectors into embryonic stem cells or by nuclear transfer into appropriate recipient cells (Polites and Pinkert, DNA Microinjection and Transgenic Animal Production, page 15 to 68 in Pinkert, 1994, Transgenic animal technology: a laboratory handbook, Academic Press, London, UK; Houdebine, 1997, Harwood Academic Publishers, Amsterdam, The Netherlands; Doetschman, Gene Transfer in Embryonic Stem Cells, page 115 to 146 in Pinkert, 1994, supra; Wood, Retrovirus-Mediated Gene Transfer, page 147 to 176 in Pinkert, 1994, supra; Monastersky, Gene Transfer Technology; Alternative Techniques and Applications, page 177 to 220 in Pinkert, 1994, supra).
- [258] If the above described nucleic acids are integrated into so-called "targeting vectors" or "knock-out" gene constructs (Pinkert, 1994, supra), it is possible after transfection of embryonic stem cells and homologous recombination, for example, to generate knock-out mice which, in general, as heterozygous mice, show decreased expression of the nucleic acid, while homozygous mice no longer exhibit expression of the nucleic acid.

The animals thus produced can also be used for the analysis of liver disorders, such as for example HCC, and/or epithelial cancers.

- [259] Knock-out gene constructs are known to the person skilled in the art, for example, from the US patents 5,625,122; US 5,698,765; US 5,583,278 and US 5,750,825.
- [260] In a further aspect the invention relates to an antibody or a fragment, wherein the antibody or antibody fragment is directed against a polypeptide according to the invention, a functional variant thereof or against a nucleic acid coding for the polypeptide, or a variant thereof.
- [261] Compared to the state of the art, these antibody or a fragment thereof surprisingly allow improved, more sensitive, earlier, faster, and/or non-invasive diagnosis and/or improved, sustained and/or more effective treatment of the liver disorders and/or other epithelial cancers.
- The term "antibody" or "antibody fragment" is understood according to the present invention as also meaning antibodies or antigen-binding parts thereof prepared by genetic engineering and optionally modified, such as, for example, chimeric antibodies, humanized antibodies, multifunctional antibodies, bi- or oligospecific antibodies, single-stranded antibodies, F(ab) or F(ab)<sub>2</sub> fragments (see, for example, EP-B1-0 368 684, US 4,816,567; WO 98/24884). The antibodies according to the invention can for example be used for diagnosis, prevention and/or treatment of disorders according to the invention such as liver disorders, for example HCC, and/or epithelial cancers.
- [263] The invention further relates to a method for producing an antibody or antibody fragment, preferably a polyclonal or monoclonal antibody, specific for the polypeptides or functional variants thereof encoded by the nucleic acids according to the invention, or variants thereof for example for the diagnosis and/or prevention and/ or treatment of disorders according to the invention. The process is carried out according to methods generally known to the person skilled in the art by immunizing a mammal, for example a rabbit, with a nucleic acid according to the invention or their variants thereof, or with a polypeptide according to the invention or parts thereof or functional variants thereof, having at least 6 amino acid length, preferably having at least 8 amino acid length, in particular having at least 12 amino acid length, if appropriate in the presence of, for example, Freund's adjuvant and/or aluminum hydroxide gels (see, for example, Harlow and Lane, 1998, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Press, New York, USA, Chapter 5, pp. 53-135). The polyclonal antibodies formed in the animal as a result of an immunological reaction can then be easily isolated from the blood according to generally known methods and purified, for example, by means of column chromatography. Monoclonal antibodies can be produced, for example, according to the known method

of Winter & Milstein (Winter and Milstein, 1991, Nature, 349:293-299).

The present invention further relates to an antibody or antibody fragments directed against a polypeptide described above and reacts specifically with the polypeptides described above, where the above-mentioned parts of the polypeptide are either immunogenic themselves or can be rendered immunogenic by coupling to suitable carriers, such as, for example, bovine serum albumin or keyhole limpet hemocyanin to increase in their immunogenicity. This antibody is either polyclonal or monoclonal; preferably it is a monoclonal antibody.

[265] Still further, the present invention relates to the generation and/or production of an antibody or antibody fragment specific for the polypeptide according to the invention from a recombinant antibody expression library, such as for example described by Knappik et al. (2000, J. Molec. Biol., 296:57-86).

[266] In another embodiment of the invention, it is provided an array, wherein the array contains at least two compounds selected from the group consisting of a polypeptide according to the invention, a functional variant thereof, a nucleic acid encoding the polypeptide, a non-functional mutant variant nucleic acid and an antibody or an antibody fragment directed against the polypeptide. Alternatively, the array may contain at least one component according to the invention in combination with previously described components implicated in neoplastic or metabolic liver disorders or epithelial cancers.

[267] Within the meaning of the invention the term "array" refers to a solid-phase or gellike carrier upon which at least two compounds are attached or bound in one-, two- or three-dimensional arrangement. Such arrays are generally known to the person skilled in the art and are typically generated on glass microscope slides, specially coated glass slides such as polycation-, nitrocellulose- or biotin- coated slides, cover slips, and membranes such as for example membranes based on nitrocellulose or nylon.

The aforementioned arrays include bound polypeptides according to the invention or functional variants thereof or nucleic acids coding for the polypeptides, or variants thereof, fusion proteins according to the invention or antibodies or antibody fragments directed against polypeptides according to the invention or functional variants thereof or cells expressing polypeptides according to the invention or functional variants thereof or at least two cells expressing at least one nucleic acid according to the invention, or variants thereof. Nucleic acids coding for these, or variants thereof can also be part of an array. Such arrays can be employed for analysis and/or diagnosis of liver disorders, preferably of HCC, and/or epithelial cancer.

[269] The invention further relates to a method of producing arrays according to the invention, wherein at least two compounds according to the invention are bound to a carrier material.

- [270] Methods of producing such arrays, for example based on solid-phase chemistry and photo-labile protective groups are generally known (US 5,744,305). Such arrays can also brought into contact with substances or a substance libraries and tested for interaction, for example for binding or change of conformation.
- The invention further relates to a process for preparing an array immobilized on a support material for analysis and/or diagnosis of disorders according to the invention such as a liver disorder, preferably of HCC, in which at least two nucleic acids, at least two polypeptides or at least two antibodies or antibody fragments, and/or at least two cells, or at least one of the aforementioned components in combination with other components relevant to neoplastic and metabolic liver disorders or epithelial cancers, as described above, is used for preparation. The arrays produced by such process can be employed for the diagnosis of disorders according to the invention.
- In another aspect the invention relates to a diagnostic comprising at least one compound selected from the group consisting of a polypeptide according to the SEQ ID 1 to SEQ ID 93 or functional variants thereof, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, and an antibody or an antibody fragment directed against one of the aforementioned polypeptides, combined or together with suitable additives or auxiliaries.
- [273] In a preferred embodiment the invention relates to a diagnostic comprising a polypeptide according to the SEQ ID 1 or a functional variant thereof, a nucleic acid encoding the aforementioned polypeptide, a variant of the aforementioned nucleic acid, and an antibody or an antibody fragment directed against the aforementioned polypeptide, combined or together with suitable additives or auxiliaries.
- [274] In a further aspect the invention relates to a diagnostic comprising at least one compound selected from the group consisting of a nucleic acid according to the SEQ ID 94 to SEQ ID 186 or variants thereof, combined with suitable additives or auxiliaries.
- [275] In a preferred embodiment the invention relates to a diagnostic comprising a nucleic acid according to the SEQ ID 94 or a variant thereof, combined with suitable additives or auxiliaries
- [276] Compared to the state of the art, this diagnostic surprisingly allows improved, more sensitive, earlier, faster, and/or non-invasive diagnosis of liver disorders and/or other epithelial cancers.
- [277] Within the meaning of the invention "suitable additives" or "auxiliaries" are generally known to the person skilled in the art and comprise, for example, physiological saline solution, demineralized water, gelatin or glycerol-based protein stabilizing reagents. Alternatively, the nucleic acid or polypeptide according to the invention may be lyophilized for stabilization.

In another examplea diagnostic kit based on the nucleic acid sequences according to the invention could be generated. Such a kit may be designed specifically to detect cells altered as a result of the described disorders resident in the circulatory system and thereby detectable in serum from test patients. Additional examples of diagnostic kits includes enzyme linked immunosorbent assays (ELISA), radioimmunoassays (RIA), and detection of an immune reaction or specific antibodies to the polypeptides according to the invention including detection of specific responding immune cells.

[279] In a preferred embodiment the diagnostic according to the invention contains a probe, preferentially a DNA probe.

For example, it is possible according to the present invention to prepare a diagnostic based on the polymerase chain reaction (PCR). Under defined conditions, preferably using primers specific for a nucleic acid according to the invention as a DNA probe PCRs specific for the nucleic acid sequences of the invention will be utilized to monitor both the presence, and especially the amount, of specific nucleic acids according to the invention in a sample isolated from a patient obtained for diagnostic or therapeutic purposes. This opens up a further possibility of obtaining the described nucleic acids, for example by isolation from a suitable gene or cDNA library, for example from a liver disorder-specific or liver specific gene bank, with the aid of a suitable probe (see, for example, J. Sambrook et al., 1989, Molecular Cloning. A Laboratory Manual 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY Chapter 8 pages 8.1 to 8.81, Chapter 9 pages 9.47 to 9.58 and Chapter 10 pages 10.1 to 10.67).

Suitable probes are, for example, DNA or RNA fragments having a length of about 50-1000 nucleotides, preferably having a length of about 10 to about 100 nucleotides, preferably about 100 to about 200 nucleotides, in particular having a length of about 200-500 nucleotides, whose sequence can be derived from the polypeptides according to SEQ ID 1 to SEQ ID 93, and functional variants thereof, and nucleic acids coding for the polypeptides, preferably according to SEQ ID 94 to SEQ ID 186, and variants thereof.

Alternatively, it is preferably possible with the aid of the derived nucleic acid sequences to synthesize oligonucleotides that are suitable as primers for a polymerase chain reaction. Using this, the nucleic acid described above or parts of this can be amplified and isolated from cDNA, for example HCC-specific cDNA. Suitable primers are, for example, DNA fragments having a length of about 10 to 100 nucleotides, preferably having a length of about 15 to 50 nucleotides, in particular having a length of 17 to 30 nucleotides, whose sequence can be derived from the polypeptides according to SEQ ID 1 to SEQ ID 93 from the nucleic acids according to SEQ ID 94 to SEQ ID 186. The design and synthesis of such primers is generally known to the

person skilled in the art. The primers may additionally contain restriction sites, e.g. suitable for integration of the amplified sequence into vectors, or other adapters or overhang sequences, e.g. having a marker molecule such as a fluorescent marker attached, generally known to the skilled worker.

- In another aspect of the invention it is provided a method of diagnosis of a disorder according to the invention, wherein at least one compound selected from the group consisting of a polypeptide according to the sequence of SEQ ID 1 to SEQ ID 93, functional variants thereof, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, and an antibody directed against one of the aforementioned polypeptides or antibody fragment thereof, is identified in the sample of a patient and compared with at least one compound of a reference library or of a reference sample.
- In a preferred embodiment of the method the disorder of the liver is a disorder selected from the group consisting of cirrhosis, alcoholic liver disease, chronic hepatitis, Wilson's disease, haemochromatosis, hepatocellular carcinoma, benign liver neoplasms, and focal nodular hyperplasia.
- [285] In a preferred embodiment of the method the epithelial cancer is an adenocarcinoma of any organ other than liver, preferably of an organ selected from the group consisting of the lung, the stomach, the kidney, the colon, the prostate, the skin, and the breast.
- [286] Compared to the state of the art, this diagnostic surprisingly allows improved, more sensitive, earlier, faster, and/or non-invasive diagnosis of the liver disorders and/or other epithelial cancers.
- [287] Preferably the sample is isolated from a patient by non-invasive methods as described above.
- [288] For example, serum detection of specific deregulated gene proteins via ELISA assay is one application, alternatively one or a panel of antibodies to deregulated gene products may be used, from which a diagnostic score is deduced based on the combinations of, and the expression levels of gene products expressed in the diseased tissue or in serum from diseased individuals.
- [289] A preferred diagnostic according to the invention contains the described polypeptide or the immunogenic parts thereof described in greater detail above. The polypeptide or the parts thereof, which are preferably bound to a solid phase, e.g. of nitrocellulose or nylon, can be brought into contact *in vitro*, for example, with the body fluid to be investigated, e.g. blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, in order thus to be able to react, for example, with autoimmune antibodies present in e.g. the blood of the patient. The antibody-peptide complex can then be detected, for example, with the aid of labeled antihuman IgG antibodies. The labeling involves, for example, an enzyme, such as peroxidase,

which catalyses a color or chemiluminescent reaction. The presence and the amount of autoimmune antibody present can thus be detected easily and rapidly by means of the color.

In addition the diagnostic may be directed to detecting an endogenous antibody or fragment thereof present in the sample isolated from a patient which antibody or fragment thereof is directed against a polypeptide according to the invention. Detection of such autoimmune antibodies may be accomplished by methods generally known to the skilled artisan, e.g. by immunoaffinity assays using polypeptides according to the invention or functional variants thereof or parts thereof as a probe. Preferably the presence of such autoimmune antibodies is indicative of the patient suffering from a disorder according to the invention.

A further diagnostic, that is subject matter of the present invention, contains the antibodies according to the invention themselves. With the aid of these antibodies, it is possible, for example, to easily and rapidly investigate a tissue sample as to whether the concerned polypeptide according to the invention is present in an increased amount in order to thereby obtain an indication of possible disease including liver disorders, for example HCC. In this case, the antibodies according to the invention are preferably labeled directly, or more commonly for example these are detected with a specific secondary antibody indirectly, such as with an enzyme or fluorescent molecule, as already described above. The specific antibody-peptide complex can thereby be detected easily, and rapidly, e.g., by means of an enzymatic color reaction.

In still another aspect of the invention it is provided a method for identifying at least one nucleic acid according to the SEQ ID 94 to SEQ ID 186, or a variant thereof differentially expressed in a sample isolated from a patient relative to a reference library or a reference sample comprising the following steps: (a) detecting the expression of at least one nucleic acid according to the SEQ ID 94 to SEQ ID 186, or a variant thereof in a sample isolated from a patient, (b) comparing the expression of said nucleic acid(s) detected in step (a) with the expression of the same nucleic acid(s) in a reference library or in a reference sample, (c) identifying said nucleic acid(s) which is (are) differentially expressed in the sample isolated from the patient compared to the reference library or the reference sample.

[293] Compared to the state of the art the method surprisingly allows improved, more sensitive, earlier, faster, and/or non-invasive identification of differentially expressed nucleic acids according to the invention that provides a useful basis for diagnosing a disorder according to the invention.

[294] Preferably at least 2, at least 3, at least 4 at least 5, at least 6, or at least 7 nucleic acids are identified.

[295] In another preferred embodiment of the method said nucleic acid(s) is (are) detected

by PCR based detection or by a hybridization assay.

In another preferred embodiment of the method the expression of said nucleic acid is compared by a method selected from the group consisting of solid-phase based screening methods, hybridization, subtractive hybridization, differential display, and RNase protection assay.

In a further preferred embodiment of the method the sample isolated from the patient is selected from the group consisting of liver tissue, a liver cell, tissue from another organ subject to cancerous transformation, a cell from this organ, blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, and feces.

Preferably the reference sample is isolated from a source selected from a non-diseased sample of the same patient or a non-diseased sample from another subject. The selection of appropriate reference samples is generally known to the person skilled in the art. In particular the reference sample may be selected from the group consisting of liver tissue, a liver cell, blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, and feces.

[299] In another preferred embodiment of the method, the reference library is an expression library or a data base comprising clones or data on non-diseased expression of at least one nucleic acid according to the invention in samples that preferably may be selected from the group consisting of liver tissue, a liver cell, blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, and feces.

In another aspect of the invention it is provided a method of diagnosing a liver disorder, or an epithelial cancer comprising the following steps: (a) detecting the expression of at least one nucleic acid according to the SEQ ID 94 to SEQ ID 186, or a variant thereof in a sample isolated from a patient, (b) comparing the expression of said nucleic acid(s) detected in step (a) with the expression of the same nucleic acid(s) in a reference library or in a reference sample, (c) identifying said nucleic acid which is differentially expressed in the sample isolated from the patient compared to the reference library or the reference sample, and (d) matching said nucleic acid(s) identified in step (c) with said nucleic acid(s) differentially expressed in a pathologic reference sample or pathologic reference library, wherein the matched nucleic acid(s) is (are) indicative of the patient suffering from a liver disorder or an epithelial cancer.

[301] Compared to the state of the art, this method of diagnosing surprisingly allows improved, more sensitive, earlier, faster, and/or non-invasive diagnosis of the liver disorders and/or other epithelial cancers.

[302] In another preferred embodiment of the method of diagnosis, the pathologic reference sample is isolated from a diseased sample from another patient. The latter patient having been diagnosed as suffering from the disorder according to the invention

[304]

which is to be diagnosed. The selection of appropriate pathologic reference samples is generally known to the person skilled in the art. In particular the pathologic reference sample may be selected from the group consisting of liver tissue, a liver cell, blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, and feces.

In another preferred embodiment of the method of diagnosis, the pathologic reference library is a data base comprising data on differential expression of the at least one nucleic acid according to the invention in samples isolated from at least one patient, excluding the patient under diagnosis, suffering from the disorder according to the invention to be diagnosed in the inventive method relative to control expression in a reference sample or reference library. The pathologic reference library preferably also relates to a differential expression library comprising nucleic acids according to the invention which are differentially expressed in samples isolated from at least one

the invention to be diagnosed in the inventive method relative to control expression in a reference sample or reference library. The selection of an appropriate pathologic reference library is generally known to the person skilled in the art.

patient, excluding the patient under diagnosis, suffering from the disorder according to

Preferably the liver disorder is a disorder selected from the group consisting of cirrhosis, alcoholic liver disease, chronic hepatitis, Wilson's Disease, haemochromatosis, hepatocellular carcinoma, benign liver neoplasms, and focal nodular hyperplasia. In particular the epithelial cancer is an adenocarcinoma of any organ other than liver, preferably of an organ selected from the group consisting of the lung, the stomach, the kidney, the colon, the prostate, the skin, and the breast.

[305] Within the meaning of the invention the term "detecting a nucleic acid" refers to a method that preferably uncovers, visualizes, separates or allows recognition of the nucleic acid according to the invention from the background of the other components present in the sample. Such methods are generally known to the person skilled in the art and include in situ hybridization, PCR amplification, gel electrophoresis, northern blots, solid phase array (gene chips) based methods, nuclease protection methods (as described and referenced in Alberts, et al. 2002, The Molecular Biology of the Cell, 4<sup>th</sup> ed. Garland, New York, USA).

Within the meaning of the invention the term "comparing the expression of said nucleic acid(s) detected in step (a) with the expression of the same nucleic acid(s) in a reference library or in a reference sample" refers to a comparison of the expression of the two groups of said nucleic acid(s) on a quantitative or qualitative level by means of an experimental procedure such as differential display, subtractive hybridization, RNAse protection assay, or especially DNA chip hybridization. Moreover a comparison of experimental data on said nucleic acid(s) detected in step (a) with the

[310]

expression of the same nucleic acid(s) in a reference library as defined above is also included herein.

[307] The term "identifying said nucleic acid(s) which is (are) differentially expressed in the sample isolated from the patient compared to the reference library or the reference sample" within the meaning of the present invention is understood to mean selecting said nucleic acid(s) which is (are) differentially expressed compared to the reference library or the reference samples which fulfills the following criteria: the level of differential expression of the detected said nucleic acid(s) compared to the reference library or the reference samples is greater than about 2 fold, preferably greater than about 5 fold, more preferred greater than about 10 fold upregulated.

The term "matching said nucleic acid(s) identified in step (c) with said nucleic acid(s) differentially expressed in a pathologic reference sample or pathologic reference library " within the meaning of the invention is understood to mean that said nucleic acid(s) identified in step (c) is (are) compared with said nucleic acid(s) differentially expressed in a pathologic reference sample or pathologic reference library. Then said nucleic acid(s) identified in step (c) that is (are) also differentially expressed in the pathologic reference sample or pathologic reference library is (are) matched, i.e. said identical pair is identified and allocated. Since the differential expression of said nucleic acid(s) in the pathologic reference sample or pathologic reference library is (are) indicative of a disorder according to the invention, such correspondence with the sample then indicates that the patient, suffers from that disorder.

[309] Preferably the sample is isolated from a patient by non-invasive or preferably minimally invasive methods such as described above, including venupuncture.

The methods of diagnosing according to the invention allows early detection of a liver disorder and/or an epithelial cancer, and/or non-invasive diagnosis of the disorder, based on an essentially concordant expression pattern of the nucleic acids according to the invention detected in the samples isolated from an animal and/or a human patient suffering from a liver disorder and/or an epithelial cancer relative to a reference sample or relative to a reference library. The method has the additional advantage that it also provides additional and novel diagnostic parameters to characterize different subtypes of liver disorders, such as for example subtypes of HCC.

[311] The term "essentially concordant expression pattern" of the nucleic acids according to the invention refers to a pattern of expression that is essentially reproducible from patient to patient or subject to subject, provided that the patients or subjects compared are in the same or comparable pathological condition or healthy condition, respectively.

- In still another aspect of the invention it is provided a method for identifying at least one polypeptide according to the SEQ ID 1 to SEQ ID 93, or a functional variant thereof differentially expressed in a sample isolated from a patient relative to a reference library or a reference sample comprising the following steps: (a) detecting the expression of at least one polypeptide according to the SEQ ID 1 to SEQ ID 93, or a functional variant thereof in a sample isolated from a patient, (b) comparing the expression of said polypeptide(s) detected in step (a) with the expression of said polypeptide(s) in a reference library or in a reference sample, (c) identifying said polypeptide(s) which is (are) differentially expressed in the sample isolated from the patient compared to the reference library or the reference sample.
- [313] Compared to the state of the art, this method surprisingly allows improved, more sensitive, earlier, faster, and/or non-invasive identification of differentially expressed polypeptides according to the invention that provides a useful basis for diagnosing a disorder according to the invention.
- [314] Preferably at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7 polypeptides are identified.
- [315] Preferably the sample is isolated from a patient by non-invasive or minimally invasive methods such as described above, including venupuncture.
- [316] In another embodiment of the method the sample is a sample as defined further above. Preferably the reference sample is a reference sample as defined above.
- In another preferred embodiment of the method, the reference library is an expression library or a data base comprising clones or data on non-diseased expression of the at least one polypeptide according to the invention in samples that preferably may be selected from the group consisting of liver tissue, a liver cell, blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, or feces. Such databases are generated as a result of the cDNA microarray expression analysis according to the invention and are known to persons skilled in the art. Further reference libraries useable according to the invention have been described above.
- In another aspect of the invention it is provided a method of diagnosing a liver disorder or an epithelial cancer comprising the following steps: (a) detecting the expression of at least one polypeptide according to the SEQ ID 1 to SEQ ID 93, or a functional variant thereof in a sample isolated from a patient, (b) comparing the expression of said polypeptide(s) detected in step (a) with the expression of said polypeptide(s) in a reference library or in a reference sample, (c) identifying said polypeptide(s) which is (are) differentially expressed in the sample isolated from the patient compared to the reference library or the reference sample, and (d) matching said polypeptide(s) identified in step (c) with said polypeptide(s) differentially expressed in a pathologic reference sample orpathologic reference library, wherein the

matched polypeptide(s) is (are) indicative of the patient suffering from a liver disorder or an epithelial cancer.

- [319] Compared to the state of the art, this method of diagnosing surprisingly allows improved, more sensitive, earlier, faster, and/or non-invasive diagnosis of the liver disorders and/or other epithelial cancers.
- [320] Preferably at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7 polypeptides are identified.
- Within the meaning of the invention the term "detecting a polypeptide" refers to a method that preferably uncovers, visualizes, separates and/or allows recognition of the polypeptide according to the invention from the background of the other components present in the sample. Such methods are generally known to the person skilled in the art and includes gel electrophoresis, chromatographic techniques, immunoblot analysis, immunohistochemistry, enzyme based immunoassay, mass spectroscopy, high pressure liquid chromatography, surface plasmon resonance, and/or antibody and protein arrays as described above (Ausubel, F.A. et al., eds., 1990, Current Protocols in Molecular Biology. Greene Publishing and Wiley-Interscience, New York, USA, Chapter 10; Myszka and Rich 2000, Pharm. Sci. Technol. Today 3:310-317). Preferably proteins and polypeptides are prepared from the sample by disruption of the cells with physical sheering or ultrasonic means, for example. Protein is denatured and stabilized with reducing agent treatment and heating and the protein is size fractionated on electrophoretic polyacrylamide gels.
- [322] Within the meaning of the invention the term "comparing the expression of said polypeptide(s) detected in step (a) with the expression of the same polypeptide(s) in a reference library or in a reference sample " refers to a comparison of the expression of the two groups of polypeptide(s) on a quantitative and/or qualitative level by means of an experimental procedure such as two dimensional gel electrophoresis, chromatographic separation techniques, immunoblot analysis, surface plasmon resonance, immunohistochemistry, and enzyme based immunoassay. In two dimensional gel electrophoresis, all peptides are first resolved according to isoelectric point in the first electrophoretic dimension and then by size according to methods well known to persons experienced in the art. Moreover a comparison of experimental data on the at least one polypeptide detected in step 1 with the expression of the polypeptide in a reference library as defined above is also included herein.
- [323] The term "Identifying said polypeptide(s) which is (are) differentially expressed in the sample isolated from the patient compared to the reference library or the reference sample" within the meaning of the present invention is understood to mean selecting said polypeptide(s) which is (are) differentially expressed compared to the reference library or the reference samples which fulfills the following criteria: the level of dif-

ferential expression of the detected polypeptide(s) compared to the reference library or the reference samples is greater than about 2 fold, preferably greater than about 5 fold, more preferred greater than about 10 fold upregulated.

The term "matching said polypeptide(s) identified in step (c) with said polypeptide(s) differentially expressed in a pathologic reference sample or pathologic reference library " within the meaning of the invention is understood to mean that said polypeptide(s) identified in step (c) is compared with said polypeptide(s) differentially expressed in a pathologic reference sample or pathologic reference library. Then said polypeptide(s) identified in step (c) that is (are) also differentially expressed in the pathologic reference sample or pathologic reference library is (are) matched, i.e. said identical pair(s) is (are) identified and allocated. Since the differential expression of said polypeptide(s) in the pathologic reference sample or pathologic reference library is (are) indicative of a disorder according to the invention, such correspondence with the differential expression in the sample then indicates that the patient suffers from that disorder.

- [325] Preferably the sample is isolated from a patient by non-invasive or minimally invasive methods such as described above, including venupuncture.
- [326] In another embodiment of the method the sample is a sample as defined further above. Preferably the reference sample is a reference sample as defined above.
- In another preferred embodiment of the method of diagnosis, the reference library is an expression library or a dataset comprising clones or data on non-diseased expression of the at least one polypeptide according to the invention in samples that preferably may be selected from the group consisting of liver tissue, a liver cell, blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, and feces.
- [328] An example of a data base according to the invention and further experimental reference libraries useable according to the invention have been described above.
- [329] In another preferred embodiment of the method of diagnosis, the pathologic reference sample is a pathologic reference sample as has been defined above.
- In another preferred embodiment of the method of diagnosis, the pathologic reference library is a data base comprising data on differential expression of said polypeptide(s) according to the invention in samples isolated from at least one patient, excluding the patient under diagnosis, suffering from the disorder according to the invention to be diagnosed in the inventive method relative to control expression in a reference sample or reference library. The pathologic reference library also relates to a differential expression library comprising polypeptides according to the invention which are differentially expressed in samples isolated from at least one patient, excluding the patient under diagnosis, suffering from the disorder according to the

invention to be diagnosed in the inventive method relative to control expression in a reference sample or reference library. The selection of an appropriate pathologic reference library is generally known to the person skilled in the art.

[331] Preferably the liver disorder is a disorder selected from the group consisting of cirrhosis, alcoholic liver disease, chronic hepatitis, Wilson's Disease, haemochromatosis, hepatocellular carcinoma, benign liver neoplasms, and focal nodular hyperplasia. In particular the epithelial cancer is an adenocarcinoma of any organ other than liver, preferably of an organ selected from the group consisting of the lung, the stomach, the kidney, the colon, the prostate, the skin, and the breast.

[332] The methods of diagnosing according to the invention allows early detection of a liver disorder and/or epithelial cancer, and/or non-invasive diagnosis of the disorder, based on an essentially concordant expression pattern of the polypeptides according to the invention detected in the samples isolated from an animal and/or a human patient suffering from a liver disorder and/or epithelial cancer relative to a reference sample or relative to a reference library. The method has the additional advantage that it also provides additional and novel diagnostic parameters to characterize different subtypes of liver disorders, such as for example subtypes of HCC.

[333] The term "essentially concordant expression pattern" of the polypeptides according to the invention refers to a pattern of expression that is essentially reproducible from patient to patient or subject to subject, provided that the patients or subjects compared are in the same or comparable pathological condition or healthy condition, respectively.

[334] In another aspect of the invention it is provided a pharmaceutical composition comprising at least one compound selected from the group consisting of a polypeptide according to SEQ ID 1 to 93, a functional variant thereof, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, a nucleic acid which is a non-functional mutant variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, a cell comprising one of the aforementioned nucleic acids, a cell comprising the aforementioned vector, an antibody or a fragment of the antibody directed against one of the aforementioned polypeptides, a vector comprising a nucleic acid coding for the aforementioned antibody, a cell comprising the vector comprising a nucleic acid coding for the aforementioned antibody, and a cell comprising the vector comprising a nucleic acid coding for the aforementioned antibody fragment, combined or together with suitable additives or auxiliaries. In a preferred embodiment the pharmaceutical composition contains at least one cell according to the invention, combined or mixed together with suitable additives or auxiliaries.

[336]

[338]

[335] When compared to the state of the art of therapy of liver disorders, and/or other epithelial cancers the pharmaceutical composition according to the invention surprisingly provide an improved, sustained and/or more effective treatment.

A pharmaceutical composition in the sense of the invention encompasses medicam ents which can be used for preventing and/or treating liver disorders and/or epithelial cancer. The pharmaceutical composition includes, for instance, a stabilized recombinant antibody that has been produced by expression of specific antibody gene fragments in a cellular system, preferably a eukaryotic system. A recombinant antibody therapeutic for instance, is delivered by injection into the diseased liver region or into the venous or arterial vascular systems or into the hepatic portal system. The injections can be repeated at regular intervals to achieve therapeutic efficacy. Therapeutics according this invention may also be employed in combinations with other chemical, antibody, or any other therapeutic application to improve efficacy.

[337] An antibody or other specific-binding partner can be conjugated to a second molecule, such as a cytotoxic agent, and used for targeting the second molecule to a tissue-antigen positive cell (Viteta E.S. et al, 1993, Immunotoxin therapy, in DeVita Jr. V.T. et al., eds, Cancer: Principles and Practice of Oncology, 4<sup>th</sup> ed., J.B. Lippincott Co., Philadelphia, 2624-2636). Examples of cytotoxic agents include, but are not limited to, antimetabolites, alkylating agents, anthracyclines, antibiotics, anti-mitotic agents, radioisotopes and chenotherapeutic agents. Techniques for conjugating therapeutic agents to antibodies are well known in prior art.

In addition to immunotherapy, polynucleotides and polypeptides can be used as targets for non-immunotherapeutic applications, e.g. using compounds which interfere with function, expression, assembly of the genes according to the invention, including but not limited to modulation(s) of the enzymatic active site(s) of the polypeptide(s), change of the protein(s) structure(s), interaction(s) via small molecules, etc.

[339] The present invention also relates to a process producing a pharmaceutical composition for the treatment and/or prevention of disorders according to the invention, for example, HCC, in which at least one component selected from the group consisting of a polypeptide according to the invention, a functional variant thereof, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, a nucleic acid which is a non-functional mutant variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, a cell comprising one of the aforementioned nucleic acids, a cell comprising the aforementioned vector, an antibody or a fragment of the antibody directed against one of the aforementioned polypeptides, a vector comprising a nucleic acid coding for one of the aforementioned antibodies, a cell comprising the

vector comprising a nucleic acid coding for one of the aforementioned antibodies, and a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibody fragments, is combined or mixed together with suitable additives.

[340] The present invention furthermore relates to a pharmaceutical composition produced by this process for the treatment and/or prevention of liver disorders and/or epithelial cancers, for example, HCC, which contains at least one component selected from the group consisting of a polypeptide according to the invention, a functional variant thereof, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, a nucleic acid which is a nonfunctional mutant variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, a cell comprising one of the aforementioned nucleic acids, a cell comprising the aforementioned vector, an antibody or a fragment of the antibody directed against one of the aforementioned polypeptides, a vector comprising a nucleic acid coding for one of the aforementioned antibodies, a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibodies, and a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibody fragments, if appropriate together with suitable additives and auxiliaries.

- [341] The invention furthermore relates to the use of this pharmaceutical composition for the prevention and/or treatment of liver disorders, for example, HCC and/or epithelial cancer.
- Preferably the pharmaceutical composition is employed for the treatment of a liver disorder selected from the group consisting of cirrhosis, alcoholic liver disease, chronic hepatitis, Wilson's Disease, haemochromatosis, hepatocellular carcinoma, benign liver neoplasms, and focal nodular hyperplasia. In particular the phramaceutical composition is employed for the treatment of an epithelial cancer that is an adenocarcinoma of any organ other than liver, preferably of an organ selected from the group consisting of the lung, the stomach, the kidney, the colon, the prostate, the skin, and the breast.
- Therapy can also be carried out in a conventional manner generally known to the person skilled in the art, e.g. by means of oral application or via intravenous injection of the pharmaceutical compositions according to the invention. It is thus possible to administer the pharmaceutical composition comprising the suitable additives or auxiliaries, such as, for example, physiological saline solution, demineralized water, stabilizers, proteinase inhibitors.
- [344] A therapy based on the use of cells, which express at least one polypeptide according to the invention, functional variants thereof or nucleic acids coding for the

:: ,

polypeptide, or variants thereof can be achieved by using autologous or heterologous cells. Preferred cells comprise liver cells, for example primary cultures of liver cells, liver populating stem or progenitor cells, or blood cells. The cells can be applied to the tissue, preferably to the blood or injected into the liver, with suitable carrier material. Such therapy is preferably based on the notion that upon expression and/or release of a polypeptide according to the invention the polypeptide stimulates an immune response in the patient in need of the treatment.

[345]

Preferably the therapeutical approach is directed toward inhibiting the function and/or expression of at least one polypeptide according to the invention and/or the function and/or expression of at least one nucleic acid according to the invention. Such inhibition of the expression and/or function preferably reduces the expression and/or function of the targeted nucleic acid/polypeptide significantly, for example by 50%, in particular by 80% and most preferably by 95%. The inhibition of the expression and/or function preferably abolishes the expression and/or functioning of the targeted nucleic acid/polypeptide. The inhibition can occur at any level, including transcription, translation, and/or perdurance of the nucleic acid (e.g. degradation, stability) in the cell. For inhibiting the biological activity of polypeptides according to the invention e.g. antibodies and small molecules can be targeted to cell-surface, exposed, extracellular, ligand binding, functional, etc. domains of the polypeptide. The term "antagonist/inhibitor" in the sense of the present invention can be directed to, or targeted to any part of the nucleotide and polypeptide according to the invention.

[346]

Such reduction or abolished expression and/or functioning of the targeted nucleic acid/polypeptide can be determined using conventional assays for determining the expression and/or functioning of a nucleic acid/polypeptide generally known to the person skilled in the art. In particular such assays for determining the function comprise methods for comparing the biological activity of the targeted nucleic acid/polypeptide before and after administration of the pharmaceutical composition. Preferably such assays for determining the expression comprise methods for comparing the level of expression of the targeted nucleic acid/polypeptide before and after administration of the pharmaceutical composition.

[347]

Such therapy is preferably accomplished by the use of a nucleic acid having a sequence complementary to one of nucleic acids according to the invention, i.e. an antisense molecule or a RNA interference molecule which reduces or abolishes the translation of transcribed nucleic acids according to the invention and thereby inhibits the function and/or expression of the targeted nucleic acid/polypeptide.

[348]

In a preferred embodiment, the pharmaceutical composition comprises a nucleic acid having a complementary sequence which is an antisense molecule or an RNA interference molecule.

- Preferably such nucleic acid having a complementary sequence may be employed in the form of a vector or a cell comprising such nucleic acid. On the polypeptide level the therapy may in particular be carried out by the use of an antibody or an antibody fragment directed against a polypeptide according to the invention. The antibody or antibody fragment may be administered directly to the patient or preferably the nucleic acid encoding the antibody is contained in a vector which is preferably contained in a cell. The cell or vector may then be administered to the patient in need of such treatment.
- [350] When compared to the state of the art of therapy of liver disorders, and/or other epithelial cancers the method of treating according to the invention surprisingly provide an improved, sustained and/or more effective treatment.
- [351] The invention further relates to a method of treating a patient suffering from of a liver disorder, wherein at least one component selected from the group consisting of a polypeptide according to the invention, a functional variant thereof, a nucleic acid encoding the polypeptide, a variant of one of the aforementioned nucleic acids, a nucleic acid which is a non-functional mutant variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, a cell comprising the vector, an antibody directed against the polypeptide, a fragment of the antibody, a vector comprising a nucleic acid coding for the antibody, and a cell comprising the vector comprising a nucleic acid coding for the antibody fragment, optionally combined or together with suitable additives and/or auxilaries, is administered to the patient in need of a treatment in a therapeutically effective amount.
- Preferably the method of treatment is directed to a liver disorder selected from the group consisting of cirrhosis, alcoholic liver disease, chronic hepatitis, Wilson's disease, haemochromatosis, hepatocellular carcinoma, benign liver neoplasms, and focal nodular hyperplasia. In particular the method of treatment is directed to an epithelial cancer that is an adenocarcinoma of any organ other than liver, preferably of an organ selected from the group consisting of the lung, the stomach, the kidney, the colon, the prostate, the skin, and the breast.
- [353] Methods of administering such compounds or cells have been described in detail above.
- [354] The term "therapeutically effective amount" refers to the administration of an amount of the compound to the patient that results in an "effective treatment" as defined above. Determination of the therapeutically effective amount of the compound(s) is generally known to the person skilled in the art.

[355] Such methods of treating allow effective treatment of a liver disorder and/or epithelial cancers as described above.

In another aspect of the invention it is provided a method of stimulating an immune response in a patient suffering from a liver disorder and/or an epithelial cancer to a polypeptide according to the invention, or a functional variant thereof, wherein at least one component selected from the group consisting of a polypeptide according to the invention, a functional variant thereof, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, a cell comprising one of the aforementioned nucleic acids, and a cell comprising the aforementioned vector, is administered to the patient in need of such treatment in an amount effective to stimulate the immune response in the patient.

[357] When compared to the state of the art of therapy of liver disorders and/or other epithelial cancers, the method of stimulating an immune response according to the invention surprisingly provides an improved, sustained and/or more effective immunization.

[358] In another aspect of the invention it is provided a method of preventing a patient from developing a liver disorder and/or an epithelial cancer, wherein at least one component selected from the group consisting of a polypeptide according to the invention, a functional variant thereof, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a nucleic acid which is a non-functional mutant variant of one of the aforementioned nucleic acids, a cell comprising one of the aforementioned nucleic acids, and a cell comprising the aforementioned vector, is administered to the patient in need of such preventive treatment in a therapeutically effective amount.

[359] When compared to the state of the art of therapy of liver disorders, and/or other epithelial cancers the method of preventing according to the invention surprisingly provides an improved, sustained and/or more effective preventive measure.

Preferably the method of preventing and/or method of stimulating an immune response is directed to a liver disorder selected from the group consisting of cirrhosis, alcoholic liver disease, chronic hepatitis, Wilson's Disease, haemochromatosis, hepatocellular carcinoma, benign liver neoplasms, and focal nodular hyperplasia. In particular, preferably the method of preventing and/or method of stimulating an immune response is directed to an epithelial cancer which is an adenocarcinoma of any organ other than liver, preferably of an organ selected from the group consisting of the lung, the stomach, the kidney, the colon, the prostate, the skin, and the breast.

- In another aspect of the invention it is provided a method of identifying a pharmacologically active compound comprising the following steps (a) providing at least one
  nucleotide according to the SEQ ID 94 to SEQ ID 186, or a variant thereof, (b)
  contacting said nucleotide(s) with suspected to be pharmacologically active
  compound(s), (c) assaying the interaction of said nucleotide(s) of step (a) with said
  compound(s) suspected to be pharmacologically active, (d) identifying said
  compound(s) suspected to be pharmacologically active which directly or indirectly
  interact with said nucleotide(s) of step (a).
- In a further aspect the invention relates to a method of identifying at least one pharmacologically active compound comprising the following steps: (a) providing at least one polypeptide according to the SEQ ID 1 to SEQ ID 93, or a functional variant thereof, (b) contacting said polypeptide(s), with suspected to be pharmacologically active compound(s), (c) assaying the interaction of said polypeptide(s) of step (a) with saidcompound(s) suspected to be pharmacologically active, (d) identifying said compound (s) suspected to be pharmacologically active which directly or indirectly interact with said polypeptide(s) of step (a).
- Preferably said nucleotide(s) or said polypeptide(s) is (are) provided in a form selected from the group of said nucleotide(s) or said polypeptide(s) is (are) attached to a column, said nucleotide(s) or said polypeptide(s) is (are) attached to an array, said nucleotide(s) or said polypeptide(s) is (are) contained in an electrophoresis gel, said nucleotide(s) or said polypeptide(s) is (are) attached to a membrane, and said nucleotide(s) or said polypeptide(s) is (are) expressed by a cell.
- It is preferred but not intended to be limited to assay the interaction by a method selected from the group of enzyme and fluorescence based cellular reporter assays in which interaction of the compound suspected to be pharmacological active with a recombinant fusion protein including said polypeptide(s) of step (a) is detected. The interaction may preferably also be assayed by displacement of specific nucleic acid binding aptamer molecule(s) on the recombinant fusion protein, surface plasmon resonance, HPLC and mass spectroscopy.
- Preferably the direct or indirect interaction is selected from the group consisting of induction of the expression of said nucleotide(s) or said polypeptide(s), inhibition of the expression of said nucleotide(s) or said polypeptide(s), activation of the function of said nucleotide(s) or said polypeptide(s), inhibition of the function of said nucleotide(s) or said polypeptide(s).
- In a preferred embodiment a method for identifying an antagonist/inhibitor against the nucleotide according to the SEQ ID 94 to SEQ ID 186, or a variant thereof, comprising (a) contacting at least one nucleotide according to the SEQ ID 94 to SEQ ID 186 with a putative antagonist/inhibitor, and (b) determining whether the putative

antagonist/inhibitor prevents the activity of the nucleotide.

In a further aspect of the invention, a method for identifying a putative antagonist/ inhibitor against the polypeptide according to the SEQ ID 1 to SEQ ID 93, or a functional variant thereof, comprising (a) contacting at least one polypeptide according to the SEQ ID 1 to SEQ ID 93 with the putative antagonist/inhibitor, and (b) determining whether the putative antagonist/ inhibitor prevents the activity of the polypeptide.

[368] The term "pharmacologically active substance" in the sense of the present invention is understood as meaning all those molecules, compounds and/or compositions and substance mixtures which can interact under suitable conditions with a nucleotide according to the SEQ ID 94 to 186 or variants thereof, if appropriate together with suitable additives and/or auxiliaries.

[369] The term "pharmacologically active substance" in the sense of the present invention is also understood as meaning all those molecules, compounds and/or compositions and substance mixtures which can interact under suitable conditions with polypeptide according to the SEQ ID 1 to 93 or functional variants thereof, if appropriate together with suitable additives and/or auxiliaries.

[370] Possible pharmacologically active substances are simple chemical (organic or inorganic) molecules or compounds, but can also include peptides, proteins or complexes thereof. Examples of pharmacologically active substances are organic molecules that are derived from libraries of compounds that have been analyzed for their pharmacological activity. On account of their interaction, the pharmacologically active substances can influence the expression and/or function(s) of the nucleotide or polypeptide in vivo or in vitro or alternatively only bind to the nucleotides or polypeptides described above or enter into other interactions of covalent or non-covalent manner with them.

[371] A suitable test system, for example, that can be used in accordance with the invention is based on identifying interactions with the two hybrid system (Fields and Sternglanz, 1994, Trends in Genetics, 10, 286-292; Colas and Brent, 1998 TIBTECH, 16, 355-363). In this test system, cells are transformed with expression vectors that express fusion proteins that consist of at least one polypeptide according to the invention and a DNA-binding domain of a transcription factor such as Gal4 or LexA. The transformed cells also contain a reporter gene whose promoter contains binding sites for the corresponding DNA-binding domain. By means of transforming a further expression vector, which expresses a second fusion protein consisting of a known or unknown polypeptide and an activation domain, for example from Gal4 or herpes simplex virus VP16, the expression of the reporter gene can be greatly increased if the second fusion protein interacts with the investigated polypeptide according to the

invention. This increase in expression can be used for identifying new interacting partners, for example by preparing a cDNA library from e.g., liver tissue, or diseased liver tissue for the purpose of constructing the second fusion protein. In a preferred embodiment, the interaction partner is an inhibitor of at least one of the polypeptides according to the SEQ ID 1 to 93 (encoded by the SEQ ID 94 to 186) or functional variants thereof. This test system can also be used for screening substances that inhibit an interaction between the polypeptide according to the invention and an interacting partner. Such substances decrease the expression of the reporter gene in cells that are expressing fusion proteins of the polypeptide according to the invention and the interacting partner (Vidal and Endoh, 1999, Trends in Biotechnology, 17: 374-81). In this way, it is possible to rapidly identify novel active compounds that can be employed for the therapy of and/or prevention of liver disorders and/or epithelial cancer.

[372]

Assays for identifying pharmacologically active substances that exert an influence on the expression of proteins are well known to the skilled person (see, for example, Sivaraja et al., 2001, US 6,183,956). Thus, cells that express a polypeptide according to the SEQ ID 1 for example, or functional variants thereof can be cultured as a test system for analyzing gene expression in vitro, with preference being given to liver cells. Gene expression is analyzed, for example, at the level of the mRNA or of the proteins using methods generally known to the person skilled in the art. In this connection, the quantity of a polypeptide according to the SEQ ID 1 to 93 (encoded by the SEQ ID 94 to 186) or mRNA present after adding one or more putative pharmacologically active substances to the cell culture is measured and compared with the corresponding quantity in a control culture. This is done, for example, with the aid of an antibody specifically directed against the polypeptide according to the SEQ ID 1 to 93 (encoded by the SEQ ID 94 to 186), or a functional variant thereof, which can be used to detect the polypeptide present in the lysate of the cells. The amount of expressed polypeptide can be quantified by methods generally known to the person skilled in the art using, for example, an ELISA or a Western blot. In this connection, it is possible to carry out the analysis as a high-throughput method and to analyze a very large number of substances for their suitability as modulators of the expression of at least one of the polypeptides according to the SEQ ID 1 to 93 (encoded by the SEO ID 13 to 24) (Sivaraja et al., 2001, US 6,183,956). In this connection, the substances to be analyzed can be taken from substance libraries (see, e.g. DE19816414) that can contain many thousands of substances, which are frequently very heterogeneous.

[373]

The invention will now be further illustrated below with the aid of the figures and examples, representing preferred embodiments and features of the invention without the invention being restricted hereto.

[374] [375]

# Figure 1 to 8 RNA expression levels in hepatocellular carcinoma (HCC) samples

Summary boxplot of expression values in HCC versus non-diseased liver cDNA microarray experiments is provided. The box plot is a graphical representation of  $\log_2$  expression value ratios with the median value indicated by a horizontal line in each box. The extent of each box indicates the iqr = interquartile range (+/-  $25^{th}$  percentile of median value); whiskers indicate of 1.5 times the iqr. Ratios that do not fall within this range are indicated with small circles. For each nucleic acid according to the invention (SEQ ID 95 to 186) elevated expression is apparent in HCC in comparison to non-diseased liver samples. For gene abbreviations see Tables 2A to 2D (\*\*) c-syn represents three alternative nucleotide transcripts with corresponding three protein products.

[377]

## [378] Figure 9 to 99: RNA expression levels in various diseased liver samples and normal tissue(s)

[379] Summary boxplots of expression values (SEQ ID 94 to 186) inHepatocellular Carcinoma (HCC), Focal Nodular Hyperplasia (FNH) and Cirrhosis samples (Cirrh.) versus non-neoplastic liver cDNA microarray experiments are provided. The box plot analogs are used as described in Figure 1. For each nucleic acid according to the invention, elevated expression is apparent in HCCs and most of the FNHs samples.

Legend: A= HCC; B= FNH; C= Cirrh. For gene abbreviations see Table 2A to 2D (\*\*) c-syn represents three alternative nucleotide transcripts with corresponding three protein products.

[380] [381]

# Figure 100 to 104: Verification of differential gene expression when compared to normal tissue(s) and other types of cancer

The Assay-On-Demand (Applied Biosystems, USA) quantitative PCR (Q-PCR) method is utilized for verification of disease deregulated expression of nucleic acids PACE4; BIGH3; s.t.OCIA; SDCCAG28; Rab2; TM4SF4; DAD-1. In Figures 100 to 103, for example, the following commercially available Assay-On-Demand primers are employed: Hs00159844\_m1 for PACE4 (SEQ ID 98); Hs00154671\_m1 for BIGH3 (SEQ ID 99); Hs00215197\_m1 for s.t.OCIA (SEQ ID 101); Hs00246405\_m1 for SDCCAG28 (SEQ ID 102); Hs00234094\_m1 for Rab2 target (SEQ ID 106), Hs00270335\_m1 for TM4SF4 (SEQ ID 112); Hs00154671\_m1 for DAD-1 (SEQ ID 140). In another example (Figure 104), the AKR1C1 PCR product is monitored accordingly by incorporation of fluorescent double-stranded DNA intercalating molecules such as SYBR green. The increased expression of AKR1C1 (SEQ ID 96) in

WO 2005/085861

HCC when compared to normal liver (NNL) is verified by using the SEQ ID 199 and SEQ ID 200 primers; data for B and C are not available. Overall, Mann-Whitney-U Test (non-parametric test applied for non-normally distributed data) is performed as Wilcoxon Rank Sum Test (Hollander & Wolfe, 1973, Nonparametric statistical inference. New York: John Wiley & Sons, pgs. 27-33, 68-75; Bauer, D.F., 1972, J. Amer. Statistical Assoc. 67, pgs 687-690). The expression values typically do not fit to a normal distribution so averaging the values may be misleading. However, analysis of the median values demonstrates significant differences in most of the cases between experimental and reference values, particularly in the large data sets.

[383] Legend: A= Hepatocellular Carcinoma (HCC); B= Focal Nodular Hyperplasia (FNH); C= Cirrhosis (Cirrh.); D= Non-Neoplastic liver (NNL). For gene abbreviations see Table 2A to 2D.

#### Figure 105: SDCCAG28 protein expression in tissues

[385] Protein extracts are subjected to immunoblot analysis with HuCAL<sup>TM</sup> antibodies (Morphosys AG, Germany) specific to recombinant SDCCAG28 protein (e.g., MOR3491 anti ORI010), in order to determine the level of expression of the protein in human tissues [a= ORI010 (human SDCCAG28 recombinant protein); b= Hepatocellular Carcinoma (HCC); c= Normal Liver (NL); d= hepatoma HepG2 cell line. Annotated 33kDa position reflects a size of the predicted SDCCAG28 protein. Following incubation with an anti-HIS mouse antibody to specifically detect the HuCAL™ antibody and a horse-radish peroxidase (HRP) conjugated anti-mouse antibody the immune complexes are detected with a chemiluminescent HRP substrate. It is evident that the native SDCCAG28 protein migrates slightly faster than the recombinant SDCCAG28 protein (approximately 44 kDa band in lane a compared with 40.5 kDa bands prominent in lanes b and d). The intensities of the SDCCAG28 protein band are clearly stronger in the HCC tissue and in the HepG2 hepatoma cell line lysate (lanes b and d, respectively) than in the normal liver tissue (lane c). These analyses indicate that SDCCAG28 protein, the functional product of the SDCCAG28 mRNA specifically upregulated in HCC, is also highly overexpressed in HCC when compared to NNL.

[386] [387]

[384]

## Figure 106 to 107: Expression of HCC deregulated genes correlates with proliferation of hepatoma cells

[388] Proliferation-dependent expression of target gene sequences according to the invention in hepatoma cells Hep3B (Figure 106) and HepG2 (Figure 107) following serum stimulation for 8 hours (black columns) and for 12 hours (white columns) of quiescent cells. The log<sub>2</sub>-transformed ratios of serum-stimulated vs. quiescent expression values from cDNA microarray experiment readout are provided. The

substantial increase in the level of expression of these sequences (for example, (ZNF216) SEQ ID 95; (AKR1C1) SEQ ID 96; (PACE4) SEQ ID 98; (SDCCAG28) SEQ ID 102; (TMP21) SEQ ID 104 and (RAB2) SEQ ID 106) in proliferating compared to quiescent hepatoma cells suggests that elevated expression of these sequences is functionally significant for liver cancer cell growth. For gene abbreviations see Table 2A to 2D.

[389] [390]

## Figure 108 to 109: Effect of dUT specific inhibitor on growth of proliferating liver cancer (hepatoma) cell lines

[391] Specific dUT enzyme inhibitor (DMT-dU

(5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyuridine) (Sigma; No. D7279) is added to the hepatoma cells (Hep3B in Figure 108 and HepG2 in Figure 109) at the 10, 25, 50, 100, 250 and 500  $\mu$ M final concentrations in a maximum of 3  $\mu$ l of the appropriate solvent. Following incubation of the cells for 24 (black columns) and 48 hours (white columns) respectively, cell viability is assessed via an MTT

(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) reduction assay known in the prior art (CellTiter 96 Aqueous One Solution Cell Proliferation Assay; Promega), and plotted relative to the number of cells in wells not treated with the inhibitor (control = 0; no inhibitor added). The relationship between the increased concentration of the inhibitor and absorbance (A= 495nm) reflects the Hep3B/ HepG2 cytostatic/ anti-proliferative response, suggesting that dUT gene correlates with human liver tumor cell proliferation.

#### **Examples**

[392] [393]

#### Example 1: Preparation of HCC subtracted cDNA libraries

RNA is isolated from three pathologist-confirmed HCC tumor samples and from three pathologist-confirmed non-diseased human liver samples using the TRIZOL reagent (Invitrogen) according to standard methods (Chomczynski & Sacchi, 1987, Anal. Biochem. 162:156-159). The tissues used for the generation of cDNA libraries is from patients that provided specific informed consent for utilization of this material for research purposes, including commercial research. mRNA is converted to double stranded cDNA with reverse transcriptase and DNA polymerase as described in the instructions provided in the "PCR select cDNA subtraction kit" from Clontech Laboratories. To enrich for cDNAs specifically increased and decreased in HCC, cDNAs expressed in common and at similar levels in the reference liver pool and in HCC are removed by subtractive suppressive hybridization (SSH) according to the instructions provided in this kit and as described by Diatchenko et al. (1996, Proc. Natl. Acad. Sci.

17

USA 93:6025-6030). The SSH steps are performed in both directions (subtracting non-diseased liver cDNAs from HCC cDNAs and subtracting HCC cDNAs from non-diseased liver cDNAs) so the resulting cDNA molecules represent nucleic acid sequences both up- and down-regulated in HCC but do not represent those that are not differentially expressed. In addition a normalized but not subtracted HCC cDNA library is generated to better represent rare mRNA transcripts in HCC tissues. These cDNAs are separately cloned into the pCRII vector (Invitrogen) by ligation into this plasmid followed by electrophoretic transformation into *E. coli* XL-1-Blue electroporation-competent cells (Stratagene). The cloning is carried out as described by the supplier of the vector and competent cells. Cloned differentially expressed cDNAs are plated onto selective (ampicillin) media to isolate individual clones. 960 clones are isolated from each SSH library and 384 clones isolated from the normalized HCC library and cultures established in 96-well microtiter plates. Together these cDNA clones provide a unique representation of mRNA expression specific for human HCC tissue.

[395]

#### Example 2: Preparation and hybridization of HCC cDNA microarrays

[396] [397]

1 ml cultures of the SSH cDNA library clones described above are established and the cDNA inserts amplified by PCR with primers specific to the vector sequence flanking the cDNA inserts. The M13 forward (5'- gtaaaacgacggccag-3'; SEQ ID 42) and M13 reverse primers (5:-caggaaacagctatgac-3'; SEQ ID 43) are employed for the PCR amplification of clone inserts. Fifty microliters of the bacterial cultures are heat denatured at 95°C for 10 minutes, debris removed by centrifugation, and 2 µl of the supernatant included in a standard PCR [1X Amplitaq PCR buffer, 2.5 mM MgCl<sub>2</sub>, 37.5 nM each primer, 0.5 mM each of dATP, dCTP, dGTP and dTTP and 1.5 units Amplitaq DNA polymerase (Applied Biosystems)]. Reaction conditions are 95°C for 5 minutes followed by 35 cycles of: 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 60 seconds; then followed by 72°C for 7 minutes and then cooled to 4°C. Amplification of cDNA inserts is confirmed by electrophoresis of a 5% of the PCR on a 1% agarose gel comprising 0.4 mg/ml ethidium bromide and run in 1X Tris Acetate EDTA (TAE; 40mM Tris-acetate, 1mM EDTA, pH 7.5) buffer. Each of the SSH clone amplified insert sequences is affixed to sialinized glass microscope slides (GAPS Corning) using a GeneticMicrosystems 417 cDNA arrayer robot to generate custom HCC cDNA microarrays. The protocol for spotting the cDNA inserts to the slides is according to that published by Hedge et al. (2000, Biotechniques 29:548-560) except that PCR products are spotted directly from the PCR microtiter plates without purification or adjustment of the cDNA buffer. In addition to the SSH cDNA clone inserts, numerous control DNAs are spotted onto the microarrays as controls for hybridization reactions. Further,

approximately 2000 publicly available cDNA clones corresponding to genes previously reported to be involved in cancer are purchased from the German Genome Research Center (RZPD), expanded, amplified and spotted onto these microarrays as described above. For preparation of hybridization probes, 20 micrograms of RNA from additional pathology-confirmed liver disorders and from the same quantity of pooled non-diseased liver RNA is converted to cy5-fluorescence-labeled and cy3-fluorescence-labeled cDNA, respectively (cy5-CTP and cy3-CTP, Pharmacia) using reverse transcriptase according to the standard methods (Hedge et al., 2000, Biotechniques 29: 548-560). Using this protocol, these labeled cDNAs are competitively hybridized to the HCC microarrays. Following prehybridization at 42°C for 45 minutes in 5X SCC (0.75 M sodium citrate, 75 mM sodium citrate, pH 7.0); 0.1% SDS (sodium dodecyl sulfate) and 1% BSA (bovine serum albumin), the hybridization is carried out overnight at 42°C in buffer comprising 50% formamide, 5XSSC, and 0.1% SDS. Hybridized slides are washed in stringent conditions (twice at 42°C in 1X SSC, 0.1% SDS for 2 minutes each; twice at room temperature in 0.1X SSC, 0.1% SDS for 4 minutes each; and twice at room temperature in 0.05X SSC for 2 minutes each), dried and analyzed with the Genetic Microsystems 418 cDNA microarray scanner and associated Imagene 4.1 image analysis software according to the manufacture's recommendations.

[398]

... [399]

# Example 3: Independent verification of differential expression of the nucleic acids and polypeptides according to the invention

[400]

RNA is isolated from human patient samples as described in detail above. HCC samples for this analysis are not from the same patients as employed for production of the HCC SSH library or for cDNA microarray chip hybridization. In addition to HCC samples, RNA is prepared from independent non-diseased liver samples to assess expression of the nucleic acids according to the invention in non-diseased liver tissue. Further, RNA is prepared from additional non-diseased and cancer tissues to assess expression of the nucleic acids according to the invention in other normal human tissues and other human cancers. One mg of RNA is converted to single-strand cDNA with the aid of Superscript reverse transcriptase (Invitrogen) in dATP, dCTP, dGTP, and dTTP (0.4 mM each), 7.5 nM random 6-nucleotide primer (hexamers), 10 mM dithiothreitol and 1 unit RNAse inhibitor using standard procedures known in the art (Sambrook et al., Molecular Cloning, 2<sup>nd</sup> ed., 1989, Cold Spring Harbor Press, NY, USA, pp. 5.52-5.55). The presence or absence and the relative concentration of the nucleic acids according to the invention is then confirmed and verified by amplification of these sequences from the cDNA with primer pairs specific to each nucleic acid according to the invention in quantitative kinetic PCR experiments. The

Assay-On-Demand (Applied Biosystems, USA) quantitative PCR method well known for the person skilled in the art might be utilized for verification of disease deregulated expression of nucleic acids according to the invention (Figure 3A/3B). For example, the Assay-On-Demand ID primer numbers for PACE 4, BIGH3, s.t.OCIA, SDCCAG28, Rab2, PRKAR1A, PRDX1, IQGAP2, TM4SF4, DAD-1 target genes are given in the following Table 8.

[401] [402]

Table 8: Target clones and their Assay-On-Demand ID Table 8

Gene	Assay ID (Catalogue Number)			
PACE4	Hs00159844_m1			
BIGH3	Hs00154671_m1			
s.t.Ocia	Hs00215197_m1			
SDCCAG28	Hs00246405_m1			
Rab2	Hs00234094_m1			
PRKARIA	Hs00267597_m1			
PRDX1	Hs 00602020_m1			
IQGAP2	Hs00183606_m1			
TM4SF4	"· Hs00270335_m1			
DAD-1	Hs00154671_m1			

[403]

[404]

In further example, AKR1C1 PCR product is monitored accordingly by incorporation of fluorescent double-stranded DNA intercalating molecules such as SYBR green. The AKR1C1 cDNA is validated by using following primers: AKR1C1-p1, 5'- ttggaaaggtcactgaaaaatct-3' (SEQ ID 199) and AKR1C1-p2, 5'-gctggctgcggttgaagttgg-3' (SEQ ID 200) verifying the specific expression of this gene (SEQ ID 96) in HCCs when compared to normal liver samples (Figure 104).

[405]

Usally PCR is performed according to the manufacturer's instructions using TaqMan Universal PCR Mastermix (Cat.Nr. 4304437; Applied Biosystems, Branchburg, New Jersey USA). Kinetic quantitative PCR analyses are performed by using the 7000 Sequence Detection System (Applera). The PCR Setup included two reference genes [GAPDH and Beta-Actin (GAPDH primers used = GAPDH-p1, SEQ ID 187; GAPDH-P2, SEQ ID 188; GAPDH-p3, SEQ ID 189) (B-Actin primers used = BActin-p1, SEQ ID 190; BActin-p2, SEQ ID 191; BActin-p3, SEQ ID 192)] which are used for independent normalisation of the investigated target genes. A standard curve

(125ng, 25ng, 5ng and 1ng) is used for proper calculation of the expression data. The PCR sample contained 12.5 ng of cDNA, 12.5 µl Universal PCR Mastermix and 1.25µl Assay-On-Demand reagent to give a final volume of 25µl. PCR conditions are used according to the manufacture's instructions (2 min 50°C, 10 min 95°C followed by 40 cycles of 15 sec 95°C and 1 min at 60°C). Amplification of cDNA inserts is additionally confirmed by electrophoresis of a 10% of the PCR on a 2.5% agarose gel comprising 0.5 mg/ml ethidium bromide and run in 1X Tris Acetate EDTA (TAE) buffer. Standard controls for RT-PCR including RNAse treatment of samples prior to cDNA synthesis and omission of reverse transcriptase routinely demonstrate the specificity of these reactions. The kinetic quantitative RT-PCR (Q-PCR) verifies the over expression of sequences according to the invention in liver cancer and other liver disorder relative to non-diseased liver (Figures 100 to 104).

[406]

. . . .

Furthermore, the protein expression analyses indicate that for example SDCCAG28 protein, the functional product of SDCCAG28 mRNA specifically upregulated in HCC, is also significantly overexpressed in HCC (Figure 105). To detect SDCCAG28 protein expression in HCC samples standard western blot analysis known in the prior art is performed using protein extracts derived from frozen tissues (stored in liquid nitrogen). The 50 µm sections are obtained (HCC, normal liver) using a refrigerated microtome (cyrocut, Leica CM3050), wherein the identity and homogeneity of the tissues under scrutiny is verified by H&E-staining of sections taken before, in between and after each cutting process. Tissues sections (HCC, normal liver), SDCCAG28 antigen (Morphosys AG, Germany) and HepG2 cells are resuspended in ice-cold RIPA-buffer (50 mM Tris-HCl pH 7.4, 250 mM NaCl, 0.1% SDS, 1% deoxycholate, 1% NP-40) supplemented with 2 μg/ml leupeptin, 2 μg/ml pepstatin, 2 μg/ml aprotinin, 1 mM phenylmethylsulfonylfluoride (PMSF), and 2 mM dithiothreitol followed by homogenization through sonication (2 bursts of 5 seconds) on ice. After incubation for 20 minutes on ice, the lysates are cleared by two centrifugational steps in a microcentrifuge at 13 000 rpm for 15 minutes at 4°C and the supernatants are collected. Protein concentrations are determined by the Bradford assay(Biorad) using bovine serum albumin as a standard. Equal amounts of protein (typically 10-30 µg) are separated on a 12% SDS-PAGE gel and transferred electrophoretically to a polyvinylidene diflouride (PVDF) membrane (Hybond-P, Amersham Biosciences) through Semidry-blotting (TE 70, Amersham). The membrane is blocked for 1 hour (or overnight) at room temperature in blocking solution [5 to 10% milkpowder (Micrbiology/Lactan:1.15363.0500) in TBS-T (25 mM Tris-HCl pH 7.4, 137 mM NaCl, 3 mM KCl, comprising 0.1% Tween-20 (Merck: 822184) and 2% BSA (Sigma: A-7906)] and incubated with the primary antibody specific for the SDCCAG28 recombinant protein (Morphosys AG, Germany), usually in the concentration between

30ng to 50ng/ml in TBS-T/1% milk solution at 4°C overnight with agitation. After removal of the primary antibody solution and several washes in TBS-T, the membrane is incubated with a mouse anti-HIS antibody to specifically detect the primary antibody (Dianova, 1:25000) followed by a rabbit anti-mouse HRP (horse-radish peroxidase)-conjugated antibody (Dako, 1: 1000) for one hour at room temperature. Following several washes in TBS-T, detection is performed through chemiluminiscence (ECL, Amersham) detection of HRP activity and exposing the membrane to x-ray film.

These data provide independent verification of deregulated expression of the nucleic acids and polypeptides according to the invention in HCC. Expression of the nucleic acids and polypeptides according to the invention is either absent or observed only at very low levels in non-diseased liver, thereby validating the differential expression of these nucleic acids identified by hybridization to the cDNA microarray. The results provide surprising evidence that the nucleic acids and polypeptides according to the invention can be used to diagnose, prevent and/or treat disorders according to the invention.

[408] [409]

[410]

### Example 4: Sequences according to the invention are increased in proliferating liver cancer (hepatoma) cell lines

Human hepatoma cell lines (Hep3B, HepG2) are cultured in DMEM supplemented with 10% fetal bovine serum (FBS) in a humidified incubator with 5% CO at 37°C. The cells are split to about 20% confluency and subsequently rendered quiescent by culturing in the absence of serum for 3 days. After the starvation period, the cells are stimulated to proliferate by the addition of 10 % FBS to the media. Samples are taken before and following the induction of cell growth (0, 8 and 12 hours) for the preparation of RNA and for determination of the position of the cells in the cell cycle by FACS (fluorescence activated cell sorting) analysis. Accordingly, to determine the cell cycle distribution by propidium iodide (PI) staining, the cells are harvested by trypsinization, washed twice with phosphate buffered saline (PBS) and finally resuspended in 500 µl PBS. Subsequently, 5 ml prechilled methanol is added. After 10 minutes incubation at -20°C the cell suspension is directly used for FACS analysis following 3 times washing in PBS, resuspended in 500 µl propidium iodide (PI) staining buffer (DNA-Prep Stain, Part No. 6604452; Beckman Coulter) and incubated for 15 minutes at 37°C. Finally, 70 µl of 1M NaCl is added and the samples are kept on ice protected from light prior to analysis on an EPICS XL-MCL flow cytometer (Beckman Coulter). Cells prepared from an asynchronous cell population are used as reference.

[411] The isolated RNA is used to monitor the expression of genes in quiescent vs. pro-

liferating hepatoma cells by cDNA microarray analysis. Following labeling with fluorescent dyes as described in example 2, the RNAs are hybridized on a specifically developed HCC- specific cDNA microarray chip that also contained control genes which are known to be expressed in a cell cycle dependent manner. Finally, the data are analysed using ImaGene 4.1 and GeneSight software packages. The signals obtained for 0 hours samples isolated before the addition of serum are used as reference. The log<sub>2</sub>-transformed ratios of serum-stimulated vs. quiescent expression values from the cDNA experiment readout is provided in Figure 106 to 107.

These data indicate that the sequences according to the invention are correlated with human liver tumor cell proliferation. Compared to the state of the art, these nucleic acids and polypeptides therefore surprisingly allow improved, more sensitive, earlier, faster, and/or non-invasive diagnosis of the liver disorders and/or epithelial cancers.

[413] [414]

### Example 5: Effect of dUT specific small molecule inhibitor on growth of proliferating liver cancer (hepatoma) cell lines

[415] To determine the effects of small molecule inhibitors of activity of enzyme polypeptides according to the invention on the growth of human hepatoma cells, for example a specific dUT inhibitor (DMT-dU (5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyuridine) (Sigma; No. D7279) is employed. Hep3B or HepG2 cells are seeded into 96-well plates at 10,000 and 7,500 cells, respectively, in a total volume of 150 µl of growth DMEM media supplemented with 10% fetal calf serum. The next day of incubation at 37 °C, the dUT enzyme inhibitor is added to the cells at the 10, 25, 50, 100, 250 and 500 µM final concentrations in a maximum of 3 µl of the appropriate solvent. Following incubation of the cells for 24 and 48 hours, cell viability is assessed via an MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) reduction assay known in the prior art (CellTiter 96 Aqueous One Solution Cell Proliferation Assay; Promega) according to the manufacturer's instructions. Thirty µl of the assay reagent are added directly to the culture wells, incubated for 1-2 hours and then absorbance at 495 nm is recorded using a microtiter plate reader (Anthos 2010; Anthos Labtec Instruments). Each value represents the mean of at least 4 replicates. Control cells (= 0)

[416] The relationship between the increased concentration of the inhibitor and absorbance indicates that application of the aforementioned specific dUT inhibitor to hepatoma cells elicits a cytostatic/ anti-proliferative response, suggesting a specific role of the dUT gene in human liver tumor cell proliferation.

receive solvent only (Figures 108 to 109)

[417] [418]

### Example 6: Elevation of enzymatic activity in hepatoma cells correlates with

#### AKR1C1 target gene overexpression in liver disorders

- [419] A comparison of the enzymatic activity of a target gene encoded polypeptide gives insight whether a deregulation of mRNA transcript is also reflected by a significant increase in activity that indicates its functional role in tumor biology. In a substrate-specific reaction, the activity of AKR1C1 (SEQ ID 96) is determined (see below Table 9).
- [420] Enzymatic assays are performed by using lysates prepared from frozen tissues (stored in liquid nitrogen) or from cell pellets derived from asynchronously growing human hepatoma cell lines (Hep3B, HepG2). 50 µm sections obtained from pieces of frozen tissues using a freezing microtome (Cryocut, Leica CM3050) and the identity and homogeneity of the tissues under scrutiny is verified by a pathologist following H &E-staining of sections taken before, in between, and after each cutting process.

  Tissues sections as well as frozen cell pellets are resuspended in ice-cold lysis buffer (50 mM KPO<sub>4</sub> pH 7.0, 10 mM KOAc, 2 mM MgCl<sub>2</sub>) supplemented with 2 µg/ml leupeptin, 2 µg/ml pepstatin, 2 µg/ml aprotinin, 1 mM phenylmethylsulfonylfluoride, and 2 mM dithiothreitol followed by homogenization through sonication (2 bursts of 3 seconds) on ice. After incubation for 15 minutes on ice, the lysates are cleared by two centrifugation steps in a microcentrifuge at 13,000 rpm for 15 minutes at 4°C and the supernatants are collected. Protein concentrations are determined by the Bradford assay (Biorad) using bovine serum albumin as a standard.
- The AKR1C1 enzymatic activity is measured spectrophotometrically based on the oxidation of 1-acenaphthenol in 1.0 ml systems containing 1 mM 1-acenaphthenol (in 4% methanol), 2.3 mM NAD<sup>+</sup>, and various amounts of whole cell lysate in 100 mM potassium phosphate buffer (pH 7.0). Reactions runs at 25°C wherein the change in absorbance of pyridine nucleotide over time is monitored at 340 nm on a Beckman DU640 spectrophotometer. Absorbance values are plotted versus time, and slope-values versus time (min<sup>-1</sup>) are calculated from initial reaction velocities using linear least-squares regression analysis, see Table 9 (HCC = Hepatocellular Carcinoma; NNL = Non-Neoplastic (Normal) Liver).

[422]

[423]

[424]

[425]

[426] Table 9: Enzymatic assay for AKR1C1 (SEQ ID 96)

[427]

Table 9

Tissue	Protein con-	Slope	Weighted Mean of

	centration [µg	time '1	the slope
	]	[min <sup>-1</sup> ]	[min <sup>-1</sup> ]
NNL1	100	0.0048	0.0043
	200	0.0076	
NNL2	100	0.0057	0.0054
	200	0.0102	
HCC11	100	0.0130	0.0127
	200	0.0247	
HCC28	100	0.0097	0.0095
	200	0.0187	
НСС30	100	0.0334	0.0317
	200	0.0599	
HCC2	100	0.0136	0.0102
	200	0.0137	
HCC13	100	0.0158	0.0128
	200	0.0197	

[428]

[429]

The HCC samples (HCC11, HCC28, HCC30 and HCC2) are characterized by a weighted mean of the slope approximately 2-3-fold higher than the NNL samples. These data clearly show the correlation between the upregulation of AKR1C1 gene transcript in HCC with the induction of the AKR1C1 enzymatic activity in hepatoma cell lines, suggesting that the sequences according to the invention are correlated with human liver tumor cell proliferation. Compared to the state of the art, these nucleic acids and polypeptides therefore surprisingly allow improved, more sensitive, earlier, faster, and/or non-invasive diagnosis of the liver disorders and/or epithelial cancers.

[430]

[431]

## [432] Example 7: A method of diagnosing using HCC specific probes

[433]

A diagnostic method for disorders according to the invention preferably based on the polymerase chain reaction (PCR) can be established. A standard PCR detection of nucleic acid sequences of the invention can be sufficient to identify, for example, circulating HCC tumor cells in the blood stream of the patient. Detection of expression of nucleic acid sequences of the invention in tumor biopsy material however, such as from a fine needle biopsy, would also be a preferred indication for this diagnostic procedure. Nucleic acid sequences of the invention, ZNF216 (SEQ ID 95) for example, are not detected in most non-diseased tissues and relatively specifically expressed in e.g. HCC. Elevated expression of this nucleic acid in FNH and HCC is also demonstrated indicating the potential discriminatory power of such an approach for differential diagnosis of liver diseases (Figures 1 and 9; Tables 3A/4A).

[434] The PCR diagnostic would preferably require approximately 1 pg, preferably at least 100 ng, more preferably at least 1 µg of RNA isolated from patient material. In the preferred utilization the RNA would be isolated according to standard procedures from, e.g., the white blood cell fraction preferably from circulating blood obtained by the minimally invasive venupuncture procedure. In this preferred case, the procedure would detect the presence of HCC tumor cells in the blood circulatory system. RNA could similarly be isolated from liver or other tissue biopsy material.

[435] For specific detection of ZNF216, the PCR diagnostic would include several primers specific for ZNF216 nucleic acid sequence, including a specific primer set for cDNA synthesis from the RNA generated from the patient sample, such as for example (ZNF216-p1, 5'-ttctttctgcacatgaaacatctg-3' (SEO ID 195). Also included would be forward and reverse PCR primers specific for ZNF 216 nucleic acid sequence such as for example, ZNF216-p2, 5'-gagaggacaaaataactaccc-3' (SEQ ID 196) and ZNF216-p3. 5'-caattcaggagctttttcttca-3' (SEQ ID 197), and for increased specificity and heightened sensitivity a fluorescently-labeled hydrolysis probe would be included such as, for example, ZNF216-pr, 5'-tactgggctgagaaactgatggactgggctga-3', SEQ ID 198 (from nucleotide 694 to 663 of the SEQ ID 95 reverse strand). The specificity of this detection assay may be further heightened with alternative primers specific for the ZNF216 sequence including an independent pair of specific PCR forward and reverse primers ("nested" primers) located on the amplicon of the outer forward and reverse PCR primers. In this case the probe primer would be specific for the amplicon the nested PCR primer pair.

[436] Quantitative assessment of AKR1C1 mRNA levels, for example, may also be achieved in such detection strategies as illustrated in Figure 3C using kinetic quantitative PCR with, for example:

cDNA may be prepared from the patient RNA sample following digestion of the RNA with RNAse-free DNAse-1 (Roche) to eliminate potential contamination by genomic DNA. This contamination possibility is further controlled by including primers for PCR amplification from sequences of different exons of the gene such that PCR products resulting from a genomic DNA template (and thereby not reflective of expression of the mRNA corresponding to for example ZNF216) would be larger than the RNA specific PCR products. cDNA synthesis can e.g. be primed by the ZNF216-specific ZNF216-p1 (SEQ ID 195;at about 1 μM) with the aid of reverse tran-

scriptase [such as Maloney murine leukemia virus reverse transcriptase (Roche) at about 2 unit/reaction] in an appropriate buffer such as 50 mM Tris-HCl, 6 mM MgCl2, 40 mM KCl, and 10 mM dithiotreitol, pH 8.5. Also required in the cDNA synthesis reaction is dATP, dCTP, dGTP and dTTP, each at about 1 mM, RNAse inhibitor, such as placental RNAse inhibitor (Roche) at about 1-10 units/reaction. cDNA synthesis would be preferably carried out at 42°C for 30 to 60 minutes followed by heating at 95° C for 10 minutes to denature the RNA template. The resulting cDNA can be employed as the template for a PCR to detect ZNF 216 in the blood (or liver or tissue biopsy sample). The additional reagents required for PCR detection of ZNF216 would preferably also be provided including: 10X Taq DNA polymerase buffer (500 mM Tris-Cl pH 8.3, 25 mM MgCl<sub>2</sub>, 0.1% Triton X-100); a mixture of dATP, dCTP, dGTP and dTTP for a final concentration of 0.2 mM each; Tag DNA polymerase (2.5U/reaction), and ZNF216 specific primers such as ZNF216-p1 (SEQ ID 195), ZNF216-p2 (SEQ ID 196) and ZNF216-p3, (SEQ ID 197), and for increased specificity and heightened sensitivity a fluorescently-labelled hydrolysis probe ZNF216-pr, SEQ ID 198 (0.1 - 1 µM final concentration). A positive control for PCR amplification such DNA from a plasmid clone with the ZNF216 sequence insert would preferably also be included (1-10 ng/reaction). The PCR can e.g. be carried out over 22-40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 60 seconds. As indicated above, preferred additional sensitivity and specificity may be achieved in this diagnostic procedure by utilization of the additional ZNF216primer set located within the sequence amplified with the original PCR primer set. In this case a subsequent PCR under conditions similar to those utilized in the first PCR reaction except that would be employed to amplify the nested sequence in a reaction that included 1-10 µl of the first PCR as the template DNA. Alternatively, the reaction may preferably be carried with the first primer set for 10-15 cycles after which and 1-10 ul of this reaction then included as template in a new PCR reaction with nested primers (and including all the necessary PCR components). Detection of ZNF216 specific PCR product(s) should preferably utilize agarose gel electrophoresis as is known in the art and described in previous examples. Included in the diagnostic should preferably be a comparable fluid or tissue extract as a control for such PCR-based diagnostic test. This may include serum or plasma from non-diseased individuals and/or serum, plasma or tissue extracts from an appropriate animal model. If the PCR-determined expression of the nucleic acid according to the invention such as the product of the reaction with primers ZNF216-p1 (SEQ ID 195), ZNF216-p2 (SEQ ID 196), ZNF216-p3 (SEQ ID 197) and ZNF 216-pr (SEQ ID 198) is upregulated in the sample isolated from the patient relative to the control and if in particular the upregulated expression essentially matches the disorder specific (mean) expression ratios then such matching is indicative

of the patient suffering from the disorder. Variations on this approach can also be appreciated. The cDNA synthesis and PCR amplifications can be carried our sequentially or simultaneously in a single reaction vessel utilizing heat stabile DNA polymerases with reverse transcriptase activities, such as provided by the Titan one-tube or Carboxydothermus DNA polymerase one-set RT-PCR systems from Roche. Alternatively the PCR product can be monitored by incorporation of fluorescently labeled primers or various fluorescence-based indicators of PCR product including the Taqman probe hydrolysis systems, as described above and with fluorescent double-stranded DNA intercalating molecules such as SYBR green. The fluorescent-based approaches provide advantage as the accumulation of PCR product can be continuously monitored to achieve sensitive quantitative assessment of expression of the nucleic acid according to the invention. This should be particularly advantageous for nucleic acids increased in blood or tissues of disorders according to the invention but also present at lower levels in non-diseased patients and tissues such that quantitative information about the level of expression of the nucleic acid is acquired. Further, as with this example, accurate quantitation of nucleic acid expression levels contributes to differential diagnosis, between cirrhosis and HCC for example. Comparison of this data with supplied standards indicative of disease and absence of disease provides an important advantage for such a diagnostic procedure.

[438] Additional variations on this diagnostic strategy include simultaneous detection of multiple nucleic acids according to the invention and/or of nucleic acids according to the invention together with other nucleic acids implicated in the disorder. Further hybridization-based diagnostic detection of nucleic acids according to the invention is also envisioned. In this case mRNA detection preferably utilizing detection of RNA transferred to a membrane by capillary or electrophoretic blotting, RNAse protection or in situ hybridization on patient cells or tissue biopsy samples is also effective.

[439] By similar methods and variants thereof the nucleic acids according to the invention and/or of nucleic acids according to the invention together with other nucleic acids can be utilized for diagnosis of the disorders according to the invention.

[440]

## [441] Example 8: A method of diagnosing via antibody detection of polypeptides according to the invention

[442] A preferred diagnostic method for disorders according to the invention is based on antibodies directed against a polypeptide according to the invention. For example, a diagnostic procedure may preferably employ serum detection of specific upregulated gene proteins via enzyme-linked immunosorbent assay (ELISA) assay. In a simple form the diagnostic assay preferably includes a microtiter plate or strip of microtiter wells, e.g., thoroughly coated with an isolated and purified antibody specific to a

polypeptide according to the invention such as, ZNF216 (SEQ ID 2), AKR1C1 (SEO ID 3). The antibody may for example be an affinity purified polyclonal antibody, such as is commonly raised in rabbits, for example, or a purified monoclonal antibody such as is commonly produced in mice according to procedures well established in the art (Cooper, H.M. & Paterson, Y., (2000), In Current Protocols in Molecular Biology (Ansubel, F.A. et al., eds.) pp. 11.12.1 – 11.12.9, Greene Publ. & Wiley Intersci., NY): (Fuller S.A. et al., (1992), In Current Protocols in Molecular Biology (Ansubel, F.A. et al., eds.) pp. 11.4.1 - 11.9.3, Greene Publ. & Wiley Intersci., NY). Preferably, the antibody may a recombinant antibody obtained from phage display library panning and purification as has been described by Knappik et al. (2000, J. Molec. Biol. 296:57-86) or by Chadd and Chamow (2001 Curr. Opin. Biotechnol.12:188-94), or a fragment thereof. The antibody coating is preferably achieved by dilution of the anti-ZNF216.pr antibody or anti-AKR1C1.pr antibody to 1-100 µg/ml in a standard coating solution such as phosphate buffered saline (PBS). The antibody is preferably bound to the absorptive surface of the microtiter well (such as a Nunc Maxisorp immunoplate) for 60 minutes at 37°C, or overnight at room temperature or 4°C. Prior to binding sample to the coated wells, the wells are preferably thoroughly blocked from non-specific binding by incubation for 15-60 minutes at room temperature in a concentrated protein solution such as 5% bovine serum albumin in phosphate buffered saline or 5% non-fat dry milk powder resuspended in the same buffer. Preferably, the patient sample material is then applied to the microtiter wells, diluted into the blocking solution to increase specificity of detection. The sample may be for example plasma or serum or protein extract from tissue biopsy or surgical resection prepared according to methods well known in the art (Smith, J.A. (2001) In, Current Protocols in Molecular Biology, Ausubel, F.A. et al., eds) pp. 10.0.1-10.0.23, Greene Publ. & Wiley Intersci., NY). In particular, the patient sample is brought into contact with the antibody-coated well for 30-120 minutes (or longer) at room temperature or at 4°C. Non-specifically interacting proteins are preferably removed by extensive washing with a standard wash buffer such as 0.1 M Tris-buffered saline with 0.02-0.1% Tween 20, for example. Washes are preferably carried out for 3-10 minutes and repeated 3-5 times. Detection of ZNF216 polypeptide in the patient sample is for example achieved by subsequent binding reaction with a second, independent anti-ZNF216 antibody, generated as described above, recognizing a distinct epitope on the ZNF216 polypeptide in the standard twosite 'sandwich' type ELISA. Binding of the second anti-ZNF216 antibody or AKR1C1 antibody is for example achieved by incubating the wells in the antibody (at a concentration of 1-100 µg/ml in blocking solution, for example) at room temperature for 30-60 minutes followed by extensive washing as in the previous step. The second antibody may preferably be directly coupled to an enzyme capable of producing a

colorigenic or fluorgenic reaction product in the presence of an appropriate substrate, such as alkaline phosphatase. Alternatively, for example an anti-species and antiisotype specific third antibody, so coupled to an enzyme, is employed to generate a reaction product that preferably can be detected in a standard spectrophotometric plate reader instrument. For the reaction product development, the washed (as above) antibody-antigen-enzyme complex is preferably exposed to the colorigenic substrate, such as AttoPhos from Roche for about 10 minutes at room temperature, the reaction may be stopped with a low pH buffer such as 50 mM Tris-HCl pH 5.5, or can instead be directly assayed. The amount of specifically bound ZNF216 polypeptide or AKR1C1 polypeptide is for example determined by measurement of the amount of the enzymatic reaction product in each well following excitation at the appropriate wavelength in the spectrophotometer (420 nm in this case). Measurement is preferably made in the plate reader at the emission wavelength (560 nm in this case). Preferably included in the diagnostic is a ZNF216 protein standard or an AKR1C1 protein standard, such as purified recombinant ZNF216 polypeptide or AKR1C1 polypeptide, for example. A dilution series of this protein standard is preferably included in parallel in the ELISA as a control for the reactions and to deduce a protein standard curve for comparison of polypeptide expression levels as is well known in the art. A concentration range corresponding indicative of the particular liver disorder(s) should preferably be provided in the diagnostic. In addition, a comparable fluid or tissue extract should preferably also be included as a control for such ELISA test. This may preferably include serum or plasma from non-diseased individuals and/or serum, plasma or tissue extracts from an appropriate animal model. Such ELISA detection diagnostics are common in the art (see for example, Hauschild et al., 2001, Cancer Res. 158:169-77). The sample: control protein levels determined by ELISA are compared with ELISA-determined disorder specific protein expression ratio values preferably determined in pathologist-confirmed tissues of patients suffering from a disorder according to the invention in relation to control samples. In case the protein level of the sample: control essentially matches the disorder specific protein expression ratio values such matching is preferably indicative of the patient suffering from the disorder. Preferably such diagnosis is carried out for more than 1 polypeptide according to the invention.

[443]

In addition the diagnostic may be directed to detecting an endogenous antibody directed against a polypeptide according to the invention, or a functional variant thereof or fragment thereof present in the sample isolated from a patient which antibody or fragment thereof is directed against a polypeptide according to the invention. Detection of such autoimmune antibodies may be accomplished by methods generally known to the skilled artisan, e.g. by immunoaffinity assays such the ELISA

described in detail above using polypeptides according to the invention or functional variants thereof or parts thereof as a probe. The presence of such autoimmune antibodies is indicative of the patient suffering from a disorder according to the invention.

[444]

In addition or alternatively, a relevant diagnostic kit based upon immunohistochemical detection of at least one polypeptide according to the invention can be formulated. In such a kit, for example a purified antibody or antibodies specific for the polypeptide(s) according to the invention can be included as well as preferably the reagents necessary to detect the binding of the antibody (ies) to patient cells or tissue sections. These reagents include, for example a specific anti-species and subtype specific secondary antibody -directed against a polypeptide according to the invention of a functional variant thereof- preferably coupled to an enzyme capable of catalysis of e.g. a colorigenic substrate or coupled to a fluorophore (such as Texas Red, for example). Preferably the enzymatic substrate would also be included as well as washing and incubation buffers. An additional optional component of such a kit may be a section of positive control tissue, e.g. liver, or tissues or a section from a packed pellet of cells specifically expressing the polypeptide(s) as a positive tissue control. Instructions provided would include preferred and/or alternative methods of antigen retrieval for detection of the polypeptide(s) according to the invention or e.g., indication that frozen, rather than formalin fixed and paraffin-embedded tissue material should be employed. In this case, recommendations would preferably be included for fixation of frozen tissue sample sections, such as immersion in ice-cold acetone for 10 minutes. Further instructions would preferably provide recommendations for the concentration of antibodies to use in the detection of the gene product(s) as well as e.g., recommended and suggested incubation times and temperatures for exposure of the tissue to the immunological reagents provided. Preferred reaction buffers for the antibody incubations, such as 0.01% - 0.1% tween-20 comprising phosphate buffered saline including 3% normal sheep serum, could also be included. Further, specific conditions for washing of the tissue sections prior to and following incubation in the specific antibody would be preferably included, such as for example, 4 washes with 0.1% tween-20 comprising phosphate buffered saline for 5 minutes each. Such immunohistochemical detection protocols are known to a person skilled in the art. In general the kit would preferably include a panel of images of specific immunohistochemical staining results from positive and negative tissue examples and in particular tables indicating which result is indicative of the patient suffering from the disorder to be diagnosed as a user guide. Utilization of such a kit would preferably rule out, support or confirm diagnoses of the aforementioned liver disorders, liver cancer, or epithelial cancers according to the invention.

- As specified above for nucleic acid-based diagnostic approaches, diagnostics based on detection and/or quantitation of polypeptides according to the invention may include 1 or more of such polypeptides. Moreover, simultaneous detection of such polypeptides together with other peptides implicated in the disorders according to the invention may be employed in such diagnostics.
- It will be apparent to those skilled in the art that various modifications can be made to the compositions and processes of this invention. Thus, it is intended that the present invention cover such modifications and variations, provided they come within the scope of the appended claims and their equivalents. All publications cited herein are incorporated in their entireties by reference.

[447]

#### **Claims**

- [001] A diagnostic comprising at least one compound selected from the group consisting of the polypeptide according to SEQ ID 1 to 93, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, and an antibody or an antibody fragment directed against one of the aforementioned polypeptides, combined or together with suitable additives or auxiliaries.
- [002] The diagnostic according to claim 1, wherein the nucleic acid is a probe.

  [003] The diagnostic according to claim 2, wherein the probe is a DNA probe.
- [004] A pharmaceutical composition comprising at least one component selected from the group consisting of the polypeptide according to claim 1, a polypeptide according to SEQ ID 1 to 93, a functional variant of one of the aforementioned polypeptides, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, a nucleic acid which is a nonfunctional mutant variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, a cell comprising one of the aforementioned nucleic acids, a cell comprising the aforementioned vector, an antibody or a fragment of the antibody directed against one of the aforementioned polypeptides, an antibody or a fragment of the antibody directed against a functional variant of one of the aforementioned polypeptides, a vector comprising a nucleic acid coding for one of the aforementioned antibodies, a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibodies, and a cell comprising the vector comprising a nucleic acid coding for one of the aforementioned antibody fragments, combined or together with suitable additives or auxiliaries.
- [005] The pharmaceutical composition according to claim 4, wherein the nucleic acid having a complementary sequence is an antisense molecule or an RNA interference molecule.
- [006] A method of diagnosis of a liver disorder or an epithelial cancer, wherein at least one compound selected from the group consisting of a polypeptide according to the sequence of SEQ ID 1 to SEQ ID 93, a functional variant of one of the aforementioned polypeptides, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, a nucleic acid which is a non-functional mutant variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, an antibody or a fragment of the antibody directed

against one of the aforementioned polypeptides, and an antibody or a fragment of the antibody directed against a functional variant of one of the aforementioned polypeptides, is identified in the sample of a patient and compared with at least one compound of a reference library or of a reference sample.

- [007] The method according to claim 6, wherein the liver disorder, is a disorder selected from the group consisting of cirrhosis, alcoholic liver disease, chronic hepatitis, Wilson's Disease, haemochromatosis, hepatocellular carcinoma, benign liver neoplasms, and focal nodular hyperplasia.
- [008] The method according to claim 6, wherein the epithelial cancer is an adenocarcinoma of an organ selected from the group consisting of the lung, the stomach, the kidney, the colon, the prostate, the skin, and the breast.
- [009] A method of treating a patient suffering from a liver disorder or an epithelial cancer, wherein at least one component selected from the group consisting of a polypeptide according SEQ ID 1 to 93, a functional variant of one of the aforementioned polypeptides, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, a nucleic acid which is a non-functional mutant variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, a cell comprising one of the aforementioned nucleic acids, a cell comprising the aforementioned vector, an antibody or a fragment of the antibody directed against one of the aforementioned polypeptides, an antibody or a fragment of the antibody directed against a functional variant of one of the aforementioned polypeptides, a vector comprising a nucleic acid coding for the antibody, a cell comprising the vector comprising a nucleic acid coding for the antibody, and a cell comprising the vector comprising a nucleic acid coding for the antibody fragment, combined or together with suitable additives or auxiliaries, is administered to the patient in need of a the treatment in a therapeutically effective amount.
- [010] The method of treating according to claim 9, wherein the nucleic acid having a complementary sequence is an antisense molecule or an RNA interference molecule.
- [011] The method of treating according to claim 10, wherein the RNA interference molecule is administered in the form of a double stranded RNA or a vector expressing the double stranded RNA.
- [012] The method according to claim 10, wherein the RNA interference molecule has a size range selected from the group consisting of from 15 to 30 nucleotides.
- [013] The method according to one of claims 9 to 12, wherein the liver disorder, is a

disorder selected from the group consisting of cirrhosis, alcoholic liver disease, chronic hepatitis, Wilson's Disease, haemochromatosis, hepatocellular carcinoma, benign liver neoplasms, and focal nodular hyperplasia.

- [014] The method according to one of claims 9 to 13, wherein the epithelial cancer is an adenocarcinoma of an organ selected from the group consisting of the lung, the stomach, the kidney, the colon, the prostate, the skin, and the breast.
- [015] A method of stimulating an immune response to a polypeptide according to the sequence of SEQ ID 1 to SEQ ID 93, or a functional variant thereof in a patient suffering from a liver disorder or an epithelial cancer, wherein at least one component selected from the group consisting of a polypeptide according to the sequence of SEQ ID 1 to SEQ ID 93, a functional variant thereof, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, and a cell comprising the aforementioned vector, is administered to the patient in need of such treatment in an amount effective to stimulate the immune response in the patient.
- A method for identifying at least one nucleic acid according to SEQ ID 94 to SEQ ID 186, or a variant thereof differentially expressed in a sample isolated from a patient relative to a reference library or a reference sample comprising the following steps: (a) detecting the expression of at least one nucleic acid. according to SEQ ID 94 to SEQ ID 186, or a variant thereof in a sample isolated from a patient, (b) comparing the expression of said nucleic acid(s) detected in step (a) with the expression of the said nucleic acid(s) in a reference library or in a reference sample, (c) identifying said nucleic acid(s) which is (are) differentially expressed in the sample isolated from the patient compared to the reference library or the reference sample.
- A method of diagnosing a liver disorder or an epithelial cancer comprising the following steps: (a) detecting the expression of at least one nucleic acid according to SEQ ID 94 to SEQ ID 186, or a variant thereof in a sample isolated from a patient, (b) comparing the expression of said nucleic acid(s) detected in step (a) with the expression of said nucleic acid(s) in a reference library or in a reference sample, (c) identifying said(s) nucleic acid which is (are) differentially expressed in the sample isolated from the patient compared to the reference library or the reference sample, and (d) matching said nucleic acid(s) identified in step (c) to said nucleic acid(s) differentially expressed in a pathologic reference sample or pathologic reference library, wherein the matched nucleic acid(s) is (are) indicative of the patient suffering from a liver disorder or an

epithelial cancer. [018]The method according to claim 17, wherein in step (a) at least 2 nucleic acids are identified. [019]The method according to claim 17, wherein in step (a) the detection of said nucleic acid(s) is (are) by PCR based detection or by a hybridization assay. [020] The method according to one of claims 17 to 19, wherein in step (b) the expression of said nucleic acid(s) is compared by a method selected from the group consisting of solid-phase based screening methods, hybridization. subtractive hybridization, differential display, and RNase protection assay. [021] The method according to one of claims 17 to 20, wherein the sample isolated from the patient is selected from the group consisting of liver tissue, a liver cell, tissue from another organ subject to cancerous transformation, a cell from this organ, blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, and feces. [022] The method according to one of claims 17 to 21, wherein the reference sampleis isolated from a source selected from a non-diseased sample of the same patient and a non-diseased sample from another subject. The method according to one of claims 17 to 22, wherein the reference sampleis [023] selected from the group consisting of liver tissue, a liver cell, blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, and feces. [024] The method according to one of claims 17 to 23, wherein the reference libraryis an expression library or a data base comprising clones or data on liver disorder-specific expression of said nucleic acid(s) of step (a). [025] The method according to one of claims 17 to 24, wherein the pathologic reference sample is isolated from a source selected from a diseased sample from another patient suffering from a liver disorder or epithelial cancer. [026] The method according to claim 17 to 25, wherein the pathologic reference library is a data base comprising data on differential expression of said nucleic acid(s) in step (a) in samples isolated from another patient suffering from a liver disorder or epithelial cancer relative to control expression in a reference sample or reference library. [027] The method according to claim 17 to 26, wherein the liver disorder, is a disorder selected from the group consisting of hepatocellular carcinoma, benign liver neoplasms, and cirrhosis. [028] The method according to claim 17 to 26, wherein the epithelial cancer is an adenocarcinoma of an organ selected from the group consisting of the lung, the stomach, the kidney, the colon, the prostate, the skin and the breast.

40

- [029] A method for identifying at least one polypeptide according to SEQ ID 1 to SEQ ID 93, or a functional variant thereof differentially expressed in a sample isolated from a patient relative to a reference library or a reference sample comprising the following steps: (a) detecting the expression of at least one polypeptide according to SEQ ID 1 to SEQ ID 93, or a functional variant thereof in a sample isolated from a patient, (b) comparing the expression of said polypeptide(s) detected in step (a) with the expression of said polypeptide(s) in a reference library or in a reference sample, (c) identifying said polypeptide(s) which is (are) differentially expressed in the sample isolated from the patient compared to the reference library or the reference sample.
- [030] A method of diagnosing a liver disorder or epithelial cancers comprising the following steps: (a) detecting the expression of at least one polypeptide according to SEQ ID 1 to SEQ ID 93, or functional variants thereof in a sample isolated from a patient, (b) comparing the expression of said polypeptide(s) detected in step (a) with the expression of said polypeptide(s) in a reference library or in a reference sample, (c) identifying said polypeptide(s) which is (are) differentially expressed in the sample isolated from the patient compared to the reference library or the reference sample, and (d) matching said polypeptide(s) identified in step (c) with said polypeptide(s) differentially expressed in a pathologic reference sample or pathologic reference library, wherein the matched polypeptide(s) are indicative of the patient suffering from a liver disorder, or an epithelial cancer.
- [031] The method according to claim 30, wherein at least 2 polypeptides are identified.
- [032] The method according to claim 30 or 31, wherein the polypeptides are detected by a method selected from the group consisting of gel electrophoresis, chromatographic techniques, immunoblot analysis, immunohistochemistry, enzyme based immunoassay, surface plasmon resonance, HPLC, mass spectroscopy, immunohistochemistry, and enzyme based immunoassay.
- [033] The method according to one of claims 30 to 32, wherein the polypeptides are compared by a method selected from the group consisting of two dimensional gel electrophoresis, chromatographic separation techniques, immunoblot analysis, surface plasmon resonance, immunohistochemistry, and enzyme based immunoassay.
- [034] The method according to one of claims 30 to 33, wherein the sample isolated from a patient is selected from the group consisting of liver tissue, a liver cell, tissue from another organ subject to cancerous transformation, a cell from this organ, blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, and feces.

- [035] The method according to one of claims 30 to 34, wherein the reference sampleis isolated is from a source selected from a non-diseased sample of the same patient and a non-diseased sample from another subject. [036] The method according to one of claims 30 to 35 wherein the reference sample is selected from the group consisting of liver tissue, a liver cell, blood, serum, plasma, ascitic fluid, pleural effusion, cerebral spinal fluid, saliva, urine, semen, and feces. [037] The method according to one of claims 30 to 36, wherein the reference libraryis an expression library or a data base comprising clones or data on liver disorder-specific expression of said polypeptide(s) of step (a). [038] The method according to claim 30 to 37, wherein the pathologic reference sample is isolated from a source selected from a diseased sample from another patient suffering from a liver disorder and epithelial cancer. [039] The method according to claim 30 to 38, wherein the pathologic reference library is a data base comprising data on differential expression of said polypeptide(s) of step (a) in samples isolated from another patient, suffering from a liver disorder or epithelial cancer, relative to control expression in a reference sample or reference library. [040] The method according to claim 30 to 39, wherein the liver disorders is a disorder selected from the group consisting of hepatocellular carcinoma, benign liver neoplasms, and cirrhosis. [041] The method according to one of claims 30 to 40, wherein the epithelial cancer is an adenocarcinoma of an organ selected from the group consisting of the lung, the stomach, the kidney, the colon, the prostate, the skin, and the breast. A method of preventing a patient from developing a liver disorder or an [042] epithelial cancer, wherein at least one component selected from the group consisting of a polypeptide according to the sequence of SEO ID 1 to SEO ID 93, a functional variant thereof, a nucleic acid encoding one of the aforementioned polypeptides, a variant of one of the aforementioned nucleic acids, a nucleic acid having a sequence complementary to one of the aforementioned nucleic acids, a nucleic acid which is a non-functional mutant variant of one of the aforementioned nucleic acids, a vector comprising one of the aforementioned nucleic acids, or a variant thereof, a cell comprising one of the aforementioned nucleic acids, or a variant thereof, and a cell comprising the aforementioned vector, is administered to the patient in need of such preventive treatment in a
- [043] A method of identifying a pharmacologically active compound comprising the following steps: (a) providing at least one polypeptide according to the SEQ ID 1

therapeutically effective amount.

to 93, or a functional variant thereof, (b) contacting said polypeptide(s) with (a) compound(s) suspected to be pharmacologically active, (c) assaying the interaction of said polypeptide(s) of step (a) with said compound(s) suspected to be pharmacologically active, (d) identifying said compound(s) suspected to be pharmacologically active which directly or indirectly interact with said polypeptide(s) of step (a).

- [044] The method according to claim 43, wherein said polypeptide(s) of step (a) is (are) attached to a column, said polypeptide(s) is (are) attached to an array, contained in an electrophoresis gel, attached to a membrane, or is (are) expressed by a cell.
- [045] The method according to claim 43 or 44, wherein the interaction is assayed enzyme or fluorescence based cellular reporter methods.
- [046] The method according to claim 43 or 44, wherein the interaction is assayed by surface plasmon resonance, HPLC, or mass spectroscopy.
- [047] The method according to claim 43, wherein the direct or indirect functional interaction of step (d) is selected from the group consisting of induction of the expression of said polypeptide(s) of step (a), inhibition of said polypeptide(s), activation of the function of said polypeptide(s), and inhibition of the function of said polypeptide(s).
- [048] An isolated polypeptide comprising a sequence according to SEQ ID 32, or a functional variant thereof.
- [049] A fusion protein comprising a polypeptide according to claim 48.
- [050] An isolated nucleic acid, or a variant thereof encoding the polypeptide according to claim 48.
- [051] The nucleic acid according to claim 50, wherein the nucleic acid is a single-stranded or double-stranded RNA.
- [052] The nucleic acid according to claim 50, wherein the nucleic acid comprises a nucleic acid according to SEQ ID 125.
- [053] A vector comprising a nucleic acid according to claim 50.
- [054] The vector according to claim 53, wherein the vector is selected from the group consisting of a knock-out gene construct, a plasmid, a shuttle vector, a phagemid, a cosmid, a viral vector, and an expression vector.
- [055] A cell comprising the nucleic acid according to claim 50.
- [056] A cell comprising the vector according to claim 53.
- [057] The cell according to claim 56, wherein the cell is a transgenic embryonic non-human stem cell.
- [058] A transgenic non-human mammal comprising the nucleic acid according to claim 50.


WO 2005/085861 PCT/EP2005/050897

100


[059]	An antibody or an antibody fragment thereof, wherein the antibody is directed
	against the polypeptide according to claim 48 or against the nucleic acid
	according to claim 50.
[060]	A nucleic acid which comprises a nucleic acid having a sequence complementary
	to the nucleic acid according to claim 50 or a non-functional mutant variant of
	the nucleic acid according to claim 50.
[061]	The nucleic acid according to claim 60, wherein the nucleic acid having a com-
	plementary sequence is an antisense molecule or an RNA interference molecule.
[062]	A vector comprising the nucleic acid according to claim 60.
[063]	The vector according to claim 62, wherein the vector is selected from the group
	consisting of a plasmid, a shuttle vector, a phagemid, a cosmid, a viral vector,
	and an expression vector.
[064]	A cell comprising the nucleic acid according to claim 62.
[065]	A cell comprising the vector according to claim 64.

عيدد


[Fig. 001]




[Fig. 002]




[Fig. 003]



[Fig. 004]




[Fig. 005]




6/106


[Fig. 006]




[Fig. 007]



[Fig. 008]




[Fig. 009]




[Fig. 010]







[Fig. 011]



[Fig. 012]




[Fig. 013]




[Fig. 014]






[Fig. 015]

### PRK1R1A




[Fig. 016]




[Fig. 017]

# SDCCAG28




[Fig. 018]



[Fig. 019]






WO 2005/085861 PCT/EP2005/050897

20/106


[Fig. 020]






• 14

[Fig. 021]




[Fig. 022]




[Fig. 023]

# HSPC1




[Fig. 024]




[Fig. 025]

### GAP-SH3




[Fig. 026]

Crisp-3




[Fig. 027]






[Fig. 028]




[Fig. 029]


# LOC51716




[Fig. 030]



[Fig. 031]




[Fig. 032]




[Fig. 033]

# PTPRZ1




[Fig. 034]

# Rab9 effector of p40




[Fig. 035]






[Fig. 036]






[Fig. 037]






[Fig. 038]




WO 2005/085861 PCT/EP2005/050897

[Fig. 039]





[Fig. 040]




В


C

[Fig. 041]






[Fig. 042]




[Fig. 043]




[Fig. 044]

## PKCI-1




[Fig. 045]







[Fig. 046]



[Fig. 047]




[Fig. 048]




[Fig. 049]


### **MARCKS**




[Fig. 050]



[Fig. 051]




[Fig. 052]




[Fig. 053]






[Fig. 054]




[Fig. 055]






[Fig. 056]






[Fig. 057]




[Fig. 058]






[Fig. 059]




[Fig. 060]




[Fig. 061]






[Fig. 062]




[Fig. 063]






[Fig. 064]






[Fig. 065]






[Fig. 066]




[Fig. 067]




[Fig. 068]





[Fig. 069]






4


[Fig. 070]






[Fig. 071]






[Fig. 072]

# CTNNA1




[Fig. 073]

#### **ADCYAP1**




[Fig. 074]






[Fig. 075]

# topoisomerase II b




[Fig. 076]

### **UMP-CMPK**




[Fig. 077]






[Fig. 078]




[Fig. 079]




[Fig. 080]






[Fig. 081]






[Fig. 082]




[Fig. 083]






[Fig. 084]




[Fig. 085]






[Fig. 086]




[Fig. 087]






[Fig. 088]




...

[Fig. 089]




[Fig. 090]




[Fig. 091]






[Fig. 092]




[Fig. 093]




[Fig. 094]






[Fig. 095]




[Fig. 096]






[Fig. 097]




[Fig. 098]

# PPP1R15A





[Fig. 099]







[Fig. 100]






[Fig. 101]







[Fig. 102]



DAD 1





[Fig. 104]




104/106


[Fig. 105]








[Fig. 108]





# eolf-seql-S000001.txt SEQUENCE LISTING

:120> NUCLEIC ACIDS AND ENCODED POLYPEPTIDES FOR USE IN LIVER DIS PRDERS

AND EPITHELIAL CANCER.

:130> 1230FPC

:150> EP04100857.4

151> 2004-03-03

150> EP04100858.2

151> 2004-03-03

160> 205

170> PatentIn version 3.2

210> 1

211> 4185

212> DNA

213> Homo sapiens

400> 1

ggccgcgag cgcagtggtg tggagcgcgc cgggtcccgg agccggctgt ctgagggatg 60

acgagacga gcccactagt gtcccccgag cgggcccaac ccccggacta caccttcccg 120

cgggctcgg gcgctcactt tccgcaggtg cccgggggcg cggtccgagt ggcggcggcg 180

ccggctcgg gcccctctcc gccaggctcg ccgggccacg accgcgagcg gcagccactg 240

tggatcggg cccggggcgc ggcggcccag ggccagaccc aaaccgtggc ggcgcaggcc 300

aggetetgg cegeteagge egeggeggea geceaegeeg eteaggeeea eegegagegg 360

acgagttcc cggaggatcc tgagttcgag gcggtggtgc ggcaggccga gctggccatc 420

agogotgoa totttocoga gogoatotao cagggotoca goggaagota ottogtoaag 480

acceteagg ggaggateat tgetgtette aaacecaaga atgaagagee etatgggeat

#### eolf-seal-S000001.txt

540

:ttaatccta agtggaccaa gtggctgcag aagctgtgct gtccttgctg ctttggccgt 600

- jactgccttg tccttaacca gggctatctc tcagaagcag gggccagcct ggtggaccaa
  660
- laactggaac tcaacattgt tccccgtaca aaggtagtat acctggccag tgagaccttc 720
- lactatagtg ccattgaccg agtgaagtcc aggggcaagc ggcttgcact agagaaagtg 780
- caaaagttg gacagcggtt taaccgcatc gggctaccac caaaggttgg ttcattccag
- :tctttgttg aaggctacaa agatgcagac tattggctgc ggcgttttga agcagaacct 900
- :ttcctgaga acactaaccg gcaactactg ctccagtttg agcggttggt ggtgctggat 960
- acatcatcc gcaacactga tcgaggcaat gacaactggc tgattaaata tgactgtcca 1020
- tggatagtt ctagctctcg ggacacagac tgggtggtgg tgaaggagcc tgttatcaag 1080
- tggctgcca tagacaatgg gctggccttc ccactgaagc atcctgactc ctggagggca 1140
- atccttttt actgggcctg gttgccccag gcgaaagtcc cattttctca ggagatcaaa 1200
- atctgatcc ttccaaagat atcggaccct aacttcgtca aggacttgga agaggaccta 1260
- atgaactct tcaagaaaga tcctggtttc gacaggggcc agttccataa gcagattgct 1320
- tcatgcggg gccagatctt aaatctgacc caggccttga aagacaacaa gagtcccctg 1380
- acctcgtcc agatgccacc tgtgattgtc gagacggccc gttcccacca gcggtcttct 1440
- gcgagtcct acacacagag ctttcagagc cggaagccct tcttttcatg gtggtagctc 1500
- agaggcagg cagaggaaat attgtcagag actggtggga ggaagcctgg ggagtggggt 1560
- caggaaaag ccagagaagc cggtggagag cagcaccttt aagagccctc tctctctgct 1620

# eolf-seql-S000001.txt

- gccaccctg ctcagagett tecacccaca gggagaagea caatcaggaa cagtgagtge 1680
- cctcgccct tctgatgtgg gggaggctgg agctccatgc acgtagtcca gatgcctggg 1740
- aggaacate teeetteeag catetgetgg tageaggetg ggacagteec tteetteeet 1800
- aaaccctgc tctattgcaa ttccctatta tattctgcat cagaaaaaca aacaaacaa 1860
- aacaacttt aaatgettgt agcagaacce egggteatet eatgteagaa acetttaate 1920
- aggcctaaa tttgcataga cctgacattc agctgccttg cagttgcttc ctcccatgag 1980
- caaggtggt gtcagagggc aactggatga ctcgcagtac cacagcactg ggacagacag 2040
- agccacacc tttcttttgg gtttttgcca agcctcctcc atctcccatc agtgctgtgg 2100
- ctggctgca agcctcgaaa cagttctcct ggaagggagg tttttgcttt acccccgcca 2160
- cacttccgc acacaatcat agagaacctc tctgctctct gctggcctac agcttgtctg 2220
- ttctcaagc agaggcagga agagctagtc ttagcattta tattttaata ggaagttgac 2280
- cccagcatg taaaagtgat ccacgcagcc ggagtgtatg ccgggagcta agtggtctat 2340
- ggtgaacat atcccacctt gcttcctgag tccttggtcc caatcttctc atttgttcct 2400
- tcgttttaa atttttccc cccaactctt ttgatgtaag agttcagttt gtcttcggga 2460
- tgggtctct gcaagggctc tgggatgagt cttggcttcc aagaggacag gctattaggt 2520
- cttggactt ttttctgtgc taccgctgct gcttggtgga agtaacagga cgtggattct 2580
- cctcataag tggcagtttc ccttttctct ctgacttgtc ctaggccgat ttctctatgg 2640
- :tccctgag aaaggtgagg cccaaaggag agaggccttc aaactgtccc aggtcctgcg
  2700

eolf-seql-S000001.txt

- pageteagtg egtatettet tgetteeafg tgtettttee cetgetgeet eacteceae 2760
- >cccacttgc caggtgtttg agccatttct acaccaaagc aaagtacggc ctcaggaggg 2820
- igtaaaaagg gtgccatctg tgtctggagg ggcagctgtg ttcatgccct gtgctactgg 2880
- icatttcaca attctggcac cttgcgattg gtcagtcaac ctcagaaagt aactatcttg 2940
- laggittgaa aaacaaccaa agaaagggag tgaggactat ggctgcatgt cctctgcttg 3000
- :ccggctgca gagcagagat gtgcagcct ctggtcagct ggtccaggct ggtcccgcc
  3060
- igtccccttc cagtccagcc accaagagtc cacttgtccc gggcttccac ctggctgaca
  3120
- //gaagaattt ctgagagctg gatgtgcatg ccctgtggac gaaggtacag ctcgcctgcc 3180
- :gccccaatc ccagccccga caatcacatg cagctgactc ggacactggc cttgggaaca 3240
- ıtgttcgaga gaacacttgc cccttgactg taggagccag aaggggaccc aggtgtgcat 3300
- .gctctctgt agacattttt acccaaacct gttggtaaag tgcccatctg gtgctcaaga 3360
- agcctgggg gtctaacagg gagcccggct gcctcacctg gccacagcct ccacaccaga 3420
- ctccacatt gtcttgatcc agaccagctc tgtgatcaga aggaaattgg gtccagtgta 3480
- gagagaget ggteetggge etggeaggea agagtgtggg catcetttee tggeetttet 3540
- cactetece teaageetgt geteaggttg cettgaatgt ggaetetgga agageeaggg 3600
- cccagaatg ccgggggagg cttctgagtg gcactcatgg aacaccgtcc ctctgccagc 3660
- ataggccct gcctccagtg tcagggaatg gaggctgggc tgcgagagtg ttgctgccc 3720
- tgtgtcatt cttctaatcc aatgtagaaa ttgtacgtaa tgtatttaaa tcaacgcaaa 3780
- gtatgaata acaaatacag ttctgacctt ttttgtccag tttctttggg ggaaggaaga

eolf-seql-S000001.txt

3840

aaagaaggt aggaacggaa ttttgagggc aaagaaacct gtgtttccat ggaattgctg 3900

gacgtggct cctggggcta tttctcccta ataaaggatg atccaggtcc tcatttccaa 3960

gtcccaatg ctctgaaaac caaaagtatt ttcataaccc atttgaaacc aaacctgacc 4020

gaacttaca ctgataggaa gctatgggta attatgatgt gttcctttta gtgtgattct 4080

tgttgcaga aatgtcaata tattttatga catggttccc tactagggat tatacagtat 4140

tgctgacta cttcctaaga gccaaaaata aaaaatctga attcc 4185

210> 2

211> 2425

212> DNA

213> Homo sapiens

400> 2

cggccgccg gtcctccctc cacctcctcc tcggcccccc ctcgcttccc tcctcccact 60

cccgagete eggegtegte eeggeeacge tegacgetge tgcaggaaca aaggaagace 120

cgcggcggc ggcggcgca cctccgcctg ctgctccgac ccgctcccgg cccgcggcgg 180

ggcaccagg gcgcccggct cagccttccc ggaggcctcg gcccggcctc atcgtgccgg 240

ttcgcgcgc gaacccggct ttcgcatttg ggaccctgca ggaaaaatat ggctcaggag 300

ctaaccaga ccccggggcc catgctgtgt agcacaggat gtggctttta tggaaatcct 360

jgacaaatg gaatgtgttc agtttgctac aaagaacatc ttcagaggca gcaaaatagt
420

gcagaatga gcccaatggg gacagctagt ggttccaaca gtcctacctc agattctgca 480

otgtacaga gagcagacac tagcttaaac aactgtgaag gtgctgctgg cagcacatct 540

aaaaatcaa gaaatgtgcc tgtggctgcc ttgcctgtaa ctcagcaaat gacagaaatg

#### eolf-seql-S000001.txt

600

gcatttcaa gagaggacaa aataactacc ccgaaaacag aggtgtcaga gccagttgtc 660

- ctcagccca gtccatcagt ttctcagccc agtacttctc agagtgaaga aaaagctcct 720
- aattgccca aaccaaagaa aaacagatgt ttcatgtgca gaaagaaagt tggtcttaca 780
- ggtttgact gccgatgtgg aaatttgttt tgtggacttc accgttactc tgacaagcac 840
- actgtccgt atgattacaa agcagaagct gcagcaaaaa tcagaaaaga gaatccagtt 900
- ttgtggctg aaaaaattca gagaatataa attacttctt gtgaagagac tgaaactttg 960
- ttttatttt aatatatcgt aggaaaacat taaagagcag atgcatggcc atttttcttt 1020
- atgttctcc agagttttac attacacttg tctgtcttat aattgatatt ttaggatgtt 1080
- gggtgtttg ttacaggcag aattggatag atacagccct acaaatgtat atgccctccc 1140
- tgaaaaaaa ttggatgaaa atctgcacag caaagtgaaa cacacagata ataggaacaa 1200
- atgtagttc ccatgtgcca aacaaaataa atgaaatctc tgcatgtttg cagcatatct 1260
- octtttggg aatgtaatca aggtataatc tttggctagt gttatgtgcc tgtatttttt 1320
- laaatggta caccagaaaa ggactggcag tctacttcta ccatagttaa acttcaccct 1380
- ittaatttc acaacatatt ctttggaagc aggaagaaat gctcataaag aggatcagac 1440
- :tctttccc gtgaaaccag tatttggcgc catatataag cctggttaaa ttggtcatct 1500
- lagctgtca aataagacat tctgtgaaag gtaaacatcg aaactggtta taagtaaaac 1560
- itcaagcca acaacagggt cttgagataa cctttgaagc ttattgtact ggcctgcacc 1620
- jaagatgtc tgcattactc attgctaaaa atgtgtagca cagaactgca ctaggattaa 1680

#### eolf-seql-S000001.txt

ttgtttaca agaagaaatt taaactctac gtttggtttt cacatacagc agctctattg 1740

- ataacatgc atctgaattt taagttgcaa aggtatctga ataatttttc atgtgcatct 1800
- ttgtcgaat gttttggttc aagaaagaat gtttaaagct ttttaaaaga cttcagttct 1860
- aatgtaact gtaccettet geatggaaaa teataaceaa eatggetgea gtagaettet 1920
- agtggtatc cagcgccact tgcagagggc tgctttatca tattgtactt gggtgtagga 1980
- tctagtgtt cttgggtgta ttgcatgggc tgcattatct acagcattgt acaataacaa 2040
- tagaaaagg cagtatactt cactgatgct tgtctggtaa taatcacttc tgtgttataa 2100
- ggaaggttt tttgtgatgt atgaaacttg tgttttttat atataaatga gtatagttag 2160
- yttgtggta atgcctgttt tcatctgtaa atagttaagt atgtacacga ggcactactt 2220
- igatttatt gcaatgttca gtcctagttt ttacttttat tcttaaagca ttcagttttg
  2280
- :ttcaattt tatgtacctt agttctgagt tagacctgca gatgtgtaca gatagttcat
  2340
- Ittatgtat tgcacataat catgctattc agcattgatg ctatattgta ttatgtaaat 2400
- ataaaagcc atgtacagag ggaaa 2425
- 210> 3
- 211> 1220
- ?12> DNA
- ?13> Homo sapiens
- 100> 3
- jccaggcta gtgacagaaa tggattcgaa atatcagtgt gtgaagctga atgatggtca
- tcatgcct gtcctgggat ttggcaccta tgcgcctgca gaggttccta aaagtaaagc 120
- tagaggcc accaaattgg caattgaagc tggcttccgc catattgatt ctgctcattt 180

# eolf-seql-S000001.txt

- itacaataat gaggagcagg ttggactggc catccgaagc aagattgcag atggcagtgt 240
- jaagagagaa gacatattct acacttcaaa gctttggtgc aattcccatc gaccagagtt 300
- ggtccgacca gccttggaaa ggtcactgaa aaatcttcaa ttggattatg ttgacctcta
  360
- cttattcat tttccagtgt ctgtaaagcc aggtgaggaa gtgatcccaa aagatgaaaa 420
- ggaaaaata ctatttgaca cagtggatct ctgtgccacg tgggaggccg tggagaagtg 480
- aaagatgca ggattggcca agtccatcgg ggtgtccaac ttcaaccgca ggcagctgga 540
- iatgatecte aacaagecag ggeteaagta caageetgte tgeaaceagg tggaatgtea
  600
- ccttacttc aaccagagaa aactgctgga tttctgcaag tcaaaagaca ttgttctggt 660
- gcctatagt gctctgggat cccaccgaga agaaccatgg gtggacccga actccccggt 720
- ctcttggag gacccagtcc tttgtgcctt ggcaaaaaag cacaagcgaa ccccagccct 780
- attgccctg cgctaccagc tacagcgtgg ggttgtggtc ctggccaaga gctacaatga 840
- cagcgcatc agacagaacg tgcaggtgtt tgaattccag ttgacttcag aggagatgaa 900
- gccatagat ggcctaaaca gaaatgtgcg atatttgacc cttgatattt ttgctggccc 960
- cctaattat ccattttctg atgaatatta acatggaggg cattgcatga ggtctgccag 1020
- aggccctgc gtgtggatgg tgacacagag gatggctcta tgctggtgac tggacacatc 1080
- cctctggtt aaatctctcc tgcttggtga tttcagcaag ctacagcaaa gcccattggc 1140
- agaaaaaaa agacaataat tttgtttttt cattttgaaa aaattaaatg ctctctccta 1200
- agattette acetaaaaa 1220

# eolf-seql-S000001.txt

- :210> 4
- :211> 1816
- :212> DNA
- :213> Homo sapiens
- :400> 4
- tegeettet ggetetgeea tgeeetgete tgaagagaea eeegeeattt eacceagtaa 60
- cgggcccgg cctgcggagg tgggcggcat gcagctccgc tttgcccggc tctccgagca 120
- gccacggc cccaccggg gctccgcgc cgccgcggc tacgacctgt acagtgccta 180
- gattacaca ataccaccta tggagaaagc tgttgtgaaa acggacattc agatagcgct 240
- ccttctggg tgttatggaa gagtggctcc acggtcaggc ttggctgcaa aacactttat 300
- gatgtagga gctggtgtca tagatgaaga ttatagagga aatgttggtg ttgtactgtt 360
- aattttggc aaagaaagt ttgaagtcaa aaaaggtgat cgaattgcac agctcatttg 420
- gaacggatt ttttatccag aaatagaaga agttcaagcc ttggatgaca ccgaaagggg 480
- tcaggaggt tttggttcca ctggaaagaa ttaaaattta tgccaagaac agaaaacaag 540
- agtcatacc tttttcttaa aaaaaaaaa aaagtttttg cttcaagtgt tttggtgttt 600
- gcacttctg taaacttact agctttacct tctaaaagta ctgcattttt tactttttt 660
- atgatcaag gaaaagatcg ttaaaaaaaa acacaaagaa gtttttcttt gtgtttggat 720
- aaaaagaaa ctttgttttt ccgcaattga aggttgtatg taaatctgct ttgtggtgac 780
- octgtattt aactcatatg atctcccttc agcaacttat tttgctttaa ttgctttaaa 900
- cttaagcaa tatttttat tcagtaaaca aattctttca caaggtacaa aatcttgcat 960

eolf-seql-S000001.txt

agctgaact aaaataaaaa tgaaaaggag agattaaagg tattccttgt tcttcccttc 1020

- cttcactag tctaaaaact tctttttaat cttaagattc tttgtgatga gggtgagaaa 1080
- agaatcctc agtttatttt tccactatta atctttcttt tgataaatcc tctattgact 1140
- ggtagaggt atgtttgtga aagacatgta acttggggat ttgttacttt aggtttgttc 1200
- cttgaattt catctcatca ggcaaattgt actagttgta gttacgagtt ttccctcagt 1260
- aagtagcaa taggctgtaa tcaagaaaat atgccattta tagagataag ataaatgaaa 1320
- aatacttca gccaccaggt ttttctgtct cacatacata agcagcattt cattgcagat 1380
- tgggactga ttctgtggct taccttgatt aacatctttt ggaagttttg ctagtgtgct 1440
- tcctttctt tactatgttt ctcagattcc tttgtatcag ggttttgggt gtcacttagg 1500
- tttgtccat cagattctgt gagacaccag gcatcgtttt gaggatgtgg gttatacaca 1560
- ggagtgctt ctggaactat cagcccactt gaccacccag tttgtggaag cacaggcaag 1620
- gtgttcttt tctggtgatt ctccaggcca tttaataccc tgcaatgtaa ttgtccctct 1680
- tggctcaca tttcattagt gagccatgaa atcaactcag tgggacatag ccagcatttt 1740
- gcataccag gttgggctat aaaatatttc tgttgtcaat aaattttaaa tgttttcctg 1800

taaaaaaaa aaaaaa 1816

- 210> 5
- 211> 4553
- 212> DNA
- 213> Homo sapiens
- 400> 5
- >gcgggccg aggacgcctc tggggcggca ccgcgtcccg agagccccag aagtcggcgg 60

eolf-seql-S000001.txt gaagtttcc ccggtggggg gcgtttcggg cctcccggac ggctctcggc cccggagccc 120 gtcgcagga gcgcgggccc gggggcggga acgcgccgcg gccgcctcct cctccccggc 180 cccgcccgc ggcggtgttg gcggcggcgg tggcggcggc ggcggcgctt ccccggcgcg 240 ageggettt aaaaggegge actecaceee eeggegeact egeagetegg gegeegegeg geotytogo ogotatycot degogogogo ogoctycyco ogygodocyg cogocycoc 360 480 getgeetge egeetgetee gegeeeeege egegeeeegt etacaceaac caetgggegg 540 gcaagtgct gggcggcccg gccgaggcgg accgcgtggc ggcggcgcac gggtacctca cttgggcca gattggaaac ctggaagatt actaccattt ttatcacagc aaaaccttta 660 aagatcaac cttgagtagc agaggccctc acaccttcct cagaatggac ccccaggtga 720 atggctcca gcaacaggaa gtgaaacgaa gggtgaagag acaggtgcga agtgacccgc 780 jgcccttta cttcaacgac cccatttggt ccaacatgtg gtacctgcat tgtggcgaca jaacagtcg ctgccggtcg gaaatgaatg tccaggcagc gtggaagagg ggctacacag 900 laaaaacgt ggtggtcacc atccttgatg atggcataga gagaaatcac cctgacctgg 960 occaaatta tgattcctac gccagctacg acgtgaacgg caatgattat gacccatctc 1020 acgatatga tgccagcaat gaaaataaac acggcactcg ttgtgcggga gaagttgctg

1140 cgcatgct ggacggcgat gtcacagatg tggtcgaggc aaagtcgctg ggcatcagac

itcagcaaa caattcctac tgcatcgtgg gcatagcgta caatgccaaa ataggaggca

1080

eolf-seql-S000001.txt

1200

caactacat cgacatttac agtgccagct gggggccgga cgacgacggc aagacggtgg 1260 cgggcccgg ccgactggct aagcaggctt tcgagtatgg cattaaaaag ggccggcagg cctgggctc cattttcgtc tgggcatctg ggaatggcgg gagagagggg gactactgct 1380 gtgcgatgg ctacaccaac agcatctaca ccatctccgt cagcagcgcc accgagaatg 1440 ctacaagcc ctggtacctg gaagagtgtg cctccaccct ggccaccacc tacagcagtg 1500 ggcctttta tgagcgaaaa atcgtcacca cggatctgcg tcagcgctgt accgatggcc 1560 cactgggac ctcagtctct gcccccatgg tggcgggcat catcgccttg gctctagaag 1620 aaacagcca gttaacctgg agggacgtcc agcacctgct agtgaagaca tcccggccgg 1680 ccacctgaa agcgagcgac tggaaagtga acggcgcggg tcataaagtt agccatttct 1740 tggatttgg tttggtggac gcagaagctc tcgttgtgga ggcaaagaag tggacagcag 1800 gccatcgca gcacatgtgt gtggccgcct cggacaagag acccaggagc atccccttag 1860 gcaggtgct gcggactacg gccctgacca gcgcctgcgc ggagcactcg gaccagcqqq 1920 jgtctactt ggagcacgtg gtggttcgca cctccatctc acacccacgc cgaggagacc 1980 ccagatcta cctggtttct ccctcgggaa ccaagtctca acttctggca aagaggttgc jgatctttc caatgaaggg tttacaaact gggaattcat gactgtccac tgctggggag 2100 laaggctga agggcagtgg accttggaaa tccaagatct gccatcccag gtccgcaacc 2160 Jgagaagca agggaagttg aaagaatgga gcctcatact gtatggcaca gcagagcacc 2220 jtaccacac cttcagtgcc catcagtccc gctcgcggat gctggagctc tcagccccag 2280

.gctggagcc 2340	acccaaggct	gccctgtcac	cctcccaggt	ggaagttcct	gaagatgagg
agattacac 2400	agctcaatcc	accccaggct	ctgctaatat	tttacagacc	agtgtgtgcc
tccggagtg 2460	tggtgacaaa	ggctgtgatg	gccccaatgc	agaccagtgc	ttgaactgcg
ccacttcag 2520	cctggggagt	gtcaagacca	gcaggaagtg	cgtgagtgtg	tgccccttgg
ctactttgg 2580	ggacacagca	gcaagacgct	gtcgccggtg	ccacaagggg	tgtgagacct
ctccagcag 2640	agctgcgacg	cagtgcctgt	cttgccgccg	cgggttctat	caccaccagg
gatgaacac 2700	ctgtgtgacc	ctctgtcctg	caggatttta	tgctgatgaa	agtcagaaaa
ttgccttaa 2760	atgccaccca	agctgtaaaa	agtgcgtgga	tgaacctgag	aaatgtactg
ctgtaaaga 2820	aggattcagc	cttgcacggg	gcagctgcat	tcctgactgt	gagccaggca
ctactttga 2880	ctcagagctg	atcagatgtg	gggaatgcca	tcacacctgc	ggaacctgcg
ggggccagg 2940	cagagaagag	tgcattcact	gtgcgaaaaa	cttccacttc	cacgactgga
gtgtgtgcc 3000	agcctgtggt	gagggcttct	acccagaaga	gatgccgggc	ttgccccaca
agtgtgtcg 3060	aaggtgtgac	gagaactgct	tgagctgtgc	aggctccagc	aggaactgta
caggtgtaa 3120	gacgggcttc	acacagctgg	ggacctcctg	catcaccaac	cacacgtgca
caacgctga 3180	cgagacattc	tgcgagatgg	tgaagtccaa	ccggctgtgc	gaacggaagc
cttcattca 3240	gttctgctgc	cgcacgtgcc	tcctggccgg	gtaagggtgc	ctagctgccc
cagagggca 3300	ggcactccca	tccatccatc	cgtccacctt	cctccagact	gtcggccaga
tctgtttca 3360	ggagcggcgc	cctgcacctg	acagctttat	ctccccagga	gcagcatctc

- gagcaccca agccaggtgg gtggtggctc ttaaggaggt gttcctaaaa tggtgatatc 3420
- :tctcaaatg ctgcttgttg gctccagtct tccgacaaac taacaggaac aaaatgaatt 3480
- :tgggaatcc acagctctgg ctttggagca gcttctggga ccataagttt actgaatctt 3540
- :aagaccaaa gcagaaaaga aaggcgcttg gcatcacaca tcactcttct ccccgtgctt 3600
- .tctgcggct gtgtagtaaa tctccccggc ccagctggcg aaccctgggc catcctcaca 3660
- gtgacaaag ggccagcagt ctacctgctc gttgcctgcc actgagcagt ctggggacgg 3720
- ttggtcaga ctataaataa gataggtttg agggcataaa atgtatgacc actggggccg 3780
- agtatetat ttetacatag teagetaett etgaaaetge ageagtgget tagaaagtee 3840
- attccaaag ccagaccaga agattctatc ccccgcagcg ctctcctttg agcaagccga 3900
- ctctccttg ttaccgtgtt ctgtctgtgt cttcaggagt ctcatggcct gaacgaccac 3960
- tcgacctga tgcagagcct tctgaggaga ggcaacagga ggcattctgt ggccagccaa 4020
- aggtaccc gatggccaag caattcctct gaacaaaatg taaagccagc catgcattgt 4080
- aatcatcca tcacttccca ttttatggaa ttgcttttaa aatacatttg gcctctgccc 4140
- tcagaagac tcgtttttaa ggtggaaact cctgtgtctg tgtatattac aagcctacat 4200
- acacagttg gatttattct gccaaacctg tgtaggcatt ttataagcta catgttctaa 4260
- ttttaccga tgttaattat tttgacaaat atttcatata ttttcattga aatgcacaga 4320
- ctgcttgat caattccctt gaatagggaa gtaacatttg ccttaaattt tttcgacctc 4380
- tetttetee atattgteet geteecetgt ttgacgacag tgeatttgee ttgteacetg 4440
- gagctggag agaacccaga tgttgtttat tgaatctaca actctgaaag agaaatcaat

eolf-seql-S000001.txt

4500

jaagcaagta caatgttaac cctaaattaa taaaagagtt aacatcccat ggc 4553

:210> 6

:211> 2691

:212> DNA

:213> Homo sapiens

:400> 6

settgcccgt cggtcgctag ctcgctcggt gcgcgtcgtc ccgctccatg gcgctcttcg
60

.geggetget ggetetegee etggetetgg ceetgggee egeegegaee etggegggte 120

egccaagtc gccctaccag ctggtgctgc agcacagcag gctccggggc cgccagcacg

rccccaacgt gtgtgctgtg cagaaggtta ttggcactaa taggaagtac ttcaccaact 240

caagcagtg gtaccaaagg aaaatctgtg gcaaatcaac agtcatcagc tacgagtgct 300

tcctggata tgaaaaggtc cctggggaga agggctgtcc agcagcccta ccactctcaa 360

cctttacga gaccctggga gtcgttggat ccaccaccac tcagctgtac acggaccgca 420

ggagaagct gaggcctgag atggagggc ccggcagctt caccatcttc gcccctagca 480

cgaggcctg ggcctccttg ccagctgaag tgctggactc cctggtcagc aatgtcaaca 540

tgagctgct caatgccctc cgctaccata tggtgggcag gcgagtcctg actgatgagc 600

gaaacacgg catgaccctc acctctatgt accagaattc caacatccag atccaccact
660

tcctaatgg gattgtaact gtgaactgtg cccggctcct gaaagccgac caccatgcaa 720

caacggggt ggtgcacctc atcgataagg tcatctccac catcaccaac aacatccagc
780

gatcattga gatcgaggac acctttgaga cccttcgggc tgctgtggct gcatcagggc 840

caacacgat gcttgaaggt aacggccagt acacgctttt ggccccgacc aatgaggcct

Page 15

eolf-seql-S000001.txt

900

.cgagaagat ccctagtgag actttgaacc gtatcctggg cgacccagaa gccctgagag 960 cctgctgaa caaccacatc ttgaagtcag ctatgtgtgc tgaagccatc gttgcggggc 1020 .gtctgtaga gaccctggag ggcacgacac tggaggtggg ctgcagcggg gacatgctca 1080 :tatcaacgg gaaggcgatc atctccaata aagacatcct agccaccaac ggggtgatcc 1140 ctacattga tgagctactc atcccagact cagccaagac actatttgaa ttggctgcag 1200 gtctgatgt gtccacagcc attgaccttt tcagacaagc cggcctcggc aatcatctct tggaagtga gcggttgacc ctcctggctc ccctgaattc tgtattcaaa gatggaaccc 1320 tccaattga tgcccataca aggaatttgc ttcggaacca cataattaaa gaccagctgg 1380 ctctaagta tctgtaccat ggacagaccc tggaaactct gggcggcaaa aaactgagag ttttgttta tcgtaatagc ctctgcattg agaacagctg catcgcggcc cacgacaaga 1500 ggggaggta cgggaccctg ttcacgatgg accgggtgct gacccccca atggggactg 1560 catggatgt cctgaaggga gacaatcgct ttagcatgct ggtagctgcc atccagtctg 1620 aggactgac ggagaccctc aaccgggaag gagtctacac agtctttgct cccacaaatg 1680 agcetteeg ageeetgeea ecaagagaac ggageagaet ettgggagat geeaaggaac 1740 tgccaacat cctgaaatac cacattggtg atgaaatcct ggttagcgga ggcatcgggg 1800 cctggtgcg gctaaagtct ctccaaggtg acaagctgga agtcagcttg aaaaacaatg ggtgagtgt caacaaggag cctgttgccg agcctgacat catggccaca aatggcgtgg 1920 ccatgtcat caccaatgtt ctgcagcctc cagccaacag acctcaggaa agaggggatg 1980

#### eolf-seql-S000001.txt

acttgcaga ctctgcgctt gagatcttca aacaagcatc agcgttttcc agggcttccc 2040

gaggtctgt gcgactagcc cctgtctatc aaaagttatt agagaggatg aagcattagc 2100

tgaagcact acaggaggaa tgcaccacgg cagctctccg ccaatttctc tcagatttcc 2160

cagagactg tttgaatgtt ttcaaaacca agtatcacac tttaatgtac atgggccgca 2220

cataatgag atgtgagcct tgtgcatgtg ggggaggagg gagagagatg tacttttaa 2280

tcatgttcc ccctaaacat ggctgttaac ccactgcatg cagaaacttg gatgtcactg 2340

ctgacattc acttccagag aggacctatc ccaaatgtgg aattgactgc ctatgccaag 2400

ccctggaaa aggagcttca gtattgtggg gctcataaaa catgaatcaa gcaatccagc 2460

tcatgggaa gtcctggcac agtttttgta aagcccttgc acagctggag aaatggcatc 2520

ttataaget atgagttgaa atgttetgte aaatgtgtet cacatétaca egtggettgg 2580

ggcttttat ggggccctgt ccaggtagaa aagaaatggt atgtagagct tagatttccc 2640

attgtgaca gagccatggt gtgtttgtaa taataaaacc aaagaaacat a 2691

210> 7

211> 3600

212> DNA

213> Homo sapiens

400> 7

gtggagctg tcgcctagcc gctatcgcag agtggagcgg ggctgggagc aaagcgctga
60

jgagctcgg tacgccgccg cctcgcaccc gcagcctcgc gcccgccgcc gcccgtcccc
120

jagaaccat ggagtctggc agtaccgccg ccagtgagga ggcacgcagc cttcgagaat 180

igagctcta cgtccagaag cataacattc aagcgctgct caaagattct attgtgcagt
240

- jtgcactgc tcgacctgag agacccatgg cattcctcag ggaatacttt gagaggttgg
  300
- gaaggagga ggcaaaacag attcagaatc tgcagaaagc aggcactcgt acagactcaa 360
- Jgaggatga gatttctcct cctccaccca acccagtggt taaaggtagg aggcgacgag
- igctatcag cgctgaggtc tacacggagg aagatgcggc atcctatgtt agaaaggtta
  480
- accaaaaga ttacaagaca atggccgctt tagccaaagc cattgaaaag aatgtgctgt 540
- itcacatct tgatgataat gagagaagtg atatttttga tgccatgttt tcggtctcct
  600
- latcgcagg agagactgtg attcagcaag gtgatgaagg ggataacttc tatgtgattg
  660
- caaggaga gacggatgtc tatgttaaca atgaatgggc aaccagtgtt ggggaaggag 720
- jagctttgg agaacttgct ttgatttatg gaacaccgag agcagccact gtcaaagcaa 780
- jacaaatgt gaaattgtgg ggcatcgacc gagacagcta tagaagaatc ctcatgggaa 840
- :acactgag aaagcggaag atgtatgagg aattccttag taaagtctct attttagagt
  900
- :ctggacaa gtgggaacgt cttacggtag ctgatgcatt ggaaccagtg cagtttgaag
  960
- .gggcagaa gattgtggtg cagggagaac caggggatga gttcttcatt attttagagg 1020
- jtcagctgc tgtgctacaa cgtcggtcag aaaatgaaga gtttgttgaa gtgggaagat 1080
- gggccttc tgattatttt ggtgaaattg cactactgat gaatcgtcct cgtgctgcca 1140
- igttgttgc tcgtggcccc ttgaagtgcg ttaagctgga ccgacctaga tttgaacgtg
  1200
- cttggccc atgctcagac atcctcaaac gaaacatcca gcagtacaac agttttgtgt 1260
- ctgtctgt ctgaaatctg cctcctgtgc ctcccttttc tcctctcccc aatccatgct 1320

- cactcatgc aaactgcttt attttcccta cttgcagcgc caagtggcca ctggcatcgc 1380
- igcttcctgt ctgtttatat attgaaagtt gcttttattg caccattttc aatttggagc 1440
- ıttaactaaa tgctcataca cagttaaata aatagaaaga gttctatgga gactttgctg 1500
- tactgcttc tctttgtgca gtgttagtat tcaccctggg cagtgagtgc catgctttt 1560
- igtgagggca gatcccagca cctattgaat taccatagag taatgatgta acagtgcaag 1620
- tttttttt taagtgacat aattgtccag ttataagcgt atttagactg tggccatata 1680
- gctgtattt ctttgtagaa taaatggttt ctcattaaac tctaaagatt agggaaaatg 1740
- atatagaaa atcttagtat agtagaaaga catctgcctg taattaaact agtttaaggg 1800
- ggaaaaatg cccatttttg ctaattatca atgggatatg attggttcag ttttttttt 1860
- ccagagttg ttgtttgcca agctaatctg cctggtttta tttatatctt gttattaatg 1920
- ttcttctcc aattctgaaa tacttttgag tatggctatc tatacctgcc ttttaagttt 1980
- aaactaact catagattgc aaatattggt tagtatttaa ctacatctgc ctcggctcac 2040
- aattccgat tagaccttta tccagctagt gccaaataat tgatcagatg ctgaattgag 2100
- ataagaatt tgaggtctac attcttggtt gttaatttag agcgtttggt taaagtatgt 2160
- cttcagctg actccagtat aatctcctct gctcattaaa ctgattccag gagattggat 2220
- tgctgtgac tagatacaga tggagcaaat gtcctaacag agaaatagag gtgatgctgc 2280
- aaagggaga aatgccaggc ggacaaagtt cagtgtcggg aattttcccc gtgacattca 2340
- tggggcatg agattttgga agaagttttt tactttggtt tagtcttttt ttccttcctt 2400
- ttattcagc tagaatttct ggtgggttga tggtagggta taatgtgtct gtgttgcttc

eolf-seql-S000001.txt

2460

- laattggtct gaaaggctat cctgcggaaa gtcctgcttt cctatctagc atttatttct 2520
- :tggcaaact tttctttctt ttcttttta aagtaaactt gtgtattgag tcttaactgt 2580
- tttcagtat tttccagcct tatgtgttac attattccaa tgatacccaa cagtttattt 2640
- tattattt tttaaacaaa atttcacagt tctgtaatgt aggcactttt attttcattg 2700
- gatttatat ataaggtaat gtagggttat atttgggagt gactgcaagc atttttccat 2760
- tgtgtgcaa ctaactgact ctgttattga tcccttctcc tgccctttcc caggtaattt 2820
- aattggtca tggtagattt ttttcataga tttgaaaaac ttttaggttg ttaccaagta 2880
- gaagtataa atctggggaa gaggttttat ttacatttta gggtgggtaa gaaagccacc 2940
- tgttacaaa ttttttaatt tccaaaataa tctatattaa atgagggttt ctgatctgta 3000
- tttgtgttt agctaccttt ttatatttaa aaaattaaaa atgaaaatta cgttcttaca 3060
- gcttaaagc ttgatttgat ctttgtttaa atgccaaaat gtacttaaat gagttactta 3120
- aatgccata aaattgcagt ttcatgtatg tatataatca tgctcatgta tatttagtta
  3180
- gtataatgc tttctgagtg agttttactc ttaaatcatt tggttaaatc atttggcttg 3240
- tgtttactc ccttctgtag tttttaatta aaaactttaa agataagtct acattaaaca 3300
- tgatcacat ctaaagcttt atctttgtgt aatctaagta tatgtgagaa atcagaattg 3360
- cataatttg tcttagttga tattcaaggc tttaaaagtc attattcctg ggcttggtaa 3420
- tgaatttat gagatttact gctctagaaa gtatagatgg cgaaaggacc gttttgtatt 3480
- cttcctgat taccagtctg attataccat gtgtgctaat atacttttt tgttatagat 3540

Page 20

#### eolf-seql-S000001.txt

210> 8

211> 1434

212> DNA

213> Homo sapiens

:400> 8

agcccctgt ctggatgact tcttgcggct gttctacccc tccccctccc cgcggtacct 60

gcacttttc tecetecetg ecceeteteg agtecaceet eegggeette tgeecetgat 120

gcttggttt tccttgcagt cgcctgctgc tgtcgtcggg aggaaagatg aatgggaggg 180

tgattttcg agagccgaat gcagaggttc caagaccaat tccccacata gggcctgatt 240

cattccaac agaggaagaa aggagagtct tcgcagaatg caatgatgaa agcttctggt 300

cagatctgt gcctttggct gcaacaagta tgttgattac tcaaggatta attagtaaag 360

aatactttc aagtcatccc aaatatggtt ccatccctaa acttatactt gcttgtatca 420

gggatactt tgctggaaaa ctttcttatg tgaaaacttg ccaagagaaa ttcaagaaac

tgaaaattc cccccttgga gaagctttac gatcaggaca agcacgacga tcttcaccac 540

tgggcacta ttatcaaaag tcaaaatatg actcaagtgt gagtggtcaa tcatcttttg 600

gacatecee ageageagae aacatagaaa tgetteetea ttatgageea atteeattea 660

ttcttctat gaatgaatct gctcccactg gtattactga tcatattgtc caaggacctg 720

tcccaacct tgaagaaagt cctaaaagaa aaaatattac atatgaggaa ttaaggaata 780

Jaacagaga gtcatatgaa gtatctttaa cacaaaagac tgacccctca gtcaggccta 840

jcatgaaag agtgccaaaa aaagaagtca aagtaaacaa gtatggagat acttgggatg 900

#### eolf-seql-S000001.txt

Itgaaaaat tacatcattg gacatgaagg agtttcaaca tccagcttca tctaggtggt 960

atgattacc tgcatgcttt gagctcagca gcagtcttca taaacacatt taaaacaaga 1020

sctgggttt ttgtggtttg acttctatgg tgttttaaaa aaacacagat ttttagtgtt
1080

stattgtgt aaatgtactc accttaggga ttcatttgaa tgatggtatt ataccatgat 1140

ytatacagt ttgtgaaatt gttgcaaggg caaagataac tcttaaaaaa ccgtcgagat 1200

lcaatgctc tagaatcagc atataagaaa ataaatgata tctgcatgtt gaattggggt 1260

jatgggggg agcaagcata atttttaagt gtgaagcttt gcatcaagaa attattaaaa 1320

jcttttttt ctccagtatt ttctgtatta tcttaatgtt tatggcaaat aaaatgtaaa 1380

jaacatgcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaa aaaa 1434

?10> 9

211> 1414

?12> DNA

?13> Homo sapiens

100> 9

şattgagga acccatttcc tcattctgca aattgcaaac ctgagggccc aaagagggac 60

/gggcttgc caggtctcag caggctgtga gcaagagcta aagcctaatc ctcctgcctt
120

ggctggag ccttccttgt accccagggt cagtgtcttt gttggataca ggcttagatt 180

ctgactgt accetgagaa cetaggggag tecetgttee caattettet eetaceeeca 240

ttggcctg atggaggaag accetgetgt gttgagatga gcaccagage caagaagetg 300

gaggatet ggagaattet ggaggaagag gagagtgttg etggagetgt acagaceetg 360

totcaggt cocaggaagg tggcgtcaca totgcagccg cgtcgacgtt gtcggagcct 420

# eolf-seql-S000001.txt

- :Cgcggagga cccaggagag ccggactagg accagggccc tgggcctccc cacactcccc 480
- tggagaagc tggcggcctc tacagagccc caagggcctc ggccggtcct gggccgtgag 540
- gtgtccagg tgcccgatga ccaagacttt cgcagcttcc ggtcagagtg tgaggctgag 600
- rtgggctgga acctgaccta tagcagggct ggggtgtctg tctgggtgca ggctgtggag 660
- tggatcgga cgctgcacaa gatcaagtgc cggatggagt gctgtgatgt gccagccgag 720
- .cactctacg acgtcctaca cgacattgag taccgcaaga aatgggacag caacgtcatt 780
- agacttttg acatcgcccg cttgacagtc aacgctgacg tgggctatta ctcctggagg 840
- gtcccaage ccctgaagaa ccgtgatgte atcaccetee geteetgget ccccatggge 900
- ctgattaca tcattatgaa ctactcagtc aaacatccca aatacccacc tcggaaagac 960
- tggtccgag ctgtgtccat ccagacgggc tacctcatcc agagcacagg gcccaagagc 1020
- gcgtcatca cctacctggc ccaggtggac cccaaaggct ccttacccaa gtgggtggtg 1080
- ataaatctt ctcagttcct ggctcccaag gccatgaaga agatgtacaa ggcgtgcctc 1140
- agtaccccg agtggaaaca gaagcacctg cctcacttca agccgtggct gcacccggag 1200
- agagecegt tgccgagect ggegetgteg gagetgtegg tgcageatge ggaeteaetg 1260
- agaacatcg acgagagcgc ggtggccgag agcagagagg agcggatggg cggcggggc 1320
- gcgagggca gcgacgacga cacctcgctc acctgagcga cgcaccgctt cagggacgga 1380
- acaggaccg gcggagccct ggggcggcgg ccgc 1414

210> 10 211> 1262

- :212> DNA
- :213> Homo sapiens
- :400> 10
- ctctcgcga gatccctact ggctataaag gcagcgcccc ggagagctct tgcgcgtctt 60
- rttcttgcct ggtgtcggtg gttagtttct gcgacttgtg ttgggactgg tgagtgtggg 120
- !agtgcggcc cctgcggagt gaggcgcggc gcgcccttct tgcctgttgc ctcttcctcc
  180
- cctgtccgg ggcccgcccg cgctcgggtg ggggtgctgt gatgcgtgag gcagccgggg 240
- aggcccgga gtccgagact gcttgagcgc tgcgcacacc cctctcgtgg gcccccacg 300
- aggtgcggg aacctggttg aaccccaagc tgataggaag atgtcttcag gaaatgctaa 360
- attgggcac cctgcccca acttcaaagc cacagctgtt atgccagatg gtcagtttaa 420
- gatatcagc ctgtctgact acaaaggaaa atatgttgtg ttcttctttt accctcttga
  480
- ttcaccttt gtgtgcccca cggagatcat tgctttcagt gatagggcag aagaatttaa 540
- aaactcaac tgccaagtga ttggtgcttc tgtggattct cacttctgtc atctagcatg
  600
- gtcaataca cctaagaaac aaggaggact gggacccatg aacattcctt tggtatcaga 660
- ccgaagcgc accattgctc aggattatgg ggtcttaaag gctgatgaag gcatctcgtt 720
- aggggcctt tttatcattg atgataaggg tattcttcgg cagatcactg taaatgacct 780
- cctgttggc cgctctgtgg atgagacttt gagactagtt caggccttcc agttcactga 840
- aaacatggg gaagtgtgcc cagctggctg gaaacctggc agtgatacca tcaagcctga
  900
- gtccaaaag agcaaagaat atttctccaa gcagaagtga gcgctgggct gttttagtgc 960
- aggctgcgg tgggcagcca tgagaacaaa acctcttctg tattttttt ttccattagt 1020

eolf-segl-S000001.txt

.aaacacaag acttcagatt cagccgaatt gtggtgtctt acaaggcagg cctttcctac 1080

gggggtgga gagaccagcc tttcttcctt tggtaggaat ggcctgagtt ggcgttgtgg 1140

caggctact ggtttgtatg atgtattagt agagcaaccc attaatcttt tgtagtttgt 1200

a 1262

210> 11

211> 4108

212> DNA

213> Homo sapiens

400> 11

ctccagcac catgtctggt ttgtctggcc caccagcccg gcgcggccct tttccgttag
60

gttgctgct tttgttcctg ctcggcccca gattggtcct tgccatctcc ttccatctgc 120

cattaactc tcgcaagtgc ctccgtgagg agattcacaa ggacctgcta gtgactggcg 180

gtacgagat ctccgaccag tctgggggcg ctggcggcct gcgcagccac ctcaggatca 240

agattctgc tggccatatt ctctactcca aagaggatgc aaccaagggg aaatttgcct 300

taccactga agattatgac atgtttgaag tgtgttttga gagcaaggga acagggcgga 360

acctgacca actcgtgatc ctagacatga agcatggagt ggaggcgaaa aattacgaag 420

gattgcaaa agttgagaag ctcaaaccat tagaggtaga gctgcgacgc ctagaagacc 480

ttcagaatc tattgttaat gattttgcct acatgaagaa gagagaagag gagatgcgtg 540

Laccaacga gtcaacaaac actcgggtcc tatacttcag catcttttca atgttctgtc 600

cattggact agetacetgg caggtettet acetgegacg ettetteaag gecaagaaat 660

- gattgagta atgaatgagg catattetee teccacettg taceteagee ageagaacat 720
- gctgggacg tgcctggcct aaggcatcct accaacagca ccatcaaggc acgttggagc 780
- ttcttgcca gaactgatct cttttggtgt gggaggacat ggggtaccac ctacacccaa 840
- aagtcaatg agggacttct ttttaatttg gtaggatttt gactggtttt gcaacaatag
  900
- tctattatt agagtcacct atgacaaaaa ataggggtta cctagataat gccaaagtca 960
- catttgtcc cgggttccct tgtgtgatct gtttggacta tgttttcttt tcttctcca 1020
- ttgctcagc agcttgggct tccattctag ttcttttacc aagatttttg tgtgaccatg 1080
- tgacttcat ttggattgcc ctctttcaat ttccttgtga aaacaccctt aactttctct 1140
- tacccttag ctgaaatgtt tacatagctt ctggtgatat cttttcatga ttttatatct 1200
- ttaaaatgg tgatggatgt gacacctcat aaaagtgagc tttgaactgt agataactct 1260
- aaagaaaat gtcattttag acaattaaaa tatttgtgct caactgcttg aacttttttc 1320
- tgtatgtgt atttaattct atgcaatatt atcacatgtg tagattcatg tgaccaccat 1380
- acaagagac agaacagttc tgtcacatgg atcccttgca ctgccctttt acagccgcag 1440
- cacatecet teettatace etcaceceaa eetgtggeta eeactgttet gteetecate 1500
- stgtaattt tgtcatttca agaatgttgt atgaatggaa tcatacagaa tgtaatctta 1560
- aaggctgat ctttttcat tcagcataat tcccttgaaa tccatccaag ttgttgcatg 1620
- itgaatagt ttcttccttt ttttctttta aaaatgtttt atatatttag ggggtataag 1680
- cagatttc ttacatgcat atattgcatc gtggtgaagt gggggcagtt ccttttgatt 1740
- tgagtagt attccatggt atggatgtac cacagtttgc ttaaccattc acccactaaa

eolf-segl-S000001.txt

1800

- gacataaga gttgttttca gttttttgcc ctaataaagc tgctgtgaac attcatgtac 1860
- ggtttttat gtgaacatac attttcattt tctgggataa atgctcaaaa gggcaactgt 1920
- gggttgtat ggtaaacaca tatatttttg taagaaacta ccctactctt tttccagagt 1980
- gctctactt tttacataca gccactcata caattcagac agcaatgtat gattgatcca 2040
- tttcttcac atcctcacca gcatttggta ttactactat tttttatctt aaccattcac 2100
- tagatgtgt gtaatgatac cacatgtggt tttaatttgc atttccaatg gctaatgatg 2160
- tgagtatet ttttgtgtge taatttgeea tetatgtate etetteggtg aaatgtette 2220
- tgtcttttg tctattttct atttaggtca tttgttcttt ttactattga gttttgagag 2280
- ttttttata tatcctagat aaaattcctc tgttagatat gtggttgctt gaatttttaa 2340
- ataacttct accaaggaaa aataagtaaa atttccaacc cttgcatggc cagtcactta 2400
- ttaattcct gtccttcagt gttccatcta gagaattaag agatatgatg tataaaatag
- catcgaggg ccattaagag agtaaatact taaaaataca tgttatgaaa gcaaagccaa 2520
- aatcactgt aggagtatga gttgcctaag ggccaaaact aatgtaaata agagaaagtg 2580
- gatataaa tgaccattgt ttataaacag tcatgaaaaa tgctgtgact tgaaatcttt 2640
- cacatete ecaagaaagt aggtaggagt ttateettte egtaatetet ttttaaeeet 2700
- stgactatt acagggcttg tttaatcaca gtggcaagaa ttacatgtat cttacagtaa 2760
- Jaaacagaa tactggaatc gttagagaac cctgatgtgt tgacctggat aaagtacaaa 2820
- jtggaagag ggaatgagtt atgctgttaa aatctcaggc tattctgtta atgttcctgc 2880

- actatgaac ccaaactttt tttttcccc ttttgactcc ttgtgtcttc ctctcctgtg 2940
- cataaaagt agttctgtcg ttaacttgta caacattgcc atctgctgtt gagaattggt 3000
- ggtactgct tctgagaacc tggctgcaga tccttagcat aggcagcaaa tgttgagaaa 3060
- tctatctgt agtattacat atactaagtt acagaggatg catccaagta gagaaaataa 3120
- tgctgcaac gcccaggctg gagtgcaatg gcactatete agetegetge aacetteace 3240
- cctgggttc aagcaattct cctgcctcag cctcctgagt agctgggaat ataggtgcac 3300
- ccaccatgc ctggctaatt tttgtatttt cagtagaagc agagtttcac catattggcc 3360
- ggttggtct cgaactcctg acctcaagtg atctgcctgc ctcagcctcc caaagtgctg 3420
- gattacacg cgtgagccac cacacccagc ctccatcttt aaacttttaa atgtggaatt 3480
- ctatcatgt accgttagcc taacaagatt ttctttccta tttctgactg gtgcctttcc 3540
- ctttttagg agcaacgaaa gctactctct tagttatgtt cttgtgatgt gacaaaatgt 3600
- aagaagata ggagaagaga atattttatt tcgttgatgc ttttgttccc aagtgtgacc 3660
- taaacttaa gctttgtagg agttgacatt ctttcatgtc ccttcccttt actcatgccg 3720
- aactatcaa ctgggacatt ttgtgctttt ggtttaaaag ttaattgata ttatactttg
  3780
- ittatcta aaaagtaaat gtatttgcct ttgacaaaag actgacacaa gagcaaataa 3840
- otttaaaat cgggtgttat gtgctttcct ccatttttga gcatattatc caaaatggtc 3900
- jtataatat aaatgagaat gatgcagttt aagtaagcct tgttatacca ttgtcatgga 3960

eolf-segl-S000001.txt

ccctgtcat aaagccattt cttggtttgt ttgggaaaga ggcatatggg atttatacag 4020

ttcacttgt aaatgttgga ttggggattt ttgtgtaaat tttctcaaat aaaggctagc 4080

gaaaccgaa aaaaaaaaa aaaaaaaa 4108

- 210> 12
- 211> 5767
- 212> DNA
- 213> Homo sapiens
- 400> 12
- agggaggag agttcacttt tacttcagtg tcagcgcgcg gcggccgtgg ctggctctgg 60
- gagagagca ccgagggagt gggtcgcaga tcttcgggcg gctaggggaa atcggcgaga 120
- gcgggatcc gagcgcccg gcggggcgca gagcccgcga gcctggccag cgagggtagc 180
- gcggggggc gcgccccggg cgggcccccg gagacgcgca ggatgccaca cgaagagctg 240
- cgtcgctgc agagaccccg ctatggctct attgtggacg atgaaaggct ctctgcagag 300
- agatggatg agaggaggcg gcagaacatt gcttatgaat atctgtgcca cttagaggaa 360
- ccaaaaggt ggatggaagt ttgcttagtt gaagaattgc caccaaccac tgaattggaa 420
- aagggctcc ggaatggagt ttaccttgca aagttagcca agttctttgc cccgaaaatg 480
- tatcagaga aaaagatcta tgatgtggaa caaacacgtt ataagaagtc tggccttcat 540
- itcgacaca cagataatac cgtccagtgg ttaagagcga tggagtctat tggtctaccc
  600
- agatatttt atccagaaac aacagatgtc tatgatcgga aaaacatacc aagaatgata 660
- ittgcattc acgcactgag tttgtatctg ttcaaactag gaatagcacc ccagatccag
  720
- itttgttgg gcaaagtaga cttcacagag gaggaaatca gtaatatgag aaaagaactt 780

eolf-seql-S000001.txt

agaaatatg gaatacagat gccatctttc agcaaaatag gtggtattct ggccaatgaa 840

- tgtccgtgg atgaagctgc attacatgct gcagttatag ccattaatga agcagttgaa 900
- aaggaatag cagagcaaac cgttgtaaca ctaagaaacc caaatgcggt tttaacttta
  960
- tggatgaca accttgcacc agaatatcag aaagaactct gggatgccaa aaagaaaaaa 1020
- aggaaaatg caagactgaa gaatagctgt atttcagaag aagaaagaga tgcttatgaa 1080
- aactgctga cacaagcaga aatccaaggc aatattaata aagtcaacag gcaggctgca 1140
- Iggaccata tcaatgctgt cattccggaa ggtgaccccg agaatacgct gcttgcactg 1200
- agaaaccag aggcccagct gcctgctgtt tatccctttg ctgctgccat gtatcagaac 1260
- lactittca acciccagaa acagaacacc atgaactact tggcccacga ggagctittg 1320
- tgctgtgg aaatgttgtc tgctgttgct ttactaaacc aggccttgga aagcaacgat 1380
- :tgtgtctg tgcagaatca actcagaagc cccgcaatag gcttaaacaa tctggacaag 1440
- :atatgtgg aacgttatgc aaacacacta ctctctgtta aactagaagt tttatcccaa 1500
- ggcaagata acttaagctg gaatgaaatt cagaattgta ttgatatggt taatgctcaa 1560
- :tcaagaag aaaatgaccg agttgtagct gtagggtaca tcaatgaagc tattgatgaa 1620
- gaatcctt tgaggacttt agaaactttg ctcctaccta ctgcgaatat tagtgatgtg 1680
- occagece atgeceagea etaceaggat gttttatace atgetaaate acagaaacte 1740
- agactetg agagtgttte caaagtgett tggetggatg agatacagea ageegtegat 1800
- ggccaacg tggacgagga cagagcaaaa caatgggtta ctctggtggt tgatgttaat 1860
- gtgtttgg aaggaaaaa atcaagtgat attttgtctg tattgaagtc ttccacttct

eolf-seql-S000001.txt

1920

atgcaaatg acataatccc ggagtgtgct gacaaatact atgatgccct tgtgaaggca 1980

aagagetea aatetgaaag agtgtetagt gaeggtteat ggeteaaaet eaacetgeae 2040

aaaaatatg actactatta caacactgat tcaaaagaga gttcctgggt cacacctgaa 2100

catgcttct ataaagaatc atggctcaca ggaaaagaaa tcgaggacat tattgaggaa 2160

tcacagtag gttacattcg tgagaatata tggtctgctt cagaagagtt gcttcttcgc 2220

ttcaagcca caagctcagg acccatcctt agggaagagt ttgaagctag aaaatcattt 2280

tgcatgaac aagaagagaa tgtggtcaaa atacaggctt tttggaaagg atataaacaa 2340

ggaaggagt atatgcacag gcggcaaacg ttcattgata atactgattc tgttgtgaag 2400

ttcagtcct ggttccgaat ggcaactgca agaaagagct atctttcaag actacagtat 2460 .

tcagagatc ataataatga aattgtgaaa atacagtcac tgttgagagc gaacaaagct 2520

gagatgact acaaaacatt ggttggctct gaaaacccac cattaacagt aattcgcaaa 2580

itgtatacc tgctggacca aagtgatttg gatttccagg aggaactaga ggttgcacga
2640

Laagggaag aagtagtgac caagatcagg gccaatcaac agctggaaaa agacctgaac 2700

gatggaca tcaagattgg actgctggtg aagaacagga tcacactaga ggatgtaatt 2760

cacacagta aaaagctgaa caagaaaaaa ggaggagaaa tggaaatact gaataacacc 2820

1Caaccaag gaataaaaag tttgagtaag gagaggagaa aaacactaga aacatatcag 2880

agetgtttt acettttaca gaccaaceet ttataettgg etaagetgat tttecagatg 2940

cagaaca agtccactaa atttatggat actgttattt tcacactata taattatgcc 3000

# eolf-seql-S000001.txt

taatcagc gagaagaata totacttoto aagottttta aaactgotot ggaggaagaa 3060

:aaaatcaa aagtggacca ggtacaggac atagttactg gtaaccctac agtcatcaag 3120

ggtcgtca gcttcaatag aggtgcccgg ggacagaaca ccctgcgcca actcctggct 3180

agtggtaa aagagatcat cgacgacaag tcgctgatta tcaacacaaa ccctgtagag 3240

gtacaagg cttgggtgaa ccaactagaa acacagactg gagaggccag caagttgcct 3300

ıtgatgtga ccacagaaca agctctaaca tacccagaag tgaaaaataa actggaggct 3360

cattgaga acctgagaag ggtcaccgac aaagtcctga attctatcat ttcttccctt 3420

tctactgc cttatggatt gaggtatata gccaaagtac tgaagaattc gatccatgag 3480

attccccg atgcaacaga agatgagcta ttaaagattg ttggaaacct cctgtactat 3540

gtacatga atccagccat tgtagctcca gatggctttg atatcatcga catgacagct 3600

aggtcaga taaattctga ccaaaggaga aacttaggat cagtggccaa ggttcttcag 3660

cgcagcct ccaacaagct gtttgaagga gaaaatgagc atctctcatc tatgaacaat 3720

tttatcag agacgtatca ggaattcagg aaatatttca aagaagcatg taatgtccct 3780

gccagaag agaagtttaa tatggacaaa tacacagacc tggtgacagt cagcaaacca 3840

catttata tttcaattga agaaatcatc agcacacat cactcctgtt ggaacaccag 3900

tgcaattg cccctgagaa aaatgactta ctgagtgaat tgctggggtc gctgggagag 3960

gccaaccg tggaatcttt tcttggggaa ggagcagttg accccaatga ccctaacaag 4020

aaatacac taagtcagct ttcaaagacc gagatttctc ttgtcttgac aagcaaatat 4080

- acatagagg acggtgaagc tatagatagc cgaagcctca tgataaagac caagaagctg 4140
- taattgatg tgatccggaa ccagccaggg aacacattga cagaaatctt agagacacca 4200
- caactgcgc aacaggaggt agaccatgcc acggacatgg tgagccgtgc aatgatagat 4260
- ccaggactc cagaagaaat gaagcatagc caatctatga ttgaagatgc acagctgcct 4320
- ttgagcaga agaagaggaa aatccagagg aatcttcgga cgttggaaca gactggacac 4380
- tgtcatccg aaaataaata ccaagacatt ctcaatgaga ttgccaagga tattcgaaat 4440
- aaagaatct atcgtaagct tcgaaaagct gaattggcaa aacttcagca gaccctgaat 4500
- cacttaaca agaaggcagc attttatgaa gagcaaatca attattatga cacctacata 4560
- agacttgtt tagacaactt aaaaagaaaa aatactcgga gatcaattaa actagatgga 4620
- aaggagaac ccaaaggggc gaagagagcg aagccagtga agtacactgc agcaaagctg
  4680
- atgagaaag gtgtcctgct agatatagat gatcttcaaa caaaccagtt taagaatgtt 4740
- catttgata tcatagctac tgaagatgta ggcattttcg atgtaagatc aaaattcctt 4800
- jtgttgaga tggaaaaggt gcaactcaat attcaggatt tacttcagat gcaatatgaa 4860
- Jagtagctg taatgaaaat gtttgataag gttaaagtga atgtaaacct tctcatatac 4920
- gctgaaca agaagttcta tggaaagtga agtgcctaca gaaatttctt ggattctgta 4980
- catctggat taggaaatga atttgtttaa tatttttgtt tttaaacatg attgaaatca 5040
- gcttataa atgtgtgatt ttttttaaat gaccaaaact gttctgaaga atgtacccag 5100
- :gccttttt gctaatttga tactataata gaatgagaca taaaatgaat taatggaaac 5160
- :atccacac tgtactgtga tataggtact ctgatttaaa actttggaca tcctgtgatc

eolf-seal-S000001.txt

5220

gttttaaag ttggggggtg ggaaatttag ctgactaggg acaaacatgt aaacctattt 5280

:cctatgaaa aaagttttaa.atgtcccact tgaataacgt aattcttcat agttttttta 5340

tctatggat aaatggaaac ctaattattt gtaatgaatt atttagacag ttctaagccc 5400

gtcttctgg gagttatcaa ttttaaagag aacttttgtg caattcaaat gaagttttta 5460

aagtaattg aaaatgacaa cacaataaca ctttctgtat aaaagtatat attttatgtg 5520

tttattcct actaaatgaa agtgcactac tgcctcatgt aaagactctt gcacgcagag 5580

ctttaagtg actaaggaac aacatagata gtgagcatag tccccacctc caccctcac 5640

atttatttg aatacttcaa ttgtgcctct caattttttg taatgctaaa aaatcagtat 5700

tagatggtt tttaaatgta ttctctggaa attgttttat gtaaaataaa tgttacttaa 5760

tccatt 5767

210> 13

211> 1148

212> DNA

213> Homo sapiens

400> 13

ctcggtcgg gcgctgtctc cctcggctct gcgggtgtca gttcgtccgg cttcctcaca 60

cccctcact cccggcggct gacagcagca gcggcggcgg cgggcggcgc ctggcgtttc 120

aggctgagc ggcaccgggg ttggggcgcg gaggaggagc agcagcggga ggaggagccg

gtgccctgg cactgagcgg ccgcggccat ggcgtacgcc tatctcttca agtacatcat 240

atcggcgac acaggtgttg gtaaatcatg cttattgcta cagtttacag acaagaggtt 300

cagecagtg catgacetta etattggtgt agagtteggt getegaatga taactattga

eolf-seql-S000001.txt

360

gggaaacag ataaaacttc agatatggga tacggcaggg caagaatcct ttcgttccat 420

- :acaaggtcg tattacagag gtgcagcagg agctttacta gtttacgata ttacacggag 480
- gatacattc aaccacttga caacctggtt agaagatgcc cgccagcatt ccaattccaa 540
- atggtcatt atgcttattg gaaataaaag tgatttagaa tctagaagag aagtaaaaa 600
- gaagaaggt gaagcttttg cacgagaaca tggactcatc ttcatggaaa cgtctgctaa 660
- ractgcttcc aatgtagaag aggcatttat taatacagca aaagaaattt atgaaaaaat 720
- .caagaagga gtctttgaca ttaataatga ggcaaatggc attaaaattg gccctcagca 780
- gctgctacc aatgcaacac atgcaggcaa tcagggagga cagcaggctg ggggcggctg  $840\,$
- tgttgagtc tgtttttact gtctagctgc ccaacggggc ctactcactt attctttcac 900
- ccctctcct cctgctcagc tgagacatga aactatttga aatggcttta tgtcacagaa 960
- actttaatc cgtcaaattc ttgtataact ttgaataaat ggttaatgtt cacttaaaag 1020
- cagattttg gagattgtat tcatatctat ttgcatttga tttctaggtc aattgatgtg 1080
- ttatttttg ttaaatgttg tcttgtgccc ttaactacga actgaattgt attaaacact 1140

caaagtc 1148

210> 14

211> 1814

212> DNA

213> Homo sapiens

400> 14

caaaaccaa cgcctggctc ggagcagcag cctctgaggt gtccctggcc agtgtccttc 60

acctgtcca caagcatggg gaacatcttc gccaacctct tcaagggcct ttttggcaaa

eolf-seql-S000001.txt

120

aagaaatgc gcatcctcat ggtgggcctg gatgctgcag ggaagaccac gatcctctac agcttaagc tgggtgagat cgtgaccacc attcccacca taggcttcaa cgtggaaacc 240 tggagtaca agaacatcag cttcactgtg tgggacgtgg gtggccagga caagatccgg 300 ccctgtggc gccactactt ccagaacaca caaggcctga tcttcgtggt ggacagcaat 360 acagagage gtgtgaacga ggcccgtgag gageteatga ggatgetgge egaggaegag 420 teegggatg etgteeteet ggtgttegee aacaageagg aceteeceaa egecatgaat oggeegaga teacagaeaa getggggetg eacteactae geeacaggaa etggtaeatt 540 600 ageteegga accagaagtg aacgegacce ecetecetet caeteetett geeetetget lactoteat gtggcaaacg tgcggctcgt ggtgtgagtg ccagaagctg cctccgtggt 720 iggtcaccg tgtgcatcgc accgtgctgt aaatgtggca gacgcagcct gcggccaggc 780 itttattta atgtaaatag tttttgtttc caatgaggca gtttctggta ctcctatgca 840 :attactca gctttttta ttgtaaaaag aaaaatcaac tcactgttca gtgctgagag jgatgtagg cccatgggca cctggcctcc aggagtcgct gtgttgggag agccggccac 960 ecttggct tagagctgtg ttgaaatcca ttttggtggt tggttttaac ccaaactcag 1020 scatttttt aaaatagtta agaatccaag tcgagaacac ttgaacacac agaagggaga 1080 :ccgcctag catagatttg cagttacggc ctggatgcca gtcgccagcc cagctgttcc 1140 tcgggaac atgaggtggt ggtggcgcag cagactgcga tcaattctgc atggtcacag 1200

#### eolf-seql-S000001.txt

agagatece egeaactege tigteetigg gleaceetge attecatage catgigetig 1260

coctgtgct cocacggttc ccaggggcca ggctgggagc ccacagccac cccactatgc 1320

Jeaggeege cetacecace tteaggeage etatgggaeg eaggeeceat etgteeeteg 1380

ccgcgtgt ggccagagtg gtccgtcgtc cccaacactc gtgctcgctc agacactttg 1440

caggatgtc tggggcctca ccagcaggag cgcgtgcaag ccgggcaggc ggtccaccta 1500

acceacage ecctegggag caccecacet etgtgtgtga tgtagettte teteceteag 1560

stgcaaggg tccgatttgc catcgaaaaa gacaacctct acttttttct tttgtatttt 1620

ltaaacact gaagctggag ctgttaaatt tatcttgggg aaacctcaga actggtctat 1680

:ggtgtcgt aggaacctct tactgctttc aatacacgat tagtaatcaa ctgttttgta
1740

icttgtttt cagttttcat ttcgacaaac aagcactgta attatagcta ttagaataaa 1800

octottaac tatt 1814

?10> 15

11> 2912

:12> DNA

:13> Homo sapiens

100> 15

igttgcttc agcgtcccgg tgtggctgtg ccgttggtcc tgtgcggtca cttagccaag
60

gcctgagg aaacccagac ccaagaccaa ccgatggagg aggaggaggt tgagacgttc 120

ctttcagg cagaaattgc ccagttgatg tcattgatca tcaatacttt ctactcgaac 180

agagatet ttetgagaga geteatttea aatteateag atgeattgga eaaaateegg 240

tgaaactt tgacagatcc cagtaaatta gactctggga aagagctgca tattaacctt 300

- taccgaaca aacaagatcg aactotcact attgtggata ctggaattgg aatgaccaag 360
- ctgacttga tcaataacct tggtactatc gccaagtctg ggaccaaagc gttcatggaa 420
- ctttgcagg ctggtgcaga tatctctatg attggccagt tcggtgttgg tttttattct
  480
- cttatttgg ttgctgagaa agtaactgtg atcaccaaac ataacgatga tgagcagtac 540
- cttgggagt cctcagcagg gggatcattc acagtgagga cagacacagg tgaacctatg
  600
- jtcgtggaa caaaagttat cctacacctg aaagaagacc aaactgagta cttggaggaa
  660
- jaagaataa aggagattgt gaagaaacat tctcagttta ttggatatcc cattactctt
  720
- :tgtggaga aggaacgtga taaagaagta agcgatgatg aggctgaaga aaaggaagac 780
- lagaagaag aaaaagaaaa agaagagaaa gagtcggaag acaaacctga aattgaagat 840
- :tggttctg atgaggaaga agaaagaag gatggtgaca agaagaagaa gaagaagatt 900
- cgacgata ttactaatga ggagtacgga gaattctata agagcttgac caatgactgg 1020
- lagatcact tggcagtgaa gcatttttca gttgaaggac agttggaatt cagagccctt 1080
- atttgtcc cacgacgtgc tccttttgat ctgtttgaaa acagaaagaa aaagaacaat 1140
- caaattgt atgtacgcag agttttcatc atggataact gtgaggagct aatccctgaa 1200
- tctgaact tcattagagg ggtggtagac tcggaggatc tccctctaaa catatcccgt 1260
- gatgttgc aacaaagcaa aattttgaaa gttatcagga agaatttggt caaaaaatgc 1320
- agaactct ttactgaact ggcggaagat aaagagaact acaagaaatt ctatgagcag

eolf-seql-S000001.txt

octotaaaa acataaagot tggaatacac gaagactoto aaaatoggaa gaagotttoa 1440

19ctgttaa ggtactacac atctgcctct ggtgatgaga tggtttctct caaggactac 1500

jcaccagaa tgaaggagaa ccagaaacat atctattata tcacaggtga gaccaaggac 1560

1ggtagcta actcagcctt tgtggaacgt cttcggaaac atggcttaga agtgatctat 1620

gattgagc ccattgatga gtactgtgtc caacagctga aggaatttga ggggaagact 1680

agtgtcag tcaccaaaga aggcctggaa cttccagagg atgaagaaga gaaaaagaag 1740

iggaagaga aaaaaacaaa gtttgagaac ctctgcaaaa tcatgaaaga catattggag 1800

laaaagttg aaaaggtggt tgtgtcaaac cgattggtga catctccatg ctgtattgtc 1860

laagcacat atggctggac agcaaacatg gagagaatca tgaaagctca agccctaaga 1920

icaactcaa caatgggtta catggcagca aagaaacacc tggagataaa ccctgaccat 1980

cattattg agaccttaag gcaaaaggca gaggctgata agaacgacaa gtctgtgaag 2040

tctggtca tcttgcttta tgaaactgcg ctcctgtctt ctggcttcag tctggaagat 2100

:ccagacac atgctaacag gatctacagg atgatcaaac ttggtctggg tattgatgaa 2160

tgacccta ctgctgatga taccagtgct gctgtaactg aagaaatgcc acccttgaa 2220

agatgacg acacatcacg catggaagaa gtagactaat ctctggctga gggatgactt 2280

ctgttcag tactctacaa ttcctctgat aatatatttt caaggatgtt tttctttatt 2340

tgttaata ttaaaaagtc tgtatggcat gacaactact ttaaggggaa gataagattt 2400

gtctacta agtgatgctg tgatacctta ggcactaaag cagagctagt aatgcttttt 2460

gtttcatg ttggttcttt cacagatggg gtaacgtgca ctgtaagacg tatgtaacat

eolf-seql-S000001.txt

2520

atgttaact ttgtgtggtc taaagtgttt agctgtcaag ccggatgcct aagtagacca 2580

atcttgtta ttgaagtgtt ctgagctgta tcttgatgtt tagaaaagta ttcgttacat 2640

itgtaggat ctactttttg aacttttcat tccctgtagt tgacaattct gcatgtacta 2700

cctctaga aataggttaa actgaagcaa cttgatggaa ggatctctcc acagggcttg 2760

ittocaaag aaaagtattg tttggaggag caaagttaaa agcctaccta agcatatcgt 2820

lagctgttc aaatactcga gcccagtctt gtggatggaa atgtagtgct cgagtcacat 2880

tgcttaaa gttgtaacaa atacagatga gt 2912

210> 16

?11> 3369

?12> DNA

?13> Homo sapiens

100> 16

;ttttcagg agcccgagcg agggcgccgc ttttgcgtcc gggaggagcc aaccgtggcg
60

iggcggcgc ggggaggcgt cccagagtct cactctgccg cccaggctgg actgcagtga 120

caateteg getgaetgea accaetgeet eeagggttea agegattete ttgeeteage 180

.cccaagta gctgggatta cagattgatg ttcatgttcc tggcactact acaagattca 240

ictcctgat gctactgaca acgtggcttc tccacagtca ccaaaccagg gatgctatac
300

igacttccc tactctcatc tgctccagcc ccctgacctt atagttgccc agctttcctg
360

aattgact ttgcccatca atacacagga tttagcatcc agggaagatg tcggagcctc 420

atgttaat tttctaattg agaatgttgg cgctgtccga acctggagac aggaaaacaa 480

agteettt eteetgatte accaaaaaat aaaataetga etaceateae tgtgatgaga

#### eolf-seql-S000001.txt

540

1620

tectatagt eteaggaact gaagtettta aacaaceagg gaccetetge eectagaata gaacatact agaagtccct tctgctagga caacgaggat catgggagac cacctggacc 660 teteetagg agtggtgete atggeeggte etgtgtttgg aatteettee tgeteetttg 720 tggccgaat agccttttat cgtttctgca acctcaccca ggtcccccag gtcctcaaca cactgagag gctcctgctg agcttcaact atatcaggac agtcactgct tcatccttcc 840 ctttctgga acagctgcag ctgctggagc tcqqqaqcca qtataccccc ttgactattg caaggaggc cttcagaaac ctgcccaacc ttagaatctt ggacctggga agtagtaaga 960 atactictt gcatccagat gcttttcagg gactgttcca tctgtttgaa cttagactgt 1020 tttctgtgg tctctctgat gctgtattga aagatggtta tttcagaaat ttaaaggctt 1080 sactogott ggatotatoo aaaaatoaga ttogtagoot ttacottoat cottoatttg 1140 jaagttgaa ttccttaaag tccatagatt tttcctccaa ccaaatattc cttgtatgtg 1200 acatgaget egageecta caagggaaaa egeteteett ttttageete geagetaata 1260 ottgtatag cagagtetea gtggaetggg gaaaatgtat gaacceatte agaaacatgg jctggagat actagatgtt tctggaaatg gctggacagt ggacatcaca ggaaacttta 1380 laatgccat cagcaaaagc caggcettet etttgattet tgcccaccac atcatgggtg 1440 gggtttgg cttccataac atcaaagatc ctgaccagaa cacatttgct ggcctggcca lagttcagt gagacacctg gatctttcac atgggtttgt cttctccctg aactcacgag 1560 tttgagac actcaaggat ttgaaggttc tgaaccttgc ctacaacaag ataaataaga

Page 41

- tgcagatga agcattttac ggacttgaca acctccaagt tctcaatttg tcatataacc 1680
- tctggggga actttacagt tcgaatttct atggactacc taaggtagcc tacattgatt 1740
- gcaaaagaa tcacattgca ataattcaag accaaacatt caaattcctg gaaaaattac 1800
- gaccttgga tctccgagac aatgctctta caaccattca ttttattcca agcatacccg 1860
- tatcttctt gagtggcaat aaactagtga ctttgccaaa gatcaacctt acagcgaacc 1920
- catccactt atcagaaaac aggctagaaa atctagatat tctctacttt cttctacggg 1980
- acctcatct ccagattctc attttaaatc aaaatcgctt ctcctcctgt agtggagatc 2040
- aaccccttc agagaatccc agcttagaac agcttttcct tggagaaaat atgttgcaac 2100
- tgcctggga aactgagctc tgttgggatg tttttgaggg actttctcat cttcaagttc 2160
- gtatttgaa tcataactat cttaattccc ttccaccagg agtatttagc catctgactg 2220
- attaagggg actaagcctc aactccaaca ggctgacagt tctttctcac aatgatttac 2280
- tgctaattt agagateetg gacatateea ggaaceaget eetageteet aateetgatg 2340
- atttgtatc acttagtgtc ttggatataa ctcataacaa gttcatttgt gaatgtgaac 2400
- tagcacttt tatcaattgg cttaatcaca ccaatgtcac tatagctggg cctcctgcag 2460
- catatattg tgtgtaccct gactcgttct ctggggtttc cctcttctct ctttccacgg 2520
- ggttgtga tgaagaggaa gtcttaaagt ccctaaagtt ctcccttttc attgtatgca 2580
- egtcactct gactctgttc ctcatgacca tcctcacagt cacaaagttc cggggcttct 2640
- :tttatctg ttataagaca gcccagagac tggtgttcaa ggaccatccc cagggcacag 2700

eolf-seql-S000001.txt

acctgatat gtacaaatat gatgcctatt tgtgcttcag cagcaaagac ttcacatggg 2760

- gcagaatgc tttgctcaaa cacctggaca ctcaatacag tgaccaaaac agattcaacc 2820
- gtgctttga agaaagagac tttgtcccag gagaaaaccg cattgccaat atccaggatg 2880
- catctggaa cagtagaaag atcgtttgtc ttgtgagcag acacttcctt agagatggct 2940
- gtgccttga agccttcagt tatgcccagg gcaggtgctt atctgacctt aacagtgctc 3000
- catcatggt ggtggttggg tccttgtccc agtaccagtt gatgaaacat caatccatca 3060
- aggetttgt acagaaacag cagtatttga ggtggcctga ggatctccag gatgttggct 3120
- taacattcc gttgcaaact gtagcaacca tctcctaatc aaaggagcaa tttccaactt 3240
- tctcaagcc acaaataact cttcactttg tatttgcacc aagttatcat tttggggtcc 3300
- stotggagg tittittt cittitgcta ciatgaaaac aacataaatc totcaattit 3360

gtatcaaa 3369

- 210> 17
- 211> 2855
- 212> DNA
- 213> Homo sapiens
- 100> 17
- igtggcagt tatatagacc ggcggcggag cacgcgtgtg tgcggacgca gttgcgtgag
- ggtttgtac tatcctcggt gctgtggtgc agagctagtt cctctccagc tcagccgcgt
  120
- jgtttggac atatttgact cttttccccc caggttgaat tgaccaaagc aatggtgatg
  180
- 1gaagccta gtcccctgct ggtcgggcgg gaatttgtga gacagtatta cacactgctg 240

- laccaggccc cagacatgct gcatagattt tatggaaaga actcttctta tgtccatggg 300
- gattggatt caaatggaaa gccagcagat gcagtctacg gacagaaaga aatccacagg 360
- laagtgatgt cacaaaactt caccaactgc cacaccaaga ttcgccatgt tgatgctcat
  420
- (ccacgctaa atgatggtgt ggtagtccag gtgatggggc ttctctctaa caacaaccag 480
- sctttgagga gattcatgca aacgtttgtc cttgctcctg aggggtctgt tgcaaataaa 540
- tctatgttc acaatgatat cttcagatac caagatgagg tctttggtgg gtttgtcact 600
- agcctcagg aggagtctga agaagaagta gaggaacctg aagaaagaca gcaaacacct 660
- aggtggtac ctgatgattc tggaactttc tatgatcagg cagttgtcag taatgacatg 720
- aagaacatt tagaggagcc tgttgctgaa ccagagcctg atcctgaacc agaaccagaa 780
- aagaacctg tatctgaaat ccaagaggaa aagcctgagc cagtattaga agaaactgcc 840
- ctgaggatg ctcagaagag ttcttctcca gcacctgcag acatagctca gacagtacag 900
- aagacttga ggacattttc ttgggcatct gtgaccagta agaatcttcc acccagtgga
  960
- ctgttccag ttactgggat accacctcat gttgttaaag taccagcttc acagccccgt 1020
- cagagtcta agcctgaatc tcagattcca ccacaaagac ctcagcggga tcaaagagtg 1080
- gagaacaac gaataaatat tootooocaa aggggaccca gaccaatccg tgaggctggt 1140
- agcaaggtg acattgaacc ccgaagaatg gtgagacacc ctgacagtca ccaactcttc 1200
- ttggcaacc tgcctcatga agtggacaaa tcagagctta aagatttctt tcaaagttat 1260
- jaaacgtgg tggagttgcg cattaacagt ggtgggaaat tacccaattt tggttttgtt
  1320
- Egittgatg attctgagcc tgttcagaaa gtccttagca acaggcccat catgttcaga

#### eolf-seql-S000001.txt

1380

- gtgaggtcc gtctgaatgt cgaagagaag aagactcgag ctgccaggga aggcgaccga 1440
- gagataatc gccttcgggg acctggaggc cctcgaggtg ggctgggtgg tggaatgaga 1500
- gccctcccc gtggaggcat ggtgcagaaa ccaggatttg gagtgggaag ggggcttgcg 1560
- cacggcagt gaatcttcat ggatcttcat gcagccatac aaaccctggt tccaacagaa 1620
- ggtgaattt tcgacagcct ttggtatctt ggagtatgac cccagtctgt tataaactgc 1680
- taagtttgt ataattttac tttttttgtg tgttaatggt gtgtgctccc tctccctctc 1740
- tccctttcc tgacctttag tctttcactt ccaattttgt ggaatgatat tttaggaata 1800
- cggactttt aaagaagcaa aaaaaaagac tgaatttcct tgcttacttt gcatatacag 1860
- ctggatttt tttttttt ttacagccat ttccccaaag gaatgtcttg catattactg 1920
- cattiggta tgtttcattc attggaatat ttcttatttt ctacgtgttt gaaaagcctg 1980
- aagaaatac aggatttgat aatattttga aggcaggaaa aacccaaatt gtttcttctt 2040
- gagagtcat gactaccttc tggtgtggag aaattgccat tggaaaattt gacaattttg
  2100
- ttctcactg gtatgtttaa aaactgaata aaaggaatag aattttttt tgataaagga 2160
- cacaaaaca attctaaaac ctaactgttt ttaccattga aatttaaatt gtgataatag 2220
- Etttaaatg totagaatgo aactgatagg ottttottga actgttagtt tttttgaagt 2280
- jttttttca tgtttaattt gtatttgtaa aaaaacaaaa agcaaaaaaa ttcccaaaac . 2340
- lagataaca accagagcaa aactgttgtg ccttctattt atctttgatt tcagtcttgg 2400
- lattgttta aaaaaaaat ctagatttgt tttattaggt tcagagtatg tggggaatta  $2460\,$

### eolf-seql-S000001.txt

agaatccct ctttcatcac tttgtgtatg tcttttgtta acatatttgt tatgccttat 2520

ctaaaattg agtctcaaac tggaatgcct ttgaagacag atgcttctat agaggttctt 2580

gacctaaat agttcagcat ttgtatttt attctggtat ctaatcagat tcctaatcat 2640

gcccgtaag aaggaatgtt actttaatat tggactttgc tcatgtgctc gtgtccgcat 2700

tttttttt cttaaaatca tagccatatg gtaaattttc tattttgtta tggttctctt 2760

tattgatgg gcatgcagtg ggtgttactt ggaaatggcc aatttttatt aaaatatttc 2820

ggaagaaaa tttaaaaaaa aaaaaaaaaaa aaaaa 2855

210> 18

211> 2128

212> DNA

213> Homo sapiens

400> 18

tggaaacca ctgcaatgac attattccca gtgctgttgt tcctggttgc tgggctgctt 60

catcttttc cagcaaatga agataaggat cccgctttta ctgctttgtt aaccacccaa 120

cacaagtgc aaagggagat tgtgaataag cacaatgaac tgaggagagc agtatctccc 180

ctgccagaa acatgctgaa gatggaatgg aacaaagagg ctgcagcaaa tgcccaaaag 240

jggcaaacc agtgcaatta cagacacagt aacccaaagg atcgaatgac aagtctaaaa 300

Jtggtgaga atctctacat gtcaagtgcc tccagctcat ggtcacaagc aatccaaagc 360

jgtttgatg agtacaatga ttttgacttt ggtgtagggc caaagactcc caacgcagtg 420

:tggacatt atacacaggt tgtttggtac tcttcatacc tcgttggatg tggaaatgcc
480

ectgtccca atcaaaaagt tctaaaatac tactatgttt gccaatattg tcctgctggt 540

- attgggcta atagactata tgtcccttat gaacaaggag caccttgtgc cagttgccca 600
- ataactgtg acgatggact atgcaccaat ggttgcaagt acgaagatct ctatagtaac 660
- gtaaaagtt tgaagctcac attaacctgt aaacatcagt tggtcaggga cagttgcaag 720
- cctcctgca attgttcaaa cagcatttat taaatacgca ttacacaccg agtagggcta 780
- gtagagagg agtcagatta tctacttaga tttggcatct acttagattt aacatatact 840
- gctgagaaa ttgtaggcat gtttgataca catttgattt caaatgtttt tcttctggat 900
- tgcttttta ttttacaaaa atatttttca tacaaatggt taaaaagaaa caaaatctat 960
- acaacaact ttggattttt atatataaac tttgtgattt aaatttactg aatttaatta 1020
- ggtgaaaat tttgaaagtt gtattctcat atgactaagt tcactaaaac cctggattga 1080
- agtgaaaat tatgttccta gaacaaaatg tacaaaaaga acaatataat tttcacatga 1140
- ccttggct gtagttgcct ttcctagctc cactctaagg ctaagcatct tcaaagacgt 1200
- itcccatat gctgtcttaa ttcttttcac tcattcaccc ttcttcccaa tcatctggct 1260
- jcatcctca caattgagtt gaagctgttc ctcctaaaac aatcctgact tttattttgc 1320
- laaatcaat acaatccttt gaatttttta tctgcataaa ttttacagta gaatatgatc 1380
- laccttcat ttttaaacct ctcttctctt tgacaaaact tccttaaaaa agaatacaag
- :aatatagg taaataccct ccactcaagg aggtagaact cagtcctctc ccttgtgagt 1500
- tcactaaa atcagtgact cacttccaaa gagtggagta tggaaaggga aacatagtaa 1560
- ttacaggg gagaaaatg acaaatgacg tcttcaccaa gtgatcaaaa ttaacgtcac 1620

eolf-seql-S000001.txt

:agtgataag tcattcagat ttgttctaga taatctttct aaaaattcat aatcccaatc 1680

- aattatgag ctaaaacatc cagcaaactc aagttgaagg acattctaca aaatatccct
- gggtatttt agagtattcc tcaaaactgt aaaaatcatg gaaaataagg gaatcctgag 1800
- aacaatcac agaccacatg agactaagga gacatgtgag ccaaatgcaa tgtgcttctt 1860
- gatcagatc ctggaacaga aaaagatcag taatgaaaaa actgatgaag tctgaataga 1920
- tctggagta tttttaacag tagtgttgat ttcttaatct tgacaaatat agcagggtaa 1980
- gtaagatga taacgttaga gaaactgaaa ctgggtgagg gctatctagg aattctctgt 2040
- ctatcttac caaattttcg gtaagtctaa gaaagcaatg caaaataaaa agtgtcttga 2100
- aaaaaaaa aaaaaaaaa aaaaaaaa 2128
- 210> 19
- 211> 1428
- 212> DNA
- 213> Homo sapiens
- 400> 19
- ttcaggtca gggagaatgt ataaatgtcc attgccatcg aggttctgct atttttgaga 60
- gctgaagca actccaagga cacagttcac agaaatttgg ttctcagccc caaaatactg 120
- ttgaattgg agacaattac aaggactctc tggccaaaaa cccttgaaga ggccccgtga 180
- ggaggcagt gaggagettt tgattgetga eetgtgtegt accaeeceag aatgtgeaet 240
- ggggctgtg ccagatgcct gggggggacc ctcattcccc ttgcttttt tggcttcctg 300
- staacatcc tgttattttt teetggagga aaagtgatag atgacaacga ccaeetttee
- aagagatet ggtttttegg aggaatatta ggaageggtg tettgatgat etteeetgeg
  420

- tggtgttct tgggcctgaa gaacaatgac tgctgtgggt gctgcggcaa cgagggctgt 480
- ggaagcgat ttgcgatgtt cacctccacg atatttgctg tggttggatt cttgggagct 540
- gatactcgt ttatcatctc agccatttca atcaacaagg gtcctaaatg cctcatggcc 600
- atagtacat ggggctaccc cttccacgac ggggattatc tcaatgatga ggccttatgg 660
- acaagtgcc gagagcctct caatgtggtt ccctggaatc tgaccctctt ctccatcctg 720
- tggtcgtag gaggaatcca gatggttctc tgcgccatcc aggtggtcaa tggcctcctg 780
- ggaccctct gtggggactg ccagtgttgt ggctgctgtg ggggagatgg acccgtttaa 840
- cctccgaga tgagctgctc agactctaca gcatgacgac tacaatttct tttcataaaa
  900
- ttcttctct tcttggaatt attaattcct atctgcttcc tagctgataa agcttagaaa 960
- ggcagttat tccttctttc caaccagctt tgctcgagtt agaattttgt tattttcaaa 1020
- aaaaaatag tttggccact taacaaattt gatttataaa tctttcaaat tagttccttt 1080
- tagaattta ccaacaggtt caaagcatac ttttcatgat ttttttatta caaatgtaaa 1140
- tgtataaag tcacatgtac tgccatacta cttctttgta tataaagatg tttatatctt 1200
- ggaagtttt acataaatca aaggaagaaa gcacatttaa aatgagaaac taagaccaat 1260
- tctgttttt aagaggaaaa agaatgattg atgtatccta agtattgtta tttgttgtct 1320
- tttttgctg ccttgcttga gttgcttgtg actgatcttt tgaggctgtc atcatggcta 1380
- ggttctttt atgtatgtta aattaaaacc tgaattcaga ggtaacgt
  1428
- 210> 20
- 211> 2948
- 212> DNA

- 213> Homo sapiens
- :400> 20
- .ggtaatgat taatctgtca ggcacaaaag ggattgtttt ggggatttcg ggttctaagt 60
- gcagattca aacaaatagc agcgaacagg gaatgacagt tccaccagaa gacgattaag 120
- cacagcete taattggaac ggeatttgta cagteagaga etettaceag acateteeag 180
- aatctgtga gccattgtca aaacgtccat tttcatctgg ctgtgaaagt gaggaccaca 240
- caggtaggt attggtagaa acaggagtee teagagaage eccaagatge ageetgaggg 300
- gcagaaaag ggaaaaagct tcaagcagag actggtcttg aagagcagct tagcgaaaga 360
- accetetet gagttettgg geaegtteat ettgattgte ettggatgtg getgtgttge 420
- caagetatt eteagtegag gaegttttgg aggggteate actateaatg ttggatttte 480
- atggcagtt gcaatggcca tttatgtggc tggcggtgtc tctggtggtc acatcaaccc 540
- gctgtgtct ttagcaatgt gtctctttgg acggatgaaa tggttcaaat tgccatttta
  600
- gtgggagcc cagttettgg gagcetttgt gggggetgca accgtetttg gcatttacta 660
- gatggactt atgtcctttg ctggtggaaa actgctgatc gtgggagaaa atgcaacagc 720
- cacattttt gcaacatacc cagctccgta tctatctctg gcgaacgcat ttgcagatca 780
- Jgagccccc agaggcctag agcccattgc catcggcctc ctgattattg tcattgcttc 900
- ccctggga ctgaacagtg gctgtgccat gaacccagct cgagacctga gtcccagact 960
- tcactgcc ttggcaggct gggggtttga agtcttcaga gctggaaaca acttctggtg 1020
- ittcctgta gtgggccctt tggttggtgc tgtcattgga ggcctcatct atgttcttgt

eolf-seql-S000001.txt

1080

- attgaaatc caccatccag agcctgactc agtctttaag gcagaacaat ctgaggacaa 1140
- .ccagagaaa tatgaactca gtgtcatcat gtagtggcat gctcagctct ggatttgcag 1200
- cagtttggg attctcttca gaaagatggc atctaagtgt ctgtgttctt gtaagcctga 1260
- gtggaatcc acccagtttt gtctgctagc catatgggac atctaattgg aaaagcatct 1320
- cataaaagt ttggaaacaa tgaccacttc tctaccattg tcccccaccc cacccccag 1380
- ataacgctg actgtcccct gaaacagcct tctctcctgc cctgtttatt tcatcctcga 1440
- gggaattct tgctaggtaa gcactaataa ctcggcatct tgacgatagt cccatttggg 1500
- ggtttcagc tgcactatct gtatgaaatg gtgtcaccaa aacccttttc ttcagtatcg 1560
- caaagatta cattctgagt accaaccaaa ccctaaattg aaagacaaaa ctatggtttc 1620
- gtcaacata ttcatgaatt agggagctaa tgggttaagc ttccagttcc cgctatgcta 1680
- tggatttgt ataaatactg atattctcca aacctagtgg tgtagggagc aagagaatgc 1740
- gctggaagg cacaagggga ggacattgtg gcattcagaa actgcaggag acaagatgaa 1800
- ttgagaagc caaatggaat ttttaatgga aaccatttat cagattaatc tcttgctctc 1860
- tgcatttta gaggacacca attaatttcc tggtctttag tatataataa cctaaaatac 1920
- attgtaacc tcagtcatga aaaatacatc actctgtctt tttagctcaa atgtattttc 1980
- taattgccc acttgagaac agacatttga caagttatat caacgactgt gcttgtccat 2040
- attttacac atgccctaga agccaaaact gaaagccact ggatcctggt ctagctgaat 2100
- tcagagtg ggaggtctcc aaaaagatat taccttattg ggcttaacaa ttcacaaggc 2160

# eolf-segl-S000001.txt

ctttcacac ccattatcta atttaatcct cataatgact atgtgaggca aatgccacat 2220

gcccatttt tcagataaag aaacaaaatc ttagggaaga taagttgagt tgtccaagag 2280

acactgaaa gttgaatgtt atctaatgca ttcctctacc tttcagaaga tcagtagctg 2340

ctgagaatc tttgccaaat cttccttgct agccagaagt ggaattggca gcttctagaa 2400

atgtacacc tctggacaaa atgttcctca atcttaagat acaaagaccc tcattgtctg 2460

gtctattcc cacacttact gagtacagat gaaggaaagt ggtagcaatt taatcataac 2520

ttcatttgc tgaaaaacat tatgagaagg cctcccttcc taagccacct ctggtcttgc 2580

aagtettga tettgettee tgeeageace aaacattaca tteaggggat tteetetgge 2640

cagtetttt eccettgaag tietetaata gatgitaett tigacaaaag ategeetatg 2700

jttacaagc accaggggat gctctacatc aagggatgca ccttcagtca aactgtcaaa 2760

agcccagaa ttcccaaagg cattaggttt cccaactgct ttgtgctgat atcagaacag 2820

igaaattaa atgtgaaatg tttctgatga cttatgttct acaatctatg gacatacggg 2880

Ettttttt cttgctttga agctacctgg atatttccta tttgaaataa aattgttcgg 2940

attgtt 2948

?10> 21

?11> 2270

?12> DNA

?13> Homo sapiens

100> 21

:acggagac ctcgcaggct cccggaactg tcgcccttcc aggatgtggc tccctgctct
60

stoctggcc actotogctg cttccgcggc ttgggcagtg catccgtcct cgccacctgt 120

# eolf-seql-S000001.txt

igtggacacc gtgcatggca aagtgttggg gaagttcatc agcttagaag gatttgcaca 180 sectification galactic transfer of the section of t 240 .actccaccg cagectgcag ageogtggag ctttgtgaag aatgccacct tgtacctcc 300 atgttcacc caagatccaa ggcggggggg gcagttaatc tcagagctat ttacaaaccg 360 .aaagagaac attcctctca agctttctga agactgtctt tacctcaata tttacactcc 420 gctgacttg accaagaaaa acaggctgcc ggtgatggtg tggatccacg gaggggggt 480 atggtgggt gcggcatcaa cctatgatgg gctggccctt gctgcccatg aaaacgtggt gtggtgacc attcaatatc gcctgggcat ctggggattc ttcagcacag gggatgaaca 600 agcccgggg aactggggtc acctggacca gctggctgcc ctgcactggg tccaqqacaa 660 attgccagc tttggaggga acccaggctc tgtgaccatc tttggagggt cagcgggagg gaaagtgtc tctgttcttg ttttgtctcc attggccaag aacctcttcc accgggccat 780 tctgagagt ggcgtggccc tcacttctgt tctggtgaag aaaggtgatg tcaagccctt gctgaggta ggtctccggc tggtacgtct ctggctggac acccacacct ccttggctct 900 tgctcctga atcctcaggg atctctcttg tggttggttg tagctaatgt tctcctagaa 960 cactgaggc accaatggct gagcaggaag ggcgaggaga caccttgatc agcgtcccag 1020 ttcacagec aggcaaaccg acacaggget tggaagggat ttgccaaggg cagcaggtga 1080 ccgggcaga gctgggactc cagctcatgg ccctagcagc cagtacagtg ccctgtctgt 1140 accacacte cacctatgtg ccagggeetg gtgeeatgtt gggeagtgat ggtgtettgt

1200

- statctcagg gtctgagttc tgtggaccca cttgtgggct gtgggcctga agcagttcca 1260
- :actgagcgc ctgataacca gggttggttc ctggagaatt cactcattga ttcatttgtt 1320
- :acacaacaa aactaggtga ctaagtgaag gcaaaaacaa gaaatgggca gacgtcatcc 1380
- ttggctcaa agccagatgt ccgtgtggag gggacataga cactgcatgg gccctatgtg 1440
- ctctgcatt ctagtcagac atctaacacc tccccaagct tcttgctata atgtaggaat 1500
- gatgaatag ctacagaatc acacaactag aaagtgtcac ctatgacaag agcagtgaag 1560
- tgaggtact tgctgccaca gcagaatcta aagaaagcat tgagtcctgg ggctggacga 1620
- gttaccagg gaaggettge ttggaaaagt gactaatgag teaggageaa ggaaegteea 1680
- ggagtggga gcagcacatg cgcgtgctgt ggcaggagga cgcatcccaa tcgggaggga
- agacagaga cagagccgat ggggccagag caggcagaac aggcggagca cggcgagtac 1800
- gacagaggg gacgttggga ggggccaccc tgcacaggac cctggcaagg attttgtcat 1860
- atctggaga gtggttgaaa gccaaaggaa gaggtgatcg ataggaatcc agacctaggc 1920
- gaggatege ceaetggage cagtggeatg gaggattteg gtagatttga aagettgttt 1980
- gggaaagca tccaaattta aagggccggt acataggagg agagaaaatg gggatgccaa 2040
- aatttttag aatttttgag aattttttaa gaattcattg gttataagca acagttgccc 2100
- ttgaccaga cttaagtcaa gaaggagcat tagcctggtg tggtggctca tgcctgtaat 2160
- cctgcaatt tgggagacca aatgagaagg attgcttgag cccaggagtt tgagaccagc 2220

eolf-seql-S000001.txt

(210> 22

:211> 674

:212> DNA

:213> Homo sapiens

:400> 22

cccttggtt ccgcccgcgc gtcacgtgac cccagcgcct acttgggctg aggagccgcc 60

regtecete geogagtece etegecagat teceteegte geogecaaga tgatgtgegg

igegccctcc gccacgcagc cggccaccgc cgagacccag cacatcgccg accaggtgag
 180

rtcccagctt gaagagaaag aaaacaagaa gttccctgtg tttaaggccg tgtcattcaa 240

iagccaggtg gtcgcgggga caaactactt catcaaggtg cacgtcggcg acgaggactt
 300

gtacacctg cgagtgttcc aatctctccc tcatgaaaac aagcccttga ccttatctaa 360

taccagacc aacaaagcca agcatgatga gctgacctat ttctgatcct gactttggac 420

aggcccttc agccagaaga ctgacaaagt catcctccgt ctaccagagc gtgcacttgt 480

atcctaaaa taagcttcat ctccgggctg tgccccttgg ggtggaaggg gcaggattct 540

cagctgctt ttgcatttct cttcctaaat ttcattgtgt tgatttcttt ccttcccaat 600

ggtgatctt aattactttc agaatatttt caaaatagat atatttttaa aatccttaaa 660

aaaaaaaa aaaa 674

210> 23

211> 3189

212> DNA

213> Homo sapiens

400> 23

- gtogggtoc ogaggtoago ogagatttet caggtocoto oggococoto ootggagtoo 180
- cagcgcctc cggtgtccag aggatcggac acggcccggc ccggccatgg cctcgttgct
  240
- aaggtggat caggaagtga agctcaaggt tgattctttc agggagcgga tcacaagtga
  300
- gcagaagac ttggtggcaa atttttccc aaagaagtta ttagaacttg atagttttct 360
- aaggaacca atcttaaaca tccatgacct aactcagatc cactctgaca tgaatctccc 420
- gtccctgac cccattcttc tcaccaatag ccatgatgga ctggatggtc ccacttataa 480
- aagcgaagg ttggatgagt gtgaagaagc cttccaagga accaaggtgt ttgtgatgcc 540
- aatgggatg ctgaaaagca accagcagct ggtggacatt attgagaaag tgaaacctga 600
- atccggctg ttgattgaga aatgtaacac ggtcaaaatg tgggtacagc tcctgattcc 660
- aggatagaa gatggaaaca actttggggt gtccattcag gaggaaacag ttgcagagct 720
- agaactgtt gagagtgaag ctgcatctta tctggaccag atttctagat attatattac 780
- agagccaaa ttggtttcta aaatagctaa atatccccat gtggaggact atcgccgcac 840
- gtgacagag attgatgaga aagaatatat cagccttcgg ctcatcatat cagagctgag 900
- aatcaatat gtcactctac atgacatgat cctgaaaaat atcgagaaga tcaaacggcc 960
- oggagcage aatgeagaga etetgtaetg aggeeaggge eagggeeagg ggaetetgtg 1020
- jtctggctc aagaccgaca ttgccttggt ttgttacatg actatcgtga tggggaaact
  1080
- Jctggaaat agtaatcaca cctctctgtt tttagttaga gtctaatgaa actctcatct 1140
- jttctgtga tgtgtttacc tctttttca ggcctcagga actcttctat ttccttccct
  1200
- ataccccac acccaacctg tcgtaatttc tggagaactc caggtttgtg tgtgcaggat

## eolf-seql-S000001.txt

1260

ttggcacaa aaatacctgt gttttcattc tcccctctc tccctctgt gtcttgcgct 1320

tatgttttc ttccgtttga taattagttg gttaaaagct gagggaaccg gaaggaaagt 1380

ctaggtgtt ttttaggaac tagggtggcg gggggacgaa cttctcttcc tcacatgagg 1440

tactgtttc tttcctctgt ggggcattgg atcctcccac agttgccctg gtgatgactt 1500

gggcttccc atctgtgtac atcccacttt gaatcttgat cgtgacaaga aataccttag 1560

ccttcagtc aattccgaag ctccttcagt tgtttttata atgggcgttt tcacatgcac 1620

tatgtgtat gcatgtatac gcccatacag acatgcacac acagactcct actccattag 1680

taacatacc ctccctctcc acaacccctg tcacatacct ttcaggaggt gacagttgtc 1740

tagttgtca tctacccaga caaacgtcct gggcccgtcc tccctcctga tactgtagcc 1800

cttggtacc cagggtgagt tggtggagaa cagagagatg agaagcagag ggcttgggga 1860

agcctgttc ctctctgact cagccctttt tggcattatt gcaagagctt gactcctggt 1920

gccttttcc cagccagttt tcagttgggg tgaaggtttc tgcaagtgtg aggtccagat 1980

stgctgctc atgttgggct ttccttttgg gaactatttc tctttattta tagtgtcggg 2040

ttccgggga aagcaatcat tggtgtgtat gtgtatgtgc atgcacacac gtgcatatac 2100

catttgtgt atgtggaaat gtgctgggca agtcaaaact atagaagagt tgcctcctgt 2160

octogaato ttocagagat atcacttaat tgttaacago ttttgtgtta atccccttca 2220

ccctagct cttttattct accacggctg gagagttgat acctgcagtc agcctgccag 2280

jactcttag tgtctgtttc tgacttattt ttcctgtctc tgtcttccaa ccccaataa 2340

## eolf-seql-S000001.txt

atttccacc ggggatgcat catttttact cccaatattc tgtagagagg gagtcaggat 2400

ctgtcttcc cacgaatagt actcagtaac aaaccaattg cattttagtt gggcagtgct 2460

ccacccacc ctccagatcc cttccagcta aaacccttcc cccttccctc catgtgtttc 2520

cagtttccc gtttcgtttg ttggactgtt ccactgccc tcctcctcac cctatcaccc 2580

tggatcgta atgtaaaatt cttttaccat gtcaagaaat tattaaaaat acaggtactt 2640

gacctcttt ctaaagccgc agaccctggt gcaatgctct ggtggctagg gatgtactca 2700

gctcatatg tgtgcacgct tggacaccca cctccatgga cacctagcca ccctgttgtg 2760

gtccttatg ccagttgagc tgaatctttt ccccagtata gtggaaagac tgaggcttct 2820

cctactgag caaggttggg tgcttcattt gtgttcagtc tgaattatgg gaaagttagc 2880

cttcccaga cctaagctgc cttctcccc tactttcaga agatcctagt tccttccttc 2940

cgagtgata cccatgaact gccagtagag gctgctatcg ttccatgtgt aaggaatgaa 3000

tggttcaag gcgcgtccta cccagtcatt ttctttacct tatactaatt cttcctgaat 3060

atgtcttca gtttcttgag gagactccta gttttggttt tcaaattact tggagggctg 3120

staggaatc tatctcctc tgaaataaag tttcctcatc ttccaccttg caaaaaaaa 3180

3189

210> 24

211> 3338

212> DNA

213> Homo sapiens

100> 24

cagecegg eccegeegee eeggetgege aegegaegee eccteeagge eccegeteetg

# eolf-seql-S000001.txt

:gccctattt ggtcattcgg ggggcaagcg gcgggagggg aaacgtgcgc ggccgaaggg 120 laagcggagc cggcgccggc tgcgcagagg agccgctctc gccgccgcca cctcggctgg agcccacga ggctgccgca tcctgccctc ggaacaatgg gactcggcgc gcgaggtgct gggccgcgc tgctcctggg gacgctgcag gtgctagcgc tgctgggggc cgcccatgaa 300 gcgcagcca tggcggagac tctccaacat gtgccttctg accatacaaa tgaaacttcc 360 acagtactg tgaaaccacc aacttcagtt gcctcagact ccagtaatac aacggtcacc 420 ccatgaaac ctacagcggc atctaataca acaacaccag ggatggtctc aacaaatatg 480 cttctacca ccttaaagtc tacacccaaa acaacaagtg tttcacagaa cacatctcag 540 tatcaacat ccacaatgac cgtaacccac aatagttcag tgacatctgc tgcttcatca 600 taacaatca caacaactat gcattctgaa gcaaagaaag gatcaaaatt tgatactggg 660 gctttgttg gtggtattgt attaacgctg ggagttttat ctattcttta cattggatgc 720 aaatgtatt actcaagaag aggcattcgg tatcgaacca tagatgaaca tgatgccatc

tttaaggaa atccatggac caaggatgga atacagattg atgctgccct atcaattaat 840

ttggtttat taatagttta aaacaatatt ctctttttga aaatagtata aacaggccat 900

catataatg tacagtgtat tacgtaaata tgtaaagatt cttcaaggta acaagggttt 960

ggttttgaa ataaacatct ggatcttata gaccgttcat acaatggttt tagcaagttc 1020

tagtaagac aaacaagtcc tatcttttt tttttggctg gggtgggggc attggtcaca 1080

atgaccagt aattgaaaga cgtcatcact gaaagacaga atgccatctg ggcatacaaa 1140

- aagaagttt gtcacagcac tcaggattit gggtatcttt tgtagctcac ataaagaact 1200
- cagtgcttt tcagagctgg atatatctta attactaatg ccacacagaa attatacaat 1260
- aaactagat ctgaagcata atttaagaaa aacatcaaca ttttttgtgc tttaaactgt 1320
- gtagttggt ctagaaacaa aatactccaa gaaaaagaaa attttcaaat aaaacccaaa 1380
- taatagctt tgcttagccc tgttagggat ccattggagc attaaggagc acatattttt 1440
- ttaacttct tttgagcttt caatgttgat gtaatttttg ttctctgtgt aatttaggta 1500
- actgcagtg tttaacataa taatgtttta aagacttagt tgtcagtatt aaataatcct 1560
- gcattatag ggaaaaaacc tcctagaagt tagattattt gctactgtga gaatattgtc 1620
- ccactggaa gttactttag ttcatttaat tttaatttta tattttgtga atattttaag 1680
- actgtagag ctgctttcaa tatctagaaa tttttaattg agtgtaaaca cacctaactt 1740
- aagaaaaag aaccgcttgt atgattttca aaagaacatt tagaattcta tagagtcaaa 1800
- ctatagcgt aatgctgtgt ttattaagcc agggattgtg ggacttcccc caggcaacta 1860
- acctgcagg atgaaaatgc tatattttct ttcatgcact gtcgatatta ctcagatttg 1920
- ggaaatgac atttttatac taaaacaaac accaaaatat tttagaataa attcttagaa 1980
- yttttgaga ggaattttta gagaggacat ttcctccttc ctgatttgga tattccctca 2040
- atccctcct cttactccat gctgaaggag aagtactctc agatgcatta tgttaatgga 2100
- igaaaaagc acagtattgt agagacacca atattagcta atgtattttg gagtgttttc
  2160
- attttacag tttatattcc agcactcaaa actcagggtc aagttttaac aaaagaggta 2220
- jtagtcaca gtaaatacta agatggcatt tctatctcag agggccaaag tgaatcacac

eolf-seql-S000001.txt

2280

- agtttctga aggtcctaaa aatagctcag atgtcctaat gaacatgcac ctacatttaa 2340
- aggagtaca ataaaactgt tgtcagcttt tgttttacag agaacgctag atattaagaa 2400
- tttgaaatg gatcatttct acttgctgtg cattttaacc aataatctga tgaatataga 2460
- igaaattttc tgaaaaatac atttagatta gtttagtttg aaggagaggt gggctgatgg 2580
- tgagttgta tgttactaac ttggccctga ctggttgtgc aaccattgct tcatttcttt 2640
- caaaatgta gttaagatat actttattct aatgaaggcc ttttaaattt gtccactgca 2700
- tcttggtat ttcactactt caagtcagtc agaacttcgt agaccgacct gaagtttctt 2760
- ttgaatact tgtttcttta gcactttgaa gatagaaaaa ccacttttta agtactaagt 2820
- atcatttgc cttgaaagtt tcctctgcat tgggtttgaa gtagtttagt tatgtctttt 2880
- ctctgtatg taagtagtat aatttgttac tttcaaatac ccgtactttg aatgtaggtt 2940
- ttttgttgt tgttatctat aaaaattgag ggaaatggtt atgcaaaaaa atattttgct 3000
- tggaccata tttcttaagc ataaaaaaat gctcagtttt gcttgcattc cttgagaatg 3060
- atttatctg aagatcaaaa caaacaatcc agatgtataa gtactaggca gaagccaatt 3120
- taaaatttc cttgaataat ccatgaaagg aataattcaa atacagataa acagagttgg 3180
- agtatatta tagtgataat tttgtatttt caamaaaaaa aaagttaaac tcttctttc 3240
- ttttattat aatgaccagc ttttggtatt tcattgttac caagttctat ttttagataa 3300
- attgttctc cttctaaaaa aaaaaaaaa aaaaaaaa 3338

# eolf-seql-S000001.txt

210> 25 211> 7941

212> DNA

213> Homo sapiens

400> 25

acacatacg cacgcacgat ctcacttcga tctatacact ggaggattaa aacaaacaaa 60

aaaaaaaac attteetteg eteceette eteteeaete tgagaageag aggageegea 120

ggcgagggg ccgcagaccg tctggaaatg cgaatcctaa agcgtttcct cgcttgcatt 180 .

agctcctct gtgtttgccg cctggattgg gctaatggat actacagaca acagagaaaa 240

ttgttgaag agattggctg gtcctataca ggagcactga atcaaaaaaa ttggggaaag 300

aatatccaa catgtaatag cccaaaacaa tctcctatca atattgatga agatcttaca 360

aagtaaatg tgaatcttaa gaaacttaaa tttcagggtt gggataaaac atcattggaa 420

acacattca ttcataacac tgggaaaaca gtggaaatta atctcactaa tgactaccgt 480

tcagcggag gagtttcaga aatggtgttt aaagcaagca agataacttt tcactgggga 540

aatgcaata tgtcatctga tggatcagag catagtttag aaggacaaaa atttccactt
600

agatgcaaa tctactgctt tgatgcggac cgattttcaa gttttgagga agcagtcaaa 660

jaaaaggga agttaagagc tttatccatt ttgtttgagg ttgggacaga agaaaatttg
720

atttcaaag cgattattga tggagtcgaa agtgttagtc gttttgggaa gcaggctgct 780

lagatecat teatactgtt gaacettetg ceaaacteaa etgacaagta ttacatttae 840

atggctcat tgacatctcc tccctgcaca gacacagttg actggattgt ttttaaagat 900

agttagca tetetgaaag eeagttgget gttttttgtg aagttettae aatgeaacaa 960

# eolf-seql-S000001.txt

ctggttatg 1020	tcatgctgat	ggactactta	caaaacaatt	ttcgagagca	acagtacaag
tctctagac 1080	aggtgttttc	ctcatacact	ggaaaggaag	agattcatga	agcagtttgt
gttcagaac 1140	cagaaaatgt	tcaggctgac	ccagagaatt	ataccagcct	tcttgttaca
gggaaagac 1200	ctcgagtcgt	ttatgatacc	atgattgaga	agtttgcagt	tttgtaccag
agttggatg 1260	gagaggacca	aaccaagcat	gaatttttga	cagatggcta	tcaagacttg
gtgctattc 1320	tcaataattt	gctacccaat	atgagttatg	ttcttcagat	agtagccata
gcactaatg 1380	gcttatatgg	aaaatacagc	gaccaactga	ttgtcgacat	gcctactgat
atcctgaac 1440	ttgatctttt	ccctgaatta	attggaactg	aagaaataat	caaggaggag
aagagggaa 1500	aagacattga	agaaggcgct	attgtgaatc	ctggtagaga	cagtgctaca
accaaatca 1560	ggaaaaagga	accccagatt	tctaccacaa	cacactacaa	tcgcataggg
cgaaataca 1620	atgaagccaa	gactaaccga	tccccaacaa	gaggaagtga	attctctgga
agggtgatg 1680	ttcccaatac	atctttaaat	tccacttccc	aaccagtcac	taaattagcc
cagaaaaag 1740	atatttcctt	gacttctcag	actgtgactg	aactgccacc	tcacactgtg
aaggtactt 1800	cagcctcttt	aaatgatggc	tctaaaactg	ttcttagatc	tccacatatg
acttgtcgg 1860	ggactgcaga	atccttaaat	acagtttcta	taacagaata	tgaggaggag
gtttattga 1920	ccagtttcaa	gcttgatact	ggagctgaag	attcttcagg	ctccagtccc

caacttctg ctatcccatt catctctgag aacatatccc aagggtatat attttcctcc

maaacccag agacaataac atatgatgtc cttataccag aatctgctag aaatgcttcc 2040

- aagattcaa cttcatcagg ttcagaagaa tcactaaagg atccttctat ggagggaaat 2100
- tgtggtttc ctagctctac agacataaca gcacagcccg atgttggatc aggcagagag 2160
- gctttctcc agactaatta cactgagata cgtgttgatg aatctgagaa gacaaccaag 2220
- ccttttctg caggcccagt gatgtcacag ggtccctcag ttacagatct ggaaatgcca 2280
- attattcta cctttgccta cttcccaact gaggtaacac ctcatgcttt taccccatcc 2340
- ccagacaac aggatttggt ctccacggtc aacgtggtat actcgcagac aacccaaccg 2400
- tatacaatg gtgagacacc tcttcaacct tcctacagta gtgaagtctt tcctctagtc 2460
- cccctttgt tgcttgacaa tcagatcctc aacactaccc ctgctgcttc aagtagtgat 2520
- cggccttgc atgctacgcc tgtatttccc agtgtcgatg tgtcatttga atccatcctg 2580
- cttcctatg atggtgcacc tttgcttcca ttttcctctg cttccttcag tagtgaattg 2640
- ttcgccatc tgcatacagt ttctcaaatc cttccacaag ttacttcagc taccgagagt 2700
- ataaggtgc ccttgcatgc ttctctgcca gtggctgggg gtgatttgct attagagccc 2760
- gccttgctc agtattctga tgtgctgtcc actactcatg ctgcttcaga gacgctggaa 2820
- ttggtagtg aatctggtgt tctttataaa acgcttatgt tttctcaagt tgaaccaccc 2880
- Jeagtgatg ceatgatgea tgeaegttet teagggeetg aacettetta tgeettgtet 2940
- ataatgagg gctcccaaca catcttcact gtttcttaca gttctgcaat acctgtgcat 3000
- attotgtgg gtgtaactta toagggttoo ttatttagog goodtagooa tataccaata 3060
- catagtett egitaataac eecaactgea teattactge ageetaetea tgeeetetet 3120
- jtgatgggg aatggtctgg agcctcttct gatagtgaat ttcttttacc tgacacagat

eolf-seql-S000001.txt

3180

- Iggctgacag cccttaacat ttcttcacct gtttctgtag ctgaatttac atatacaaca 3240
- ctgtgtttg gtgatgataa taaggcgctt tctaaaagtg aaataatata tggaaatgag 3300
- ectgaactgc aaattccttc tttcaatgag atggtttacc cttctgaaag cacagtcatg 3360
- ccaacatgt atgataatgt aaataagttg aatgcgtctt tacaagaaac ctctgtttcc 3420
- tttctagca ccaagggcat gtttccaggg tcccttgctc ataccaccac taaggttttt 3480
- atcatgaga ttagtcaagt tccagaaaat aacttttcag ttcaacctac acatactgtc 3540
- ctcaagcat ctggtgacac ttcgcttaaa cctgtgctta gtgcaaactc agagccagca 3600
- cctctgacc ctgcttctag tgaaatgtta tctccttcaa ctcagctctt attttatgag 3660
- cctcagctt cttttagtac tgaagtattg ctacaacctt cctttcaggc ttctgatgtt 3720
- acaccttgc ttaaaactgt tcttccagct gtgcccagtg atccaatatt ggttgaaacc 3780
- ccaaagttg ataaaattag ttctacaatg ttgcatctca ttgtatcaaa ttctgcttca 3840
- gtgaaaaca tgctgcactc tacatctgta ccagtttttg atgtgtcgcc tacttctcat 3900
- tgcactctg cttcacttca aggtttgacc atttcctatg caagtgagaa atatgaacca 3960
- ttttgttaa aaagtgaaag ttcccaccaa gtggtacctt ctttgtacag taatgatgag 4020
- tgttccaaa cggccaattt ggagattaac caggcccatc ccccaaaagg aaggcatgta 4080
- ttgctacac ctgttttatc aattgatgaa ccattaaata cactaataaa taagcttata 4140
- attccgatg aaattttaac ctccaccaaa agttctgtta ctggtaaggt atttgctggt 4200
- ttccaacag ttgcttctga tacatttgta tctactgatc attctgttcc tataggaaat 4260

# eolf-seql-S000001.txt

iggcatgttg ccattacagc tgtttctccc cacagagatg gttctgtaac ctcaacaaag 4320 tgctgtttc cttctaaggc aacttctgag ctgagtcata gtgccaaatc tgatgccqgt 4380 tagtgggtg gtggtgaaga tggtgacact gatgatgatg gtgatgatga tgatgacaga 4440 atagtgatg gettatecat teataagtgt atgteatget cateetatag agaateacag 4500 aaaaggtaa tgaatgatto agacacccac gaaaacagto ttatggatca gaataatcca 4560 tctcatact cactatctga gaattctgaa gaagataata gagtcacaag tgtatcctca 4620 acagtcaaa ctggtatgga cagaagtcct ggtaaatcac catcagcaaa tgggctatcc 4680 aaaagcaca atgatggaaa agaggaaaat gacattcaga ctggtagtgc tctgcttcct 4740 tcagccctg aatctaaagc atgggcagtt ctgacaagtg atgaagaaag tggatcaggg 4800 aaggtacct cagatagcct taatgagaat gagacttcca cagatttcag ttttgcagac 4860 ctaatgaaa aagatgctga tgggatcctg gcagcaggtg actcagaaat aactcctgga 4920 teceacagt ecceaacate atetyttaet agegagaact cagaagtytt ecaegtttea 4980 aggcagagg ccagtaatag tagccatgag tctcgtattg gtctagctga ggggttggaa ccgagaaga aggcagttat accccttgtg atcgtgtcag ccctgacttt tatctgtcta 5100 tggttcttg tgggtattct catctactgg aggaaatgct tccagactgc acacttttac tagaggaca gtacatcccc tagagttata tccacacctc caacacctat ctttccaatt 5220 cagatgatg teggageaat tecaataaag caettteeaa ageatgttge agatttaeat

5280

caagtagtg ggtttactga agaatttgag acactgaaag agttttacca ggaagtgcag 5340

- gctgtactg ttgacttagg tattacagca gacagctcca accacccaga caacaagcac 5400
- agaatcgat acataaatat cgttgcctat gatcatagca gggttaagct agcacagctt 5460
- octgaaaagg atggcaaact gactgattat atcaatgcca attatgttga tggctacaac 5520
- .gaatgatat gggaacataa tgtggaagtt attgtcatga taacaaacct cgtggagaaa 5640
- gaaggagaa aatgtgatca gtactggcct gccgatggga gtgaggagta cgggaacttt 5700
- tggtcactc agaagagtgt gcaagtgctt gcctattata ctgtgaggaa ttttactcta 5760
- gaaacacaa aaataaaaaa gggctcccag aaaggaagac ccagtggacg tgtggtcaca 5820
- agtateact acacgeagtg geetgacatg ggagtaceag agtaeteect geeagtgetg 5880
- cctttgtga gaaaggcagc ctatgccaag cgccatgcag tggggcctgt tgtcgtccac 5940
- gcagtgctg gagttggaag aacaggcaca tatattgtgc tagacagtat gttgcagcag 6000
- ttcaacacg aaggaactgt caacatattt ggcttcttaa aacacatccg ttcacaaaga 6060
- attatttgg tacaaactga ggagcaatat gtcttcattc atgatacact ggttgaggcc 6120
- tacttagta aagaaactga ggtgctggac agtcatattc atgcctatgt taatgcactc 6180
- tcattcctg gaccagcagg caaaacaaag ctagagaaac aattccagct cctgagccag 6240
- caaatatac agcagagtga ctattctgca gccctaaagc aatgcaacag ggaaaagaat 6300
- gaacttett etateateee tgtggaaaga teaagggttg geattteate eetgagtgga 6360
- aaggcacag actacatcaa tgcctcctat atcatgggct attaccagag caatgaattc 6420
- tcattaccc agcaccctct ccttcatacc atcaaggatt tctggaggat gatatgggac

eolf-seql-S000001.txt

6480

- lataatgccc aactggtggt tatgattcct gatggccaaa acatggcaga agatgaattt 6540 jtttactggc caaataaaga tgagcctata aattgtgaga gctttaaggt cactcttatg 6600
- jctgaagaac acaaatgtct atctaatgag gaaaaactta taattcagga ctttatctta 6660
- şaagctacac aggatgatta tgtacttgaa gtgaggcact ttcagtgtcc taaatggcca 6720
- iatccagata gccccattag taaaactttt gaacttataa gtgttataaa agaagaagct
  6780
- |ccaataggg atgggcctat gattgttcat gatgagcatg gaggagtgac ggcaggaact 6840
- tctgtgctc tgacaaccct tatgcaccaa ctagaaaaag aaaattccgt ggatgtttac 6900
- :aggtagcca agatgatcaa tctgatgagg ccaggagtct ttgctgacat tgagcagtat
  6960
- agtttetet acaaagtgat eeteageett gtgageacaa ggeaggaaga gaateeatee 7020
- cctctctgg acagtaatgg tgcagcattg cctgatggaa atatagctga gagcttagag 7080
- ctttagttt aacacagaaa ggggtggggg gactcacatc tgagcattgt tttcctcttc 7140
- taaaattag gcaggaaaat cagtctagtt ctgttatctg ttgatttccc atcacctgac 7200
- gtaactttc atgacatagg attctgccgc caaatttata tcattaacaa tgtgtgcctt 7260
- ttgcaagac ttgtaattta cttattatgt ttgaactaaa atgattgaat tttacagtat 7320
- tctaagaat ggaattgtgg tatttttttc tgtattgatt ttaacagaaa atttcaattt 7380
- tagaggtta ggaattccaa actacagaaa atgtttgttt ttagtgtcaa atttttagct 7440
- tatttgtag caattatcag gtttgctaga aatataactt ttaatacagt agcctgtaaa 7500
- aaaacactc ttccatatga tattcaacat tttacaactg cagtattcac ctaaagtaga 7560

## eolf-seql-S000001.txt

ataatctgt tacttattgt aaatactgcc ctagtgtctc catggaccaa atttatattt 7620

taattgtag attittatat titactactg agtcaagtit tctagtictg tgtaattgtt 7680

agtttaatg acgtagttca ttagctggtc ttactctacc agttttctga cattgtattg 7740

gttacctaa gtcattaact ttgtttcagc atgtaatttt aacttttgtg gaaaatagaa 7800

taccttcat tttgaaagaa gtttttatga gaataacacc ttaccaaaca ttgttcaaat 7860

gtttttatc caaggaattg caaaaataaa tataaatatt gccattaaaa aaaaaaaaa 7920

aaaaaaaaa a 7941

210> 26

211> 1530

212> DNA

213> Homo sapiens

400> 26

gtcccgccc acgtgaagcc agcctaactg agctctggac tttggggaca gctgtcagtg 120

cctaggccg caggacacca tgaagcaact gccagtcttg gaacctggag acaagcccag 180

aaagcaaca tggtacacct tgactgtccc tggagacagc ccctgtgctc gagttggcca 240

agctgttca tatttacccc cagttggtaa tgccaagaga gggaaggtct tcattgttgg 300

ggagcaaat ccaaacagaa gcttctcaga cgtgcacacc atggatctgg gaaaacacca 360

tgggactta gatacctgca agggcctctt gccccggtat gaacatgcta gcttcattcc 420

tcctgcaca cctgaccgta tctgggtatt tggaggtgcc aaccaatcag gaaatcgaaa 480

gtctacaa gtcctgaatc ctgaaaccag gacgtggacc acgccagaag tgaccagccc 540

### eolf-seql-S000001.txt

- ccaccatcc ccaagaacat tccacacatc atcggcagcc attggaaacc agctatatgt 600
- :tttgggggc ggagagagag gtgcccagcc cgtgcaggac acgaagctgc atgtgtttga 660
- :gcaaacact ctgacctggt cacagccaga gacacttgga aatcctccat ctccccggca 720
- ggtcatgtg atggtggcag cagggacaaa gctcttcatc cacggaggct tggcggggga 780
- agattctat gatgacctcc actgcattga tataagtgac atgaaatggc agaagctaaa 840
- .cccactggg gctgctccag caggctgtgc tgcccactca gctgtggcca tgggaaaaca 900
- gtgtacatc tttggtggaa tgactcctgc aggagcactg gacacaatgt accagtatca 960
- acagaagag cagcattgga ccttgcttaa atttgatact cttctacccc ctggacgatt 1020
- gaccattcc atgtgtatca ttccatggcc agtgacgtgt gcttctgaga aagaagattc 1080
- aactctctc actctgaacc atgaagctga gaaagaggat tcagctgaca aagtaatgag 1140
- cacagtggt gactcacatg aggaaagcca gactgctaca ctgctctgtt tggtgtttgg 1200
- gggatgaat acagaagggg aaatctatga cgattgtatt gtgactgtag tggactaata 1260
- aacccacat ttttattacc tgtcagttac tttcagaata gttaagtaaa acattagctg 1320
- tttatacct ccaaaatatc ttctgcatta tatatctgtt tttctcctac tttggtaggt 1380
- aagaaacta atgcaaataa ttcttatgtg cactaaacct tgctatattg cctctcaaaa 1440

210> 27 211> 2314

## eolf-seql-S000001.txt

:212> DNA

:213> Homo sapiens

:400> 27

gegegeaca gagegagete ttgcageete eeegeeeete eegeaacget egaeeeeagg 60

ttcccccgg ctcgcctgcc cgccatggcc gacaaggaag cagccttcga cgacgcagtg

aagaacgag tgatcaacga ggaatacaaa atatggaaaa agaacacccc ttttctttat 180

atttggtga tgacccatgc tctggagtgg cccagcctaa ctgcccagtg gcttccagat 240

taaccagac cagaagggaa agatttcagc attcatcgac ttgtcctggg gacacacaca 300

cggatgaac aaaaccatct tgttatagcc agtgtgcagc tccctaatga tgatgctcag 360

ttgatgcgt cacactacga cagtgagaaa ggagaatttg gaggttttgg ttcagttagt 420

gaaaaattg aaatagaaat caagatcaac catgaaggag aagtaaacag ggcccgttat 480

tgccccaga accettgtat catcgcaaca aagacteett ccagtgatgt tettgtettt 540

actatacaa aacatccttc taaaccagat ccttctggag agtgcaaccc agacttgcgt 600

tccgtggac atcagaagga aggctatggg ctttcttgga acccaaatct cagtgggcac 660

tacttagtg cttcagatga ccataccatc tgcctgtggg acatcagtgc cgttccaaag 720

agggaaaag tggtagatgc gaagaccatc tttacagggc atacggcagt agtagaagat 780

tttcctggc atctactcca tgagtctctg tttgggtcag ttgctgatga tcagaaactt 840

tgatttggg atactcgttc aaacaatact tccaaaccaa gccactcagt tgatgctcac 900

stgctgaag tgaactgcct ttctttcaat ccttatagtg agttcattct tgccacagga 960

cagetgaca agactgttge ettgtgggat etgagaaate tgaaaettaa gttgeattee 1020

eolf-seql-S000001.txt

ltgagtcac ataaggatga aatattccag gttcagtggt cacctcacaa tgagactatt 1080

lagottoca gtggtactga togcagactg aatgtotggg atttaagtaa aattggagag 1140

lacaatccc cagaagatgc agaagacggg ccaccagagt tgttgtttat tcatggtggt 1200

ltactgcca agatatctga tttctcctgg aatcccaatg aaccttgggt gatttgttct 1260

latcagaag acaatatcat gcaagtgtgg caaatggcag agaacattta taatgatgaa 1320

iccctgaag gaagcgtgga tccagaagga caagggtcct agatatgtct ttacttgttg 1380

jattttaga ctcccctttt ttcttctcaa ccctgagagt gatttaacac tggttttgag 1440

agacttta ttcagctatc cctctatata ataggtacca ccgataatgc tattagccca 1500

iccgtgggt ttttctaaat attaataggg gggcttgatt caacaaagcc acagacttaa 1560

sttgaaatt ttcttcagga attttctagt aacccaggtc taaagtagct acagaaaggg 1620

latattatg tgtgattatt tttcttctta tgctatatcc ccaagttttt cagactcatt
1680

lagtaaagg ctagagtgag taaggaatag agccaaatga ggtaggtgtc tgagccatga 1740

rtataaata ctgaaagatg tcacttttat tcaggaaata gggggagttc aagtcgtata 1800

ttcctact cgaaaatctt gacacctgac tttccaggat gcacattttc atacgtagac 1860

gtttcctc ttggtttctt cagttaagtc aaaacaacac gttcctcttt ccccatatat 1920

atatattt ttgctcgtta gtgtatttct tgagctgttt tcatgttgtt tatttcctgt 1980

ccaagttg taaagatgta tgtttttacc tgacagttat accacaggta gactgtcaag 2100

gagaagag tgaatcaata acttgtattt gttttaaaaa ttaaattaat ccttgataag

eolf-seql-S000001.txt

2160

gttgctttt tttttttagg agttagtcct tgaccactag tttgatgcca tctccatttt 2220

ggtgacctg tttcaccagc aggcctgtta ctctccatga ctaactgtgt aagtgcttaa 2280

atggaataa attgcttttc tacataaaaa aaaa 2314

210> 28

211> 2848

212> DNA

213> Homo sapiens

400> 28

cttctccc ggcggttagt gctgagagtg cggagtgtgt gctccgggct cggaacacac 60

tttattatt aaaaaatcca aaaaaaatct aaaaaaatct tttaaaaaac cccaaaaaaa 120

ttacaaaaa atccgcgtct cccccgccgg agacttttat tttttttctt cctcttttat 180

aaataaccc ggtgaagcag ccgagaccga cccgcccgcc cgcggccccg cagcagctcc 240

agaaggaac caagagaccg aggccttccc gctgcccgga cccgacaccg ccaccctcgc 300

ccccgccgg cagccggcag ccagcggcag tggatcgacc ccgttctgcg gccgttgagt
360

gttttcaat teeggttgat ttttgteect etgegettge teecegetee ecteeceeg 420

ctccggccc ccagccccgg cactcgctct cctcctcta cggaaaggtc gcggcctgtg 480

cctgcgggc agccgtgccg agatgaaccc cagtgccccc agctacccca tggcctcgct
540

tacgtgggg gacctccacc ccgacgtgac cgaggcgatg ctctacgaga agttcagccc 600

jccgggccc atcctcca tccgggtctg cagggacatg atcacccgcc gctccttggg 660

cacgegtat gtgaacttee ageageegge ggaegeggag egtgetttgg acaceatgaa 720

ittgatgtt ataaagggca agccagtacg catcatgtgg tctcagcgtg atccatcact

eolf-seql-S000001.txt

780

1860

logcaaaagt ggagtaggca acatattcat taaaaatctg gacaaatcca ttgataataa 1gcactgtat gatacatttt ctgcttttgg taacatcctt tcatgtaagg tggtttgtga gaaaatggt tccaagggct acggatttgt acactttgag acgcaggaag cagctgaaag 960 igctattgaa aaaatgaatg gaatgctcct aaatgatcgc aaagtatttg ttggacqatt 1020 laagtotogt aaagaacgag aagotgaact tggagotagg gcaaaagaat tcaccaatgt 1080 :tacatcaag aattttggag aagacatgga tgatgagcgc cttaaggatc tctttgggcc :gccttaagt gtgaaagtaa tgactgatga aagtggaaaa tccaaaggat ttggatttgt 1200 lagctttgaa aggcatgaag atgcacagaa agctgtggat gagatgaacg gaaaggagct 1260 aatggaaaa caaatttatg ttggtcgagc tcagaaaaag gtggaacggc agacggaact 1320 .aagcgcaaa tttgaacaga tgaaacaaga taggatcacc agataccagg gtgttaatct 1380 tatgtgaaa aatcttgatg atggtattga tgatgaacgt ctccqqaaaq agttttctcc. 1440 .tttggtaca atcactagtg caaaggttat gatggagggt ggtcgcagca aagggtttgg 1500 tttgtatgt ttctcctccc cagaagaagc cactaaagca gttacagaaa tgaacggtag attgtggcc acaaagccat tgtatgtagc tttagctcag cgcaaagaag agcgccaggc 1620 cacctcact aaccagtata tgcagagaat ggcaagtgta cgagctgttc ccaaccctgt 1680 atcaacccc taccagccag cacctccttc aggttacttc atggcagcta tcccacagac cagaaccgt gctgcatact atcctcctag ccaagttgct caactaagac caagtcctcg 1800

tggactgct cagggtgcca gacctcatcc attccaaaat atgcccggtg ctatccqccc

- igctgctcct agaccaccat ttagtactat gagaccagct tcttcacagg ttccacgagt 1920
- atgtcaaca cagcgtgttg ctaacacatc aacacagaca atgggtccac gtcctgcagc 1980
- gcagccgct gcagctactc ctgctgtccg caccgttcca cagtataaat atgctgcagg 2040
- $_{\rm igttcgcaat}$  cctcagcaac atcttaatgc acagccacaa gttacaatgc aacagcctgc  $_{\rm 2100}$
- gttcatgta caaggtcagg aacctttgac tgcttccatg ttggcatctg ccctcctca 2160
- gagcaaaag caaatgttgg gtgaacggct gtttcctctt attcaagcca tgcaccctac 2220
- cttgctggt aaaatcactg gcatgttgtt ggagattgat aattcagaac ttcttcatat 2280
- ctcgagtct ccagagtcac tccgttctaa ggttgatgaa gctgtagctg tactacaagc 2340
- caccaaget aaagaggetg cecagaaage agttaacagt gecaceggtg ttecaactgt 2400
- taaaattga tcagggacca tgaaaagaaa cttgtgcttc accgaagaaa aatatctaaa 2460
- atcgaaaaa cttaaatatt atggaaaaaa aacattgcaa aatataaaat aaataaaaaa 2520
- ggaaaggaa actttgaacc ttatgtaccg agcaaatgcc aggtctagca aacataatgc 2580
- agtcctaga ttacttattg atttaaaaac aaaaaaacac aaaaaatagt aaaatataaa 2640
- acaaattaa tgttttatag accctgggaa aaagaatttt cagcaaagta caaaaattta 2700
- agcattcct ttctttaatt ttgtaattct ttactgtgga atagctcaga atgtcagttc 2760
- gttttaagt aacagaattg ataactgagc aaggaaacgt aatttggatt ataaaattct 2820
- gctttaata aaaattcctt aaacagtg 2848
- 210> 29 211> 2424

## eolf-seql-S000001.txt

:212> DNA

:213> Homo sapiens

:400> 29

ctggaactc tagcacgccg agtgaacttg aatctttggc tatttaagga ggactgggtt 60

gttgtgaag ttgcggtgat ccagcgcaga gccccgtcct gattgatcgc atcgcggggc 120

cagatgact gtaaaatgaa tagatgaaat tettgettet egaagatttt ettgggeate 180

.cccggaaag tgcgttttaa ggcgaagtca tgatgtattc tcccatctgt ctcactcagg 240

tgaatttca cccattcatg gaagcacttc ttccacatgt ccgtgcaatt gcctatactt 300

gttcaacct gcaggctcga aaacgcaagt actttaaaaa gcatgagaag cgaatgtcaa 360

ggatgaaga aagagcagtc aaagatgagc ttctcagtga aaagcctgaa atcaaacaga 420

gtgggcatc caggctcctt gccaaactgc gcaaagatat tcgccaggag tatcgagagg 480

ctttgtgct caccgtgact ggcaagaagc acccgtgctg tgtcttatcc aatcccgacc 540

gaagggtaa gattaggaga atcgactgcc tgcgacaggc agacaaagtc tggcgtctgg
600

tctagtcat ggtgatcctg ttcaaaggca tccccttgga aagtaccgat ggagagcggc 660

catgaaatc cccacattgc acaaacccag cactttgtgt ccagccacat catatcacag 720

atcagttaa ggagcttgat ttgtttttgg catactacgt gcaggagcaa gattctggac 780

atcaggaag tccaagccac aatgatcctg ccaagaatcc tccaggttac cttgaggata 840

ttttgtaaa atctggagtc ttcaatgtat cagaacttgt aagagtatcc agaacgccca 900

aacccaggg aactggagtc aacttcccaa ttggagaaat cccaagccaa ccatactatc 960

tgacatgaa ctcgggggtc aatcttcaga ggtctctgtc ttctccacca agcagcaaaa 1020

Page 76

- acccaaaac tatatccata gaygaaaata tggaaccaag tcctacagga gacttttacc 1080
- ctctccaag ttcaccagct gctggaagtc gaacatggca cgaaagagat caagatatgt 1140
- ttctccgac tactatgaag aagcctgaaa agccattgtt cagctctgca tctccacagg 1200
- ttcttcccc aagactgagc actttccccc agcaccacca tcccggaata cctggagttg 1260
- acacagtgt catctcaact cgaactccac ctccaccttc accgttgcca tttccaacac 1320
- agctateet tecteeagee ceategaget acttttetea tecaacaate agatateete 1380
- ccacctgaa tcctcaggat actctgaaga actatgtacc ttcttatgac ccatccagtc 1440
- acaaaccag.ccagtcctgg tacctgggct agcttggttc ctttccaagt gtcaaatagg 1500
- cacccatct taccggccaa tgtccaaaat tacggtttga acataattgg agaacctttc 1560
- ttcaagcag aaacaagcaa ctgagggaaa aagaaacaca acaatagttt aagaaatttt 1620
- tttttaaat aaaaaaagg aaaagaggaa gactggacaa aacaacacaa aggcagaaag 1680
- aaagaaact gaagaaagaa gataatagac cagcaattgc agcacttaca atcactaatt 1740
- ccttaaggt taaactgtaa tgacataaaa agggtcgatg atatttcact gatggtagat 1800
- jcagcccct gcaacgtagc ctttgttaca tgaagtccgc tgggaaatag atgttctgtc
  1860
- statgacaa tatattttaa ctgactttct agatgcctta atatttgcat gataagctag 1920
- ttattggt ttagtattct tgttgtttac gcatggaatc actattcctg gttatctcac 1980
- lacgaaggc taggaggcgg cgtcagagat gctgggtgac agagccatga gccagccatt 2040
- :ataagcac tctgatttct aaaagttaaa aaaaatatat gaaatctctg tagcctttag
  2100
- :atcagtac agatttatta aatttcggcc cttaacccag ccttttccag tgtgtaaccc

eolf-segl-S000001.txt

2160

jtttgaaat cttaaaaaaa gaaaaaatga aaaaaaaagg aaaaaaagaa aaaaggaaaa 2220

lacagtttg aacacaaagg ctctatggaa gaaatgcctc tatgtaggtg aagtgttctc 2280

tgcatgca acagtaaaaa ttaatataat attttcccca caaaagaaac acttaacaga 2340

ggcaagtgc aatttattaa atttatattc ttaaaggggg aattcatgga ttattaaggt 2400

:ttcaggcc cttggggact ctta
2424

10> 30

!11> 838

!12> DNA

13> Homo sapiens

100> 30

:tctttttc cggctggaac catggagggt gtagaagaga agaagaagga ggttcctgct 60

gccagaaa cccttaagaa aaagcgaagg aatttcgcag agctgaagat caagcgcctg 120

(aaagaagt ttgcccaaaa gatgcttcga aaggcaagga ggaagcttat ctatgaaaaa 180

:aaagcact atcacaagga atataggcag atgtacagaa ctgaaattcg aatggcgagg 240

ggcaagaa aagctggcaa cttctatgta cctgcagaac ccaaattggc gtttgtcatc 300

aatcagag gtatcaatgg agtgagccca aaggttcgaa aggtgttgca gcttcttcgc 360

tcgtcaaa tcttcaatgg aacctttgtg aagctcaaca aggcttcgat taacatgctg 420

gattgtag agccatatat tgcatggggg taccccaatc tgaagtcagt aaatgaacta 480

ctacaagc gtggttatgg caaaatcaat aagaagcgaa ttgctttgac agataacgct 540

gattgctc gatctcttgg taaatacggc atcatctgca tggaggattt gattcatgag 600

ctatactg ttggaaaacg cttcaaagag gcaaataact tcctgtggcc cttcaaattg

eolf-segl-S000001.txt

660

>ttctccac gaggtggaat gaagaaaaag accacccatt ttgtagaagg tggagatgct
720

Jcaacaggg aggaccagat caacaggctt attagaagaa tgaactaagg tgtctaccat 780

ittatttt ctaagctggt tggttaataa acagtacctg ctctcaaatt gaaaaaaa 838

?10> 31

211> 3514

?12> DNA

?13> Homo sapiens

100> 31

:catctggc cagccccgc ccctcctccc ggcgtcagcc cgccagaggc cgcgcggggc
60

:gggcttcg gccgatcagc ccgggaggcc ccgccgcgcc cccttggccc gcgcgccgt 120

stcacagtg gaagaggcgc ccgcgctgcg ctgcccggag gagccgtcgc gcgcccgctt 180

:tgttcggc tggttcctgc cagctcgagg acaaaacacg cgtgcgcgcg gcgggcgagc 240

:gctcgccg cctcagtcgc cagcgccggg cgcagtccgc ctttttccgg agcagactgg
300

geggtget agteggtage ageggeegee geageggete egeaetggeg aacegaggge 360

¡aaaaaggc ggggttgacg gctttttggt aggagtgggc tggaccggac gccagagaca
420

.ggctccca aggcaagagg gactgtggcc ctgcgtcggc tctgctcgga actgctgacc 480

aggaattt acgccccttc gtttttctct tctgattctt ctcttctccc aagcccgcgt 540

cctcacgc gtggcctctc tccttgccgg gagggccgcg atggaggtcc cgcccaggct 600

cccatgtg ccgccgccat tgttcccctc cgctcccgct actttagcct cccgcagcct 660

cccattgg cggccgcggc cgccgcggca gctagccccg ctcctccctt cgctcgctcc 720

gctccgcc cggcaggggg cgcgccgggc ccagcgccac gtcaccgccc agcagccctc

eolf-seql-S000001.txt

780

gattggcg ggcggggcgg ctataaaggg agggcgcagg cggcgcccgg atctcttccg 840

gccatttt aaatccagct ccatacaacg ctccgccgcc gctgctgccg cgacccggac 900

regegeeag cacecectg eegacagete egteactatg gaggatatga acgagtacag 960

latatagag gaattcgcag agggatccaa gatcaacgcg agcaagaatc agcaggatga 1020

gtaaaatg tttattggag gcttgagctg ggatacaagc aaaaaagatc tgacagagta 1080

tgtctcga tttggggaag ttgtagactg cacaattaaa acagatccag tcactgggag 1140

.caagagga tttggatttg tgcttttcaa agatgctgct agtgttgata aggttttgga 1200

tgaaagaa cacaaactgg atggcaaatt gatagatccc aaaagggcca aagctttaaa 1260

Iggaaagaa cctcccaaaa aggtttttgt gggtggattg agcccggata cttctgaaga 1320

aaattaaa gaatattttg gagcctttgg agagattgaa aatattgaac ttcccatgga 1380

.caaaaaca aatgaaagaa gaggattttg ttttatcaca tatactgatg aagagccagt 1440

aaaaattg ttagaaagca gataccatca aattggttct gggaagtgtg aaatcaaagt 1500

cacaaccc aaagaggtat ataggcagca acagcaacaa caaaaaggtg gaagaggtgc 1560

cagctggt ggacgaggtg gtacgagggg tcgtggccga ggtcagggcc aaaactggaa 1620

aaggattt aataactatt atgatcaagg atatggaaat tacaatagtg cctatggtgg 1680

atcaaaac tatagtggct atggcggata tgattatact gggtataact atgggaacta 1740

gatatgga cagggatatg cagactacag tggccaacag agcacttatg gcaaggcatc 1800

gagggggt ggcaatcacc aaaacaatta ccagccatac taaaggagaa cattggagaa 1860

### eolf-seql-S000001.txt

lcagcggga acttcattgc aggccgtgtg tcaccctgac cacgtctatc tctgggggtc 1920

acgttgcg ggcagagcgc aaggcataca ccagaaaacg ctgtcctgtg gaggagatgt 1980

laagtaacc catcttgcag gacgacattg aagattggtc ttctgttgat ctaagatgat 2040

ttttgtaa aagactttct agtgtacaag acaccattgt gtccaactgt atatagctgc 2100

lattagttt tctttgtttt tactttgtcc tttgctatct gtgttatgac tcaatgtgga 2160

tgtttata cacattttat ttgtatcatt tcatgttaaa cctcaaataa atgcttcctt 2220

gtgattgc ttttctgcgt caggtactac atagctctgt aaaaaatgta atttaaaata 2280

caataatt aaggcacagt tgattttgta gagtattggt ccatacagag aaactgtggt 2340

tttataaa tagccagcca gcgtcaccct cttctccaat ttgtaggtgt attttatgct 2400

taaggett catetteec etgtaactga gatttetace acacetttga acaatgttet 2460

cccttctg gttatctgaa gactgtcctg aaaggaagac ataagtgttg tgattagtag 2520

gctttgta atcataacac aatgagtaat tcttgtataa aagttcagat acaaaaggag 2580

ctgtaaaa ctggtaggag ctatggttta agagcattgg aagtagttac aactcaagga 2640 .

ttggtaga aaggtatgag tttggtcgaa aaattaaaat agtggcaaaa taagatttag 2700

gtgttttc tcagagccgc cacaagattg aacaaaatgt tttctgtttg ggcatcctga 2760

aagttgta ttagctgtta atgctctgtg agtttagaga aaagtcttga tagtaaatct 2820

tttttgac acagtgcatg aactaagtag ttaaatattt acatattcag aaaggaatag 2880

gaaaaggt atcttggtta tgacaaagtc attacaaatg tgactaagtc attacaaatg 2940

eolf-seql-S000001.txt

gactgagtc attacagtgg accetetggg tgeattgaaa agaateegtt ttatateeag 3000

- tttcagagg acctggaata ataataagct ttggattttg cattcagtgt agttggattt 3060
- jggaccttg gcctcagtgt tatttactgg gattggcata cgtgttcaca ggcagagtag 3120
- tgatctcac acaacgggtg atctcacaaa actggtaagt ttcttatgct catgagccct
  3180
- contituent tittaattig gigootgoaa ottiottaac aatgatiota ottootgggo 3240
- atcacatta taatgctctt ggcctctttt ttgctgctgt tttgctattc ttaaacttag
  3300
- caagtacc aatgttggct gttagaaggg attctgttca ttcaacatgc aactttaggg 3360
- atggaagta agttcatttt taagttgtgt .ggtcagtagg tgcggtgtct agggtagtga 3420
- occtgtaag ttcaaattta tgattaggtg acgagttgac attgagattg teetttteec 3480
- :gatcaaaa aaatgaataa agccttttta aacg 3514
- ?10> 32
- 211> 1186
- ?12> DNA
- ?13> Homo sapiens
- 100> 32
- :agttcaga tggtctaacc attgttctat atgtgcattt tagttaatat tgtgtattaa
  60 .
- gataagtc ttaatgctca aagtatgtta aaaatagatg tagtaaatca gtccctttgt
  120
- latgtcctt ttgttagttt ttaggaaggc ctgtcctctg ggagtgacct ttattagtcc 180
- :cccttgga gctagacatc ctgtacttag tcacggggat ggtggaagag ggagaagag 240
- igggtgaag ggaagggctc tttgctagta tctccatatc tagacgatgg ttttagatga 300
- Laccacagg totacaagag cgtttttagt aaagtgcctg tgttcattgt ggacaaagtt 360

eolf-seql-S000001.txt

tattttgc aacatctaag ctttacgaat ggggtgacaa cttatgataa aaactagagc 420

- igtgaatta gcctatttgt aaataccttt gttataattg ataggataca tcttggacat 480
- jaattgtta agccacctct gagcagtgta tgtcaggact tgttcattag gttggcagca
  540
- iggggcaga aggaattata caggtagaga tgtatgcaga tgtgtccata tatgtccata 600
- :tacatttt gatagccatt gatgtatgca tctcttggct gtactataag aacacattaa
  660
- :caatggaa atacactttg ctaatatttt aatggtatag atctgctaat gaattctctt 720
- jcatttaaa tcagaactct gccaatgctt ttatctagag gcgtgttgcc atttttgtct 840
- itatgaaat ttctgtccca agaaaggcag gattacatct ttttttttt ttttagcagt 900
- :gagttggt gtagtgtatt cttggttatc agaatactca tatagctttg ggattttgaa 960
- ggtaaata ttcatgatgt gtgaaaaatc atgatacata ctgtacagtc tcagtcccat 1020
- laattggat gttgtgccta cacacaggat ctagaagaat atgtcaaact ataaactgct
  1080
- stgattgtg aatgactttg ttctttgctt gtgtttttca atttcctata atgcacatac 1140
- lacttttaa aaaataaagg ttattttaaa agcctgtatt aagccc
  1186
- :10> 33
- :11> 606
- 112> DNA
- :13> Homo sapiens
- 00> 33
- acgcaaga cgccgggcct acagcgggag cgtgaggaaa gccgtgcgtt gcgttccaag 60
- atctgtga gcccgcggag tatacaccat gagcaaagct caccctcccg agttgaaaaa 120

eolf-seql-S000001.txt

tttatggac aagaagttat cattgaaatt aaatggtggc agacatgtcc aaggaatatt 180

- 29gggattt gatcccttta tgaaccttgt gatagatgaa tgtgtggaga tggcgactag 240
- ggacaacag aacaatattg gaatggtggt aatacgagga aatagtatca tcatgttaga 300
- gccttggaa cgagtataaa taatggctgt tcagcagaga aacccatgtc ctctctccat 360
- Jggcctgtt ttactatgat gtaaaaatta ggtcatgtac attttcatat tagacttttt 420
- itaaataaa cttttgtaat agtcaaaaat gctttctcag atgttctgaa tatagaatat
  480
- agctctcat tccagttttt tctaacatga attttcctgg ttgacattga tttcaaaggg 540

1aaaa 606

- 210> 34
- ?11> 1579
- 212> DNA
- ?13> Homo sapiens
- 100> 34
- :ccttcgcg tactgacgga aacactggcg gcacatattg aggccgtatt tcaggatcag 60
- :gccggttc gaacacacgc gagaagagca aagaagttaa aagagaagtg tctgtgtggc
- cttccacg tgggtgaagg actgtgccag ctgagaggtg gtagagcagg aagctgcctg 180
- sacctccat thattiggtg aaaaaccgcc gcccttaaga gagcaagtcg agggccgtgt  $240\,$
- Igagttgga ggagagaaat gaaattttgg aagagtcagc agaagatcgt cagtatttaa 300
- :acatcaca tcatgcgtga gtacaagcta gtggtccttg gttcaggagg cgttgggaag 360
- :tgctctga cagttcagtt tgttcaggga atttttgttg aaaaatatga cccaacgata 420

- aagatteet acagaaagea agttgaagte gattgecaae agtgtatget egaaateetg
  480
- atactgcag ggacagagca atttacagca atgagggatt tgtatatgaa gaacggccaa 540
- gttttgcac tagtatattc tattacagct cagtccacgt ttaacgactt acaggacctg 600
- gggaacaga ttttacgggt taaggacacg gaagatgttc caatgatttt ggttggcaat 660.
- aatgtgacc tggaagatga gcgagtagtt ggcaaagagc agggccagaa tttagcaaga 720
- agtggtgta actgtgcctt tttagaatct tctgcaaagt caaagatcaa tgttaatgag 780
- tattttatg acctggtcag acagataaat aggaaaacac cagtggaaaa gaagaagcct 840
- aaaagaaat catgtctgct gctctaggcc catagtcagc agcagctctg agccagatta. 900
- aggaatgaa gaactgttgc ctaattggaa agtgccagca ttccagactt caaaaataaa 960
- aatctgaag aggcttctcc tgttttatat attatgtgaa gaatttagat cttatattgg
  1020
- ttgcacaag ttccctggag aaaaaaattg ctctgtgtat atctcttgga aaataagaca 1080
- tagtatttc tcctttgcaa tagcagttat aacagatgtg aaaatatact tgactctaat 1140
- igattatac aaaagagcat ggatgcattt caaatgttag atattgctac tataatcaaa
  1200
- jatttcata ttgatctttt tatcatgatc ctacctatca agcactaaaa agttgaacca 1260
- latacttta tatctgtaat gatactgatt atgaaatgtc ccctgaaact cattgcagca 1320
- ataactttt ttgagtcatt gacttcattt tatatttaaa aaattatgga atatcatctg 1380
- Cattatatt ctaattaaaa ttgtgcataa tgctttggaa aaatgggtct tttataggaa 1440
- laaactggg ataactgatt tctatggctt tcaaagctaa aatatataat atactaaacc 1500
- ictctaata ttgcttcttg tgttttactg tcagattaaa ttacagcttt tatggatgat

eolf-seql-S000001.txt

1560

aaattttag tacattttc 1579

210> 35

211> 4160

212> DNA

213> Homo sapiens

400> 35

cgcttgcgg aggattgcgt tgacgagact cttatttatt gtcaccaacc tgtggtggaa 60

ttgcagttg cacattggat ctgattcgcc ccgccccgaa tgacgcctgc ccggaggcag 120

jaaagtaca gccgcgccgc cccaagtcag cctggacaca taaatcagca cgcggccgga 180

aaccccgca atctctgcgc ccacaaaata.caccgacgat gcccgatcta.ctttaagggc 240

jaaacccac gggcctgaga gactataaga gcgttcccta ccgccatgga acaacgggga 300

agaacgccc cggccgcttc gggggcccgg aaaaggcacg gcccaggacc cagggaggcg 360

Jgggagcca ggcctgggct ccgggtcccc aagacccttg tgctcgttgt cgccgcggtc 420

igctgttgg tctcagctga gtctgctctg atcacccaac aagacctagc tccccagcag
480

jagcggccc cacaacaaaa gaggtccagc ccctcagagg gattgtgtcc acctggacac 540

itatctcag aagacggtag agattgcatc tcctgcaaat atggacagga ctatagcact
600

ictggaatg acctcctttt ctgcttgcgc tgcaccaggt gtgattcagg tgaagtggag
660

:aagtccct gcaccacgac cagaaacaca gtgtgtcagt gcgaagaagg caccttccgg
720

lagaagatt ctcctgagat gtgccggaag tgccgcacag ggtgtcccag agggatggtc 780

uggtcggtg attgtacacc ctggagtgac atcgaatgtg tccacaaaga atcaggtaca 840

gcacagtg gggaagcccc agctgtggag gagacggtga cctccagccc agggactcct

Page 86

### eolf-seql-S000001.txt

900

1980

cctctccct gttctctctc aggcatcatc ataggagtca cagttgcagc cgtagtcttg 960 ttgtggctg tgtttgtttg caagtcttta ctgtggaaga aagtccttcc ttacctgaaa 1020 gcatctgct caggtggtgg tggggaccct gagcgtgtgg acagaagctc acaacgacct 1080 gggctgagg acaatgtcct caatgagatc gtgagtatct tgcagcccac ccaggtccct agcaggaaa tggaagtcca ggagccagca gagccaacag gtgtcaacat gttgtccccc 1200 gggagtcag agcatctgct ggaaccggca gaagctgaaa ggtctcagag gaggaggctg tggttccag caaatgaagg tgatcccact gagactctga gacagtgctt cgatgacttt .1320. . cagacttgg tgccctttga ctcctgggag ccgctcatga ggaagttggg cctcatggac 1380 atgagataa aggtggctaa agctgaggca gcgggccaca gggacacctt gtacacgatg 1440 gataaagt gggtcaacaa aaccgggcga gatgcctctg tccacaccct gctggatgcc 1500 iggagacgc tgggagagag acttgccaag cagaagattg aggaccactt gttgagctct 1560 jaaagttca tgtatctaga aggtaatgca gactctgcca tgtcctaagt gtgattctct 1620 laggaagtc agaccttccc tggtttacct tttttctgga aaaagcccaa ctggactcca 1680 cagtagga aagtgccaca attgtcacat gaccggtact ggaagaaact ctcccatcca 1740 :atcaccca gtggatggaa catcctgtaa cttttcactg cacttggcat tatttttata 1800 sctgaatgt gataataagg acactatgga aatgtctgga tcattccgtt tgtgcgtact :gagatttg gtttgggatg tcattgtttt cacagcactt ttttatccta atgtaaatgc 1920

:tatttatt tatttgggct acattgtaag atccatctac acagtcgttg tccgacttca

- ttgatacta tatgatatga accttttttg ggtgggggt gcggggcagt tcactctgtc 2040
- cccaggctg gagtgcaatg gtgcaatctt ggctcactat agccttgacc tctcaggctc 2100
- agogattot cocaceteag ceatecaaat agetgggaee acaggtgtge accaceaege 2160
- cggctaatt ttttgtattt tgtctagata taggggctct ctatgttgct cagggtggtc 2220
- cgaatteet ggaeteaage agtetgeeca eeteagaete eeaaageggt ggaattagag 2280
- cgtgagccc ccatgcttgg ccttaccttt ctacttttat aattctgtat gttattattt 2340
- itgaacatg aagaaacttt agtaaatgta cttgtttaca tagttatgtg aatagattag 2400
- laaacataa aaggaggaga catacaatgg gggaagaaga agaagtcccc tgtaagatgt 2460
- ectgtctgg gttccagccc tccctcagat gtactttggc ttcaatgatt ggcaacttct 2520
- laggggcca gtcttttgaa ctggacaacc ttacaagtat atgagtatta tttataggta 2580
- itgtttaca tatgagtcgg gaccaaagag aactggatcc acgtgaagtc ctgtgtgtgg 2640
- ggtcccta cctgggcagt ctcatttgca cccatagccc ccatctatgg acaggctggg 2700
- lagaggcag atgggttaga tcacacataa caatagggtc tatgtcatat cccaagtgaa 2760
- tgagccct gtttgggctc aggagataga agacaaaatc tgtctcccac gtctgccatg 2820
- :atcaaggg ggaagagtag atggtgcttg agaatggtgt gaaatggttg ccatctcagg 2880
- stagatggc ccggctcact tctggttatc tgtcaccctg agcccatgag ctgcctttta 2940
- igtacagat tgcctacttg aggaccttgg ccgctctgta agcatctgac tcatctcaga
  3000
- tgtcaatt cttaaacact gtggcaacag gacctagaat ggctgacgca ttaaggtttt 3060

eolf-seql-S000001.txt

itcttgtgt cctgttctat tattgtttta agacctcagt aaccatttca gcctctttcc 3120

jcaaaccct tctccatagt atttcagtca tggaaggatc atttatgcag gtagtcattc
3180

iggagtttt tggtcttttc tgtctcaagg cattgtgtgt tttgttccgg gactggtttg 3240

jtgggacaa agttagaatt gcctgaagat cacacattca gactgttgtg tctgtggagt 3300

taggagtg gggggtgacc tttctggtct ttgcacttcc atcctctccc acttccatct 3360

jcatcccac gcgttgtccc ctgcacttct ggaaggcaca gggtgctgct gcctcctggt 3420

:ttgccttt gctgggcctt ctgtgcagga cgctcagcct cagggctcag aaggtgccag 3480

cggtccca ggtcccttgt cccttccaca gaggccttcc tagaagatgc atctagagtg 3540

agcettat cagtgtttaa gatttgtett ttatttttaa ttttttgag acagaatete 3600

tctctcgc ccaggctgga gtgcaacggt acgatcttgg ctcagtgcaa cctccgcctc 3660

gggttcaa gcgattctcg tgcctcagcc tccggagtag ctgggattgc aggcacccgc 3720

!ccacgcct ggctaatttt tgtattttta gtagagacgg ggtttcacca tgttggtcag 3780

:tggtctcg aactcctgac ctcaggtgat ccaccttggc ctccgaaagt gctgggatta 3840

ggcgtgag ccaccagcca ggccaagcta ttcttttaaa gtaagcttcc tgacgacatg 3900

ataattgg gggttttgtt gtttagttac attaggcttt gctatatccc caggccaaat 3960

catgtgac acaggacage catagtatag tgtgtcactc gtggttggtg tcctttcatg 4020

tctgccct gtcaaaggtc cctatttgaa atgtgttata atacaaacaa ggaagcacat 4080

tgtacaaa atacttatgt atttatgaat ccatgaccaa attaaatatg aaaccttata 4140

aaaaaaaa aaaaaaaaa

eolf-seql-S000001.txt

4160

210> 36

211> 666

212> DNA

213> Homo sapiens

400> 36

caggettgg ctgcgccctc tcgcgccgca cgctctgcgg gttcctccct tcttccgagc
60

tctcctctg gccgccgcgc gggagagagg ccgagatggc agatgagatt gccaaggctc 120

ggtcgctcg gcctggtggc gacacgatct ttgggaagat catccgcaag gaaataccag 180

caaaatcat ttttgaggat gaccggtgcc ttgctttcca tgacatttcc cctcaagcac 240

aacacattt tctggtgata cccaagaaac atatatccca gatttctgtg gcagaagatg 300

tgatgaaag tcttcttgga cacttaatga ttgttggcaa gaaatgtgct gctgatctgg 360

cctgaataa gggttatcga atggtggtga atgaaggttc agatggtgga cagtctgtct 420

tcacgttca tctccatgtt cttggaggtc ggcaaatgca ttggcctcct ggttaagcac 480

ttttgggga taattttctc ttctttaggc aatgattaag ttaggcaatt tccagtatgt 540

magtaacac acttatttt gcctgtgtat ggagagattc aagaaataat tttaaaaccg 600

₃aaaa

666

210> 37

211> 3683

212> DNA

?13> Homo sapiens

100> 37

ttggcaggc ggcggctgca gggcaggtcc aggggccaca tggctgaggg ggacgcaggg
60

- gcgaccaga ggcagaatga ggaaattgaa gcaatggcag ccatttatgg cgaggagtgg 120
- gtgtcattg atgactgtgc caaaatattt tgtattagaa ttagcgacga tatagatgac 180
- ccaaatgga cactttgctt gcaggtgatg ctgccgaatg aatacccagg tacagctcca 240
- ctatctacc agttgaatgc tccttggctt aaagggcaag aacgtgcgga tttatcaaat 300
- gccttgagg aaatatatat tcagaatatc ggtgaaagta ttctttacct gtgggtggag 360
- aaataagag atgttcttat acaaaaatct cagatgacag aaccaggccc agatgtaaag 420
- agaaaactg aagaggaaga tgttgaatgt gaagatgatc tcattttagc atgtcagccg 480
- aaagttcgg ttaaagcatt ggattttgat atcagtgaaa ctcggacaga agtagaagta 540
- magaattac ctccgattga tcatggcatt cctattacag accgaagaag tacttttcag 600
- cacacttgg ctccagtggt ttgtcccaaa caggtgaaaa tggttctttc caaattgtat 660
- agaataaga aaatagctag tgccacccac aacatctatg cctacagaat atattgtgag 720
- ataaacaga ccttcttaca ggattgtgag gatgatgggg aaacagcagc tggtgggcgt 780
- :tcttcatc tcatggagat tttgaatgtg aagaatgtca tggtggtagt atcacgctgg
  840
- itggaggga ttctgctagg accagatcgc tttaaacata tcaacaactg tgccagaaac 900
- :actagtgg aaaagaacta cacaaattca cctgaggagt catctaaggc tttgggaaag 960
- icaaaaaag taagaaaaga caagaagagg aatgaacatt aatacctgaa actataggaa 1020
- gettaattt geetataatt atatatacat teeatagtea teaaggaata tattgtgeag 1080
- jagagtatc cttgactgct taagtcagcc agttcagcat ggataccaac attagctttt
  1140
- tcttggtt atatcatctg ccaaaaatag agaacttatg atctattcat gtgtgtttca

eolf-seql-S000001.txt

1200

gcttatttg ggagaactaa tttgaactta atcaccactt catctaattt tagcaaggta cagttgccc agggcagtac ctgaattaac tgtccatttc agtacatgtc aagtgccttt 1320 ttaggtgga gaagaaatgt ctctagagga atataaatac ctgatttctt gtcatcgaga 1380 tcttgtact gttaaatgaa tattgccttt tactgctctt tatggcttat tggaatagga 1440 ctcatttaa gattgatctt ggagagtttc ttcttgtgat tttagttcat aagtatgtca 1500 otttcattt tatagtgttc atcattgagt aatggattaa gtgaaaatcc aggagtatcc octgcagtt atgtgctgag gtgataattc atccaacata tttgttagca taaatattat 1620 ettcagttt ctgttgcaaa ttggtgattg tgaaattaca gaaagtgatt ttctagtctg 1680 ittttttgt ttaattcttg taatgtaagc aataaatatg gagtgtcagt agtctccttc accccagaa atgtgttggt gtaacattct cgtttctttt aacaacctgg aagtaccttt 1800 itgtgatct tcactgagga attagaacta tgatagaagt taggctgtgg caaatgggac 1860 :tcgtagag tgggatagag gtggcagaat gaacctggtg tagggcagga gtatgttgtg 1920 igttacate aatttgatge atgettteea tetgeactee agaeggettt eteagtteea 1980 jattttgca gagagaagga gcaaaccttt tcattggaaa aacagaaaca accctcccc

:atttttc ccctctattc atcaaacctt tatgtatctt tcatcttcca gttacctcta 2100

scatttaga tagtgaaatt tacctttgag atataacaat aagtgattaa ctgttcactt 2160

agatgtaa tggcaaacaa ttgttaaaag ttattaactg atcacagatt tgcctggact 2220

ccttccca gggagggaac agaagttagg aggcaacttt gggatggtgc tagagcatgg 2280

Page 92

- aagcacaga gaattggaca aacaggtett tttetetttt etetgatgtt ttaeetttaa 2340
- agatccaac atccttaccg ttggtatttt tagtaaggtt atagtaaata gctttacacc 2400
- ggatggatt ctgaaatata aattctaaat tatatttgtt ataactatat tttatgttgt 2460
- tgttatcag gagccatcag agaatgacct ttttgtgttt ggaacacttg gttccatgaa 2520
- agtatgctt tgtgttttaa ctgttaaaat aatttaaaaa ttaattattt tacataatta 2580
- agaagttaa aaactattaa cattaaataa tttcacaatt tcaacatgtc aaacctatga 2640
- gggagatag gaaacaatga gaaacttact tttgctcctt tatacagaat tattaactat 2700
- ttttactaa ctaaaaaact ctagtattct ttacctaaag tcaattggct ggtaagaggg 2760
- gagatgcaa aattctccag ctctgaactt ggagctactt cacactctac tcttaatgga 2820
- acttgaact aatgatagat agtattttt tcctctattt aaaatttttg tcttgattag 2880
- agatttttc agttctccat ataataattt tctacaatca gatctatgct gtggcatatt 2940
- sgctttatt taaaaatttt tttttagaga tgagttcttg ctctgtcacc taggctggag 3000
- jcagtggca tgatcatggc tcactgcagc cttgaccttc cagcctgcca agtagctggg 3060
- tacagaca ggcatgtgct attacacctg gctaattttt aaagtttttt ttgtaaagat 3120
- jggtctttc tatgttgccc aggctcgtct tgagctcctg gcctcaatcg atcttcctgc 3180
- aggttttg gaattacagg tgtgagccac catgcctggc ctgctttgac atattttata 3240
- gtgttaat tacaaatagt cttcatatgc cagaatataa gagcaagtgt tatctacttt 3300
- agatggga attgcagaag ctgcatcaaa agtatgcttt gaggtatata tagtgaaaca 3360

eolf-seql-S000001.txt

agcetttet gaagagaatt atateaaact aattacaace aagaaataat agtatgaage 3420

- gatgctgtt tggaggacag gaaaatttat cgggaaaatt acataatccc tctgattcca 3480
- tatccagag atagccatta ttattaatat ttggtatgta catccttata ttatttttt 3540
- ttatgcatg attttgtata tatggttatt tttctttcca taaaaatggt attaaactgt 3600
- tatactgtt ttgtagccta catatttcat atagaagtat attgttaaca ttttccatgt 3660
- aataaatat tctatggctt tct 3683

210> 38

211> 3251

212> DNA

213> Homo sapiens

400> 38

- agcaactat gaaataatcg tagtatgaga ggcagagatc ggggcgagac aatggggatg 60
- gggcgcggg agccccgttc cggcttagca gcacctccca gccccgcaga ataaaaccga 120
- cgcgcccc tccgcgcgc cctccccc agtgcggagc gggaggaggc ggcggcgcc 180
- aggaggagg aggaggagc cccggaggag gaggcgttgg aggtcgaggc ggaggcggag 240
- jgcggcatg agacgagcgt ggcggccgcg gctgctcggg gccgcgctgg ttgcccattg
  360
- cagcggcgt ctgcagctcg cttcaagatg gccgcttggc tcgcattcat tttctgctga
  420
- sgactttta actttcattg tetttteege eegettegat egeetegege eggetgetet 480
- :ccgggatt ttttatcaag cagaaatgca tcgaacaacg agaatcaaga tcactgagct
  540
- latccccac ctgatgtgtg tgctttgtgg agggtacttc attgatgcca caaccataat 600

- gaatgtcta cattccttct gtaaaacgtg tattgttcgt tacctggaga ccagcaagta 660

- agaagaagg gatttttatg cagctcatcc ttctgctgat gctgccaatg gctctaatga 840
- gatagagga gaggttgcag atgaagataa gagaattata actgatgatg agataataag 900
- ttatccatt gaattctttg accagaacag attggatcgg aaagtaaaca aagacaaaga 960
- aaatctaag gaggaggtga atgataaaag atacttacga tgcccagcag caatgactgt 1020
- atgcactta agaaagtttc tcagaagtaa aatggacata cctaatactt tccagattga 1080
- gtcatgtat gaggaggaac ctttaaagga ttattataca ctaatggata ttgcctacat 1140
- tatacctgg agaaggaatg gtccacttcc attgaaatac agagttcgac ctacttgtaa 1200
- agaatgaag atcagtcacc agagagatgg actgacaaat gctggagaac tggaaagtga 1260
- cctgggagt gacaaggcca acagcccagc aggaggtatt ccctccacct cttcttgttt 1320
- octagodoc agtactocag tgoagtotoc toatocacag tttoctoaca tttocagtac 1380
- atgaatgga accagcaaca gccccagcgg taaccaccaa tcttcttttg ccaatagacc 1440
- gaaaatca tcagtaaatg ggtcatcagc aacttcttct ggttgatacc tgagactgtt 1500
- 199aaaaaa attttaaacc cctgatttat atagatatct tcatgccatt acagctttct 1560
- jatgctaat acatgtgact atcgtccaat ttgctttctt ttgtagtgac attaaatttg
  1620
- tataaaag atggactaca tgtgatactc ctatggacgt taattgaaaa gaaagattgt 1680
- sttataaag aattggtttc ttggaaagca ggcaagactt tttctctgtg ttaggaaaga

### eolf-seql-S000001.txt

1740

gggaaatgg tttctgtaac cattgtttgg atttggaagt actctgcagt ggacataagc 1800

ttgggccat agtttgttaa tctcaactaa cgcctacatt acattctcct tgatcgttct 1860

gttattacg ctgttttgtg aacctgtaga aaacaagtgc tttttatctt gaaattcaac 1920

aacggaaag aatatgcata gaataatgca ttctatgtag ccatgtcact gtgaataacg 1980

tttcttgca tatttagcca ttttgattcc tgtttgattt atacttctct gttgctacgc 2040

aaaccgatc aaagaaaagt gaacttcagt tttacaatct gtatgcctaa aagcgggtac 2100

accepttat titactgact tettaaate attegettit etaagaatea gategeatta 2160

gcttgttgt acaatgccat attggtatat gacataacag gaaacagtat tgtatgatat 2220

Ettataaat gotataaaga aatattgtgt ttoatgcatt cagaaatgat tgttaaaatt 2280

cccaactg gttcgacctt tgcagatacc cataacctat gttgagcctt gcttaccagc
2340

agaatatt tttaatgtgg atatctaatt ctaaagtctg ttccattaga agcaattggc 2400

catctttct atactttata tacttttctc cagtaataca tgtttacttt aaaaattgtt 2460

cagtgaaga aaaaccttta actgagaaat atggaaaccg tcttaatttt ccattggcta 2520

jatggaatt aatattgtat tttaaaaatg catattgatc actataattc taaaacaatt
2580

Ittaaataa accagcaggt tgctaaaaga aggcatttta tctaaagtta ttttaatagg 2640

jgtatagca gtaattttaa atttaagagt tgcttttaca gttaacaatg gaatatgcct 2700

tctgctat gtctgaaaat agaagctatt tattatgagc ttctacaggt atttttaaat 2760

Jagcaagca tgttgaattt aaaatatgaa taaccccacc caacaatttt cagtttattt 2820

### eolf-seql-S000001.txt

ttgctttgg tcgaacttgg tgtgtgttca tcacccatca gttatttgtg agggtgttta 2880

tctatatga atattgtttc atgtttgtat gggaaaattg tagctaaaca tttcattgtc 2940

ccagtctgc aaaagaagca caattctatt gctttgtctt gcttatagtc attaaatcat 3000

acttttaca tatattgctg ttacttctgc tttctttaaa aatatagtaa aggatgtttt 3060

tgaagtcac aagatacata tatttttatt ttgacctaaa tttgtacagt cccattgtaa 3120

tgttgtttc taattataga tgtaaaatga aatttcattt gtaattggaa aaaatccaat 3180

aaaaaaaa a 3251

210> 39

211> 2855

212> DNA

213> Homo sapiens

100> 39

igtggcagt tatatagacc ggcggcggag cacgcgtgtg tgcggacgca gttgcgtgag
60

jgtttgtac tatcctcggt gctgtggtgc agagctagtt cctctccagc tcagccgcgt 120

Jgtttggac atatttgact cttttccccc caggttgaat tgaccaaagc aatggtgatg 180

igaagccta gtcccctgct ggtcgggcgg gaatttgtga gacagtatta cacactgctg 240

iccaggccc cagacatgct gcatagattt tatggaaaga actcttctta tgtccatggg 300

jattggatt caaatggaaa gccagcagat gcagtctacg gacagaaaga aatccacagg 360

lagtgatgt cacaaaactt caccaactgc cacaccaaga ttcgccatgt tgatgctcat 420

cacgctaa atgatggtgt ggtagtccag gtgatggggc ttctctctaa caacaaccag 480

- ctttgagga gattcatgca aacgtttgtc cttgctcctg aggggtctgt tgcaaataaa
  540
- tctatgttc acaatgatat cttcagatac caagatgagg tctttggtgg gtttgtcact 600
- agcctcagg aggagtctga agaagaagta gaggaacctg aagaaagaca gcaaacacct 660
- aggtggtac ctgatgattc tggaactttc tatgatcagg cagttgtcag taatgacatg 720
- pagaacatt tagaggagcc tgttgctgaa ccagagcctg atcctgaacc agaaccagaa 780
- aagaacctg tatctgaaat ccaagaggaa aagcctgagc cagtattaga agaaactgcc 840
- stgaggatg ctcagaagag ttcttctcca gcacctgcag acatagctca gacagtacag 900
- lagacttga ggacattttc ttgggcatct gtgaccagta agaatcttcc acccagtgga 960
- stgttccag ttactgggat accacctcat gttgttaaag taccagcttc acagccccgt 1020
- lagagtota agootgaato toagattoca coacaaagao otoagoggga toaaagagtg 1080
- Jagaacaac gaataaatat teeteeccaa aggggaecca gaccaateeg tgaggetggt 1140
- ${\it lgcaaggtg}$  acattgaacc ccgaagaatg gtgagacacc ctgacagtca ccaactcttc 1200
- tggcaacc tgcctcatga agtggacaaa tcagagctta aagatttctt tcaaagttat 1260
- gaaacgtgg tggagttgcg cattaacagt ggtgggaaat tacccaattt tggttttgtt
  1320
- gtttgatg attctgagcc tgttcagaaa gtccttagca acaggcccat catgttcaga 1380
- rtgaggtcc gtctgaatgt cgaagagaag aagactcgag ctgccaggga aggcgaccga 1440
- agataatc gccttcgggg acctggaggc cctcgaggtg ggctgggtgg tggaatgaga 1500
- ccctcccc gtggaggcat ggtgcagaaa ccaggatttg gagtgggaag ggggcttgcg 1560

- cacggcagt gaatetteat ggatetteat geagecatae aaaceetggt tecaacagaa 1620
- ggtgaattt tcgacagcct ttggtatctt ggagtatgac cccagtctgt tataaactgc 1680
- taagtttgt ataattttac tttttttgtg tgttaatggt gtgtgctccc tctccctctc 1740
- tccctttcc tgacctttag tctttcactt ccaattttgt ggaatgatat tttaggaata 1800
- cggactttt aaagaagcaa aaaaaaagac tgaatttcct tgcttacttt gcatatacag 1860
- ctggatttt tttttttt ttacagccat ttccccaaag gaatgtcttg catattactg 1920
- catttggta tgtttcattc attggaatat ttcttatttt ctacgtgttt gaaaagcctg 1980
- aagaaatac aggatttgat aatattttga aggcaggaaa aacccaaatt gtttcttctt 2040
- jagagtcat gactaccttc tggtgtggag aaattgccat tggaaaattt gacaattttg 2100
- ttctcactg gtatgtttaa aaactgaata aaaggaatag aattttttt tgataaagga 2160
- cacaaaaca attctaaaac ctaactgttt ttaccattga aatttaaatt gtgataatag 2220
- itttaaatg totagaatgo aactgatagg ottttottga actgttagtt tttttgaagt 2280
- jttttttca tgtttaattt gtatttgtaa aaaaacaaaa agcaaaaaaa ttcccaaaac 2340
- sagataaca accagagcaa aactgttgtg cettetattt atetttgatt teagtettgg 2400
- lattgttta aaaaaaaaat ctagatttgt tttattaggt tcagagtatg tggggaatta 2460
- igaatccct ctttcatcac tttgtgtatg tcttttgtta acatatttgt tatgccttat 2520
- taaaattg agtctcaaac tggaatgcct ttgaagacag atgcttctat agaggttctt 2580
- jacctaaat agttcagcat ttgtattttt attctggtat ctaatcagat tcctaatcat 2640
- secogtaag aaggaatgtt actttaatat tggactttgc tcatgtgctc gtgtccgcat

eolf-seq1-S000001.txt

2700

tttttttt cttaaaatca tagccatatg gtaaattttc tattttgtta tggttctctt 2760

tattgatgg gcatgcagtg ggtgttactt ggaaatggcc aatttttatt aaaatatttc 2820

ggaagaaaa tttaaaaaaa aaaaaaaaaa aaaaa 2855

210> 40

211> 1396

212> DNA

213> Homo sapiens

400> 40

cgtaattaa aaggcggcgg aagaaggtgg gagggtcatg acgcagcgag tttcagtcgt 60

acttttctg ggggcatcgc ggcgtcccct tttttttgcc tttaaagtaa aacgtcgccc. 120

gacgcaccc cccgcgtatt tcggggggcg gaggcggcgg gccacggcgc gaagaggggc 180

gtgctgacg ccggccggtc acgtgggcgt gttgtggggg ggaggggcgc cgccgcggg 240

cggttccgg gcggttggga gcgcgcgagc tagcgagcga gaggcagccg cgcccgccgc 300

jcccctgct ctgtatgccg ctctctcccg gcgcggccgc cgccgatcac agcagcagga
360

ccaccgccg ccgcggttga tgtggttggg ccggggctga ggaggccgcc aagatgccgc 420

jtccaagtc ccggaagatc gcgatcctgg gctaccggtc tgtggggaaa tcctcattga
480

jattcaatt tyttgaagge caatttytyg acteetacga teeaaceata gaaaacaett 540

tacaaagtt gatcacagta aatggacaag aatatcatct tcaacttgta gacacagccg
600

gcaagatga atattctatc tttcctcaga catactccat agatattaat ggctatattc 660

gtgtattc tgttacatca atcaaaagtt ttgaagtgat taaagttatc catggcaaat 720

ıttggatat ggtggggaaa gtacaaatac ctattatgtt ggttgggaat aagaaagacc

eolf-seql-S000001.txt

780

gcatatgga aagggtgatc agttatgaag aagggaaagc tttggcagaa tcttggaatg 840

agctttttt ggaatcttct gctaaagaaa atcagactgc tgtggatgtt tttcgaagga 900

aattttgga ggcagaaaaa atggacgggg cagcttcaca aggcaagtct tcatgctcgg
960

jatgtgatt ctgctgcaaa gcctgaggac actgggaata tattctacct gaagaagcaa 1020

stgcccgtt ctccttgaag ataaactatg cttcttttt cttctgttaa cctgaaagat 1080

cattiggg teagagetee cetecettea gattatgtta actetgagte tgtecaaatg 1140

jttcacttc cattttcaaa ttttaagcaa tcatattttc aatttatata ttgtatttct
1200 .....

aatattatg accaagaatt ttatcggcat taatttttca gtgtagtttg ttgtttaaaa 1260

latgtaatc atcaaaatga tgcatattgt tacactacta ttaactaggc ttcagtatat 1320

igtgtttat ttcattgtgt taaatgtata cttgtaaata aaatagctgc aaacctcaaa 1380

laaaaaaaa aaaaaa 1396

?10> 41

?11> 2589

212> DNA

?13> Homo sapiens

100> 41

laccaggga gatttctcca ttttcctctt gtctacagtg cggctacaaa tctgggattt 60

:ttattact tcttttttt tcgaactaca cttgggctcc tttttttgtg ctcgacttt 120

accetttt teeeteete etgtgetget getttttgat etettegaet aaaatttttt 180

tccggagt gtatttaatc ggttctgttc tgtcctctcc accaccccca ccccctccc 240

eggtgtgt gtgccgctgc cgctgttgcc gccgccgctg ctgctgctgc tcgccccgtc

Page 101

### eolf-seq1-S000001.txt

300

tacaccaa cccgaggete titgtitece etetiggate tgitgagitt etitgtigaa lagocagoa tgggtgccca gttctccaag accgcagoga agggagaago cgccgcggag 420 jgcctgggg aggcggctgt ggcctcgtcg ccttccaaag cgaacggaca ggagaatggc 480 acgtgaagg taaacggcga cgcttcgccc gcggccgccg agtcgggcgc caaggaggag gcaggeca acggcagege eceggeegee gacaaggagg agecegegge egeegggage 600 jggcggcgt cgccctcctc ggccgagaaa ggtgagccgg ccgccgccgc tgcccccgag eggggcca gcccggtaga gaaggaggcc cccgcggaag gcgaggctgc cgagcccggc :ggccacgg ccgcggaggg agaggccgcg tcggccgcct cctcgacttc ttcgcccaag :cgaggacg gggccacgcc ctcgcccagc aacgagaccc cgaaaaaaaa aaagaagcgc :ttccttca agaagtcttt caagctgagc ggcttctcct tcaagaagaa caagaaggag 900 tggagaag gcggtgaggc tgaggcgcc gctgccgaag gcggcaagga cgaggccgcc 960 Igggcgcag ctgcggccgc cgccgaggcg ggcgcggcct ccggggagca ggcagcggcg 1020 gggcgagg aggcggcagc gggcgaggag ggggcggcgg gtggcgaccc gcaggaggcc gccccagg aggccgctgt cgcgccagag aagccgcccg ccagcgacga gaccaaggcc egaggage ccagcaaggt ggaggagaaa aaggccgagg aggccgggge cagcgccgcc 1200 ctgcgagg ccccctccgc cgccgggccc ggcgccccc cggagcagga ggcagcccc 1260 ggaggage cegeggeege egeageeteg teageetgeg eageeeete acaggaggee 1320 gcccgagt gcagtccaga agcccccca gcggaggcgg cagagtaaaa gagcaagctt 1380

- gtgagata atcgaagaac ttttctccc cgtttgtttg ttggagtggt gccaggtact 1440
- Etttggaga acttgtctac aaccagggat tgattttaaa gatgtctttt tttattttac 1500
- Itttttaa gcaccaaatt ttgttgtttt tttttttctc ccctccccac agatcccatc 1560
- Saaatcatt ctgttaacca ccattccaac aggtcgagga gagcttaaac accttcttcc 1620
- rtgccttgt ttctctttta tttttattt tttcgcatca gtattaatgt ttttgcatac 1680
- tgcatctt tattcaaaag tgtaaacttt ctttgtcaat ctatggacat gcccatatat 1740
- laggagatg ggtgggtcaa aaagggatat caaatgaagt gataggggtc acaatgggga 1800
- ittgaagtg gtgcataaca ttgccaaaat agtgtgccac tagaaatggt gtaaaggctg 1860
- tttttttt ttttttaaa gaaaagttat taccatgtat tttgtgaggc aggtttacaa 1920
- ıctacaagt cttgagttaa gaaggaaaga ggaaaaaaga aaaaacacca atacccagat 1980
- .aaaaaaaa aaaaacgatc atagtcttag gagttcattt aaaccatagg aacttttcac 2040
- atctcatg ttagctgtac cagtcagtga ttaagtagaa ctacaagttg tataggcttt 2100
- tgtttatt gctggtttat gaccttaata aagtgtaatt atgtattacc agcagggtgt 2160
- ttaactgt gactattgta taaaaacaaa tcttgatatc cagaagcaca tgaagtttgc 2220
- ctttccac cctgcccatt tttgtaaaac tgcagtcatc ttggaccttt taaaacacaa 2280
- tttaaact caaccaagct gtgataagtg gaatggttac tgtttatact gtggtatgtt 2340
- tgattaca gcagataatg ctttctttc cagtcgtctt tgagaataaa ggaaaaaaa 2400
- ttcagatg caatggtttt gtgtagcatc ttgtctatca tgttttgtaa atactggaga 2460

eolf-seql-S000001.txt

getttgace aatttgactt agagatggaa tgtaactttg ettacaaaaa ttgetattaa 2520

ctcctgctt aaggtgttct aattttctgt gagcacacta aaagcgaaaa ataaatgtga 2580

taaaatgt 2589

210> 42

211> 1466

212> DNA

213> Homo sapiens

400> 42

Jggctgctg ggactcgtcg tcggttggcg actcccggac gttaggtagt ttgttgggcc 60

jgttctgag gccttgcttc tctttacttt tccactctag gccacgatgc cgcagtacca 120

acctgggag gagttcagcc gcgctgccga gaagctttac ctcgctgacc ctatgaaggc 180

sgtgtggtt ctcaaatata ggcattctga tgggaacttg tgtgttaaag taacagatga 240

:tagtttgt ttggtgtata aaacagacca agctcaagat gtaaagaaga ttgagaaatt
300

Cacagteaa etaatgegae ttatggtage caaggaagee egeaatgtta eeatggaaac 360

jagtgaatg gtttgaaatg aagactttgt cgtgtactta ggaagtaaat atcttttgaa
420

lagagaaag gttgggacag aaagtacttt atgtaactaa gtgggctgtt cagaagctta 480

 $_{1}$ ggtcattt tttgtaattt tctttttaat tactttagag agctagggat gcaaatgttt  $_{540}$ 

:agttagaa agcctttatt tacttttgga aattgaacaa gaaatgcatc tgtcttagaa 600

:tggagatt atttgatgtt aggtaaaaca tgtaattgtt tctctggcaa atttgtatca 660

.aatttgaa aatgagatat taggaaaaac caattcttct taaatttagt tcatctttct 720

aaaagaac attaaatgta accattttgt cagatccatg tattttggag cataaaatgt 780

eolf-seql-S000001.txt

tgctgttgt gaccaataaa tataaaatat ggtaattgga attaactcca caccatagta 840

- gcattgtta tacatactgt gtacctaatt atgtatagca gtgtagtctc aattatatct 900
- aaagtaatt gtgactaaca agtatgcttt gccttatttc cacatttaaa ctacctgtta
  960
- tataaggga tttgtagtat cagcttgttg agcaatgact ttgaatctag ttttcagtga 1020
- cagaagcag cagttatttg agtgtatgaa tggaatgatg atcactgtgc tataatgtac 1080
- gaaaccacc atattacaga aatatttact acatattttc catctgtagt ttctcagaag 1140
- gctatggat tagtttgaac tgtcaaatcc ttgcatactt ctgtgacacc cctgcccatt
   1200
- tctgtcttt aattaaccaa ggtgttaggt gtgactgtca caactgttat gttttccagt 1260
- aactagaag cacgatattt gataattata tttgtatttc accacctaaa tgtaatgttg 1320
- itcctcaag aatgaaatga aggcactaca ttgaaatatg ttttgtataa atttgtcatg
  1380
- -gaacagca ttttagcatg gtaagttccc ttagctatat gaattttggc atgtttcaga 1440
- igatcagta aataaaatat tagata 1466
- 210> 43
- 211> 1815
- 212> DNA
- ?13> Homo sapiens
- 100> 43
- jggagatga tccgagccgc gccgccgccg ctgttcctgc tgctgctgct gctgctgctg
- agtgtcct gggcgtcccg aggcgaggca gcccccgacc aggacgagat ccagcgcctc 120
- cgggctgg ccaagcagcc gtctttccgc cagtactccg gctacctcaa aagctccggc 180
- caagcacc tocactactg gtttgtggag toccagaagg atoccgagaa cagcoctgtg 240

- tgctttggc tcaatggggg tcccggctgc agctcactag atgggctcct cacagagcat 300
- gccccttcc tggtccagcc agatggtgtc accctggagt acaaccccta ttcttggaat 360
- tgattgcca atgtgttata cctggagtcc ccagctgggg tgggcttctc ctactccgat 420
- acaagtttt atgcaactaa tgacactgag gtcgcccaga gcaattttga ggcccttcaa 480
- atttettee geetetttee ggagtacaag aacaacaac tttteetgae eggggagage 540
- atgctggca totacatoco caccotggco gtgctggtca tgcaggatoc cagcatgaac 600
- tcaggggc tggctgtggg caatggactc tcctcctatg agcagaatga caactccctg
  660
- cotacttig cotactacca tggccttctg gggaacaggc tttggtcttc tctccagacc. 720
- actgctgct ctcaaaacaa gtgtaacttc tatgacaaca aagacctgga atgcgtgacc 780
- atottcagg aagtggcccg catcgtgggc aactctggcc tcaacatcta caatctctat 840
- scccgtgtg ctggagggt gcccagccat tttaggtatg agaaggacac tgttgtggtc 900
- iggatttgg gcaacatctt cactcgcctg ccactcaagc ggatgtggca tcaggcactg
  960
- gegeteag gggataaagt gegeatggae eeceetgea eeaacacaac agetgettee 1020
- octacctca acaacccgta cgtgcggaag gccctcaaca tcccggagca gctgccacaa 1080
- iggacatgt gcaactttct ggtaaactta cagtaccgcc gtctctaccg aagcatgaac
  1140
- eccagtate tgaagetget tageteacag aaataccaga teetattata taatggagat 1200
- agacatgg cctgcaattt catgggggat gagtggtttg tggattccct caaccagaag 1260
- ggaggtgc agcgccggcc ctggttagtg aagtacgggg acagcgggga gcagattgcc 1320
- scttcgtga aggagttctc ccacatcgcc tttctcacga tcaagggcgc cggccacatg

eolf-seql-S000001.txt

1380

ttcccaccg acaagccct cgctgccttc accatgttct cccgcttcct gaacaagcag 1440

catactgat gaccacagca accageteca eggeetgatg eageeeetee eageetetee 1500

jetaggaga gteetettet aageaaagtg eeeetgeagg egggttetge egeeaggaet 1560

occettee cagageett tacateeeag aetgggeeca gggteteeea tagacageet 1620

Jgggcaagt tagcacttta ttcccgcagc agttcctgaa tggggtggcc tggccccttc 1680

stgcttaaa gaatgccctt tatgatgcac tgattccatc ccaggaaccc aacagagctc 1740

Jgacagece acagggaggt ggtggaegga etgtaattga tagattgatt atggaattaa 1800.

:tgggtaca gcttc 1815

210> 44

211> 3315

212> DNA

?13> Homo sapiens

100> 44

jttctcgcg ggacaccgac ggggagcgga agccaggagg tattgctgct tcggcgaccg
60

jcggcggca gcggcggcgg cggctgtggc agagtctgtg cctgtggcgg tgacggcggc
120

igagcaagc gctgccctcg cagagcagcc ttggggtcgc cggccgctcg cagcgttgtg
180

 $\iota ggggcggg$  ccggacgctg agcggagcag ctgcgccacg ggtggcattg tgtgtcccag 240

stgccggag cgagtcccag aagagaggcg aggctaagcc cagagcgctg ggttgcttca 300

agggaaga ctcccttccc cctgcttcag gctgctgagc actgagcagc gctcagaatg 360

agecateg ceaaatatga etteaaaget aetgeagaeg aegagetgag etteaaaagg 420

ggacatec teaaggtttt gaacgaagaa tgtgateaga actggtacaa ggeagagett

## eolf-seql-S000001.txt

480

- atggaaaag acggcttcat tcccaagaac tacatagaaa tgaaaccaca tccgtggttt 540
- :tggcaaaa tccccagagc caaggcagaa gaaatgctta gcaaacagcg gcacgatggg
  600
- cettetta teegagagag tgagageget eetggggaet tetecetete tgteaagttt 660
- Jaaacgatg tgcagcactt caaggtgctc cgagatggag ccgggaagta cttcctctgg 720
- iggtgaagt tcaattcttt gaatgagetg gtggattatc acagatctac atctgtctcc
  780
- Jaaaccagc agatatteet gegggacata gaacaggtge cacageagee gacataegte 840
- 1ggccctct ttgactttga tccccaggag gatggagagc tgggcttccg ccggggagat 900
- :tatccatg tcatggataa ctcagacccc aactggtgga aaggagcttg ccacgggcag
  960
- ocggcatgt ttccccgcaa ttatgtcacc cccgtgaacc ggaacgtcta agagtcaaga 1020
- ¡caattatt taaagaaagt gaaaaatgta aaacacatac aaaagaatta aacccacaag
  1080
- gcctctga cagcagcctg tgagggagtg cagaacacct ggccgggtca ccctgtgacc 1140
- ctcacttt ggttggaact ttagggggtg ggagggggg ttggatttaa aaatgccaaa 1200
- :ttacctat aaattaagaa gagtttttat tacaaatttt cactgctgct cctctttccc 1260
- :cctttgtc tttttttca tcctttttc tcttctgtcc atcagtgcat gacgtttaag 1320
- cacgtata gtcctagctg acgccaataa taaaaaacaa gaaaccaagt gggctggtat 1380
- tctctatg caaaatgtct gttttagttg gaatgactga aagaagaaca gctgttcctg 1440
- ttcttcgt atatacacac aaaaaggagc gggcagggcc gctcgatgcc tttgctgttt 1500
- cttcctcc agaggagggg acttgtagga atctgccttc cagcccagac ccccagtgta 1560

### eolf-seql-S000001.txt

tttgtccaa gttcacagta gagtagggta gaaggaaagc atgtctctgc ttccatggct 1620

- sctgagaaa gcccacctgg gctgggcgcg gtggctcacg cctgtaatcc cagcactttg
  1680
- Jaggccaag gtgggcggat cacaaggtca ggagttcgag accaacctag ccaacatggt 1740
- laaccccgt ctctactaaa aataagaaat tagccgggtg tggcacgcac ctgtagtccc 1800
- jctacttgg gagcctgagg caggagaatc gcttgaacct gggaagtgga ggttgagtga 1860
- cgggaccg tgccattgta ctccagcctg ggtgacagag cgagattccg tctcaaaaaa 1920
- laaaaaaaa agcccacctg aaagcctgtc tctttccact ttgttggccc ttccagtggg 1980
- tatcgagc atgttgtttt ttcatagtgc ctttttcctt atttcaaggg ttgcttctga 2040
- ggtgtttt ttttttttt ttaatttgtt ttgttttaaa ataagttaaa ggcagtccag 2100
- jcttttcag ccaatttgtc tectactctg tgtaaatatt tttccctccg ggcaggggag 2160
- agggtaga gcaaaggaga caaagcagga gtggaaggtg aggcgttctc ctgcttgtac 2220
- lagocagga ggotttaago tocagottta agggttgtga gccccttggg ggttcaggga 2280
- stgcttgcc cagggtgcag tgtgagtgtg atgggccacc ggggcaagag ggaaggtgac 2340
- jcccagctc tcccacatcc cactggatct ggcttacagg ggggtcggaa gcctgtcctc 2400
- :cgtctcgg gggttgtggc ccccgcccc tccctatatg cacccctgga accagcaagt 2460
- cagacaag gagagcggag gaggaagtca tgggaacgca gcctccagtt gtagcaggtt 2520
- :actattcc tatgctgggg tacacagtga gagtactcac ttttcacttg tcttgctctt 2580
- mattgggcc atggctttca tcctgtgtcc cctgacctgt ccaggtgagt gtgagggcag 2640

eolf-seql-S000001.txt

actgggaag ctggagtgct gcttgtgcct cccttcccag tgggctgtgt tgactgctgc 2700

- ccccaccc taccgatggt cccaggaagc agggagagtt ggggaaggca agattggaaa 2760
- acaggaaga ccaaggccic ggcagaactc tctgtcttct ctccacttct ggtcccctgt 2820
- gtgatgtgc ctgtaatctt tttctccacc caaacccctt cccacgacaa aaacaagact 2880
- cctccctct cttccgggag ctggtgacag ccttgggcct ttcagtccca aagcggccga 2940
- jggagtete eeteegaete eagatatgaa eagggeeeag geetggageg tttgetgtge 3000
- aggaggcgg cagctettet gggcagagee tgteeeegee tteeeteact etteeteate 3060
- tgcttctct tttcctcgca gatgataaaa ggaatctggc attctacacc tggaccattt
  3120
- attgtttta ttttggaatt ggtgtatatc atgaagcctt gctgaactaa gttttgtgtg 3180
- atatattta aaaaaaaat cagtgtttaa ataaagacct atgtacttaa tcctttaact 3240
- geggatag catttggtag gtagtgatta actgtgaata ataaatacac aatgaattet 3300

laaaaaaaa aaaaa 3315

- 210> 45
- 211> 2225
- 212> DNA
- ?13> Homo sapiens
- 100> 45
- jacatggcg cgcgagctgc gggcgctgct gctgtggggc cgccgcctgc ggcctttgct
  60
- gggcgccg gcgctggcgg ccgtgccggg aggaaaacca attctgtgtc ctcggaggac 120
- cageceag ttgggeecea ggegaaacee ageetggage ttgeaggeag gaegaetgtt 180
- gcacgcag accgccgagg acaaggagga acccctgcac tcgattatca gcagcacaga 240

- agcgtgcag ggttccactt ccaaacatga gttccaggcc gagacaaaga agcttttgga 300
- attgttgcc cggtccctgt actcagaaaa agaggtgttt atacgggagc tgatctccaa 360
- gccagcgat gccttggaaa aactgcgtca caaactggtg tctgacggcc aagcactgcc 420
- gaaatggag attcacttgc agaccaatgc cgagaaaggc accatcacca tccaggatac 480
- ggtatcggg atgacacagg aagagctggt gtccaacctg gggacgattg ccagatcggg 540
- tcaaaggcc ttcctggatg ctctgcagaa ccaggctgag gccagcagca agatcatcgg 600
- cagtttgga gtgggtttct actcagcttt catggtggct gacagagtgg aggtctattc 660
- cgctcggca gccccgggga gcctgggtta ccagtggctt.tcagatggtt ctggagtgtt.
- jaaatcgcc gaagcttcgg gagttagaac cgggacaaaa atcatcatcc acctgaaatc 780
- jactgcaag gagttttcca gcgaggcccg ggtgcgagat gtggtaacga agtacagcaa 840
- itcgtcagc ttccccttgt acttgaatgg aaggcggatg aacaccttgc aggccatctg
  900
- atgatggac cccaaggatg tcggtgagtg gcaacatgag gagttctacc gctacgtcgc 960
- laggeteac gacaageee getacaeeet geactataag aeggaegeac egeteaaeat 1020
- gcagcatc ttctacgtgc ccgacatgaa accgtccatg tttgatgtga gccgggagct 1080
- gctccagc gttgcactgt acagccgcaa agtcctcatc cagaccaagg ccacggacat 1140
- stgcccaag tggctgcgct tcatccgagg tgtggtggac agtgaggaca ttcccctgaa 1200
- tcagccgg gagctgctgc aggagagcgc actcatcagg aaactccggg acgttttaca 1260
- agaggctg atcaaattct tcattgacca gagtaaaaaa gatgctgaga agtatgcaaa 1320
- tttttgaa gattacggcc tgttcatgcg ggagggcatt gtgaccgcca ccgagcagga

eolf-seql-S000001.txt

1380

jtCaaggag gacatagcaa agctgctgcg ctacgagtcc tcggcgctgc cctccgggca 1440

taaccage eteteagaat aegeeageeg eatgegggee ggeaccegea acatetaeta 1500

tgtgcgcc cccaaccgtc acctggcaga gcactcaccc tactatgagg ccatgaagaa 1560

laagacaca gaggttetet tetgetttga geagtttgat gageteacee tgetgeacet 1620

gtgagttt gacaagaaga agctgatctc tgtggagacg gacatagtcg tggatcacta 1680

laggaggag aagtttgagg acaggtcccc agccgccgag tgcctatcag agaaggagac 1740

jaggagete atggeetgga tgagaaatgt getggggteg egtgteacea aegtgaaggt 1800

iccctccga ctggacaccc accctgccat ggtcaccgtg ctggagatgg gggctgcccg
1860

acttectg egeatgeage agetggeeaa gaeceaggag gagegegeae ageteetgea 1920

ccacgctg gagatcaacc ccaggcacgc gctcatcaag aagctgaatc agctgcgcgc 1980

igcgagect ggcctggctc agctgctggt ggatcagata tacgagaacg ccatgattgc 2040

sctggactt gttgacgacc ctagggccat ggtgggccgc ttgaatgagc tgcttgtcaa 2100

|ccctggag cgacactgac agccaggggg ccagaaggac tgacaccaca gatgacagcc 2160

acctcctt gagctttatt tacctaaatt taaaggtatt tcttaacccg aaaaaaaaa 2220

.aaa 2225

10> 46

11> 1501

12> DNA

13> Homo sapiens

00> 46

agaggaca cgaccaagat ggcggcggtg tctggcttgg tgcggagacc ccttcgggag

### eolf-seql-S000001.txt

60

1140

tctccgggc tgctgaagag gcgctttcac tggaccgcgc cggctgcgct gcaggtgaca ttcgtgatg ctataaatca gggtatggat gaggagctgg aaagagatga gaaggtattt 180 Egettggag aagaagttge ceagtatgat ggggeataea aggttagteg agggetgtgg 240 agaaatatg gagacaagag gattattgac actcccatat cagagatggg ctttgctgga itgctgtag gtgcagctat ggctgggttg cggcccattt gtgaatttat gaccttcaat 360 ictccatgc aagccattga ccaggttata aactcagctg ccaagaccta ctacatgtct jtggccttc agcctgtgcc tatagtcttc aggggaccca atggtgcctc agcaggtgta stgcccagc actcacagtg ctttgctgcc tggtatgggc actgcccagg cttaaaggtg 540 :cagtccct ggaattcaga ggatgctaaa ggacttatta aatcagccat tcgggataac 600 atccagtgg tggtgctaga gaatgaattg atgtatgggg ttccttttga atttctcccg 660 lagctcagt caaaagattt tctgattcct attggaaaag ccaaaataga aaggcaagga acatataa ctgtggtttc ccattcaaga cctgtgggcc actgcttaga agctgcagca 780 :gctatcta aagaaggagt tgaatgtgag gtgataaata tgcgtaccat tagaccaatg 840 ıcatggaaa ccatagaagc cagtgtcatg aagacaaatc atcttgtaac tgtggaagga sctggccac agtttggagt aggagctgaa atctgtgcca ggatcatgga aggtcctgcg 960 :caatttcc tggatgctcc tgctgttcgt gtcactggtg ctgatgtccc tatgccttat 1020 :aaagattc tagaggacaa ctctatacct caggtcaaag acatcatatt tgcaataaag 1080 aacattaa atatttagtt tggacttgaa tatcaagtcg ttgaaattta tttgaaatac

### eolf-seql-S000001.txt

gctggcac tgcacctgga tttgtactgc aagacctgac tattcataaa ggaaaacgat 1200

ctaaagca acagcaggta tttttgtaca gggaagttta aatgtgtttg tgtatggaaa 1260

statecact etectecect agatgecatg etteettttg tetgttaegg ttgecatgtt 1320

Ittgaataa caaattatat cacattttat cctctctcac cacaaggaca aagtatggat 1380

Iggcagagt cctgatgaaa gatgtatcca aacaagataa cttatatgta taaaattaaa 1440

atataata cacatttact gttagtttgt tttgataagg aataaaggaa tttctaacat 1500

1501

210> 47

?11> 699

!12> DNA

:13> Homo sapiens

100> 47

itccggtgt ggtcgacggg tcctccaaga gtttggggcg cggaccggag taccttgcgt
60

:agttatgt cggcgtcggt agtgtctgtc atttcgcggt tcttagaaga gtacttgagc 120

cacteege agegtetgaa gttgetggae gegtaeetge tgtatataet getgaeeggg 180

:gctgcagt tcggttactg tctcctcgtg gggaccttcc ccttcaactc ttttctctcg
240

cttcatct cttgtgtggg gagtttcatc ctagcggttt gcctgagaat acagatcaac 300

acagaaca aageggattt ecaaggeate teeceagage gageetttge tgattttete 360

tgccagca ccatcctgca ccttgttgtc atgaactttg ttggctgaat cattctcatt 420

cttaattg aggagtagga gactaaaaga atgttcactc tttgaatttc ctggataaga 480

tctggaga tggcagctta ttggacacat ggattttctt cagatttgac acttactgct 540

### eolf-seql-S000001.txt

gctctgctt tttatgacag gagaaaagcc cagagttcac tgtgtgtcag aacaactttc
600

aacaaacat ttattaatcc agcctctgcc tttcattaaa tgtaaccttt tgctttccaa
660

ttaaagaac tccatgccac tcctcaaaaa aaaaaaaaa 699

210> 48

211> 829

212> DNA

213> Homo sapiens

400> 48

Jgggagtga aagcgaaagc ccgggcgact agccgggaga ccagagatct agcgactgaa 60

cagcatggc caagccgtgt ggggtgcgcc tgagcgggga agcccgcaaa caggtggagg 120

ettcagaca gaatetttte caggaggetg aggaatteet etacagatte ttgccacaga 180

setcegggc cecactggac atccccatec cagaccetec acceaaggat gatgagatgg
300

lacagataa gcaggagaag aaagaagtcc ataagtgtgg atttctccct gggaatgaga 360

igtcctgtc cctgcttgcc ctggttaagc cagaagtctg gactctcaaa gagaaatgca 420

ctggtgat tacatggatc caacacctga tccccaagat tgaagatgga aatgattttg 480

gtagcaat ccaggagaag gtgctggaga gggtgaatgc cgtcaagacc aaagtggaag 540

:ttccagac aaccatttcc aagtacttct cagaacgtgg ggatgctgtg gccaaggcct 600

:aaggagac tcatgtaatg gattaccggg ccttggtgca tgagcgagat gaggcagcct 660

ggggagct cagggccatg gtgctggacc tgagggcctt ctatgctgag ctttatcata 720

atcagcag caacctggag aaaattgtca acccaaaggg tgaagaaaag ccatctatgt 780

### eolf-seql-S000001.txt

tgaacccg ggactagaag gaaaataaat gatctatatg ttgtgtgga 829

- ?10> 49
- 211> 965
- 212> DNA
- ?13> Homo sapiens
- 100> 49
- igcttgtcc tctatgactt acccagaagg caacgcttct ctttctggtc aaaatggctg
  60
- :aagcaggc cgtttcagca tcaggcaagt ggctggatgg tattcgaaaa tggtattaca 120
- :gctgcagg attcaataaa ctggggttaa tgcgagatga tacaatatac gaggatgaag 180
- gtaaaaga agccataaga agacttcctg agaaccttta taatgacagg atgtttcgca 240
- :aagagggc actggacctg aacttgaagc atcagatctt gcctaaagag cagtggacca 300
- tatgaaga ggaaaatttc taccttgaac cgtatctgaa agaggttatt cgggaaagaa 360
- $_{
  m igaaagaga}$  agaatgggca aagaagtaat catgtagttg aagtctgtgg atgcagctgt  $_{
  m 420}$
- tgaagatg gttaaacttg aaacaaacaa ttttaagaat tatttggtct gaagatgttt 480
- ctttaaat aaatgtctat tgtaatggct ggagtttttg aattccaaac cttatactga 540
- aactactg aatcccttta ctgttaaatt tttttccaaa ctttcaagat atatttagtt 600
- gtttaact gctacttgga gctcagaagc cactttatca gttttcctca ctggttggat 660
- cctatcag tttatggaag gatataactt ccgtaagtta catccttatg gaagctactg 720
- taaaagaa gggggtatgc accccctagt ttgccaagat tgagaaatag cctcttcact 780
- tatgcaaa cagatttgat tttgcatcct atcatttaaa aagaaattat gtctgcaccc 840
- acataggc atacttaagt aatatacata ctcctgtgct aacatgtata ctagaaaaca 900

### eolf-seql-S000001.txt

3aaa 965

210> 50

211> 653

212> DNA

213> Homo sapiens

100> 50

Jgacgaggg cgcgtgggtg aggaaggtca ggtctaggaa ctctaactcc ttgccactca 60

jaaatgtcc tccctttcag aatatgcctt ccgcatgtct cgtctcagtg cccggctatt
120

jgtgaagtc accaggccta ctaattccaa gtctatgaaa gtggtgaaac tgtttagtga 180

tgcccttg gccaagaaga aggagactta tgattggtat ccaaatcacc acacttacgc 240

jaactcatg cagacgctcc gatttcttgg actctacaga gatgagcatc aggattttat
300

jatgagcaa aaacgactaa agaagcttcg tggaaaggag aaaccaaaga aaggagaagg 360

laaagagca gcaaaaagga aatagtgttg gtccctcaag agggagactt tcttcctcag

gcggagag aagaaagtgc atttattgtc tttccacata ttggaggaat gtcatcttcc 480

laatgaagt ttatttggag gaacacagtc atctccttgg tgaaatctaa tccggttaca 540

gtggctgg tttcttgaac acattctaac tgtgcaaaat tatcttggcc ttggccgtgt 600

itgtgaggt ttacctgatt ctctaatgaa ataaatacct aagttattgt ttg
653

10> 51

11> 1610

12> DNA

13> Homo sapiens

00> 51

gcgccagt cgcctagcag gtcctctacc ggcttattcc tgtgccggat cttcatcggc

## eolf-seql-S000001.txt

60

Paggggcca ctgagacgtt tctgcctccc tctttcttcc tccgctcttt ctcttccctc 120

contract type type of the contract of the cont

:tctgccca tcacaagtgc cactaccgcc atgggcctca ctatctcctc cctcttctcc
240

Jactatttg gcaagaagca gatgcgcatt ttgatggttg gattggatgc tgctggcaag 300

saaccattc tgtataaact gaagttaggg gagatagtca ccaccattcc taccattggt
360

taatgtgg aaacagtaga atataagaac atttgtttca cagtatggga tgttggtggt 420

lagatagaa ttaggcctct ctggaagcat tacttccaga atacccaggg tcttattttt 480

ggtagata gcaacgatcg tgaaagaatt caggaagtag cagatgagct gcagaaaatg 540

:tctggtag atgaattgag agatgcagtg ctgctacttt ttgcaaacaa acaggatttg 600

:aaatgcta tggccatcag tgaaatgaca gataaactag ggcttcagtc tcttcgtaac
660

jaacatggt atgttcaagc cacttgtgca acacaaggaa ctggtctgta tgaaggactt
720

ictggctgt caaatgagct ttcaaaacgt taaatgaaat tggatatcta accaaggaca
780

stttgataa aattggtcta ggcttgttac aacaaaatta gtttgtatct tggttattaa 840

:agtatctg ggactggttt gggcagaata ttaaacttat tttgttgcca attattgttt 900

cgagtata atgttgctat ttagcaatgt gcttggtttt aaagaaattc tccttgggaa 960

aagtatcc tettttaatt ttaetteeca taagegtaaa tgeetggaea tagetettgt 1020

acctttaa ataaattgtt tgagtgtttt tgagccccag acaaataatg ttttaaagtt 1080

cccttgct actttactga tacctttatc attcctgaga cagtttgcta atttaaaaat 1140

# eolf-seql-S000001.txt

tagcattcc attigtattt attictctcc cttgccaaaa agattttcta atactgcttg 1200

- accagccag agaaagatcc aaaacactac tcagctctct tgcactgagg aaatttttcc 1260
- cctacattg actcctggcc tacatcagcc aaacttaacc ttggtggggt ttggatttga 1320
- agccaatta gttctgtgct ggttgcaaag aattgatatt tagatggttt ttaatactca 1380
- cagattgtc ttcccatatt gtgtcttttt tatgttgcat gttgcttttg ttatcagcct 1440
- attttttgc tcagtatatg atagttctgc tgatgttttg tttattgggc agacatatct 1500
- cattaagag tttttggaaa actcatcaaa ttcgatgaat acattttctt cataacccat 1560
- ggaattat tootaataaa atgataaaat acgtaaaaaa aaaggaatto 1610
- 210> 52
- 211> 4221
- 212> DNA
- 213> Homo sapiens
- 100> 52
- 19cggcagt ggagttcgct gcgcgctgtt gggggccacc tgtcttttcg cttgtgtccc 60
- otttetagt gtegegeteg agteeegaeg ggeegeteea ageetegaea tgtegtaeaa 120
- :acgtggta acggcccaga agcccaccgc cgtgaacggc tgcgtgaccg gacactttac 180
- :cggccgaa gacttaaacc tgttgattgc caaaaacacg agattagaga tctatgtggt 240
- lccgccgag gggcttcggc ccgtcaaaga ggtgggcatg tatgggaaga ttgcggtcat
  300
- gagcttttc aggcccaagg gggagagcaa ggacctgctg tttatcttga cagcgaagta
  360
- $\begin{array}{c} \text{latgcctgc atcctggagt ataaacagag tggcgagagc attgacatca ttacgcgagc} \\ 420 \end{array}$
- :atggcaat gtccaggacc gcattggccg cccctcagag accggcatta ttggcatcat 480

# eolf-seql-S000001.txt

- Jaccetgag tgccggatga ttggcctgcg tetetatgat ggccttttca aggttattcc 540
- ctagatege gataataaag aacteaagge etteaacate egeetggagg agetgeatgt 600
- attgatgtc aagttcctat atggttgcca agcacctact atttgctttg tctaccagga 660
- octcagggg cggcacgtaa aaacctatga ggtgtctctc cgagaaaagg aattcaataa 720
- Jgcccttgg aaacaggaaa atgtcgaagc tgaagcttcc atggtgatcg cagtcccaga 780
- Scotttggg ggggccatca tcattggaca ggagtcaatc acctatcaca atggtgacaa 840
- :acctggct attgcccctc ctatcatcaa gcaaagcacg attgtgtgcc acaatcgagt
  900
- jaccctaat ggctcaagat acctgctggg agacatggaa ggccggctct tcatgctgct
  960
- tggagaag gaggaacaga tggatggcac cgtcactctc aaggatctcc gtgtagaact 1020
- ttggagag acctctattg ctgagtgctt gacatacctt gataatggtg ttgtgtttgt 1080
- $_{\mathrm{J}}$ ggtctcgc ctgggtgact cccagcttgt gaagctcaac gttgacagta atgaacaagg  $_{\mathrm{1140}}$
- cctatgta gtggccatgg aaacctttac caacttagga cccattgtcg atatgtgcgt 1200
- stggacctg gagaggcagg ggcaggggca gctggtcact tgctctgggg ctttcaagga 1260
- gttctttg cggatcatcc ggaatggaat tggaatccac gagcatgcca gcattgactt 1320
- :caggcatc aaaggattat ggccactgcg gtctgaccct aatcgtgaga cttatgacac 1380
- tggtgctc tcttttgtgg gccagacaag agttctcatg ttaaatggag aggaggtaga 1440
- aaaccgaa ctgatgggtt tcgtggatga tcagcagact ttcttctgtg gcaacgtggc 1500
- atcagcag cttatccaga tcacttcagc atcggtgagg ttggtctctc aagaacccaa 1560

eolf-seql-S000001.txt jctctggtc agtgaatgga aggagcctca ggccaagaac atcagtgtgg cctcctgcaa 1620 agcagccag gtggtggtgg ctgtaggcag ggccctctac tatctgcaga tccatcctca 1680 jagctccgg cagatcagcc acacagagat ggaacatgaa gtggcttgct tggacatcac 1740 ccattagga gacagcaatg gactgtcccc tctttgtgcc attggcctct ggacggacat 1800 loggotogt atottgaagt tgccctcttt tgaactactg cacaaggaga tgctgggtgg 1860 jagatcatt cctcgctcca tcctgatgac cacctttgag agtagccatt acctcctttg 1920 jccttggga gatggagcgc ttttctactt tgggctcaac attgagacag gtctgttgag 1980 Jaccgtaag aaggtgactt tgggcaccca gcccaccgta ttgaggactt ttcgttctct 2040 ctaccacc aacgtetttg ettgttetga eegeeccact gteatetata geageaacea 2100 laattggtc ttctcaaatg tcaacctcaa ggaagtgaac tacatgtgtc ccctcaattc 2160 jatggctat cctgacagcc tggcgctggc caacaatagc accctcacca ttggcaccat 2220 satgagate cagaagetge acattegeae agtteeecte tatgagtete caaggaagat 2280 :gctaccag gaagtgtccc agtgtttcgg ggtcctctcc agccgcattg aagtccaaga 2340 egagtggg ggcacgacag cettgaggee cagegetage acceaggete tgtecageag taagetee ageaagetgt tetecageag caetgeteet catgagacet cetttggaga 2460 aggtggag gtgcataacc tacttatcat tgaccaacac acctttgaag tgcttcatgc 2520 accagttt ctgcagaatg aatatgccct cagtctggtt tcctgcaagc tgggcaaaga 2580 ccaacact tacttcattg tgggcacagc aatggtgtat cctgaagagg cagagcccaa 2640 agggtcgc attgtggtct ttcagtattc ggatggaaaa ctacagactg tggctgaaaa

Page 121

### eolf-seql-S000001.txt

2700

3720

3780

Jaagtgaaa ggggccgtgt actctatggt ggaatttaac gggaagctgt tagccagcat latagcacg gtgcggctct atgagtggac aacagagaag gacgtgcgca ctgagtgcaa 2820 lactacaac aacatcatgg coctctacct gaagaccaag ggcgacttca toctggtggg 2880 jaccttatg cgctcagtgc tgctgcttgc ctacaagccc atggaaggaa actttgaaga 2940 ittgctcga gactttaatc ccaactggat gagtgctgtg gaaatcttgg atgatgacaa 3000 :ttctgggg gctgaaaatg cctttaactt gtttgtgtgt caaaaggata gcgctgccac ictgacgag gagcggcagc acctccagga ggttggtctt ttccacctgg gcgagtttgt .3120 latgicitt igccacggci ciciggiaat gcagaatcig ggigagacii ccaccccac 3180 :aaggeteg gtgetetteg geaeggteaa eggeatgata gggetggtga ceteaetgte 3240 jagagetgg tacaacetee tgetggacat geagaatega eteaataaag teateaaaag 3300 stggggaag atcgagcact ccttctggag atcctttcac accgagcgga agacagaacc 3360 sccacaggt ttcatcgacg gtgacttgat tgagagtttc ctggatatta gccgcccaa 3420 tgcaggag gtggtggcaa acctacagta tgacgatggc agcggtatga agcgagaggc 3480 ctgcagac gacctcatca aggttgtgga ggagctaact cggatccatt agccaagggc ggggcccc tttgctgacc ctccccaaag gctttgccct gctgccctcc ccctcctctc 3600 ccatcgtc ttcttggcca tgggaggcct ttccctaagc cagctgcccc cagagccaca 3660 tcccctat gtggaagtgg ggcgggcttc atagagactt gggaatgagc tgaaggtgaa

Page 122

attitctc cctggatttt taccagtctc acatgattcc agccatcacc ttagaccacc

### eolf-seql-S000001.txt

igccttgat tggtgttgcc agttgtcctc cttccgggga aggattttgc agttctttgg 3840

Igaaaggaa gctgtgcgtg tgtgtgtgtg tatgtgtgtg tgtgtatgtg tatctcacac 3900

catgcattg teetetttt atttagattg geagtgtagg gagttgtggg tagtggggaa 3960

1999ttagg agggtttcat tgtctgtgaa gtgagacctt ccttttactt ttcttctatt 4020

ctctgaga gcatcaggcc tagaggcctg actgccaagc catgggtagc ctgggtgtaa 4080

icctggaga tggtggatga tccccacgcc acagcccttt tgtctctgca aactgccttc 4140

cggaaaga agaaggtggg aggatgtgaa ttgttagttt ctgagtttta ccaaataaag 4200

igaatataa gaagaaaaaa a 4221

10> 53

:11> 1470

112> DNA

!13> Homo sapiens

100> 53

lagccgcca gcgaggctgg ggatggggc gccgctgctc tctcccggct ggggagccgg
60

ictgccggc cggcgctggt ggatgctgct ggcgcccctg ctgccggcgc tgctgctggt
120

:ggcccgcg ggggccctgg tggagggct ctactgcggc acgcgggact gctacgaggt 180

tgggcgtg agccgctcgg cgggcaaggc ggagatcgcg cgggcctacc gccagctggc 240

ggcgctac caccetgace getaceggee ecagecegga gaegagggee eegggeggae 300

cgcagagc gccgaggagg ctttcctgct ggtggcaacc gcctacgaga cactcaaggt 360

ctcaggca gctgcagagc ttcaacagta ctgtatgcag aatgcctgca aggatgcct 420

tggtgggt gttccagctg gaagtaaccc cttccgggag cctagatcct gtgctttact 480

# eolf-seql-S000001.txt

- ottcaagtc tcaagaaaac acttttccct aacttttaga gatatttcag ccctttcctg
- Jgcctggtc ctatagccaa aatcacagat attcatgagt ttctacttga gtgagaaaac 660
- Jggtgaagg aatagaattt taaatagtaa taactgcttg ttttttttgt gcaagtactt 720
- latacataa gataaacaaa aaccttacca ccaaacatac caaaatgcac ctctttcata 780
- jtgagttac taagatttct atacctggaa tatcatgtat gtttcattta ctggatgttt 840
- lattttagg aaggaaaata gttttgttta tttaaacaac tgaatactta taaactgttg
  900
- :cctggaag ttatttattc cataaaaaat ttgttctttt gtcatgaatt tataattcct 960
- latgaagac cagaaagtac aaattgctgg gaggaagaat aggctttatt aatcaactga 1020
- ;tcttgatt tttctaaatg ggaagattgc tttattttta acactaatta tgggagcaga 1080
- cttagcaa acttctttgg aaaagttaat gttatgatgt gcattaggct gccccatcgt 1140
- atataaat gaagcagatt tgatttttgt attcttacgt ttctctgctt tgtagttgtg 1200
- tgtactta aagaaataca gaatttcata tatttaaaaa tgtttaaaat gtgacccaca 1260
- acattgta aatgattaaa aactaacatg aaaatattac aacctaaaag aattcttaac 1320
- cacaagtg ttttacttcg acgatgtgcc tttgatttaa tttgggacac ttttttagaa 1380
- atacatta ttcgtgtttg caacggtctt tgaagagctt ggaaataaaa tttctgctta 1440
- taatcaaa aaaaaaaaa aaaaaaaaaa 1470
- 10> 54 11> 3321

eolf-seql-S000001.txt

- 212> DNA
- 213> Homo sapiens
- 400> 54
- igtgagtct ataactcgga gccgttgggt cggttcctgc tattccggcg cctccactcc
  60
- :cccccgcg ggtctgctct gtgtgccatg gacggcattg tcccagatat agccgttggt
  120
- paaagcggg gatctgacga gcttttctct acttgtgtca ctaacggacc gtttatcatg
  180
- Jcagcaact cggcttctgc agcaaacgga aatgacagca agaagttcaa aggtgacagc 240
- jaagtgcag gcgtcccctc tagagtgatc cacatccgga agctccccat cgacgtcacg
  300
- igggggaag tcatctcct ggggctgccc tttgggaagg tcaccaacct cctgatgctg
  360
- 1ggggaaaa accaggcctt catcgagatg aacacggagg aggctgccaa caccatggtg 420
- lctactaca cctcggtgac ccctgtgctg cgcggccagc ccatctacat ccagttctcc
  480
- iccacaagg agctgaagac cgacagctct cccaaccagg cgcgggccca ggcggccctg  $540\,$
- iggcggtga actcggtcca gtcggggaac ctggccttgg ctgcctcggc ggcggccgtg 600
- lcgcaggga tggcgatggc cgggcagagc cccgtgctca ggatcatcgt ggagaacctc
  660
- ctaccetg tgaccetgga tgtgetgeac cagattttet ccaagttegg cacagtgttg 720
- igatcatca cottoaccaa gaacaaccag ttocaggooc tgotgoagta tgoggaccoc 780
- gagegeee ageaegeeaa getgtegetg gaegggeaga acatetaeaa egeetgetge 840
- gctgcgca tcgacttttc caagctcacc agcctcaacg tcaagtacaa caatgacaag 900
- ccgtgact acacacgccc agacctgcct tccggggaca gccagccctc gctggaccag 960
- catggccg cggccttcgg tgcacctggt ataatctcag cctctccgta tgcaggagct 1020

eolf-seql-S000001.txt gtttccctc ccacctttgc cattcctcaa gctgcaggcc tttccgttcc gaacgtccac 1080 jegecetgg ceceetgge cateceeteg geggeggegg cagetgegge ggeaggtegg 1140 regecatee egggeetgge gggggeagga aattetgtat tgetggteag caaceteaae 1200 cagagagag teacaceeca aageetettt attettteg gegtetaegg tgaegtgeag 1260 jcgtgaaga tcctgttcaa taagaaggag aacgccctag tgcagatggc ggacggcaac 1320 aggeceage tggceatgag ceacetgaae gggeaeaage tgeaegggaa geceateege 1380 cacgetet egaageacea gaaegtgeag etgeeeegeg agggeeagga ggaeeaggge 1440 igaccaagg actacggcaa ctcacccctg caccgcttca agaagccggg ctccaagaac iccagaaca tattcccgcc ctcggccacg ctgcacctct ccaacatccc gccctcagtc 1560 cgaggagg atctcaaggt cctgttttcc agcaatgggg gcgtcgtcaa aggattcaag 1620 cttccaga aggaccgcaa gatggcactg atccagatgg gctccgtgga ggaggcggtc 1680 iggocotca ttgacotgoa caaccacgao ctoggggaga accaccacot gogggtotoo 1740 :ctccaagt ccaccatcta ggggcacagg ccccacggc cgggccccct ggcgacaact. 1800 :catcattc cagagaaaag ccactttaaa aacagctgaa gtgaccttag cagaccagag tttatttt tttaaagaga aatcagttta cctgttttta aaaaaattaa atctagttca. 1920 :ttgctcac cctgcggtga cagggacagc tcaggctctt ggtgactgtg gcagcgggag 1980 cccggccc tccacacccg gggccagacc ctcggggcca tgccttggtg gggcctgtgt 2040 ggcgtggg gcctgcaggt gggcgccccg accacgactt ggcttccttg tqccttaaaa 2100 cetgeett eetgeageea caeacceace eggggtgtee tggggaeeca aggggtggg

## eolf-seql-S000001.txt

2160

3240

jgtcacacc agagagaggc agggggcctg gccggctcct gcaggatcat gcagctgggg jcggcggcc gcggctgcga caccccaacc ccagccctct aatcaagtca cgtgattctc ottcacccc gcccccaggg ccttcccttc tgcccccagg cgggctcccc gctgctccag 2340 geggaget ggtegaeata atetetgtat tatataettt geagttgeag aegtetgtge 2400 lagcaatat ttccagttga ccaaatattc taatcttttt tcatttatat gcaaaagaaa 2460 agttttaag taacttttta tagcaagatg atacaatggt atgagtgtaa tctaaacttc . 25.80 iggacccag tttccagaga gcaggcgggg ccgcccagtg ggtcaggcac agggagccc 2640 stcctatct tagagcccct gagcttcagg gaaggggcgg gcgtgtcgcc gcctctggca gcctccgg ttgccttaca ccacgccttc acctgcagtc gcctagaaaa cttgctctca 2760 icttcaggg ttttttcttc cttcaaattt tggaccaaag tctcatttct gtgttttgcc 2820 sectotgat getgggacce ggaaggeggg egeteeteet gtettetetg tgetettet 2880 :egececeg egteetgtee egggggetet cetaggatee eettteegta aaagegtgta 2940 :aagggtgt aaatatttat aattttttat acctgttgtg agacccgagg ggcggcggcg gtttttta tggtgacaca aatgtatatt ttgctaacag caattccagg ctcagtattg 3060 accgcgga gccacagggg accccacgca cattccgttg ccttacccga tggcttgtga 3120 cggagaga accgattaaa accgtttgag aaactcctcc cttgtctagc cctgtgttcg 3180 gtggacgc tgtagaggca ggttggccag tctgtacctg gacttcgaat aaatcttctg

Page 127

### eolf-seq1-S000001.txt

aaaaaaaaa aaaaaaaaa a 3321

- 210> 55
- 211> 2181
- 212> DNA
- ?13> Homo sapiens
- 100> 55
- eggcagetg etgaceegee ategecatgg eeegegggaa agecaaggag gagggeaget 120
- jaagaaatt catctggaac tcagagaaga aggagtttct gggcaggacc ggtggcagtt
  180
- jtttaagat ccttctattc tacgtaatat tttatggctg cctggctggc atcttcatcg
  240
- laccatcca agtgatgctg ctcaccatca gtgaatttaa gcccacatat caggaccgag
  300
- /gccccgcc aggattaaca cagattcctc agatccagaa gactgaaatt tcctttcgtc 360
- aatgatcc caagagctat gaggcatatg tactgaacat agttaggttc ctggaaaagt 420
- :aaagattc agcccagagg gatgacatga tttttgaaga ttgtggcgat gtgcccagtg 480
- .ccgaaaga acgaggagac tttaatcatg aacgaggaga gcgaaaggtc tgcagattca 540
- cttgaatg gctgggaaat tgctctggat taaatgatga aacttatggc tacaaagagg 600
- aaaccgtg cattattata aagctcaacc gagttctagg cttcaaacct aagcctccca 660
- aatgagtc cttggagact tacccagtga tgaagtataa cccaaatgtc cttcccgttc 720
- tgcactgg caagcgagat gaagataagg ataaagttgg aaatgtggag tattttggac 780
- ggcaactc ccctggtttt cctctgcagt attatccgta ctatggcaaa ctcctgcagc 840

### eolf-seql-S000001.txt

paratacct gragerectg etggergtae agtteaceaa tettaccatg garactgaaa 900

:cgcataga gtgtaaggcg tacggtgaga acattgggta cagtgagaaa gaccgttttc 960 .

ggacgttt tgatgtaaaa attgaagtta agagctgatc acaagcacaa atctttccca 1020

agccattt aataagttaa aaaaagatac aaaaacaaaa acctactagt cttgaacaaa 1080

gtcatacg tatgggacct acacttaatc tatatgcttt acactagctt tctgcattta 1140

aggttaga atgtaaatta aagtgtagca atagcaacaa aatatttatt ctactgtaaa 1200

¡acaaaaga aaaagaaaaa ttgagccttg ggacgtgccc atttttactg taaattatga
1260

ccgtaact gacttgtagt aagcagtgtt tctggcccct aagtattgct gccttgtgta 1320

ttatttag tgtacagtac tacaggtgca tactctggtc atttttcaag ccatgtttta 1380

gtatctgt tttctacttt atgtgagcaa ggtttgctgt ccaaggtgta aatattcaac 1440

gaataaaa ctggcatggt aattttttt ttttttttt ttttgttttt tggctctttc 1500

aggtaatg gcccatcgat gagcattttt aacatactcc atagtctttt cctgtggtgt 1560

ggtcttta tttttatttt tttcctgggg gctggggtgg gggtttgtca tgggggaact 1620

cctttaaa ttttaagtga cactacagaa aaacacaaaa aggtgatggg ttgtgttatg 1680

tgtattga atgctgtctt gacatctctt gccttgtcct ccggtatgtt ctaaagctgt 1740

ctgagatc tggatctgcc catcactttg gctagtgaca gggctaatta atttgcttta 1800

cattltct tttactttcc tttttcctt tctggaggca tcacatgctg gtgctgtgtc 1860

tatgaatg ttttaaccat tttcatggtg gaagaatttt atatttatgc agttgtacaa 1920

eolf-seql-S000001.txt

- Ittattttt ttctgcaaga aaaagtgtaa tgtatgaaat aaaccaaagt cacttgtttg 1980
- laataaatc tttattttga actttataaa aagcaatgca gtaccccata gactggtgtt 2040
- latgttgtc tacagtgcaa aatccatgtt ctaacatatg taataattgc caggagtaca 2100
- gctcttgt tgatcttgta ttcagtcagg ttaaaacaac ggacaataaa agaatgaaca 2160
- laaaaaaaa aaaaaaaaa a 2181
- 210> 56
- 211> 1330
- ?12> DNA
- ?13> Homo sapiens
- 100> 56
- :aacctttc caagggagtg gttgtgtgat cgccatctta gggaaaagat gttctcgtcc 60
- :ggcgcacc tggcgcggc gaaccccttc aacacgccac atctgcagct ggtgcacgat 120
- stategggg accteegeag cageteecea gggeeeaegg geeageeeeg eegeeetege 180
- icctggcag ccgccgccgt ggaagagtac agttgtgaat ttggctccgc gaagtattat 240
- :actgtgtg gctttggtgg ggtcttaagt tgtggtctga cacacactgc tgtggttccc
  300
- ggatttag tgaaatgccg tatgcaggtg gacccccaaa agtacaaggg catatttaac 360
- [attctcag ttacacttaa agaggatggt gttcgtggtt tggctaaagg atgggctccg
  420
- tttccttg gctactccat gcagggactc tgcaagtttg gcttttatga agtctttaaa 480
- cttgtata gcaatatgct tggagaggag aatacttatc tctggcgcac atcactatat 540
- ggctgcct ctgccagtgc tgaattcttt gctgacattg ccctggctcc tatggaagct 600
- taaggttc gaattcaaac ccagccaggt tatgccaaca ctttgaggga tgcagctccc 660

eolf-seq1-S000001.txt

- iaatgtata aggaagaagg cctaaaagca ttctacaagg gggttgctcc tctctggatg
  720
- jacagatac catacaccat gatgaagttc gcctgctttg aacgtactgt tgaagcactg
  780
- 1Caagtttg tggttcctaa gccccgcagt gaatgttcaa agccagagca gctggttgta 840
- :atttgtag caggttacat agctggagtc ttttgtgcaa ttgtttctca ccctgctgat 900
- stgtggtat ctgtgttgaa taaagaaaaa ggtagcagtg cttctctggt cctcaagaga 960
- tggattta aaggtgtatg gaagggactg tttgcccgta tcatcatgat tggtaccctg
- tgcactac agtggtttat ctatgactcc gtgaaggtct acttcagact tcctcgccct 1080
- cccacctg agatgccaga gtctctgaag aaaaagcttg ggttaactca gtagttagat 1140
- aagcaaat gtggactgaa tctgcttgtt gatcagtgtt tgaagaaagt gcaaaaggaa 1200
- tttatata tttgacagtg taggaaattg tctattcctg atataattac tgtagtactc 1260
- gcttaagg caagagtttc agatttactg ttgaaataaa cccaactgtt catgaaaaaa 1320

aaaaaaaa 1330

- 10> 57
- 11> 3214
- 12> DNA
- 13> Homo sapiens
- 00> 57
- gtgggagg agccagcggc cggggaggtt ctagtctgtt ctgtcttgcg gcagccgccc 60
- ttctgcgc ggtcacgccg agccagcgcc tgggcctgga accgggccgt agcccccca 120
- ttcgccca ccacctccct accatggacc cccgcaaagt gaacgagctt cgggcctttg 180
- aaaatgtg taagcaggat ccgagcgttc tgcacaccga ggaaatgcgc ttcctgaggg 240

eolf-seql-S000001.txt

jtgggtgga gagcatgggt ggtaaagtac cacctgctac tcagaaagct aaatcagaag 300

- laataccaa ggaagaaaaa cctgatagta agaaggtgga ggaagactta aaggcagacg 360
- iccatcaag tgaggaaagt gatctagaaa ttgataaaga aggtgtgatt gaaccagaca 420
- :gatgctcc tcaagaaatg ggagatgaaa atgcggagat aacggaggag atgatggatc
  480
- Jgcaaatga taaaaaagtg gctgctattg aagccctaaa tgatggtgaa ctccagaaag 540
- :attgactt attcacagat gccatcaagc tgaatcctcg cttggccatt ttgtatgcca
  600
- jagggccag tgtcttcgtc aaattacaga agccaaatgc tgccatccga gactgtgaca 660
- igccattga aataaatcct gattcagctc agccttacaa gtggcggggg aaagcacaca 720
- ecttctagg ccactgggaa gaagcagccc atgatcttgc ccttgcctgt aaattggatt 780
- gatgaaga tgctagtgca atgctgaaag aagttcaacc tagggcacag aaaattgcag 840
- ıcatcggag aaagtatgag cgaaaacgtg aagagcgaga gatcaaagaa agaatagaac 900
- ıgttaagaa ggctcgagaa gagcatgaga gagcccagag ggaggaagaa gccagacgac 960
- rtcaggage teagtatgge tetttteeag gtggetttee tgggggaatg eetggtaatt 1020
- cccggagg aatgcctgga atgggagggg gcatgcctgg aatggctgga atgcctggac 1080
- aatgaaat tettagtgat eeagaggtte ttgeageeat geaggateea gaagttatgg
- gctttcca ggatgtggct cagaacccag caaatatgtc aaaataccag agcaacccaa 1200
- gttatgaa teteateagt aaattgteag eeaaatttgg aggteaageg taatgteett 1260
- gataaata aagcccttgc tgaaggaaaa gcaacctaga tcaccttatg gatgtcgcaa 1320
- atacaaac cagtgtacct ctgaccttct catcaagaga gctggggtgc tttgaagata

### eolf-seql-S000001.txt

1380

- tocotacco ototococca aatgoagotg aagoatttta cagtggtttg coattagggt 1440
- ttcattcag ataatgtttt cctactagga attacaaact ttaaacactt tttaaatctt 1500
- aaaatattt aaaacaaatt taaagggcct gttaattctt atatttttct ttactaatca 1560
- :ttggattt ttttctttga attattggca gggaatatac ttatgtatgg aagattactg
  1620
- ctgagtga aataaaagtt attagtgcga ggcaaacata actcatttga ggataaagtt 1680
- jtgttggat atgtggttcc tgatgcattt tgacttgtct ttttaaatgc tttatctttt 1740
- otttaaaga tttatttaa taaaactaat tgggaccacc cgtatttcag taggacctgg 1800 . . .
- lagggattg gaagtacttg gcagggcagc agcaatcttg ctgtgtttga tataacatgc 1860
- ccttgggc aggttgccct taaatcttac actgtggtga agggatgttt tttttgtaat 1920
- stgcagtag agttggagta cttagttctc ttgttgtcca gtatatctaa taagtgtttt 1980
- catattatt tocacgtaag ggaaataagg tagtactttt ctttttatat ttctatgctt 2040
- laattotot ttootagtoa aaaattgooc aaatotgtgt ttgotttotg ottgotacat 2100
- gtctccct tactttctt gagctaaaga caggcttttt ccaccggcat catcactgct 2160
- catcatta acagcgtaat tatacaagca tatttaatgc tgagtttaat ttaatatgta 2220
- acatatgg taattgtagg gtaataccca caacaactgt agtttcttac ttggccaaga 2280
- latgcttat ttaagtgtta gacttccatt ctggcaaaat cttgccttat cagaagacat 2340
- gaaagagg gattcccttt ggtgtttggt cttctactta gaaaaaccta ttgcagttag 2400
- tatcttgt agtattcatc tttgtattct gaagataagg tttgaattaa attgatacac 2460

### eolf-seql-S000001.txt

cagagggga accgattttt tttatccaat gtgaattata aatgagataa tccacagtta 2520

tcattgtgg agttgttgag actatgaaag actcattgtc tttgtattca gctcttaaat 2580

gtgtaacta tatccccacc tctgcttgct ttctttccct cccctccaat gataaagaaa 2640

tgataaatt ttctgttgtg cattcaattc ttattttaaa taagactaag tataggcatt 2700

tacctgaca ttgctacgtt tctaccagtg tttcaattta aagtgctagt gtttaaaaac 2760

ttttcaagg gataaggcct tctgtacttt gcttatttga agaatcagtg gtaggagcag 2820

gaagtaaat totatggagt acatttotaa aataccacat ttotgaaatc ataaataagt 2880

tattcaggt tctaaccctt tgctgtacac aagcagacag aaatgcatct gttacataaa 2940

jagaaaaag ctattatgct gatggagcat gctttttaaa tcctttaaaa acactcacca 3000

ataaacttg catttgagct tgtgtgttct tttgttaatg tgtagagttc tcctttctcg 3060

aattgccag tgtgtacttg gcttaactca agaacagttt cttctggatt ccttatttga 3120

tatttaac ctaattatat tctaatattg caaatattac cataagtggg taaaagtaaa 3180

tcctcttc tgaaaaaaaa aaaaaaaaaa aaaa 3214

210> 58

211> 2973

212> DNA

?13> Homo sapiens

220>

?21> misc\_feature

?22> (1275)..(1275)

223> n is a, c, g, t or u

20>

21> misc\_feature

!22> (2933)..(2933)

eolf-seql-S000001.txt

223> n is a, c, g, t or u

100> 58

- Jaggcaaat gttaatgagg caatgttaaa tatggaccca atgtcagaca aatacataga 60
- iggagtaag ggccaactct catgcataag gtatcccatc ctatagcaaa tcagatatat 120
- jgtacgctt gatgccacaa attttttaaa aaattgtcca ttttgttgcg tgtgcacctc
   180
- :gccataaa tttgagtcag caccagcgac agctctgcag tcctcctatg tggtactgat
  240
- iggtggttg cagagettea geteacagea acacaatgea getgageagg caageacage 300
- cacagocag aaacagttoo gactotacag aacaagacga cotttaagtt toocagagaa 360
- itgagatgc tgatgttgaa gacgacacca cgggtaagat gttatttaaa tcagtaaaag 420
- tgactttg gaatcttttt cctttttctt ttaagaaaaa gtcaacgtta ggattaaata 480
- ıtattcaat agcaagtgca tgcaccagaa atttgctgca gtgtcagttg agggatattt 540
- tatacatt cagtcactct gtaaatatac atattgtttt cctttaaaat gggcactgaa 600
- atacagaa aaaaatcact ttataaaatg tgaggtttat aggtactgtg ttggtctgga 660
- .tttcaagt gctttttaca aagatatatt tatcctaaaa acatacagat aaaaatttcg 720
- .gactgctt taatatctaa ataaaatcta ccctatatac acacattgaa ttacattacc 780
- cagagatt aaaaaaaaa gacacgacag ccatttttct catctgagta agaaagcata 840
- atcaaaaa tagtaatago ctacaactgo aactatttat ttgcaaagaa tgctatttta 900
- gagaaaat aaaggagaa atgcaggaga gagtagggag agagtctctc tctaccacat 1020
- cccaatga aggattaagc attgactata aatgaaggga gctttgttag tttaatcact

### eolf-seql-S000001.txt

1080

- jaacaatta taaaaggact cgacaacaac gaggtttatt gaaaattttg cctaatgcta
  1140
- stgacccat gcagatgcct aaactgtatt tgcatattaa aagaagggtg tatctgtttg
- :tctaggct ttgatggaat atcagatatt gaaaatgtct ctctgcctgt tcatccttct
  1260
- :ttctcaca cctgntattt tatgcatttg tcctctccaa tgtatatgca cagagaggca
  1320
- aggcatgtg gactgttcag gcagaaactt gtctacatta ccatctggac tgcaagagaa 1380
- attatacat ttaaacctgt cttataacca ctttactgat ctgcataacc agttaaccca 1440
- lataccaat ctgaggaccc tggacatttc aaacaacagg cttgaaagcc tgcctgctca .1500
- tacctcgg tctctgtgga acatgtctgc tgctaacaac aacattaaac ttcttgacaa 1560
- octgatact gcttatcagt ggaatcttaa atatctggat gtttctaaga acatgctgga 1620
- laggitgic cicattaaaa atacactaag aagictcgag gitcicaacc icagitagiaa 1680
- laactttgg acagttccaa ccaacatgcc ctccaaacta catatcgtgg acctgtctaa 1740
- lattetttg acacaaatte ttecaggtae attaataaae etgacaaate teacacatet 1800
- :acctgcac aacaataagt tcacattcat tccagaccaa tcttttgacc aactctttca 1860
- tgcaagag ataaccettt acaataacag gtggtcatgt gaccacaaac aaaacattac 1920
- acttactg aagtggatga tggaaacaaa agcccatgtg atagggactc catgttctac 1980
- :aaatatca totttaaagg aacataacat gtatoocaca cottotggat ttacotoaag 2040
- tattcact gtaagtggga tgcagacagt ggacaccatt aactctctga gtgtggtaac 2100
- aacccaaa gtgaccaaaa tacccaaaca atatcgaaca aaggaaacaa cgtttggtgc 2160

# eolf-seql-S000001.txt

ictctaagc aaagacacca cctttactag cactgataag gcttttgtgc cctatccaga 2220

jatacatcc acagagacta tcaattcaca tgaagcagca gctgcaactc taactattca
2280

stccaagat ggaatggtca caaacacaag cctcactagc tcaacaaaat catccccaac 2340

CCatgacc ctaagtatca ctagtggcat gccaaataat ttctctgaaa tgcctcaaca 2400

igcacaacc cttaacttat ggagggaaga gacaaccaca aatgtaaaga ctccattacc 2460

ctgtggca aatgcttgga aagtaaatgc ttcatttctc ttattgctca atgttgtggt 2520

itgctggct gtctgagggt ctgcattttc tgaaactaat gaaagcactc ctccctgatg 2580

ıcagttggg aaaatatgtc catatctaac cagtgattcg agctatattt aagtattcaa 2640

laagccagt cttaacattt ctaactctga tgtaaatgaa gtaacttgtc ttaaataaaa 2700

laatgcaca atgtcttggt acttgctgct attttactgt cttaattaag taaactaatg 2760

stttctttt ataaaaaaa tgaaatgttt taaggcttca atttattgca caaaatataa 2820

catctaaa ctttaatatg tattttatgt atgtttacac tgtcaaacat ctggaaaata 2880

aggtctat gctcataact gtgtcatttg gctttccagt cataccaact ttnagcagaa 2940

aaaatgac ctcaccattt ttgttctagg gat 2973

- 10> 59
- 11> 872
- 12> DNA
- 13> Homo sapiens
- 00> 59

ggcagcca tetegeegtg agacageaag tgtegegeag eegtgegatg ttgteeteta 60

gccatgta ttcggctcct ggcagagact tggggatgga accgcacaga gccgcgggcc 120

### eolf-seql-S000001.txt

ittgcagct gcgattttcg ccctacgttt tcaacggagg tactatactg gcaattgctg
180

- agaagattt tgcaattgtt gcttctgata ctcgattgag tgaagggttt tcaattcata 240
- Jcgggatag ccccaaatgt tacaaattaa cagacaaaac agtcattgga tgcagcggtt 300
- :catggaga ctgtcttacg ctgacaaaga ttattgaagc aagactaaag atgtataagc 360
- :tccaataa taaggccatg actacggggg caattgctgc aatgctgtct acaatcctgt 420
- itcaaggcg cttctttcca tactatgttt acaacatcat cggtggactt gatgaagaag
   480
- laagggggc tgtatacagc tttgatccag tagggtctta ccagagagac tccttcaagg 540
- :ggaggctc agcaagtgcc atgctacagc ccctgcttga caaccaggtt ggttttaaga
  600
- patgcagaa tgtggagcat gttccgctgt ccttggacag agccatgcgg ctggtgaaag 660
- :gtcttcat ttctgcggct gagagagatg tgtacactgg ggacgcactc cggatctgca
  720
- igtgaccaa agagggcatc agggaggaaa ctgtttcctt aaggaaggac tgatctgtgt
  780
- tcttatca ccaatcagtt cagacctggt tgattttgta ctttggaact gtaccttgga 840
- gttttgtt tattaaaaga gaaacctgaa gt 872
- :10> 60
- :11> 356
- :12> DNA
- :13> Homo sapiens
- 00> 60
- ttetetet egegegegt gtggtggeag eaggegeage eeageetega aatgeagaae 60
- egeoggeg agttegtgga cetgtaegtg eegeggaaat geteegetag caategeate 120
- cggtgcca aggaccacgc atccatccag atgaacgtgg ccgaggttga caaggtcaca 180

### eolf-seql-S000001.txt

Jcaggttta atggccagtt taaaacttat gctatctgcg gggccattcg taggatgggt 240

agtcagatg attccattct ccgattggcc aaggccgatg gcatcgtctc aaagaacttt 300

jactggaga gaatcacaga tgtggaatat ttgtcataaa taaataatga aaacct 356

210> 61

211> 3069

212> DNA

213> Homo sapiens

400> 61

lacatacaa agggattgcc aggacctgcg gcggcggcgg cggcggcggg ggctggggcg

jggggccgg accatgagcc gctgagccgg gcaaacccca ggccaccgag ccagcggacc 180

:cggagcgc agccctgcgc cgcggaccag gctccaacca ggcggcgagg cggccacacg 240

iccgagcca gcgacccccg ggcgacgcgc ggggccaggg agcgctacga tggaggcgct 300

itggcccgg ggcgcctca cgggtcccct gagggcgctc tgtctcctgg gctgcctgct
360

igccacgcc gccgccgcgc cgtcgcccat catcaagttc cccggcgatg tcgccccaa
420

lcggacaaa gagttggcag tgcaatacct gaacaccttc tatggctgcc ccaaggagag 480

gcaacctg tttgtgctga aggacacact aaagaagatg cagaagttct ttggactgcc 540

agacaggt gatcttgacc agaataccat cgagaccatg cggaagccac gctgcggcaa 600

cagatgtg gccaactaca acttcttccc tcgcaagccc aagtgggaca agaaccagat 660

catacagg atcattggct acacacctga tctggaccca gagacagtgg atgatgcctt 720

ictcgtgcc ttccaagtct ggagcgatgt gaccccactg cggttttctc gaatccatga 780

# eolf-seql-S000001.txt

- ggagaggca gacatcatga tcaactttgg ccgctgggag catggcgatg gatacccctt 840
- gacggtaag gacggactcc tggctcatgc cttcgcccca ggcactggtg ttgggggaga 900
- tcccatttt gatgacgatg agctatggac cttgggagaa ggccaagtgg tccgtgtgaa 960
- tatggcaac gccgatgggg agtactgcaa gttccccttc ttgttcaatg gcaaggagta 1020
- aacagctgc actgatactg gccgcagcga tggcttcctc tggtgctcca ccacctacaa
  1080
- ittgagaag gatggcaagt acggcttctg tccccatgaa gccctgftca ccatgggcgg
  1140
- aacgctgaa ggacagccct gcaagtttcc attccgcttc cagggcacat cctatgacag 1200
- gcaccact gagggccgca cggatggcta ccgctggtgc ggcaccactg aggactacga 1260
- egcgacaag aagtatggct tetgecetga gacegeeatg tecaetgttg gtgggaacte 1320
- Jaaggtgcc ccctgtgtct tccccttcac tttcctgggc aacaaatatg agagctgcac 1380
- lgcgccggc cgcagtgacg gaaagatgtg gtgtgcgacc acagccaact acgatgacga 1440
- gcaagtgg ggcttctgcc ctgaccaagg gtacagcctg ttcctcgtgg cagcccacga 1500
- ttggccac gccatggggc tggagcactc ccaagaccet ggggccctga tggcacccat 1560
- :acacctac accaagaact tccgtctgtc ccaggatgac atcaagggca ttcaggagct 1620
- :atggggcc tctcctgaca ttgaccttgg caccggccc accccacac tgggccctgt 1680
- ictcctgag atctgcaaac aggacattgt atttgatggc atcgctcaga tccgtggtga 1740
- ttcttcttc ttcaaggacc ggttcatttg gcggactgtg acgccacgtg acaagcccat 1800
- ggcccctg ctggtggcca cattctggcc tgagctcccg gaaaagattg atgcggtata 1860

eolf-seql-S000001.txt

jaggcccca caggaggaga aggctgtgtt ctttgcaggg aatgaatact ggatctactc 1920

jccagcacc ctggagcgag ggtaccccaa gccactgacc agcctgggac tgcccctga 1980

¿tccagcga gtggatgccg cctttaactg gagcaaaaac aagaagacat acatctttgc 2040

ggagacaaa ttctggagat acaatgaggt gaagaagaaa atggatcctg gctttcccaa 2100

tcatcgca gatgcctgga atgccatccc cgataacctg gatgccgtcg tggacctgca 2160

ggcggcggt cacagctact tcttcaaggg tgcctattac ctgaagctgg agaaccaaag 2220

tgaagage gtgaagtttg gaagcatcaa atccgactgg ctaggetget gagetggeec 2280

gctcccac aggcccttcc tctccactgc cttcgataca ccgggcctgg agaactagag 2340

ggacccgg aggggcctgg cagccgtgcc ttcagctcta cagctaatca gcattctcac 2400

ctacctgg taatttaaga ttccagagag tggctcctcc cggtgcccaa gaatagatgc 2460

ractgtact cctcccaggc gccccttccc cctccaatcc caccaaccct cagagccacc
2520

:taaagaga tootttgata ttttcaacgc agccctgctt tgggctgccc tggtgctgcc 2580

acttcagg ctcttctcct ttcacaacct tctgtggctc acagaaccct tggagccaat 2640

agactgte teaagaggge actggtggee egacageetg geacagggea gtgggacagg 2700

atggccag gtggccactc cagacccctg gcttttcact gctggctgcc ttagaacctt 2760

ttacatta gcagtttgct ttgtatgcac tttgtttttt tctttgggtc ttgtttttt 2820

tccactta gaaattgcat ttcctgacag aaggactcag gttgtctgaa gtcactgcac 2880

tgcatctc agcccacata gtgatggttc ccctgttcac tctacttagc atgtccctac 2940

agtctctt ctccactgga tggaggaaaa ccaagccgtg gcttcccgct cagccctccc

eolf-seql-S000001.txt

3000

JCCCCtccc ttcaaccatt ccccatggga aatgtcaaca agtatgaata aagacaccta 3060

:gagtggc 3069

?10> 62

?11> 2876

212> DNA

?13> Homo sapiens

100> 62

:ctgtgagc agcgagatcc agggacagag tctcagcctc gccgctgctg ccgccgccgc

jcccagaga ctgctgagcc cgtccgtccg ccgccaccac ccactccgga cacagaacat
120

agtcatgg ataaaaatga gctggttcag aaggccaaac tggccgagca ggctgagcga 180

ıtgatgaca tggcagcctg catgaagtct gtaactgagc aaggagctga attatccaat 240

 $\log$  iggagagga atcttctctc agttgcttat aaaaatgttg taggagcccg taggtcatct 300

[gagggtcg tctcaagtat tgaacaaaag acggaaggtg ctgagaaaaa acagcagatg
360

tcgagaat acagagagaa aattgagacg gagctaagag atatctgcaa tgatgtactg 420

:tcttttgg aaaagttctt gatccccaat gcttcacaag cagagagcaa agtcttctat 480

gaaaatga aaggagatta ctaccgttac ttggctgagg ttgccgctgg tgatgacaag 540

agggattg tegateagte acaacaagea taccaagaag ettttgaaat cagcaaaaag 600

aatgcaac caacacatcc tatcagactg ggtctggccc ttaacttctc tgtgttctat 660

tgagattc tgaactcccc agagaaagcc tgctctcttg caaagacagc ttttgatgaa 720

cattgctg aacttgatac attaagtgaa gagtcataca aagacagcac gctaataatg 780

attactga gagacaactt gacattgtgg acatcggata cccaaggaga cgaagctgaa

eolf-seql-S000001.txt

840

caggagaag gaggggaaaa ttaaccggcc ttccaacttt tgtctgcctc attctaaaat 900

cacacagta gaccatttgt catccatgct gtcccacaaa tagttttttg tttacgattt
960

:gacaggtt tatgttactt ctatttgaat ttctatattt cccatgtggt ttttatgttt
1020

atattaggg gagtagagcc agttaacatt tagggagtta tctgttttca tcttgaggtg 1080

caatatgg ggatgtggaa tttttataca agttataagt gtttggcata gtacttttgg 1140

lcattgtgg cttcaaaagg gccagtgtaa aactgcttcc atgtctaagc aaagaaaact 1200

ctacatac tggtttgtcc tggcggggaa taaaagggat cattggttcc agtcacaggt 1260 .

lagtaattg tgggtacttt aaggtttgga gcacttacaa ggctgtggta gaatcatacc 1320

satggatac cacatattaa accatgtata totgtggaat actcaatgtg tacacotttg 1380

stacagetg cagaagtgtt cetttagaca aagttgtgac ceattttact etggataagg 1440

:agaaacgg ttcacattcc attatttgta aagttacctg ctgttagctt tcattatttt 1500

jctacactc attttatttg tatttaaatg ttttaggcaa cctaagaaca aatgtaaaag
1560

laagatgca ggaaaaatga attgcttggt attcattact tcatgtatat caagcacagc 1620

staaaacaa aaacccatgt atttaacttt tttttaggat ttttgctttt gtgatttttt 1680

tttttttt ttgatacttg cctaacatgc atgtgctgta aaaatagtta acagggaaat 1740

cttgagat gatggctagc tttgtttaat gtcttatgaa attttcatga acaatccaag 1800

taattgtt aagaacacgt gtattaaatt catgtaagtg gaataaaagt tttatgaatg

cttttcaa ctactttctc tacagctttt catgtaaatt agtcttggtt ctgaaacttc 1920

### eolf-seql-S000001.txt

- ctaaaggaa attgtacatt ttttgaaatt tattccttat tccctcttgg cagctaatgg 1980
- ctcttacca agtttaaaca caaaatttat cataacaaaa atactactaa tataactact 2040
- tttccatgt cccatgatcc cctctctcc tccccaccct gaaaaaaatg agttcctatt 2100
- tttctggga gagggggga ttgattagaa aaaaatgtag tgtgttccat ttaaaatttt 2160
- jcatatggc attitctaac ttaggaagcc acaatgttct tggcccatca tgacattggg 2220
- agcattaac tgtaagtttt gtgcttccaa atcacttttt ggtttttaag aatttcttga 2280
- actettata geetgeette aattitgate etttattett tetattigte aggigeacaa 2340
- attaccttc ctgttttagc cttctgtctt gtcaccaacc attcttactt ggtggccatg 2400
- acttggaaa aaggeegeat gatetttetg geteeactea gtgtetaagg eaccetgett 2460
- otttgcttg catcccacag actatttccc tcatcctatt tactgcagca aatctctcct 2520
- igttgatga gactgtgttt atctcccttt aaaaccctac ctatcctgaa tggtctgtca 2580
- gtctgcct ttaaaatcct tcctctttct tcctcctcta ttctctaaat aatgatggg 2640
- aagttata cccaaagctc actttacaaa atatttcctc agtactttgc agaaaacacc 2700
- lacaaaaat gccattttaa aaaaggtgta ttttttcttt tagaatgtaa gctcctcaag 2760
- jcagggaca atgttttctg tatgttctat tgtgcctagt acactgtaaa tgctcaataa 2820
- :attgatga tgggaggcag tgagtcttga tgataagggt gagaaactga aatccc 2876
- :10> 63
- :11> 3401
- 112> DNA
- :13> Homo sapiens

### eolf-seq1-S000001.txt

400> 63

- ggtacgagc cccgcccgag ctcaccgccc ctgctcccct ctccgaccct ttgagccgtg
  60
- ccgttgcca gatgtccaca atgggaaacg aggccagtta cccggcggag atgtgctccc 120
- ctttgacaa tgatgaaatt aaaaggctgg gcaggaggtt taagaagttg gacttggaca 180
- atcagggtc tctgagcgtg gaggagttca tgtccctgcc ggagctgcgc cacaacccgt 240
- jgtgcggcg agtgatcgac gtcttcgaca ccgacggtga tggagaagtg gacttcaagg 300
- attcatect ggggaeetee eagtteageg teaagggega egaggageag aagttgaggt 360
- igcgttcag catttacgac atggataaag atggctacat ttccaacggg gagctcttcc
  420
- jgtgctgaa gatgatggtg ggcaacaacc tgacggactg gcagctccag cagctggtcg
  480
- laaaaccat catcatcctg gacaaggatg gcgatgggaa gatatccttt gaggaattca
  540
- igctgtggt cagagacctg gagatccaca agaagctggt cctcatcgta tgagcctttt
  600
- ottacaagc accacccaac aacttctgct ttcttcccta tctctttcaa gatttgctca 660
- jacgtccaa ctgtctctct gacttatctg gaagtatttc tttttgtgaa gccatatgtc 720
- laacaggag cttcatcacc aactcagtgc tattaattct ccttctctga atgactcagg 780
- :accctata gggggaagag caagtcaaat gagcatagtg gggaaagaaa aggaaatggc 840
- :ttataaac atcttttact ttgttttgat tcaaagacca aactagaact ttaaaagttc 900
- $\iota$ aaataaga aagtatacat ttttgctgtt atttctcatc attttgtata tgggaggaaa 960
- tataattt gcatgggtgt taggtgaact gttttcattt gcttgtgttc agatatcttg 1020
- agattgtt aactteetat tgtageaaca gggaeaaata tatttgtett tgetgggeat 1080

eolf-seql-S000001.txt

cgtaatca cttttcttag gggacagaat cccatctttt ccttcggcag attgcagccc 1140

- attccccac aatgcatcca gaaatcgctg tgcatgtttg aggggtagga gttcatttgg 1200
- stoctcotg acttgttgct coagetootg aacagaaact agettoaggg etettatagg 1260
- latgctaag cetggactaa gtgcccaget cagecateat ceteattage agtgggttte 1320
- igggttggc agcccacacc agcattaatt tcaatgaagg ggacctccag ctaaataggg 1380
- lagcaaagt gttctcccag aaagtgctct cacctccgac actggtccct accccaggt 1440
- jagacaatg agacatttag ttagttgtcc tacggaggag aggcagtaga gtcaggctgc 1500
- stggaatct ccctaggatg ccaaagtggc attatgtctg ttgctcacag atgcagagac 1560
- jacaattgt gtctccacag cagaggtgga tgctagctac accagctatg ctgattttga
  1620
- latcagatc tgaggcctag aagagaaact gagagctctc tcattccagg aagccttttc
  1680
- tagtggaa cattcagtgc agaagtcctc acacactaac agatctccac cattgggtga 1740
- :cggagcct gtggttccag gggagatcca gaatgcatgt gtctcttccc acgcatttat 1800
- .catgttgg tagctttaga tcagccatgg tgagaaaaga acaaaagctt ttagttgttt 1860
- gttttgtt ttggagaatt tgtttaccag taaatacatc actgcctgta ccccaaatgt 1920
- ccagctcc ctgaggtgtc ccacatacta ttgtgagttc tcagagcatg aactgtcctc 1980
- aagagcag ggctaggact tgtcccagca tctgtgcctc cataccaatc ctctttctca 2040
- gagaacca cttcccatat aagatgctta aggctctcaa aacagcagaa caatgaaaca 2100
- ctctccct acacttgctt agccaagaga taccactcag gtaacttttt tcaggacatg 2160
- agatctgt ttcaaggaga tttactgcta ttttatttgg aagaagctgg caactggtct

### eolf-seql-S000001.txt

2220

Jaccaaaat agaaaaaaa aaaaaaagtc cacaaattta atcacttgta gggaacccat 2280

:atcaaggt accctaccat atacttttgt atttaataga ttacttagaa accacaaaaa
2340

iggaateet tacceettea atteetgtte aaceetaaaa actgtgataa acgeteecaa 2400

ctgtggtg atcagggtta tgtaatgttc aaagattcag acacacctgg gtttggattc 2460

;ttgcaact gggttgttat cacactcact tctttttagc tgtgtgagca tgaataattt
2520

ttagcctc tctgtgtctt tccacctaat taaagaggat ccaccccagg gttattttga 2580

jattcaaaa aggcatgcaa cacacetgga gcacaattec actttcattc aactaattec
2640

tecettee ecettetee ecttetacaa gateaatatg taaaggagae atgaggetta 2700

ggttgctt ttgaacactt acttagttct tagctacacc cactctaaaa ttaactggac 2760

tagtgtac agcccatgtc caagcccaga gagaaaacaa tgggaacaat ttcaaggtcc 2820

accactcc ttcatttgca gaggggacaa cagactttct gaccagagaa ctggagaatt 2880

taaaacaa aatctctcat tccagcccaa cctatttaac tttttgtgga ggaattttac 2940

ggaggaag tgagcacatg tcatgctagc caagaggaca ttattgtcat taaagagagg 3000

ttatttat acaccetgea atgtgeacat taaaatatgg aaattttaaa attatgacea 3060

ggcttgaa acatattgga ttacatgctc acatttaaca aagagaggaa atgtgtttca 3120

ttctggag tggctggaat ttacaagcta attgttcaat aaatctactc aagatagtta 3180

taaggett tgtggcaatg acettgaact gagageetgt atetggattt ageaettgaa 3240

atctaact ggatatttgg gttaaaagaa tcacatttat tcccaaatcg gaatgctttg 3300

### eolf-seql-S000001.txt

:tttcctgt cagttaattg ccagttgcca acaaatctag ttctatacag tttcttggga
3360

jatgataat aaacatttat tgagcaaaaa aaaaaaaaa a
3401

- 210> 64
- 211> 3454
- ?12> DNA
- 213> Homo sapiens
- 100> 64
- jaaatgact gctgtccatg caggcaacat aaacttcaag tgggatccta aaagtctaga 60
- itcaggact ctggcagttg agagactgtt ggagcctctt gttacacagg ttacaaccct
  120
- jtaaacacc aatagtaaag ggccctctaa taagaagaga ggtcgttcta agaaggccca
  180
- ;ttttggct gcatctgttg aacaagcaac tgagaatttc ttggagaagg gggataaaat 240
- ¡caaaagag agccagtttc tcaaggagga gcttgtggtt gctgtagaag atgttcgaaa 300
- :aaggtgat ttgatgaagg ctgctgctgg agagttcgca gatgatccct gctcttctgt 360
- lagcgaggc aacatggttc gggcagctcg agctttgctc tctgctgtta cccggttgct
  420
- ittttggct gacatggcag atgtctacaa attacttgtt cagctgaaag ttgtggaaga 480
- gtatattg aaactgagga atgctggcaa tgaacaagac ttagggaatc agtataaagc 540
- taaaacct gaagtggata agctgaacat tatggcagca aaaagacaac aggaattgaa 600
- atgttggg catcgtgatc agatggctgc ggctagagga atcctgcaga gcaacgttcc 660
- tectetat actgeatece aggeatgeet acageaceet gatgtegeag eetataagge 720
- acagggac ctgatataca agcagctgca gcaggcggtc acagggattt ccaatgcagc 780
- aggccact gcctcagacg atgcctcaca gcaccagggt ggaggaggag gagaactggc 840

# eolf-seql-S000001.txt

- latgcactc aataactttg acaaacaaat cattgtggac cccttgagct tcagcgagga 900
- >gctttagg ccttccctgg aggagcgtct ggaaagcatc attagtgggg ctgccttgat 960
- jccgactcg tcctgcacgc gtgatgaccg tcgtgagcga attgtggcag agtgtaatgc 1020
- jtccgccag gcctgcagga cctgcgtttc ggagtacatg ggcaatgctg gacgtaaaga 1080
- igaagtgat gcactcaatt ctgcaataga taaaatgacc aagaagacca gggacttgcg 1140
- igacagctt cgcaaagctg tcatggacca cgtttcagat tctttcctgg aaaccaatgt
  1200
- cacttttg gtattgattg aagctgcaaa gaatggaaat gagaaagaag ttaaggaata 1260
- rcccaagtt ttccgtgaac atgccaacaa attgattgag gttgccaact tggcctgttc 1320
- itctcaaat aatgaagaag gtgtaaagct tgttcgaatg tctgcaagcc agttagaagc 1380
- gttgtcct caggttatta atgctgcaac ctgggcttta gcaccaaaac cacagagtaa 1440
- :tggcccaa gagaacatgg atcttttaa agaacaatgg gaaaaacaag tccgtgttct 1500
- cagatgct gtcgatgaca ttacttccat tgatgacttc ttggctgtct cagagaatca 1560
- ttttggaa gatgtgaaca aatgtgtcat tgctctccaa gagaaggatg tggatggcct 1620
- accgcaca gctggtgcaa ttcgaggccg ggcagcccgg gtcattcacg tagtcacctc 1680
- agatggac aactatgagc caggagtcta cacagagaag gttctggaag ccactaagct 1740
- tetecaac acagteatge caegttttac tgagcaagta gaagcageeg tggaageet 1800
- gctcggac cctgcccagc ccatggatga gaatgagttt atcgatgctt cccgcctggt 1860
- atgatggc atccgggaca tcaggaaagc agtgctgatg ataaggaccc ctgaggagtt 1920

eolf-seql-S000001.txt

Jatgactet gaetttgaga cagaggattt tgatgteaga agegagaega gegteeagae 1980

Jaagacgat cagctgatag ctggccagag tgcccgggcg atcatggctc agcttcccca 2040

Jagcaaaaa gcgaagattc gggaacaggt ggccagcttc caggaagaaa agagcaagct 2100

Jatgctgaa gtgtccaaat gggacgacag tggcaatgac atcattgtgc tggccaagca 2160

itgtgcatg attatgatgg agatgacaga ctttacccga ggtaaaggac cactcaaaaa 2220

icatcggat gtcatcagtg ctgccaagaa aattgctgag gcaggatcca ggatggacaa 2280

ttggccgg accattcgag accattgccc cgactcggct tgcaagcagg acctgctggc 2340

:acctgcaa cgcatcgccc tctactgcca ccagctgaac atctgcagca aggtcaaggc 2400

jaggtgcag aatctcggcg gggagcttgt tgtctctggg gtggacagcg ccatgtccct 2460

itccaggca gccaagaact tgatgaatgc tgtggtgcag acagtgaagg catcctacgt 2520

¡cctctacc aaataccaaa agtcacaggg tatggcttcc ctcaaccttc ctgctgtgtc
2580

ıtgaagatg aaggcaccag agaaaaagcc attggtgaag agagagaaac aggatgagac 2640

agaccaag attaaacggg catctcagaa gaagcacgtg aacccagtgc aggccctcag 2700

ragttcaaa gctatggaca gcatctaagt ctgcccaggc cggccgcccc cacccctctg 2760

tectgaat atcagteact gttegteact caaatgaatt tgetaaatae aacaetgata 2820

agattcca cagggaaatg ggcagactga accagtccag gtggtgaatt ttccaagaac 2880

agtttaag ttgattaaaa atgcttttag aatgcaggag cctacttcta gctgtatttt 2940

gtatgctt aaataaaata aaattcataa ccaagagatc cacattagct tgttagtaat 3000

tctgacca agccgagatg ccattctctt agtgatggcg gcgttaggtt tgagagaagg

eolf-seq1-S000001.txt

3060

ittggctca acttcagttg agagggtgca gtccagacag cttgactgct tttaaatgac 3120

laagatgac ctgtggtaag caacctggca tcttaggaag cagtccttga gaaggcatgt 3180

cagaaagg tetetgagga caaacteact cagtaaaaca taatgtatea tgaagaaaac 3240

jattctcta tgacatgaaa tgaaaatttt aatgcattgt tataattact aatgtacgct
3300

tgcaggac attaataaag ttgcttttt aggctacagt gtctcgatgc cataatcaga 3360

:acactttt tttcctcttt ctcccagctt caaatgcaca attcatcatt gggctcactt 3420

.aataactg cagtgtttcc gccttgcgtt gcag 3454

- :10> 65
- :11> 1939
- :12> DNA
- :13> Homo sapiens

00> 65

tgaccatg tgtagcggag cgaggctggc cctgctggtc tatgggataa tcatgcacag

gcgtctac agctcacctg ccgccgccgg actccggttc cccgggatca ggccagagga 120

aggcgtac ggcgaggacg gaaacceget gccagacttc ggtggctcgg agccgccggg

cagggage eccgeeteeg egeegege egeegeegee tggtacegee eggeegggag 240

gagatgtc gcccacggga tccttaacga ggcctaccgc aaagtgctgg accagctgtc  $300\,\cdot$ 

ccgggaag cacctgcagt cgctcgtggc ccggggcgtg ggtgggagcc tcggcggcgg 360

cgggggac gacgcggagc cgctctccaa gcgccactcg gacgggatct tcacggacag 420

acagccgc taccggaaac aaatggctgt caagaaatac ttggcggccg tcctagggaa 480

ggtataaa caaagggtta aaaacaaagg acgccgaata gcttatttgt agcgatgggt

eolf-seql-S000001.txt

540

accagetae ectgtgtata cagecetgae geaatgaaaa gtegttttee aaactgaete 600

1Cagtcatc gctcgtgtgt tctatccaaa catgtattta tgtaatgaag taaagccatt 660

latgaatat tttgataata atattgtttt tctttctaca aagcactaga gaatgcacag 720

:atatatat ataaagtata gagagaagtt catacaaagc gtgcacaagg attgaaaatt 840

jcccgagct gtttatgttt ttataaaaat aaatagaaaa gtagacaatc attgttttga 900

:attactcc tatttttgta aactggaatt aaaaggatag tatttttatc catgacaggc 960

gaagatat tactacttac catttgctac tgtacataaa caatgatgcc ctgctccagg 1020

gattttga ggtaaagata tggagaattg ctgaagggca ttctttccca gtgagtctct

ggcaggct gcttcaatcc cagcctaact caactgggct ctgtccccct ggttgggtgg 1140

lattocaat atttotgott totttgatto toottttatg tgtagttgto totottoaga 1200

ctcagccc agaagaaaat tctcctgata aaacaacagc tcgatccaaa ttgtgcttct 1260

ccagaatt cacgcctctc cctaggagaa gagttgagga actgtacaga aaagggcggc 1320

cgttagac cgctctcttt tctgtacttc ctgagtggcc agggaatcta atatccccaa 1380

tagggcaa ttggaacaaa gtgaaggaca tagaggtata ttggaagagg cagagcctga 1440

tggtagga ggacgaccct ggaaatggac tggtttgaga ttgccccagg tctgggaagc 1500

agggcaaa tecagteeca gtggteetga etttgggege tgggtattgg aaatggatge 1560

agtacaat gtgtttttct ccagtgctgt ccatgcttct catcttgtga aatggccagg 1620

### eolf-seql-S000001.txt

cottcct ttgaaacctg ctctgtagga gctacccttt tcctttgtgg ttttatggag 1680

ctctcctt cctaccctcc tgcactgttt aagtactgtt taccattttt cattcacttc 1740

ttaaactt gtgaatgctt ctcacttttt tttttgtttg atgcaggcac ttattgtaaa 1800

ttagaaac ccctctgtag ccactagtaa gtaattatgc actaaatatg aaccctttgt 1860

cttgttta ttgagtttgt aggtaaaatg tatttttcta cattattgct tattgcttag 1920

laaatttat ttcataaaa 1939

- !10> 66
- !11> 2193.
- :12> DNA
- :13> Homo sapiens
- :00> 66
- |cacgaggc gggggcgtt catgacgcgc ctcgggggcg gtcctcgggc gcgcaccgct 60
- cttacact cgggcctcag aagtccgtgc cagtgaccgg agcggcggcg gcgagcggtt 120
- ttgtgggc tagaagaatc ctgcaaaaat gtctctctat ccatctctcg aagacttgaa 180
- tagacaaa gtaattcagg ctcaaactgc tttttctgca aaccctgcca atccagcaat 240
- tgtcagaa gcttctgctc ctatccctca cgatggaaat ctctatccca gactgtatcc 300
- agetetet caatacatgg ggetgagttt aaatgaagaa gaaatacgtg caagtgtgge 360
- tggtttct ggtgcaccac ttcaggggca gttggtagca agaccttcca gtataaacta 420
- tggtggct cctgtaactg gtaatgatgt tggaattcgt agagcagaaa ttaagcaagg 480
- ttcgtgaa gtcattttgt gtaaggatca agatggaaaa attggactca ggcttaaatc 540
- tagataat ggtatatttg ttcagctagt ccaggctaat tctccagcct cattggttgg 600

### eolf-seql-S000001.txt

tgagattt ggggaccaag tacttcagat caatggtgaa aactgtgcag gatggagctc 660

- iataaagcg cacaaggtgc tcaaacaggc ttttggagag aagattacca tgaccattcg
  720
- iacaggccc tttgaacgga cgattaccat gcataaggat agcactggac atgttggttt
  780
- tctttaaa aatggaaaaa taacatccat agtgaaagat agctctgcag ccagaaatgg 840
- ttctcacg gaacataaca tctgtgaaat caatggacag aatgtcattg gattgaagga 900
- ctcaaatt gcagacatac tgtcaacatc tgggactgta gttactatta caatcatgcc 960
- cttttatc tttgaacata ttattaagcg gatggcacca agcattatga aaagcctaat 1020
- accacacc attectgagg tttaaaatte acggcaccat ggaaatgtag etgaacgtet 1080
- agtttcct tctttggcaa cttctgtatt atgcacgtga agccttcccg gagccagcga 1140
- atatgctg catgaggacc tttctatctt acattatggc tggggatctt actctttcat 1200
- gatacctt gttcagattt caaaatagtt gtagccttat cctggtttta cagatgtgaa 1260
- ttcaagag atttactgac tttcctagaa tagtttctct actggaaacc tgatgctttt 1320
- aagccatt gtgattagga tgactgttac aggcttagct ttgtgtgaaa accagtcacc 1380
- tctcctag gtaatgagta gtgctgtcat attactttag ttctatagca tacttgcatc 1440
- taacatgc tatcatagta catttagaat gattgccttt gatttttttt tttaaattct 1500
- gtgtgtgt gtgtaaaatg ccaattaaga acactggttt cattccatgt aagcattaaa 1560
- gtgtatgt aggtttcaag agattgtgat gattcttaaa ttttaactac cttcacttaa 1620
- tgcttgaa ctgtcgcctt aactatgtta agcatctaga ctaaaagcca aaatataatt 1680

eolf-seql-S000001.txt

tgctgcct ttctaaaaac ccaaaatgta gttctctatt aacctgaaat gtacactagc 1740

tttagtca acacataatg gaaacttett tettetaaaa gttgeeagtg eeacttttaa 1860

lagtgaatc actatatgtg atgtaaaagt tattacacta aacaggataa acttttgact
1920

ccttttgt tcatttgtgg attaagtggt ataatactta attttggcat ttgactctta 1980

rattatgta acctagctac tttgggatgg tcttagaata tttttctgat aacttgttcc 2040

ttcctgac tcctccttgc aaacaaaatg atagttgaca ctttatcctg attttttct 2100

tttttggt ttatgtctat tctaattaaa tatgtataaa taaagttaca ttttagtctg 2160

:aaaaaaaa aaaaaaaaa aaa 2193

10> 67

11> 5189

12> DNA

13> Homo sapiens

00> 67

ggccaagt cgggtggctg cggcgggga gccggcgtgg gcggcggcaa cggggcactg 60

ctgggtga acaatgctgc aaaaaaagaa gagtcagaaa ctgccaacaa aaatgattct  $120^{\circ}$ 

aaagaagt tgtctgttga gagagtgtat cagaagaaga cacaacttga acacattctt 180

tcgtcctg atacatatat tgggtcagtg gagccattga cgcagttcat gtgggtgtat 240

tgaagatg taggaatgaa ttgcagggag gttacctttg tgccaggttt atacaagatc 300

tgatgaaa ttttggttaa tgctgctgac aataaacaga gggataagaa catgacttgt 360

taaagttt ctattgatcc tgaatctaac attataagca tttggaataa tgggaaaggc 420

eolf-segl-S000001.txt

- tccagtag tagaacacaa ggtagagaaa gtttatgttc ctgctttaat ttttggacag
- tttaacat ccagtaacta tgatgatgat gagaaaaag ttacaggtgg tcgtaatggt 540
- tggtgcaa aactttgtaa tattttcagt acaaagttta cagtagaaac agcttgcaaa 600
- atacaaac acagttttaa gcagacatgg atgaataata tgatgaagac ttctgaagcc 660
- aattaaac attttgatgg tgaagattac acatgcataa cattccaacc agatctgtcc 720
- atttaaga tggaaaaact tgacaaggat attgtggccc tcatgactag aagggcatat 780
- tttggctg gttcgtgtag aggggtcaag gtcatgttta atggaaagaa attgcctgta 840
- tggatttc gcagttatgt agatctttat gtgaaagaca aattggatga aactggggtg 900
- cctgaaag ttattcatga gcttgcaaat gaaagatggg atgtttgtct cacattgagt 960
- aaaaggat tccagcaaat cagctttgta aatagtattg caactacaaa aggtggacgg 1020
- cgtggatt atgtggtaga tcaagttgtt ggtaaactga ttgaagtagt taagaaaaag 1080
- caaagctg gtgtatcagt gaaaccattt caagtaaaaa accatatatg ggtttttatt 1140
- ttgcctta ttgaaaatcc aacttttgat tctcagacta aggaaaacat gactctgcag 1200
- caaaagtt ttgggtctaa atgccagctg tcagaaaaat tttttaaagc agcctctaat 1260
- tggcattg tagaaagtat cctgaactgg gtgaaattta aggctcagac tcagctgaat 1320
- gaagtgtt catcagtaaa atacagtaaa atcaaaggta ttcccaaact ggatgatgct 1380
- tgatgctg gtggtaaaca ttccctggag tgtacactga tattaacaga gggagactct 1440
- caaatcac tggctgtgtc tggattaggt gtgattggac gagacagata cggagttttt 1500
- actcaggg gcaaaattct taatgtacgg gaagcttctc ataaacagat catggaaaat

#### eolf-seql-S000001.txt

1560

tgaaataa ataatattat taaaatagtt ggtctacaat ataagaaaag ttacgatgat 1620

agaatete tgaaaacett aegetatgga aagattatga ttatgaeega teaggateaa 1680

tggttctc acataaaagg cctgcttatt aatttcatcc atcacaattg gccatcactt 1740

gaagcatg gttttcttga agagttcatt actcctattg taaaggcaag caaaaataag 1800

ggaacttt ccttctacag tattcctgaa tttgacgaat ggaaaaaaca tatagaaaac 1860

gaaagcct ggaaaataaa gtactataaa ggattgggta ctagtacagc taaagaagca 1920

ggaatatt ttgctgatat ggaaaggcat cgcatcttgt ttagatatgc tggtcctgaa 1980 .

tgatgctg ccattacctt ggcatttagt aagaagaaga ttgatgacag aaaagaatgg 2040

aacaaatt ttatggaaga ccggagacag cgtaggctac atggcttacc agagcaattt 2100

atatggta ctgcaacaaa gcatttgact tataatgatt tcatcaacaa ggaattgatt 2160

cttctcaa actcagacaa tgaaagatct ataccatctc ttgttgatgg ctttaaacct 2220

ccagcgga aagttttatt tacctgtttc aagaggaatg ataaacgtga agtaaaagtt 2280

ccagttgg ctggctctgt tgctgagatg tcggcttatc atcatggaga acaagcattg 2340

gatgacta ttgtgaattt ggctcagaac tttgtgggaa gtaacaacat taacttgctt 2400

gcctattg gtcagtttgg aactcggctt catggtggca aagatgctgc aagccctcgt 2460

tattttca caatgttaag cactttagca aggctacttt ttcctgctgt ggatgacaac 2520

ccttaagt tcctttatga tgataatcaa cgtgtagagc ctgagtggta tattcctata 2580

tcccatgg ttttaataaa tggtgctgag ggcattggta ctggatgggc ttgtaaacta 2640

## eolf-seql-S000001.txt

Caactatg atgctaggga aattgtgaac aatgtcagac gaatgctaga tggcctggat 2700

tcatccca tgcttccaaa ctacaaaaac tttaaaggca cgattcaaga acttggtcaa 2760

ccagtatg cagtcagtgg tgaaatattt gtagtggaca gaaacacagt agaaattaca 2820

gcttccag ttagaacttg gacacaggta tataaagaac aggttttaga acctatgcta 2880

tggaacag ataaaacacc agcattaatt tctgattata aagaatatca tactgacaca 2940

tgtgaaat ttgtggtgaa aatgactgaa gagaaactag cacaagcaga agctgctgga 3000

gcataaag tttttaaact tcaaactact cttacttgta attccatggt actttttgat 3060

tatgggat gtctgaagaa atatgaaact gtgcaagaca ttctgaaaga attctttgat 3120

acgattaa gttattacgg tttacgtaag gagtggcttg tgggaatgtt gggagcagaa 3180

tacaaagc ttaacaatca agcccgtttc attttagaga agatacaagg gaaaattact 3240

agagaata ggtcaaagaa agatttgatt caaatgttag tccagagagg ttatgaatct 3300

cccagtga aagcctggaa agaagcacaa gaaaaggcag cagaagagga tgaaacacaa 3360

ccagcatg atgatagttc ctccgattca ggaactcctt caggcccaga ttttaattat 3420

tttaaata tgtctctgtg gtctcttact aaagaaaaag ttgaagaact gattaaacag 3480

agatgcaa aagggcgaga ggtcaatgat cttaaaagaa aatctccttc agatctttgg 3540

agaggatt tagcggcatt tgttgaagaa ctggataaag tggaatctca agaacgagaa 3600

Lgttctgg ctggaatgtc tggaaaagca attaaaggta aagttggcaa acctaaggtg 3660

gaaactcc agttggaaga gacaatgccc tcaccttatg gcagaagaat aattcctgaa
3720

eolf-seql-S000001.txt

tacagcta tgaaggcaga tgccagcaaa aagttgctga agaagaagaa gggtgatctt 3780

ttactgcag cagtaaaagt ggaatttgat gaagaattca gtggagcacc agtagaaggt 3840

aggagaag aggcattgac tccatcagtt cctataaata aaggtcccaa acctaagagg 3900

gaagaagg agcctggtac cagagtgaga aaaacaccta catcatctgg taaacctagt 3960

aaagaaag tgaagaaacg gaatccttgg tcagatgatg aatccaagtc agaaagtgat 4020

ggaagaaa cagaacctgt ggttattcca agagattctt tgcttaggag agcagcagcc 4080

aagaccta aatacacatt tgatttctca gaagaagagg atgatgatgc tgatgatgat 4140

tgatgaca ataatgattt agaggaattg aaagttaaag catctcccat aacaaatgat 4200

ggaagatg aatttgttcc ttcagatggg ttagataaag atgaatatac attttcacca 4260

caaatcaa aagccactcc agaaaaatct ttgcatgaca aaaaaagtca ggattttgga 4320

tetettet cattteette atatteteag aagteagaag atgatteage taaatttgae 4380

taatgaag aagattetge ttetgttttt teaceateat ttggtetgaa acagacagat 4440

agttccaa gtaaaacggt agctgctaaa aagggaaaac cgtcttcaga tacagtccct 4500

gcccaaga gagccccaaa acagaagaaa gtagtagagg ctgtaaactc tgactcggat 4560

agaatttg gcattccaaa gaagactaca acaccaaaag gtaaaggccg aggggcaaag 4620

aaggaaag catctggctc tgaaaatgaa ggcgattata accctggcag gaaaacatcc 4680

aacaacaa gcaagaaacc gaagaagaca tettttgate aggatteaga tgtggacate 4740

cccctcag acttccctac tgagccacct tctctgccac gaaccggtcg ggctaggaaa 4800

agtaaaat attttgcaga gtctgatgaa gaagaagatg atgttgattt tgcaatgttt

eolf-seql-S000001.txt

4860

ttaagtgc ccaaagagca caaacatttt tcaacaaata tcttgtgttg tccttttgtc 4920

ctctgtct cagacttttg tacatctggc ttattttaat gtgatgatgt aattgacggt 4980

tttattat tgtggtaggc cttttaacat tttgttctta cacatacagt tttatgctct 5040

tttactca ttgaaatgtc acgtactgtc tgattggctt gtagaattgt tatagactgc 5100

tgcattag cacagatttt aattgtcatg gttacaaact acagacctgc tttttgaaat 5160

aatttaaa cattaaaaat ggaactgtg 5189

10> 68

11> 2836

12> DNA

13> Homo sapiens

00> 68

ccctcagc gtccggccga ggcgcggtgt atgctgagcc gctgccgcag cgggctgctc 60

cgtcctgg gccttagctt cctgctgcag acccgccggc cgattctcct ctgctctcca 120

tctcatga agccgctggt cgtgttcgtc ctcggcggcc ccggcgccgg caaggggacc 180

gtgcgccc gcatcgtcga gaaatatggc tacacacac tttctgcagg agagctgctt 240

tgatgaaa ggaagaaccc agattcacag tatggtgaac ttattgaaaa gtacattaaa 300

aggaaaga ttgtaccagt tgagataacc atcagtttat taaagaggga aatggatcag 360

aatggctg ccaatgctca gaagaataaa ttcttgattg atgggtttcc aagaaatcaa 420

caacette aaggatggaa caagaceatg gatgggaagg cagatgtate tttegttete 480

itttgact gtaataatga gatttgtatt gaacgatgtc ttgagagggg aaagagtagt 540

laggagtg atgacaacag agagagettg gaaaagagaa ttcagaccta cettcagtca

eolf-seql-S000001.txt

600

aaagccaa ttattgactt atatgaagaa atggggaaag tcaagaaaat agatgcttct 660

atctgttg atgaagtttt tgatgaagtt gtgcagattt ttgacaagga aggctaattc 720

aacctgaa agcatccttg aaatcatgct tgaatattgc tttgatagct gctatcatga 780

ccttttta aggcaattct aatctttcat aactacatct caattagtgg ctggaaagta 840

tggtaaaa caaagtaaat ttttttatgt tctttttttg gtcacaggag tagacagtga 900

tcaggttt aacttcacct tagttatggt gctcaccaaa cgaagggtat cagctatttt

tttaaatt caaaaagaat atccctttta tagtttgtgc cttctgtgag caaaactttt 1020

gtacgcgt atataccct ctagtaatca caacatttta ggatttaggg atacctgctt 1080

tettttte ttgcaagttt taaattteea aeettaagtg aatttgtgga eeaaatttea 1140

ggaacttt ttgtgtagtc agttcttgca caatgtgttt ggtaaacaaa ctcaaaatgg 1200

tcttagga gcattttagt gtttattaaa taactgacca tttgctgtag aaagatgaga 1260

acttaagc tttgttttac tacaacttgt acaaagttgt atgacagggc atattctttg 1320

tccaagat ttgggttggg ggcactaggg gttcagagcc tggcagaatt gtcagcttta 1380

ctgacata atctaagggt atggggcaag gatcacatct aatgcttgtg tccttatact 1440

attatata gtgttattca tgattcagct gatcttaaca aaattcgtag cagtggaacc 1500

gaaatgca tgtggctaga tttatgctaa aatgattctc agttagcatt ttagtaacac 1560

caaaggtt tttttttgtt tgttttctag acttaataaa agcttaggat taattagaag 1620

gcaatcta gttaaatttc ccatttgtat tttattttct tgaatacttt tttcatagtt 1680

### eolf-seq1-S000001.txt

ttgtttaa aaagatttaa aaatcattgc actttggtca gaaaaataat aaatatatct 1740

taaatgtt tgattccctt ccttgctatt tttattcagt agatttttgt ttggcatcat 1800

tgaagcac cgaaagataa atgattttta aaaggctata gagtccaaag gaatattctt 1860

acaccaat tetteettta aaaatetetg aggaatttgt tttegeetta etttttte 1920

ctgtcaca atgctaagtg gtatccgagg ttcttaatat gagatttaaa atcttaaaat 1980

ttcttatt ttcagcactt acatcatttg gtacacaggg tcaaataggg caaataattt 2040

tctttgta taatagattt gatatttaaa gtcactggaa ataggacaag ttaatggatg 2100

tttatatt ttaatagaat catttatttc tatgtgttat gaaattcact taatgataaa 2160

tttcaaca tacttgccat tagaaaacaa agtattgcta agtactataa catattggcc 2220

taaaattc atattgagat tatcttggtt tcttggaaga gataggaatg agttcttatc 2280

gtgttgca ggccagcaaa tacagaggtg gtttaatcaa acagctctag tatgaagcaa 2340

gtaaagac taaggtttcg agagcattcc tactcacata agtgaagaaa tctgtcagat 2400

gaatctaa atatttatag tgagattgtg aaagcaacct taaagttttg aagaagactg 2460

gagactag gtgctttgct tcctttcatc aggtatcttt ctgtggcatt tgagaacaga 2520

ccaagaaa catggtaatt actaaattat gaggctttgc tttttgtttg cttttaagta 2580

aaaacatg ttggcaacat tgagttttgg agttgattga gataatatga cttaactagt 2640

tgtcattc catttgttaa agatacagtc accaagaatg ttttgagttt tttgaaagac 2700

caatttaa gccttgctta tttttaaatt atttccattc agtgatgttg gatgtatatc 2760

eolf-seql-S000001.txt

.aaaaaaaa aaaaaa 2836

- 10> 69
- 11> 1500
- 12> DNA
- 13> Homo sapiens
- 00> 69
- ttggagga gttgttgtta ggccgtcccg gagacccggt cgggagggag gaaggtggca 60
- atggtgtt ggaaagcact atggtgtgtg tggacaacag tgagtatatg cggaatggag 120
- ttcttacc caccaggctg caggcccagc aggatgctgt caacatagtt tgtcattcaa 180
- accegcag caaccetgag aacaacgtgg gcettateae actggetaat gactgtgaag 240
- ctgaccac actcaccca gacactggcc gtatcctgtc caagctacat actgtccaac 300
- aagggcaa gatcaccttc tgcacgggca tccgcgtggc ccatctggct ctgaagcacc 360
- caaggcaa gaatcacaag atgcgcatca ttgcctttgt gggaagccca gtggaggaca 420
- gagaagga tctggtgaaa ctggctaaac gcctcaagaa ggagaaagta aatgttgaca 480
- atcaattt tggggaagag gaggtgaaca cagaaaagct gacagccttt gtaaacacgt. 540
- aatggcaa agatggaacc ggttctcatc tggtgacagt gcctcctggg cccagtttgg
  600
- gatgctct catcagttct ccgattttgg ctggtgaagg tggtgccatg ctgggtcttg 660
- gccagtga ctttgaattt ggagtagatc ccagtgctga tcctgagctg gccttggccc 720
- cgtgtatc tatggaagag cagcggcagc ggcaggagga ggaggcccgg cgggcagctg 780
- gcttctgc tgctgaggcc gggattgcta cgactgggac tgaaggtgaa agaggtggaa 840

eolf-segl-S000001.txt

cgaagtcc tgggactgcg ggatgctaaa cattgaaagc tgggtgtagg cactgcaggg 900

lagtgtgga ggtctgacag ggtaggaata tgtgggaggg ctgggctagg aatggccttg
960

ggctggcc tgtgtggata tggcaccaat tctaccctgc tcctcttttc cttttcccag

tcagacga tgccctgctg aagatgacca tcagccagca agagtttggc cgcactgggc 1080

cctgacct aagcagtatg actgaggaag agcagattgc ttatgccatg cagatgtccc 1140

cagggage agagtttgge caggeggaat cageagaeat tgatgeeage teagetatgg 1200

acatctga gccagccaag gaggaggatg attacgacgt gatgcaggac cccgagttcc 1260

cagagtgt cctagagaac.ctcccaggtg tggatcccaa caatgaagcc attcgaaatg 1320

atgggctc cctggcctcc caggccacca aggacggcaa gaaggacaag aaggaggaag 1380

aagaagtg agactggagg gaaagggtag ctgagtctgc ttaggggact gcatgggaag 1440

cggaatat agggttagat gtgtgttatc tgtaaccatt acagcctaaa taaagcttgg 1500

10> 70

11> 895

12> DNA

13> Homo sapiens

00> 70

catcttgc gtccccgcgt gtgtgcgcct aatctcaggt ggtccacccg agaccccttg 60

caccaacc ctagtccccc gcgcggcccc ttattcgctc cgacaagatg aaagaaacaa 120

atgaacca ggaaaaactc gccaaactgc aggcacaagt gcgcattggt gggaaaggaa 180

gctcgcag aaagaagaag gtggttcata gaacagccac agcagatgac aaaaaacttc 240

ttctcctt aaagaagtta ggggtaaaca atatctctgg tattgaagag gtgaatatgt 300

eolf-seql-S000001.txt

:acaaacca aggaacagtg atccacttta acaaccctaa agttcaggca tctctggcag 360

- gaacacttt caccattaca ggccatgctg agacaaagca gctgacagaa atgctaccca
  420
- :atcttaaa ccagcttggt gcggatagtc tgactagttt aaggagactg gccgaagctc
   480
- |CCCaaaca atctgtggat ggaaaagcac cacttgctac tggagaggat gatgatgatg
  540
- gttccaga tcttgtggag aattttgatg aggcttccaa gaatgaggca aactgaattg 600
- Itcaacttc tgaagataaa acctgaagaa gttactggga gctgctattt tatattatga 660
- gcttttta agaaattttt gtttatggat ctgataaaat ctagatctct aatattttta 720
- cccaagcc ccttggacac tgcagctctt ttcagttttt gcttatacac aattcattct 780
- gcagctaa ttaagccgaa gaagcctggg aatcaagttt gaaacaaaga ttaataaagt 840
- 10> 71
- 11> 1777
- 12> DNA
- 13> Homo sapiens
- 00> 71
- ctaccete geoegeeeg eggteeteeg teggttetet cattagteea eggtetggte 60
- cagctacc cgccttcgtc tccgagtttg cgactcgcgg gaccggcgtc cccggcgcga 120
- aggctgga ctcggattcg ttgcctgagc aatggctgcc atccggaaga aactggtgat 180
- ttggtgat ggagcctgtg gaaagacatg cttgctcata gtcttcagca aggaccagtt 240
- cagaggtg tatgtgccca cagtgtttga gaactatgtg gcagatatcg aggtggatgg 300
- agcaggta gagttggctt tgtgggacac agctgggcag gaagattatg atcgcctgag 360

eolf-seql-S000001.txt

:ccctctcc tacccagata ccgatgttat actgatgtgt ttttccatcg acagccctga 420

- gtttagaa aacatcccag aaaagtggac cccagaagtc aagcatttct gtcccaacgt 480
- ccatcatc ctggttggga ataagaagga tcttcggaat gatgagcaca caaggcggga 540
- tagccaag atgaagcagg agccggtgaa acctgaagaa ggcagagata tggcaaacag 600
- ttggcgct tttgggtaca tggagtgttc agcaaagacc aaagatggag tgagagaggt 660
- ttgaaatg gctacgagag ctgctctgca agctagacgt gggaagaaaa aatctggttg 720
- ttgtcttg tgaaaccttg ctgcaagcac agcccttatg cggttaattt tgaagtgctg 780
- tattaatc ttagtgtatg attactggcc titttcatit atctataatt tacctaagat 840
- caaatcag aagtcatctt gctaccagta tttagaagcc aactatgatt attaacgatg 900
- caacccgt ctggcccacc agggtccttt tgacactgct ctaacagccc tcctctgcac 960
- ccacctga cacaccagge getaattcaa ggaatttett aacttettge ttettetag 1020
- agagaaac agttggtaac ttttgtcaat taggctgtaa ctactttata actaacatgt 1080
- tgccctat tatctgtcag ctgcaaggta ctctggtgag tcaccacttc agggctttac 1140
- cgtaacag attttgttgg catagctctg gggtgggcag ttttgaaaat gggctcaacc 1200
- aaaagccc aagttcatgc agctgtggca gagttacagt tctgtggttt catgttagtt 1260
- cttatagt tactgtgtaa ttagtgccac ttaatgtatg ttaccaaaaa taaatatatc 1320
- cccagact agatgtagta ttttgtataa ttggattcta atactgtcat ctcaagaagt 1380
- atggttta aagaagtgta ttggaaataa agtcagatgg aaattcattt taaattcccg 1440
- igtcactt ttctgataaa agatggccat attacccctt ttcggcccca tgtatctcag

eolf-seql-S000001.txt

1500

.ccccatgg agctgggcta agtaaatagg aattggtttc acgcctcagg caattagaca 1560

ttggaaga tggcataacc tgtctcacct ggacttaagc gtctggctct aattcacagt 1620

tctttctc ctcactgtat ccaggttccc tcccagagga gccaccagtt ctcatgggtg 1680

actcagtc tctcttctct ccagctgact aaactttttt tctgtaccag ttaatttttc 1740

actactaa tagaataaag gcagttttct aaaaaaa 1777

10> 72

11> 1336

12> DNA

13>. Homo sapiens

00> 72

ggcttgca gagccggcgc cggaggagac gcacgcagct gactttgtct tctccgcacg 60

tgttacag aggtctccag agccttctct ctcctgtgca aaatggcaac tcttaaggaa 120

actcattg caccagttgc ggaagaagag gcaacagttc caaacaataa gatcactgta 180

gggtgttg gacaagttgg tatggcgtgt gctatcagca ttctgggaaa gtctctggct 240

tgaacttg ctcttgtgga tgttttggaa gataagctta aaggagaaat gatggatctg 300

gcatggga gcttatttct tcagacacct aaaattgtgg cagataaaga ttattctgtg 360

cgccaatt ctaagattgt agtggtaact gcaggagtcc gtcagcaaga aggggagagt 420

gctcaatc tggtgcagag aaatgttaat gtcttcaaat tcattattcc tcagatcgtc 480

gtacagtc ctgattgcat cataattgtg gtttccaacc cagtggacat tcttacgtat 540

tacctgga aactaagtgg attacccaaa caccgcgtga ttggaagtgg atgtaatctg 600

ttctgcta gatttcgcta ccttatggct gaaaaacttg gcattcatcc cagcagctgc

eolf-seql-S000001.txt

660

tggatgga ttttggggga acatggcgac tcaagtgtgg ctgtgtggag tggtgtgaat 720

ggcaggtg tttctctcca ggaattgaat ccagaaatgg gaactgacaa tgatagtgaa 780

ttggaagg aagtgcataa gatggtggtt gaaagtgcct atgaagtcat caagctaaaa 840

atatacca actgggctat tggattaagt gtggctgatc ttattgaatc catgttgaaa 900

tctatcca ggattcatcc cgtgtcaaca atggtaaagg ggatgtatgg cattgagaat 960

agtcttcc tgagccttcc atgtatcctc aatgcccggg gattaaccag cgttatcaac 1020

gaagctaa aggatgatga ggttgctcag ctcaagaaaa gtgcagatac cctgtgggac 1080

ccagaagg acctaaaaga cctgtgacta gtgagctcta ggctgtagaa atttaaaaac 1140

caatgtga ttaactcgag cctttagttt tcatccatgt acatggatca cagtttgctt 1200

atcttctt caatatgtga atttgggctc acagaatcaa agcctatgct tggtttaatg 1260

aaaaaaaa aaaaaa 1336

10> 73

11> 1414

12> DNA

13> Homo sapiens

00> 73

ctctgccc gccccagcc ctcgcccac cctcggcgcc cgcacatctg cctgctcagc 60

cagacggc gcccggaccc ccgggcgcgg gatccagcca ggtgggagcc ccgcagatga 120

tetetgaa ggtgtgeetg aaccagtgee ageetgeeet gtetgeagea teggeetgat 180

jgtggtga ctgatccctc agggctccgg agccatgtgg cccaacggca gttccctggg

### eolf-seql-S000001.txt

240

L320

cctgtttc cggcccacaa acattaccct ggaggagaga cggctgatcg cctcgccctg 300 tegeegee teettetgeg tggtgggeet ggeeteeaac etgetggeee tgagegtget 360 cgggcgcg cggcaggggg gttcgcacac gcgctcctcc ttcctcacct tcctctgcgg 420 togtoctc accgaettee tggggetget ggtgaceggt accategtgg tgteceagea 480 ccgcgctc ttcgagtggc acgccgtgga ccctggctgc cgtctctgtc gcttcatggg 540 tegteatg atettetteg geetgteece getgetgetg ggggeegeea tggeeteaga 600 gctacctg ggtatcaccc ggcccttctc gcgcccggcg gtcgcctcgc agcgccgcgc gggccacc gtggggctgg tgtgggcggc cgcgctggcg ctgggcctgc tgcccctgct 720 gcgtgggt cgctacaccg tgcaataccc ggggtcctgg tgcttcctga cgctgggcgc agtccggg gacgtggcct tcgggctgct cttctccatg ctgggcggcc tctcggtcgg 840 tgtccttc ctgctgaaca cggtcagcgt ggccaccctg tgccacgtct accacgggca aggeggee cageagegte ecegggaete egaggtggag atgatggete ageteetggg 960 tcatggtg gtggccagcg tgtgttggct gccccttctg gtcttcatcg cccagacagt 1020 tgcgaaac ccgcctgcca tgagccccgc cgggcagctg tcccgcacca cggagaagga igctcate tactigegeg tggccacetg gaaccagate etggaceeet gggtgtatat 1140 iqttecge egegeegtge teeggegtet eeageetege eteageacee ggeeeaggte 1200 igtocoto cagococago teacgoagog otocgggotg cagtaggaag tggacagago L260 sectoreg egecttteeg eggageeett ggeeettegg acageeeate tgeetgttet

## eolf-seql-S000001.txt

lggattcag gggctggggg tgctggatgg acagtgggca tcagcagcag ggttttgggt 1380

Jaccccaat ccaaccggg gacccccaac tect 1414

- :10> 74
- :11> 3080
- 112> DNA
- :13> Homo sapiens
- :00> 74
- :ccctttat ttccactccc cacccgcgtg gctttgctct ccctctcccc cctcagctcg 60
- :tgtatttg gagctccgga agctgccggc gactctcccc tggagcagcg tgactgacac 120
- gctcctat tcagctggga ggagggagag gggaggagaa ggggagggcc gcgggaggag 180
- rtacgagtg gccgaccacg gatttgcatt gccgaggacg ggaccccagg gcagcgaagc 240
- aatggcca acatgcaggg actggtggaa agactggaac gagctgtcag ccgcctggag 300
- gctgtctg cagagtccca caggccccct gggaactgcg gggaagtcaa tggtgtcatt 360
- aggtgtgg caccetecgt ggaageettt gacaagetga tggacagtat ggtggeegag 420
- tttaaaga acagtaggat ccttgctggg gacgtggaga cccatgcaga aatggtgcac 480
- tgctttcc aggcccagcg ggctttcctt ctgatggcct ctcagtacca acaaccccac 540
- gaatgacg tggccgcact tctgaaaccc atatcggaaa agattcagga aatccaaact 600
- cagagaga gaaaccgggg gagtaacatg tttaatcatc tttcggccgt cagcgaaagc 660
- ccctgccc ttggatggat agctgtgtct cccaaacctg gtccttatgt caaggagatg 720
- tgacgctg ccacctttta cactaacagg gtcttaaagg actacaaaca cagtgatttg 780
- tcatgtgg attgggtgaa gtcatatttg aacatttgga gtgaacttca agcatacatc 840

### eolf-seql-S000001.txt

ggaacacc acaccacggg cctcacatgg agcaaaacag gtcctgtagc atccacagta 900

agogtttt ctgtcctctc ctctgggcct ggccttcctc caccccctcc tcctctgcct 960

tccagggc cacctccact tttcgagaat gaaggcaaaa aagaggaatc ttctccttca 1020

ctcagctt tatttgccca acttaaccag ggagaagcaa ttacaaaagg gctccgccat 1080

cacagatg accagaagac atacaaaaat cccagcctgc gggctcaagg agggcaaact 1140

atotocca ccaaaagtca cactocaagt cccacatoto ctaaatotta toottotoaa 1200

acatgccc cagtgttgga gttggaagga aagaaatgga gagtggagta ccaagaggac 1260

gaatgacc ttgtgatttc agagactgag ctgaaacaag tggcttacat tttcaaatgc 1320

aaaatcaa ctattcagat aaaagggaaa gtaaactcca ttataattga caactgtaaa 1380

acteggee tggtgtttga caatgtggtg ggeattgtgg aagtgateaa eteceaggae  $1440\,$ 

tcaaatcc aggtaatggg gagagtgcca acaatttcca ttaataagac agaaggttgc 1500

catatacc tcagtgaaga tgcattagac tgtgagatcg tgagcgccaa gtcatctgaa 1560

gaacatac ttatccctca ggatggtgat tatagagaat ttcccattcc tgaacagttc
1620

jacagcat gggatggatc caagttaatc actgaacctg cagaaattat ggcctaactt
1680

lgagagac cgaacccct cacctgaatc cccctctatc aaacaaacaa aaaagcagca

aaagagct agaagttgca gtagccccta ctgctttagc tttggcctcc aacgattctg 1800

statagat acagcactgt ttctggcacg cctcgtgggc attttgaaat atttaacgtt 1860

stcatgat ttgcctttgt gtgtgatttt agttccacat gatgacttgt gaacattagg 1920

eolf-seq1-S000001.txt

tttaaagg aaaaaaaaa agaattetgt teeesteata teatgaacae agtaactgat 1980

gtaaaaag actgcatgat tcacttttac acttatattt cattgctagt taaaaaataa 2040

.cctttgag aatctaagat gtacattttt accttttagg caatttcaat ataatgtaga 2100

tagtagtg tgccctgaaa aatgtacacg ttttttctta ttgttaccac atgttcacct 2160

atcagcgt ggatactgtc agcatgagta catatttcaa cccacgcttg taaaagacat 2220

gagtttat aaaggaccaa attcagttcc ttggtccttg gaagacctat attctctgta 2280

tactgaaa accgaaagtc aattctaatt attcatctta catatttttc caccatgtca 2340

tgaaaact tgcttttctt ctgcataaga gattcttatg ccaaaaacat taaacagaag 2400

atcatttt ttttgctatg taatacctcg caactttgct ctaaaatcaa gctcagttat 2460

ttttccaa gtttgaacat gttaaatatc agatgccttg taaattatgt ctttaacgtt 2520

cttataga ctaatttcct cttttccacc tgccagactt gctaaccaag ctcgaaaatg 2580

catgaaaa agccatacat gtattatttc tcctaaaacc taaggcatta tctgttggtt 2640

gcttgctg ctcctatttt gtagtcttga tagtagatgc ttcttcagcg taagagtagc 2700

tgatattc ctttttatct tttcagtaca tagtgctgaa aaatctgcaa cttcttggat 2760

tatttaat gaattatagt ataatgcttg caggcccagt acaagcatat atattgtgcc 2820

ttacagcc tttggaatac attgtttcca ttttttaaat atcttctata tccatatagt 2880

tcaaatta ttaatgctca tgtaccaagg ttttgctata aaagttttgt ctgtatgaat 2940

tgtggctt tagtaaataa tcatttttca actgtaaact tattctgaaa taaagtaaaa 3000

eolf-seql-S000001.txt

3060

aaaaaaaa aaaaaaaaaa 3080

10> 75

11> 2181

12> DNA

13> Homo sapiens

00> 75

agageega getetggage eteagegage ggaggaggag gegeagggee gaeggeegag 60

ctgcggtg agagccagcg ggccagcgc agcctcaaca gccgccagaa gtacacgagg 120

ccggcggc ggcgtgtgcg tgtaggcccg tgtgcgggcg gcggcgcggg aggagcgcgg 180

cggcagcc ggctgggcg.ggtggcatca tggacgagaa ggtgttcacc.aaggagctgg. 240

cagtggat cgagcagctg aacgagtgca agcagctgtc cgagtcccag gtcaagagcc 300

tgcgagaa ggctaaagaa atcctgacaa aagaatccaa cgtgcaagag gttcgatgtc 360

gttactgt ctgtggagat gtgcatgggc aatttcatga tctcatggaa ctgtttagaa 420

ggtggcaa atcaccagat acaaattact tgtttatggg agattatgtt gacagaggat 480

tattcagt tgaaacagtt acactgcttg tagctcttaa ggttcgttac cgtgaacgca 540

accattct tcgagggaat catgagagca gacagatcac acaagtttat ggtttctatg 600

gaatgttt aagaaaatat ggaaatgcaa atgtttggaa atattttaca gatctttttg 660

tatettee teteactgee ttggtggatg ggeagatett etgtetaeat ggtggtetet 720

ccatctat agatacactg gatcatatca gagcacttga tcgcctacaa gaagttcccc 780

jagggtcc aatgtgtgac ttgctgtggt cagatccaga tgaccgtggt ggttggggta 840

ictcctcg aggagctggt tacacctttg ggcaagatat ttctgagaca tttaatcatg

# eolf-seql-S000001.txt

900

caatggcct cacgttggtg tctagagctc accagctagt gatggaggga tataactggt 960

ccatgaccg gaatgtagta acgattttca gtgctccaaa ctattgttat cgttgtggta

ccaagctgc aatcatggaa cttgacgata ctctaaaata ctctttcttg cagtttgacc 1080

agcacctcg tagaggcgag ccacatgtta ctcgtcgtac cccagactac ttcctgtaat 1140

aaattttaa acttgtacag tattgccatg aaccatatat cgacctaatg gaaatgggaa 1200

agcaacagt aactccaaag tgtcagaaaa tagttaacat tcaaaaaact tgttttcaca 1260

Jgaccaaaa gatgtgccat ataaaaatac aaagcctctt gtcatcaaca gccgtgacca

ttagaatg aaccagttca ttgcatgctg aagcgacatt gttggtcaag aaaccagttt

ggcatage getatttgta gttacttttg etttetetga gagaetgeag ataataagat

aaacatta acacctcgtg aatacaattt aacttccatt tagctatagc tttactcagc 1500

gactgtag ataaggatag cagcaaacaa tcattggagc ttaatgaaca tttttaaaaa 1560

attaccaa ggcctccctt ctacttgtga gttttgaaat tgttctttt attttcaggg

accgttta atttaattat atgatttgtc tgcactcagt ttattcccta ctcaaatctc

occcatgt tgttctttgt tattgtcaga acctggtgag ttgttttgaa cagaactgtt

:tcccctt cctgtaagac gatgtgactg cacaagagca ctgcagtgtt tttcataata

ttgtgaa ctaagaactg agaaggtcaa attttaattg tatcaatggg caagactggt.860

.gtttatt aaaaaagtta aatcaattga gtaaatttta gaatttgtag acttgtaggt

ataaaaa tcaagggcac tacataacct ctctggtaac tccttgacat tcttcagatt

### eolf-seql-S000001.txt

cttcagga tttatttgta tttcacatat tacaatttgt cacattgttg gtgtgcactt 2040

rtgggttct tcctgcatat taacttgttt gtaagaaagg aaatctgtgc tgcttcagta 2100

acttaatt gtaaaaccat ataacttgag atttaagtct ttgggttgtg ttttaataaa 2160

agcatgtt ttcaggtaga g 2181

10> 76

11> 1315

12> DNA

13> Homo sapiens

00> 76

cttccgtc cagaccggaa cccaagatgg ctgcgctgtt gctgagacac gttggtcgtc 60

tgcctccg agcccacttt agccctcagc tctgtatcag aaatgctgtt cctttgggaa 120

acggccaa agaagagatg gagcggttct ggaataagaa tataggttca aaccgtcctc 180

tctcccca cattactatc tacagttggt ctcttcccat ggcgatgtcc atctgccacc 240

ggcactgg tattgctttg agtgcagggg tctctctttt tggcatgtcg gccctgttac 300

cctgggaa ctttgagtct tatttggaac ttgtgaagtc cctgtgtctg gggccagcac 360

atccacac agctaagttt gcacttgtct tccctctcat gtatcatacc tggaatggga 420

cgacactt gatgtgggac ctaggaaaag gcctgaagat tccccagcta taccagtctg 480

gtggttgt cctggttctt actgtgttgt cctctatggg gctggcagcc atgtgaagaa 540

gaggetee cageateate tteetacaea ttattacatt cacceatett tetgtttgte 600

tcttatct ccagcctggg aaaagttctc cttatttgtt tagatccttt tgtattttca 660 .

tctccttg gagcagtaga gtacctggta gaccataata gtggaaaagg gtctagttt 720

### eolf-seql-S000001.txt

:ccttgttt ctaaagatga ggtggctgca aaaactcccc ttttttgccc acagcttgcc 780

ctctcggc ctagaagcag ttattctctc tccatattgg gctttgattt gtgctgaggg 840

agettttg geteettett eetgagaeag tggaaaeaat geeagetetg tggettetge 900

tggggatg ggccgggttg gggggtgggt tgggtgaagc tttgggttgc cactgcctgt 960

gtttgctg gcttaaagga caattctctt tcattggtga gagcccaggc cattaacaac 1020

acacagtg ttattgaaag aagagggtg ggggtggagg ggaattagtc tgtcccagct 1080

agggagat aaagagggct agttagttct tggagcagct gcttttgagg agaaaatata 1140

gctttgga cacgaggaag atctagaaaa ttatcattga acatattaat ggttatttct 1200

ttcttgga tttccagaaa agcctcttaa ttttatgctt tctcatcgaa gtaatgtacc 1260

ttttttct gaaactgaat taaatactca ttttaaaaaa aaaaaaaaa aaaaa 1315

- 10> 77
- 11> 1249
- 12> DNA
- 13> Homo sapiens
- 00> 77

cacgagec agggttteet etteaagtag gtetaaaaca tttttttet eattgaette 60

tcctgttc taactgccag tactcagaag tcagagttga gagacagagg cacccggac 120

agacgtga agcactgaat aaatagatca gaatgactga aaaagcccca gagccacatg 180

gaggagga tgacgatgat gagctggaca gcaagctcaa ttataagcct ccaccacaga 240

tccctgaa agagctgcag gaaatggaca aagatgatga gagtctaatt aagtacaaga 300 .

acgctgct gggagatggt cctgtggtga cagatccgaa agcccccaat gtcgttgtca 360

### eolf-seql-S000001.txt

:Cggctcac cctggtttgt gagagtgccc cgggaccaat caccatggac cttactggag 420

- ctggaagc cctcaaaaag gaaaccattg tgttaaagga aggttctgaa tatagagtca 480
- attcactt caaagtgaac agggatattg tgtcaggcct gaaatacgtt cagcacacct 540
- :aggactgg ggtgaaagtg gataaagcaa catttatggt tggcagctat ggacctcggc 600
- gaggagta tgagttcctc actccagttg aggaggctcc caagggcatg ctggcccgag 660
- acgtacca caacaagtcc ttettcaccg acgatgacaa gcaagaccac etcagetggg 720
- tggaacct gtcgattaag aaggagtgga cagaatgaat gcatccacc cgttccccac 780
- ttgccacc tggaagaatt ctctcaggcg tgttcagcac cctgtccctc ctccctgtcc 840
- agctgggt ccctcttcaa cactgccaca tttccttatt gatcgatctt ttcccaccct 900
- cactcaac gtggtcccta gaacaagagg cttaaaaccg ggctttcacc caacctgctc 960
- tctgatcc tccatcaggg ccagatcttc cacgtctcca tctcagtaca caatcattta 1020
- atttccct gtcttacccc tattcaagca actagaggcc agaaaatggg caaattatca 1080
- aacaggtc tttgactcag gttccagtag ttcattctaa tgcctagatt cttttgtggt 1140
- ttgctggc ccaatgagtc cctagtcaca tcccctgcca gagggagttc ttcttttgtg 1200
- agacactg taaacgacac aagagaacaa gaataaaaca ataactgtg 1249
- 10> 78
- 11> 1890
- 12> DNA
- 13> Homo sapiens
- 00> 78
- egegageg gaegeggeag egeetetgte tegettttte ttattttee eccettteee 60

## eolf-seql-S000001.txt

:ttcttttt tttttttct tttcttttct cccctcccc cctttcacca tttcccctcg 120

- iggcgcttt ccccgggcag gggcagagcc ggtctcaccc cccgcctctc cccggccccc
  180
- :cgccctat ggcgagaggg agccccctcc caacccgggc tcgagcggcg gcggcctcag 240
- :cgggggtc atcatggaac taattcgctg accgacccag cggccgcagc cgtgcgtccc 300
- :tcgagcgc cagcgcccgc gcccgcgccc cccgatccgc ttcccctttc tccctcctca 360
- tggccgag tcgtcccgcg cgcaccgcct ccgcgcgcct atgagaatga ggtggtaacg 420
- rececegga tgacceegeg teaceactgt gaggeetaca getetgeegg ggaggaggag 480
- ggaggaag aggaggagaa ggtagctaca gcaagctggg tagcaggcag atccaaagga 540
- tcatgaag tttccagggc ctttggaaaa ccagagattg tctttcctgt tggaaaaggc 600
- tcactagg gaagcacaga tgtggaaagt gaatgtgcgg aaaatgcctt caaatcagaa 660
- tttctcca tcccagagag atgaagtaat tcaatggctg gccaaactca agtaccaatt 720
- acctttac ccagaaacat ttgctctggc tagcagtctt ttggataggt ttttagctac 780
- taaaggct catccaaaat acttgagttg tattgcaatc agctgttttt tcctagctgc 840
- agactgtt gaggaagatg agagaattcc agtactaaag gtattggcaa gagacagttt 900
- gtggatgt tcctcatctg aaattttgag aatggagaga attattctgg ataagttgaa 960
- gggatctt cacacagcca caccattgga ttttcttcat attttccatg ccattgcagt 1020
- caactagg cctcagttac ttttcagttt gcccaaattg agcccatctc aacatttggc 1080
- tccttacc aagcaactac ttcactgtat ggcctgcaac caacttctgc aattcagagg 1140

eolf-seql-S000001.txt

ccatgctt getetggcca tggttagtet ggaaatggag aaactcatte etgattgget 1200

ctcttaca attgaactgc ttcagaaagc acagatggat agctcccagt tgatccattg 1260

3ggagett gtggeacate acctttetae tetgeagtet teeetgeete tgaatteegt 1320

:atgtctac cgtcccctca agcacaccct ggtgacctgt gacaaaggag tgttcagatt 1380

satccetce tetgteecag geceagaett etecaaggae aacageaage cagaagtgee 1440

stcagaggt acagcagcct tttaccatca tctcccagct gccagtgggt gcaagcagac 1500

ctactaaa cgcaaagtag aggaaatgga agtggatgac ttctatgatg gaatcaaacg 1560

:tctataat gaagataatg tctcagaaaa tgtgggttct gtgtgtggca ctgatttatc 1620

gacaagag ggacatgett eccettgtee acetttgeag eetgtttetg teatgtagtt 1680

:aacaagtg ctacctttga gtgtaaacta aggtagacta ctttgggaat gagaacatgc 1740

aatcagga aaggctgtag aaggaaatat accttaacag gctgatttgg agtgagccag

aaaaaaaa taaaactctc attatttgtg tggctaatta taattcagcg ttatttaagc 1860

ataaagac caaaaaaaaa aaaaaaaaaa 1890

10> 79

11> 1124

12> DNA

13> Homo sapiens

00> 79

cgctgcca ccgcaccccg ccatggagcg gccgtcgctg cgcgccctgc tcctcggcgc 60

ctgggctg ctgctcctgc tcctgcccct ctcctcttcc tcctcttcgg acacctgcgg 120

eolf-seql-S000001.txt

gcgacgcg tgcggctgct gccctatgtg cgcccgcggc gagggcgagc cgtgcggggg 240

gcggcgcc ggcagggggt actgcgcgcc gggcatggag tgcgtgaaga gccgcaagag 300

ggaagggt aaagccgggg cagcagccgg cggtccgggt gtaagcggcg tgtgcgtgtg 360

agageege tacceggtgt geggeagega eggeaceace taccegageg getgeeaget 420

gcgccgcc agccagaggg ccgagagccg cggggagaag gccatcaccc aggtcagcaa, 480

gcacctgc gagcaaggtc cttccatagt gacgccccc aaggacatct ggaatgtcac 540

gtgcccag gtgtacttga gctgtgaggt catcggaatc ccgacacctg tcctcatctg 600

acaaggta aaaaggggtc actatggagt tcaaaggaca gaactcctgc ctggtgaccg. .\_\_ 660

acaacctg gccattcaga cccggggtgg cccagaaaag catgaagtaa ctggctgggt 720

tggtatct cctctaagta aggaagatgc tggagaatat gagtgccatg catccaattc 780

aaggacag getteageat eageaaaaat tacagtggtt gatgeettae atgaaatace  $840\,$ 

tgaaaaaa ggtgaaggtg ccgagctata aacctccaga atattattag tctgcatggt 900

aaagtagt catggataac tacattacct gttcttgcct aataagtttc ttttaatcca 960

ccactaac actttagtta tattcactgg ttttacacag agaaatacaa aataaagatc 1020

acatcaag actatctaca aaaatttatt atatatttac agaagaaaag catgcatatc 1080

- 10> 80
- 11> 1867
- 12> DNA
- 13> Homo sapiens
- )0> 80

eolf-seql-S000001.txt

rttcgctgt ggcgggcgcc tgggccgccg gctgtttaac ttcgcttccg ctggcccata

- gatctttg cagtgaccca gcagcatcac tgtttcttgg cgtgtgaaga taacccaagg 120
- ttgaggaa gttgctgaga agagtgtgct ggagatgctc taggaaaaaa ttgaatagtg 180
- acgagttc cagcgcaagg gtttctggtt tgccaagaag aaagtgaaca tcatggatca 240
- acaacage etgecacett aegeteaggg ettggeetee eeteagggtg ceatgactee 300
- gaateeet atetttagte caatgatgee ttatggeaet ggaetgaeee caeageetat 360
- agaacacc aatagtotgt otattttgga agagcaacaa aggcagcagc agcaacaaca 420
- agcagcag cagcagcagc agcagcagca gcagcagcagc agcagcagca 480
- agcagcag cagcagcagc agcagcagca gcaacaggca gtggcagctg cagccgttca 540
- agtcaacg tcccagcagg caacacaggg aacctcaggc caggcaccac agctcttcca 600
- cacagact ctcacaactg caccettgcc gggcaccact ccactgtatc cctccccat 660
- ctcccatg accccatca ctcctgccac gccagcttcg gagagttctg ggattgtacc 720
- agctgcaa aatattgtat ccacagtgaa tcttggttgt aaacttgacc taaagaccat 780
- cacttcgt gcccgaaacg ccgaatataa tcccaagcgg tttgctgcgg taatcatgag 840
- taagagag ccacgaacca cggcactgat tttcagttct gggaaaatgg tgtgcacagg 900
- ccaagagt gaagaacagt ccagactggc agcaagaaaa tatgctagag ttgtacagaa 960
- tgggtttt ccagctaagt tcttggactt caagattcag aatatggtgg ggagctgtga 1020
- tgaagttt cctataaggt tagaaggcct tgtgctcacc caccaacaat ttagtagtta 1080
- agccagag ttatttcctg gtttaatcta cagaatgatc aaacccagaa ttgttctcct

eolf-seql-S000001.txt

1140

tttttgtt tctggaaaag ttgtattaac aggtgctaaa gtcagagcag aaatttatga 1200

catttgaa aacatctacc ctattctaaa gggattcagg aagacgacgt aatggctctc 1260

gtaccett geeteecea ecceettett ttttttttt taaacaaate agtttgtttt 1320

taccttta aatggtggtg ttgtgagaag atggatgttg agttgcaggg tgtggcacca 1380

tgatgccc ttctgtaagt gcccaccgcg ggatgccggg aaggggcatt atttgtgcac 1440

agaacacc gcgcagcgtg actgtgagtt gctcataccg tgctgctatc tgggcagcgc 1500

cccattta tttatatgta gattttaaac actgctgttg acaagttggt ttgagggaga 1560

actttaag tgttaaagcc acctctataa ttgattggac tttttaattt taatgttttt 1620

ccatgaac cacagttttt atatttctac cagaaaagta aaaatctttt ttaaaagtgt 1680

tttttcta atttataact cctaggggtt atttctgtgc cagacacatt ccacctctcc 1740

tattgcag gacagaatat atgtgttaat gaaaatgaat ggctgtacat attttttct 1800

cttcagag tactctgtac aataaatgca gtttataaaa gtgttaaaaa aaaaaaaaa 1860

aaaaa 1867

10> 81

11> 3236

12> DNA

13> Homo sapiens

00> 81

ccgggcgg cgtgggcgtg agaggcgggg cggggccgcg ctctgcttgc caatgtcttt 60

aggtcacc cggaaggcac gcggaacctc ggcgcggtgc ttccagcagg gtctctccgc 120

stocages ecgegeeest egeogegges etegggegte tgegeegeag etgeegeee

eolf-seql-S000001.txt

180

cototttg gagtototog oggootoaaa gogoggootg ogtogottoo ggoagttoco 240

.ccgcgggc gatggctgcc gctgggggcg cccggctgct gcgcgccgct tctgctgtcc 300

ggcggccc ggccggccgg tggctgcacc acgctgggtc ccgcgctgga tccagcggcc 360

ctgaggaa ccgggggccg ggcgggagcg cggaggcgag ccggtcgctg agcgtgtcgg 420

cgggcccg gagcagctca gaagataaaa taacagtcca ctttataaac cgtgatggtg 480

acattaac aaccaaagga aaagttggtg attctctgct agatgttgtg gttgaaaata 540

ctagatat tgatggcttt ggtgcatgtg agggaaccct ggcttgttca acctgtcacc .600

atctttga agatcacata tatgagaagt tagatgcaat cactgatgag gagaatgaca 660

ctcgatct ggcatatgga ctaacagaca gatcacggtt gggctgccaa atctgtttga 720

aaatctat ggacaatatg actgttcgag tgcctgaaac agtggctgat gccagacaat 780

attgatgt gggcaagacc teetgaacta gaacaaatag gaatatttte atggaatttt  $840\,$ 

ctattttt ataattatta tttcttaaag tgattaaatg agaacatgga tgagtggact 900

atattatg actagcttta ctattttaat tcaccttgca taactactga attttgtcat 960

ttgaaagt atgcaatttt tattttggtt atattacaaa aatgtcaatc aaatattaaa 1020

atagttaa tgtgatagaa aaaccttaca tattttttc ttatgtttgt ttagcgactt 1080

gcaaaatg ttttcatata atctcatctg tttacctaga agataggtta aggaaatata 1140

attattcc tgtttgatgt gggtgaaggc agagatctaa cctggcttgt ttagggccat 1200

cactaatt agaaaatctg tgctagaacc tgtgtcttat tcctataagc tatgtgttca 1260

# eolf-seql-S000001.txt

iCtgaaact ggagaaatta tgactatttt atttatagta gtagttaaat ctgaatgtgt 1320

ggacaaaa atatttaatt gctcagtaaa ctgcttaact tcaaagatag ttattgacct 1380

ıtaaataaa tatttcaaaa ttttgattcg gaagactaag tctggacgta gacattataa 1440

sctatcaaa gaagtttgat ctctgttttg actaaactag aggaaaaatg attggatgtg
1500

tattettt tetaageaga atggtttaae tttgtaetet ttgaaaaata atgetgattt 1560

aaatctct gcctataaca gaatggaaac cttatgaatg aattgtgttt ctctgtcctg

ictggagaa gggaatgagc aggctgacac gttgcacagc cccaggtggc gccattctct
1680

.cgcaagga tggggctgca gggtgagcag cgtgggctgc agtgtgtcag tcccaggagt 1740

gggagtgg caagcaccac agattaccac gtatgtgtgg aagacattcg tactcttatc 1800

tactataa ataaattcat aaaagttaac aaaggggtac acagtatggt ctttggaaat 1860

aataaaac atcaactaac ttggactaat tgtgaggaag agcagaacaa attagtagaa 1920

aggttata agacaattga gttagcttca tgtgtattat tgcagcttga tcatttatat 1980

atatttgt ctagtacaat gcttgacata cagcattgtg ttatgcccat tggggacaca 2040

ggtgaaca agacaaggaa tgccatcagg gaattcacct tttattagga aaatataaaa 2100

tgtatgta tgtgcagata atttgcttga actaaactga ctagttctgc taaataagat 2160

taaactaa ttcatatgta aaaagtgatt aggaagaact tgaagtatca tttgatgctt 2220

taactatt gagtagtttt ttttttttt ttttggtggg gggagcgggg gacagggtct 2280

ctctgtca ctcaggccag agtacaatag tatgatctcg gctcactgca acttctgcct 2340

eolf-seq1-S000001.txt

Cagtttca agggattctc gtgcctcagc ctcccaggta gctggtacta caggcacgga 2400

accacgee tggetaattt ttgtattttt tetagggaca gggttttace acgttgeeca 2460

sctggtctt gaacttttga gctcgagtga tccacccacc tcagcctccc aaaatgctgg 2520

ttacagat gtgagccacc gtgcttggcc ataactattg aatgctttct atgtggagag 2580

scttgtctt aattttctgt tgctataata gaataacaca gactgggtaa tttataaaga 2640

agagattt atttggatca tggttctgga ggctgggagg tccaagagca tggtaccagc 2700

ctgcttgg catctggtga cagctttctt gctgcatcat tacatggtgg aagggcaaga 2760

atgcgagt gagagcaaga gggcaaaatg attateettt tateaggage eeacttetga 2820

taactaac ccacacctga gataacggca ttaatccatt catgaggtct ctgctcttaa 2880

gagateae etettaaagg acceaeettt eaatgeeatt acaetggeaa tttaatttea 2940

atgagttt tggaggggac attcaaacca tagcagtgct ataattttaa agtacttcaa 3000

ccaattta ttctcttaat tagcttcatt attcttgtct ttgtgtgtgg attacctaaa 3060

ctccttcc agagctactt taatgattat attcaaccaa agcactctaa aatttagagt 3120

aaattgtc ttatatttca aattagaaaa gttcaaatga agtttaattg tgttatttta 3180

- 10> 82
- 11> 787
- 12> DNA
- 13> Homo sapiens
- 00> 82

actgtgga ggggcgcacg cccggaagcg gcgagggtag ccatgacggc ctccgtgctg 60

eolf-seql-S000001.txt

magtatet egetageeet gegeeegaet agegggette tgggaaettg geagaegeag

- tagagaga ctcaccagcg agcgtcattg ttgtctttct gggaactcat tcccatgaga 180
- agaacete ttegaaaaaa gaagaaggta gateetaaaa aagaeeaaga ageaaaggag 240
- cttgaaaa ggaagatccg aaaactggaa aaggctactc aagagctaat tcctattgaa 300
- ttttatta cccctctaaa gttcttggat aaagcaagag agcggcctca ggtggagctc 360
- ctttgagg agactgagag gagagctctg cttctgaaga agtggtcctt gtacaagcag 420
- agagcgta agatggagag ggacaccatc agggctatgc tagaagccca gcaggaagct 480
- ggaggaac tgcaactgga atccccgaag ctccatgctg aggccatcaa gcgggatcct ...
- cctgttcc cctttgagaa ggaagggcca cattacacac caccgatccc taactaccaa 600
- ccctgaag gcaggtacaa tgacatcacc aaggtgtaca cacaagtgga gtttaagaga 660
- gacttgca ggctgctatc cttaacatgc tgcccctgag agtaggaatg accagggttc 720
- gtctgctt tccacagaat caggcatgct gttaataaat actggtttaa tcaaaaaaa 780

aaaaa 787

- 10> 83
- 11> 912
- 12> DNA
- 13> Homo sapiens
- 00> 83
- agggatet gageagetee ttetageate etteateett eaggtaceag ceateeagae 60
- tgcttgag ctgcagaaac tgagaccaga cctctggcct ggccctcccc aggggcctcc 120
- tcctatag tcactgcttc tgcatcagat actttcagct gcaactccct actgggtggg 180

eolf-seql-S000001.txt

acceattt caggeagaag gttttggtae eetecaetga eeetaeaeee agggetgeta 240

- gccgcttg tggcttcagg atgaaaggtg agaccccggt gaacagcact atgagtattg 300
- caagcacg caagatggtg gaacagetta agattgaage cagettgtgt eggataaagg 360
- tocaagge ageageagae etgatgaett aetgtgatge eeaegeetgt gaggateeee 420
- atcacccc tgtgcccact tcggagaacc ccttccggga gaagaagttc ttctgtgctc 480
- ctctgagc tcccctgtcc cttctcacaa ctcctccctt ttccctctcc tgggcccttc 540
- gaccatgt gaggttatct gaagcacaag gcccaccctc acctatctgt cgaccccatt 660
- ctaccacc tttgtggccg accccaagca ccccagagat atgaggcacc ctttgctcca 720
- cacagoag ggccccgtca gactotgcca gcgcgtcctg cccgcttccc tcggtgacct 780
- tcagacaa tggagaggga tgggccaggt tcttgctctc agtctcacct ggagctactg 840
- agggtaaa gccatttgaa gaataaagtc atccagagcc ccaaaaaaaa aaaaaaaaa 900

aaaaaaaa aa 912

- 10> 84
- 11> 1700
- 12> DNA
- 13> Homo sapiens
- 00> 84
- agcogoco gggococogo cagootocot cotogogtoo otoggtgtoo toogogggoo 60
- sqcgatgc ggctgggccc gaggaccgcg gcgttggggc tgctgctgct gtgcgccgcc
  120
- gccggcg ccggcaaggc cgaggagctg cactacccgc tgggcgagcg ccgcagcgac 180

#### eolf-seql-S000001.txt

- regacegeg aggegetget gggegteeag gaagatgtgg atgaatatgt taaactegge 240
- cgaagagc agcaaaaaag actgcaggcg atcataaaga aaatcgactt ggactcagat 300
- rctttctca ctgaaagtga actcagttca tggattcaga tgtcttttaa gcattatgct
  360
- gcaagaag caaaacaaca gtttgttgaa tatgataaaa acagtgatga tactgtgact 420
- ggatgaat ataacattca gatgtatgat cgtgtgattg actttgatga gaacactgct 480
- ggatgatg cagaagagga gtcctttagg aagcttcact taaaggacaa gaagcgattt 540
- aaaagcta accaggattc aggtcccggt ttgagtcttg aagaatttat tgcttttgag 600
- tcctgaag aagttgatta tatgacggaa tttgtcattc aagaagcttt agaagaacat .....
- caaaaatg gtgatggatt tgttagtttg gaagaatttc ttggtgatta caggtgggat 720
- aactgcaa atgaagatcc agaatggata cttgttgaga aagacagatt cgtgaatgat 780
- tgacaaag ataacgatgg caggcttgat ccccaagagc tgttaccttg ggtagtacct 840
- taatcagg gcattgcaca agaggaggcg cttcatctaa ttgatgaaat ggatttgaat 900
- tgacaaaa agctctctga agaagagatt ctggaaaacc cggacttgtt tctcaccagt 960
- agccacag attatggcag acagctccat gatgactatt tctatcatga tgagctttaa 1020
- tccgagcc tgtctcagta gagtactggc tccttttata atttgttacc agctttactt 1080
- gtgataaa atattgatgt tgtattttac actcttaagt cttaaccaca gtcagaatta 1140
- ttaatgta gaattataat tttggctctt ttaggaaaaa acaaaatctg atatttttcc 1200
- acgtattg agcaacaaaa tattaatatt gtgccatatg acaacaaagt ctttcctaaa 1260
- ctccatct gtttagtact gtattgtgga atatttgagt tctatttcca gacttgaaaa

eolf-seql-S000001.txt

1320

tggaggat tttagagatg cctgaacaat attatttaag tagtatgtga ccgagctata

ıttttttgt ttttgttcta agtagattta atttgggaac tgacaggaca atgtttttag 1440

ttagcatt ttgtttaaaa acctttaaag aaacctttag aaggacttag acctcacata 1500

aatgttga gaagttetge ttaattttaa aatggtttet ataaagggtt ttattgtatg

atagaact ttatattttt gcatatgtat agaggataat tatatttaat gtataactat 1620

cattatgg tgagtggaat ttgacattgt ccaaaccttt ttcatttttg agtgattaaa 1680

. . . . . .

tgaaatgt cctttgtaaa 1700...

10> 85

11> 961

12> DNA

13> Homo sapiens

00> 85

gaggcgtg cgaactggtg gcagtgagag acttcggcgg acatggctcc cagcgtgcca 60

ggcagaac ccgagtatcc taaaggcatc cgggccgtgc tgctggggcc tcccggggcc 120

taaaggga cccaggcacc cagattggct gaaaacttct gtgtctgcca tttagctact 180

ggacatgc tgagggccat ggtggcttct ggctcagagc taggaaaaaa gctgaaggca 240

tatggatg ctgggaaact ggtgagtgat gaaatggtag tggagctcat tgagaagaat 300

ggagaccc ccttgtgcaa aaatggtttt cttctggatg gcttccctcg gactgtgagg 360

ggcagaaa tgctcgatga cctcatggag aagaggaaag agaagcttga ttctgtgatt 420

attcagca teccagaete tetgetgate egaagaatea eaggaagget gattcaeeee 480

gagtggcc gttcctacca cgaggagttc aaccctccaa aagagcccat gaaagatgac

eolf-seql-S000001.txt

540

caccgggg aaccettgat ccgtcgatca gatgataatg aaaaggeett gaaaatccgc 600

gcaagest accaectea aaccaeceea eteatagagt actaeaggaa acgggggate 660

ictccgcca tcgatgcatc ccagaccccc gatgtcgtgt tcgcaagcat cctagcagcc 720

ctccaaag ccacatgtaa agacttggtt atgtttatct aatgttgggt ccaagaagga 780

ttctttcc atccctgtga ggcaatggt gggaatgata ggacaggcaa agagaagctt 840

tcaggcta gcaaaaatat catttgatgt attgattaaa aaagcacttg cttgatgtat 900

ttggcgtg tgtgctactc tcatctgtgt gtatgtgtgt tgtgtgtgtg tgtgtgtgca 960 .

961

10> 86

11> 700

12> DNA

13> Homo sapiens

00> 86

ggcgtgag aagccatgag cagcaaagtc tctcgcgaca ccctgtacga ggcggtgcgg 60

agtcctgc acgggaacca gcgcaagcgc cgcaagttcc tggagacggt ggagttgcag 120

cagcttga agaactatga tccccagaag gacaagcgct tctcgggcac cgtcaggctt 180

gtccactc cccgccctaa gttctctgtg tgtgtcctgg gggaccagca gcactgtgac 240

ggctaagg ccgtggatat ccccacatg gacatcgagg cgctgaaaaa actcaacaag 300

taaaaaac tggtcaagaa gctggccaag aagtatgatg cgtttttggc ctcagagtct 360

gatcaage agattccaeg aateetegge eeaggtttaa ataaggeagg aaagtteeet 420

cctgctca cacacaacga aaacatggtg gccaaagtgg atgaggtgaa gtccacaatc

eolf-seql-S000001.txt

480

gttccaaa tgaagaaggt gttatgtctg gctgtagctg ttggtcacgt gaagatgaca 540

cgatgagc ttgtgtataa cattcacctg gctgtcaact tcttggtgtc attgctcaag 600

.aaactggc agaatgtccg ggccttatat atcaagagca ccatgggcaa gccccagcgc 660

atattaag gcacatttga ataaattcta ttaccagttc 700

10> 87

11> 3750

12> DNA

13> Homo sapiens

00> 87

cggcgcgc gcggccccgg cgagcagggg aagccggtgg ccgcggctgc ggaacgggcg 60

ggctgccg gtttcgtaac cgtcgctcct cctcgctgac tcgcgggctg tgaggcctgg 120

cggctcgg gccgcaccgc gcggggccgc tcggagtgga ggccgcctgg gggcaggcgg 180

tagaggag caggtacatg tgaagatttt ttggcagctt agcgtggaaa ccattgatca 240

ctgctctc atttctacct gttctgtgtt ggcaagggag agtgcccaaa tgagcaagat 300

cgcagcaa aacagcactc caggggtgaa cggaattagt gttatccata cccaggcaca 360

ccagcggc ttacagcagg ttcctcagct ggtgcctgct ggccctgggg gaggaggcaa 420

ctgtggct cccagcaagc agagcaaaaa gagttcgccc atggatcgaa acagtgacga 480

atcggcaa cgccgagaga ggaacaacat ggctgtgaaa aagagccggt tgaaaagcaa 540

agaaagca caagacacac tgcagagagt caatcagctc aaagaagaga atgaacggtt 600

aagcaaaa atcaaattgc tgaccaagga attaagtgta ctcaaagatt tgtttcttga 660

atgcacac aaccttgcag acaacgtaca gtccattagc actgaaaata cgacagcaga

eolf-seql-S000001.txt

720

gcgacaat gcaggacagt agacctcacc ctttccagac tttagagctt gtggcttgaa 780

ttaaaggt gtgaccaccg acaccactca tgtcaatggc tgaaagttgt ccatttccat 840

ctcaaaga cccattggag gctattttct gggatcagca ctgaagagtt gattagctaa 900

atgttagc cttgtaattc gaatatctgg ttttaaatga tagaggtttt tgtgggaatc 960

aatccccc aaatgttaag gtatatggta aaaaaagaaa tatctgggat cccgatgttc 1020

aataaatc ctgacttccc aagaaatgct tcttttttaa gttgacaaaa ggaatgggga 1080

tggcaggc cgcgcagaag gttcttggtt ttaatggata ggctgaattg gattaagaaa 1140

ttgaatgc cacctatggt aatctatttg tgattttctt ctaaattatg tattataaat 1200

gtagagct atagaaagca atgagtgtgt aatttggagt gattttatat atggcataaa 1260

ttgtttta acataattag tactgttttc ccccaaaagt acaagttttt gagtagcaat 1320

caggitaa giaaagaaac ticatcacat citataggia gigtiggicc aattgactia 1380

aaatacaa ataacattta ggaagcaaat agattaaaca caaaaataaa actaaagcat 1440

gaattatg titttgagat acctttgggc ttagattggc attgttttat tctaaaaacc 1500

actcagtg gtgtagagaa acttgtgtac caaaatttta gtttctgcag atgctagtgt 1560

ttttggat acaattttga caaccaagtt agtaaacaaa atatcttaac agtttgatga 1620

caagctac tgatgagggt ttggaatatt aattcagaag gtagtttctc ttgtgttcaa 1680

tagctgcc atggggctgt tacttttaaa gtcaaaattt tcttctgaag gctcattttg 1740

atttgatc ttaaccaagt gattattaga gaaatgtatc aactccatgc catctcccaa 1800

## eolf-seql-S000001.txt

taattgtc taagaaaact tgaaagtgta aggttttaac ctttaattta tttctcttaa 1860

acatettt tgatattgtt gttgtgacat ttetttttet ggttagtggg ettteeagae 1920

tgtaccac tgcttctgtt tattcattta tatgcttttg tgtcccataa attatttcag 1980

aatgctga taaaactcag gatattgaca tttttgttga gactaaaaaa tggcagtcgc 2040

aagtaggg actctagagt ctggcttacg tcagtgttgg tagtttagat tgtctttgtc 2100

egtttttt ettetett ttgetttett ttettetet tttttetta geacagttet 2160

ctcaaatt tgtgtatttt ttgtgtgcct gggctggaga tgagagactg agtcataact 2220

tttaaaag tttgtgttat caggtatctt atttgaacat ggtcattttt ggccacattg 2280

gtttcata ctaggacttg ggatgatgta gccagaataa aactcaagtt gcaccctccg 2340

tggtggaa gattgctgac cgtgccgttt ctgggcagga gaagacatca tggtgtccag 2400

actcagca aagccattct taagagtcgt gaggtccttc tgaatgtaaa actggagccc 2460

gagaagct gtcccaggag ggctgttaac tccctataga gccaggagac aggatagggg 2520

tctagggt ccaacaccag cttaccttgg agtatgaatc tacccatgaa ggatgagaga 2580

ttttgaaa aactagccag gacacaccca caggatccta ctggctcctt agcagctgat 2640

gtgttaca taattaactt aattggagat gcattaggtc acttgaatgt ataagcaagc 2700

ctatggta ggcgctacag acatttaaat ctcttgggaa ttcgatgctc ccatggaatt 2760

taccagtt atatgaattg acttaagtat cttgaaaaag aaactttaga gaaagcatca 2820

ggtgtgta ctcagtattt caaatcagaa cacaagattg gaacttttgg aaaaatgggt 2880

eolf-seql-S000001.txt

laagettte etattageea tggaaatgea aagtttagea gaageaagea attaggeaga 2940

lacaaaaat gttaagcatg gtgttgtcta tcttattgaa gtggttggaa atgaaagctt 3000

:aatttgat agatttatca gtataaaatt agggaaacca cgtgtgggga atgaatcaat 3060

agagette gggaattgtg aggtgaettt tgtaactttt gttetgtgtg tgaeetgtga 3120

cactagga tgtgatctgc ccttgtgggc aggtccagca tagttaggag ttaggcttta 3180

:ataaattt ctagctgcat ctgagtctcc tgggatgggt gctctttggc tggttttggc 3240

ICGGatggt gagatcagag cagctcttcc tgctgctggc ccctgcaatc agttgttggg 3300

.gccagtgc agatcactaa gtagtaagat tttaatcaaa cacgaccagg tccgaaatgc 3360

rgtcatgag tgtgaaattc tcaaatttac ataaaaagta gaagtataga cagtttaaca 3420

tggtatta aaggagagga aattgtagca gcttttcacg tttcccagtc cccattagag 3480

cttgagac cttgtacctg aacaacccat tttgcactca gtgctttctg atgccttagg 3540

aattgttt tgtttcacaa aagctgggaa ggaagaagtc cattctgcag ctgttagatc 3600

cctctcag gaaaaagtac taacttgttc tttttgttcc tggctttcat cagtttgtga 3660

tttctcta tttttttaa atataatttt atttcttca acaaatataa aataaaaaac 3720

ctttggaa caatgaaaaa aaaaaaaaaa 3750

- 10> 88
- 11> 1526
- 12> DNA
- 13> Homo sapiens
- 00> 88

atctgcgc aggcgcccgg ctcctaagtc tacccaggaa ctgaccctgc tctctccttt 60

eolf-seql-S000001.txt

- ctgttaga catgggcact ccacagaagg atgttattat caagtcagat gcaccggaca 120
- ttgttatt ggagaaacat gcagattata tcgcatccta tggctcaaag aaagatgatt 180
- gaatactg tatgtctgag tatttgagaa tgagtggcat ctattggggt ctgacagtaa 240
- gateteat gggacaaett eategeatga atagagaaga gattetggea titattaagt 300
- tgccaaca tgaatgtggt ggaataagtg ctagtatcgg acatgatcct catcttttat 360
- actcttag tgctgtccag attcttacgc tgtatgacag tattaatgtt attgacgtaa 420
- aaagttgt ggaatatgtt aaaggtctac agaaagaaga tggttctttt gctggagata 480
- tggggaga aattgacaca agattetett tttgtgeggt ggcaactttg getttgttgg 540
- aagcttga tgctattaat gtggaaaagg caatcgaatt tgttttatcc tgtatgaact 600
- gacggtgg atttggttgc agaccaggtt ctgaatccca tgctgggcag atctattgtt 660
- acaggatt totggotatt acaagtcagt tgcatcaagt aaattotgat ttacttggot 720
- tggctttg tgaacgacaa ttaccctcag gcgggctcaa tggaaggccg gagaagttac 780
- gatgtatg ctactcatgg tgggtcctgg cttccctaaa gataattgga agacttcatt 840
- attgatag agagaaactg cgtaatttca ttttagcatg tcaagatgaa gaaacggggg 900
- tttgcaga caggccagga gatatggtgg atcettttca tacettattt ggaattgetg 960
- ttgtcact tttgggagaa gaacagatta aacctgttaa tcctgtcttt tgcatgcctg 1020
- gaagtgct tcagagagtg aatgttcagc ctgagctagt gagctagatt cattgaattg 1080
- agttgcat agtatagttt tgccatttta acatttctgt atttgaagtg cttatcgaat 1140
- aaaagtga ctactgttaa tattttgtat attgtgttaa attaatttta ataaattata

eolf-seql-S000001.txt

1200

stgttattc tgactacagt tctttgtgta tacttctgtg tctgttatgt tcaataactg 1320

rctaacata aaataactct aggtttctac ttgatttttc ccccatgtat acctttcatc
1380

¡ttctatag caagttgatg taaattggtt tgtcaacaag aatgttaact gatgaaagtg
1440

ltagaaccc atacatgaat taaatgatgc acaaaataaa tggctgttga aatttgaaaa 1500

taaaaaaa aaaaaaaaa aaaaaa 1526

10> .89 . ...

11> 2650

!12> DNA

!13> Homo sapiens

:00> 89

:cgcgctgg tggcggcggc gcgtcgttgc agttgcgcca tctgtcagga gcggagccgg
60

aggaggg gctgccgcgg gcgaggagga ggggtcgccg cgagccgaag gccttcgaga 120

egcccgcc gcccggcggc gagagtagag gcgaggttgt tgtgcgagcg gcgcgtcctc 180

ccgcccgg gcgcgcgcg cttctcccag cgcaccgagg accgcccggg cgcacacaa 240

gggccggg gacaccccgg cgccgcccc tcggtgctct cggaaggccc accggctccc 360

gcccgccg gggacccccc ggagccgcct cggccgcgcc ggaggagggc ggggagagga 420

atgtgagt gggctccgga gcctcagcgc cgcgcagttt ttttgaagaa gcaggatgct 480

tctaaacg tggaaaaaga ccagtcctgc ctctgttgta gaagacatgt ggtgtatata 540

gtttgtga tcgttggcgg acattttgga atttagataa tgggctgtgt gcaatgtaag

eolf-seql-S000001.txt

600

taaagaag caacaaaact gacggaggag agggacggca gcctgaacca gagctctggg 660

.ccgctatg gcacagaccc cacccctcag cactacccca gcttcggtgt gacctccatc 720

caactaca acaacttcca cgcagccggg ggccaaggac tcaccgtctt tggaggtgtg 780

ctcttcgt ctcatacggg gaccttgcgt acgagaggag gaacaggagt gacactcttt 840

ggcccttt atgactatga agcacggaca gaagatgacc tgagttttca caaaggagaa 900

atttcaaa tattgaacag ctcggaagga gattggtggg aagcccgctc cttgacaact 960

agagacag gttacattcc cagcaattat gtggctccag ttgactctat ccaggcagaa 1020

gtggtact ttggaaaact tggccgaaaa gatgctgagc gacagctatt gtcctttgga 1080

cccaagag gtacctttct tatccgcgag agtgaaacca ccaaaggtgc ctattcactt 1140

tatccgtg attgggatga tatgaaagga gaccatgtca aacattataa aattcgcaaa 1200

tgacaatg gtggatacta cattaccacc cgggcccagt ttgaaacact tcagcagctt 1260

acaacatt actcagagag agctgcaggt ctctgctgcc gcctagtagt tccctgtcac 1320

agggatgc caaggcttac cgatctgtct gtcaaaacca aagatgtctg ggaaatccct 1380

agaatccc tgcagttgat caagagactg ggaaatgggc agtttgggga agtatggatg 1440

tacctgga atggaaacac aaaagtagcc ataaagactc ttaaaccagg cacaatgtcc 1500

cgaatcat tccttgagga agcgcagatc atgaagaagc tgaagcacga caagctggtc 1560

gctctatg cagtggtgtc tgaggagccc atctacatcg tcaccgagta tatgaacaaa 1620

aagtttac tggatttctt aaaagatgga gaaggaagag ctctgaaatt accaaatctt 1680

### eolf-seql-S000001.txt

ggacatgg cagcacaggt ggctgcagga atggcttaca tcgagcgcat gaattatatc 1740

ltagagatc tgcgatcagc aaacattcta gtggggaatg gactcatatg caagattgct 1800

icttcggat tggcccgatt gatagaagac aatgagtaca cagcaagaca aggtgcaaag 1860

:Ccccatca agtggacggc ccccgaggca gccctgtacg ggaggttcac aatcaagtct 1920

icgtgtggt cttttggaat cttactcaca gagctggtca ccaaaggaag agtgccatac 1980

aggeatga acaaccggga ggtgctggag caggtggage gaggetacag gatgccetge 2040

gcaggact gccccatctc tctgcatgag ctcatgatcc actgctggaa aaaggaccct 2100

lagaacgcc ccacttttga gtacttgcag agcttcctgg aagactactt taccgcgaca 2160

 $_{\rm igccccagt}$  accaacctgg tgaaaacctg taaggcccgg gtctgcggag agaggccttg  $_{\rm 2220}$ 

:ccagagge tgccccaccc ctccccatta gctttcaatt ccgtagccag ctgctcccca 2280

ageggaac egeceaggat cagattgeat gtgactetga agetgaegaa ettecatgge 2340

tcattaat gacacttgtc cccaaatccg aacctcctct gtgaagcatt cgagacagaa 2400

ttgttatt tctcagactt tggaaaatgc attgtatcga tgttatgtaa aaggccaaac 2460

ctgttcag tgtaaatagt tactccagtg ccaacaatcc tagtgctttc cttttttaaa 2520

tgcaaatc ctatgtgatt ttaactctgt cttcacctga ttcaactaaa aaaaaaaaag 2580

ttattttc caaaagtggc ctctttgtct aaaacaataa aattttttt catgttttaa 2640

aaaaccaa 2650

10> 90 11> 2073

### eolf-seql-S000001.txt

- 212> DNA
- ?13> Homo sapiens
- 100> 90
- latttagat aatgggctgt gtgcaatgta aggataaaga agcaacaaaa ctgacggagg 60
- jagggacgg cagcctgaac cagagetetg ggtaccgeta tggcacagac cccaccete
  120
- scactaccc cagcttcggt gtgacctcca tccccaacta caacaacttc cacgcagccg
  180
- // iggccaagg actcaccgtc tttggaggtg tgaactcttc gtctcatacg gggaccttgc 240
- acgagagg aggaacagga gtgacactct ttgtggccct ttatgactat gaagcacgga 300
- gaagatga cctgagtttt cacaaaggag aaaaatttca aatattgaac agctcggaag 360
- gattggtg ggaagcccgc tccttgacaa ctggagagac aggttacatt cccagcaatt 420
- gtggctcc agttgactct atccaggcag aagagtggta ctttggaaaa cttggccgaa 480
- gatgctga gcgacagcta ttgtcctttg gaaacccaag aggtaccttt cttatccgcg 540
- agtgaaac caccaaaggt gcctattcac tttctatccg tgattgggat gatatgaaag 600
- gaccatgt caaacattat aaaattcgca aacttgacaa tggtggatac tacattacca 660
- cgggccca gtttgaaaca cttcagcagc ttgtacaaca ttactcagag aaagctgatg 720
- ttgtgttt taacttaact gtgattgcat cgagttgtac cccacaaact tctggattgg 780
- aaagatgc ttgggaagtt gcacgtcgtt cgttgtgtct ggagaagaag ctgggtcagg 840
- tgtttcgc tgaagtgtgg cttggtacct ggaatggaaa cacaaaagta gccataaaga 900
- cttaaacc aggcacaatg tcccccgaat cattccttga ggaagcgcag atcatgaaga 960
- ctgaagca cgacaagctg gtccagctct atgcagtggt gtctgaggag cccatctaca 1020

eolf-seql-S000001.txt

gtcaccga gtatatgaac aaaggaagtt tactggattt cttaaaagat ggagaaggaa 1080

igctctgaa attaccaaat cttgtggaca tggcagcaca ggtggctgca ggaatggctt 1140

:atcgagcg catgaattat atccatagag atctgcgatc agcaaacatt ctagtgggga 1200

ggactcat atgcaagatt gctgacttcg gattggcccg attgatagaa gacaatgagt 1260

acagcaag acaaggtgca aagttcccca tcaagtggac ggcccccgag gcagccctgt 1320

gggaggtt cacaatcaag tetgaegtgt ggtettttgg aatettaete acagagetgg 1380

accaaagg aagagtgcca tacccaggca tgaacaaccg ggaggtgctg gagcaggtgg 1440

regaggeta caggatgeee tgeeegeagg actgeeecat etetetgeat gageteatga 1500

cactgctg gaaaaaggac cctgaagaac gccccacttt tgagtacttg cagagcttcc 1560

gaagacta ctttaccgcg acagagcccc agtaccaacc tggtgaaaac ctgtaaggcc 1620

iggtctgcg gagagaggcc ttgtcccaga ggctgcccca cccctcccca ttagctttca 1680

tccgtagc cagctgctcc ccagcagcgg aaccgcccag gatcagattg catgtgactc 1740

aagctgac gaacttccat ggccctcatt aatgacactt gtccccaaat ccgaacctcc 1800

tgtgaagc attcgagaca gaaccttgtt atttctcaga ctttggaaaa tgcattgtat 1860

atgttatg taaaaggcca aacctctgtt cagtgtaaat agttactcca gtgccaacaa 1920

ctagtgct ttccttttt aaaaatgcaa atcctatgtg attttaactc tgtcttcacc 1980

attcaact aaaaaaaaa aagtattatt ttccaaaagt ggcctctttg tctaaaacaa 2040

aaattttt tttcatgttt taacaaaaac caa 2073

eolf-seql-S000001.txt

- :10> 91
- :11> 2000
- :12> DNA
- :13> Homo sapiens
- 00> 91
- .gcgcaggt ctgaggagct gagaagggag gcttacgtga agggaattta gataatgggc 60
- tgtgcaat gtaaggataa agaagcaaca aaactgacgg aggagaggga cggcagcctg 120
- .ccagaget etgggtaceg etatggeaca gaececacee etcageacta ecceagette 180
- tgtgacct ccatccccaa ctacaacaac ttccacgcag ccgggggcca aggactcacc 240
- ctttggag gtgtgaactc ttcgtctcat acggggacct tgcgtacgag aggaggaaca 300
- agtgacac tctttgtggc cctttatgac tatgaagcac ggacagaaga tgacctgagt 360
- tcacaaag gagaaaaatt tcaaatattg aacagctcgg aaggagattg gtgggaagcc 420
- ctccttga caactggaga gacaggttac attcccagca attatgtggc tccagttgac 480
- tatccagg cagaagagtg gtactttgga aaacttggcc gaaaagatgc tgagcgacag 540
- attgtcct ttggaaaccc aagaggtacc tttcttatcc gcgagagtga aaccaccaaa 600
- tgcctatt cactttctat ccgtgattgg gatgatatga aaggagacca tgtcaaacat 660
- taaaattc gcaaacttga caatggtgga tactacatta ccacccgggc ccagtttgaa 720
- acttcagc agcttgtaca acattactca ggtacctgga atggaaacac aaaagtagcc 780
- aaagactc ttaaaccagg cacaatgtcc cccgaatcat tccttgagga agcgcagatc  $840\,$
- yaagaagc tgaagcacga caagctggtc cagctctatg cagtggtgtc tgaggagccc 900
- stacatcg teacegagta tatgaacaaa ggaagtttae tggatttett aaaagatgga 960
- aggaagag ctctgaaatt accaaatctt gtggacatgg cagcacaggt ggctgcagga

eolf-seql-S000001.txt

1020

ggcttaca tegagegeat gaattatate catagagate tgegateage aaacatteta 1080

ggggaatg gactcatatg caagattgct gacttcggat tggcccgatt gatagaagac 1140

ıtgagtaca cagcaagaca aggtgcaaag ttccccatca agtggacggc ccccgaggca 1200

cctgtacg ggaggttcac aatcaagtct gacgtgtggt cttttggaat cttactcaca 1260

gctggtca ccaaaggaag agtgccatac ccaggcatga acaaccggga ggtgctggag 1320

ggtggagc gaggctacag gatgccctgc ccgcaggact gccccatctc tctgcatgag 1380

catgatec actgetggaa aaaggaceet gaagaaegee eeacttttga gtaettgeag

cttcctgg aagactactt taccgcgaca gagccccagt accaacctgg tgaaaacctg 1500

aggecegg gtetgeggag agaggeettg teecagagge tgeeceacee eteeceatta 1560

tttcaatt ccgtagccag ctgctcccca gcagcggaac cgcccaggat cagattgcat 1620

gactctga agctgacgaa cttccatggc cctcattaat gacacttgtc cccaaatccg 1680

cctcctct gtgaagcatt cgagacagaa ccttgttatt tctcagactt tggaaaatgc 1740

tgtatcga tgttatgtaa aaggccaaac ctctgttcag tgtaaatagt tactccagtg 1800

aacaatcc tagtgctttc cttttttaaa aatgcaaatc ctatgtgatt ttaactctgt 1860

tcacctga ttcaactaaa aaaaaaaag tattatttc caaaagtggc ctctttgtct 1920

aacaataa aattttttt catgttttaa caaaaaccaa aaaaaaaaa aaaaaaaaa 1980

aaaaaaaa aaaaaaaaa 2000

10> 92

eolf-seql-S000001.txt

- 2349
- ?12> DNA
- ?13> Homo sapiens

100> 92

- stottatog gttoccatoc cagttgttga tottatgcaa gacgotgcac gaccocgogc 60
- :gcttgtcg ccacggcact tgaggcagec ggagatactc tgagttactc ggagcccgac 120
- ctgagggt gagatgaacg cgctggcctc cctaaccgtc cggacctgtg atcgcttctg 180
- :agaccgaa ccggcgctcc tgccccggg gtgacgcgca gccccagcc gcccagacac 240
- ggccccag gccaagcacc ccatcaggct accccgtgga gggatgccca ccctttcttc 300
- cctgtccc cagtgatggg cctcctcagc cgcgcctgga gccgcctgag gggcctggga 360
- tctagage cetggetggt ggaageagta aaaggageag etetggtaga agetggeetg 420
- gggagaag ctaggactcc tctggcaatc ccccataccc cttggggcag acgccctgga 480
- ggaggctg aagacagtgg aggccctgga gaggacagag aaacactggg gctgaaaacc 540
- cagttccc ttcctgaagc ctggggactt ttggatgatg atgatggcat gtatggtgag 600
- agaggcaa ccagtgtccc tagagggcag ggaagtcaat ttgcagatgg ccagcgtgct 660
- cctgtctc ccagccttct gataaggaca ctgcaaggtt ctgataagaa cccaggggag 720
- gaaagccg aggaagagg agttgctgaa gaggagggag ttaacaagtt ctcttatcca 780
- atcacacc gggagtgttg tccagccgtg gaggaggagg acgatgaaga agctgtaaag 840
- agaagete acagaacete tacttetgee ttgteteeag gateeaagee eageacttgg 900
- gtcttgcc caggggagga agagaatcaa gccacggagg ataaaagaac agaaagaagt 960
- aggageca ggaagaeete egtgteeeee egatetteag geteegaeee eaggteetgg

### eolf-seql-S000001.txt

igtatcgtt caggagaggc gtccgaggag aaggaggaaa aggcacacga agaaactggg 1080 laggagaag ctgcccagg gccgcaatcc tcagccccag cccagaggcc ccagctcaag 1140 octggtggt gccaacccag tgatgaagag gagagtgagg tcaagccttt gggggcagct 1200 1gaaggatg gagaagctga gtgtcctccc tgcatccccc caccaagtgc cttcctgaag 1260 ctgggtgt attggccagg agaggacaca gaggaagagg aagatgagga agaagatgag 1320 acagtgact ctggatcaga tgaggaagag ggagaagctg aggcttcctc ttccactcct 1380 tacaggtg tettettgaa gteetgggte tateageeag gagaggacae agaggaggag 1440 lagatgagg acagtgatac aggatcagcc gaggatgaaa gagaagctga gacttctgct 1500 :cacacccc ctgcaagtgc tttcttgaag gcctgggtgt atcggccagg agaggacacg 1560 ggaggagg aagatgagga tgtggatagt gaggataagg aagatgattc agaagcagcc 1620 aggagaag ctgagtcaga cccacatccc tcccacccgg accagagtgc ccacttcagg 1680 sctggggat atcgacctgg aaaagagaca gaggaagagg aagctgctga ggactgggga 1740 agetgage cetgeceett eegagtggee atetatgtae etggagagaa geeacegeet 1800 etgggete etectagget geeesteega etgeaaagge ggeteaageg eccagaaace 1860 tactcatg atccggaccc tgagactccc ctaaaggcca gaaaggtgcg cttctccgag 1920 ggtcactg tccatttcct ggctgtctgg gcagggccgg cccaggccgc ccgccagggc 1980 ctgggage agettgeteg ggategeage egettegeae geegeatege eeaggeeeag 2040 ggagetga geceetgeet cacceetget geeegggeea gageetggge aegeeteagg

2100

eolf-seql-S000001.txt

CCcacctt tagccccat ccctgccctc acccagacct tgccttcctc ctctgtccct 2160

gtccccag tccagaccac gcccttgagc caagctgtgg ctacaccttc ccgctcctct 2220

tgctgcag cggctgccct ggacctcagt gggaggcgtg gctgagacca actggtttgc 2280

ataattta ttaactattt attttttcta agtgtgggtt tatataagga ataaagcctt 2340

gatttgt 2349

10> 93

11> 3162

12> DNA

13> Homo sapiens

00> 93

gccctagc cctctttcgg ggatactggc cgacccctc ttccttttcc cctttagtga
60

gcctcccc cgtcgccgcg cggcttcccg gagccgactg cagactccct cagcccggtg 120

ccccgcgt ccggacgccg aggtcgcggc ttcgcagaaa ctcgggcccc tccatccgcc 180

cagaaaag ggagcgatgt tgatctcagg aagcacaaag ggaccttcct agctctgact 240

accacgga gctcaccctg gacagtatca ctccgtggag gaagactgtg agactgtggc 300

gaagccag attgtagcca cacatccgcc cctgccctac cccagagccc tggagcagca 360

tggctgca gatcacagac acagtgagga tatgagtgta ggggtgagca cctcagccc 420

tttcccca acctcgggca caagcgtggg catgtctacc ttctccatca tggactatgt 480

tgttcgtc ctgctgctgg ttctctctct tgccattggg ctctaccatg cttgtcgtgg 540

ggggccgg catactgttg gtgagctgct gatggcggac cgcaaaatgg gctgccttcc 600

tggcactg tecetgetgg ecaeetteea gteageegtg gecateetgg gtgtgeegte 660

eolf-seql-S000001.txt

sagatctac cgatttggga cccaatattg gttcctgggc tgctgctact ttctggggct 720

- tgatacct gcacacatct tcatccccgt tttctaccgc ctgcatctca ccagtgccta 780
- lagtacctg gagcttcgat tcaataaaac tgtgcgagtg tgtgggaactg tgaccttcat 840
- .ttcagatg gtgatctaca tgggagttgt gctctatgct ccgtcattgg ctctcaatgc
  900
- tgactggc tttgatctgt ggctgtccgt gctggccctg ggcattgtct gtaccgtcta 960
- cagctetg ggtgggetga aggeegteat etggaeagat gtgtteeaga eactggteat 1020
- tcctcggg cagctggcag ttatcatcgt ggggtcagcc aaggtgggcg gcttggggcg 1080
- tgtgggcc gtggcttccc agcacggccg catctctggg tttgagctgg atccagaccc 1140
- ttgtgcgg cacaccttct ggaccttggc cttcgggggt gtcttcatga tgctctcctt 1200
- acggggtg aaccaggctc aggtgcagcg gtacctcagt tcccgcacgg agaaggctgc 1260
- tgctctcc tgttatgcag tgttcccctt ccagcaggtg tccctctgcg tgggctgcct 1320
- ttggcctg gtcatgttcg cgtattacca ggagtatccc atgagcattc agcaggctca 1380
- cagcccca gaccagttcg teetgtaett tgtgatggat eteetgaagg geetgeeagg 1440
- tgccaggg ctcttcattg cctgcctctt cagcggctct ctcagcacta tatcctctgc 1500
- ttaattca ttggcaactg ttacgatgga agacctgatt cgaccttggt tccctgagtt 1560
- ctgaagcc cgggccatca tgctttccag aggccttgcc tttggctatg ggctgctttg 1620
- taggaatg gcctatattt cctcccagat gggacctgtg ctgcaggcag caatcagcat 1680
- ttggcatg gttgggggac cgctgctggg actcttctgc cttggaatgt tctttccatg 1740
- staaccct cotggtgctg ttgtgggcct gttggctggg ctcgtcatgg ccttctggat

#### eolf-seql-S000001.txt

1800

igcatcggg agcatcgtga ccagcatggg cttcagcatg ccaccctctc cctctaatgg
1860
.ccagcttc tccctgccca ccaatctaac cgttgccact gtgaccacac tgatgccctt

1920

ctaccttc tccaagccca cagggctgca gcggttctat tccttgtctt acttatggta 1980

gtgctcac aactccacca cagtgattgt ggtgggcctg attgtcagtc tactcactgg 2040

gaatgcga ggccggtccc tgaaccctgc aaccatttac ccagtgttgc caaagctcct 2100

ccctcctt ccgttgtcct gtcagaagcg gctccactgc aggagctacg gccaggacca 2160

tcgacact ggcctgtttc ctgagaagcc gaggaatggt gtgctggggg acagcagaga 2220

aggaggcc atggccctgg atggcacagc ctatcagggg agcagctcca cctgcatcct 2280

aggagacc tecetgtgat gttgacteag gaccegeet etgteeteae tgtgeeagge 2340

tagccaga ggccaccctg tagtacaggg atgagtcttg gtgtgttctg cagggacagg 2400

tggatgat ctagctcata ccaaaggacc ttgttctgag aggttcttgc ctgcaggaga 2460

ctgtcaca tctcaagcat gtgaggcacc gtttttctcg tcgcttgcca atctgtttt 2520

aaggatca ggctcgtagg gagcaggatc atgccagaaa tagggatgga agtgcatcct 2580

gggaaaaa gataatggct tctgattcaa catagccata gtcctttgaa gtaagtggct 2640

aaacagca ctctggttat aattgcccca gggcctgatt caggactgac tctccaccat 2700

aactggaa getgetteee etgtagteee eattteagta eeagttetge eageeaeagt 2760

gcccctat tattactttc agattgtctg tgacactcaa gcccctctca tttttatctg 2820

tacctcca ttctgaagag ggaggttttg gtgtccctgg tcctctggga atagaagatc 2880

## eolf-seql-S000001.txt

itttgtctt tgtgtagagc aagcacgttt tccacctcac tgtctccatc ctccacctct 2940

igatggaca cttaagagac ggggcaaatg tggatccaag aaaccagggc catgaccagg 3000

cactgtgg agcagccatc tatctacctg actcctgagc caggctgccg tggtgtcatt 3060

stgtcatcc gtgctctgtt tccttttgga gtttcttctc cacattatct ttgttcctgg 3120

gaataaaaa ctaccattgg acctaaaaaa aaaaaaaaa aa
3162

- 110> 94
- !11> 20
- !12> DNA
- :13> Homo sapiens
- !00> 94
- :acatcgct cagacaccat 20
- :10> 95
- :11> 17
- 112> DNA
- :13> Homo sapiens
- 00> 95

caggcgcc caatacg

- 10> 96
- 11> 28
- 12> DNA
- 13> Homo sapiens
- 00> 96

aatccgtt gactccgacc ttcacctt 28

- 10> 97
- 11> 20
- 12> DNA
- 13> Homo sapiens
- 00> 97

ggccaacc gcgagaagat 20

eolf-seql-S000001.txt

```
?10> 98
?11> 20
?12> DNA
13> Homo sapiens
100> 98
:caccggag tccatcacga
  20
10> 99
:11> 32
12> DNA
:13> Homo sapiens
:00> 99
:atgtacgt tgctatccag gctgtgctat cc
:10> 100
.11> 25
12> DNA
13> Homo sapiens
00> 100
actgggac gacatggaga aaatc
 25
10> 101
11> 22
12> DNA
13> Homo sapiens
00> 101
tggctggg gtgttgaagg tc
 22
10> 102
11> 21
12> DNA
13> Homo sapiens
00> 102
gaggacaa aataactacc c
21
10> 103
11> 22
12> DNA
```

eolf-seql-S000001.txt

?13> Homo sapiens

100> 103 lattcagga gctttttctt ca

10> 104

!11> 22

!12> DNA

13> Homo sapiens

100> 104

lattcagga gctttttctt ca 22

:10> 105

:11> 32

:12> DNA

:13> Homo sapiens

:00> 105

.ctgggctg agaaactgat ggactgggct ga
32

10> 106

11> 23

12> DNA

13> Homo sapiens

00> 106

ggaaaggt cactgaaaaa tct

10> 107

11> 21

12> PRT

13> Homo sapiens

00> 107

y Cys Thr Gly Gly Cys Thr Gly Cys Gly Gly Thr Thr Gly Ala Ala 5 10 15

y Thr Thr Gly Gly 20

10> 108

11> 17

12> DNA

eolf-seql-S000001.txt

:13> Homo sapiens

:00> 108

:gcgggcta cgacctg

:10> 109

:11> 20

12> DNA

13> Homo sapiens

00> 109

ccactctt ccataacacc 20

10> 110

11> 32

12> DNA

13> Homo sapiens

00> 110

tccgtttt cacaacagct ttctccatag gt 32

10> 111

11> 16

12> DNA

13> Homo sapiens

00> 111

aaaacgac ggccag 16

10> 112

11> 17

12> DNA

13> Homo sapiens

00> 112

ggaaacag ctatgac

10> 113 11> 479 12> PRT

13> Homo sapiens

00> 113

: Asp Glu Thr Ser Pro Leu Val Ser Pro Glu Arg Ala Gln Pro Pro

eolf-seql-S000001.txt

5

15

- p Tyr Thr Phe Pro Ser Gly Ser Gly Ala His Phe Pro Gln Val Pro 20 25 30
- .y Gly Ala Val Arg Val Ala Ala Ala Ala Gly Ser Gly Pro Ser Pro 35 40 45
- O Gly Ser Pro Gly His Asp Arg Glu Arg Gln Pro Leu Leu Asp Arg 50 55 60
- .a Arg Gly Ala Ala Ala Gln Gly Gln Thr Gln Thr Val Ala Ala Gln 70  $\phantom{000}$  75  $\phantom{000}$  80
- a Gln Ala Leu Ala Ala Gln Ala Ala Ala Ala Ala His Ala Ala Gln 85 90 95
- a His Arg Glu Arg Asn Glu Phe Pro Glu Asp Pro Glu Phe Glu Ala 100 105 110
- l Val Arg Gln Ala Glu Leu Ala Ile Glu Arg Cys Ile Phe Pro Glu 115 120 125
- g Ile Tyr Gln Gly Ser Ser Gly Ser Tyr Phe Val Lys Asp Pro Gln 130 135 140
- y Arg Ile Ile Ala Val Phe Lys Pro Lys Asn Glu Glu Pro Tyr Gly 5 150 155 160
- s Leu Asn Pro Lys Trp Thr Lys Trp Leu Gln Lys Leu Cys Cys Pro 165 170 175
- s Cys Phe Gly Arg Asp Cys Leu Val Leu Asn Gln Gly Tyr Leu Ser 180 185 190
- u Ala Gly Ala Ser Leu Val Asp Gln Lys Leu Glu Leu Asn Ile Val 195 200 205
- o Arg Thr Lys Val Val Tyr Leu Ala Ser Glu Thr Phe Asn Tyr Ser 210 215 220

eolf-seql-S000001.txt

- la Ile Asp Arg Val Lys Ser Arg Gly Lys Arg Leu Ala Leu Glu Lys 25 230 235 240
- il Pro Lys Val Gly Gln Arg Phe Asn Arg Ile Gly Leu Pro Pro Lys 245 250 255
- il Gly Ser Phe Gln Leu Phe Val Glu Gly Tyr Lys Asp Ala Asp Tyr 260 265 270
- :P Leu Arg Arg Phe Glu Ala Glu Pro Leu Pro Glu Asn Thr Asn Arg 275 280 285
- n Leu Leu Gln Phe Glu Arg Leu Val Val Leu Asp Tyr Ile Ile 290 295 300
- g Asn Thr Asp Arg Gly Asn Asp Asn Trp Leu Ile Lys Tyr Asp Cys 310 315 320
- o Met Asp Ser Ser Ser Ser Arg Asp Thr Asp Trp Val Val Lys 325 330 335
- u Pro Val Ile Lys Val Ala Ala Ile Asp Asn Gly Leu Ala Phe Pro 340 345 350
- u Lys His Pro Asp Ser Trp Arg Ala Tyr Pro Phe Tyr Trp Ala Trp 355 360 365
- u Pro Gln Ala Lys Val Pro Phe Ser Gln Glu Ile Lys Asp Leu Ile 370 375 380
- u Pro Lys Ile Ser Asp Pro Asn Phe Val Lys Asp Leu Glu Glu Asp 5 390 395 400
- u Tyr Glu Leu Phe Lys Lys Asp Pro Gly Phe Asp Arg Gly Gln Phe 405 410 415
- s Lys Gln Ile Ala Val Met Arg Gly Gln Ile Leu Asn Leu Thr Gln 420 425 430
- a Leu Lys Asp Asn Lys Ser Pro Leu His Leu Val Gln Met Pro Pro 435 440 445

## eolf-seql-S000001.txt

31 Ile Val Glu Thr Ala Arg Ser His Gln Arg Ser Ser Ser Glu Ser 450 460

/r Thr Gln Ser Phe Gln Ser Arg Lys Pro Phe Phe Ser Trp Trp
55 470 475

210> 114

211> 213

212> PRT

213> Homo sapiens

100> 114

et Ala Gln Glu Thr Asn Gln Thr Pro Gly Pro Met Leu Cys Ser Thr 5 10 15

.y Cys Gly Phe Tyr Gly Asn Pro Arg Thr Asn Gly Met Cys Ser Val 20 25 30

's Tyr Lys Glu His Leu Gln Arg Gln Gln Asn Ser Gly Arg Met Ser 35 40 45

to Met Gly Thr Ala Ser Gly Ser Asn Ser Pro Thr Ser Asp Ser Ala 50 60

er Val Gln Arg Ala Asp Thr Ser Leu Asn Asn Cys Glu Gly Ala Ala 70 75 80

y Ser Thr Ser Glu Lys Ser Arg Asn Val Pro Val Ala Ala Leu Pro 85 90 95

1 Thr Gln Gln Met Thr Glu Met Ser Ile Ser Arg Glu Asp Lys Ile 100 105 110

r Thr Pro Lys Thr Glu Val Ser Glu Pro Val Val Thr Gln Pro Ser 115 120 125

o Ser Val Ser Gln Pro Ser Thr Ser Gln Ser Glu Glu Lys Ala Pro 130 135 140

u Leu Pro Lys Pro Lys Lys Asn Arg Cys Phe Met Cys Arg Lys Lys 5 150 155 160

# eolf-seql-S000001.txt

al Gly Leu Thr Gly Phe Asp Cys Arg Cys Gly Asn Leu Phe Cys Gly 165 170 175

eu His Arg Tyr Ser Asp Lys His Asn Cys Pro Tyr Asp Tyr Lys Ala 180 185 190

lu Ala Ala Ala Lys Ile Arg Lys Glu Asn Pro Val Val Val Ala Glu 195 200 205

ys Ile Gln Arg Ile 210

210> 115

211> 323

212> PRT

213> Homo sapiens

100> 115

et Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp Gly His Phe Met 5 10 15

to Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser 20 25 30

- rs Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala Gly Phe Arg His 35 : 40 45
- .e Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala 50 55 60
- e Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe
- r Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro Glu Leu Val Arg 85 90 95
- o Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp 100 105 110
- u Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val 115 120 125

### eolf-seq1-S000001.txt

- e Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu 130 135 140
- s Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp Ala Gly Leu Ala 5 150 155 160
- s Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln Leu Glu Met Ile 165 170 175
- u Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu 180 185 190
- s His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser 195 200 205
- s Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu  $\dots$  210 215 220  $\dots$
- u Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val 5 230 235 . 240
- u Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala 245 250 255
- u Arg Tyr Gln Leu Gln Arg Gly Val Val Leu Ala Lys Ser Tyr 260 265 270
- n Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu 275 280 285
- r Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg 290 295 300
- E Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser 310 315 320
- > Glu Tyr
- .0> 116 .1> 164

eolf-seql-S000001.txt

- 12> PRT
- 13> Homo sapiens
- 00> 116
- t Pro Cys Ser Glu Glu Thr Pro Ala Ile Ser Pro Ser Lys Arg Ala 5 10 15
- g Pro Ala Glu Val Gly Gly Met Gln Leu Arg Phe Ala Arg Leu Ser 20 25 30
- u His Ala Thr Ala Pro Thr Arg Gly Ser Ala Arg Ala Ala Gly Tyr 35 40 45
- p Leu Tyr Ser Ala Tyr Asp Tyr Thr Ile Pro Pro Met Glu Lys Ala 50 55 60
- 1 Val Lys Thr Asp Ile Gln Ile Ala Leu Pro Ser Gly Cys Tyr Gly 70 75 80
- g Val Ala Pro Arg Ser Gly Leu Ala Ala Lys His Phe Ile Asp Val 85 90 95
- y Ala Gly Val Ile Asp Glu Asp Tyr Arg Gly Asn Val Gly Val Val 100 105 110
- u Phe Asn Phe Gly Lys Glu Lys Phe Glu Val Lys Lys Gly Asp Arg 115 120 125
- e Ala Gln Leu Ile Cys Glu Arg Ile Phe Tyr Pro Glu Ile Glu Glu 130 135 140
- $\frac{1}{5}$  Gln Ala Leu Asp Asp Thr Glu Arg Gly Ser Gly Gly Phe Gly Ser  $\frac{1}{5}$
- r Gly Lys Asn
- 10> 117
- l1> 969
- l2> PRT
- 13> Homo sapiens
- )0> 117

### eolf-seql-S000001.txt

- t Pro Pro Arg Ala Pro Pro Ala Pro Gly Pro Arg Pro Pro Pro Arg 5
- a Ala Ala Ala Thr Asp Thr Ala Ala Gly Ala Gly Gly 20 25 30
- a Gly Gly Ala Gly Gly Pro Gly Phe Arg Pro Leu Ala Pro Arg Pro 35 40 45
- p Arg Trp Leu Leu Leu Leu Ala Leu Pro Ala Ala Cys Ser Ala Pro 50 55 60
- o Pro Arg Pro Val Tyr Thr Asn His Trp Ala Val Gln Val Leu Gly
  70 75 80
- u Gly Gln Ile Gly Asn Leu Glu Asp Tyr Tyr His Phe Tyr His Ser 100 105 110
- s Thr Phe Lys Arg Ser Thr Leu Ser Ser Arg Gly Pro His Thr Phe 115 120 125
- u Arg Met Asp Pro Gln Val Lys Trp Leu Gln Gln Gln Glu Val Lys 130 135 140
- g Arg Val Lys Arg Gln Val Arg Ser Asp Pro Gln Ala Leu Tyr Phe 150 155 160
- n Asp Pro Ile Trp Ser Asn Met Trp Tyr Leu His Cys Gly Asp Lys 165 170 175
- n Ser Arg Cys Arg Ser Glu Met Asn Val Gln Ala Ala Trp Lys Arg 180 185 190
- y Tyr Thr Gly Lys Asn Val Val Val Thr Ile Leu Asp Asp Gly Ile 195 200 205
- u Arg Asn His Pro Asp Leu Ala Pro Asn Tyr Asp Ser Tyr Ala Ser 210 215 220

Page 218

### eolf-seq1-S000001.txt

- /r Asp Val Asn Gly Asn Asp Tyr Asp Pro Ser Pro Arg Tyr Asp Ala 25 230 235 240
- er Asn Glu Asn Lys His Gly Thr Arg Cys Ala Gly Glu Val Ala Ala 245 250 255
- er Ala Asn Asn Ser Tyr Cys Ile Val Gly Ile Ala Tyr Asn Ala Lys 260 265 270
- e Gly Gly Ile Arg Met Leu Asp Gly Asp Val Thr Asp Val Val Glu 275 280 285
- .a Lys Ser Leu Gly Ile Arg Pro Asn Tyr Ile Asp Ile Tyr Ser Ala 290 295 300
- er Trp Gly Pro Asp Asp Asp Gly Lys Thr Val Asp Gly Pro Gly Arg 310 315 320
- u Ala Lys Gln Ala Phe Glu Tyr Gly Ile Lys Lys Gly Arg Gln Gly 325 330 335
- u Gly Ser Ile Phe Val Trp Ala Ser Gly Asn Gly Gly Arg Glu Gly 340 345 350
- p Tyr Cys Ser Cys Asp Gly Tyr Thr Asn Ser Ile Tyr Thr Ile Ser 355 360 365
- l Ser Ser Ala Thr Glu Asn Gly Tyr Lys Pro Trp Tyr Leu Glu Glu 370 380
- s Ala Ser Thr Leu Ala Thr Thr Tyr Ser Ser Gly Ala Phe Tyr Glu 5 390 395 400
- g Lys Ile Val Thr Thr Asp Leu Arg Gln Arg Cys Thr Asp Gly His 405 410 415
- r Gly Thr Ser Val Ser Ala Pro Met Val Ala Gly Ile Ile Ala Leu 420 425 430
- a Leu Glu Ala Asn Ser Gln Leu Thr Trp Arg Asp Val Gln His Leu Page 219

445

eolf-seql-S000001.txt

u Val Lys Thr Ser Arg Pro Ala His Leu Lys Ala Ser Asp Trp Lys

- .1 Asn Gly Ala Gly His Lys Val Ser His Phe Tyr Gly Phe Gly Leu 470 475 480
- .l Asp Ala Glu Ala Leu Val Val Glu Ala Lys Lys Trp Thr Ala Val 485 490 495
- o Ser Gln His Met Cys Val Ala Ala Ser Asp Lys Arg Pro Arg Ser 500 510
- e Pro Leu Val Gln Val Leu Arg Thr Thr Ala Leu Thr Ser Ala Cys 515 520 525
- a Glu His Ser Asp Gln Arg Val Val Tyr Leu Glu His Val Val 530 535 540
- g Thr Ser Ile Ser His Pro Arg Gly Asp Leu Gln Ile Tyr Leu 550 555 560
- l Ser Pro Ser Gly Thr Lys Ser Gln Leu Leu Ala Lys Arg Leu Leu 565 570 575
- p Leu Ser Asn Glu Gly Phe Thr Asn Trp Glu Phe Met Thr Val His 580 585 590
- s Trp Gly Glu Lys Ala Glu Gly Gln Trp Thr Leu Glu Ile Gln Asp 595 600 605
- u Pro Ser Gln Val Arg Asn Pro Glu Lys Gln Gly Lys Leu Lys Glu 610 620
- Ser Leu Ile Leu Tyr Gly Thr Ala Glu His Pro Tyr His Thr Phe 630 635 640
- r Ala His Gln Ser Arg Ser Arg Met Leu Glu Leu Ser Ala Pro Glu 645 650 655

eolf-seql-S000001.txt
u Glu Pro Pro Lys Ala Ala Leu Ser Pro Ser Gln Val Glu Val Pro
660 665 670

- u Asp Glu Glu Asp Tyr Thr Ala Gln Ser Thr Pro Gly Ser Ala Asn 675 680 685
- e Leu Gln Thr Ser Val Cys His Pro Glu Cys Gly Asp Lys Gly Cys 690 695 700
- ip Gly Pro Asn Ala Asp Gln Cys Leu Asn Cys Val His Phe Ser Leu 710 715 720
- y Ser Val Lys Thr Ser Arg Lys Cys Val Ser Val Cys Pro Leu Gly 725 730 735
- r Phe Gly Asp Thr Ala Ala Arg Arg Cys Arg Arg Cys His Lys Gly
  740 745 750
- 's Glu Thr Cys Ser Ser Arg Ala Ala Thr Gln Cys Leu Ser Cys Arg 755 760 765
- g Gly Phe Tyr His His Gln Glu Met Asn Thr Cys Val Thr Leu Cys 770 775 780
- o Ala Gly Phe Tyr Ala Asp Glu Ser Gln Lys Asn Cys Leu Lys Cys 5 790 795 800
- s Pro Ser Cys Lys Lys Cys Val Asp Glu Pro Glu Lys Cys Thr Val 805 810 815
- s Lys Glu Gly Phe Ser Leu Ala Arg Gly Ser Cys Ile Pro Asp Cys 820 825 830
- u Pro Gly Thr Tyr Phe Asp Ser Glu Leu Ile Arg Cys Gly Glu Cys 835 840 845
- s His Thr Cys Gly Thr Cys Val Gly Pro Gly Arg Glu Glu Cys Ile 850 855 860
- 5 Cys Ala Lys Asn Phe His Phe His Asp Trp Lys Cys Val Pro Ala 5 870 875 880

# eolf-seql-S000001.txt

- 's Gly Glu Gly Phe Tyr Pro Glu Glu Met Pro Gly Leu Pro His Lys 885 890 895
- tl Cys Arg Arg Cys Asp Glu Asn Cys Leu Ser Cys Ala Gly Ser Ser 900 905 910
- g Asn Cys Ser Arg Cys Lys Thr Gly Phe Thr Gln Leu Gly Thr Ser 915 920 925
- 's Ile Thr Asn His Thr Cys Ser Asn Ala Asp Glu Thr Phe Cys Glu 930 935 940
- t Val Lys Ser Asn Arg Leu Cys Glu Arg Lys Leu Phe Ile Gln Phe 5 950 955 960
- s Cys Arg Thr Cys Leu Leu Ala Gly 965

10> 118

11> 683

12> PRT

13> Homo sapiens

00> 118

- t Ala Leu Phe Val Arg Leu Leu Ala Leu Ala Leu Ala Leu 5 10 15
- y Pro Ala Ala Thr Leu Ala Gly Pro Ala Lys Ser Pro Tyr Gln Leu 20 25 30
- l Leu Gln His Ser Arg Leu Arg Gly Arg Gln His Gly Pro Asn Val 35 40 45
- s Ala Val Gln Lys Val Ile Gly Thr Asn Arg Lys Tyr Phe Thr Asn 50 55 60
- s Lys Gln Trp Tyr Gln Arg Lys Ile Cys Gly Lys Ser Thr Val Ile 70 75 80
- r Tyr Glu Cys Cys Pro Gly Tyr Glu Lys Val Pro Gly Glu Lys Gly 85 90 95

### eolf-seql-S000001.txt

- /s Pro Ala Ala Leu Pro Leu Ser Asn Leu Tyr Glu Thr Leu Gly Val 100 105 110
- al Gly Ser Thr Thr Thr Gln Leu Tyr Thr Asp Arg Thr Glu Lys Leu 115 120 125
- rg Pro Glu Met Glu Gly Pro Gly Ser Phe Thr Ile Phe Ala Pro Ser 130 135 140
- sn Glu Ala Trp Ala Ser Leu Pro Ala Glu Val Leu Asp Ser Leu Val
  15 150 155 160
- er Asn Val Asn Ile Glu Leu Leu Asn Ala Leu Arg Tyr His Met Val 165 170 175
- .y Arg Arg Val Leu Thr Asp Glu Leu Lys His Gly Met Thr Leu Thr . 180 185 190
- er Met Tyr Gln Asn Ser Asn Ile Gln Ile His His Tyr Pro Asn Gly 195 200 205
- e Val Thr Val Asn Cys Ala Arg Leu Leu Lys Ala Asp His His Ala 210 215 220
- r Asn Gly Val Val His Leu Ile Asp Lys Val Ile Ser Thr Ile Thr 230 235 240
- n Asn Ile Gln Gln Ile Ile Glu Ile Glu Asp Thr Phe Glu Thr Leu 245 250 255
- g Ala Ala Val Ala Ala Ser Gly Leu Asn Thr Met Leu Glu Gly Asn 260 265 270
- y Gln Tyr Thr Leu Leu Ala Pro Thr Asn Glu Ala Phe Glu Lys Ile 275 280 285
- o Ser Glu Thr Leu Asn Arg Ile Leu Gly Asp Pro Glu Ala Leu Arg 290 295 300
- p Leu Leu Asn Asn His Ile Leu Lys Ser Ala Met Cys Ala Glu Ala 5 310 315 320

Page 223

### eolf-seql-S000001.txt

- te Val Ala Gly Leu Ser Val Glu Thr Leu Glu Gly Thr Thr Leu Glu 325 330 335
- 11 Gly Cys Ser Gly Asp Met Leu Thr Ile Asn Gly Lys Ala Ile Ile 340 345 350
- er Asn Lys Asp Ile Leu Ala Thr Asn Gly Val Ile His Tyr Ile Asp 355 360 365
- Leu Leu Ile Pro Asp Ser Ala Lys Thr Leu Phe Glu Leu Ala Ala 370 375 380
- u Ser Asp Val Ser Thr Ala Ile Asp Leu Phe Arg Gln Ala Gly Leu 390 395 400
- y Asn His Leu Ser Gly Ser Glu Arg Leu Thr Leu Leu Ala Pro Leu 405 410 415
- % in Ser Val Phe Lys Asp Gly Thr Pro Pro Ile Asp Ala His Thr Arg 420 425 430
- in Leu Leu Arg Asn His Ile Ile Lys Asp Gln Leu Ala Ser Lys Tyr 435 440 445
- u Tyr His Gly Gln Thr Leu Glu Thr Leu Gly Gly Lys Lys Leu Arg
  450 455 460
- 1 Phe Val Tyr Arg Asn Ser Leu Cys Ile Glu Asn Ser Cys Ile Ala 470 475 480
- a His Asp Lys Arg Gly Arg Tyr Gly Thr Leu Phe Thr Met Asp Arg 485 490 495
- 1 Leu Thr Pro Pro Met Gly Thr Val Met Asp Val Leu Lys Gly Asp 500 505 510
- n Arg Phe Ser Met Leu Val Ala Ala Ile Gl<br/>n Ser Ala Gly Leu Thr 515 520 525
- u Thr Leu Asn Arg Glu Gly Val Tyr Thr Val Phe Ala Pro Thr Asn Page 224

eolf-seql-S000001.txt 530 535 540

lu Ala Phe Arg Ala Leu Pro Pro Arg Glu Arg Ser Arg Leu Leu Gly 550 555 560

- 3P Ala Lys Glu Leu Ala Asn Ile Leu Lys Tyr His Ile Gly Asp Glu 565 570 575
- .e Leu Val Ser Gly Gly Ile Gly Ala Leu Val Arg Leu Lys Ser Leu 580 590
- .n Gly Asp Lys Leu Glu Val Ser Leu Lys Asn Asn Val Val Ser Val 595 600 605
- n Lys Glu Pro Val Ala Glu Pro Asp Ile Met Ala Thr Asn Gly Val 610 620
- ll His Val Ile Thr Asn Val Leu Gln Pro Pro Ala Asn Arg Pro Gln 630 635 640
- u Arg Gly Asp Glu Leu Ala Asp Ser Ala Leu Glu Ile Phe Lys Gln 645 650 655
- a Ser Ala Phe Ser Arg Ala Ser Gln Arg Ser Val Arg Leu Ala Pro 660 665 670
- 1 Tyr Gln Lys Leu Leu Glu Arg Met Lys His 675 680

10> 119

11> 381

12> PRT

13> Homo sapiens

00> 119

- t Glu Ser Gly Ser Thr Ala Ala Ser Glu Glu Ala Arg Ser Leu Arg 5 10 15
- u Cys Glu Leu Tyr Val Gln Lys His Asn Ile Gln Ala Leu Leu Lys 20 25 30
- p Ser Ile Val Gln Leu Cys Thr Ala Arg Pro Glu Arg Pro Met Ala Page 225

eolf-seq1-S000001.txt
40 45

ie Leu Arg Glu Tyr Phe Glu Arg Leu Glu Lys Glu Glu Ala Lys Gln 50 55 60

- e Gln Asn Leu Gln Lys Ala Gly Thr Arg Thr Asp Ser Arg Glu Asp 70 75 80
- u Ile Ser Pro Pro Pro Pro Asn Pro Val Val Lys Gly Arg Arg Arg 85 90 95
- rg Gly Ala Ile Ser Ala Glu Val Tyr Thr Glu Glu Asp Ala Ala Ser 100 105 110
- r Val Arg Lys Val Ile Pro Lys Asp Tyr Lys Thr Met Ala Ala Leu 115 120 125
- .a Lys Ala Ile Glu Lys Asn Val Leu Phe Ser His Leu Asp Asp Asn 130 135 140
- u Arg Ser Asp Ile Phe Asp Ala Met Phe Ser Val Ser Phe Ile Ala 5 150 155 160
- y Glu Thr Val Ile Gln Gln Gly Asp Glu Gly Asp Asn Phe Tyr Val 165 170 . 175
- e Asp Gln Gly Glu Thr Asp Val Tyr Val Asn Asn Glu Trp Ala Thr 180 185 190
- r Val Gly Glu Gly Gly Ser Phe Gly Glu Leu Ala Leu Ile Tyr Gly 195 200 205
- r Pro Arg Ala Ala Thr Val Lys Ala Lys Thr Asn Val Lys Leu Trp 210 215 220
- y Ile Asp Arg Asp Ser Tyr Arg Arg Ile Leu Met Gly Ser Thr Leu 5 230 235 240
- g Lys Arg Lys Met Tyr Glu Glu Phe Leu Ser Lys Val Ser Ile Leu 245 250 255

- lu Ser Leu Asp Lys Trp Glu Arg Leu Thr Val Ala Asp Ala Leu Glu 260 265 270
- co Val Gln Phe Glu Asp Gly Gln Lys Ile Val Val Gln Gly Glu Pro 275 280 285
- Ly Asp Glu Phe Phe Ile Ile Leu Glu Gly Ser Ala Ala Val Leu Gln 290 295 300
- rg Arg Ser Glu Asn Glu Glu Phe Val Glu Val Gly Arg Leu Gly Pro 310 315 320
- er Asp Tyr Phe Gly Glu Ile Ala Leu Leu Met Asn Arg Pro Arg Ala 325 330 335
- .a Thr Val Val Ala Arg Gly Pro Leu Lys Cys Val Lys Leu Asp Arg 340 345 350
- to Arg Phe Glu Arg Val Leu Gly Pro Cys Ser Asp Ile Leu Lys Arg 355 360 365
- :n Ile Gln Gln Tyr Asn Ser Phe Val Ser Leu Ser Val 370 375 380
- :10> 120
- :11> 245
- :12> PRT
- 13> Homo sapiens
- 00> 120
- t Asn Gly Arg Ala Asp Phe Arg Glu Pro Asn Ala Glu Val Pro Arg
  5 10 15
- o Ile Pro His Ile Gly Pro Asp Tyr Ile Pro Thr Glu Glu Glu Arg 20 25 30
- g Val Phe Ala Glu Cys Asn Asp Glu Ser Phe Trp Phe Arg Ser Val 35 40 45
- o Leu Ala Ala Thr Ser Met Leu Ile Thr Gln Gly Leu Ile Ser Lys 50 55 60

eolf-seq1-S000001.txt
-Y Ile Leu Ser Ser His Pro Lys Tyr Gly Ser Ile Pro Lys Leu Ile
70 75 80

- u Ala Cys Ile Met Gly Tyr Phe Ala Gly Lys Leu Ser Tyr Val Lys 85 90 95
- ir Cys Gln Glu Lys Phe Lys Lys Leu Glu Asn Ser Pro Leu Gly Glu 100 105 110
- .a Leu Arg Ser Gly Gln Ala Arg Arg Ser Ser Pro Pro Gly His Tyr 115 120 125
- r Gln Lys Ser Lys Tyr Asp Ser Ser Val Ser Gly Gln Ser Ser Phe 130 135 140
- .1 Thr Ser Pro Ala Ala Asp Asn Ile Glu Met Leu Pro His Tyr Glu 5 150 155 . 160
- o Ile Pro Phe Ser Ser Ser Met Asn Glu Ser Ala Pro Thr Gly Ile 165 170 175
- r Asp His Ile Val Gln Gly Pro Asp Pro Asn Leu Glu Glu Ser Pro 180 185 190
- s Arg Lys Asn Ile Thr Tyr Glu Glu Leu Arg Asn Lys Asn Arg Glu 195 200 205
- r Tyr Glu Val Ser Leu Thr Gln Lys Thr Asp Pro Ser Val Arg Pro 210  $\,$  220  $\,$
- t His Glu Arg Val Pro Lys Lys Glu Val Lys Val Asn Lys Tyr Gly 230 235 240
- p Thr Trp Asp Glu 245
- 10> 121
- 11> 359
- 12> PRT
- 13> Homo sapiens
- 00> 121

- et Ser Thr Arg Ala Lys Leu Arg Arg Ile Trp Arg Ile Leu Glu

  5 10 15
- lu Glu Glu Ser Val Ala Gly Ala Val Gln Thr Leu Leu Arg Ser 20 25 30
- n Glu Gly Gly Val Thr Ser Ala Ala Ala Ser Thr Leu Ser Glu Pro 35 40 45
- co Arg Arg Thr Gln Glu Ser Arg Thr Arg Thr Arg Ala Leu Gly Leu 50 55 60
- to Thr Leu Pro Met Glu Lys Leu Ala Ala Ser Thr Glu Pro Gln Gly 70 75 80
- to Arg Pro Val Leu Gly Arg Glu Ser Val Gln Val Pro Asp Asp Gln 85 90 95
- :p Phe Arg Ser Phe Arg Ser Glu Cys Glu Ala Glu Val Gly Trp Asn 100 105 110
- u Thr Tyr Ser Arg Ala Gly Val Ser Val Trp Val Gln Ala Val Glu 115 120 125
- t Asp Arg Thr Leu His Lys Ile Lys Cys Arg Met Glu Cys Cys Asp 130 135 140
- l Pro Ala Glu Thr Leu Tyr Asp Val Leu His Asp Ile Glu Tyr Arg 5 150 155 160
- s Lys Trp Asp Ser Asn Val Ile Glu Thr Phe Asp Ile Ala Arg Leu 165 170 175
- r Val Asn Ala Asp Val Gly Tyr Tyr Ser Trp Arg Cys Pro Lys Pro 180 185 190
- u Lys Asn Arg Asp Val Ile Thr Leu Arg Ser Trp Leu Pro Met Gly
  195 200 205
- a Asp Tyr Ile Ile Met Asn Tyr Ser Val Lys His Pro Lys Tyr Pro 210 215 220

- to Arg Lys Asp Leu Val Arg Ala Val Ser Ile Gln Thr Gly Tyr Leu 25 230 235 240
- e Gln Ser Thr Gly Pro Lys Ser Cys Val Ile Thr Tyr Leu Ala Gln. 245 250 255
- ll Asp Pro Lys Gly Ser Leu Pro Lys Trp Val Val Asn Lys Ser Ser 260 265 270
- .n Phe Leu Ala Pro Lys Ala Met Lys Lys Met Tyr Lys Ala Cys Leu 275 280 285
- 's Tyr Pro Glu Trp Lys Gln Lys His Leu Pro His Phe Lys Pro Trp 290 295 300
- u His Pro Glu Gln Ser Pro Leu Pro Ser Leu Ala Leu Ser Glu Leu 5 310 315
- r Val Gln His Ala Asp Ser Leu Glu Asn Ile Asp Glu Ser Ala Val 325 330 335
- a Glu Ser Arg Glu Glu Arg Met Gly Gly Ala Gly Glu Gly Ser 340 345 350
- p Asp Asp Thr Ser Leu Thr 355
- 10> 122
- 11> 199
- 12> PRT
- 13> Homo sapiens
- 00> 122
- t Ser Ser Gly Asn Ala Lys Ile Gly His Pro Ala Pro Asn Phe Lys
  5 10 15
- a Thr Ala Val Met Pro Asp Gly Gln Phe Lys Asp Ile Ser Leu Ser 20 25 30
- o Tyr Lys Gly Lys Tyr Val Val Phe Phe Phe Tyr Pro Leu Asp Phe 35 40 45

- r Phe Val Cys Pro Thr Glu Ile Ile Ala Phe Ser Asp Arg Ala Glu 50 55 60
- u Phe Lys Lys Leu Asn Cys Gln Val Ile Gly Ala Ser Val Asp Ser 70 75 80
- s Phe Cys His Leu Ala Trp Val Asn Thr Pro Lys Lys Gln Gly Gly 85 90 95
- u Gly Pro Met Asn Ile Pro Leu Val Ser Asp Pro Lys Arg Thr Ile 100 105 110
- a Gln Asp Tyr Gly Val Leu Lys Ala Asp Glu Gly Ile Ser Phe Arg 115 120 125
- y Leu Phe Ile Ile Asp Asp Lys Gly Ile Leu Arg Gln Ile Thr Val . . . . 130 135
- n Asp Leu Pro Val Gly Arg Ser Val Asp Glu Thr Leu Arg Leu Val 5 150 155 160
- n Ala Phe Gln Phe Thr Asp Lys His Gly Glu Val Cys Pro Ala Gly 165 170 175
- p Lys Pro Gly Ser Asp Thr Ile Lys Pro Asp Val Gln Lys Ser Lys 180 185 190
- u Tyr Phe Ser Lys Gln Lys 195
- 10> 123
- 11> 219
- 12> PRT
- 13> Homo sapiens
- 00> 123
- E Ser Gly Leu Ser Gly Pro Pro Ala Arg Arg Gly Pro Phe Pro Leu 5 10 15
- 1 Leu Leu Leu Phe Leu Leu Gly Pro Arg Leu Val Leu Ala Ile 20 25 30

- r Phe His Leu Pro Ile Asn Ser Arg Lys Cys Leu Arg Glu Glu Ile 35 40 45
- s Lys Asp Leu Leu Val Thr Gly Ala Tyr Glu Ile Ser Asp Gln Ser 50 55 60
- y Gly Ala Gly Gly Leu Arg Ser His Leu Arg Ile Thr Asp Ser Ala 70 75 80
- y His Ile Leu Tyr Ser Lys Glu Asp Ala Thr Lys Gly Lys Phe Ala 85 90 95
- e Thr Thr Glu Asp Tyr Asp Met Phe Glu Val Cys Phe Glu Ser Lys 100 105 110
- y Val Glu Ala Lys Asn Tyr Glu Glu Ile Ala Lys Val Glu Lys Leu 130 135 140
- 5 Pro Leu Glu Val Glu Leu Arg Arg Leu Glu Asp Leu Ser Glu Ser 5 150 155 160
- ≥ Val Asn Asp Phe Ala Tyr Met Lys Lys Arg Glu Glu Glu Met Arg 165
  170
  175
- ) Thr Asn Glu Ser Thr Asn Thr Arg Val Leu Tyr Phe Ser Ile Phe 180 185 190
- : Met Phe Cys Leu Ile Gly Leu Ala Thr Trp Gln Val Phe Tyr Leu 195 200 205
- Arg Phe Phe Lys Ala Lys Lys Leu Ile Glu 210 215
- .0> 124
- .1> 1575
- .2> PRT
- .3> Homo sapiens
- 10> 124

- t Pro His Glu Glu Leu Pro Ser Leu Gln Arg Pro Arg Tyr Gly Ser 5 10 15
- e Val Asp Asp Glu Arg Leu Ser Ala Glu Glu Met Asp Glu Arg Arg 20 25 30
- g Gln Asn Ile Ala Tyr Glu Tyr Leu Cys His Leu Glu Glu Ala Lys 35 40 45
- g Trp Met Glu Val Cys Leu Val Glu Glu Leu Pro Pro Thr Thr Glu 50 55 60
- u Glu Glu Gly Leu Arg Asn Gly Val Tyr Leu Ala Lys Leu Ala Lys 70 75 80
- n Thr Arg Tyr Lys Lys Ser Gly Leu His Phe Arg His Thr Asp Asn 100 105 110
- r Val Gln Trp Leu Arg Ala Met Glu Ser Ile Gly Leu Pro Lys Ile 115 120 125
- 3 Tyr Pro Glu Thr Thr Asp Val Tyr Asp Arg Lys Asn Ile Pro Arg
  130 135 140
- Ile Tyr Cys Ile His Ala Leu Ser Leu Tyr Leu Phe Lys Leu Gly
  150 155 160
- e Ala Pro Gln Ile Gln Asp Leu Leu Gly Lys Val Asp Phe Thr Glu 165 170 175
- 1 Glu Ile Ser Asn Met Arg Lys Glu Leu Glu Lys Tyr Gly Ile Gln
  180 185 190
- : Pro Ser Phe Ser Lys Ile Gly Gly Ile Leu Ala Asn Glu Leu Ser 195 200 205
- . Asp Glu Ala Ala Leu His Ala Ala Val Ile Ala Ile Asn Glu Ala 210 215 220

- al Glu Lys Gly Ile Ala Glu Gln Thr Val Val Thr Leu Arg Asn Pro 25 230 235 240
- sn Ala Val Leu Thr Leu Val Asp Asp Asn Leu Ala Pro Glu Tyr Gln 245 250 255
- ys Glu Leu Trp Asp Ala Lys Lys Lys Glu Glu Asn Ala Arg Leu 260 265 270
- ys Asn Ser Cys Ile Ser Glu Glu Glu Arg Asp Ala Tyr Glu Glu Leu 275 280 285
- eu Thr Gln Ala Glu Ile Gln Gly Asn Ile Asn Lys Val Asn Arg Gln 290 295 300
- La Ala Val Asp His Ile Asn Ala Val Ile Pro Glu Gly Asp Pro Glu 310 315 320
- 3n Thr Leu Leu Ala Leu Lys Lys Pro Glu Ala Gln Leu Pro Ala Val 325 330 335
- /r Pro Phe Ala Ala Ala Met Tyr Gln Asn Glu Leu Phe Asn Leu Gln 340 345 350
- /s Gln Asn Thr Met Asn Tyr Leu Ala His Glu Glu Leu Leu Ile Ala 355 360 365
- il Glu Met Leu Ser Ala Val Ala Leu Leu Asn Gln Ala Leu Glu Ser 370 375 380
- in Asp Leu Val Ser Val Gln Asn Gln Leu Arg Ser Pro Ala Ile Gly
  390 395 400
- u Asn Asn Leu Asp Lys Ala Tyr Val Glu Arg Tyr Ala Asn Thr Leu 405 410 415
- u Ser Val Lys Leu Glu Val Leu Ser Gln Gly Gln Asp Asn Leu Ser 420 425 430
- p Asn Glu Ile Gln Asn Cys Ile Asp Met Val Asn Ala Gln Ile Gln Page 234

445

eolf-seq1-S000001.txt 435 440

lu Glu Asn Asp Arg Val Val Ala Val Gly Tyr Ile Asn Glu Ala Ile 450 455 460

- sp Glu Gly Asn Pro Leu Arg Thr Leu Glu Thr Leu Leu Pro Thr 65 470 475 480
- la Asn Ile Ser Asp Val Asp Pro Ala His Ala Gln His Tyr Gln Asp 485 490 495
- al Leu Tyr His Ala Lys Ser Gln Lys Leu Gly Asp Ser Glu Ser Val 500 510
- er Lys Val Leu Trp Leu Asp Glu Ile Gln Gln Ala Val Asp Glu Ala 515 520 525
- 5n Val Asp Glu Asp Arg Ala Lys Gln Trp Val Thr Leu Val Val Asp 530 540
- al Asn Gln Cys Leu Glu Gly Lys Lys Ser Ser Asp Ile Leu Ser Val 550 555 560
- eu Lys Ser Ser Thr Ser Asn Ala Asn Asp Ile Ile Pro Glu Cys Ala 565 570 575
- 3p Lys Tyr Tyr Asp Ala Leu Val Lys Ala Lys Glu Leu Lys Ser Glu 580 590
- rg Val Ser Ser Asp Gly Ser Trp Leu Lys Leu Asn Leu His Lys Lys 595 600 605
- 'r Asp Tyr Tyr Tyr Asn Thr Asp Ser Lys Glu Ser Ser Trp Val Thr 610 620
- to Glu Ser Cys Phe Tyr Lys Glu Ser Trp Leu Thr Gly Lys Glu Ile 630 635 640
- u Asp Ile Ile Glu Glu Val Thr Val Gly Tyr Ile Arg Glu Asn Ile 645 650 655

- rp Ser Ala Ser Glu Glu Leu Leu Leu Arg Phe Gln Ala Thr Ser Ser 660 665 670
- Ly Pro Ile Leu Arg Glu Glu Phe Glu Ala Arg Lys Ser Phe Leu His 675 680 685
- lu Gln Glu Glu Asn Val Val Lys Ile Gln Ala Phe Trp Lys Gly Tyr 690 695 700
- /s Gln Arg Lys Glu Tyr Met His Arg Arg Gln Thr Phe Ile Asp Asn 710 715 720
- ir Asp Ser Val Val Lys Ile Gln Ser Trp Phe Arg Met Ala Thr Ala 725 730 735
- tg Lys Ser Tyr Leu Ser Arg Leu Gln Tyr Phe Arg Asp His Asn Asn 740 745 . 750
- u Ile Val Lys Ile Gln Ser Leu Leu Arg Ala Asn Lys Ala Arg Asp. 765 760 765
- ip Tyr Lys Thr Leu Val Gly Ser Glu Asn Pro Pro Leu Thr Val Ile
  770 780
- g Lys Phe Val Tyr Leu Leu Asp Gln Ser Asp Leu Asp Phe Gln Glu 790 795 800
- u Leu Glu Val Ala Arg Leu Arg Glu Glu Val Val Thr Lys Ile Arg 805 810 815
- a Asn Gln Gln Leu Glu Lys Asp Leu Asn Leu Met Asp Ile Lys Ile 820 825 830
- y Leu Leu Val Lys Asn Arg Ile Thr Leu Glu Asp Val Ile Ser His 835 840 845
- r Lys Lys Leu Asn Lys Lys Gly Glu Met Glu Ile Leu Asn 850 855 860
- n Thr Asp Asn Gln Gly Ile Lys Ser Leu Ser Lys Glu Arg Arg Lys 5 870 875 880

- r Leu Glu Thr Tyr Gln Gln Leu Phe Tyr Leu Leu Gln Thr Asn Pro 885 890 895
- u Tyr Leu Ala Lys Leu Ile Phe Gln Met Pro Gln Asn Lys Ser Thr 900 905 910
- s Phe Met Asp Thr Val Ile Phe Thr Leu Tyr Asn Tyr Ala Ser Asn 915 920 925
- n Arg Glu Glu Tyr Leu Leu Leu Lys Leu Phe Lys Thr Ala Leu Glu 930 935 940
- u Glu Ile Lys Ser Lys Val Asp Gln Val Gln Asp Ile Val Thr Gly 950 955 960
- n Pro Thr Val Ile Lys Met Val Val Ser Phe Asn Arg Gly Ala Arg 965 970 975
- y Gln Asn Thr Leu Arg Gln Leu Leu Ala Pro Val Val Lys Glu Ile 980 985 990
- each Asp Asp Lys Ser Leu Ile Ile Asn Thr Asn Pro Val Glu Val Tyr 995 1000 1005
- 3 Ala Trp Val Asn Gln Leu Glu Thr Gln Thr Gly Glu Ala Ser 1010 1015 1020
- Leu Pro Tyr Asp Val Thr Thr Glu Gln Ala Leu Thr Tyr Pro 1025 1030 1035
- 1 Val Lys Asn Lys Leu Glu Ala Ser Ile Glu Asn Leu Arg Arg 1040 1045 1050
- . Thr Asp Lys Val Leu Asn Ser Ile Ile Ser Ser Leu Asp Leu 1055 1060 1065
- Pro Tyr Gly Leu Arg Tyr Ile Ala Lys Val Leu Lys Asn Ser 1070 1075 1080
- His Glu Lys Phe Pro Asp Ala Thr Glu Asp Glu Leu Leu Lys 1085 1090 1095

### eolf-seql-S000001.txt

le Val Gly Asn Leu Leu Tyr Tyr Arg Tyr Met Asn Pro Ala Ile 1100 1105 1110 al Ala Pro Asp Gly Phe Asp Ile Ile Asp Met Thr Ala Gly Gly 1115 1120 1125 ln Ile Asn Ser Asp Gln Arg Arg Asn Leu Gly Ser Val Ala Lys 1130 . 1135 1140al Leu Gln His Ala Ala Ser Asn Lys Leu Phe Glu Gly Glu Asn 1145 lu His Leu Ser Ser Met Asn Asn Tyr Leu Ser Glu Thr Tyr Gln 1165 lu Phe Arg Lys Tyr Phe Lys Glu Ala Cys Asn Val Pro Glu Pro 1185 · lu Glu Lys Phe Asn Met Asp Lys Tyr Thr Asp Leu Val Thr Val 1190 1195 1200er Lys Pro Val Ile Tyr Ile Ser Ile Glu Glu Ile Ile Ser Thr 1205 1210 1215 is Ser Leu Leu Glu His Gln Asp Ala Ile Ala Pro Glu Lys 1220 1225 1230 3n Asp Leu Leu Ser Glu Leu Leu Gly Ser Leu Gly Glu Val Pro 1235 1240 1245 1240 1245 ir Val Glu Ser Phe Leu Gly Glu Gly Ala Val Asp Pro Asn Asp 1250 1255 1260 to Asn Lys Ala Asn Thr Leu Ser Gln Leu Ser Lys Thr Glu Ile 1265 1270 er Leu Val Leu Thr Ser Lys Tyr Asp Ile Glu Asp Gly Glu Ala 1280 1285 e Asp Ser Arg Ser Leu Met Ile Lys Thr Lys Lys Leu Ile Ile

Page 238

eolf-seql-S000001.txt 1295 1300 1305

SP Val Ile Arg Asn Gln Pro Gly Asn Thr Leu Thr Glu Ile Leu 1310 1315 1320

- lu Thr Pro Ala Thr Ala Gln Glu Val Asp His Ala Thr Asp 1325 1330 1335
- m >t Val Ser Arg Ala Met Ile Asp Ser Arg Thr Pro Glu Glu Met 1340 1350
- /s His Ser Gln Ser Met Ile Glu Asp Ala Gln Leu Pro Leu Glu 1355 1360 1365
- ln Lys Lys Arg Lys Ile Gln Arg Asn Leu Arg Thr Leu Glu Gln 1370 . 1375 . 1380
- ır Gly His Val Ser Ser Glu Asn Lys Tyr Gln Asp Ile Leu Asn 1385 1390 1395
- u Ile Ala Lys Asp Ile Arg Asn Gln Arg Ile Tyr Arg Lys Leu 1400 1405 1410
- g Lys Ala Glu Leu Ala Lys Leu Gln Gln Thr Leu Asn Ala Leu 1415 1420 1425
- In Lys Lys Ala Ala Phe Tyr Glu Glu Glu Ile Asn Tyr Tyr Asp 1430 1435 1440
- r Tyr Ile Lys Thr Cys Leu Asp Asn Leu Lys Arg Lys Asn Thr 1445 1450 1455
- g Arg Ser Ile Lys Leu Asp Gly Lys Gly Glu Pro Lys Gly Ala 1460 1465 1470
- s Arg Ala Lys Pro Val Lys Tyr Thr Ala Ala Lys Leu His Glu 1475 1480 1485
- s Gly Val Leu Leu Asp Ile Asp Asp Leu Gln Thr Asn Gln Phe 1490 1495 1500

eolf-seql-S000001.txt

ys Asn Val Thr Phe Asp Ile Ile Ala Thr Glu Asp Val Gly Ile 1505 1510 1515

- he Asp Val Arg Ser Lys Phe Leu Gly Val Glu Met Glu Lys Val 1520 1530
- ln Leu Asn Ile Gln Asp Leu Leu Gln Met Gln Tyr Glu Gly Val 1535 1540 1545
- la Val Met Lys Met Phe Asp Lys Val Lys Val Asn Val Asn Leu 1550 1560
- eu Ile Tyr Leu Leu Asn Lys Lys Phe Tyr Gly Lys 1565 1570 1575

210> 125

211> 212

212> PRT

213> Homo sapiens

100> 125

- et Ala Tyr Ala Tyr Leu Phe Lys Tyr Ile Ile Ile Gly Asp Thr Gly 5 10 15
- % al Gly Lys Ser Cys Leu Leu Leu Gln Phe Thr Asp Lys Arg Phe Gln 20 25 30
- To Val His Asp Leu Thr Ile Gly Val Glu Phe Gly Ala Arg Met Ile 35 40 45
- ir Ile Asp Gly Lys Gln Ile Lys Leu Gln Ile Trp Asp Thr Ala Gly
  50
- in Glu Ser Phe Arg Ser Ile Thr Arg Ser Tyr Tyr Arg Gly Ala Ala 70 75 80
- .y Ala Leu Leu Val Tyr Asp Ile Thr Arg Arg Asp Thr Phe Asn His 85 90 95
- Thr Trp Leu Glu Asp Ala Arg Gln His Ser Asn Ser Asn Met 100 105 110

eolf-seql-S000001.txt
al Ile Met Leu Ile Gly Asn Lys Ser Asp Leu Glu Ser Arg Arg Glu
115 120 125

- al Lys Lys Glu Glu Gly Glu Ala Phe Ala Arg Glu His Gly Leu Ile 130 135 140
- he Met Glu Thr Ser Ala Lys Thr Ala Ser Asn Val Glu Glu Ala Phe 45 150 155 160
- le Asn Thr Ala Lys Glu Ile Tyr Glu Lys Ile Gln Glu Gly Val Phe 165 170 175
- sp Ile Asn Asn Glu Ala Asn Gly Ile Lys Ile Gly Pro Gln His Ala 180 185 190
- la Thr Asn Ala Thr His Ala Gly Asn Gln Gly Gly Gln Gln Ala Gly 195 200 205
- Ly Gly Cys Cys 210

210> 126

?11> 181

?12> PRT

?13> Homo sapiens

100> 126

- et Gly Asn Ile Phe Ala Asn Leu Phe Lys Gly Leu Phe Gly Lys Lys 5 10 15
- .u Met Arg Ile Leu Met Val Gly Leu Asp Ala Ala Gly Lys Thr Thr  $20 \hspace{1cm} 25 \hspace{1cm} 30$
- e Leu Tyr Lys Leu Lys Leu Gly Glu Ile Val Thr Thr Ile Pro Thr 35 40 45
- e Gly Phe Asn Val Glu Thr Val Glu Tyr Lys Asn Ile Ser Phe Thr 50 55 60
- 1 Trp Asp Val Gly Gly Gln Asp Lys Ile Arg Pro Leu Trp Arg His 70 75 80

eolf-seql-S000001.txt

- yr Phe Gln Asn Thr Gln Gly Leu Ile Phe Val Val Asp Ser Asn Asp 85 90 95
- rg Glu Arg Val Asn Glu Ala Arg Glu Glu Leu Met Arg Met Leu Ala 100 105 110
- lu Asp Glu Leu Arg Asp Ala Val Leu Leu Val Phe Ala Asn Lys Gln 115 120 125
- Sp Leu Pro Asn Ala Met Asn Ala Ala Glu Ile Thr Asp Lys Leu Gly 130 135 140
- $\ni$ u His Ser Leu Arg His Arg Asn Trp Tyr Ile Gln Ala Thr Cys Ala 150 150 155 160
- eu Arg Asn Gln Lys 180

210> 127

211> 732

?12> PRT

- ?13> Homo sapiens
- 100> 127
- et Pro Glu Glu Thr Gln Thr Gln Asp Gln Pro Met Glu Glu Glu 5 10 15
- ıl Glu Thr Phe Ala Phe Gln Ala Glu Ile Ala Gln Leu Met Ser Leu 20 25 30
- e Ile Asn Thr Phe Tyr Ser Asn Lys Glu Ile Phe Leu Arg Glu Leu 35 40 45
- e Ser Asn Ser Ser Asp Ala Leu Asp Lys Ile Arg Tyr Glu Thr Leu 50 55 60
- r Asp Pro Ser Lys Leu Asp Ser Gly Lys Glu Leu His Ile Asn Leu
  70 75 80

eolf-seql-S000001.txt le Pro Asn Lys Gln Asp Arg Thr Leu Thr Ile Val Asp Thr Gly Ile 85 90 95

- ly Met Thr Lys Ala Asp Leu Ile Asn Asn Leu Gly Thr Ile Ala Lys
- er Gly Thr Lys Ala Phe Met Glu Ala Leu Gln Ala Gly Ala Asp Ile 115 120 125
- er Met Ile Gly Gln Phe Gly Val Gly Phe Tyr Ser Ala Tyr Leu Val 130 135 140
- la Glu Lys Val Thr Val Ile Thr Lys His Asn Asp Asp Glu Gln Tyr 45 150 155 160
- la Trp Glu Ser Ser Ala Gly Gly Ser Phe Thr Val Arg Thr Asp Thr 165 170 175
- ly Glu Pro Met Gly Arg Gly Thr Lys Val Ile Leu His Leu Lys Glu 180 185 190
- sp Gln Thr Glu Tyr Leu Glu Glu Arg Arg Ile Lys Glu Ile Val Lys 195 200 205
- /s His Ser Gln Phe Ile Gly Tyr Pro Ile Thr Leu Phe Val Glu Lys 210 220
- Lu Arg Asp Lys Glu Val Ser Asp Asp Glu Ala Glu Glu Lys Glu Asp 230 240
- ys Glu Glu Glu Lys Glu Lys Glu Lys Glu Ser Glu Asp Lys Pro 245 250 255
- u Ile Glu Asp Val Gly Ser Asp Glu Glu Glu Glu Lys Lys Asp Gly 260 265 270
- p Lys Lys Lys Lys Lys Ile Lys Glu Lys Tyr Ile Asp Gln Glu 275 280 285
- u Leu Asn Lys Thr Lys Pro Ile Trp Thr Arg Asn Pro Asp Asp Ile 290 295 300

#### eolf-segl-S000001.txt

hr Asn Glu Glu Tyr Gly Glu Phe Tyr Lys Ser Leu Thr Asn Asp Trp 310 315 320

lu Asp His Leu Ala Val Lys His Phe Ser Val Glu Gly Gln Leu Glu 325 330 335

he Arg Ala Leu Leu Phe Val Pro Arg Arg Ala Pro Phe Asp Leu Phe 340 350

lu Asn Arg Lys Lys Lys Asn Asn Ile Lys Leu Tyr Val Arg Arg Val 355 360 365

ne Ile Met Asp Asn Cys Glu Glu Leu Ile Pro Glu Tyr Leu Asn Phe 370 380

le Arg Gly Val Val Asp Ser Glu Asp Leu Pro Leu Asn Ile Ser Arg 35 390 395

lu Met Leu Gl<br/>n Gl<br/>n Ser Lys Ile Leu Lys Val Ile Arg Lys As<br/>n Leu 405 415

il Lys Lys Cys Leu Glu Leu Phe Thr Glu Leu Ala Glu Asp Lys Glu 420 425 430

In Tyr Lys Lys Phe Tyr Glu Gln Phe Ser Lys Asn Ile Lys Leu Gly 435

Le His Glu Asp Ser Gln Asn Arg Lys Lys Leu Ser Glu Leu Leu Arg 450 455 460

'r Tyr Thr Ser Ala Ser Gly Asp Glu Met Val Ser Leu Lys Asp Tyr i5 470 475 480

's Thr Arg Met Lys Glu Asn Gln Lys His Ile Tyr Tyr Ile Thr Gly 485 490 495

u Thr Lys Asp Gln Val Ala Asn Ser Ala Phe Val Glu Arg Leu Arg 500 505 510

rs His Gly Leu Glu Val Ile Tyr Met Ile Glu Pro Ile Asp Glu Tyr 515 520 525

### eolf-seql-S000001.txt

- ys Val Gln Gln Leu Lys Glu Phe Glu Gly Lys Thr Leu Val Ser Val 530 540
- ar Lys Glu Gly Leu Glu Leu Pro Glu Asp Glu Glu Glu Lys Lys Lys 550 555 560
- ln Glu Glu Lys Lys Thr Lys Phe Glu Asn Leu Cys Lys Ile Met Lys 565 570 575
- 3p Ile Leu Glu Lys Lys Val Glu Lys Val Val Val Ser Asn Arg Leu 580 585 590
- 11 Thr Ser Pro Cys Cys Ile Val Thr Ser Thr Tyr Gly Trp Thr Ala 595 600 605
- 3n Met Glu Arg Ile Met Lys Ala Gln Ala Leu Arg Asp Asn Ser Thr 610 615 620
- et Gly Tyr Met Ala Ala Lys Lys His Leu Glu Ile Asn Pro Asp His 630 635 640
- er Ile Ile Glu Thr Leu Arg Gln Lys Ala Glu Ala Asp Lys Asn Asp 645 650 655
- rs Ser Val Lys Asp Leu Val Ile Leu Leu Tyr Glu Thr Ala Leu Leu 660 670
- r Ser Gly Phe Ser Leu Glu Asp Pro Gln Thr His Ala Asn Arg Ile 675 680 685
- r Arg Met Ile Lys Leu Gly Leu Gly Ile Asp Glu Asp Asp Pro Thr 690 695 700
- a Asp Asp Thr Ser Ala Ala Val Thr Glu Glu Met Pro Pro Leu Glu 5 710 715 720
- y Asp Asp Asp Thr Ser Arg Met Glu Glu Val Asp 725 730

10> 128

- 211> 858
- 212> PRT
- 213> Homo sapiens
- 400> 128
- et Gly Asp His Leu Asp Leu Leu Gly Val Val Leu Met Ala Gly 5 10 15
- ro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe 20 25 30
- yr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr 35 40 45
- lu Arg Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser 50 55 60
- er Phe Pro Phe Leu Glu Gln Leu Gln Leu Glu Leu Gly Ser Gln 70 75 80
- yr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn 85 90 95
- eu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro 100 105 110
- sp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe 115 120 125
- /s Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu 130 135 140
- vs Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu 15 150 155 160
- rr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp 165 170 175
- te Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro 180 185 190
- u Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu Page 246

205

eolf-seq1-S000001.txt 195 200

yr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg 210 215 220

- sn Met Val Leu Glu Ile Leu Asp Val Ser Gly Asn Gly Trp Thr Val 25 230 235 240
- sp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe 245 250 255
- er Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His 260 265 270
- sn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser 275 280 285
- er Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn 290 295 300
- er Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala 310 315 320
- r Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp 325 330 335
- sn Leu Gl<br/>n Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Tyr 340 <br/> 345 <br/> 350
- er Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln 355 360 365
- 's Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu 370 380
- 's Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His 390 395 400
- te Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val 405 410 415

- hr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu
  420 425 430
- sn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro 435 440 445
- is Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser 450 455 460
- ly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu 55 470 475 480
- ly Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp 485 490 495
- al Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn 500 505 510
- /r Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu 515 520 525
- cg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn 530 540
- p Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu 15 550 555 560
- eu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile 565 570 575
- ir His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn 580 585 590
- p Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile 595 600 605
- r Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu 610 620
- r Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe 630 635 640

## eolf-seql-S000001.txt

er Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr 645 650 655

le Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys 660 665 670

hr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro 675 680 685

sp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe 690 695 700

or Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser 710 715 720

sp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro
725 730 735

ly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg
740 745 750

/s Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys 755 760 765

 $\ge$ u Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn 770 780

er Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu 35 790 795 800

et Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu 805 810 815

rg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu 820 825 830

er Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn 835 840 845

e Pro Leu Gln Thr Val Ala Thr Ile Ser 850 855

Page 249

## eolf-seql-S000001.txt

210> 129

211> 466

212> PRT

213> Homo sapiens

400> 129

- et Val Met Glu Lys Pro Ser Pro Leu Leu Val Gly Arg Glu Phe Val 5 10 15
- rg Gln Tyr Tyr Thr Leu Leu Asn Gln Ala Pro Asp Met Leu His Arg 20 25 30
- ne Tyr Gly Lys Asn Ser Ser Tyr Val His Gly Gly Leu Asp Ser Asn 35 40 45
- Lys.Pro Ala Asp Ala Val Tyr Gly Gln Lys Glu Ile His Arg Lys 50 55 60
- il Met Ser Gln Asn Phe Thr Asn Cys His Thr Lys Ile Arg His Val 70 75 80
- p Ala His Ala Thr Leu Asn Asp Gly Val Val Val Gln Val Met Gly 85 90 95
- eu Leu Ser Asn Asn Asn Gln Ala Leu Arg Arg Phe Met Gln Thr Phe
- l Leu Ala Pro Glu Gly Ser Val Ala Asn Lys Phe Tyr Val His Asn 115 120 125
- p Ile Phe Arg Tyr Gln Asp Glu Val Phe Gly Gly Phe Val Thr Glu 130 135 140
- o Gln Glu Glu Ser Glu Glu Glu Val Glu Glu Pro Glu Glu Arg Gln 5 150 155 160
- n Thr Pro Glu Val Val Pro Asp Asp Ser Gly Thr Phe Tyr Asp Gln 165 170 175
- a Val Val Ser Asn Asp Met Glu Glu His Leu Glu Glu Pro Val Ala 180 185 190

Page 250

- lu Pro Glu Pro Asp Pro Glu Pro Glu Pro Glu Gln Glu Pro Val Ser 195 200 205
- lu Ile Gln Glu Glu Lys Pro Glu Pro Val Leu Glu Glu Thr Ala Pro 210 215 220
- lu Asp Ala Gln Lys Ser Ser Ser Pro Ala Pro Ala Asp Ile Ala Gln 25 230 235 240
- hr Val Gln Glu Asp Leu Arg Thr Phe Ser Trp Ala Ser Val Thr Ser 245 250 255
- ys Asn Leu Pro Pro Ser Gly Ala Val Pro Val Thr Gly Ile Pro Pro 260 265 270
- is Val Val Lys Val Pro Ala Ser Gln Pro Arg Pro Glu Ser Lys Pro 275 280 285
- lu Ser Gln Ile Pro Pro Gln Arg Pro Gln Arg Asp Gln Arg Val Arg 290 295 300
- lu Gln Arg Ile Asn Ile Pro Pro Gln Arg Gly Pro Arg Pro Ile Arg 310 315 320
- Lu Ala Gly Glu Gln Gly Asp Ile Glu Pro Arg Arg Met Val Arg His 325 330 335
- to Asp Ser His Gln Leu Phe Ile Gly Asn Leu Pro His Glu Val Asp 340 345 350
- rs Ser Glu Leu Lys Asp Phe Phe Gln Ser Tyr Gly Asn Val Val Glu 355 360 365
- u Arg Ile Asn Ser Gly Gly Lys Leu Pro Asn Phe Gly Phe Val Val 370 375 380
- ie Asp Asp Ser Glu Pro Val Gln Lys Val Leu Ser Asn Arg Pro Ile 5 390 395 400
- t Phe Arg Gly Glu Val Arg Leu Asn Val Glu Glu Lys Lys Thr Arg Page 251

eolf-seql-S000001.txt

405

415

la Ala Arg Glu Gly Asp Arg Arg Asp Asn Arg Leu Arg Gly Pro Gly

ly Pro Arg Gly Gly Leu Gly Gly Met Arg Gly Pro Pro Arg Gly

ly Met Val Gln Lys Pro Gly Phe Gly Val Gly Arg Gly Leu Ala Pro 460

cg Gln

210> 130

211> 245

?12> PRT

?13> Homo sapiens

100> 130

et Thr Leu Phe Pro Val Leu Leu Phe Leu Val Ala Gly Leu Leu Pro 10

er Phe Pro Ala Asn Glu Asp Lys Asp Pro Ala Phe Thr Ala Leu Leu

ır Thr Gln Thr Gln Val Gln Arg Glu Ile Val Asn Lys His Asn Glu

u Arg Arg Ala Val Ser Pro Pro Ala Arg Asn Met Leu Lys Met Glu 50

p Asn Lys Glu Ala Ala Ala Asn Ala Gln Lys Trp Ala Asn Gln Cys 70 75

n Tyr Arg His Ser Asn Pro Lys Asp Arg Met Thr Ser Leu Lys Cys 90

y Glu Asn Leu Tyr Met Ser Ser Ala Ser Ser Ser Trp Ser Gln Ala

e Gln Ser Trp Phe Asp Glu Tyr Asn Asp Phe Asp Phe Gly Val Gly Page 252

125

eolf-seq1-S000001.txt 115 120

ro Lys Thr Pro Asn Ala Val Val Gly His Tyr Thr Gln Val Val Trp 130 135 140

- yr Ser Ser Tyr Leu Val Gly Cys Gly Asn Ala Tyr Cys Pro Asn Gln 45 150 155 160
- /s Val Leu Lys Tyr Tyr Tyr Val Cys Gln Tyr Cys Pro Ala Gly Asn 165 170 175
- cp Ala Asn Arg Leu Tyr Val Pro Tyr Glu Gln Gly Ala Pro Cys Ala 180 185 190
- er Cys Pro Asp Asn Cys Asp Asp Gly Leu Cys Thr Asn Gly Cys Lys 195 200 205
- r Glu Asp Leu Tyr Ser Asn Cys Lys Ser Leu Lys Leu Thr Leu Thr 210 215 220
- 's Lys His Gln Leu Val Arg Asp Ser Cys Lys Ala Ser Cys Asn Cys 230 235 240
- er Asn Ser Ile Tyr 245

:10> 131

:11> 202

:12> PRT

:13> Homo sapiens

:00> 131

- t Cys Thr Gly Gly Cys Ala Arg Cys Leu Gly Gly Thr Leu Ile Pro
- u Ala Phe Phe Gly Phe Leu Ala As<br/>n Ile Leu Leu Phe Phe Pro Gly 20  $\phantom{000}25\phantom{000}$  30
- y Lys Val Ile Asp Asp Asn Asp His Leu Ser Gln Glu Ile Trp Phe 35 40 45
- e Gly Gly Ile Leu Gly Ser Gly Val Leu Met Ile Phe Pro Ala Leu Page 253

eolf-seql-S000001.txt
50 55 60

al Phe Leu Gly Leu Lys Asn Asn Asp Cys Cys Gly Cys Cys Gly Asn 5 70 75 80

- lu Gly Cys Gly Lys Arg Phe Ala Met Phe Thr Ser Thr Ile Phe Ala 85 90 95
- al Val Gly Phe Leu Gly Ala Gly Tyr Ser Phe Ile Ile Ser Ala Ile 100 105 110
- er Ile Asn Lys Gly Pro Lys Cys Leu Met Ala Asn Ser Thr Trp Gly 115 120 125
- /r Pro Phe His Asp Gly Asp Tyr Leu Asn Asp Glu Ala Leu Trp Asn
  130
  135
  140
- /s Cys Arg Glu Pro Leu Asn Val Val Pro Trp Asn Leu Thr Leu Phe 15 150 155 160
- er Ile Leu Leu Val Val Gly Gly Ile Gln Met Val Leu Cys Ala Ile 165 170 175
- in Val Val Asn Gly Leu Leu Gly Thr Leu Cys Gly Asp Cys Gln Cys 180 185 190
- 's Gly Cys Cys Gly Gly Asp Gly Pro Val

!10> 132

:11> 295

!12> PRT

:13> Homo sapiens

:00> 132

- t Gln Pro Glu Gly Ala Glu Lys Gly Lys Ser Phe Lys Gln Arg Leu 5 10 15
- l Leu Lys Ser Ser Leu Ala Lys Glu Thr Leu Ser Glu Phe Leu Gly
- r Phe Ile Leu Ile Val Leu Gly Cys Gly Cys Val Ala Gln Ala Ile Page 254

45

eolf-seql-S000001.txt 35 40

eu Ser Arg Gly Arg Phe Gly Gly Val Ile Thr Ile Asn Val Gly Phe 50 60

- er Met Ala Val Ala Met Ala Ile Tyr Val Ala Gly Gly Val Ser Gly 5 70 75 80
- ly His Ile Asn Pro Ala Val Ser Leu Ala Met Cys Leu Phe Gly Arg 85 90 95
- et Lys Trp Phe Lys Leu Pro Phe Tyr Val Gly Ala Gln Phe Leu Gly 100 105 110
- la Phe Val Gly Ala Ala Thr Val Phe Gly Ile Tyr Tyr Asp Gly Leu 115 120 125
- et Ser Phe Ala Gly Gly Lys Leu Leu Ile Val Gly Glu Asn Ala Thr 130 135 140
- la His Ile Phe Ala Thr Tyr Pro Ala Pro Tyr Leu Ser Leu Ala Asn 45 150 155 160
- la Phe Ala Asp Gln Val Val Ala Thr Met Ile Leu Leu Ile Ile Val 165 170 175
- ne Ala Ile Phe Asp Ser Arg Asn Leu Gly Ala Pro Arg Gly Leu Glu 180 185 190
- co Ile Ala Ile Gly Leu Leu Ile Ile Val Ile Ala Ser Ser Leu Gly
  195 200 205
- eu Asn Ser Gly Cys Ala Met Asn Pro Ala Arg Asp Leu Ser Pro Arg 210 225 220
- Phe Thr Ala Leu Ala Gly Trp Gly Phe Glu Val Phe Arg Ala Gly 230 235 240
- in Asn Phe Trp Trp Ile Pro Val Val Gly Pro Leu Val Gly Ala Val 245 250 255

eolf-seql-S000001.txt

le Gly Gly Leu Ile Tyr Val Leu Val Ile Glu Ile His His Pro Glu 260 265 270

- ro Asp Ser Val Phe Lys Ala Glu Gln Ser Glu Asp Lys Pro Glu Lys 275 280 285
- yr Glu Leu Ser Val Ile Met 290 295
- 210> 133
- 211> 288
- 212> PRT
- 213> Homo sapiens
- 400> 133
- et Trp Leu Pro Ala Leu Val Leu Ala Thr Leu Ala Ala Ser Ala Ala 5 10 15
- cp Ala Val His Pro Ser Ser Pro Pro Val Val Asp Thr Val His Gly 20 25 30
- /s Val Leu Gly Lys Phe Ile Ser Leu Glu Gly Phe Ala Gln Pro Val 35 40 45
- La Val Phe Leu Gly Ile Pro Phe Ala Lys Pro Pro Leu Gly Pro Leu 50 55 60
- rg Phe Thr Pro Pro Gln Pro Ala Glu Pro Trp Ser Phe Val Lys Asn 70 75 80
- .a Thr Leu Tyr Pro Pro Met Phe Thr Gln Asp Pro Arg Gly Gly 85 90 95
- n Leu Ile Ser Glu Leu Phe Thr Asn Arg Lys Glu Asn Ile Pro Leu 100 105 110
- 's Leu Ser Glu Asp Cys Leu Tyr Leu Asn Ile Tyr Thr Pro Ala Asp 115 120 125
- u. Thr Lys Lys Asn Arg Leu Pro Val Met Val Trp Ile His Gly Gly 130 135 140

- ly Leu Met Val Gly Ala Ala Ser Thr Tyr Asp Gly Leu Ala Leu Ala 45 150 155 160
- la His Glu Asn Val Val Val Thr Ile Gln Tyr Arg Leu Gly Ile 165 170 175
- cp Gly Phe Phe Ser Thr Gly Asp Glu His Ser Pro Gly Asn Trp Gly 180 185 190
- is Leu Asp Gln Leu Ala Ala Leu His Trp Val Gln Asp Asn Ile Ala 195 200 205
- er Phe Gly Gly Asn Pro Gly Ser Val Thr Ile Phe Gly Gly Ser Ala 210 215 220
- .y Gly Glu Ser Val Ser Val Leu Val Leu Ser Pro Leu Ala Lys Asn 230 235 240
- eu Phe His Arg Ala Ile Ser Glu Ser Gly Val Ala Leu Thr Ser Val 245 250 255
- u Val Lys Lys Gly Asp Val Lys Pro Leu Ala Glu Val Gly Leu Arg 260 265 270
- u Val Arg Leu Trp Leu Asp Thr His Thr Ser Leu Ala Leu Cys Ser 275 280 285
- 10> 134
- 11> 98
- 12> PRT
- 13> Homo sapiens
- 00> 134
- t Met Cys Gly Ala Pro Ser Ala Thr Gln Pro Ala Thr Ala Glu Thr 5 10 15
- n His Ile Ala Asp Gln Val Arg Ser Gln Leu Glu Glu Lys Glu Asn 20 25 30
- s Lys Phe Pro Val Phe Lys Ala Val Ser Phe Lys Ser Gln Val Val 35 40 45

eolf-seq1-S000001.txt

la Gly Thr Asn Tyr Phe Ile Lys Val His Val Gly Asp Glu Asp Phe 50 55 60

- al His Leu Arg Val Phe Gln Ser Leu Pro His Glu Asn Lys Pro Leu 5 70 75 80
- hr Leu Ser Asn Tyr Gln Thr Asn Lys Ala Lys His Asp Glu Leu Thr 85 90 95

yr Phe

210> 135

211> 254

212> PRT

213> Homo sapiens

400> 135

- et Ala Ser Leu Lys Val Asp Gln Glu Val Lys Leu Lys Val Asp 5 10 15
- er Phe Arg Glu Arg Ile Thr Ser Glu Ala Glu Asp Leu Val Ala Asn 20 25 30
- ne Phe Pro Lys Lys Leu Leu Glu Leu Asp Ser Phe Leu Lys Glu Pro 35 40 45
- le Leu Asn Ile His Asp Leu Thr Gln Ile His Ser Asp Met Asn Leu 50 55 60
- to Val Pro Asp Pro Ile Leu Leu Thr Asn Ser His Asp Gly Leu Asp 70 75 80
- y Pro Thr Tyr Lys Lys Arg Arg Leu Asp Glu Cys Glu Glu Ala Phe.
  85 90 95
- .n Gly Thr Lys Val Phe Val Met Pro Asn Gly Met Leu Lys Ser Asn 100 105 110
- n Gln Leu Val Asp Ile Ile Glu Lys Val Lys Pro Glu Ile Arg Leu 115 120 125

eolf-seql-S000001.txt
eu Ile Glu Lys Cys Asn Thr Val Lys Met Trp Val Gln Leu Leu Ile
130 135 140

- ro Arg Ile Glu Asp Gly Asn Asn Phe Gly Val Ser Ile Gln Glu Glu 45 150 155 160
- hr Val Ala Glu Leu Arg Thr Val Glu Ser Glu Ala Ala Ser Tyr Leu 165 170 175
- sp Gln Ile Ser Arg Tyr Tyr Ile Thr Arg Ala Lys Leu Val Ser Lys 180 185 190
- le Ala Lys Tyr Pro His Val Glu Asp Tyr Arg Arg Thr Val Thr Glu 195 200 205
- le Asp Glu Lys Glu Tyr Ile Ser Leu Arg Leu Ile Ile Ser Glu Leu 210 215 220
- rg Asn Gln Tyr Val Thr Leu His Asp Met Ile Leu Lys Asn Ile Glu 25 230 235 240
- /s Ile Lys Arg Pro Arg Ser Ser Asn Ala Glu Thr Leu Tyr 245 250
- 210> 136
- 211> 189
- ?12> PRT
- ?13> Homo sapiens
- 100> 136
- et Gly Leu Gly Ala Arg Gly Ala Trp Ala Ala Leu Leu Gly Thr 5 10 15
- u Gln Val Leu Ala Leu Leu Gly Ala Ala His Glu Ser Ala Ala Met 20 25 30
- .a Glu Thr Leu Gln His Val Pro Ser Asp His Thr Asn Glu Thr Ser 35 40 45
- on Ser Thr Val Lys Pro Pro Thr Ser Val Ala Ser Asp Ser Ser Asn 50 55 60

- hr Thr Val Thr Thr Met Lys Pro Thr Ala Ala Ser Asn Thr Thr Thr 5 70 75 80
- ro Gly Met Val Ser Thr Asn Met Thr Ser Thr Thr Leu Lys Ser Thr 85 90 95
- ro Lys Thr Thr Ser Val Ser Gln Asn Thr Ser Gln Ile Ser Thr Ser 100 105 110
- ar Met Thr Val Thr His Asn Ser Ser Val Thr Ser Ala Ala Ser Ser 115 120 125
- al Thr Ile Thr Thr Met His Ser Glu Ala Lys Lys Gly Ser Lys 130 135 140
- eu Ser Ile Leu Tyr Ile Gly Cys Lys Met Tyr Tyr Ser Arg Arg Gly 165 170 175
- te Arg Tyr Arg Thr Ile Asp Glu His Asp Ala Ile Ile 180 185
- 210> 137
- 211> 2314
- ?12> PRT
- 13> Homo sapiens
- 100> 137
- et Arg Ile Leu Lys Arg Phe Leu Ala Cys Ile Gln Leu Cys Val 5 10 15
- 's Arg Leu Asp Trp Ala Asn Gly Tyr Tyr Arg Gln Gln Arg Lys Leu 20 25 30
- .l Glu Glu Ile Gly Trp Ser Tyr Thr Gly Ala Leu Asn Gln Lys Asn 35 40 45
- p Gly Lys Lys Tyr Pro Thr Cys Asn Ser Pro Lys Gln Ser Pro Ile 50 55 60

eolf-seql-S000001.txt sn Ile Asp Glu Asp Leu Thr Gln Val Asn Val Asn Leu Lys Lys Leu 5 70 75 80

- ys Phe Gln Gly Trp Asp Lys Thr Ser Leu Glu Asn Thr Phe Ile His 85 90 95
- sn Thr Gly Lys Thr Val Glu Ile Asn Leu Thr Asn Asp Tyr Arg Val 100 105 110
- er Gly Gly Val Ser Glu Met Val Phe Lys Ala Ser Lys Ile Thr Phe 115 120 125
- is Trp Gly Lys Cys Asn Met Ser Ser Asp Gly Ser Glu His Ser Leu 130 135 140
- sp Arg Phe Ser Ser Phe Glu Glu Ala Val Lys Gly Lys Gly Lys Leu 165 170 175
- rg Ala Leu Ser Ile Leu Phe Glu Val Gly Thr Glu Glu Asn Leu Asp 180 185 190
- ne Lys Ala Ile Ile Asp Gly Val Glu Ser Val Ser Arg Phe Gly Lys 195 200 205
- ln Ala Ala Leu Asp Pro Phe Ile Leu Leu Asn Leu Leu Pro Asn Ser 210 · 215 220
- ir Asp Lys Tyr Tyr Ile Tyr Asn Gly Ser Leu Thr Ser Pro Pro Cys 230 235 240
- or Asp Thr Val Asp Trp Ile Val Phe Lys Asp Thr Val Ser Ile Ser 245 250 255
- u Ser Gln Leu Ala Val Phe Cys Glu Val Leu Thr Met Gln Gln Ser 260 265 270
- y Tyr Val Met Leu Met Asp Tyr Leu Gln Asn Asn Phe Arg Glu Gln 275 280 285

- In Tyr Lys Phe Ser Arg Gln Val Phe Ser Ser Tyr Thr Gly Lys Glu 290 295 300
- lu Ile His Glu Ala Val Cys Ser Ser Glu Pro Glu Asn Val Gln Ala 05 310 315 320
- sp Pro Glu Asn Tyr Thr Ser Leu Leu Val Thr Trp Glu Arg Pro Arg 325 330 335
- al Val Tyr Asp Thr Met Ile Glu Lys Phe Ala Val Leu Tyr Gln Gln 340 345 350
- eu Asp Gly Glu Asp Gln Thr Lys His Glu Phe Leu Thr Asp Gly Tyr 355 360 365
- ln Asp Leu Gly Ala Ile Leu Asn Asn Leu Leu Pro Asn Met Ser Tyr 370 380
- al Leu Gln Ile Val Ala Ile Cys Thr Asn Gly Leu Tyr Gly Lys Tyr 85 390 395 400
- er Asp Gln Leu Ile Val Asp Met Pro Thr Asp Asn Pro Glu Leu Asp 405 410 415
- eu Phe Pro Glu Leu Ile Gly Thr Glu Glu Ile Ile Lys Glu Glu 420 425 430
- lu Gly Lys Asp Ile Glu Glu Gly Ala Ile Val Asn Pro Gly Arg Asp 435 440 445
- er Ala Thr Asn Gln Ile Arg Lys Lys Glu Pro Gln Ile Ser Thr Thr 450 455 460
- or His Tyr Asn Arg Ile Gly Thr Lys Tyr Asn Glu Ala Lys Thr Asn 55 470 475 480
- cg Ser Pro Thr Arg Gly Ser Glu Phe Ser Gly Lys Gly Asp Val Pro
  485 490 495
- % on Thr Ser Leu Asn Ser Thr Ser Gln Pro Val Thr Lys Leu Ala Thr 500 505 510

- lu Lys Asp Ile Ser Leu Thr Ser Gln Thr Val Thr Glu Leu Pro Pro 515 520 525
- is Thr Val Glu Gly Thr Ser Ala Ser Leu Asn Asp Gly Ser Lys Thr 530 540
- al Leu Arg Ser Pro His Met Asn Leu Ser Gly Thr Ala Glu Ser Leu 45 550 555 560
- sn Thr Val Ser Ile Thr Glu Tyr Glu Glu Glu Ser Leu Leu Thr Ser 565 570 575
- he Lys Leu Asp Thr Gly Ala Glu Asp Ser Ser Gly Ser Ser Pro Ala 580 585 590
- hr Ser Ala Ile Pro Phe Ile Ser Glu Asn Ile Ser Gln Gly Tyr Ile 595 600 605
- he Ser Ser Glu Asn Pro Glu Thr Ile Thr Tyr Asp Val Leu Ile Pro 610 620
- lu Ser Ala Arg Asn Ala Ser Glu Asp Ser Thr Ser Ser Gly Ser Glu 25 630 635 640
- lu Ser Leu Lys Asp Pro Ser Met Glu Gly Asn Val Trp Phe Pro Ser 645 650 655
- er Thr Asp Ile Thr Ala Gln Pro Asp Val Gly Ser Gly Arg Glu Ser 660 665 670
- ne Leu Gln Thr Asn Tyr Thr Glu Ile Arg Val Asp Glu Ser Glu Lys 675 680 685
- r Thr Lys Ser Phe Ser Ala Gly Pro Val Met Ser Gln Gly Pro Ser 690 695 700
- 11 Thr Asp Leu Glu Met Pro His Tyr Ser Thr Phe Ala Tyr Phe Pro 710 715 720
- ır Glu Val Thr Pro His Ala Phe Thr Pro Ser Ser Arg Gln Gln Asp Page 263

725 eolf-seql-S000001.txt

735

- eu Val Ser Thr Val Asn Val Val Tyr Ser Gln Thr Thr Gln Pro Val 740  $\phantom{000}745$   $\phantom{000}750$
- yr Asn Gly Glu Thr Pro Leu Gln Pro Ser Tyr Ser Ser Glu Val Phe  $755 \hspace{1.5cm} 760 \hspace{1.5cm} 765$
- ro Leu Val Thr Pro Leu Leu Leu Asp Asn Gln Ile Leu Asn Thr Thr 770 780
- ro Ala Ala Ser Ser Ser Asp Ser Ala Leu His Ala Thr Pro Val Phe 85 790 795 800
- ro Ser Val Asp Val Ser Phe Glu Ser Ile Leu Ser Ser Tyr Asp Gly 805 810 815
- la Pro Leu Pro Phe Ser Ser Ala Ser Phe Ser Ser Glu Leu Phe 820 825 830
- rg His Leu His Thr Val Ser Gln Ile Leu Pro Gln Val Thr Ser Ala 835 840 845
- or Glu Ser Asp Lys Val Pro Leu His Ala Ser Leu Pro Val Ala Gly 850 855 860
- ly Asp Leu Leu Glu Pro Ser Leu Ala Gln Tyr Ser Asp Val Leu 870 875 875
- er Thr Thr His Ala Ala Ser Glu Thr Leu Glu Phe Gly Ser Glu Ser 885 890 895
- ly Val Leu Tyr Lys Thr Leu Met Phe Ser Gln Val Glu Pro Pro Ser 900 910
- er Asp Ala Met Met His Ala Arg Ser Ser Gly Pro Glu Pro Ser Tyr 915 920 925
- .a Leu Ser Asp Asn Glu Gly Ser Gln His Ile Phe Thr Val Ser Tyr 930 935 940

eolf-seql-S000001.txt
er Ser Ala Ile Pro Val His Asp Ser Val Gly Val Thr Tyr Gln Gly
45 950 955 960

- er Leu Phe Ser Gly Pro Ser His Ile Pro Ile Pro Lys Ser Ser Leu 965 970 975
- le Thr Pro Thr Ala Ser Leu Leu Gln Pro Thr His Ala Leu Ser Gly 980 985 990
- sp Gly Glu Trp Ser Gly Ala Ser Ser Asp Ser Glu Phe Leu Leu Pro 995 1000 1005
- sp Thr Asp Gly Leu Thr Ala Leu Asn Ile Ser Ser Pro Val Ser 1010 1015 1020
- al Ala Glu Phe Thr Tyr Thr Thr Ser Val Phe Gly Asp Asp Asn 1025  $\phantom{\bigg|}$  1030  $\phantom{\bigg|}$  1035
- ys Ala Leu Ser Lys Ser Glu Ile Ile Tyr Gly Asn Glu Thr Glu 1040 1045 1050
- ${
  m Eu}$  Gln Ile Pro Ser Phe Asn Glu Met Val Tyr Pro Ser Glu Ser 1055 1060 1065
- ir Val Met Pro Asn Met Tyr Asp Asn Val Asn Lys Leu Asn Ala 1070 1075 1080
- er Leu Gln Glu Thr Ser Val Ser Ile Ser Ser Thr Lys Gly Met 1085 1090 1095
- ne Pro Gly Ser Leu Ala His Thr Thr Thr Lys Val Phe Asp His 1100 1110
- u Ile Ser Gln Val Pro Glu Asn Asn Phe Ser Val Gln Pro Thr 1115 1120 1125
- .s Thr Val Ser Gln Ala Ser Gly Asp Thr Ser Leu Lys Pro Val 1130 1140
- u Ser Ala Asn Ser Glu Pro Ala Ser Ser Asp Pro Ala Ser Ser 1145 1150 1155

### eolf-seql-S000001.txt

lu Met Leu Ser Pro Ser Thr Gln Leu Leu Phe Tyr Glu Thr Ser 1160 1165 1170

- la Ser Phe Ser Thr Glu Val Leu Leu Gln Pro Ser Phe Gln Ala 1175 1180 1185
- er Asp Val Asp Thr Leu Leu Lys Thr Val Leu Pro Ala Val Pro 1190 1195 1200
- er Asp Pro Ile Leu Val Glu Thr Pro Lys Val Asp Lys Ile Ser 1205 1210 1215
- er Thr Met Leu His Leu Ile Val Ser Asn Ser Ala Ser Ser Glu 1220 1225 1230
- sn Met Leu His Ser Thr Ser Val Pro Val Phe Asp Val Ser Pro 1235 1240 1245
- ar Ser His Met His Ser Ala Ser Leu Gln Gly Leu Thr Ile Ser 1250 1260
- yr Ala Ser Glu Lys Tyr Glu Pro Val Leu Leu Lys Ser Glu Ser 1265 1270 1275
- er His Gln Val Val Pro Ser Leu Tyr Ser Asn Asp Glu Leu Phe 1280 1285 1290
- In Thr Ala Asn Leu Glu Ile Asn Gln Ala His Pro Pro Lys Gly
  1295 1300 1305
- rg His Val Phe Ala Thr Pro Val Leu Ser Ile Asp Glu Pro Leu 1310 1320
- In Thr Leu Ile Asn Lys Leu Ile His Ser Asp Glu Ile Leu Thr 1325 1330 1335
- er Thr Lys Ser Ser Val Thr Gly Lys Val Phe Ala Gly Ile Pro 1340 1350
- r Val Ala Ser Asp Thr Phe Val Ser Thr Asp His Ser Val Pro 1355 1360 1365

Page 266

le	Gly 1370	Asn	ı Gly	His	Val	Ala 1375	Ile	Thr	Ala	. Val	Ser 1380	Pro	His	Arg
sp	Gly 1385	Ser	Val	Thr	Ser	Thr 1390	Lys	Leu	ı Leu	Phe	Pro 1395		Lys	Ala
hr	Ser 1400	Glu	Leu	Ser	His	Ser 1405	Ala	Lys	Ser	Asp	Ala 1410		Leu	Val
ly	Gly 1415	Gly	Glu	Asp	Gly	Asp 1420	Thr	Asp	Asp	Asp	Gly 1425		Asp	Asp
sp	Asp 1430	Arg	Asp	Ser	Asp	Gly 1435	Leu	Ser	Ile	His	Lys 1440		Met	Ser
γs	Ser 1445	Ser	Tyr	Arg	Glu	Ser 1450	Gln	Glu	Lys	Val	Met 1455		Asp	Ser
зp	Thr 1460	His	Glu	Asn	Ser	Leu 1465	Met	Asp	Gln	Asn	Asn 1470	Pro	Ile	Ser
γr	Ser 1475	Leu	Ser	Glu	Asn	Ser 1480	Glu	Glu	Asp	Asn	Arg 1485	Val	Thr	Ser
ıl	Ser 1490	Ser	Asp	Ser	Gln	Thr 1495	Gly	Met	Asp	Arg	Ser 1500	Pro	Gly	Lys
er	Pro 1505	Ser	Ala	Asn	Gly	Leu 1510	Ser	Gln	Lys	His	Asn 1515	Asp	Gly	Lys
.u	Glu 1520	Asn	Asp	Ile	Gln	Thr 1525	Gly	Ser	Ala	Leu	Leu 1530	Pro	Leu	Ser
:0	Glu 1535	Ser	Lys	Ala	Trp	Ala 1540	Val	Leu	Thr	Ser	Asp 1545	Glu	Glu	Ser
.у	Ser 1550	Gly	Gln	Gly	Thr	Ser 1555	Asp	Ser	Leu	Asn	Glu 1560	Asn	Glu	Thr
:r	Thr	Asp	Phe	Ser	Phe		Asp Page		Asn	Glu	Lys	Asp	Ala	Asp

eolf-seql-S000001.txt 1565 1570 1575

ly Ile Leu Ala Ala Gly Asp Ser Glu Ile Thr Pro Gly Phe Pro 1580 1585 1590

- is Val Ser Glu Ala Glu Ala Ser Asn Ser Ser His Glu Ser Arg 1610 1615 1620
- le Gly Leu Ala Glu Gly Leu Glu Ser Glu Lys Lys Ala Val Ile 1625 1630 1635
- ro Leu Val Ile Val Ser Ala Leu Thr Phe Ile Cys Leu Val Val 1640 1650
- $\ge$ u Val Gly Ile Leu Ile Tyr Trp Arg Lys Cys Phe Gln Thr Ala 1655 1660 1665
- is Phe Tyr Leu Glu Asp Ser Thr Ser Pro Arg Val Ile Ser Thr 1670 1680
- co Pro Thr Pro Ile Phe Pro Ile Ser Asp Asp Val Gly Ala Ile 1685 1690 1695
- to Ile Lys His Phe Pro Lys His Val Ala Asp Leu His Ala Ser 1700 1705 1710
- er Gly Phe Thr Glu Glu Phe Glu Thr Leu Lys Glu Phe Tyr Gln 1715 1720 1725
- u Val Gln Ser Cys Thr Val Asp Leu Gly Ile Thr Ala Asp Ser 1730 1740
- er Asn His Pro Asp Asn Lys His Lys Asn Arg Tyr Ile Asn Ile 1745 1750 1755
- l Ala Tyr Asp His Ser Arg Val Lys Leu Ala Gln Leu Ala Glu 1760 1765 1770

eolf-seql-S000001.txt ys Asp Gly Lys Leu Thr Asp Tyr Ile Asn Ala Asn Tyr Val Asp ly Tyr Asn Arg Pro Lys Ala Tyr Ile Ala Ala Gln Gly Pro Leu ys Ser Thr Ala Glu Asp Phe Trp Arg Met Ile Trp Glu His Asn al Glu Val Ile Val Met Ile Thr Asn Leu Val Glu Lys Gly Arg rg Lys Cys Asp Gln Tyr Trp Pro Ala Asp Gly Ser Glu Glu Tyr ly Asn Phe Leu Val Thr Gln Lys Ser Val Gln Val Leu Ala Tyr yr Thr Val Arg Asn Phe Thr Leu Arg Asn Thr Lys Ile Lys Lys ly Ser Gln Lys Gly Arg Pro Ser Gly Arg Val Val Thr Gln Tyr is Tyr Thr Gln Trp Pro Asp. Met Gly Val Pro Glu Tyr Ser Leu to Val Leu Thr Phe Val Arg Lys Ala Ala Tyr Ala Lys Arg His .a Val Gly Pro Val Val Val His Cys Ser Ala Gly Val Gly Arg ir Gly Thr Tyr Ile Val Leu Asp Ser Met Leu Gln Gln Ile Gln s Glu Gly Thr Val Asn Ile Phe Gly Phe Leu Lys His Ile Arg er Gln Arg Asn Tyr Leu Val Gln Thr Glu Glu Gln Tyr Val Phe 

eolf-seql-S000001.txt

	eoir-seqi-S000001.txt													
le	His 1985	Asp	Thr	Leu	Val	Glu 1990	Ala	Ile	Leu	Ser	Lys 1995		Thr	Glu
al	Leu 2000	Asp	Ser	His	Ile	His 2005	Ala	Tyr	Val	Asn	Ala 2010	Leu	Leu	Ile
ro	Gly 2015	Pro	Ala	Gly	Lys	Thr 2020	Lys	Leu	Glu	Lys	Gln 2025		Gln	Leu
эu	Ser 2030	Gln	Ser	Asn	Ile	Gln 2035	Gln	Ser	Asp	Tyr	Ser 2040		Ala	Leu
γs	Gln 2045	Cys	Asn	Arg	Glu	Lys 2050	Asn	Arg	Thr	Ser	Ser 2055	Ile	Ile	Pro
al	Glu 2060	Arg	Ser	Arg	Val	Gly 2065	Ile	Ser	Ser	Leu	.Ser 2070		Glu	Gly
ır	Asp 2075	Tyr	Ile	Asn	Ala	Ser 2080	Tyr	Ile	Met	Gly	Tyr 2085	Tyr	Gln	Ser
зn	Glu 2090	Phe	Ile	Ile	Thr	Gln 2095	His	Pro	Leu	Leu	His 2100	Thr	Ile	Lys
ąį	Phe 2105	Trp	Arg	Met	Ile	Trp 2110	Asp	His	Asn	Ala	Gln 2115	Leu	Val	Val
;t	Ile 2120	Pro	Asp	Gly	Gln	Asn 2125	Met	Ala	Glu	Asp	Glu 2130	Phe	Val	Tyr
:p	Pro 2135	Asn	Lys	Asp	Glu	Pro 2140	Ile	Asn	Cys	Glu	Ser 2145	Phe	Lys	Val
ır	Leu 2150	Met	Ala	Glu	Glu	His 2155	Lys	Cys	Leu	Ser	Asn 2160	Gļu	Glu	Lys
'u	Ile 2165	Ile	Gln	Asp	Phe	Ile 2170	Leu	Glu	Ala	Thr	Gln 2175	Asp	Asp	Tyr

l Leu Glu Val Arg His Phe Gln Cys Pro Lys Trp Pro Asn Pro 2180 2185 2190

### eolf-seq1-S000001.txt

sp Ser Pro Ile Ser Lys Thr Phe Glu Leu Ile Ser Val Ile Lys 2195 2200 2205

- lu Glu Ala Ala Asn Arg Asp Gly Pro Met Ile Val His Asp Glu 2210 2215 2220
- is Gly Gly Val Thr Ala Gly Thr Phe Cys Ala Leu Thr Thr Leu 2225 2230 2235
- et His Gln Leu Glu Lys Glu Asn Ser Val Asp Val Tyr Gln Val 2240 2245 2250
- la Lys Met Ile Asn Leu Met Arg Pro Gly Val Phe Ala Asp Ile 2255 2260 2265
- lu Gln Tyr Gln Phe Leu Tyr Lys Val Ile Leu Ser Leu Val Ser 2270 2275 2280
- hr Arg Gln Glu Glu Asn Pro Ser Thr Ser Leu Asp Ser Asn Gly 2285 2290 2295
- la Ala Leu Pro Asp Gly Asn Ile Ala Glu Ser Leu Glu Ser Leu 2300 2310

al

210> . 138

211> 372

212> PRT

?13> Homo sapiens

100> 138

- et Lys Gln Leu Pro Val Leu Glu Pro Gly Asp Lys Pro Arg Lys Ala 5 10 15
- ir Trp Tyr Thr Leu Thr Val Pro Gly Asp Ser Pro Cys Ala Arg Val
- .y His Ser Cys Ser Tyr Leu Pro Pro Val Gly Asn Ala Lys Arg Gly 35 40 45

- ys Val Phe Ile Val Gly Gly Ala Asn Pro Asn Arg Ser Phe Ser Asp 50 55 60
- al His Thr Met Asp Leu Gly Lys His Gln Trp Asp Leu Asp Thr Cys 70 75 80
- /s Gly Leu Leu Pro Arg Tyr Glu His Ala Ser Phe Ile Pro Ser Cys 85 90 95
- or Pro Asp Arg Ile Trp Val Phe Gly Gly Ala Asn Gln Ser Gly Asn 100 105 110
- rg Asn Cys Leu Gln Val Leu Asn Pro Glu Thr Arg Thr Trp Thr Thr 115 120 125
- To Glu Val Thr Ser Pro Pro Pro Ser Pro Arg Thr Phe His Thr Ser 130 135 140
- er Ala Ala Ile Gly Asn Gln Leu Tyr Val Phe Gly Gly Gly Glu Arg 150 155 160
- y Ala Gln Pro Val Gln Asp Thr Lys Leu His Val Phe Asp Ala Asn 165 170 175
- r Leu Thr Trp Ser Gln Pro Glu Thr Leu Gly Asn Pro Pro Ser Pro 180 185 190
- g His Gly His Val Met Val Ala Ala Gly Thr Lys Leu Phe Ile His 195 200 205
- y Gly Leu Ala Gly Asp Arg Phe Tyr Asp Asp Leu His Cys Ile Asp 210 220
- e Ser Asp Met Lys Trp Gln Lys Leu Asn Pro Thr Gly Ala Ala Pro 5 230 235 240
- a Gly Cys Ala Ala His Ser Ala Val Ala Met Gly Lys His Val Tyr 245 250 255
- e Phe Gly Gly Met Thr Pro Ala Gly Ala Leu Asp Thr Met Tyr Gln
  Page 272

eolf-seql-S000001.txt

270

260 265

yr His Thr Glu Glu Gln His Trp Thr Leu Leu Lys Phe Asp Thr Leu 275 280 285

eu Pro Pro Gly Arg Leu Asp His Ser Met Cys Ile Ile Pro Trp Pro 290 295 300

al Thr Cys Ala Ser Glu Lys Glu Asp Ser Asn Ser Leu Thr Leu Asn 05 310 315 320

is Glu Ala Glu Lys Glu Asp Ser Ala Asp Lys Val Met Ser His Ser 325 330 335

ly Asp Ser His Glu Glu Ser Gln Thr Ala Thr Leu Leu Cys Leu Val 340 345 350

he Gly Gly Met Asn Thr Glu Gly Glu Ile Tyr Asp Asp Cys Ile Val 355 360 365

hr Val Val Asp 370

210> 139

211> 425

212> PRT

213> Homo sapiens

400> 139

et Ala Asp Lys Glu Ala Ala Phe Asp Asp Ala Val Glu Glu Arg Val 5 10 15

le Asn Glu Glu Tyr Lys Ile Trp Lys Lys Asn Thr Pro Phe Leu Tyr 20 25 30

3p Leu Val Met Thr His Ala Leu Glu Trp Pro Ser Leu Thr Ala Gln 35 40 45

cp Leu Pro Asp Val Thr Arg Pro Glu Gly Lys Asp Phe Ser Ile His 50 55 60

ng Leu Val Leu Gly Thr His Thr Ser Asp Glu Gln Asn His Leu Val Page 273

	eolf	eolf-seql-S000001.txt							
5	70	75	80						
1									

- le Ala Ser Val Gln Leu Pro Asn Asp Asp Ala Gln Phe Asp Ala Ser 85 90 95
- is Tyr Asp Ser Glu Lys Gly Glu Phe Gly Gly Phe Gly Ser Val Ser 100 105 110
- ly Lys Ile Glu Ile Glu Ile Lys Ile Asn His Glu Gly Glu Val Asn 115 120 125
- rg Ala Arg Tyr Met Pro Gln Asn Pro Cys Ile Ile Ala Thr Lys Thr 130 135 140
- ro Ser Ser Asp Val Leu Val Phe Asp Tyr Thr Lys His Pro Ser Lys 45 150 155 160
- ro Asp Pro Ser Gly Glu Cys Asn Pro Asp Leu Arg Leu Arg Gly His 165 170 175
- ln Lys Glu Gly Tyr Gly Leu Ser Trp Asn Pro Asn Leu Ser Gly His 180 185 190
- eu Leu Ser Ala Ser Asp Asp His Thr Ile Cys Leu Trp Asp Ile Ser 195 200 205
- la Val Pro Lys Glu Gly Lys Val Val Asp Ala Lys Thr Ile Phe Thr 210 215 220
- -y His Thr Ala Val Val Glu Asp Val Ser Trp His Leu Leu His Glu 25 230 235 240
- er Leu Phe Gly Ser Val Ala Asp Asp Gln Lys Leu Met Ile Trp Asp 245 250 255
- er Ala Glu Val Asn Cys Leu Ser Phe Asn Pro Tyr Ser Glu Phe Ile 275 280 285

eolf-seql-S000001.txt
eu Ala Thr Gly Ser Ala Asp Lys Thr Val Ala Leu Trp Asp Leu Arg
290 295 300

- sn Leu Lys Leu Lys Leu His Ser Phe Glu Ser His Lys Asp Glu Ile 05 310 315 320
- he Gln Val Gln Trp Ser Pro His Asn Glu Thr Ile Leu Ala Ser Ser 325 330 335
- ly Thr Asp Arg Arg Leu Asn Val Trp Asp Leu Ser Lys Ile Gly Glu 340 345 350
- lu Gln Ser Pro Glu Asp Ala Glu Asp Gly Pro Pro Glu Leu Leu Phe 355 360 365
- le His Gly Gly His Thr Ala Lys Ile Ser Asp Phe Ser Trp Asn Pro 370 375 380
- sn Glu Pro Trp Val Ile Cys Ser Val Ser Glu Asp Asn Ile Met Gln 85 390 395 400
- al Trp Gln Met Ala Glu Asn Ile Tyr Asn Asp Glu Asp Pro Glu Gly 405 410 415
- er Val Asp Pro Glu Gly Gln Gly Ser 420 425

210> 140

211> 633

212> PRT

?13> Homo sapiens

100> 140

- et Asn Pro Ser Ala Pro Ser Tyr Pro Met Ala Ser Leu Tyr Val Gly 5 10 15
- sp Leu His Pro Asp Val Thr Glu Ala Met Leu Tyr Glu Lys Phe Ser
  20 25 30
- to Ala Gly Pro Ile Leu Ser Ile Arg Val Cys Arg Asp Met Ile Thr 35 40 45

eolf-seql-S000001.txt
rg Arg Ser Leu Gly Tyr Ala Tyr Val Asn Phe Gln Gln Pro Ala Asp
50 55 60

- la Glu Arg Ala Leu Asp Thr Met Asn Phe Asp Val Ile Lys Gly Lys 70 75 80
- ro Val Arg Ile Met Trp Ser Gln Arg Asp Pro Ser Leu Arg Lys Ser 85 90 95
- ly Val Gly Asn Ile Phe Ile Lys Asn Leu Asp Lys Ser Ile Asp Asn 100 \$105\$
- ys Ala Leu Tyr Asp Thr Phe Ser Ala Phe Gly Asn Ile Leu Ser Cys 115 120 125
- ys Val Val Cys Asp Glu Asn Gly Ser Lys Gly Tyr Gly Phe Val His 130 135 140
- ne Glu Thr Gln Glu Ala Ala Glu Arg Ala Ile Glu Lys Met Asn Gly 150 150 150 160
- et Leu Leu Asn Asp Arg Lys Val Phe Val Gly Arg Phe Lys Ser Arg 165 170 175
- /s Glu Arg Glu Ala Glu Leu Gly Ala Arg Ala Lys Glu Phe Thr Asn 180 185 190
- 11 Tyr Ile Lys Asn Phe Gly Glu Asp Met Asp Asp Glu Arg Leu Lys 195 200 205
- 3p Leu Phe Gly Pro Ala Leu Ser Val Lys Val Met Thr Asp Glu Ser 210
  215
  220
- .y Lys Ser Lys Gly Phe Gly Phe Val Ser Phe Glu Arg His Glu Asp 230 235 240
- a Gln Lys Ala Val Asp Glu Met Asn Gly Lys Glu Leu Asn Gly Lys. 245 250 255
- n Ile Tyr Val Gly Arg Ala Gln Lys Lys Val Glu Arg Gln Thr Glu 260 265 270

### eolf-seql-S000001.txt

eu Lys Arg Lys Phe Glu Gln Met Lys Gln Asp Arg Ile Thr Arg Tyr 275 280 285

ln Gly Val Asn Leu Tyr Val Lys Asn Leu Asp Asp Gly Ile Asp Asp 290 295 300

lu Arg Leu Arg Lys Glu Phe Ser Pro Phe Gly Thr Ile Thr Ser Ala 05 310 315 320

ys Val Met Met Glu Gly Gly Arg Ser Lys Gly Phe Gly Phe Val Cys 325 330 335

he Ser Ser Pro Glu Glu Ala Thr Lys Ala Val Thr Glu Met Asn Gly 340 345 350

rg Ile Val Ala Thr Lys Pro Leu Tyr Val Ala Leu Ala Gln Arg Lys 355 360 365

lu Glu Arg Gln Ala His Leu Thr Asn Gln Tyr Met Gln Arg Met Ala 370 375 380

er Val Arg Ala Val Pro Asn Pro Val Ile Asn Pro Tyr Gln Pro Ala 35 390 395 400

co Pro Ser Gly Tyr Phe Met Ala Ala Ile Pro Gln Thr Gln Asn Arg
405 410 415

la Ala Tyr Tyr Pro Pro Ser Gln Val Ala Gln Leu Arg Pro Ser Pro 420 425 430

rg Trp Thr Ala Gln Gly Ala Arg Pro His Pro Phe Gln Asn Met Pro 435 440 445

.y Ala Ile Arg Pro Ala Ala Pro Arg Pro Pro Phe Ser Thr Met Arg 450 455 460

to Ala Ser Ser Gln Val Pro Arg Val Met Ser Thr Gln Arg Val Ala 35 470 475 480

in Thr Ser Thr Gln Thr Met Gly Pro Arg Pro Ala Ala Ala Ala 485 490 495

Page 277

# eolf-seql-S000001.txt

la Ala Thr Pro Ala Val Arg Thr Val Pro Gln Tyr Lys Tyr Ala Ala 500 505 510

- ly Val Arg Asn Pro Gln Gln His Leu Asn Ala Gln Pro Gln Val Thr 515 520 525
- et Gln Gln Pro Ala Val His Val Gln Gly Gln Glu Pro Leu Thr Ala 530 540
- er Met Leu Ala Ser Ala Pro Pro Gln Glu Gln Lys Gln Met Leu Gly 550 555 560
- lu Arg Leu Phe Pro Leu Ile Gln Ala Met His Pro Thr Leu Ala Gly 565 570 575
- ys Ile Thr Gly Met Leu Leu Glu Ile Asp Asn Ser Glu Leu Leu His 580 585 590
- et Leu Glu Ser Pro Glu Ser Leu Arg Ser Lys Val Asp Glu Ala Val 595 600 605
- la Val Leu Gln Ala His Gln Ala Lys Glu Ala Ala Gln Lys Ala Val 610 620
- on Ser Ala Thr Gly Val Pro Thr Val 630
- ?10> 141
- ?11> 420
- ?12> PRT
- ?13> Homo sapiens
- 100> 141
- et Met Tyr Ser Pro Ile Cys Leu Thr Gln Asp Glu Phe His Pro Phe 5 10 15
- et Glu Ala Leu Leu Pro His Val Arg Ala Ile Ala Tyr Thr Trp Phe 20 25 30
- n Leu Gln Ala Arg Lys Arg Lys Tyr Phe Lys Lys His Glu Lys Arg 35 40 45

- et Ser Lys Asp Glu Glu Arg Ala Val Lys Asp Glu Leu Leu Ser Glu 50 55 60
- ys Pro Glu Ile Lys Gln Lys Trp Ala Ser Arg Leu Leu Ala Lys Leu 5 70 75 80
- rg Lys Asp Ile Arg Gln Glu Tyr Arg Glu Asp Phe Val Leu Thr Val 85 90 95
- hr Gly Lys Lys His Pro Cys Cys Val Leu Ser Asn Pro Asp Gln Lys
- ly Lys Ile Arg Arg Ile Asp Cys Leu Arg Gln Ala Asp Lys Val Trp 115 120 125
- rg Leu Asp Leu Val Met Val Ile Leu Phe Lys Gly Ile Pro Leu Glu 130 135 140
- er Thr Asp Gly Glu Arg Leu Met Lys Ser Pro His Cys Thr Asn Pro 150 150 155 160
- la Leu Cys Val Gln Pro His His Ile Thr Val Ser Val Lys Glu Leu 165 170 175
- 3p Leu Phe Leu Ala Tyr Tyr Val Gln Glu Gln Asp Ser Gly Gln Ser 180 185 190
- y Ser Pro Ser His Asn Asp Pro Ala Lys Asn Pro Pro Gly Tyr Leu 195 200 205
- .u Asp Ser Phe Val Lys Ser Gly Val Phe Asn Val Ser Glu Leu Val 210 215 220
- g Val Ser Arg Thr Pro Ile Thr Gln Gly Thr Gly Val Asn Phe Pro 230 235 240
- e Gly Glu Ile Pro Ser Gln Pro Tyr Tyr His Asp Met Asn Ser Gly 245 250 255
- l Asn Leu Gln Arg Ser Leu Ser Ser Pro Pro Ser Ser Lys Arg Pro Page 279

eolf-seq1-S000001.txt 265

260

270

ys Thr Ile Ser Ile Asp Glu Asn Met Glu Pro Ser Pro Thr Gly Asp 275 280 285

he Tyr Pro Ser Pro Ser Ser Pro Ala Ala Gly Ser Arg Thr Trp His 290 295 300

lu Arg Asp Gln Asp Met Ser Ser Pro Thr Thr Met Lys Lys Pro Glu 310 315 320

ys Pro Leu Phe Ser Ser Ala Ser Pro Gln Asp Ser Ser Pro Arg Leu 325 330 335

er Thr Phe Pro Gln His His His Pro Gly Ile Pro Gly Val Ala His 340 345 350

er Val Ile Ser Thr Arg Thr Pro Pro Pro Pro Ser Pro Leu Pro Phe 355 360 365

Thr Gln Ala Ile Leu Pro Pro Ala Pro Ser Ser Tyr Phe Ser His 370 375 380

to Thr Ile Arg Tyr Pro Pro His Leu Asn Pro Gln Asp Thr Leu Lys 390 395 400

on Tyr Val Pro Ser Tyr Asp Pro Ser Ser Pro Gln Thr Ser Gln Ser 405 410 415

p Tyr Leu Gly 420

:10> 142

:11> 248

:12> PRT

:13> Homo sapiens

00> 142

t Glu Gly Val Glu Glu Lys Lys Glu Val Pro Ala Val Pro Glu
5 . 10 . 15

r Leu Lys Lys Arg Arg Asn Phe Ala Glu Leu Lys Ile Lys Arg Page 280

eolf-seql-S000001.txt

20

25 30

eu Arg Lys Lys Phe Ala Gln Lys Met Leu Arg Lys Ala Arg Arg Lys 35 40 45

- eu Ile Tyr Glu Lys Ala Lys His Tyr His Lys Glu Tyr Arg Gln Met 50 55 60
- yr Arg Thr Glu Ile Arg Met Ala Arg Met Ala Arg Lys Ala Gly Asn 5 70 75 80
- he Tyr Val Pro Ala Glu Pro Lys Leu Ala Phe Val Ile Arg Ile Arg 85 90 95
- ly Ile Asn Gly Val Ser Pro Lys Val Arg Lys Val Leu Gln Leu Leu 100 105 110
- rg Leu Arg Gln Ile Phe Asn Gly Thr Phe Val Lys Leu Asn Lys Ala 115 120 125
- er Ile Asn Met Leu Arg Ile Val Glu Pro Tyr Ile Ala Trp Gly Tyr 130 135 140
- co Asn Leu Lys Ser Val Asn Glu Leu Ile Tyr Lys Arg Gly Tyr Gly 150 155 160
- /s Ile Asn Lys Lys Arg Ile Ala Leu Thr Asp Asn Ala Leu Ile Ala 165 . 170 . 175
- rg Ser Leu Gly Lys Tyr Gly Ile Ile Cys Met Glu Asp Leu Ile His 180 185 190
- u Ile Tyr Thr Val Gly Lys Arg Phe Lys Glu Ala Asn Asn Phe Leu 195 200 205
- Pro Phe Lys Leu Ser Ser Pro Arg Gly Gly Met Lys Lys Lys Thr 210
  215
  220
- ir His Phe Val Glu Gly Gly Asp Ala Gly Asn Arg Glu Asp Gln Ile 5 230 235 240

eolf-seql-S000001.txt

sn Arg Leu Ile Arg Arg Met Asn 245

210> 143

211> 420 ·

212> PRT

213> Homo sapiens

400> 143

- et Glu Val Pro Pro Arg Leu Ser His Val Pro Pro Pro Leu Phe Pro 5 10 15
- er Ala Pro Ala Thr Leu Ala Ser Arg Ser Leu Ser His Trp Arg Pro 20 25 30
- rg Pro Pro Arg Gln Leu Ala Pro Leu Leu Pro Ser Leu Ala Pro Ser 35 40 45
- er Ala Arg Gln Gly Ala Arg Arg Ala Gln Arg His Val Thr Ala Gln 50 55 60
- In Pro Ser Arg Leu Ala Gly Gly Ala Ala Ile Lys Gly Gly Arg Arg 70 75 80
- rg Arg Pro Asp Leu Phe Arg Arg His Phe Lys Ser Ser Ser Ile Gln 85 90 95
- :g Ser Ala Ala Ala Ala Ala Thr Arg Thr Ala Arg Gln His Pro 100 105 110
- to Ala Asp Ser Ser Val Thr Met Glu Asp Met Asn Glu Tyr Ser Asn 115 120 125
- e Glu Glu Phe Ala Glu Gly Ser Lys Ile Asn Ala Ser Lys Asn Gln
  130 135 140
- n Asp Asp Gly Lys Met Phe Ile Gly Gly Leu Ser Trp Asp Thr Ser 150 155 160
- s Lys Asp Leu Thr Glu Tyr Leu Ser Arg Phe Gly Glu Val Val Asp 165 170 175

- ys Thr Ile Lys Thr Asp Pro Val Thr Gly Arg Ser Arg Gly Phe Gly
  180 185 190
- he Val Leu Phe Lys Asp Ala Ala Ser Val Asp Lys Val Leu Glu Leu 195 200 205
- ys Glu His Lys Leu Asp Gly Lys Leu Ile Asp Pro Lys Arg Ala Lys 210 215 220
- la Leu Lys Gly Lys Glu Pro Pro Lys Lys Val Phe Val Gly Gly Leu 25 230 235 240
- er Pro Asp Thr Ser Glu Glu Gln Ile Lys Glu Tyr Phe Gly Ala Phe 245 250 255
- ly Glu Ile Glu Asn Ile Glu Leu Pro Met Asp Thr Lys Thr Asn Glu 260 265 270
- rg Arg Gly Phe Cys Phe Ile Thr Tyr Thr Asp Glu Glu Pro Val Lys 275. 280 285
- /s Leu Leu Glu Ser Arg Tyr His Gln Ile Gly Ser Gly Lys Cys Glu 290 295 300
- le Lys Val Ala Gln Pro Lys Glu Val Tyr Arg Gln Gln Gln Gln 310 315 320
- In Lys Gly Gly Arg Gly Ala Ala Ala Gly Gly Arg Gly Gly Thr Arg 325 330 335
- .y Arg Gly Arg Gly Gln Gly Gln Asn Trp Asn Gln Gly Phe Asn Asn 340 345 350
- r Tyr Asp Gln Gly Tyr Gly Asn Tyr Asn Ser Ala Tyr Gly Gly Asp 355 360 365
- n Asn Tyr Ser Gly Tyr Gly Gly Tyr Asp Tyr Thr Gly Tyr Asn Tyr 370 375 380
- y Asn Tyr Gly Tyr Gly Gln Gly Tyr Ala Asp Tyr Ser Gly Gln Gln 5 395 400

eolf-seql-S000001.txt

er Thr Tyr Gly Lys Ala Ser Arg Gly Gly Gly Asn His Gln Asn Asn 405 410 415

yr Gln Pro Tyr 420

210> 144

211> 46

212> PRT

213> Homo sapiens

100> 144

 $lag{5}$  Leu Leu Ser Arg Gly Val Leu Pro Phe Leu Ser Tyr Met Lys Phe 5 10 15

 ${
m Su}$  Ser Gln Glu Arg Gln Asp Tyr Ile Phe Phe Phe Phe Phe Ser Ser 20 25 30

eu Ser Trp Cys Ser Val Phe Leu Val Ile Arg Ile Leu Ile 35 40 45

?10> 145

?11> 76

?12> PRT

?13> Homo sapiens

100> 145

et Ser Lys Ala His Pro Pro Glu Leu Lys Lys Phe Met Asp Lys Lys 5 10 15

u Ser Leu Lys Leu Asn Gly Gly Arg His Val Gln Gly Ile Leu Arg

.y Phe Asp Pro Phe Met Asn Leu Val Ile Asp Glu Cys Val Glu Met 35 40 45

a Thr Ser Gly Gln Gln Asn Asn Ile Gly Met Val Val Ile Arg Gly 50 55 60

n Ser Ile Ile Met Leu Glu Ala Leu Glu Arg Val 70 75

- 210> 146
- 211> 184
- 212> PRT
- 213> Homo sapiens
- 400> 146
- et Arg Glu Tyr Lys Leu Val Val Leu Gly Ser Gly Gly Val Gly Lys
  5 10 15
- er Ala Leu Thr Val Gln Phe Val Gln Gly Ile Phe Val Glu Lys Tyr 20 25 30
- sp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Glu Val Asp Cys 35 40 45
- ln Gln Cys Met Leu Glu Ile Leu Asp Thr Ala Gly Thr Glu Gln Phe 50 55 60
- hr Ala Met Arg Asp Leu Tyr Met Lys Asn Gly Gln Gly Phe Ala Leu 5 70 75 80
- al Tyr Ser Ile Thr Ala Gln Ser Thr Phe Asn Asp Leu Gln Asp Leu 85 90 95
- rg Glu Gln Ile Leu Arg Val Lys Asp Thr Glu Asp Val Pro Met Ile 100 105 110
- $\ni$ u Val Gly Asn Lys Cys Asp Leu Glu Asp Glu Arg Val Val Gly Lys 115 120 125
- lu Ser Ser Ala Lys Ser Lys Ile Asn Val Asn Glu Ile Phe Tyr Asp 15 150 155 160
- eu Val Arg Gln Ile Asn Arg Lys Thr Pro Val Glu Lys Lys Pro 165 170 175
- 's Lys Lys Ser Cys Leu Leu Leu 180

- 210> 147
- 211> 440
- 212> PRT
- 213> Homo sapiens
- 400> 147
- et Glu Gln Arg Gly Gln Asn Ala Pro Ala Ala Ser Gly Ala Arg Lys
  5 10 15
- rg His Gly Pro Gly Pro Arg Glu Ala Arg Gly Ala Arg Pro Gly Leu 20 25 30
- rg Val Pro Lys Thr Leu Val Leu Val Val Ala Ala Val Leu Leu Leu 35 40 45
- 31 Ser Ala Glu Ser Ala Leu Ile Thr Gln Gln Asp Leu Ala Pro Gln 50 55 60
- ln Arg Ala Ala Pro Gln Gln Lys Arg Ser Ser Pro Ser Glu Gly Leu 5 70 75 80
- /s Pro Pro Gly His His Ile Ser Glu Asp Gly Arg Asp Cys Ile Ser 85 90 95
- /s Lys Tyr Gly Gln Asp Tyr Ser Thr His Trp Asn Asp Leu Leu Phe 100 105 110
- 's Leu Arg Cys Thr Arg Cys Asp Ser Gly Glu Val Glu Leu Ser Pro 115 120 125
- 's Thr Thr Thr Arg Asn Thr Val Cys Gln Cys Glu Glu Gly Thr Phe 130 135 140
- rg Glu Glu Asp Ser Pro Glu Met Cys Arg Lys Cys Arg Thr Gly Cys 150 150 155
- o Arg Gly Met Val Lys Val Gly Asp Cys Thr Pro Trp Ser Asp Ile 165 170 175
- u Cys Val His Lys Glu Ser Gly Thr Lys His Ser Gly Glu Ala Pro 180 185 190

	eolf-seql-S000001.txt														
la	Val	Glu 195	Glu	Thr	Val	Thr	Ser 200	Ser	Pro	Gly	Thr	Pro 205	Ala	Ser	Pro
уs	Ser 210	Leu	Ser	Gly	Ile	Ile 215	Ile	Gly	Val	Thr	Val 220	Ala	Ala	Val	Val
∋u 25	Ile	Val	Ala	Val	Phe 230	Val	Cys	Lys		Leu 235	Leu	Trp	Lys	Lys	Val 240
∋u	Pro	Tyr	Leu		Gly		Cys		Gly 250	Gly	Gly	Gly	Asp	Pro 255	Glu
rg	Val	Asp	Arg 260	Ser	Ser	Gln	Arg	Pro 265		Ala	Glu	Asp	Asn 270	Val	Leu

- sn Glu Ile Val Ser Ile Leu Gln Pro Thr Gln Val Pro Glu Gln Glu 275 280 285
- et Glu Val Gln Glu Pro Ala Glu Pro Thr Gly Val Asn Met Leu Ser 290 295 300
- co Gly Glu Ser Glu His Leu Leu Glu Pro Ala Glu Ala Glu Arg Ser 310 315 320
- n Arg Arg Arg Leu Leu Val Pro Ala Asn Glu Gly Asp Pro Thr Glu 325 330 335
- r Leu Arg Gln Cys Phe Asp Asp Phe Ala Asp Leu Val Pro Phe Asp 340 345 350
- er Trp Glu Pro Leu Met Arg Lys Leu Gly Leu Met Asp Asn Glu Ile 355 360 365
- 's Val Ala Lys Ala Glu Ala Ala Gly His Arg Asp Thr Leu Tyr Thr 370 380
- t Leu Ile Lys Trp Val Asn Lys Thr Gly Arg Asp Ala Ser Val His 390 395 400
- r Leu Leu Asp Ala Leu Glu Thr Leu Gly Glu Arg Leu Ala Lys Gln
  405 410 415

### eolf-seql-S000001.txt

ys Ile Glu Asp His Leu Leu Ser Ser Gly Lys Phe Met Tyr Leu Glu
420 425 430

ly Asn Ala Asp Ser Ala Met Ser 435 440

210> 148

211> 126

212> PRT

213> Homo sapiens

100> 148

et Ala Asp Glu Ile Ala Lys Ala Gln Val Ala Arg Pro Gly Gly Asp 5 10 15

or Ile Phe Gly Lys Ile Ile Arg Lys Glu Ile Pro Ala Lys Ile Ile 20 25 30

ne Glu Asp Asp Arg Cys Leu Ala Phe His Asp Ile Ser Pro Gln Ala 35 40 45

to Thr His Phe Leu Val Ile Pro Lys Lys His Ile Ser Gln Ile Ser 50 55 60

il Ala Glu Asp Asp Glu Ser Leu Leu Gly His Leu Met Ile Val

y Lys Lys Cys Ala Ala Asp Leu Gly Leu Asn Lys Gly Tyr Arg Met 85 90 95

.l Val Asn Glu Gly Ser Asp Gly Gly Gln Ser Val Tyr His Val His 100 105 110

u His Val Leu Gly Gly Arg Gln Met His Trp Pro Pro Gly 115 120 125

10> 149

11> 320

12> PRT

13> Homo sapiens

00> 149

eolf-seql-S000001.txt
et Ala Glu Gly Asp Ala Gly Ser Asp Gln Arg Gln Asn Glu Glu Ile
5 10 15

- lu Ala Met Ala Ala Ile Tyr Gly Glu Glu Trp Cys Val Ile Asp Asp 20 25 30
- ys Ala Lys Ile Phe Cys Ile Arg Ile Ser Asp Asp Ile Asp Asp Pro 35 40 45
- ys Trp Thr Leu Cys Leu Gln Val Met Leu Pro Asn Glu Tyr Pro Gly 50 55 60
- hr Ala Pro Pro Ile Tyr Gln Leu Asn Ala Pro Trp Leu Lys Gly Gln 5 70 75 80
- lu Arg Ala Asp Leu Ser Asn Ser Leu Glu Glu Ile Tyr Ile Gln Asn 85 90 95
- le Gly Glu Ser Ile Leu Tyr Leu Trp Val Glu Lys Ile Arg Asp Val 100 105 110
- eu Ile Gln Lys Ser Gln Met Thr Glu Pro Gly Pro Asp Val Lys Lys 115 120 125
- /s Thr Glu Glu Glu Asp Val Glu Cys Glu Asp Asp Leu Ile Leu Ala 130 135 140
- /s Gln Pro Glu Ser Ser Val Lys Ala Leu Asp Phe Asp Ile Ser Glu 15 150 155 160
- or Arg Thr Glu Val Glu Val Glu Glu Leu Pro Pro Ile Asp His Gly 165 170 175
- .e Pro Ile Thr Asp Arg Arg Ser Thr Phe Gln Ala His Leu Ala Pro 180 185 190
- val Cys Pro Lys Gln Val Lys Met Val Leu Ser Lys Leu Tyr Glu 195 200 205
- in Lys Lys Ile Ala Ser Ala Thr His Asn Ile Tyr Ala Tyr Arg Ile
  210 215 220

# eolf-seql-S000001.txt

yr Cys Glu Asp Lys Gln Thr Phe Leu Gln Asp Cys Glu Asp Asp Gly 230 235 240

lu Thr Ala Ala Gly Gly Arg Leu Leu His Leu Met Glu Ile Leu Asn 245 250 255

al Lys Asn Val Met Val Val Val Ser Arg Trp Tyr Gly Gly Ile Leu 260 265 270

eu Gly Pro Asp Arg Phe Lys His Ile Asn Asn Cys Ala Arg Asn Ile 275 280 285

eu Val Glu Lys Asn Tyr Thr Asn Ser Pro Glu Glu Ser Ser Lys Ala 290 295 300

 $\exists$ u Gly Lys Asn Lys Lys Val Arg Lys Asp Lys Lys Arg Asn Glu His 310 315 320

210> 150

211> 326

212> PRT

213> Homo sapiens

100> 150

et His Arg Thr Thr Arg Ile Lys Ile Thr Glu Leu Asn Pro His Leu 5 10 15

et Cys Val Leu Cys Gly Gly Tyr Phe Ile Asp Ala Thr Thr Ile Ile 20 25 30

u Cys Leu His Ser Phe Cys Lys Thr Cys Ile Val Arg Tyr Leu Glu

or Ser Lys Tyr Cys Pro Ile Cys Asp Val Gln Val His Lys Thr Arg 50 55 60

o Leu Leu Asn Ile Arg Ser Asp Lys Thr Leu Gln Asp Ile Val Tyr
70 75 80

's Leu Val Pro Gly Leu Phe Lys Asn Glu Met Lys Arg Arg Arg Asp 85 90 95

### eolf-seql-S000001.txt

ne Tyr Ala Ala His Pro Ser Ala Asp Ala Ala Asn Gly Ser Asn Glu 100 105 110

- 3p Arg Gly Glu Val Ala Asp Glu Asp Lys Arg Ile Ile Thr Asp Asp 115 120 125
- lu Ile Ile Ser Leu Ser Ile Glu Phe Phe Asp Gln Asn Arg Leu Asp 130 135 140
- rg Lys Val Asn Lys Asp Lys Glu Lys Ser Lys Glu Glu Val Asn Asp 15 150 155 160
- /s Arg Tyr Leu Arg Cys Pro Ala Ala Met Thr Val Met His Leu Arg 165 170 175
- is Phe Leu Arg Ser Lys Met Asp Ile Pro Asn Thr Phe Gln Ile Asp 180 185 190
- 11 Met Tyr Glu Glu Glu Pro Leu Lys Asp Tyr Tyr Thr Leu Met Asp 195 200 205
- e Ala Tyr Ile Tyr Thr Trp Arg Arg Asn Gly Pro Leu Pro Leu Lys 210 220
- r Arg Val Arg Pro Thr Cys Lys Arg Met Lys Ile Ser His Gln Arg 230 235 240
- p Gly Leu Thr Asn Ala Gly Glu Leu Glu Ser Asp Ser Gly Ser Asp 245 250 255
- s Ala Asn Ser Pro Ala Gly Gly Ile Pro Ser Thr Ser Ser Cys Leu 260 265 270
- o Ser Pro Ser Thr Pro Val Gln Ser Pro His Pro Gln Phe Pro His 275 280 285
- e Ser Ser Thr Met Asn Gly Thr Ser Asn Ser Pro Ser Gly Asn His 290 295 300
- n Ser Ser Phe Ala Asn Arg Pro Arg Lys Ser Ser Val Asn Gly Ser 5 310 315 320

### eolf-seql-S000001.txt

er Ala Thr Ser Ser Gly 325

210> 151

211> 466

212> PRT

213> Homo sapiens

400> 151

- et Val Met Glu Lys Pro Ser Pro Leu Leu Val Gly Arg Glu Phe Val 5 10 15
- rg Gln Tyr Tyr Thr Leu Leu Asn Gln Ala Pro Asp Met Leu His Arg 20 25 30
- he Tyr Gly Lys Asn Ser Ser Tyr Val His Gly Gly Leu Asp Ser Asn 35 40 45
- Lys Pro Ala Asp Ala Val Tyr Gly Gln Lys Glu Ile His Arg Lys
  50 55 60
- al Met Ser Gln Asn Phe Thr Asn Cys His Thr Lys Ile Arg His Val
- sp Ala His Ala Thr Leu Asn Asp Gly Val Val Val Gln Val Met Gly
  85 90 95
- u Leu Ser Asn Asn Asn Gln Ala Leu Arg Arg Phe Met Gln Thr Phe 100 105 110
- ıl Leu Ala Pro Glu Gly Ser Val Ala Asn Lys Phe Tyr Val His Asn 115 120 125
- p Ile Phe Arg Tyr Gln Asp Glu Val Phe Gly Gly Phe Val Thr Glu 130 135 140
- o Gln Glu Glu Ser Glu Glu Glu Val Glu Glu Pro Glu Glu Arg Gln 5 150 155 160
- n Thr Pro Glu Val Val Pro Asp Asp Ser Gly Thr Phe Tyr Asp Gln 165 170 175

Page 292

- la Val Val Ser Asn Asp Met Glu Glu His Leu Glu Glu Pro Val Ala 180 . 185 . 190
- lu Pro Glu Pro Asp Pro Glu Pro Glu Pro Glu Gln Glu Pro Val Ser 195 200 205
- lu Ile Gln Glu Glu Lys Pro Glu Pro Val Leu Glu Glu Thr Ala Pro 210 215 220
- lu Asp Ala Gln Lys Ser Ser Pro Ala Pro Ala Asp Ile Ala Gln 25 230 235 240
- or Val Glu Asp Leu Arg Thr Phe Ser Trp Ala Ser Val Thr Ser 245 250 255
- vs Asn Leu Pro Pro Ser Gly Ala Val Pro Val Thr Gly Ile Pro Pro 260 265 270
- s Val Val Lys Val Pro Ala Ser Gln Pro Arg Pro Glu Ser Lys Pro 275 280 285
- u Ser Gln Ile Pro Pro Gln Arg Pro Gln Arg Asp Gln Arg Val Arg 290 295 300
- u Gln Arg Ile Asn Ile Pro Pro Gln Arg Gly Pro Arg Pro Ile Arg. 310 315 320
- u Ala Gly Glu Gln Gly Asp Ile Glu Pro Arg Arg Met Val Arg His. 325 330 335
- o Asp Ser His Gln Leu Phe Ile Gly Asn Leu Pro His Glu Val Asp 340 345 350
- s Ser Glu Leu Lys Asp Phe Phe Gln Ser Tyr Gly Asn Val Val Glu 355 360 365
- u Arg Ile Asn Ser Gly Gly Lys Leu Pro Asn Phe Gly Phe Val Val 370 380
- e Asp Asp Ser Glu Pro Val Gln Lys Val Leu Ser Asn Arg Pro Ile Page 293

eolf-seql-S000001.txt 35 390 395

400

et Phe Arg Gly Glu Val Arg Leu Asn Val Glu Glu Lys Lys Thr Arg
405 410 415

la Ala Arg Glu Gly Asp Arg Arg Asp Asn Arg Leu Arg Gly Pro Gly 420 425 430

ly Pro Arg Gly Gly Leu Gly Gly Gly Met Arg Gly Pro Pro Arg Gly 435 440 445

ly Met Val Gln Lys Pro Gly Phe Gly Val Gly Arg Gly Leu Ala Pro 450 455 460

g Gln

?10> 152

?11> 184

12> PRT

?13> Homo sapiens

100> 152

et Pro Gln Ser Lys Ser Arg Lys Ile Ala Ile Leu Gly Tyr Arg Ser 5 10 15

tl Gly Lys Ser Ser Leu Thr Ile Gln Phe Val Glu Gly Gln Phe Val 20 25 30

p Ser Tyr Asp Pro Thr Ile Glu Asn Thr Phe Thr Lys Leu Ile Thr 35 40 45

1 Asn Gly Gln Glu Tyr His Leu Gln Leu Val Asp Thr Ala Gly Gln 50 55 60

p Glu Tyr Ser Ile Phe Pro Gln Thr Tyr Ser Ile Asp Ile Asn Gly
70 75 80

r Ile Leu Val Tyr Ser Val Thr Ser Ile Lys Ser Phe Glu Val Ile 85 90 95

s Val Ile His Gly Lys Leu Leu Asp Met Val Gly Lys Val Gln Ile Page 294

eolf-seql-S000001.txt

100

110

ro Ile Met Leu Val Gly Asn Lys Lys Asp Leu His Met Glu Arg Val 115 120 125

le Ser Tyr Glu Glu Gly Lys Ala Leu Ala Glu Ser Trp Asn Ala Ala 130  $\phantom{000}$  135  $\phantom{000}$  140

ne Leu Glu Ser Ser Ala Lys Glu Asn Gln Thr Ala Val Asp Val Phe 45 150 155 160

rg Arg Ile Ile Leu Glu Ala Glu Lys Met Asp Gly Ala Ala Ser Gln 165 170 175

ly Lys Ser Ser Cys Ser Val Met 180

210> 153

211> 332

212> PRT

?13> Homo sapiens

100> 153

et Gly Ala Gln Phe Ser Lys Thr Ala Ala Lys Gly Glu Ala Ala Ala 5 10 15

u Arg Pro Gly Glu Ala Ala Val Ala Ser Ser Pro Ser Lys Ala Asn 20 25 30

y Gln Glu Asn Gly His Val Lys Val Asn Gly Asp Ala Ser Pro Ala 35 40 45

.a Ala Glu Ser Gly Ala Lys Glu Glu Leu Gln Ala Asn Gly Ser Ala 50 55 60

o Ala Ala Asp Lys Glu Glu Pro Ala Ala Ala Gly Ser Gly Ala Ala 70 75 80

r Pro Ser Ser Ala Glu Lys Gly Glu Pro Ala Ala Ala Ala Pro 85 90 95

u Ala Gly Ala Ser Pro Val Glu Lys Glu Ala Pro Ala Glu Gly Glu Page 295

eolf-seql-S000001.txt

100

110

- la Ala Glu Pro Gly Ser Ala Thr Ala Ala Glu Gly Glu Ala Ala Ser 115 120 125
- la Ala Ser Ser Thr Ser Ser Pro Lys Ala Glu Asp Gly Ala Thr Pro 130 135 140
- er Pro Ser Asn Glu Thr Pro Lys Lys Lys Lys Lys Arg Phe Ser Phe 150 150 155
- /s Lys Ser Phe Lys Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys 165 170 175
- lu Ala Gly Glu Gly Glu Ala Glu Ala Pro Ala Ala Glu Gly Gly 180 185 190
- ys Asp Glu Ala Ala Gly Gly Ala Ala Ala Ala Ala Glu Ala Gly 195 200 205
- .a Ala Ser Gly Glu Gln Ala Ala Pro Gly Glu Glu Ala Ala Ala 210 215 220
- .y Glu Glu Gly Ala Ala Gly Gly Asp Pro Gln Glu Ala Lys Pro Gln !5 230 235 240
- u Ala Ala Val Ala Pro Glu Lys Pro Pro Ala Ser Asp Glu Thr Lys. 245 250 255
- .a Ala Glu Glu Pro Ser Lys Val Glu Glu Lys Lys Ala Glu Glu Ala 260 265 270
- y Ala Ser Ala Ala Ala Cys Glu Ala Pro Ser Ala Ala Gly Pro Gly 275 280 285
- a Pro Pro Glu Gln Glu Ala Ala Pro Ala Glu Glu Pro Ala Ala Ala 290 295 300
- a Ala Ser Ser Ala Cys Ala Ala Pro Ser Gl<br/>n Glu Ala Gl<br/>n Pro Glu 310 315 320

eolf-seql-S000001.txt ys Ser Pro Glu Ala Pro Pro Ala Glu Ala Ala Glu 325 330

210> 154

211> 86

212> PRT

213> Homo sapiens

100> 154

- et Pro Gln Tyr Gln Thr Trp Glu Glu Phe Ser Arg Ala Ala Glu Lys 5 10 15
- eu Tyr Leu Ala Asp Pro Met Lys Ala Arg Val Val Leu Lys Tyr Arg 20 25 30
- is Ser Asp Gly Asn Leu Cys Val Lys Val Thr Asp Asp Leu Val Cys 35 40 45
- eu Val Tyr Lys Thr Asp Gln Ala Gln Asp Val Lys Lys Ile Glu Lys 50 55 60
- he His Ser Gln Leu Met Arg Leu Met Val Ala Lys Glu Ala Arg Asn 70 75 80
- il Thr Met Glu Thr Glu 85

110> 155

:11> 480

112> PRT

13> Homo sapiens

:00> 155

- t Ile Arg Ala Ala Pro Pro Pro Leu Phe Leu Leu Leu Leu Leu 5 15
- u Leu Leu Val Ser Trp Ala Ser Arg Gly Glu Ala Ala Pro Asp Gln 20 25 30
- p Glu Ile Gln Arg Leu Pro Gly Leu Ala Lys Gln Pro Ser Phe Arg 35 40 45
- n Tyr Ser Gly Tyr Leu Lys Ser Ser Gly Ser Lys His Leu His Tyr Page 297

eolf-seq1-S000001.txt
50 55 60

p Phe Val Glu Ser Gln Lys Asp Pro Glu Asn Ser Pro Val Val Leu
70 75 80

- tp Leu Asn Gly Gly Pro Gly Cys Ser Ser Leu Asp Gly Leu Leu Thr 85 90 95
- .u His Gly Pro Phe Leu Val Gln Pro Asp Gly Val Thr Leu Glu Tyr 100 105 110
- in Pro Tyr Ser Trp Asn Leu Ile Ala Asn Val Leu Tyr Leu Glu Ser 115 120 125
- to Ala Gly Val Gly Phe Ser Tyr Ser Asp Asp Lys Phe Tyr Ala Thr 130 135 140
- in Asp Thr Glu Val Ala Gln Ser Asn Phe Glu Ala Leu Gln Asp Phe
  15 150 155 160
- e Arg Leu Phe Pro Glu Tyr Lys Asn Asn Lys Leu Phe Leu Thr Gly 165 170 175
- u Ser Tyr Ala Gly Ile Tyr Ile Pro Thr Leu Ala Val Leu Val Met 180 185 190
- n Asp Pro Ser Met Asn Leu Gln Gly Leu Ala Val Gly Asn Gly Leu 195 200 205
- r Ser Tyr Glu Gln Asn Asp Asn Ser Leu Val Tyr Phe Ala Tyr Tyr 210 215 220
- s Gly Leu Leu Gly Asn Arg Leu Trp Ser Ser Leu Gln Thr His Cys 5 230 235 240
- s Ser Gln Asn Lys Cys Asn Phe Tyr Asp Asn Lys Asp Leu Glu Cys 245 250 255
- l Thr Asn Leu Gln Glu Val Ala Arg Ile Val Gly Asn Ser Gly Leu 260 265 270

eolf-seql-S000001.txt
Ile Tyr Asn Leu Tyr Ala Pro Cys Ala Gly Gly Val Pro Ser His
275 280 285

- 1e Arg Tyr Glu Lys Asp Thr Val Val Val Gln Asp Leu Gly Asn Ile 290 295 300
- 1e Thr Arg Leu Pro Leu Lys Arg Met Trp His Gln Ala Leu Leu Arg 15 310 315 320
- er Gly Asp Lys Val Arg Met Asp Pro Pro Cys Thr Asn Thr Thr Ala 325 330 335
- .a Ser Thr Tyr Leu Asn Asn Pro Tyr Val Arg Lys Ala Leu Asn Ile 340 345 350
- :o Glu Gln Leu Pro Gln Trp Asp Met Cys Asn Phe Leu Val Asn Leu 355 360 365
- .n Tyr Arg Arg Leu Tyr Arg Ser Met Asn Ser Gln Tyr Leu Lys Leu 370 380
- u Ser Ser Gln Lys Tyr Gln Ile Leu Leu Tyr Asn Gly Asp Val Asp 5 390 395
- t Ala Cys Asn Phe Met Gly Asp Glu Trp Phe Val Asp Ser Leu Asn 405 410 415
- n Lys Met Glu Val Gln Arg Arg Pro Trp Leu Val Lys Tyr Gly Asp 420 425 430
- r Gly Glu Gln Ile Ala Gly Phe Val Lys Glu Phe Ser His Ile Ala 435 440 445
- e Leu Thr Ile Lys Gly Ala Gly His Met Val Pro Thr Asp Lys Pro 450 455 460
- u Ala Ala Phe Thr Met Phe Ser Arg Phe Leu Asn Lys Gln Pro Tyr 470 475 480

10> 156

11> 217

12> PRT

eolf-seql-S000001.txt

213> Homo sapiens

100> 156

- et Glu Ala Ile Ala Lys Tyr Asp Phe Lys Ala Thr Ala Asp Asp Glu 5 10 15
- eu Ser Phe Lys Arg Gly Asp Ile Leu Lys Val Leu Asn Glu Glu Cys 20 25 30
- 3p Gln Asn Trp Tyr Lys Ala Glu Leu Asn Gly Lys Asp Gly Phe Ile 35 40 45
- to Lys Asn Tyr Ile Glu Met Lys Pro His Pro Trp Phe Phe Gly Lys 50 55 60
- e Pro Arg Ala Lys Ala Glu Glu Met Leu Ser Lys Gln Arg His Asp 70 75 80
- y Ala Phe Leu Ile Arg Glu Ser Glu Ser Ala Pro Gly Asp Phe Ser 85 90 95
- $^{:\!u}$  Ser Val Lys Phe Gly Asn Asp Val Gln His Phe Lys Val Leu Arg 100  $\phantom{0}$  105  $\phantom{0}$  110
- p Gly Ala Gly Lys Tyr Phe Leu Trp Val Val Lys Phe Asn Ser Leu 115 120 125
- n Glu Leu Val Asp Tyr His Arg Ser Thr Ser Val Ser Arg Asn Gln 130 135 140
- n Ile Phe Leu Arg Asp Ile Glu Gln Val Pro Gln Gln Pro Thr Tyr 5 150 155 160
- l Gln Ala Leu Phe Asp Phe Asp Pro Gln Glu Asp Gly Glu Leu Gly 165 170 175
- e Arg Arg Gly Asp Phe Ile His Val Met Asp Asn Ser Asp Pro Asn 180 185 190
- p Trp Lys Gly Ala Cys His Gly Gln Thr Gly Met Phe Pro Arg Asn 195 200 205

Page 300

# eolf-seql-S000001.txt

yr Val Thr Pro Val Asn Arg Asn Val 210 215

210> 157

211> 704

212> PRT

213> Homo sapiens

100> 157

- et Ala Arg Glu Leu Arg Ala Leu Leu Leu Trp Gly Arg Arg Leu Arg 10 15
- to Leu Leu Arg Ala Pro Ala Leu Ala Ala Val Pro Gly Gly Lys Pro 20 25 30
- e Leu Cys Pro Arg Arg Thr Thr Ala Gln Leu Gly Pro Arg Arg Asn. 35 40 45
- to Ala Trp Ser Leu Gln Ala Gly Arg Leu Phe Ser Thr Gln Thr Ala 50 55 60
- u Asp Lys Glu Glu Pro Leu His Ser Ile Ile Ser Ser Thr Glu Ser 70 75 80
- cl Gln Gly Ser Thr Ser Lys His Glu Phe Gln Ala Glu Thr Lys Lys 85 90 95
- :u Leu Asp Ile Val Ala Arg Ser Leu Tyr Ser Glu Lys Glu Val Phe 100 105 110
- e Arg Glu Leu Ile Ser Asn Ala Ser Asp Ala Leu Glu Lys Leu Arg 115 120 125
- s Lys Leu Val Ser Asp Gly Gln Ala Leu Pro Glu Met Glu Ile His 130 135 140
- u Gln Thr Asn Ala Glu Lys Gly Thr Ile Thr Ile Gln Asp Thr Gly 150 155 160
- e Gly Met Thr Gln Glu Glu Leu Val Ser Asn Leu Gly Thr Ile Ala 165 170 175

### eolf-seql-S000001.txt

rg Ser Gly Ser Lys Ala Phe Leu Asp Ala Leu Gln Asn Gln Ala Glu 180 185 190

la Ser Ser Lys Ile Ile Gly Gln Phe Gly Val Gly Phe Tyr Ser Ala 195 200 205

ne Met Val Ala Asp Arg Val Glu Val Tyr Ser Arg Ser Ala Ala Pro 210 215 220

Ly Ser Leu Gly Tyr Gln Trp Leu Ser Asp Gly Ser Gly Val Phe Glu 25 230 235 240

Le Ala Glu Ala Ser Gly Val Arg Thr Gly Thr Lys Ile Ile Ile His 245 250 255

u Lys Ser Asp Cys Lys Glu Phe Ser Ser Glu Ala Arg Val Arg Asp 260 265 270

l Val Thr Lys Tyr Ser Asn Phe Val Ser Phe Pro Leu Tyr Leu Asn 275 280 285

y Arg Arg Met Asn Thr Leu Gln Ala Ile Trp Met Met Asp Pro Lys 290 295 300

% For the second secon

a His Asp Lys Pro Arg Tyr Thr Leu His Tyr Lys Thr Asp Ala Pro 325 330 335

u Asn Ile Arg Ser Ile Phe Tyr Val Pro Asp Met Lys Pro Ser Met 340 345 350

e Asp Val Ser Arg Glu Leu Gly Ser Ser Val Ala Leu Tyr Ser Arg 355 360 365

s Val Leu Ile Gln Thr Lys Ala Thr Asp Ile Leu Pro Lys Trp Leu 370 380

g Phe Ile Arg Gly Val Val Asp Ser Glu Asp Ile Pro Leu Asn Leu 5 390 395 400

Page 302

- er Arg Glu Leu Leu Gln Glu Ser Ala Leu Ile Arg Lys Leu Arg Asp 405 410 415
- il Leu Gln Gln Arg Leu Ile Lys Phe Phe Ile Asp Gln Ser Lys Lys 420 425 430
- 3p Ala Glu Lys Tyr Ala Lys Phe Phe Glu Asp Tyr Gly Leu Phe Met 435 440 445
- :g Glu Gly Ile Val Thr Ala Thr Glu Gln Glu Val Lys Glu Asp Ile 450 455 460
- .a Lys Leu Leu Arg Tyr Glu Ser Ser Ala Leu Pro Ser Gly Gln Leu i5 470 475 480
- r Ser Leu Ser Glu Tyr Ala Ser Arg Met Arg Ala Gly Thr Arg Asn 485 490 495
- e Tyr Tyr Leu Cys Ala Pro Asn Arg His Leu Ala Glu His Ser Pro 500 505 510
- r Tyr Glu Ala Met Lys Lys Lys Asp Thr Glu Val Leu Phe Cys Phe 515 520 525
- u Gln Phe Asp Glu Leu Thr Leu Leu His Leu Arg Glu Phe Asp Lys 530 540
- s Lys Leu Ile Ser Val Glu Thr Asp Ile Val Val Asp His Tyr Lys 5 550 555 560
- u Glu Lys Phe Glu Asp Arg Ser Pro Ala Ala Glu Cys Leu Ser Glu 565 570 575
- s Glu Thr Glu Glu Leu Met Ala Trp Met Arg Asn Val Leu Gly Ser 580 585 590
- g Val Thr Asn Val Lys Val Thr Leu Arg Leu Asp Thr His Pro Ala 595 600 605
- t Val Thr Val Leu Glu Met Gly Ala Ala Arg His Phe Leu Arg Met Page 303

eolf-soal s000001 but

610 eolf-seql-S000001.txt 620

ln Gln Leu Ala Lys Thr Gln Glu Glu Arg Ala Gln Leu Leu Gln Pro 630 635 640

PCT/EP2005/050897

hr Leu Glu Ile Asn Pro Arg His Ala Leu Ile Lys Lys Leu Asn Gln 645 650 655

eu Arg Ala Ser Glu Pro Gly Leu Ala Gln Leu Leu Val Asp Gln Ile 660 665 670

yr Glu Asn Ala Met Ile Ala Ala Gly Leu Val Asp Asp Pro Arg Ala 675 680 685

et Val Gly Arg Leu Asn Glu Leu Leu Val Lys Ala Leu Glu Arg His 690 695 700

10> 158

?11> 359

112> PRT

:13> Homo sapiens

WO 2005/085861

:00> 158

t Ala Ala Val Ser Gly Leu Val Arg Arg Pro Leu Arg Glu Val Ser 5 10 15

y Leu Leu Lys Arg Arg Phe His Trp Thr Ala Pro Ala Ala Leu Gln 20 25 30

l Thr Val Arg Asp Ala Ile Asn Gln Gly Met Asp Glu Glu Leu Glu 35 40 45

J Asp Glu Lys Val Phe Leu Leu Gly Glu Glu Val Ala Gln Tyr Asp 50 55 60

/ Ala Tyr Lys Val Ser Arg Gly Leu Trp Lys Lys Tyr Gly Asp Lys 70 75 80

; Ile Ile Asp Thr Pro Ile Ser Glu Met Gly Phe Ala Gly Ile Ala 85 90 95

. Gly Ala Ala Met Ala Gly Leu Arg Pro Ile Cys Glu Phe Met Thr Page 304

eolf-seql-S000001.txt

100 105 110

- ne Asn Phe Ser Met Gln Ala Ile Asp Gln Val Ile Asn Ser Ala Ala 115 120 125
- ys Thr Tyr Tyr Met Ser Gly Gly Leu Gln Pro Val Pro Ile Val Phe 130 135 140
- cg Gly Pro Asn Gly Ala Ser Ala Gly Val Ala Ala Gln His Ser Gln 15 150 155 160
- /s Phe Ala Ala Trp Tyr Gly His Cys Pro Gly Leu Lys Val Val Ser 165 170 175
- co Trp Asn Ser Glu Asp Ala Lys Gly Leu Ile Lys Ser Ala Ile Arg 180 185 190
- sp Asn Asn Pro Val Val Leu Glu Asn Glu Leu Met Tyr Gly Val 195 200 205
- TO Phe Glu Phe Leu Pro Glu Ala Gln Ser Lys Asp Phe Leu Ile Pro 210 215 220
- e Gly Lys Ala Lys Ile Glu Arg Gln Gly Thr His Ile Thr Val Val 230 235 240
- er His Ser Arg Pro Val Gly His Cys Leu Glu Ala Ala Val Leu 245 250 255
- er Lys Glu Gly Val Glu Cys Glu Val Ile Asn Met Arg Thr Ile Arg 260 265 270
- o Met Asp Met Glu Thr Ile Glu Ala Ser Val Met Lys Thr Asn His 275 280 285
- u Val Thr Val Glu Gly Gly Trp Pro Gln Phe Gly Val Gly Ala Glu 290 295 300
- e Cys Ala Arg Ile Met Glu Gly Pro Ala Phe Asn Phe Leu Asp Ala 5 310 315 320

eolf-seql-S000001.txt

- to Ala Val Arg Val Thr Gly Ala Asp Val Pro Met Pro Tyr Ala Lys 325 330 335
- e Leu Glu Asp Asn Ser Ile Pro Gln Val Lys Asp Ile Ile Phe Ala 340 345 350
- e Lys Lys Thr Leu Asn Ile 355
- :10> 159
- :11> 113
- :12> PRT
- :13> Homo sapiens
- 00> 159
- t Ser Ala Ser Val Val Ser Val Ile Ser Arg Phe Leu Glu Glu Tyr 5 10 15
- u Ser Ser Thr Pro Gln Arg Leu Lys Leu Leu Asp Ala Tyr Leu Leu 20 25 30
- r Ile Leu Leu Thr Gly Ala Leu Gln Phe Gly Tyr Cys Leu Leu Val 35 40 45
- y Thr Phe Pro Phe Asn Ser Phe Leu Ser Gly Phe Ile Ser Cys Val 50 55 60
- y Ser Phe Ile Leu Ala Val Cys Leu Arg Ile Gln Ile Asn Pro Gln
  70 75 80
- n Lys Ala Asp Phe Gln Gly Ile Ser Pro Glu Arg Ala Phe Ala Asp 85 90 95
- e Leu Phe Ala Ser Thr Ile Leu His Leu Val Val Met Asn Phe Val 100 105 110

У

- 10> 160
- 11> 239
- 12> PRT
- 13> Homo sapiens

## eolf-seql-S000001.txt

400> 160

- et Ala Lys Pro Cys Gly Val Arg Leu Ser Gly Glu Ala Arg Lys Gln 5 10 15
- 31 Glu Val Phe Arg Gln Asn Leu Phe Gln Glu Ala Glu Glu Phe Leu 20 25 30
- /r Arg Phe Leu Pro Gln Lys Ile Ile Tyr Leu Asn Gln Leu Leu Gln 35 40 45
- lu Asp Ser Leu Asn Val Ala Asp Leu Thr Ser Leu Arg Ala Pro Leu 50 55 60
- sp Ile Pro Ile Pro Asp Pro Pro Pro Lys Asp Asp Glu Met Glu Thr
  5 70 75 80
- sp Lys Gln Glu Lys Lys Glu Val His Lys Cys Gly Phe Leu Pro Gly 85 90 95
- in Glu Lys Val Leu Ser Leu Leu Ala Leu Val Lys Pro Glu Val Trp
  100 105 110
- r Leu Lys Glu Lys Cys Ile Leu Val Ile Thr Trp Ile Gln His Leu 115 120 125
- e Pro Lys Ile Glu Asp Gly Asn Asp Phe Gly Val Ala Ile Gln Glu 130 135 140
- s Val Leu Glu Arg Val Asn Ala Val Lys Thr Lys Val Glu Ala Phe 150 155 160
- n Thr Thr Ile Ser Lys Tyr Phe Ser Glu Arg Gly Asp Ala Val Ala 165 170 175
- s Ala Ser Lys Glu Thr His Val Met Asp Tyr Arg Ala Leu Val His 180 185 190
- u Arg Asp Glu Ala Ala Tyr Gly Glu Leu Arg Ala Met Val Leu Asp 195 200 205

Page 307

eolf-seql-S000001.txt

eu Arg Ala Phe Tyr Ala Glu Leu Tyr His Ile Ile Ser Ser Asn Leu 210 215 220

- lu Lys Ile Val Asn Pro Lys Gly Glu Glu Lys Pro Ser Met Tyr 25 230 235
- 210> 161
- 211> 111
- ?12> PRT
- ?13> Homo sapiens
- 100> 161
- et Ala Gly Lys Gln Ala Val Ser Ala Ser Gly Lys Trp Leu Asp Gly 5 10 15
- .e Arg Lys Trp Tyr Tyr Asn Ala Ala Gly Phe Asn Lys Leu Gly Leu 20 25 30
- t Arg Asp Asp Thr Ile Tyr Glu Asp Glu Asp Val Lys Glu Ala Ile 35 40 45
- rg Arg Leu Pro Glu Asn Leu Tyr Asn Asp Arg Met Phe Arg Ile Lys 50 55 60
- g Ala Leu Asp Leu Asn Leu Lys His Gln Ile Leu Pro Lys Glu Gln
  70 75 80
- p Thr Lys Tyr Glu Glu Glu Asn Phe Tyr Leu Glu Pro Tyr Leu Lys 85 90 95
- u Val Ile Arg Glu Arg Lys Glu Arg Glu Glu Trp Ala Lys Lys 100 105 110
- 10> 162
- 11> 106
- 12> PRT
- 13> Homo sapiens
- 00> 162
- t Ser Ser Leu Ser Glu Tyr Ala Phe Arg Met Ser Arg Leu Ser Ala 5 10 15
- g Leu Phe Gly Glu Val Thr Arg Pro Thr Asn Ser Lys Ser Met Lys

  Page 308

eolf-seql-S000001.txt

20

30

al Val Lys Leu Phe Ser Glu Leu Pro Leu Ala Lys Lys Glu Thr 35 40 45

yr Asp Trp Tyr Pro Asn His His Thr Tyr Ala Glu Leu Met Gln Thr 50 55 60

eu Arg Phe Leu Gly Leu Tyr Arg Asp Glu His Gln Asp Phe Met Asp 70 75 80

lu Gln Lys Arg Leu Lys Lys Leu Arg Gly Lys Glu Lys Pro Lys Lys 85 90 95

ly Glu Gly Lys Arg Ala Ala Lys Arg Lys
100 105

210> 163

?11> 180

?12> PRT

?13> Homo sapiens

100> 163

et Gly Leu Thr Ile Ser Ser Leu Phe Ser Arg Leu Phe Gly Lys Lys 10 15

.n Met Arg Ile Leu Met Val Gly Leu Asp Ala Ala Gly Lys Thr Thr 20 25 30

e Leu Tyr Lys Leu Lys Leu Gly Glu Ile Val Thr Thr Ile Pro Thr 35 40 45

e Gly Phe Asn Val Glu Thr Val Glu Tyr Lys Asn Ile Cys Phe Thr 50 60

1 Trp Asp Val Gly Gln Asp Arg Ile Arg Pro Leu Trp Lys His 70 75 80

r Phe Gln Asn Thr Gln Gly Leu Ile Phe Val Val Asp Ser Asn Asp 85 90 95

g Glu Arg Ile Gln Glu Val Ala Asp Glu Leu Gln Lys Met Leu Leu Page 309

110

eolf-seql-S000001.txt 100 105

al Asp Glu Leu Arg Asp Ala Val Leu Leu Leu Phe Ala Asn Lys Gln
115 120 125

- sp Leu Pro Asn Ala Met Ala Ile Ser Glu Met Thr Asp Lys Leu Gly
  130
  135
  140
- $\pm$ u Gln Ser Leu Arg Asn Arg Thr Trp Tyr Val Gln Ala Thr Cys Ala 15 150 155 160
- ir Gln Gly Thr Gly Leu Tyr Glu Gly Leu Asp Trp Leu Ser Asn Glu 165 170 175

u Ser Lys Arg

:10> 164

:11> 1140

:12> PRT

:13> Homo sapiens

00> 164

- t Ser Tyr Asn Tyr Val Val Thr Ala Gln Lys Pro Thr Ala Val Asn
  5 10 15
- y Cys Val Thr Gly His Phe Thr Ser Ala Glu Asp Leu Asn Leu Leu 20 25 30
- e Ala Lys Asn Thr Arg Leu Glu Ile Tyr Val Val Thr Ala Glu Gly  $35 \hspace{1cm} 40 \hspace{1cm} 45$
- u Arg Pro Val Lys Glu Val Gly Met Tyr Gly Lys Ile Ala Val Met 50 55 60
- u Leu Phe Arg Pro Lys Gly Glu Ser Lys Asp Leu Leu Phe Ile Leu 70 75 80
- r Ala Lys Tyr Asn Ala Cys Ile Leu Glu Tyr Lys Gln Ser Gly Glu 85 90 95

110

eolf-seq1-S000001.txt 100 105

ly Arg Pro Ser Glu Thr Gly Ile Ile Gly Ile Ile Asp Pro Glu Cys 115 120 125

- rg Met Ile Gly Leu Arg Leu Tyr Asp Gly Leu Phe Lys Val Ile Pro 130 135 140
- eu Asp Arg Asp Asn Lys Glu Leu Lys Ala Phe Asn Ile Arg Leu Glu 15 150 155 160
- u Leu His Val Ile Asp Val Lys Phe Leu Tyr Gly Cys Gln Ala Pro. 165 170 175
- r Ile Cys Phe Val Tyr Gln Asp Pro Gln Gly Arg His Val Lys Thr 180 185 190
- r Glu Val Ser Leu Arg Glu Lys Glu Phe Asn Lys Gly Pro Trp Lys 195 200 205
- n Glu Asn Val Glu Ala Glu Ala Ser Met Val Ile Ala Val Pro Glu 210 215 220
- o Phe Gly Gly Ala Ile Ile Ile Gly Gln Glu Ser Ile Thr Tyr His 5 230 235 240
- n Gly Asp Lys Tyr Leu Ala Ile Ala Pro Pro Ile Ile Lys Gln Ser 245 250 255
- r Ile Val Cys His Asn Arg Val Asp Pro Asn Gly Ser Arg Tyr Leu 260 265 270
- u Gly Asp Met Glu Gly Arg Leu Phe Met Leu Leu Glu Lys Glu 275 280 285
- u Gln Met Asp Gly Thr Val Thr Leu Lys Asp Leu Arg Val Glu Leu 290 295 300
- u Gly Glu Thr Ser Ile Ala Glu Cys Leu Thr Tyr Leu Asp Asn Gly 310 315 320

Page 311

- 11 Val Phe Val Gly Ser Arg Leu Gly Asp Ser Gln Leu Val Lys Leu 325 330 335
- %;n Val Asp Ser Asn Glu Gln Gly Ser Tyr Val Val Ala Met Glu Thr 340 345 350
- ie Thr Asn Leu Gly Pro Ile Val Asp Met Cys Val Val Asp Leu Glu 355 360 365
- 'g Gln Gly Gln Gly Gln Leu Val Thr Cys Ser Gly Ala Phe Lys Glu 370 375 380
- y Ser Leu Arg Ile Ile Arg Asn Gly Ile Gly Ile His Glu His Ala 390 395 400
- r Ile Asp Leu Pro Gly Ile Lys Gly Leu Trp Pro Leu Arg Ser Asp 405 410 415
- o Asn Arg Glu Thr Tyr Asp Thr Leu Val Leu Ser Phe Val Gly Gln
  420 425 430
- r Arg Val Leu Met Leu Asn Gly Glu Glu Val Glu Glu Thr Glu Leu 435 440 445
- t Gly Phe Val Asp Asp Gln Gln Thr Phe Phe Cys Gly Asn Val Ala 450 460
- s Gln Gln Leu Ile Gln Ile Thr Ser Ala Ser Val Arg Leu Val Ser 470 475 480
- n Glu Pro Lys Ala Leu Val Ser Glu Trp Lys Glu Pro Gln Ala Lys 485 490 495
- n Ile Ser Val Ala Ser Cys Asn Ser Ser Gln Val Val Ala Val 500 505 510
- y Arg Ala Leu Tyr Tyr Leu Gln Ile His Pro Gln Glu Leu Arg Gln 515 520 525
- $_{\odot}$  Ser His Thr Glu Met Glu His Glu Val Ala Cys Leu Asp Ile Thr 530 540

#### eolf-seql-S000001.txt

ro Leu Gly Asp Ser Asn Gly Leu Ser Pro Leu Cys Ala Ile Gly Leu 45 550 555 560

- rp Thr Asp Ile Ser Ala Arg Ile Leu Lys Leu Pro Ser Phe Glu Leu 565 570 575
- eu His Lys Glu Met Leu Gly Gly Glu Ile Ile Pro Arg Ser Ile Leu 580 585 590
- et Thr Thr Phe Glu Ser Ser His Tyr Leu Leu Cys Ala Leu Gly Asp 595 600 605
- ly Ala Leu Phe Tyr Phe Gly Leu Asn Ile Glu Thr Gly Leu Leu Ser 610 620
- 3p Arg Lys Lys Val Thr Leu Gly Thr Gln Pro Thr Val Leu Arg Thr 25 630 635 640
- ne Arg Ser Leu Ser Thr Thr Asn Val Phe Ala Cys Ser Asp Arg Pro 645 650 655
- or Val Ile Tyr Ser Ser Asn His Lys Leu Val Phe Ser Asn Val Asn 660 670
- u Lys Glu Val Asn Tyr Met Cys Pro Leu Asn Ser Asp Gly Tyr Pro 675 680 685
- :p Ser Leu Ala Leu Ala Asn Asn Ser Thr Leu Thr Ile Gly Thr Ile 690 695 700
- p Glu Ile Gln Lys Leu His Ile Arg Thr Val Pro Leu Tyr Glu Ser 710 715 720
- o Arg Lys Ile Cys Tyr Gln Glu Val Ser Gln Cys Phe Gly Val Leu 725 730 735
- r Ser Arg Ile Glu Val Gln Asp Thr Ser Gly Gly Thr Thr Ala Leu 740 745 750
- g Pro Ser Ala Ser Thr Gln Ala Leu Ser Ser Ser Val Ser Ser Ser 755 760 765

- ys Leu Phe Ser Ser Ser Thr Ala Pro His Glu Thr Ser Phe Gly Glu 770 780
- lu Val Glu Val His Asn Leu Leu Ile Ile Asp Gln His Thr Phe Glu 35 790 795 800
- al Leu His Ala His Gln Phe Leu Gln Asn Glu Tyr Ala Leu Ser Leu 805 810 815
- 11 Ser Cys Lys Leu Gly Lys Asp Pro Asn Thr Tyr Phe Ile Val Gly 820 825 830
- ır Ala Met Val Tyr Pro Glu Glu Ala Glu Pro Lys Gln Gly Arg Ile 835 840 845
- 11 Val Phe Gln Tyr Ser Asp Gly Lys Leu Gln Thr Val Ala Glu Lys 850 855 860
- Lu Val Lys Gly Ala Val Tyr Ser Met Val Glu Phe Asn Gly Lys Leu 35 870 875 880
- eu Ala Ser Ile Asn Ser Thr Val Arg Leu Tyr Glu Trp Thr Thr Glu 885 890 895
- 's Asp Val Arg Thr Glu Cys Asn His Tyr Asn Asn Ile Met Ala Leu 900 905 910
- r Leu Lys Thr Lys Gly Asp Phe Ile Leu Val Gly Asp Leu Met Arg 915 920 925
- er Val Leu Leu Leu Ala Tyr Lys Pro Met Glu Gly Asn Phe Glu Glu 930 935 940
- e Ala Arg Asp Phe Asn Pro Asn Trp Met Ser Ala Val Glu Ile Leu 5 950 955 960
- p Asp Asp Asn Phe Leu Gly Ala Glu Asn Ala Phe Asn Leu Phe Val 965 970 975
- s Gln Lys Asp Ser Ala Ala Thr Thr Asp Glu Glu Arg Gln His Leu Page 314

980 eolf-seql-S000001.txt

980 985 990

ln Glu Val Gly Leu Phe His Leu Gly Glu Phe Val Asn Val Phe Cys 995 1000 1005

- is Gly Ser Leu Val Met Gln Asn Leu Gly Glu Thr Ser Thr Pro 1010 1015 1020
- nr Gln Gly Ser Val Leu Phe Gly Thr Val Asn Gly Met Ile Gly 1025 1030 1035
- $_{\odot}$ u Val Thr Ser Leu Ser Glu Ser Trp Tyr Asn Leu Leu Leu Asp 1040 1050
- et Gln Asn Arg Leu Asn Lys Val Ile Lys Ser Val Gly Lys Ile 1055 1060 1065
- Lu His Ser Phe Trp Arg Ser Phe His Thr Glu Arg Lys Thr Glu 1070 1080
- To Ala Thr Gly Phe Ile Asp Gly Asp Leu Ile Glu Ser Phe Leu 1085 1090 1095
- sp Ile Ser Arg Pro Lys Met Gln Glu Val Val Ala Asn Leu Gln
  1100 1105 1110
- 'r Asp Asp Gly Ser Gly Met Lys Arg Glu Ala Thr Ala Asp Asp 1115 1125
- u Ile Lys Val Val Glu Glu Leu Thr Arg Ile His 1130 1135 1140
- :10> 165
- :11> 153
- :12> PRT
- 113> Homo sapiens
- 00> 165
- t Gly Ala Pro Leu Leu Ser Pro Gly Trp Gly Ala Gly Ala Gly 5 10 15
- g Arg Trp Trp Met Leu Leu Ala Pro Leu Leu Pro Ala Leu Leu Page 315

eolf-seql-S000001.txt

20

30

al Arg Pro Ala Gly Ala Leu Val Glu Gly Leu Tyr Cys Gly Thr Arg
35 40 45

- 3p Cys Tyr Glu Val Leu Gly Val Ser Arg Ser Ala Gly Lys Ala Glu 50 55 60
- e Ala Arg Ala Tyr Arg Gln Leu Ala Arg Arg Tyr His Pro Asp Arg 70 75 80
- r Arg Pro Gln Pro Gly Asp Glu Gly Pro Gly Arg Thr Pro Gln Ser 85 90 95
- .a Glu Glu Ala Phe Leu Leu Val Ala Thr Ala Tyr Glu Thr Leu Lys  $100 \hspace{1.5cm} 105 \hspace{1.5cm} 110$
- l Ser Gln Ala Ala Ala Glu Leu Gln Gln Tyr Cys Met Gln Asn Ala 115 120 125
- 's Lys Asp Ala Leu Leu Val Gly Val Pro Ala Gly Ser Asn Pro Phe 130 135 140
- g Glu Pro Arg Ser Cys Ala Leu Leu 5 150
- 10> 166
- 11> 557
- 12> PRT
- 13> Homo sapiens
- 00> 166
- t Asp Gly Ile Val Pro Asp Ile Ala Val Gly Thr Lys Arg Gly Ser 5 10 15
- p Glu Leu Phe Ser Thr Cys Val Thr Asn Gly Pro Phe Ile Met Ser 20 25 30
- r Asn Ser Ala Ser Ala Ala Asn Gly Asn Asp Ser Lys Lys Phe Lys 35 40 45
- y Asp Ser Arg Ser Ala Gly Val Pro Ser Arg Val Ile His Ile Arg Page 316

eolf-seql-S000001.txt 50 55 60

ys Leu Pro Ile Asp Val Thr Glu Gly Glu Val Ile Ser Leu Gly Leu 5 70 75 80

- ro Phe Gly Lys Val Thr Asn Leu Leu Met Leu Lys Gly Lys Asn Gln
  85 90 95
- la Phe Ile Glu Met Asn Thr Glu Glu Ala Ala Asn Thr Met Val Asn . 100  $\,$  105  $\,$  110
- /r Tyr Thr Ser Val Thr Pro Val Leu Arg Gly Gln Pro Ile Tyr Ile
  115
  120
  125
- In Phe Ser Asn His Lys Glu Leu Lys Thr Asp Ser Ser Pro Asn Gln
  130
  135
  140
- la Arg Ala Gln Ala Ala Leu Gln Ala Val Asn Ser Val Gln Ser Gly
  15 150 155 160
- in Leu Ala Leu Ala Ala Ser Ala Ala Ala Val Asp Ala Gly Met Ala 165 170 175
- et Ala Gly Gln Ser Pro Val Leu Arg Ile Ile Val Glu Asn Leu Phe 180 185 190
- r Pro Val Thr Leu Asp Val Leu His Gln Ile Phe Ser Lys Phe Gly 195 200 205
- ir Val Leu Lys Ile Ile Thr Phe Thr Lys Asn Asn Gln Phe Gln Ala 210 215 220
- u Leu Gln Tyr Ala Asp Pro Val Ser Ala Gln His Ala Lys Leu Ser 5 230 235 240
- u Asp Gly Gln Asn Ile Tyr Asn Ala Cys Cys Thr Leu Arg Ile Asp 245 250 255
- e Ser Lys Leu Thr Ser Leu Asn Val Lys Tyr Asn Asn Asp Lys Ser 260 265 270

- 29 Asp Tyr Thr Arg Pro Asp Leu Pro Ser Gly Asp Ser Gln Pro Ser 275 280 285
- eu Asp Gln Thr Met Ala Ala Ala Phe Gly Ala Pro Gly Ile Ile Ser 290 295 300
- -a Ser Pro Tyr Ala Gly Ala Gly Phe Pro Pro Thr Phe Ala Ile Pro
  310 315 320
- n Ala Ala Gly Leu Ser Val Pro Asn Val His Gly Ala Leu Ala Pro 325 330 335
- u Ala Ile Pro Ser Ala Ala Ala Ala Ala Ala Ala Ala Gly Arg Ile 340 345 350
- .a Ile Pro Gly Leu Ala Gly Ala Gly Asn Ser Val Leu Leu Val Ser 355 360 365
- in Leu Asn Pro Glu Arg Val Thr Pro Gln Ser Leu Phe Ile Leu Phe 370 375 380
- y Val Tyr Gly Asp Val Gln Arg Val Lys Ile Leu Phe Asn Lys Lys 5 390 395 400
- u Asn Ala Leu Val Gln Met Ala Asp Gly Asn Gln Ala Gln Leu Ala 405 410 415
- t Ser His Leu Asn Gly His Lys Leu His Gly Lys Pro Ile Arg Ile 420 425 430
- r Leu Ser Lys His Gln Asn Val Gln Leu Pro Arg Glu Gly Gln Glu 435 440 445
- p Gln Gly Leu Thr Lys Asp Tyr Gly Asn Ser Pro Leu His Arg Phe 450 455 460
- s Lys Pro Gly Ser Lys Asn Phe Gln Asn Ile Phe Pro Pro Ser Ala 5 470 475 480
- r Leu His Leu Ser Asn Ile Pro Pro Ser Val Ser Glu Glu Asp Leu 485 490 495

# eolf-seql-S000001.txt

vs Val Leu Phe Ser Ser Asn Gly Gly Val Val Lys Gly Phe Lys Phe 500 505 510

- ne Gln Lys Asp Arg Lys Met Ala Leu Ile Gln Met Gly Ser Val Glu 515 520 525
- u Ala Val Gln Ala Leu Ile Asp Leu His Asn His Asp Leu Gly Glu 530 540
- in His His Leu Arg Val Ser Phe Ser Lys Ser Thr Ile 550 555

:10> 167

!11> 303

!12> PRT

:13> Homo sapiens

:00> 167

- t Ala Arg Gly Lys Ala Lys Glu Glu Gly Ser Trp Lys Lys Phe Ile 5 10 15
- p Asn Ser Glu Lys Lys Glu Phe Leu Gly Arg Thr Gly Gly Ser Trp 20 25 30
- e Lys Ile Leu Leu Phe Tyr Val Ile Phe Tyr Gly Cys Leu Ala Gly 35 40 45
- e Phe Ile Gly Thr Ile Gln Val Met Leu Leu Thr Ile Ser Glu Phe 50 55 60
- s Pro Thr Tyr Gln Asp Arg Val Ala Pro Pro Gly Leu Thr Gln Ile 70 75 80
- o Gln Ile Gln Lys Thr Glu Ile Ser Phe Arg Pro Asn Asp Pro Lys 85 90 95
- r Tyr Glu Ala Tyr Val Leu Asn Ile Val Arg Phe Leu Glu Lys Tyr 100 105 110
- s Asp Ser Ala Gln Arg Asp Asp Met Ile Phe Glu Asp Cys Gly Asp 115 120 125

- Pro Ser Glu Pro Lys Glu Arg Gly Asp Phe Asn His Glu Arg Gly 130 135 140
- lu Arg Lys Val Cys Arg Phe Lys Leu Glu Trp Leu Gly Asn Cys Ser 15 150 155 160
- y Leu Asn Asp Glu Thr Tyr Gly Tyr Lys Glu Gly Lys Pro Cys Ile 165 170 175
- e Ile Lys Leu Asn Arg Val Leu Gly Phe Lys Pro Lys Pro Pro Lys 180 185 190
- in Glu Ser Leu Glu Thr Tyr Pro Val Met Lys Tyr Asn Pro Asn Val 195 200 205
- u Pro Val Gln Cys Thr Gly Lys Arg Asp Glu Asp Lys Asp Lys Val 210 215 220
- .y Asn Val Glu Tyr Phe Gly Leu Gly Asn Ser Pro Gly Phe Pro Leu :5 230 235 240
- n Tyr Tyr Pro Tyr Tyr Gly Lys Leu Leu Gln Pro Lys Tyr Leu Gln 245 250 255
- o Leu Leu Ala Val Gln Phe Thr Asn Leu Thr Met Asp Thr Glu Ile 260 265 270
- g Ile Glu Cys Lys Ala Tyr Gly Glu Asn Ile Gly Tyr Ser Glu Lys 275 280 285
- p Arg Phe Gln Gly Arg Phe Asp Val Lys Ile Glu Val Lys Ser 290 295 300
- 10> 168
- 11> 361
- 12> PRT
- 13> Homo sapiens
- 00> 168
- t Phe Ser Ser Val Ala His Leu Ala Arg Ala Asn Pro Phe Asn Thr 5 10 15

- co His Leu Gln Leu Val His Asp Gly Leu Gly Asp Leu Arg Ser Ser 20 25 30
- er Pro Gly Pro Thr Gly Gln Pro Arg Arg Pro Arg Asn Leu Ala Ala 35 40 45
- la Ala Val Glu Glu Tyr Ser Cys Glu Phe Gly Ser Ala Lys Tyr Tyr 50 55 60
- Leu Cys Gly Phe Gly Gly Val Leu Ser Cys Gly Leu Thr His Thr
- .a Val Val Pro Leu Asp Leu Val Lys Cys Arg Met Gln Val Asp Pro 85 90 95
- n Lys Tyr Lys Gly Ile Phe Asn Gly Phe Ser Val Thr Leu Lys Glu ... 100 105 110
- p Gly Val Arg Gly Leu Ala Lys Gly Trp Ala Pro Thr Phe Leu Gly 115 120 125
- r Ser Met Gln Gly Leu Cys Lys Phe Gly Phe Tyr Glu Val Phe Lys 130 135 140
- .l Leu Tyr Ser Asn Met Leu Gly Glu Glu Asn Thr Tyr Leu Trp Arg 5 150 155 160
- r Ser Leu Tyr Leu Ala Ala Ser Ala Ser Ala Glu Phe Phe Ala Asp 165 170 175
- e Ala Leu Ala Pro Met Glu Ala Ala Lys Val Arg Ile Gln Thr Gln 180 185 190
- o Gly Tyr Ala Asn Thr Leu Arg Asp Ala Ala Pro Lys Met Tyr Lys 195 200 205
- u Glu Gly Leu Lys Ala Phe Tyr Lys Gly Val Ala Pro Leu Trp Met 210 215 220
- g Gln Ile Pro Tyr Thr Met Met Lys Phe Ala Cys Phe Glu Arg Thr 230 235 240

# eolf-seql-S000001.txt

il Glu Ala Leu Tyr Lys Phe Val Val Pro Lys Pro Arg Ser Glu Cys 245 250 255

- er Lys Pro Glu Gln Leu Val Val Thr Phe Val Ala Gly Tyr Ile Ala 260 265 270
- .y Val Phe Cys Ala Ile Val Ser His Pro Ala Asp Ser Val Val Ser 275 280 285
- l Leu Asn Lys Glu Lys Gly Ser Ser Ala Ser Leu Val Leu Lys Arg 290 295 300
- u Gly Phe Lys Gly Val Trp Lys Gly Leu Phe Ala Arg Ile Ile Met 310 315 320
- e Gly Thr Leu Thr Ala Leu Gln Trp Phe Ile Tyr Asp Ser Val Lys 325 330 335
- l Tyr Phe Arg Leu Pro Arg Pro Pro Pro Pro Glu Met Pro Glu Ser 340 345 350
- u Lys Lys Lys Leu Gly Leu Thr Gln 355 360
- 10> 169
- 11> 369
- 12> PRT
- 13> Homo sapiens
- 00> 169
- t Asp Pro Arg Lys Val Asn Glu Leu Arg Ala Phe Val Lys Met Cys 5 10 15
- s Gln Asp Pro Ser Val Leu His Thr Glu Glu Met Arg Phe Leu Arg 20 25 30
- u Trp Val Glu Ser Met Gly Gly Lys Val Pro Pro Ala Thr Gln Lys 35 40 45
- a Lys Ser Glu Glu Asn Thr Lys Glu Glu Lys Pro Asp Ser Lys Lys 50 55 60

Page 322

- il Glu Glu Asp Leu Lys Ala Asp Glu Pro Ser Ser Glu Glu Ser Asp 70 75 80
- u Glu Ile Asp Lys Glu Gly Val Ile Glu Pro Asp Thr Asp Ala Pro 85 90 95
- .n Glu Met Gly Asp Glu Asn Ala Glu Ile Thr Glu Glu Met Met Asp 100 105 110
- .n Ala Asn Asp Lys Lys Val Ala Ala Ile Glu Ala Leu Asn Asp Gly 115 120 125
- u Leu Gln Lys Ala Ile Asp Leu Phe Thr Asp Ala Ile Lys Leu Asn 130 135 140
- o Arg Leu Ala Ile Leu Tyr Ala Lys Arg Ala Ser Val Phe Val Lys 5 150 155 160
- u Gln Lys Pro Asn Ala Ala Ile Arg Asp Cys Asp Arg Ala Ile Glu 165 170 175
- e Asn Pro Asp Ser Ala Gln Pro Tyr Lys Trp Arg Gly Lys Ala His 180 185 190
- g Leu Leu Gly His Trp Glu Glu Ala Ala His Asp Leu Ala Leu Ala 195 200 205
- s Lys Leu Asp Tyr Asp Glu Asp Ala Ser Ala Met Leu Lys Glu Val 210 215 220
- n Pro Arg Ala Gln Lys Ile Ala Glu His Arg Arg Lys Tyr Glu Arg 5 230 235 240
- s Arg Glu Glu Arg Glu Ile Lys Glu Arg Ile Glu Arg Val Lys Lys 245 250 255
- a Arg Glu Glu His Glu Arg Ala Gln Arg Glu Glu Glu Ala Arg Arg 260 265 270
- n Ser Gly Ala Gln Tyr Gly Ser Phe Pro Gly Gly Phe Pro Gly Gly Page 323

285

eolf-seq1-S000001.txt 275 280

Pro Gly Asn Phe Pro Gly Gly Met Pro Gly Met Gly Gly Met 290 295 300

- co Gly Met Ala Gly Met Pro Gly Leu Asn Glu Ile Leu Ser Asp Pro 310 315 320
- Lu Val Leu Ala Ala Met Gln Asp Pro Glu Val Met Val Ala Phe Gln 325 330 335
- 3P Val Ala Gln Asn Pro Ala Asn Met Ser Lys Tyr Gln Ser Asn Pro 340 345 350
- /s Val Met Asn Leu Ile Ser Lys Leu Ser Ala Lys Phe Gly Gln 355 360 365

.a

?10> 170

11> 440

!12> PRT

:13> Homo sapiens

:20>

:21> misc\_feature

122> (21)..(21)

:23> Xaa can be any naturally occurring amino acid

:00> 170

- t Glu Tyr Gln Ile Leu Lys Met Ser Leu Cys Leu Phe Ile Leu Leu 5 10 15
- e Leu Thr Pro Xaa Ile Leu Cys Ile Cys Pro Leu Gln Cys Ile Cys 20 25 30
- r Glu Arg His Arg His Val Asp Cys Ser Gly Arg Asn Leu Ser Thr 35 40 45
- u Pro Ser Gly Leu Gln Glu Asn Ile Ile His Leu Asn Leu Ser Tyr 50 60

# eolf-seql-S000001.txt

3n His Phe Thr Asp Leu His Asn Gln Leu Thr Gln Tyr Thr Asn Leu 5 70 75 80

- rg Thr Leu Asp Ile Ser Asn Asn Arg Leu Glu Ser Leu Pro Ala His 85 90 95
- eu Pro Arg Ser Leu Trp Asn Met Ser Ala Ala Asn Asn Asn Ile Lys
- eu Leu Asp Lys Ser Asp Thr Ala Tyr Gln Trp Asn Leu Lys Tyr Leu 115 120 125
- sp Val Ser Lys Asn Met Leu Glu Lys Val Val Leu Ile Lys Asn Thr 130 135 140
- u Arg Ser Leu Glu Val Leu Asn Leu Ser Ser Asn Lys Leu Trp Thr 150 150 155 160
- il Pro Thr Asn Met Pro Ser Lys Leu His Ile Val Asp Leu Ser Asn 165 170 175
- :n Ser Leu Thr Gln Ile Leu Pro Gly Thr Leu Ile Asn Leu Thr Asn 180 185 190
- u Thr His Leu Tyr Leu His Asn Asn Lys Phe Thr Phe Ile Pro Asp 195 200 205
- n Ser Phe Asp Gln Leu Phe Gln Leu Gln Glu Ile Thr Leu Tyr Asn 210 215 220
- n Arg Trp Ser Cys Asp His Lys Gln Asn Ile Thr Tyr Leu Leu Lys 230 235 240
- p Met Met Glu Thr Lys Ala His Val Ile Gly Thr Pro Cys Ser Thr 245 250 255
- n Ile Ser Ser Leu Lys Glu His Asn Met Tyr Pro Thr Pro Ser Gly 260 265 270
- e Thr Ser Ser Leu Phe Thr Val Ser Gly Met Gln Thr Val Asp Thr 275 280 285

- le Asn Ser Leu Ser Val Val Thr Gln Pro Lys Val Thr Lys Ile Pro 290 295 300
- /s Gln Tyr Arg Thr Lys Glu Thr Thr Phe Gly Ala Thr Leu Ser Lys 310 315 320
- 3P Thr Thr Phe Thr Ser Thr Asp Lys Ala Phe Val Pro Tyr Pro Glu 325 330 335
- 340 Thr Ser Thr Glu Thr Ile Asn Ser His Glu Ala Ala Ala Thr 340 345 350
- eu Thr Ile His Leu Gln Asp Gly Met Val Thr Asn Thr Ser Leu Thr 355 360 365
- er Ser Thr Lys Ser Ser Pro Thr Pro Met Thr Leu Ser Ile Thr Ser 370 380
- y Met Pro Asn Asn Phe Ser Glu Met Pro Gln Gln Ser Thr Thr Leu 390 395 400
- In Leu Trp Arg Glu Glu Thr Thr Thr Asn Val Lys Thr Pro Leu Pro 405 410 415
- r Val Ala Asn Ala Trp Lys Val Asn Ala Ser Phe Leu Leu Leu 420 425 430
- n Val Val Val Met Leu Ala Val 435 440
- 10> 171
- 11> 241
- 12> PRT
- 13> Homo sapiens
- 00> 171
- t Leu Ser Ser Thr Ala Met Tyr Ser Ala Pro Gly Arg Asp Leu Gly 5 10 15
- t Glu Pro His Arg Ala Ala Gly Pro Leu Gln Leu Arg Phe Ser Pro 20 25 30

# eolf-seql-S000001.txt

- /r Val Phe Asn Gly Gly Thr Ile Leu Ala Ile Ala Gly Glu Asp Phe 35 40 45
- La Ile Val Ala Ser Asp Thr Arg Leu Ser Glu Gly Phe Ser Ile His 50 55 60
- ir Arg Asp Ser Pro Lys Cys Tyr Lys Leu Thr Asp Lys Thr Val Ile 70 75 80
- -y Cys Ser Gly Phe His Gly Asp Cys Leu Thr Leu Thr Lys Ile Ile 85 90 95
- .u Ala Arg Leu Lys Met Tyr Lys His Ser Asn Asn Lys Ala Met Thr 100 105 110
- ir Gly Ala Ile Ala Ala Met Leu Ser Thr Ile Leu Tyr Ser Arg Arg 115 120 125
- ie Phe Pro Tyr Tyr Val Tyr Asn Ile Ile Gly Gly Leu Asp Glu Glu 130 135 140
- y Lys Gly Ala Val Tyr Ser Phe Asp Pro Val Gly Ser Tyr Gln Arg 5 150 155 160
- p Ser Phe Lys Ala Gly Gly Ser Ala Ser Ala Met Leu Gln Pro Leu 165 170 175
- u Asp Asn Gln Val Gly Phe Lys Asn Met Gln Asn Val Glu His Val 180 185 190
- o Leu Ser Leu Asp Arg Ala Met Arg Leu Val Lys Asp Val Phe Ile 195 200 205
- r Ala Ala Glu Arg Asp Val Tyr Thr Gly Asp Ala Leu Arg Ile Cys 210 220
- e Val Thr Lys Glu Gly Ile Arg Glu Glu Thr Val Ser Leu Arg Lys 230 235 240

р

## eolf-seq1-S000001.txt

!10> 172

!11> 83

12> PRT

:13> Homo sapiens

:00> 172

t Gln Asn Asp Ala Gly Glu Phe Val Asp Leu Tyr Val Pro Arg Lys
5 10 15

's Ser Ala Ser Asn Arg Ile Ile Gly Ala Lys Asp His Ala Ser Ile 20 25 30

n Met Asn Val Ala Glu Val Asp Lys Val Thr Gly Arg Phe Asn Gly 35 40 45

n Phe Lys Thr Tyr Ala Ile Cys Gly Ala Ile Arg Arg Met Gly Glu 50 60

r Asp Asp Ser Ile Leu Arg Leu Ala Lys Ala Asp Gly Ile Val Ser 70 75 80

s Asn Phe

10> 173

11> 660

12> PRT

13> Homo sapiens

00> 173

t Glu Ala Leu Met Ala Arg Gly Ala Leu Thr Gly Pro Leu Arg Ala 5 10 15

u Cys Leu Leu Gly Cys Leu Leu Ser His Ala Ala Ala Ala Pro Ser 20 25 30

- o Ile Ile Lys Phe Pro Gly Asp Val Ala Pro Lys Thr Asp Lys Glu 35 40 45
- a Ala Val Gln Tyr Leu Asn Thr Phe Tyr Gly Cys Pro Lys Glu Ser 50 55 60

- 7s Asn Leu Phe Val Leu Lys Asp Thr Leu Lys Lys Met Gln Lys Phe 70 75 80
- ne Gly Leu Pro Gln Thr Gly Asp Leu Asp Gln Asn Thr Ile Glu Thr 85 90 95
- $\Rightarrow$ t Arg Lys Pro Arg Cys Gly Asn Pro Asp Val Ala Asn Tyr Asn Phe 100 105 110
- ne Pro Arg Lys Pro Lys Trp Asp Lys Asn Gln Ile Thr Tyr Arg Ile 115 120 125
- e Gly Tyr Thr Pro Asp Leu Asp Pro Glu Thr Val Asp Asp Ala Phe 130 135 140
- .a Arg Ala Phe Gln Val Trp Ser Asp Val Thr Pro Leu Arg Phe Ser 150 155 160
- g Ile His Asp Gly Glu Ala Asp Ile Met Ile Asn Phe Gly Arg Trp 165 170 175
- u His Gly Asp Gly Tyr Pro Phe Asp Gly Lys Asp Gly Leu Leu Ala 180 185 190
- s Ala Phe Ala Pro Gly Thr Gly Val Gly Gly Asp Ser His Phe Asp 195 200 205
- p Asp Glu Leu Trp Thr Leu Gly Glu Gly Gln Val Val Arg Val Lys 210 220
- r Gly Asn Ala Asp Gly Glu Tyr Cys Lys Phe Pro Phe Leu Phe Asn 230 235 240
- y Lys Glu Tyr Asn Ser Cys Thr Asp Thr Gly Arg Ser Asp Gly Phe 245 250 255
- u Trp Cys Ser Thr Thr Tyr Asn Phe Glu Lys Asp Gly Lys Tyr Gly 260 265 . 270
- e Cys Pro His Glu Ala Leu Phe Thr Met Gly Gly Asn Ala Glu Gly Page 329

285

eolf-seql-S000001.txt 275 280

ln Pro Cys Lys Phe Pro Phe Arg Phe Gln Gly Thr Ser Tyr Asp Ser 290 295 300

- vs Thr Thr Glu Gly Arg Thr Asp Gly Tyr Arg Trp Cys Gly Thr Thr 310 315 320
- u Asp Tyr Asp Arg Asp Lys Lys Tyr Gly Phe Cys Pro Glu Thr Ala 325 330 335
- et Ser Thr Val Gly Gly Asn Ser Glu Gly Ala Pro Cys Val Phe Pro 340 345 350
- te Thr Phe Leu Gly Asn Lys Tyr Glu Ser Cys Thr Ser Ala Gly Arg 355 360 365
- er Asp Gly Lys Met Trp Cys Ala Thr Thr Ala Asn Tyr Asp Asp Asp 370 375 380
- g Lys Trp Gly Phe Cys Pro Asp Gln Gly Tyr Ser Leu Phe Leu Val 390 395 400
- a Ala His Glu Phe Gly His Ala Met Gly Leu Glu His Ser Gln Asp  $405 \hspace{1.5cm} 410 \hspace{1.5cm} 415$
- o Gly Ala Leu Met Ala Pro Ile Tyr Thr Tyr Thr Lys Asn Phe Arg 420 425 430
- u Ser Gln Asp Asp Ile Lys Gly Ile Gln Glu Leu Tyr Gly Ala Ser 435 440 445
- o Asp Ile Asp Leu Gly Thr Gly Pro Thr Pro Thr Leu Gly Pro Val 450 460
- r Pro Glu Ile Cys Lys Gln Asp Ile Val Phe Asp Gly Ile Ala Gln 470 475 480
- e Arg Gly Glu Ile Phe Phe Phe Lys Asp Arg Phe Ile Trp Arg Thr 485 490 495

- al Thr Pro Arg Asp Lys Pro Met Gly Pro Leu Leu Val Ala Thr Phe 500 505 510
- :p Pro Glu Leu Pro Glu Lys Ile Asp Ala Val Tyr Glu Ala Pro Gln
  515 520 525
- u Glu Lys Ala Val Phe Phe Ala Gly Asn Glu Tyr Trp Ile Tyr Ser. 530 540
- .a Ser Thr Leu Glu Arg Gly Tyr Pro Lys Pro Leu Thr Ser Leu Gly 550 555 560
- u Pro Pro Asp Val Gln Arg Val Asp Ala Ala Phe Asn Trp Ser Lys 565 570 575
- n Lys Lys Thr Tyr Ile Phe Ala Gly Asp Lys Phe Trp Arg Tyr Asn 580 585 590
- u Val Lys Lys Met Asp Pro Gly Phe Pro Lys Leu Ile Ala Asp 595 600 605
- a Trp Asn Ala Ile Pro Asp Asn Leu Asp Ala Val Val Asp Leu Gln 610 615 620
- y Gly Gly His Ser Tyr Phe Phe Lys Gly Ala Tyr Tyr Leu Lys Leu 5 630 640
- u Asn Gln Ser Leu Lys Ser Val Lys Phe Gly Ser Ile Lys Ser Asp 645 650 655
- p Leu Gly Cys 660
- 10> 174
- 11> 245
- 12> PRT
- 13> Homo sapiens
- 00> 174
- t Asp Lys Asn Glu Leu Val Gln Lys Ala Lys Leu Ala Glu Gln Ala 5 10 15

eolf-seql-S000001.txt
.u Arg Tyr Asp Asp Met Ala Ala Cys Met Lys Ser Val Thr Glu Gln
20 25 30

- .y Ala Glu Leu Ser Asn Glu Glu Arg Asn Leu Leu Ser Val Ala Tyr 35 40 45
- 's Asn Val Val Gly Ala Arg Arg Ser Ser Trp Arg Val Val Ser Ser 50 55 60
- e Glu Gln Lys Thr Glu Gly Ala Glu Lys Lys Gln Gln Met Ala Arg 70 75 80
- u Tyr Arg Glu Lys Ile Glu Thr Glu Leu Arg Asp Ile Cys Asn Asp 85 90 95
- :l Leu Ser Leu Leu Glu Lys Phe Leu Ile Pro Asn Ala Ser Gln Ala 100 105 110
- u Ser Lys Val Phe Tyr Leu Lys Met Lys Gly Asp Tyr Tyr Arg Tyr 115 120 125
- u Ala Glu Val Ala Ala Gly Asp Asp Lys Lys Gly Ile Val Asp Gln 130 135 140
- r Gln Gln Ala Tyr Gln Glu Ala Phe Glu Ile Ser Lys Lys Glu Met 5 150 155 160
- n Pro Thr His Pro Ile Arg Leu Gly Leu Ala Leu Asn Phe Ser Val 165 170 175
- e Tyr Tyr Glu Ile Leu Asn Ser Pro Glu Lys Ala Cys Ser Leu Ala 180 185 190
- s Thr Ala Phe Asp Glu Ala Ile Ala Glu Leu Asp Thr Leu Ser Glu 195 200 205
- u Ser Tyr Lys Asp Ser Thr Leu Ile Met Gln Leu Leu Arg Asp Asn 210 215 220
- u Thr Leu Trp Thr Ser Asp Thr Gln Gly Asp Glu Ala Glu Ala Gly 5 230 235 240

## eolf-seql-S000001.txt

u Gly Gly Glu Asn. 245

110> 175

111> 173

!12> PRT

:13> Homo sapiens

100> 175

- et Ser Thr Met Gly Asn Glu Ala Ser Tyr Pro Ala Glu Met Cys Ser 5 10 15
- s Phe Asp Asn Asp Glu Ile Lys Arg Leu Gly Arg Arg Phe Lys Lys 20 25 30
- u Asp Leu Asp Lys Ser Gly Ser Leu Ser Val Glu Glu Phe Met Ser 35 40 45
- u Pro Glu Leu Arg His Asn Pro Leu Val Arg Arg Val Ile Asp Val 50 55 60
- e Asp Thr Asp Gly Asp Gly Glu Val Asp Phe Lys Glu Phe Ile Leu 70 75 80
- y Thr Ser Gln Phe Ser Val Lys Gly Asp Glu Glu Gln Lys Leu Arg 85 90 95
- y Glu Leu Phe Gln Val Leu Lys Met Met Val Gly Asn Asn Leu Thr 115 120 125
- p Trp Gln Leu Gln Gln Leu Val Asp Lys Thr Ile Ile Ile Leu Asp 130 135 140
- s Asp Gly Asp Gly Lys Ile Ser Phe Glu Glu Phe Ser Ala Val Val 5 150 155 160
- g Asp Leu Glu Ile His Lys Lys Leu Val Leu Ile Val 165 170

- ?10> 176
- 211> 907
- 112> PRT
- :13> Homo sapiens
- 100> 176
- $_{2}$ t Thr Ala Val His Ala Gly Asn Ile Asn Phe Lys Trp Asp Pro Lys 5 10 15
- er Leu Glu Ile Arg Thr Leu Ala Val Glu Arg Leu Leu Glu Pro Leu 20 25 30
- tl Thr Gln Val Thr Thr Leu Val Asn Thr Asn Ser Lys Gly Pro Ser 35 40 45
- n Lys Lys Arg Gly Arg Ser Lys Lys Ala His Val Leu Ala Ala Ser 50 55 60
- .1 Glu Gln Ala Thr Glu Asn Phe Leu Glu Lys Gly Asp Lys Ile Ala 70 75 80
- s Glu Ser Gln Phe Leu Lys Glu Glu Leu Val Val Ala Val Glu Asp 85 90 95
- l Arg Lys Gln Gly Asp Leu Met Lys Ala Ala Ala Gly Glu Phe Ala 100 105 110
- p Asp Pro Cys Ser Ser Val Lys Arg Gly Asn Met Val Arg Ala Ala 115 120 . 125
- g Ala Leu Leu Ser Ala Val Thr Arg Leu Leu Ile Leu Ala Asp Met 130 135 140
- a Asp Val Tyr Lys Leu Leu Val Gln Leu Lys Val Val Glu Asp Gly 150 155 160
- e Leu Lys Leu Arg Asn Ala Gly Asn Glu Gln Asp Leu Gly Asn Gln 165 170 175
- r Lys Ala Leu Lys Pro Glu Val Asp Lys Leu Asn Ile Met Ala Ala 180 185 190

- ys Arg Gln Glu Leu Lys Asp Val Gly His Arg Asp Gln Met Ala 195 200 205
- la Ala Arg Gly Ile Leu Gln Ser Asn Val Pro Ile Leu Tyr Thr Ala 210 215 220
- er Gln Ala Cys Leu Gln His Pro Asp Val Ala Ala Tyr Lys Ala Asn 25 230 235 240
- rg Asp Leu Ile Tyr Lys Gln Leu Gln Gln Ala Val Thr Gly Ile Ser 245 250 255
- 3n Ala Ala Gln Ala Thr Ala Ser Asp Asp Ala Ser Gln His Gln Gly 260 265 270
- -y Gly Gly Glu Leu Ala Tyr Ala Leu Asn Asn Phe Asp Lys Gln 275 280 285
- .e Ile Val Asp Pro Leu Ser Phe Ser Glu Glu Arg Phe Arg Pro Ser 290 295 300
- eu Glu Glu Arg Leu Glu Ser Ile Ile Ser Gly Ala Ala Leu Met Ala 15 310 315 320
- p Ser Ser Cys Thr Arg Asp Asp Arg Arg Glu Arg Ile Val Ala Glu 325 330 335
- 's Asn Ala Val Arg Gln Ala Cys Arg Thr Cys Val Ser Glu Tyr Met 340 345 350
- y Asn Ala Gly Arg Lys Glu Arg Ser Asp Ala Leu Asn Ser Ala Ile 355 360 365
- p Lys Met Thr Lys Lys Thr Arg Asp Leu Arg Arg Gln Leu Arg Lys 370 380
- a Val Met Asp His Val Ser Asp Ser Phe Leu Glu Thr Asn Val Pro 5 390 395 400
- u Leu Val Leu Ile Glu Ala Ala Lys Asn Gly Asn Glu Lys Glu Val 405 410 415

- % Glu Tyr Ala Gln Val Phe Arg Glu His Ala Asn Lys Leu Ile Glu 420 425 430
- al Ala Asn Leu Ala Cys Ser Ile Ser Asn Asn Glu Glu Gly Val Lys 435 440 445
- $^{3}$ u Val Arg Met Ser Ala Ser Gln Leu Glu Ala Gly Cys Pro Gln Val  $^{450}$   $^{460}$
- le Asn Ala Ala Thr Trp Ala Leu Ala Pro Lys Pro Gln Ser Lys Leu 55 470 475 480
- a Gln Glu Asn Met Asp Leu Phe Lys Glu Gln Trp Glu Lys Gln Val 485 490 495
- $^{\circ}$  Yal Leu Thr Asp Ala Val Asp Asp Ile Thr Ser Ile Asp Asp Phe 500 505 510
- eu Ala Val Ser Glu Asn His Ile Leu Glu Asp Val Asn Lys Cys Val 515 520 525
- e Ala Leu Gln Glu Lys Asp Val Asp Gly Leu Asp Arg Thr Ala Gly 530 540
- a Ile Arg Gly Arg Ala Ala Arg Val Ile His Val Val Thr Ser Glu 550 555 560
- t Asp Asn Tyr Glu Pro Gly Val Tyr Thr Glu Lys Val Leu Glu Ala 565 570 575
- r Lys Leu Ser Asn Thr Val Met Pro Arg Phe Thr Glu Gln Val 580 585 590
- u Ala Ala Val Glu Ala Leu Ser Ser Asp Pro Ala Gln Pro Met Asp 595 600 605
- u Asn Glu Phe Ile Asp Ala Ser Arg Leu Val Tyr Asp Gly Ile Arg 610 615 620
- p Ile Arg Lys Ala Val Leu Met Ile Arg Thr Pro Glu Glu Leu Asp Page 336

5		eolf-seql-S000001.txt 630 635										640			
р	Ser	Asp	Phe	Glu 645	Thr	Glu	Asp	Phe	Asp 650	Val	Arg	Ser	Glu	Thr 655	Ser
1	Gln	Thr	Glu 660	Asp	Asp	Gln	Leu	Ile 665	Ala	Gly	Gln	Ser	Ala 670	Arg	Ala
е	Met	Ala 675	Gln	Leu	Pro	Gln	Glu 680	Gln	Lys	Ala	Lys	Ile 685	Arg	Glu	Gln
1	Ala 690	Ser	Phe	Gln	Glu	Glu 695	Lys	Ser	Lys	Leu	Asp 700	Ala	Glu	Val	Ser
s 5	Trp	Asp	Asp	Ser	Gly 710	Asn	Asp	Ile	Ile	Val 715	Leu	Ala	Lys	Gln	Met 720
s	Met	Ile	Met	Met 725	Glu	Met	Thr	Asp	Phe 730	Thr	Arg	Gly	Lys	Gly 735	Pro
u	Lys	Asn	Thr 740	Ser	Asp	Val	Ile	Ser <b>7</b> 45	Ala	Ala	Lys	Lys	Ile 750	Ala	Glu
а	Gly	Ser 755	Arg	Met	Asp	Lys	Leu 760	Gly	Arg	Thr	Ile	Arg 765	Asp	His	Cys
С	Asp 770	Ser	Ala	Cys	Lys	Gln 775	Asp	Leu	Leu	Ala	Tyr 780	Leu	Gln	Arg	Ile
a 5	Leu	Tyr	Cys	His	Gln 790	Leu	Asn	Ile	Cys	Ser 795	Lys	Val	Lys	Ala	Glu 800
1	Gln	Asn	Leu	Gly 805	Gly	Glu	Leu	Val	Val 810	Ser	Gly	Val	Asp	Ser 815	Ala
:	Ser	Leu	Ile 820	Gln	Ala	Ala	Lys	Asn 825	Leu	Met	Asn	Ala	Val 830	Val	Gln
:	Val	Lys 835	Ala	Ser	Tyr	Val	Ala 840	Ser	Thr	Lys	Tyr	Gln 845	Lys	Ser	Gln

- Ly Met Ala Ser Leu Asn Leu Pro Ala Val Ser Met Lys Met Lys Ala 850 855 860
- co Glu Lys Lys Pro Leu Val Lys Arg Glu Lys Gln Asp Glu Thr Gln 870 875 880
- r Lys Ile Lys Arg Ala Ser Gln Lys Lys His Val Asn Pro Val Gln 885 890 895
- a Leu Ser Glu Phe Lys Ala Met Asp Ser Ile
  900 905
- !10> 177
- **!11> 176**
- 12> PRT
- !13> Homo sapiens
- !00> 177
- t Thr Met Cys Ser Gly Ala Arg Leu Ala Leu Leu Val Tyr Gly Ile 5 10 15
- e Met His Ser Ser Val Tyr Ser Ser Pro Ala Ala Ala Gly Leu Arg. 20 25 30
- e Pro Gly Ile Arg Pro Glu Glu Glu Ala Tyr Gly Glu Asp Gly Asn 35 40 45
- O Leu Pro Asp Phe Gly Gly Ser Glu Pro Pro Gly Ala Gly Ser Pro 50 55 60
- a Ser Ala Pro Arg Ala Ala Ala Ala Trp Tyr Arg Pro Ala Gly Arg
  70 75 80
- g Asp Val Ala His Gly Ile Leu Asn Glu Ala Tyr Arg Lys Val Leu 85 90 95
- p Gln Leu Ser Ala Gly Lys His Leu Gln Ser Leu Val Ala Arg Gly 100 105 110
- 1 Gly Gly Ser Leu Gly Gly Gly Ala Gly Asp Asp Ala Glu Pro Leu 115 120 125

- er Lys Arg His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr 130 135 140
- cg Lys Gln Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys 150 155 160
- rg Tyr Lys Gln Arg Val Lys Asn Lys Gly Arg Arg Ile Ala Tyr Leu 165 170 175
- ?10> 178
- ?11> 298
- ?12> PRT
- ?13> Homo sapiens
- 100> 178
- et Ser Leu Tyr Pro Ser Leu Glu Asp Leu Lys Val Asp Lys Val Ile 5 10 15
- .n Ala Gln Thr Ala Phe Ser Ala Asn Pro Ala Asn Pro Ala Ile Leu  $20 \hspace{1cm} 25 \hspace{1cm} 30$
- er Glu Ala Ser Ala Pro Ile Pro His Asp Gly Asn Leu Tyr Pro Arg 35 40 45
- u Tyr Pro Glu Leu Ser Gln Tyr Met Gly Leu Ser Leu Asn Glu Glu 50 55 60
- u Ile Arg Ala Ser Val Ala Val Val Ser Gly Ala Pro Leu Gl<br/>n Gly 70  $\phantom{000}75\phantom{000}$  80
- n Leu Val Ala Arg Pro Ser Ser Ile Asn Tyr Met Val Ala Pro Val 85 90 95
- r Gly Asn Asp Val Gly Ile Arg Arg Ala Glu Ile Lys Gln Gly Ile 100 105 110
- g Glu Val Ile Leu Cys Lys Asp Gln Asp Gly Lys Ile Gly Leu Arg 115 120 125
- u Lys Ser Ile Asp Asn Gly Ile Phe Val Gln Leu Val Gln Ala Asn 130 135 140

eolf-seql-S000001.txt er Pro Ala Ser Leu Val Gly Leu Arg Phe Gly Asp Gln Val Leu Gln 15 150 155 160

- e Asn Gly Glu Asn Cys Ala Gly Trp Ser Ser Asp Lys Ala His Lys 165 170 175.
- l Leu Lys Gln Ala Phe Gly Glu Lys Ile Thr Met Thr Ile Arg Asp 180 185 190
- rg Pro Phe Glu Arg Thr Ile Thr Met His Lys Asp Ser Thr Gly His 195 200 205
- cl Gly Phe Ile Phe Lys Asn Gly Lys Ile Thr Ser Ile Val Lys Asp 210 215 220
- er Ser Ala Ala Arg Asn Gly Leu Leu Thr Glu His Asn Ile Cys Glu 230 235 240
- .e Asn Gly Gln Asn Val Ile Gly Leu Lys Asp Ser Gln Ile Ala Asp 245 250 255
- e Leu Ser Thr Ser Gly Thr Val Val Thr Ile Thr Ile Met Pro Ala 260 265 270
- e Ile Phe Glu His Ile Ile Lys Arg Met Ala Pro Ser Ile Met Lys 275 280 285
- r Leu Met Asp His Thr Ile Pro Glu Val 290 295
- 10> 179
- 11> 1621
- 12> PRT
- 13> Homo sapiens
- 00> 179
- t Ala Lys Ser Gly Gly Cys Gly Ala Gly Ala Gly Val Gly Gly 5 10 15
- n Gly Ala Leu Thr Trp Val Asn Asn Ala Ala Lys Lys Glu Glu Ser 20 25 30

- .u Thr Ala Asn Lys Asn Asp Ser Ser Lys Lys Leu Ser Val Glu Arg
- l Tyr Gln Lys Lys Thr Gln Leu Glu His Ile Leu Leu Arg Pro Asp 50 55 60
- ir Tyr Ile Gly Ser Val Glu Pro Leu Thr Gln Phe Met Trp Val Tyr 70 75 80
- p Glu Asp Val Gly Met Asn Cys Arg Glu Val Thr Phe Val Pro Gly 85 90 95
- ${
  m Su}$  Tyr Lys Ile Phe Asp Glu Ile Leu Val Asn Ala Ala Asp Asn Lys 100 105 110
- n Arg Asp Lys Asn Met Thr Cys Ile Lys Val Ser Ile Asp Pro Glu 115 120 125
- r Asn Ile Ile Ser Ile Trp Asn Asn Gly Lys Gly Ile Pro Val Val 130 135 140
- u His Lys Val Glu Lys Val Tyr Val Pro Ala Leu Ile Phe Gly Gln 5 150 155 160
- u Leu Thr Ser Ser Asn Tyr Asp Asp Glu Lys Lys Val Thr Gly 165 170 175
- y Arg Asn Gly Tyr Gly Ala Lys Leu Cys Asn Ile Phe Ser Thr Lys 180 185 190
- e Thr Val Glu Thr Ala Cys Lys Glu Tyr Lys His Ser Phe Lys Gln 195 200 205
- r Trp Met Asn Asn Met Met Lys Thr Ser Glu Ala Lys Ile Lys His 210 220
- e Asp Gly Glu Asp Tyr Thr Cys Ile Thr Phe Gln Pro Asp Leu Ser 230 235 240
- s Phe Lys Met Glu Lys Leu Asp Lys Asp Ile Val Ala Leu Met Thr 245 250 255

# eolf-seql-S000001.txt

rg Arg Ala Tyr Asp Leu Ala Gly Ser Cys Arg Gly Val Lys Val Met 260 265 270

- ne Asn Gly Lys Lys Leu Pro Val Asn Gly Phe Arg Ser Tyr Val Asp 275 280 285
- 3u Tyr Val Lys Asp Lys Leu Asp Glu Thr Gly Val Ala Leu Lys Val 290 295 300
- Le His Glu Leu Ala Asn Glu Arg Trp Asp Val Cys Leu Thr Leu Ser 310 315 320
- u Lys Gly Phe Gln Gln Ile Ser Phe Val Asn Ser Ile Ala Thr Thr 325 330 335
- 's Gly Gly Arg His Val Asp Tyr Val Val Asp Gln Val Val Gly Lys 340 345 350
- u Ile Glu Val Val Lys Lys Asn Lys Ala Gly Val Ser Val Lys 355 360 365
- o Phe Gln Val Lys Asn His Ile Trp Val Phe Ile Asn Cys Leu Ile 370 380
- u Asn Pro Thr Phe Asp Ser Gln Thr Lys Glu Asn Met Thr Leu Gln 390 395 400
- O Lys Ser Phe Gly Ser Lys Cys Gln Leu Ser Glu Lys Phe Phe Lys 405 410 415
- a Ala Ser Asn Cys Gly Ile Val Glu Ser Ile Leu Asn Trp Val Lys 420 425 430
- e Lys Ala Gln Thr Gln Leu Asn Lys Lys Cys Ser Ser Val Lys Tyr 435 440 445
- r Lys Ile Lys Gly Ile Pro Lys Leu Asp Asp Ala Asn Asp Ala Gly 450 455 460
- y Lys His Ser Leu Glu Cys Thr Leu Ile Leu Thr Glu Gly Asp Ser 5 470 475 480

- .a Lys Ser Leu Ala Val Ser Gly Leu Gly Val Ile Gly Arg Asp Arg 485 490 495
- r Gly Val Phe Pro Leu Arg Gly Lys Ile Leu Asn Val Arg Glu Ala 500 505 510
- er His Lys Gln Ile Met Glu Asn Ala Glu Ile Asn Asn Ile Ile Lys 515 520 525
- e Val Gly Leu Gln Tyr Lys Lys Ser Tyr Asp Asp Ala Glu Ser Leu 530 535 540
- 's Thr Leu Arg Tyr Gly Lys Ile Met Ile Met Thr Asp Gln Asp Gln 5 55 560
- p Gly Ser His Ile Lys Gly Leu Leu Ile Asn Phe Ile His His Asn 565 570 575
- p Pro Ser Leu Leu Lys His Gly Phe Leu Glu Glu Phe Ile Thr Pro 580 585 590
- e Val Lys Ala Ser Lys Asn Lys Gln Glu Leu Ser Phe Tyr Ser Ile 595 600 605
- o Glu Phe Asp Glu Trp Lys Lys His Ile Glu Asn Gln Lys Ala Trp 610 620
- s Ile Lys Tyr Tyr Lys Gly Leu Gly Thr Ser Thr Ala Lys Glu Ala 630 635 640
- s Glu Tyr Phe Ala Asp Met Glu Arg His Arg Ile Leu Phe Arg Tyr 645 650 655
- a Gly Pro Glu Asp Asp Ala Ala Ile Thr Leu Ala Phe Ser Lys Lys 660 665 670
- s Ile Asp Asp Arg Lys Glu Trp Leu Thr Asn Phe Met Glu Asp Arg 675 680 685
- g Gln Arg Arg Leu His Gly Leu Pro Glu Gln Phe Leu Tyr Gly Thr Page 343

eolf-seql-S000001.txt
690 695 700

la Thr Lys His Leu Thr Tyr Asn Asp Phe Ile Asn Lys Glu Leu Ile 710 715 720

- $_{
  m 20}$  Phe Ser Asn Ser Asp Asn Glu Arg Ser Ile Pro Ser Leu Val Asp 725 730 735
- ly Phe Lys Pro Gly Gln Arg Lys Val Leu Phe Thr Cys Phe Lys Arg 740 745 750
- 3n Asp Lys Arg Glu Val Lys Val Ala Gln Leu Ala Gly Ser Val Ala 755 760 765
- lu Met Ser Ala Tyr His His Gly Glu Gln Ala Leu Met Met Thr Ile
  770 780
- al Asn Leu Ala Gln Asn Phe Val Gly Ser Asn Asn Ile Asn Leu Leu 35 790 795 800
- .n Pro Ile Gly Gln Phe Gly Thr Arg Leu His Gly Gly Lys Asp Ala 805 810 815
- .a Ser Pro Arg Tyr Ile Phe Thr Met Leu Ser Thr Leu Ala Arg Leu 820 825 830
- eu Phe Pro Ala Val Asp Asp Asn Leu Leu Lys Phe Leu Tyr Asp Asp 835 840 845
- n Gln Arg Val Glu Pro Glu Trp Tyr Ile Pro Ile Ile Pro Met Val 850 855 860
- $rac{\mathrm{Su}}{\mathrm{S}}$  Ile Asn Gly Ala Glu Gly Ile Gly Thr Gly Trp Ala Cys Lys Leu 870 875 875
- o Asn Tyr Asp Ala Arg Glu Ile Val Asn Asn Val Arg Arg Met Leu 885 890 895
- p Gly Leu Asp Pro His Pro Met Leu Pro Asn Tyr Lys Asn Phe Lys 900 905 910

eolf-seql-S000001.txt ly Thr Ile Gln Glu Leu Gly Gln Asn Gln Tyr Ala Val Ser Gly Glu 915 920 925

- le Phe Val Val Asp Arg Asn Thr Val Glu Ile Thr Glu Leu Pro Val 930 935 940
- rg Thr Trp Thr Gln Val Tyr Lys Glu Gln Val Leu Glu Pro Met Leu 15 950 955 960
- on Gly Thr Asp Lys Thr Pro Ala Leu Ile Ser Asp Tyr Lys Glu Tyr 965 970 975
- .s Thr Asp Thr Thr Val Lys Phe Val Val Lys Met Thr Glu Glu Lys  $980 \hspace{1.5cm} 985 \hspace{1.5cm} 990$
- eu Ala Gln Ala Glu Ala Ala Gly Leu His Lys Val Phe Lys Leu Gln 995 1000 1005
- r Thr Leu Thr Cys Asn Ser Met Val Leu Phe Asp His Met Gly 1010 1020
- 's Leu Lys Lys Tyr Glu Thr Val Gln Asp Ile Leu Lys Glu Phe 1025 1035
- Leu Asp Leu Arg Leu Ser Tyr Tyr Gly Leu Arg Lys Glu Trp Leu 1040 1050
- 1 Gly Met Leu Gly Ala Glu Ser Thr Lys Leu Asn Asn Gln Ala 1055 1060 1065
- g Phe Ile Leu Glu Lys Ile Gln Gly Lys Ile Thr Ile Glu Asn 1070 1075 1080
- g Ser Lys Lys Asp Leu Ile Gln Met Leu Val Gln Arg Gly Tyr 1085 1090 1095
- u Ser Asp Pro Val Lys Ala Trp Lys Glu Ala Gln Glu Lys Ala 1100 1105 1110
- a Glu Glu Asp Glu Thr Gln Asn Gln His Asp Asp Ser Ser Ser 1115 1120 1125

### eolf-segl-S000001.txt

SP Ser Gly Thr Pro Ser Gly Pro Asp Phe Asn Tyr Ile Leu Asn 1130 1135 1140

- et Ser Leu Trp Ser Leu Thr Lys Glu Lys Val Glu Glu Leu Ile 1145 1150 1155
- rs Gln Arg Asp Ala Lys Gly Arg Glu Val Asn Asp Leu Lys Arg 1160 1170
- 's Ser Pro Ser Asp Leu Trp Lys Glu Asp Leu Ala Ala Phe Val 1175 1180 1185
- u Glu Leu Asp Lys Val Glu Ser Gln Glu Arg Glu Asp Val Leu 1190 1200
- .a Gly. Met Ser Gly Lys Ala Ile Lys Gly Lys Val .Gly Lys Pro 1205 1215
- 's Val Lys Lys Leu Gln Leu Glu Glu Thr Met Pro Ser Pro Tyr 1220 1230
- Y Arg Arg Ile Ile Pro Glu Ile Thr Ala Met Lys Ala Asp Ala 1235 1240 1245
- r Lys Lys Leu Leu Lys Lys Lys Gly Asp Leu Asp Thr Ala 1250 1260
- a Val Lys Val Glu Phe Asp Glu Glu Phe Ser Gly Ala Pro Val 1265 1270 1275
- u Gly Ala Gly Glu Glu Ala Leu Thr Pro Ser Val Pro Ile Asn 1280 1285 1290
- s Gly Pro Lys Pro Lys Arg Glu Lys Lys Glu Pro Gly Thr Arg 1295 1300 1305
- l Arg Lys Thr Pro Thr Ser Ser Gly Lys Pro Ser Ala Lys Lys 1310 1315 1320
- l Lys Lys Arg Asn Pro Trp Ser Asp Asp Glu Ser Lys Ser Glu 1325 1330 1335

- er Asp Leu Glu Glu Thr Glu Pro Val Val Ile Pro Arg Asp Ser 1340 1350
- u Leu Arg Arg Ala Ala Ala Glu Arg Pro Lys Tyr Thr Phe Asp 1355 1360 1365
- in Asn Asp Leu Glu Glu Leu Lys Val Lys Ala Ser Pro Ile Thr 1385 1390 1395
- n Asp Gly Glu Asp Glu Phe Val Pro Ser Asp Gly Leu Asp Lys 1400 1410
- p Glu Tyr Thr Phe Ser Pro Gly Lys Ser Lys Ala Thr Pro Glu 1415 1420 1425
- s Ser Leu His Asp Lys Lys Ser Gln Asp Phe Gly Asn Leu Phe 1430 1440
- r Phe Pro Ser Tyr Ser Gln Lys Ser Glu Asp Asp Ser Ala Lys 1445 1450 1455
- e Asp Ser Asn Glu Glu Asp Ser Ala Ser Val Phe Ser Pro Ser 1460 1465 1470
- e Gly Leu Lys Gln Thr Asp Lys Val Pro Ser Lys Thr Val Ala 1475 \$1480\$
- a Lys Lys Gly Lys Pro Ser Ser Asp Thr Val Pro Lys Pro Lys 1490 1495 1500
- g Ala Pro Lys Gln Lys Lys Val Val Glu Ala Val Asn Ser Asp 1505 1510 1515
- r Asp Ser Glu Phe Gly Ile Pro Lys Lys Thr Thr Thr Pro Lys 1520 1530
- y Lys Gly Arg Gly Ala Lys Lys Arg Lys Ala Ser Gly Ser Glu Page 347

eolf-seql-S000001.txt 1535 1540 1545

sn Glu Gly Asp Tyr Asn Pro Gly Arg Lys Thr Ser Lys Thr Thr 1550 1555

- er Lys Lys Pro Lys Lys Thr Ser Phe Asp Gln Asp Ser Asp Val 1570
- sp Ile Phe Pro Ser Asp Phe Pro Thr Glu Pro Pro Ser Leu Pro 1580 1585 1590
- g Thr Gly Arg Ala Arg Lys Glu Val Lys Tyr Phe Ala Glu Ser 1595 1600 1605
- p Glu Glu Asp Asp Val Asp Phe Ala Met Phe Asn 1610 1615

10> 180

!11> 228 !12> PRT

:13> Homo sapiens

:00> 180

- t Leu Ser Arg Cys Arg Ser Gly Leu Leu His Val Leu Gly Leu Ser
- e Leu Leu Gln Thr Arg Arg Pro Ile Leu Leu Cys Ser Pro Arg Leu 20
- t Lys Pro Leu Val Val Phe Val Leu Gly Gly Pro Gly Ala Gly Lys 35 45
- y Thr Gln Cys Ala Arg Ile Val Glu Lys Tyr Gly Tyr Thr His Leu 50 55
- r Ala Gly Glu Leu Leu Arg Asp Glu Arg Lys Asn Pro Asp Ser Gln 70 75
- r Gly Glu Leu Ile Glu Lys Tyr Ile Lys Glu Gly Lys Ile Val Pro 90 .
- l Glu Ile Thr Ile Ser Leu Leu Lys Arg Glu Met Asp Gln Thr Met Page 348

110

eolf-seql-S000001.txt 100 105

a Ala Asn Ala Gln Lys Asn Lys Phe Leu Ile Asp Gly Phe Pro Arg

- n Gln Asp Asn Leu Gln Gly Trp Asn Lys Thr Met Asp Gly Lys Ala 130 135 140
- p Val Ser Phe Val Leu Phe Phe Asp Cys Asn Asn Glu Ile Cys Ile 5 150 155 160
- u Arg Cys Leu Glu Arg Gly Lys Ser Ser Gly Arg Ser Asp Asp Asn 165 170 175
- g Glu Ser Leu Glu Lys Arg Ile Gln Thr Tyr Leu Gln Ser Thr Lys 180 185 190
- o Ile Ile Asp Leu Tyr Glu Glu Met Gly Lys Val Lys Lys Ile Asp 195 200 205
- a Ser Lys Ser Val Asp Glu Val Phe Asp Glu Val Val Gln Ile Phe 210 215 220

p Lys Glu Gly 5

10> 181

11> 268

12> PRT

13> Homo sapiens

00> 181

- t Val Leu Glu Ser Thr Met Val Cys Val Asp Asn Ser Glu Tyr Met 5 10 15
- g Asn Gly Asp Phe Leu Pro Thr Arg Leu Gln Ala Gln Gln Asp Ala 20 25 30
- l Asn Ile Val Cys His Ser Lys Thr Arg Ser Asn Pro Glu Asn Asn 35 40 45
- l Gly Leu Ile Thr Leu Ala Asn Asp Cys Glu Val Leu Thr Thr Leu Page 349

eolf-seql-S000001.txt
50 55 60

- r Pro Asp Thr Gly Arg Ile Leu Ser Lys Leu His Thr Val Gln Pro 70 75 80
- ys Gly Lys Ile Thr Phe Cys Thr Gly Ile Arg Val Ala His Leu Ala 85 90 95
- eu Lys His Arg Gln Gly Lys Asn His Lys Met Arg Ile Ile Ala Phe 100 105 110
- tl Gly Ser Pro Val Glu Asp Asn Glu Lys Asp Leu Val Lys Leu Ala 115 120 125
- 's Arg Leu Lys Lys Glu Lys Val Asn Val Asp Ile Ile Asn Phe Gly 130 135 140
- u Glu Glu Val Asn Thr Glu Lys Leu Thr Ala Phe Val Asn Thr Leu 150 155 160
- n Gly Lys Asp Gly Thr Gly Ser His Leu Val Thr Val Pro Pro Gly 165 170 175
- o Ser Leu Ala Asp Ala Leu Ile Ser Ser Pro Ile Leu Ala Gly Glu 180 185 190
- y Gly Ala Met Leu Gly Leu Gly Ala Ser Asp Phe Glu Phe Gly Val 195 200 205
- p Pro Ser Ala Asp Pro Glu Leu Ala Leu Ala Leu Arg Val Ser Met 210 215 220
- u Glu Gln Arg Gln Arg Gln Glu Glu Ala Arg Arg Ala Ala Ala 5 230 235 240
- a Ser Ala Ala Glu Ala Gly Ile Ala Thr Thr Gly Thr Glu Gly Glu 245 250 255
- g Gly Gly Ile Arg Ser Pro Gly Thr Ala Gly Cys 260 265

Page 350

eolf-seql-S000001.txt

- !10> 182
- !11> 162
- 12> PRT
- :13> Homo sapiens
- :00> 182
- t Lys Glu Thr Ile Met Asn Gln Glu Lys Leu Ala Lys Leu Gln Ala 5 .10 15
- .n Val Arg Ile Gly Gly Lys Gly Thr Ala Arg Arg Lys Lys Val 20 25 30
- .l His Arg Thr Ala Thr Ala Asp Asp Lys Lys Leu Gln Phe Ser Leu 35 40 45
- s Lys Leu Gly Val Asn Asn Ile Ser Gly Ile Glu Glu Val Asn Met 50 55 60
- e Thr Asn Gln Gly Thr Val Ile His Phe Asn Asn Pro Lys Val Gln
  70 75 80
- a Ser Leu Ala Ala Asn Thr Phe Thr Ile Thr Gly His Ala Glu Thr 85 90 95
- s Gln Leu Thr Glu Met Leu Pro Ser Ile Leu Asn Gln Leu Gly Ala 100 105 110
- p Ser Leu Thr Ser Leu Arg Arg Leu Ala Glu Ala Leu Pro Lys Gln 115 120 125
- r Val Asp Gly Lys Ala Pro Leu Ala Thr Gly Glu Asp Asp Asp Asp 130
- u Val Pro Asp Leu Val Glu Asn Phe Asp Glu Ala Ser Lys Asn Glu 150 155 160
- a Asn
- 10> 183
- 11> 193
- 12> PRT
- 13> Homo sapiens

Page 351

# eolf-seql-S000001.txt

100> 183

- et Ala Ala Ile Arg Lys Leu Val Ile Val Gly Asp Gly Ala Cys
  5 10 15
- .y Lys Thr Cys Leu Leu Ile Val Phe Ser Lys Asp Gln Phe Pro Glu 20 25 30
- tl Tyr Val Pro Thr Val Phe Glu Asn Tyr Val Ala Asp Ile Glu Val 35 40 45
- P Gly Lys Gln Val Glu Leu Ala Leu Trp Asp Thr Ala Gly Gln Glu 50 60
- :p Tyr Asp Arg Leu Arg Pro Leu Ser Tyr Pro Asp Thr Asp Val Ile 70 75 80
- u Met Cys Phe Ser Ile Asp Ser Pro Asp Ser Leu Glu Asn Ile Pro 85 90 95
- u Lys Trp Thr Pro Glu Val Lys His Phe Cys Pro Asn Val Pro Ile 100 105 110
- e Leu Val Gly Asn Lys Lys Asp Leu Arg Asn Asp Glu His Thr Arg 115 120 125
- g Glu Leu Ala Lys Met Lys Gln Glu Pro Val Lys Pro Glu Glu Gly 130 140
- g Asp Met Ala Asn Arg Ile Gly Ala Phe Gly Tyr Met Glu Cys Ser 5 150 155 160
- a Lys Thr Lys Asp Gly Val Arg Glu Val Phe Glu Met Ala Thr Arg 165 170 175
- a Ala Leu Gln Ala Arg Arg Gly Lys Lys Lys Ser Gly Cys Leu Val 180 185 190

u

- 10> 184
- :11> 334
- :12> PRT
- :13> Homo sapiens
- 00> 184
- t Ala Thr Leu Lys Glu Lys Leu Ile Ala Pro Val Ala Glu Glu Glu 5 10 15
- a Thr Val Pro Asn Asn Lys Ile Thr Val Val Gly Val Gly Gln Val 20 25 30
- y Met Ala Cys Ala Ile Ser Ile Leu Gly Lys Ser Leu Ala Asp Glu 35 40 45
- u Ala Leu Val Asp Val Leu Glu Asp Lys Leu Lys Gly Glu Met Met 50 55 60
- p Leu Gln His Gly Ser Leu Phe Leu Gln Thr Pro Lys Ile Val Ala 70 75 80
- p Lys Asp Tyr Ser Val Thr Ala Asn Ser Lys Ile Val Val Thr 85 90 95
- a Gly Val Arg Gln Glu Gly Glu Ser Arg Leu Asn Leu Val Gln 100 105 110
- g Asn Val Asn Val Phe Lys Phe Ile Ile Pro Gln Ile Val Lys Tyr 115 120 125
- r Pro Asp Cys Ile Ile Ile Val Val Ser Asn Pro Val Asp Ile Leu 130 135 140
- r Tyr Val Thr Trp Lys Leu Ser Gly Leu Pro Lys His Arg Val Ile 5 150 155 160
- y Ser Gly Cys Asn Leu Asp Ser Ala Arg Phe Arg Tyr Leu Met Ala 165 170 175
- ı Lys Leu Gly Ile His Pro Ser Ser Cys His Gly Trp Ile Leu Gly 180 185 190

- lu His Gly Asp Ser Ser Val Ala Val Trp Ser Gly Val Asn Val Ala 195 200 205
- ly Val Ser Leu Gln Glu Leu Asn Pro Glu Met Gly Thr Asp Asn Asp 210 215 220
- er Glu Asn Trp Lys Glu Val His Lys Met Val Val Glu Ser Ala Tyr 230 235 240
- lu Val Ile Lys Leu Lys Gly Tyr Thr Asn Trp Ala Ile Gly Leu Ser 245 250 255
- % Ala Asp Leu Ile Glu Ser Met Leu Lys Asn Leu Ser Arg Ile His 260 265 270
- co Val Ser Thr Met Val Lys Gly Met Tyr Gly Ile Glu Asn Glu Val 275 280 285
- Leu Ser Leu Pro Cys Ile Leu Asn Ala Arg Gly Leu Thr Ser Val 290 295 300
- .e Asn Gln Lys Leu Lys Asp Asp Glu Val Ala Gln Leu Lys Lys Ser 310 315 320
- .a Asp Thr Leu Trp Asp Ile Gln Lys Asp Leu Lys Asp Leu 325 330
- :10> 185
- 11> 343
- 12> PRT
- 13> Homo sapiens
- 00> 185
- t Trp Pro Asn Gly Ser Ser Leu Gly Pro Cys Phe Arg Pro Thr Asn 5 10 15
- e Thr Leu Glu Glu Arg Arg Leu Ile Ala Ser Pro Trp Phe Ala Ala 20 25 30
- r Phe Cys Val Val Gly Leu Ala Ser Asn Leu Leu Ala Leu Ser Val 35 40 45

eolf-seql-S000001.txt Bu Ala Gly Ala Arg Gln Gly Gly Ser His Thr Arg Ser Ser Phe Leu 50 55 60

- or Phe Leu Cys Gly Leu Val Leu Thr Asp Phe Leu Gly Leu Leu Val 70 75 80
- ar Gly Thr Ile Val Val Ser Gln His Ala Ala Leu Phe Glu Trp His 85 90 95
- la Val Asp Pro Gly Cys Arg Leu Cys Arg Phe Met Gly Val Val Met 100 105 110
- le Phe Phe Gly Leu Ser Pro Leu Leu Leu Gly Ala Ala Met Ala Ser 115 120 125
- lu Arg Tyr Leu Gly Ile Thr Arg Pro Phe Ser Arg Pro Ala Val Ala 130 140
- er Gln Arg Arg Ala Trp Ala Thr Val Gly Leu Val Trp Ala Ala Ala 150 155 160
- eu Ala Leu Gly Leu Leu Pro Leu Leu Gly Val Gly Arg Tyr Thr Val 165 170 175
- n Tyr Pro Gly Ser Trp Cys Phe Leu Thr Leu Gly Ala Glu Ser Gly 180 185 190
- sp Val Ala Phe Gly Leu Leu Phe Ser Met Leu Gly Gly Leu Ser Val 195 200 205
- .y Leu Ser Phe Leu Leu Asn Thr Val Ser Val Ala Thr Leu Cys His 210 215 220
- 1 Tyr His Gly Gln Glu Ala Ala Gln Gln Arg Pro Arg Asp Ser Glu 230 235 240
- l Glu Met Met Ala Gln Leu Leu Gly Ile Met Val Val Ala Ser Val 245 250 255
- s Trp Leu Pro Leu Leu Val Phe Ile Ala Gln Thr Val Leu Arg Asn 260 265 270

# eolf-seql-S000001.txt

co Pro Ala Met Ser Pro Ala Gly Gln Leu Ser Arg Thr Thr Glu Lys 275 280 285

- tu Leu Leu Ile Tyr Leu Arg Val Ala Thr Trp Asn Gln Ile Leu Asp 290 295 300
- to Trp Val Tyr Ile Leu Phe Arg Arg Ala Val Leu Arg Arg Leu Gln 310 315 320
- to Arg Leu Ser Thr Arg Pro Arg Ser Leu Ser Leu Gln Pro Gln Leu 325 330 335
- ir Gln Arg Ser Gly Leu Gln 340

?10> 186

!11> 477

!12> PRT

!13> Homo sapiens

100> 186

- t Ala Asn Met Gln Gly Leu Val Glu Arg Leu Glu Arg Ala Val Ser 5 10 15
- g Leu Glu Ser Leu Ser Ala Glu Ser His Arg Pro Pro Gly Asn Cys 20 25 30
- y Glu Val Asn Gly Val Ile Ala Gly Val Ala Pro Ser Val Glu Ala 35 40 45
- e Asp Lys Leu Met Asp Ser Met Val Ala Glu Phe Leu Lys Asn Ser 50 55 60
- g Ile Leu Ala Gly Asp Val Glu Thr His Ala Glu Met Val His Ser 70 75 80
- a Phe Gln Ala Gln Arg Ala Phe Leu Leu Met Ala Ser Gln Tyr Gln 85 90 95
- n Pro His Glu Asn Asp Val Ala Ala Leu Leu Lys Pro Ile Ser Glu 100 105 110

### eolf-seq1-S000001.txt

- /s Ile Gln Glu Ile Gln Thr Phe Arg Glu Arg Asn Arg Gly Ser Asn 115 120 125
- et Phe Asn His Leu Ser Ala Val Ser Glu Ser Ile Pro Ala Leu Gly 130 135 140
- :p Ile Ala Val Ser Pro Lys Pro Gly Pro Tyr Val Lys Glu Met Asn
  150 150 155 160
- p Ala Ala Thr Phe Tyr Thr Asn Arg Val Leu Lys Asp Tyr Lys His 165 170 175
- er Asp Leu Arg His Val Asp Trp Val Lys Ser Tyr Leu Asn Ile Trp 180 185 190
- er Glu Leu Gln Ala Tyr Ile Lys Glu His His Thr Thr Gly Leu Thr 195 200 205
- p Ser Lys Thr Gly Pro Val Ala Ser Thr Val Ser Ala Phe Ser Val 210 215 220
- u Ser Ser Gly Pro Gly Leu Pro Pro Pro Pro Pro Pro Pro Pro Pro 230 235 240
- o Gly Pro Pro Leu Phe Glu Asn Glu Gly Lys Lys Glu Glu Ser 245 250 255
- r Pro Ser Arg Ser Ala Leu Phe Ala Gln Leu Asn Gln Gly Glu Ala 260 270
- e Thr Lys Gly Leu Arg His Val Thr Asp Asp Gln Lys Thr Tyr Lys 275 280 285
- n Pro Ser Leu Arg Ala Gln Gly Gly Gln Thr Gln Ser Pro Thr Lys 290 295 300
- r His Thr Pro Ser Pro Thr Ser Pro Lys Ser Tyr Pro Ser Gln Lys 5 310 315 320
- s Ala Pro Val Leu Glu Leu Glu Gly Lys Lys Trp Arg Val Glu Tyr 325 330 335

Page 357

#### eolf-seql-S000001.txt

- In Glu Asp Arg Asn Asp Leu Val Ile Ser Glu Thr Glu Leu Lys Gln 340 345 350
- al Ala Tyr Ile Phe Lys Cys Glu Lys Ser Thr Ile Gln Ile Lys Gly 355 360 365
- /s Val Asn Ser Ile Ile Ile Asp Asn Cys Lys Leu Gly Leu Val 370 380
- 1e Asp Asn Val Val Gly Ile Val Glu Val Ile Asn Ser Gln Asp Ile 390 395 400
- .n Ile Gln Val Met Gly Arg Val Pro Thr Ile Ser Ile Asn Lys Thr 405 410 415
- u Gly Cys His Ile Tyr Leu Ser Glu Asp Ala Leu Asp Cys Glu Ile 420 425 430
- el Ser Ala Lys Ser Ser Glu Met Asn Ile Leu Ile Pro Gln Asp Gly 435 440 445
- p Tyr Arg Glu Phe Pro Ile Pro Glu Gln Phe Lys Thr Ala Trp Asp 450 455 460
- y Ser Lys Leu Ile Thr Glu Pro Ala Glu Ile Met Ala 5 470 475
- 10> 187
- 11> 309
- 12> PRT
- 13> Homo sapiens
- 00> 187
- t Asp Glu Lys Val Phe Thr Lys Glu Leu Asp Gln Trp Ile Glu Gln 5 10 15
- u Asn Glu Cys Lys Gln Leu Ser Glu Ser Gln Val Lys Ser Leu Cys 20 25 30
- u Lys Ala Lys Glu Ile Leu Thr Lys Glu Ser Asn Val Gln Glu Val 35 40 45

Page 358

- cg Cys Pro Val Thr Val Cys Gly Asp Val His Gly Gln Phe His Asp 50 55 60
- eu Met Glu Leu Phe Arg Ile Gly Gly Lys Ser Pro Asp Thr Asn Tyr 70 75 80
- eu Phe Met Gly Asp Tyr Val Asp Arg Gly Tyr Tyr Ser Val Glu Thr 85 90 95
- il Thr Leu Leu Val Ala Leu Lys Val Arg Tyr Arg Glu Arg Ile Thr 100 105 110
- e Leu Arg Gly Asn His Glu Ser Arg Gln Ile Thr Gln Val Tyr Gly 115 120 125
- ie Tyr Asp Glu Cys Leu Arg Lys Tyr Gly Asn Ala Asn Val Trp Lys 130 135 140
- r Phe Thr Asp Leu Phe Asp Tyr Leu Pro Leu Thr Ala Leu Val Asp 150 155 160
- y Gln Ile Phe Cys Leu His Gly Gly Leu Ser Pro Ser Ile Asp Thr 165 170 175
- u Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu
  180 185 190
- y Pro Met Cys Asp Leu Leu Trp Ser Asp Pro Asp Asp Arg Gly Gly 195 200 205
- p Gly Ile Ser Pro Arg Gly Ala Gly Tyr Thr Phe Gly Gln Asp Ile 210 220
- r Glu Thr Phe Asn His Ala Asn Gly Leu Thr Leu Val Ser Arg Ala 5 230 235 240
- s Gln Leu Val Met Glu Gly Tyr Asn Trp Cys His Asp Arg Asn Val 245 250 255
- l Thr Ile Phe Ser Ala Pro Asn Tyr Cys Tyr Arg Cys Gly Asn Gln Page 359

eolf-seql-S000001.txt

260

270

la Ala Ile Met Glu Leu Asp Asp Thr Leu Lys Tyr Ser Phe Leu Gln 275 280 285

he Asp Pro Ala Pro Arg Arg Gly Glu Pro His Val Thr Arg Arg Thr 290 295 300

ro Asp Tyr Phe Leu

210> 188

211> 169

212> PRT

213> Homo sapiens

100> 188

et Ala Ala Leu Leu Arg His Val Gly Arg His Cys Leu Arg Ala 5 10 15

is Phe Ser Pro Gln Leu Cys Ile Arg Asn Ala Val Pro Leu Gly Thr 20 25 30

- or Ala Lys Glu Glu Met Glu Arg Phe Trp Asn Lys Asn Ile Gly Ser 35 40 45
- 3n Arg Pro Leu Ser Pro His Ile Thr Ile Tyr Ser Trp Ser Leu Pro 50 55 60
- et Ala Met Ser Ile Cys His Arg Gly Thr Gly Ile Ala Leu Ser Ala 70 75 80
- y Val Ser Leu Phe Gly Met Ser Ala Leu Leu Leu Pro Gly Asn Phe 85 90 95
- .u Ser Tyr Leu Glu Leu Val Lys Ser Leu Cys Leu Gly Pro Ala Leu  $100 \hspace{1cm} 105 \hspace{1cm} 110$
- e His Thr Ala Lys Phe Ala Leu Val Phe Pro Leu Met Tyr His Thr 115 120 125
- p Asn Gly Ile Arg His Leu Met Trp Asp Leu Gly Lys Gly Leu Lys Page 360

eolf-seql-S000001.txt 135 140

le Pro Gln Leu Tyr Gln Ser Gly Val Val Val Leu Val Leu Thr Val 45 150 155 160

eu Ser Ser Met Gly Leu Ala Ala Met 165

210> 189

211> 201

212> PRT

213> Homo sapiens

400> 189

et Thr Glu Lys Ala Pro Glu Pro His Val Glu Glu Asp Asp Asp 5

lu Leu Asp Ser Lys Leu Asn Tyr Lys Pro Pro Pro Gln Lys Ser Leu 20 25 . 30

's Glu Leu Gln Glu Met Asp Lys Asp Asp Glu Ser Leu Ile Lys Tyr 35 40 45

's Lys Thr Leu Leu Gly Asp Gly Pro Val Val Thr Asp Pro Lys Ala 50 60

o Asn Val Val Thr Arg Leu Thr Leu Val Cys Glu Ser Ala Pro  $70 \hspace{1cm} 75 \hspace{1cm} 80$ 

y Pro Ile Thr Met Asp Leu Thr Gly Asp Leu Glu Ala Leu Lys Lys 85 90 95

u Thr Ile Val Leu Lys Glu Gly Ser Glu Tyr Arg Val Lys Ile His 100  $$105\$ 

E Lys Val Asn Arg Asp Ile Val Ser Gly Leu Lys Tyr Val Gln His 115

Tyr Arg Thr Gly Val Lys Val Asp Lys Ala Thr Phe Met Val Gly

: Tyr Gly Pro Arg Pro Glu Glu Tyr Glu Phe Leu Thr Pro Val Glu Page 361

eolf-seql-S000001.txt 15 150 155

160

lu Ala Pro Lys Gly Met Leu Ala Arg Gly Thr Tyr His Asn Lys Ser 165 170 175

ne Phe Thr Asp Asp Asp Lys Gln Asp His Leu Ser Trp Glu Trp Asn 180 185 190

eu Ser Ile Lys Lys Glu Trp Thr Glu 195 200

?10> 190

?11> 377

!12> PRT

?13> Homo sapiens

100> 190

t Lys Phe Pro Gly Pro Leu Glu Asn Gln Arg Leu Ser Phe Leu Leu 5 10 15

u Lys Ala Ile Thr Arg Glu Ala Gln Met Trp Lys Val Asn Val Arg. 20 25 30

's Met Pro Ser Asn Gln Asn Val Ser Pro Ser Gln Arg Asp Glu Val 35 40 45

- e Gln Trp Leu Ala Lys Leu Lys Tyr Gln Phe Asn Leu Tyr Pro Glu
  50 55 60
- r Phe Ala Leu Ala Ser Ser Leu Leu Asp Arg Phe Leu Ala Thr Val 70 75 80
- s Ala His Pro Lys Tyr Leu Ser Cys Ile Ala Ile Ser Cys Phe Phe 85 90 95
- u Ala Ala Lys Thr Val Glu Glu Asp Glu Arg Ile Pro Val Leu Lys 100 105 110
- l Leu Ala Arg Asp Ser Phe Cys Gly Cys Ser Ser Ser Glu Ile Leu 115 120 125
- g Met Glu Arg Ile Ile Leu Asp Lys Leu Asn Trp Asp Leu His Thr Page 362

eolf-seql-S000001.txt 130 135 140

- a Thr Pro Leu Asp Phe Leu His Ile Phe His Ala Ile Ala Val Ser 150 155 160
- 1r Arg Pro Gln Leu Leu Phe Ser Leu Pro Lys Leu Ser Pro Ser Gln 165 170 175
- .s Leu Ala Val Leu Thr Lys Gln Leu Leu His Cys Met Ala Cys Asn 180 185 190
- .n Leu Leu Gln Phe Arg Gly Ser Met Leu Ala Leu Ala Met Val Ser 195 200 205
- u Glu Met Glu Lys Leu Ile Pro Asp Trp Leu Ser Leu Thr Ile Glu 210 215 220
- u Leu Gln Lys Ala Gln Met Asp Ser Ser Gln Leu Ile His Cys Arg 5 230 235 240
- u Leu Val Ala His His Leu Ser Thr Leu Gln Ser Ser Leu Pro Leu 245 250 255
- n Ser Val Tyr Val Tyr Arg Pro Leu Lys His Thr Leu Val Thr Cys 260 265 270
- p Lys Gly Val Phe Arg Leu His Pro Ser Ser Val Pro Gly Pro Asp 275 280 285
- e Ser Lys Asp Asn Ser Lys Pro Glu Val Pro Val Arg Gly Thr Ala 290 295 300
- a Phe Tyr His His Leu Pro Ala Ala Ser Gly Cys Lys Gln Thr Ser 310 315 320
- r Lys Arg Lys Val Glu Glu Met Glu Val Asp Asp Phe Tyr Asp Gly 325 330 335
- e Lys Arg Leu Tyr Asn Glu Asp Asn Val Ser Glu Asn Val Gly Ser 340 345 350

eolf-seql-S000001.txt

al Cys Gly Thr Asp Leu Ser Arg Gln Glu Gly His Ala Ser Pro Cys 355 360 365

- co Pro Leu Gln Pro Val Ser Val Met 370 375
- 210> 191
- 211> 282
- 212> PRT
- 213> Homo sapiens
- 100> 191
- et Glu Arg Pro Ser Leu Arg Ala Leu Leu Leu Gly Ala Ala Gly Leu 5 10 15
- eu Leu Leu Leu Pro Leu Ser Ser Ser Ser Ser Ser Asp Thr Cys 20 25 30
- y Pro Cys Glu Pro Ala Ser Cys Pro Pro Leu Pro Pro Leu Gly Cys 35 40 45
- eu Leu Gly Glu Thr Arg Asp Ala Cys Gly Cys Cys Pro Met Cys Ala 50 55 60
- g Gly Glu Gly Glu Pro Cys Gly Gly Gly Gly Ala Gly Arg Gly Tyr 70 75 80
- 's Ala Pro Gly Met Glu Cys Val Lys Ser Arg Lys Arg Arg Lys Gly 85 90 95
- 's Ala Gly Ala Ala Ala Gly Gly Pro Gly Val Ser Gly Val Cys Val 100 105 110
- 's Lys Ser Arg Tyr Pro Val Cys Gly Ser Asp Gly Thr Thr Tyr Pro 115 120 125
- r Gly Cys Gln Leu Arg Ala Ala Ser Gln Arg Ala Glu Ser Arg Gly 130 135 140
- u Lys Ala Ile Thr Gln Val Ser Lys Gly Thr Cys Glu Gln Gly Pro 150 155 160

- er Ile Val Thr Pro Pro Lys Asp Ile Trp Asn Val Thr Gly Ala Gln
  165 170 175
- 11 Tyr Leu Ser Cys Glu Val Ile Gly Ile Pro Thr Pro Val Leu Ile 180 185 190
- :p Asn Lys Val Lys Arg Gly His Tyr Gly Val Gln Arg Thr Glu Leu
  195 200 205
- eu Pro Gly Asp Arg Asp Asn Leu Ala Ile Gln Thr Arg Gly Gly Pro 210 215 220
- u Lys His Glu Val Thr Gly Trp Val Leu Val Ser Pro Leu Ser Lys. 230 235 240
- .u Asp Ala Gly Glu Tyr Glu Cys His Ala Ser Asn Ser Gln Gly Gln 245 250 255
- .a Ser Ala Ser Ala Lys Ile Thr Val Val Asp Ala Leu His Glu Ile . 260 265 270
- o Val Lys Lys Gly Glu Gly Ala Glu Leu 275 280
- 10> 192
- 11> 339
- 12> PRT
- 13> Homo sapiens
- 00> 192
- t Asp Gln Asn Asn Ser Leu Pro Pro Tyr Ala Gln Gly Leu Ala Ser 5 10 15
- o Gln Gly Ala Met Thr Pro Gly Ile Pro Ile Phe Ser Pro Met Met 20 25 30
- o Tyr Gly Thr Gly Leu Thr Pro Gln Pro Ile Gln Asn Thr Asn Ser 35 40 45
- u Ser Ile Leu Glu Glu Gln Gln Arg Gln Gln Gln Gln Gln 50 55 60

					(	eolf	-sea	1-S0	0000	1.tx	t				
ln 5	Gln	Gln	Gln	Gln	Gln 70	Gln	Gln	Gln	Gln	Gln 75	Gln	Gln	Gln	Gln	Gln 80
ln	Gln	Gln	Gln	Gln 85	Gln	Gln	Gln	Gln	Gln 90	Gln	Gln	Gln	Gln	Gln 95	Ala
al	Ala	Ala	Ala 100	Ala	Val	Gln	Gln	Ser 105	Thr	Ser	Gln	Gln	Ala 110	Thr	Gln
Lу	Thr	Ser 115	Gly	Gln	Ala	Pro	Gln 120	Leu	Phe	His	Ser	Gln 125	Thr	Leu	Thr
ır	Ala 130	Pro	Leu	Pro	Gly	Thr 135	Thr	Pro	Leu	Tyr	Pro 140	Ser	Pro	Met	Thr
50 15	Met	Thr	Pro	Ile	Thr 150	Pro	Ala	Thr	Pro	Ala 155	Ser	Glu	Ser	Ser	Gly 160
lе	Val	Pro	Gln	Leu 165	Gln	Asn	Ile	Val	Ser 170	Thr	Val	Asn	Leu	Gly 175	Cys
15	Leu	Asp	Leu 180	Lys	Thr	Ile	Ala	Leu 185	Arg	Ala	Arg	Asn	Ala 190	Glu	Tyr
;n	Pro	Lys 195	Arg	Phe	Ala	Ala	Val 200	Ile	Met	Arg	Ile	Arg 205	Glu	Pro	Arg
ır	Thr 210	Ala	Leu	Ile	Phe	Ser 215	Ser	Gly	Lys	Met	Val 220	Cys	Thr	Gly	Ala
's :5	Ser	Glu	Glu	Gln	Ser 230	Arg	Leu	Ala	Ala	Arg 235	Lys	Tyr	Ala	Arg	Val 240

- .l Gln Lys Leu Gly Phe Pro Ala Lys Phe Leu Asp Phe Lys Ile Gln 245 250 255
- n Met Val Gly Ser Cys Asp Val Lys Phe Pro Ile Arg Leu Glu Gly 260 265 270
- u Val Leu Thr His Gln Gln Phe Ser Ser Tyr Glu Pro Glu Leu Phe 275 280 285

#### eolf-seql-S000001.txt

ro Gly Leu Ile Tyr Arg Met Ile Lys Pro Arg Ile Val Leu Leu Ile 290 295 300

ne Val Ser Gly Lys Val Val Leu Thr Gly Ala Lys Val Arg Ala Glu 310 315 320

le Tyr Glu Ala Phe Glu Asn Ile Tyr Pro Ile Leu Lys Gly Phe Arg 325 330 335

is Thr Thr

210> 193

211> 184

212> PRT

?13> Homo sapiens

100> 193

et Ala Ala Ala Gly Gly Ala Arg Leu Leu Arg Ala Ala Ser Ala Val 5 10 15

ou Gly Gly Pro Ala Gly Arg Trp Leu His His Ala Gly Ser Arg Ala 20 25 30

- y Ser Ser Gly Leu Leu Arg Asn Arg Gly Pro Gly Gly Ser Ala Glu 35 40 45
- .a Ser Arg Ser Leu Ser Val Ser Ala Arg Ala Arg Ser Ser Ser Glu 50 55 60
- p Lys Ile Thr Val His Phe Ile Asn Arg Asp Gly Glu Thr Leu Thr 70 75 80
- r Lys Gly Lys Val Gly Asp Ser Leu Leu Asp Val Val Glu Asn 85 90 95
- n Leu Asp Ile Asp Gly Phe Gly Ala Cys Glu Gly Thr Leu Ala Cys 100 105 110
- r Thr Cys His Leu Ile Phe Glu Asp His Ile Tyr Glu Lys Leu Asp 115 120 125

eolf-seql-S000001.txt

la Ile Thr Asp Glu Glu Asn Asp Met Leu Asp Leu Ala Tyr Gly Leu 130 135 140

ar Asp Arg Ser Arg Leu Gly Cys Gln Ile Cys Leu Thr Lys Ser Met 150 155 160

sp Asn Met Thr Val Arg Val Pro Glu Thr Val Ala Asp Ala Arg Gln
165 170 175

er Ile Asp Val Gly Lys Thr Ser

210> 194

211> 206

212> PRT

213> Homo sapiens

100> 194

et Thr Ala Ser Val Leu Arg Ser Ile Ser Leu Ala Leu Arg Pro Thr 5 10 15

er Gly Leu Leu Gly Thr Trp Gln Thr Gln Leu Arg Glu Thr His Gln 20 25 30

:g Ala Ser Leu Leu Ser Phe Trp Glu Leu Ile Pro Met Arg Ser Glu 35 40 45

:0 Leu Arg Lys Lys Lys Val Asp Pro Lys Lys Asp Gln Glu Ala 50 55 60

rs Glu Arg Leu Lys Arg Lys Ile Arg Lys Leu Glu Lys Ala Thr Gln 70 75 80

u Leu Ile Pro Ile Glu Asp Phe Ile Thr Pro Leu Lys Phe Leu Asp 85 90 95

s Ala Arg Glu Arg Pro Gln Val Glu Leu Thr Phe Glu Glu Thr Glu
100 105 110

g Arg Ala Leu Leu Lys Lys Trp Ser Leu Tyr Lys Gln Glu 115 120 125

Page 368

### eolf-seql-S000001.txt

rg Lys Met Glu Arg Asp Thr Ile Arg Ala Met Leu Glu Ala Gln Gln 130 135 140

- lu Ala Leu Glu Glu Leu Gln Leu Glu Ser Pro Lys Leu His Ala Glu 150 155 160
- la Ile Lys Arg Asp Pro Asn Leu Phe Pro Phe Glu Lys Glu Gly Pro 165 170 175
- is Tyr Thr Pro Pro Ile Pro Asn Tyr Gln Pro Pro Glu Gly Arg Tyr 180 185 190
- 3n Asp Ile Thr Lys Val Tyr Thr Gln Val Glu Phe Lys Arg 195 200 205
- ?10> 195
- :11> 75
- ?12> PRT
- !13> Homo sapiens
- 100> 195
- %:t Lys Gly Glu Thr Pro Val Asn Ser Thr Met Ser Ile Gly Gln Ala 5 10 15
- 'g Lys Met Val Glu Gln Leu Lys Ile Glu Ala Ser Leu Cys Arg Ile 20 25 30
- 's Val Ser Lys Ala Ala Ala Asp Leu Met Thr Tyr Cys Asp Ala His 35 40 45
- a Cys Glu Asp Pro Leu Ile Thr Pro Val Pro Thr Ser Glu Asn Pro 50 55 60
- e Arg Glu Lys Lys Phe Phe Cys Ala Leu Leu
  70 75
- 10> 196
- 11> 317
- 12> PRT
- 13> Homo sapiens
- 00> 196

- et Arg Leu Gly Pro Arg Thr Ala Ala Leu Gly Leu Leu Leu Cys
  5 10 15
- la Ala Ala Gly Ala Gly Lys Ala Glu Glu Leu His Tyr Pro Leu 20 25 30
- ly Glu Arg Arg Ser Asp Tyr Asp Arg Glu Ala Leu Leu Gly Val Gln 35 40 45
- lu Asp Val Asp Glu Tyr Val Lys Leu Gly His Glu Glu Gln Gln Lys 50 60
- rg Leu Gln Ala Ile Ile Lys Lys Ile Asp Leu Asp Ser Asp Gly Phe 70 75 80
- eu Thr Glu Ser Glu Leu Ser Ser Trp Ile Gln Met Ser Phe Lys His
- m /r Ala Met Gln Glu Ala Lys Gln Gln Phe Val Glu Tyr Asp Lys Asn 100 105 110
- er Asp Asp Thr Val Thr Trp Asp Glu Tyr Asn Ile Gln Met Tyr Asp 115 120 125
- rg Val Ile Asp Phe Asp Glu Asn Thr Ala Leu Asp Asp Ala Glu Glu 130 135 140
- u Ser Phe Arg Lys Leu His Leu Lys Asp Lys Lys Arg Phe Glu Lys 150 155 160
- .a Asn Gln Asp Ser Gly Pro Gly Leu Ser Leu Glu Glu Phe Ile Ala 165 170 175
- ue Glu His Pro Glu Glu Val Asp Tyr Met Thr Glu Phe Val Ile Gln
  180 185 190
- u Ala Leu Glu Glu His Asp Lys Asn Gly Asp Gly Phe Val Ser Leu 195 200 205
- u Glu Phe Leu Gly Asp Tyr Arg Trp Asp Pro Thr Ala Asn Glu Asp 210 215 220

### eolf-seql-S000001.txt

ro Glu Trp Ile Leu Val Glu Lys Asp Arg Phe Val Asn Asp Tyr Asp 25 230 235 240

- ys Asp Asn Asp Gly Arg Leu Asp Pro Gln Glu Leu Leu Pro Trp Val 245 250 . 255
- al Pro Asn Asn Gln Gly Ile Ala Gln Glu Glu Ala Leu His Leu Ile 260 265 270
- 3p Glu Met Asp Leu Asn Gly Asp Lys Lys Leu Ser Glu Glu Glu Ile 275 280 285
- 3u Glu Asn Pro Asp Leu Phe Leu Thr Ser Glu Ala Thr Asp Tyr Gly 290 295 300
- rg Gln Leu His Asp Asp Tyr Phe Tyr His Asp Glu Leu )5 310 315

197

?11> 239

?12> PRT

?13> Homo sapiens

100> 197

- et Ala Pro Ser Val Pro Ala Ala Glu Pro Glu Tyr Pro Lys Gly Ile 5 10 15
- g Ala Val Leu Leu Gly Pro Pro Gly Ala Gly Lys Gly Thr Gln Ala 20 25 30
- O Arg Leu Ala Glu Asn Phe Cys Val Cys His Leu Ala Thr Gly Asp 35 40 45
- t Leu Arg Ala Met Val Ala Ser Gly Ser Glu Leu Gly Lys Lys Leu 50 55 60
- s Ala Thr Met Asp Ala Gly Lys Leu Val Ser Asp Glu Met Val Val 70 75 80
- u Leu Ile Glu Lys Asn Leu Glu Thr Pro Leu Cys Lys Asn Gly Phe 85 90 95

- eu Leu Asp Gly Phe Pro Arg Thr Val Arg Gln Ala Glu Met Leu Asp 100 105 110
- sp Leu Met Glu Lys Arg Lys Glu Lys Leu Asp Ser Val Ile Glu Phe 115 120 125
- er Ile Pro Asp Ser Leu Leu Ile Arg Arg Ile Thr Gly Arg Leu Ile 130 135 140
- is Pro Lys Ser Gly Arg Ser Tyr His Glu Glu Phe Asn Pro Pro Lys 45 150 155 160
- lu Pro Met Lys Asp Asp Ile Thr Gly Glu Pro Leu Ile Arg Arg Ser 165 170 175
- 3p Asp Asn Glu Lys Ala Leu Lys Ile Arg Leu Gln Ala Tyr His Thr 180 185 190
- In Thr Thr Pro Leu Ile Glu Tyr Tyr Arg Lys Arg Gly Ile His Ser 195 200 205
- la Ile Asp Ala Ser Gln Thr Pro Asp Val Val Phe Ala Ser Ile Leu 210 215 220
- .a Ala Phe Ser Lys Ala Thr Cys Lys Asp Leu Val Met Phe Ile 230 235
- 10> 198
- !11> 217
- 12> PRT
- 13> Homo sapiens
- 100> 198
- t Ser Ser Lys Val Ser Arg Asp Thr Leu Tyr Glu Ala Val Arg Glu
  5 10 15
- .l Leu His Gly Asn Gln Arg Lys Arg Arg Lys Phe Leu Glu Thr Val 20 25 30
- u Leu Gln Ile Ser Leu Lys Asn Tyr Asp Pro Gln Lys Asp Lys Arg 35 40 45

- he Ser Gly Thr Val Arg Leu Lys Ser Thr Pro Arg Pro Lys Phe Ser 50 55 60
- al Cys Val Leu Gly Asp Gln Gln His Cys Asp Glu Ala Lys Ala Val 5 70 75 80
- sp Ile Pro His Met Asp Ile Glu Ala Leu Lys Lys Leu Asn Lys Asn 85 90 . 95
- ys Lys Leu Val Lys Lys Leu Ala Lys Lys Tyr Asp Ala Phe Leu Ala 100 105 110
- er Glu Ser Leu Ile Lys Gln Ile Pro Arg Ile Leu Gly Pro Gly Leu 115 120 125
- In Lys Ala Gly Lys Phe Pro Ser Leu Leu Thr His Asn Glu Asn Met 130 135 140
- al Ala Lys Val Asp Glu Val Lys Ser Thr Ile Lys Phe Gln Met Lys 150 150 155 160
- ys Val Leu Cys Leu Ala Val Ala Val Gly His Val Lys Met Thr Asp 165 170 175
- p Glu Leu Val Tyr Asn Ile His Leu Ala Val Asn Phe Leu Val Ser 180 185 190
- eu Leu Lys Lys Asn Trp Gln Asn Val Arg Ala Leu Tyr Ile Lys Ser 195 200 205
- ir Met Gly Lys Pro Gln Arg Leu Tyr 210 215
- :10> 199
- :11> 150
- :12> PRT
- :13> Homo sapiens
- 00> 199
- t Ser Lys Ile Ser Gln Gln Asn Ser Thr Pro Gly Val Asn Gly Ile 5 10 15

eolf-seql-S000001.txt

er Val Ile His Thr Gln Ala His Ala Ser Gly Leu Gln Gln Val Pro 20 25 30

ln Leu Val Pro Ala Gly Pro Gly Gly Gly Gly Lys Ala Val Ala Pro 35 40 45

er Lys Gln Ser Lys Lys Ser Ser Pro Met Asp Arg Asn Ser Asp Glu 50 55 60

yr Arg Gln Arg Arg Glu Arg Asn Asn Met Ala Val Lys Lys Ser Arg 5 70 75 80

eu Lys Ser Lys Gln Lys Ala Gln Asp Thr Leu Gln Arg Val Asn Gln 85 90 95

 ${
m Eu}$  Lys Glu Glu Asn Glu Arg Leu Glu Ala Lys Ile Lys Leu Leu Thr 100 105 110

ys Glu Leu Ser Val Leu Lys Asp Leu Phe Leu Glu His Ala His Asn 115 120 125

eu Ala Asp Asn Val Gln Ser Ile Ser Thr Glu Asn Thr Thr Ala Asp 130 135 140

Ly Asp Asn Ala Gly Gln 15 150

210> 200

211> 331

?12> PRT

?13> Homo sapiens

100> 200

et Gly Thr Pro Gln Lys Asp Val Ile Ile Lys Ser Asp Ala Pro Asp 5 10 15

ir Leu Leu Glu Lys His Ala Asp Tyr Ile Ala Ser Tyr Gly Ser 20 25 30

's Lys Asp Asp Tyr Glu Tyr Cys Met Ser Glu Tyr Leu Arg Met Ser 35 40 45

eolf-seq1-S000001.txt

- ly Ile Tyr Trp Gly Leu Thr Val Met Asp Leu Met Gly Gln Leu His 50 60
- rg Met Asn Arg Glu Glu Ile Leu Ala Phe Ile Lys Ser Cys Gln His 5 70 75 80
- lu Cys Gly Gly Ile Ser Ala Ser Ile Gly His Asp Pro His Leu Leu 85 90 95
- yr Thr Leu Ser Ala Val Gln Ile Leu Thr Leu Tyr Asp Ser Ile Asn 100 105 110
- al Ile Asp Val Asn Lys Val Val Glu Tyr Val Lys Gly Leu Gln Lys 115 120 125
- lu Asp Gly Ser Phe Ala Gly Asp Ile Trp Gly Glu Ile Asp Thr Arg 130 135 140
- ne Ser Phe Cys Ala Val Ala Thr Leu Ala Leu Leu Gly Lys Leu Asp 45 150 155 160
- la Ile Asn Val Glu Lys Ala Ile Glu Phe Val Leu Ser Cys Met Asn 165 170 175
- ne Asp Gly Gly Phe Gly Cys Arg Pro Gly Ser Glu Ser His Ala Gly 180 185 190
- In Ile Tyr Cys Cys Thr Gly Phe Leu Ala Ile Thr Ser Gln Leu His 195 200 205
- .n Val Asn Ser Asp Leu Leu Gly Trp Trp Leu Cys Glu Arg Gln Leu 210 225 220
- to Ser Gly Gly Leu Asn Gly Arg Pro Glu Lys Leu Pro Asp Val Cys 230 235 240
- 'r Ser Trp Trp Val Leu Ala Ser Leu Lys Ile Ile Gly Arg Leu His 245 250 255
- p Ile Asp Arg Glu Lys Leu Arg Asn Phe Ile Leu Ala Cys Gln Asp 260 265 270

Page 375

### eolf-seq1-S000001.txt

lu Glu Thr Gly Gly Phe Ala Asp Arg Pro Gly Asp Met Val Asp Pro 275 280 285

he His Thr Leu Phe Gly Ile Ala Gly Leu Ser Leu Leu Gly Glu Glu 290 295 300

In Ile Lys Pro Val Asn Pro Val Phe Cys Met Pro Glu Glu Val Leu
05 310 315 320

ln Arg Val Asn Val Gln Pro Glu Leu Val Ser 325 330

210> 201

211> 537

212> PRT

213> Homo sapiens

400> 201

et Gly Cys Val Gln Cys Lys Asp Lys Glu Ala Thr Lys Leu Thr Glu 5 10 15

Lu Arg Asp Gly Ser Leu Asn Gln Ser Ser Gly Tyr Arg Tyr Gly Thr 20 25 30

3p Pro Thr Pro Gln His Tyr Pro Ser Phe Gly Val Thr Ser Ile Pro 35 40 45

on Tyr Asn Asn Phe His Ala Ala Gly Gly Gln Gly Leu Thr Val Phe 50 55 60

ly Gly Val Asn Ser Ser Ser His Thr Gly Thr Leu Arg Thr Arg Gly 70 75 80

y Thr Gly Val Thr Leu Phe Val Ala Leu Tyr Asp Tyr Glu Ala Arg. 85 90 95

ir Glu Asp Asp Leu Ser Phe His Lys Gly Glu Lys Phe Gln Ile Leu 100 105 110

in Ser Ser Glu Gly Asp Trp Trp Glu Ala Arg Ser Leu Thr Thr Gly 115 120 125

Page 376

- lu Thr Gly Tyr Ile Pro Ser Asn Tyr Val Ala Pro Val Asp Ser Ile
  130 135 140
- ln Ala Glu Glu Trp Tyr Phe Gly Lys Leu Gly Arg Lys Asp Ala Glu 45 150 155 160
- rg Gln Leu Leu Ser Phe Gly Asn Pro Arg Gly Thr Phe Leu Ile Arg 165 170 175
- lu Ser Glu Thr Thr Lys Gly Ala Tyr Ser Leu Ser Ile Arg Asp Trp 180 185 190
- sp Asp Met Lys Gly Asp His Val Lys His Tyr Lys Ile Arg Lys Leu 195 200 205
- sp Asn Gly Gly Tyr Tyr Ile Thr Thr Arg Ala Gln Phe Glu Thr Leu 210 215 220
- In Gln Leu Val Gln His Tyr Ser Glu Arg Ala Ala Gly Leu Cys Cys
  25 230 235 240
- rg Leu Val Val Pro Cys His Lys Gly Met Pro Arg Leu Thr Asp Leu 245 250 255
- er Val Lys Thr Lys Asp Val Trp Glu Ile Pro Arg Glu Ser Leu Gln 260 265 270
- eu Ile Lys Arg Leu Gly Asn Gly Gln Phe Gly Glu Val Trp Met Gly 275 280 285
- 1r Trp Asn Gly Asn Thr Lys Val Ala Ile Lys Thr Leu Lys Pro Gly 290 295 300
- 1r Met Ser Pro Glu Ser Phe Leu Glu Glu Ala Gln Ile Met Lys Lys 310 315 320
- u Lys His Asp Lys Leu Val Gln Leu Tyr Ala Val Val Ser Glu Glu 325 330 . 335
- o Ile Tyr Ile Val Thr Glu Tyr Met Asn Lys Gly Ser Leu Leu Asp Page 377

eolf-seql-S000001.txt 345

350

340

he Leu Lys Asp Gly Glu Gly Arg Ala Leu Lys Leu Pro Asn Leu Val 355 360 365

sp Met Ala Ala Gln Val Ala Ala Gly Met Ala Tyr Ile Glu Arg Met 370 380

sn Tyr Ile His Arg Asp Leu Arg Ser Ala Asn Ile Leu Val Gly Asn 85 390 395 400

ly Leu Ile Cys Lys Ile Ala Asp Phe Gly Leu Ala Arg Leu Ile Glu 405 410 415

sp Asn Glu Tyr Thr Ala Arg Gln Gly Ala Lys Phe Pro Ile Lys Trp 420 425 430

ar Ala Pro Glu Ala Ala Leu Tyr Gly Arg Phe Thr Ile Lys Ser Asp 435 440 445

11 Trp Ser Phe Gly Ile Leu Leu Thr Glu Leu Val Thr Lys Gly Arg
450 455 460

al Pro Tyr Pro Gly Met Asn Asn Arg Glu Val Leu Glu Gln Val Glu 55 470 475 480

rg Gly Tyr Arg Met Pro Cys Pro Gln Asp Cys Pro Ile Ser Leu His 485 490 495

u Leu Met Ile His Cys Trp Lys Lys Asp Pro Glu Glu Arg Pro Thr 500 510

1e Glu Tyr Leu Gln Ser Phe Leu Glu Asp Tyr Phe Thr Ala Thr Glu 515 520 525

to Gln Tyr Gln Pro Gly Glu Asn Leu 530 535

:10> 202

:11> 534

:12> PRT

:13> Homo sapiens

Page 378

# eolf-seql-S000001.txt

400> 202

- $\odot$ t Gly Cys Val Gln Cys Lys Asp Lys Glu Ala Thr Lys Leu Thr Glu 5 10 15
- lu Arg Asp Gly Ser Leu Asn Gln Ser Ser Gly Tyr Arg Tyr Gly Thr 20 25 30
- sp Pro Thr Pro Gln His Tyr Pro Ser Phe Gly Val Thr Ser Ile Pro 35 40 45
- 3n Tyr Asn Asn Phe His Ala Ala Gly Gly Gln Gly Leu Thr Val Phe 50 55 60
- Ly Gly Val Asn Ser Ser Ser His Thr Gly Thr Leu Arg Thr Arg Gly 70 75 80
- .y Thr Gly Val Thr Leu Phe Val Ala Leu Tyr Asp Tyr Glu Ala Arg 85 90 95
- ir Glu Asp Asp Leu Ser Phe His Lys Gly Glu Lys Phe Gln Ile Leu 100 105 110
- n Ser Ser Glu Gly Asp Trp Trp Glu Ala Arg Ser Leu Thr Thr Gly 115 120 125
- u Thr Gly Tyr Ile Pro Ser Asn Tyr Val Ala Pro Val Asp Ser Ile
  130 135 140
- n Ala Glu Glu Trp Tyr Phe Gly Lys Leu Gly Arg Lys Asp Ala Glu
  5 150 155 160
- rg Gln Leu Leu Ser Phe Gly Asn Pro Arg Gly Thr Phe Leu Ile Arg 165 170 175
- u Ser Glu Thr Thr Lys Gly Ala Tyr Ser Leu Ser Ile Arg Asp Trp 180 185 190
- p Asp Met Lys Gly Asp His Val Lys His Tyr Lys Ile Arg Lys Leu 195 200 205

eolf-seql-S000001.txt

p Asn Gly Gly Tyr Tyr Ile Thr Thr Arg Ala Gln Phe Glu Thr Leu
210 215 220

- n Leu Thr Val Ile Ala Ser Ser Cys Thr Pro Gln Thr Ser Gly Leu 245 250 255
- a Lys Asp Ala Trp Glu Val Ala Arg Arg Ser Leu Cys Leu Glu Lys 260 265 270
- s Leu Gly Gln Gly Cys Phe Ala Glu Val Trp Leu Gly Thr Trp Asn 275 280 285
- / Asn Thr Lys Val Ala Ile Lys Thr Leu Lys Pro Gly Thr Met Ser 290 295 300
- o Glu Ser Phe Leu Glu Glu Ala Gln Ile Met Lys Lys Leu Lys His 310 315 320
- > Lys Leu Val Gln Leu Tyr Ala Val Val Ser Glu Glu Pro Ile Tyr 325 330 335
- : Val Thr Glu Tyr Met Asn Lys Gly Ser Leu Leu Asp Phe Leu Lys 340 345 350
- Gly Glu Gly Arg Ala Leu Lys Leu Pro Asn Leu Val Asp Met Ala 355 360 365
- . Gln Val Ala Ala Gly Met Ala Tyr Ile Glu Arg Met Asn Tyr Ile 370 \$375\$
  - Arg Asp Leu Arg Ser Ala Asn Ile Leu Val Gly Asn Gly Leu Ile 390 395 400
  - Lys Ile Ala Asp Phe Gly Leu Ala Arg Leu Ile Glu Asp Asn Glu 405 410 415
  - Thr Ala Arg Gln Gly Ala Lys Phe Pro Ile Lys Trp Thr Ala Pro 420 425 430

# eolf-seql-S000001.txt

1 Ala Ala Leu Tyr Gly Arg Phe Thr Ile Lys Ser Asp Val Trp Ser 435 440 445

- Gly Ile Leu Leu Thr Glu Leu Val Thr Lys Gly Arg Val Pro Tyr 450 460
- Gly Met Asn Asn Arg Glu Val Leu Glu Gln Val Glu Arg Gly Tyr 470 475 480
- Met Pro Cys Pro Gln Asp Cys Pro Ile Ser Leu His Glu Leu Met 485 490 495
  - His Cys Trp Lys Lys Asp Pro Glu Glu Arg Pro Thr Phe Glu Tyr 500 505 510
  - Gln Ser Phe Leu Glu Asp Tyr Phe Thr Ala Thr Glu Pro Gln Tyr 515 520 525

Pro Gly Glu Asn Leu 530

- J> 203
- 1> 482
- 2> PRT
- 3> Homo sapiens
- )> 203
- Gly Cys Val Gln Cys Lys Asp Lys Glu Ala Thr Lys Leu Thr Glu 5 10 15
- Pro Thr Pro Gln His Tyr Pro Ser Phe Gly Val Thr Ser Ile Pro 35 40 45
- Tyr Asn Asn Phe His Ala Ala Gly Gly Gln Gly Leu Thr Val Phe 50 60
- Gly Val Asn Ser Ser Ser His Thr Gly Thr Leu Arg Thr Arg Gly 70 75 80

Page 381

### eolf-seql-S000001.txt

7 Thr Gly Val Thr Leu Phe Val Ala Leu Tyr Asp Tyr Glu Ala Arg 85 90 95

- : Glu Asp Asp Leu Ser Phe His Lys Gly Glu Lys Phe Gln Ile Leu 100 105 110
- Ser Ser Glu Gly Asp Trp Trp Glu Ala Arg Ser Leu Thr Thr Gly 115 120 125
- Thr Gly Tyr Ile Pro Ser Asn Tyr Val Ala Pro Val Asp Ser Ile 130 135 140
- Ala Glu Glu Trp Tyr Phe Gly Lys Leu Gly Arg Lys Asp Ala Glu 150 155 160
- Gln Leu Leu Ser Phe Gly Asn Pro Arg Gly Thr Phe Leu Ile Arg 165 170 175
- Ser Glu Thr Thr Lys Gly Ala Tyr Ser Leu Ser Ile Arg Asp Trp 180 185 190
- Asp Met Lys Gly Asp His Val Lys His Tyr Lys Ile Arg Lys Leu 195 200 205
- Asn Gly Gly Tyr Tyr Ile Thr Thr Arg Ala Gln Phe Glu Thr Leu 210 220
- Gln Leu Val Gln His Tyr Ser Gly Thr Trp Asn Gly Asn Thr Lys 230 235 240
- Ala Ile Lys Thr Leu Lys Pro Gly Thr Met Ser Pro Glu Ser Phe 245 250 255
- Glu Glu Ala Gln Ile Met Lys Lys Leu Lys His Asp Lys Leu Val 260 265 270
- Leu Tyr Ala Val Val Ser Glu Glu Pro Ile Tyr Ile Val Thr Glu 275 280 285
- Met Asn Lys Gly Ser Leu Leu Asp Phe Leu Lys Asp Gly Glu Gly 290 295 300

Page 382

## eolf-seql-S000001.txt

Ala Leu Lys Leu Pro Asn Leu Val Asp Met Ala Ala Gln Val Ala 310 315 320

- Gly Met Ala Tyr Ile Glu Arg Met Asn Tyr Ile His Arg Asp Leu 325 330 335
- Ser Ala Asn Ile Leu Val Gly Asn Gly Leu Ile Cys Lys Ile Ala 340 345 350
- Phe Gly Leu Ala Arg Leu Ile Glu Asp Asn Glu Tyr Thr Ala Arg 355 360 365
- Gly Ala Lys Phe Pro Ile Lys Trp Thr Ala Pro Glu Ala Ala Leu 370 380
- Gly Arg Phe Thr Ile Lys Ser Asp Val Trp Ser Phe Gly Ile Leu 390 395 400
  - Thr Glu Leu Val Thr Lys Gly Arg Val Pro Tyr Pro Gly Met Asn 405 410 415

  - Gln Asp Cys Pro Ile Ser Leu His Glu Leu Met Ile His Cys Trp 435 440 445
  - Lys Asp Pro Glu Glu Arg Pro Thr Phe Glu Tyr Leu Gln Ser Phe 450 455 460
  - Glu Asp Tyr Phe Thr Ala Thr Glu Pro Gln Tyr Gln Pro Gly Glu 470 475 480

Leu

- 0> 204
- 1> 674
- 2> PRT
- 3> Homo sapiens

eolf-seql-S000001.txt

)0> 204

: Ala Pro Gly Gln Ala Pro His Gln Ala Thr Pro Trp Arg Asp Ala 5 10 15

- 3 Pro Phe Phe Leu Leu Ser Pro Val Met Gly Leu Leu Ser Arg Ala 20 25 30
- ) Ser Arg Leu Arg Gly Leu Gly Pro Leu Glu Pro Trp Leu Val Glu 35 40 45
- val Lys Gly Ala Ala Leu Val Glu Ala Gly Leu Glu Gly Glu Ala 50 55 60
- Thr Pro Leu Ala Ile Pro His Thr Pro Trp Gly Arg Arg Pro Gly 70 75 80
- I Glu Ala Glu Asp Ser Gly Gly Pro Gly Glu Asp Arg Glu Thr Leu 85 90 95
- Leu Lys Thr Ser Ser Ser Leu Pro Glu Ala Trp Gly Leu Leu Asp 100 105 110
- Asp Asp Gly Met Tyr Gly Glu Arg Glu Ala Thr Ser Val Pro Arg 115 120 125
- Gln Gly Ser Gln Phe Ala Asp Gly Gln Arg Ala Pro Leu Ser Pro 130 135 140
  - Leu Leu Ile Arg Thr Leu Gln Gly Ser Asp Lys Asn Pro Gly Glu 150 155 160
  - Lys Ala Glu Glu Glu Gly Val Ala Glu Glu Glu Gly Val Asn Lys 165 170 175
  - Ser Tyr Pro Pro Ser His Arg Glu Cys Cys Pro Ala Val Glu Glu 180 185 190
- Asp Asp Glu Glu Ala Val Lys Lys Glu Ala His Arg Thr Ser Thr 195 200 205
- Ala Leu Ser Pro Gly Ser Lys Pro Ser Thr Trp Val Ser Cys Pro Page 384

210	eolf-seql-S000001.tx	t
	215	220

- ly Glu Glu Glu Asn Gln Ala Thr Glu Asp Lys Arg Thr Glu Arg Ser 230 235 240
- ys Gly Ala Arg Lys Thr Ser Val Ser Pro Arg Ser Ser Gly Ser Asp 245 250 255
- ro Arg Ser Trp Glu Tyr Arg Ser Gly Glu Ala Ser Glu Glu Lys Glu 260 265 270
- lu Lys Ala His Glu Glu Thr Gly Lys Gly Glu Ala Ala Pro Gly Pro 275 280 285
- .n Ser Ser Ala Pro Ala Gln Arg Pro Gln Leu Lys Ser Trp Trp Cys 290 295 300
- n Pro Ser Asp Glu Glu Glu Ser Glu Val Lys Pro Leu Gly Ala Ala 310 315 320
- u Lys Asp Gly Glu Ala Glu Cys Pro Pro Cys Ile Pro Pro Pro Ser 325 330 335
- a Phe Leu Lys Ala Trp Val Tyr Trp Pro Gly Glu Asp Thr Glu Glu 340 345 350
- ı Glu Asp Glu Glu Glu Asp Glu Asp Ser Asp Ser Gly Ser Asp Glu 355 360 365
- 1 Glu Gly Glu Ala Glu Ala Ser Ser Ser Thr Pro Ala Thr Gly Val 370 380
- Leu Lys Ser Trp Val Tyr Gln Pro Gly Glu Asp Thr Glu Glu Glu 390 395 400
- Asp Glu Asp Ser Asp Thr Gly Ser Ala Glu Asp Glu Arg Glu Ala 405 410 415
  - Thr Ser Ala Ser Thr Pro Pro Ala Ser Ala Phe Leu Lys Ala Trp 420 425 430

eolf-seql-S000001.txt

Tyr Arg Pro Gly Glu Asp Thr Glu Glu Glu Glu Asp Glu Asp Val 435

Ser Glu Asp Lys Glu Asp Asp Ser Glu Ala Ala Leu Gly Glu Ala

Ser Asp Pro His Pro Ser His Pro Asp Gln Ser Ala His Phe Arg

450

- Trp Gly Tyr Arg Pro Gly Lys Glu Thr Glu Glu Glu Glu Ala Ala 485 . 490 495
- Asp Trp Gly Glu Ala Glu Pro Cys Pro Phe Arg Val Ala Ile Tyr 500 505 510
- Pro Gly Glu Lys Pro Pro Pro Pro Trp Ala Pro Pro Arg Leu Pro 515 520 525
- Arg Leu Gln Arg Arg Leu Lys Arg Pro Glu Thr Pro Thr His Asp 530 540
- Asp Pro Glu Thr Pro Leu Lys Ala Arg Lys Val Arg Phe Ser Glu 550 555 560
  - Val Thr Val His Phe Leu Ala Val Trp Ala Gly Pro Ala Gln Ala 565 570 575
  - Arg Gln Gly Pro Trp Glu Gln Leu Ala Arg Asp Arg Ser Arg Phe 580 585 590
- Arg Arg Ile Ala Gln Ala Gln Glu Glu Leu Ser Pro Cys Leu Thr 595 600 605
- Ala Ala Arg Ala Arg Ala Trp Ala Arg Leu Arg Asn Pro Pro Leu 610 620
- Pro Ile Pro Ala Leu Thr Gln Thr Leu Pro Ser Ser Ser Val Pro 630 635 640
- Ser Pro Val Gln Thr Thr Pro Leu Ser Gln Ala Val Ala Thr Pro 645 650 655

#### eolf-seql-S000001.txt

: Arg Ser Ser Ala Ala Ala Ala Ala Leu Asp Leu Ser Gly Arg 660 665 670

| Gly

- .0> 205
- .1> 635
- 2> PRT
- 3> Homo sapiens
- 0> 205

Ser Val Gly Val Ser Thr Ser Ala Pro Leu Ser Pro Thr Ser Gly 5 10 15

Ser Val Gly Met Ser Thr Phe Ser Ile Met Asp Tyr Val Val Phe 20 25 30

Leu Leu Val Leu Ser Leu Ala Ile Gly Leu Tyr His Ala Cys 35 40. 45

Gly Trp Gly Arg His Thr Val Gly Glu Leu Leu Met Ala Asp Arg 50 55 60

Met Gly Cys Leu Pro Val Ala Leu Ser Leu Leu Ala Thr Phe Gln 70 75 80

Ala Val Ala Ile Leu Gly Val Pro Ser Glu Ile Tyr Arg Phe Gly 85 90 95

Gln Tyr Trp Phe Leu Gly Cys Cys Tyr Phe Leu Gly Leu Leu Ile 100 105 110

Ala His Ile Phe Ile Pro Val Phe Tyr Arg Leu His Leu Thr Ser 115 120 125

Tyr Glu Tyr Leu Glu Leu Arg Phe Asn Lys Thr Val Arg Val Cys 130 135 140

Thr Val Thr Phe Ile Phe Gln Met Val Ile Tyr Met Gly Val Val 150 155 160

- Tyr Ala Pro Ser Leu Ala Leu Asn Ala Val Thr Gly Phe Asp Leu 165 170 175
- Deu Ser Val Leu Ala Leu Gly Ile Val Cys Thr Val Tyr Thr Ala 180 185 190
- Gly Gly Leu Lys Ala Val Ile Trp Thr Asp Val Phe Gln Thr Leu 195 200 205
- Met Phe Leu Gly Gln Leu Ala Val Ile Ile Val Gly Ser Ala Lys 210 215 220
- Gly Gly Leu Gly Arg Val Trp Ala Val Ala Ser Gln His Gly Arg
- Ser Gly Phe Glu Leu Asp Pro Asp Pro Phe Val Arg His Thr Phe 245 250 255
- Thr Leu Ala Phe Gly Gly Val Phe Met Met Leu Ser Leu Tyr Gly 260 265 270
  - Asn Gln Ala Gln Val Gln Arg Tyr Leu Ser Ser Arg Thr Glu Lys 275 280 285
  - Ala Val Leu Ser Cys Tyr Ala Val Phe Pro Phe Gln Gln Val Ser 290 295 300
  - Cys Val Gly Cys Leu Ile Gly Leu Val Met Phe Ala Tyr Tyr Gln 310 315 320
  - Tyr Pro Met Ser Ile Gln Gln Ala Gln Ala Ala Pro Asp Gln Phe 325 330 335
  - Leu Tyr Phe Val Met Asp Leu Leu Lys Gly Leu Pro Gly Leu Pro 340 345 350
  - Leu Phe Ile Ala Cys Leu Phe Ser Gly Ser Leu Ser Thr Ile Ser 355 360 365
- Ala Phe Asn Ser Leu Ala Thr Val Thr Met Glu Asp Leu Ile Arg 370 380

- ro Trp Phe Pro Glu Phe Ser Glu Ala Arg Ala Ile Met Leu Ser Arg 35 390 395 400
- ly Leu Ala Phe Gly Tyr Gly Leu Leu Cys Leu Gly Met Ala Tyr Ile 405 410 415
- er Ser Gln Met Gly Pro Val Leu Gln Ala Ala Ile Ser Ile Phe Gly 420 425 430
- et Val Gly Gly Pro Leu Leu Gly Leu Phe Cys Leu Gly Met Phe Phe 435 440 445
- Cys Ala Asn Pro Pro Gly Ala Val Val Gly Leu Leu Ala Gly Leu 450 460
- Met Ala Phe Trp Ile Gly Ile Gly Ser Ile Val Thr Ser Met Gly 35 470 475 480
- le Ser Met Pro Pro Ser Pro Ser Asn Gly Ser Ser Phe Ser Leu Pro 485 490 495
- ir Asn Leu Thr Val Ala Thr Val Thr Thr Leu Met Pro Leu Thr Thr 500 510
- le Ser Lys Pro Thr Gly Leu Gln Arg Phe Tyr Ser Leu Ser Tyr Leu 515 520 525
- p Tyr Ser Ala His Asn Ser Thr Thr Val Ile Val Val Gly Leu Ile 530 540
- .1 Ser Leu Leu Thr Gly Arg Met Arg Gly Arg Ser Leu Asn Pro Ala 5 550 555 560
- r Ile Tyr Pro Val Leu Pro Lys Leu Leu Ser Leu Leu Pro Leu Ser 565 570 575
- s Gln Lys Arg Leu His Cys Arg Ser Tyr Gly Gln Asp His Leu Asp 580 585 590
- r Gly Leu Phe Pro Glu Lys Pro Arg Asn Gly Val Leu Gly Asp Ser Page 389

eolf-seql-S000001.txt
595 600 605

rg Asp Lys Glu Ala Met Ala Leu Asp Gly Thr Ala Tyr Gln Gly Ser 610 620

er Ser Thr Cys Ile Leu Gln Glu Thr Ser Leu 25 630 635

eolf-seql-S000001.txt

1160

- .0> 36
- .1> 666
- .2> DNA
- .3> Homo sapiens
- 10> 36
- iggcttgg ctgcgccctc tcgcgccgca cgctctgcgg gttcctccct tcttccgagc 60
- stoctotg googcogogo gggagagagg cogagatggo agatgagatt gocaaggoto 120
- stegeteg geetggtgge gacacgatet ttgggaagat cateegcaag gaaataccag 180
- cacattt totggtgata occaagaaac atatatooca gatttotgtg.gcagaagatg 300
- |atgaaag tcttcttgga cacttaatga ttgttggcaa gaaatgtgct gctgatctgg 360
- tgaataa gggttatcga atggtggtga atgaaggttc agatggtgga cagtctgtct 420
- acgttca tetecatgtt ettggaggte ggeaaatgea ttggeeteet ggttaageae 480
- ttgggga taattttctc ttctttaggc aatgattaag ttaggcaatt tccagtatgt 540
- gtaacac acttatttt gcctgtgtat ggagagattc aagaaataat tttaaaaccg 600

aaa

666

- 0> 37
- 1> 3683
- 2> DNA
- 3> Homo sapiens
- 0> 37
- ggcaggc ggcggctgca gggcaggtcc aggggccaca tggctgaggg ggacgcaggg 60

eolf-seql-S000001.txt

.200

ttatttg ggagaactaa tttgaactta atcaccactt catctaattt tagcaaggta .260

igttgccc agggcagtac ctgaattaac tgtccatttc agtacatgtc aagtgccttt
.320

aggtgga gaagaaatgt ctctagagga atataaatac ctgatttctt gtcatcgaga .380

ttgtact gttaaatgaa tattgccttt tactgctctt tatggcttat tggaatagga .440

.catttaa gattgatctt ggagagtttc ttcttgtgat tttägttcat aagtatgtca .500

ttcattt tatagtgttc atcattgagt aatggattaa gtgaaaatcc aggagtatcc .560

tgcagtt atgtgctgag gtgataattc atccaacata tttgttagca taaatattat .620 .....

tcagttt ctgttgcaaa ttggtgattg tgaaattaca gaaagtgatt ttctagtctg .680

tttttgt ttaattcttg taatgtaagc aataaatatg gagtgtcagt agtctccttc 740

cccagaa atgtgttggt gtaacattct cgtttctttt aacaacctgg aagtaccttt 800

gtgatct tcactgagga attagaacta tgatagaagt taggctgtgg caaatgggac 860

cgtagag tgggatagag gtggcagaat gaacctggtg tagggcagga gtatgttgtg 920

ttacatc aatttgatgc atgctttcca tctgcactcc agacggcttt ctcagttcca 980

ttttgca gagagaagga gcaaaccttt tcattggaaa aacagaaaca accctcccc 040

ttttttc ccctctattc atcaaacctt tatgtatctt tcatcttcca gttacctcta 100

atttaga tagtgaaatt tacctttgag atataacaat aagtgattaa ctgttcactt 160

gatgtaa tggcaaacaa ttgttaaaag ttattaactg atcacagatt tgcctggact 220

cttccca gggagggaac agaagttagg aggcaacttt gggatggtgc tagagcatgg 280

- jcgaccaga ggcagaatga ggaaattgaa gcaatggcag ccatttatgg cgaggagtgg
- jtgtcattg atgactgtgc caaaatattt tgtattagaa ttagcgacga tatagatgac 180
- caaatgga cactttgctt gcaggtgatg ctgccgaatg aatacccagg tacagctcca 240
- :tatctacc agttgaatgc tccttggctt aaagggcaag aacgtgcgga tttatcaaat 300
- recttgagg aaatatatat teagaatate ggtgaaagta ttetttaeet gtgggtggag 360
- aataagag atgttcttat acaaaaatct cagatgacag aaccaggccc agatgtaaag
- gaaaactg aagaggaaga tgttgaatgt gaagatgatc tcattttagc atgtcagccg 480
- aagttegg ttaaageatt ggattttgat ateagtgaaa eteggaeaga agtagaagta 540
- agaattac ctccgattga tcatggcatt cctattacag accgaagaag tacttttcag 600
- acacttgg ctccagtggt ttgtcccaaa caggtgaaaa tggttctttc caaattgtat 660
- gaataaga aaatagctag tgccacccac aacatctatg cctacagaat atattgtgag 720
- taaacaga ccttcttaca ggattgtgag gatgatgggg aaacagcagc tggtgggcgt 780
- cetteate teatggagat tttgaatgtg aagaatgtea tggtggtagt ateaegetgg 840
- lggaggga ttctgctagg accagatcgc tttaaacata tcaacaactg tgccagaaac 900
- ectagtgg aaaagaacta cacaaattca cctgaggagt catctaaggc tttgggaaag 960
- :aaaaaag taagaaaga caagaagagg aatgaacatt aatacctgaa actataggaa .020
- jttaattt gcctataatt atatatacat tccatagtca tcaaggaata tattgtgcag
- gagtate ettgactget taagteagee agtteageat ggataceaae attagetttt 140
- cttggtt atatcatctg ccaaaaatag agaacttatg atctattcat gtgtgtttca

#### eolf-seql-S000001.txt

igcacaga gaattggaca aacaggtctt tttctctttt ctctgatgtt ttacctttaa
2340

jatccaac atccttaccg ttggtatttt tagtaaggtt atagtaaata gctttacacc
2400

jatggatt ctgaaatata aattctaaat tatatttgtt ataactatat tttatgttgt
2460

ittatcag gagccatcag agaatgacct ttttgtgttt ggaacacttg gttccatgaa
:520

statgett tgtgttttaa etgttaaaat aatttaaaaa ttaattattt tacataatta :580

gaagttaa aaactattaa cattaaataa tttcacaatt tcaacatgtc aaacctatga
:640

|gagatag gaaacaatga gaaacttact tttgctcctt tatacagaat tattaactat
:700

ttactaa ctaaaaaact ctagtattct ttacctaaag tcaattggct ggtaagaggg:760

gatgcaa aatteteeag etetgaaett ggagetaett eacaetetae tettaatgga :820

ttgaact aatgatagat agtattttt tcctctattt aaaatttttg tcttgattag 880

atttttc agttctccat ataataattt tctacaatca gatctatgct gtggcatatt 940

ctttatt taaaaatttt tttttagaga tgagttcttg ctctgtcacc taggctggag 000

agtggca tgatcatggc tcactgcagc cttgaccttc cagcctgcca agtagctggg 060

acagaca ggcatgtgct attacacctg gctaattttt aaagtttttt ttgtaaagat 120

gtctttc tatgttgccc aggctcgtct tgagctcctg gcctcaatcg atcttcctgc 180

ggttttg gaattacagg tgtgagccac catgcctggc ctgctttgac atattttata 240

tgttaat tacaaatagt cttcatatgc cagaatataa gagcaagtgt tatctacttt 300

gatggga attgcagaag ctgcatcaaa agtatgcttt gaggtatata tagtgaaaca 360

eolf-segl-S000001.txt

gcctttct gaagagaatt atatcaaact aattacaacc aagaaataat agtatgaagc 3420

atgctgtt tggaggacag gaaaatttat cgggaaaatt acataatccc tctgattcca 3480

atccagag atagccatta ttattaatat ttggtatgta catccttata ttatttttt 3540

tatgcatg attitgtata tatggttatt tttctttcca taaaaatggt attaaactgt 3600

atactgtt ttgtagccta catatttcat atagaagtat attgttaaca ttttccatgt 3660

ataaatat totatggott tot 3683

10> 38

11> 3251

12> DNA

13> Homo sapiens

00> 38

gcaactat gaaataatcg tagtatgaga ggcagagatc ggggcgagac aatggggatg 60

ggcgcggg agccccgttc cggcttagca gcacctccca gccccgcaga ataaaaccga 120

gcgccccc tccgcgcgcg ccctcccccg agtgcggagc gggaggaggc ggcggcccc 180

ggaggagg aggaggagc cccggaggag gaggcgttgg aggtcgaggc ggaggcggag 240

geggeatg agacgagegt ggeggeegeg getgeteggg geegegetgg ttgeecattg 360

agcggcgt ctgcagctcg cttcaagatg gccgcttggc tcgcattcat tttctgctga 420

gactttta actttcattg tcttttccgc ccgcttcgat cgcctcgcgc cggctgctct
480

ecgggatt ttttatcaag cagaaatgca tcgaacaacg agaatcaaga tcactgagct 540

atccccac ctgatgtgt tgctttgtgg agggtacttc attgatgcca caaccataat 600

eolf-seql-S000001.txt

aatgtcta cattccttct gtaaaacgtg tattgttcgt tacctggaga ccagcaagta 660

gaagaagg gatttttatg cageteatee ttetgetgat getgeeaatg getetaatga 840

atagagga gaggttgcag atgaagataa gagaattata actgatgatg agataataag 900

tatccatt gaattctttg accagaacag attggatcgg aaagtaaaca aagacaaaga 960

aatctaag gaggaggtga atgataaaag atacttacga tgcccagcag caatgactgt
1020

gcactta agaaagtttc tcagaagtaa aatggacata.cctaatactt tccagattga 1080

catgtat gaggaggaac ctttaaagga ttattataca ctaatggata ttgcctacat l140

atacctgg agaaggaatg gtccacttcc attgaaatac agagttcgac ctacttgtaa L200

jaatgaag atcagtcacc agagagatgg actgacaaat gctggagaac tggaaagtga 1260

stgggagt gacaaggcca acagcccagc aggaggtatt ccctccacct cttcttgttt 1320

tagecce agtactecag tgeagtetee teatecaeag ttteeteaea ttteeagtae
1380

:gaatgga accagcaaca gccccagcgg taaccaccaa tcttcttttg ccaatagacc
.440

jaaaatca tcagtaaatg ggtcatcagc aacttcttct ggttgatacc tgagactgtt
.500

gaaaaaa attttaaacc cctgatttat atagatatct tcatgccatt acagctttct .560

itgctaat acatgtgact atcgtccaat ttgctttctt ttgtagtgac attaaatttg
.620

ataaaag atggactaca tgtgatactc ctatggacgt taattgaaaa gaaagattgt .680

tataaag aattggtttc ttggaaagca ggcaagactt tttctctgtg ttaggaaaga

### eolf-seql-S000001.txt

1740

ggaaatgg tttctgtaac cattgtttgg atttggaagt actctgcagt ggacataagc 1800

tgggccat agtttgttaa tctcaactaa cgcctacatt acattctcct tgatcgttct 1860

ttattacg ctgttttgtg aacctgtaga aaacaagtgc tttttatctt gaaattcaac 1920

acggaaag aatatgcata gaataatgca ttctatgtag ccatgtcact gtgaataacg 1980

ttcttgca tatttagcca ttttgattcc tgtttgattt atacttctct gttgctacgc 2040

aaccgatc aaagaaaagt gaacttcagt tttacaatct gtatgcctaa aagcgggtac 2100

ccgtttat tttactgact tgtttaaatg attcgctttt gtaagaatca gatggcatta 2160

sttgttgt acaatgccat attggtatat gacataacag gaaacagtat tgtatgatat 2220

tataaat gctataaaga aatattgtgt ttcatgcatt cagaaatgat tgttaaaatt 2280

occaactg gttcgacctt tgcagatacc cataacctat gttgagcctt gcttaccagc 2340

igaatatt tttaatgtgg atatctaatt ctaaagtctg ttccattaga agcaattggc 2400

itctttct atactttata tacttttctc cagtaataca tgtttacttt aaaaattgtt 2460

agtgaaga aaaaccttta actgagaaat atggaaaccg tcttaatttt ccattggcta 2520

itggaatt aatattgtat tttaaaaatg catattgatc actataattc taaaacaatt !580

:taaataa accagcaggt tgctaaaaga aggcatttta tctaaagtta ttttaatagg :640

statagca gtaattttaa atttaagagt tgcttttaca gttaacaatg gaatatgcct !700

ctgctat gtctgaaaat agaagctatt tattatgagc ttctacaggt atttttaaat :760

gcaagca tgttgaattt aaaatatgaa taaccccacc caacaatttt cagtttattt :820

#### eolf-seql-S000001.txt

.gctttgg tcgaacttgg tgtgtttca tcacccatca gttatttgtg agggtgttta :880

:tatatga atattgtttc atgtttgtat gggaaaattg tagctaaaca tttcattgtc :940

:agtctgc aaaagaagca caattctatt gctttgtctt gcttatagtc attaaatcat:000

:ttttaca tatattgctg ttacttctgc tttctttaaa aatatagtaa aggatgtttt:060

aagtcac aagatacata tatttttatt ttgacctaaa tttgtacagt cccattgtaa:120

ttgtttc taattataga tgtaaaatga aatttcattt gtaattggaa aaaatccaat 180

aaaaaaa a 251

- 0> 39
- 1> 2855
- 2> DNA
- 3> Homo sapiens
- 0> 39

tggcagt tatatagacc ggcggcggag cacgcgtgtg tgcggacgca gttgcgtgag 60

tttgtac tatcctcggt gctgtggtgc agagctagtt cctctccagc tcagccgcgt 120

tttggac atatttgact cttttccccc caggttgaat tgaccaaagc aatggtgatg 180

aagccta gtcccctgct ggtcgggcgg gaatttgtga gacagtatta cacactgctg 240

caggccc cagacatgct gcatagattt tatggaaaga actcttctta tgtccatggg 300

ttggatt caaatggaaa gccagcagat gcagtctacg gacagaaaga aatccacagg 360

gtgatgt cacaaaactt caccaactgc cacaccaaga ttcgccatgt tgatgctcat 420

acgetaa atgatggtgt ggtagtecag gtgatgggge ttetetetaa caacaaccag 480

#### eolf-seql-S000001.txt

ttgagga gattcatgca aacgtttgtc cttgctcctg aggggtctgt tgcaaataaa 540

statgttc acaatgatat cttcagatac caagatgagg tctttggtgg gtttgtcact 600

jcctcagg aggagtctga agaagaagta gaggaacctg aagaaagaca gcaaacacct 660

ggtggtac ctgatgattc tggaactttc tatgatcagg cagttgtcag taatgacatg
720

igaacatt tagaggagcc tgttgctgaa ccagagcctg atcctgaacc agaaccagaa 780

 ${\it igaacctg}$  tatctgaaat ccaagaggaa aagcctgage cagtattaga agaaactgcc  ${\it 840}$ 

gaggatg ctcagaagag ttcttctcca gcacctgcag acatagctca gacagtacag 900

igacttga ggacattttc ttgggcatct gtgaccagta agaatcttcc acccagtgga
960

gttccag ttactgggat accacctcat gttgttaaag taccagcttc acagccccgt .020

gagteta agectgaate teagatteea eeacaaagae eteageggga teaaagagtg .080

gaacaac gaataaatat tcctccccaa aggggaccca gaccaatccg tgaggctggt 140

caaggtg acattgaacc ccgaagaatg gtgagacacc ctgacagtca ccaactcttc 200

ggcaacc tgcctcatga agtggacaaa tcagagctta aagatttctt tcaaagttat 260

aacgtgg tggagttgcg cattaacagt ggtgggaaat tacccaattt tggttttgtt 320

tttgatg attctgagcc tgttcagaaa gtccttagca acaggcccat catgttcaga 380

gaggtcc gtctgaatgt cgaagagaag aagactcgag ctgccaggga aggcgaccga 440

gataatc gccttcgggg acctggaggc cctcgaggtg ggctgggtgg tggaatgaga 500

cctcccc gtggaggcat ggtgcagaaa ccaggatttg gagtgggaag ggggcttgcg 560

eolf-seql-S000001.txt

acggcagt gaatetteat ggatetteat geagecatae aaaceetggt tecaacagaa 1620

gtgaattt tcgacagcct ttggtatctt ggagtatgac cccagtctgt tataaactgc 1680

aagtttgt ataattttac tttttttgtg tgttaatggt gtgtgctccc tctccctctc 1740

ccctttcc tgacctttag tctttcactt ccaattttgt ggaatgatat tttaggaata 1800

ggactttt aaagaagcaa aaaaaaagac tgaatttcct tgcttacttt gcatatacag 1860

tggatttt tttttttt ttacagccat ttccccaaag gaatgtcttg catattactg 1920

atttggta tgtttcattc attggaatat ttcttatttt ctacgtgttt gaaaagcctg 1980

agaaatac aggatttgat aatattttga aggcaggaaa aacccaaatt gtttcttctt 2040

agagtcat gactaccttc tggtgtggag aaattgccat tggaaaattt gacaattttg 2100

tctcactg gtatgtttaa aaactgaata aaaggaatag aattttttt tgataaagga 2160

acaaaaca attctaaaac ctaactgttt ttaccattga aatttaaatt gtgataatag 2220

tttaaatg tctagaatgc aactgatagg cttttcttga actgttagtt tttttgaagt 2280

:tttttca tgtttaattt gtatttgtaa aaaaacaaaa agcaaaaaaa ttcccaaaac 2340

igataaca accagagcaa aactgttgtg ccttctattt atctttgatt tcagtcttgg
2400

ittgttta aaaaaaaat ctagatttgt tttattaggt tcagagtatg tggggaatta 2460

jaatccct ctttcatcac tttgtgtatg tcttttgtta acatatttgt tatgccttat
2520

:aaaattg agtctcaaac tggaatgcct ttgaagacag atgcttctat agaggttctt
!580

icctaaat agttcagcat ttgtatttt attctggtat ctaatcagat tcctaatcat
:640

ccgtaag aaggaatgtt actttaatat tggactttgc tcatgtgctc gtgtccgcat

eolf-seql-S000001.txt

2700

tttttttt cttaaaatca tagccatatg gtaaattttc tattttgtta tggttctctt 2760

attgatgg gcatgcagtg ggtgttactt ggaaatggcc aatttttatt aaaatatttc 2820

gaagaaaa tttaaaaaaa aaaaaaaaaa aaaaa 2855

10> 40

11> 1396

12> DNA

13> Homo sapiens

00> 40

gtaattaa aaggcggcgg aagaaggtgg gagggtcatg acgcagcgag tttcagtcgt 60

cttttctg ggggcatcgc ggcgtcccct tttttttgcc tttaaagtaa aacgtcgccc 120

acgcaccc cccgcgtatt tcggggggcg gaggcggcgg gccacggcgc gaagaggggc 180

tgctgacg ccggccggtc acgtgggcgt gttgtggggg ggaggggcgc cgccgcgcgg 240

ggttccgg gcggttggga gcgcgcgagc tagcgagcga gaggcagccg cgcccgccgc 300

cccctgct ctgtatgccg ctctctcccg gcgcggccgc cgccgatcac agcagcagga 360

caccgccg ccgcggttga tgtggttggg ccggggctga ggaggccgcc aagatgccgc 420

tecaagte eeggaagate gegateetgg getaceggte tgtggggaaa teeteattga 480

attcaatt tgttgaaggc caatttgtgg actcctacga tccaaccata gaaaacactt 540

acaaagtt gatcacagta aatggacaag aatatcatct tcaacttgta gacacagccg 600

caagatga atattotato tttootoaga catactocat agatattaat ggotatatto 660

rtgtattc tgttacatca atcaaaagtt ttgaagtgat taaagttatc catggcaaat 720

itggatat ggtggggaaa gtacaaatac ctattatgtt ggttgggaat aagaaagacc